


EAU16 | MUNICH

11-15 March 2016

Sharing knowledge - Raising the level of urological care



Plenary Sessions • Thematic Sessions • Abstract Sessions • Section Meetings • Live Surgery Sessions • ESU Courses • Exhibition



31st Annual EAU Congress
www.eau16.org



 European Association of Urology

6th International Congress on the History of Urology

Friday, 11 March
08:30 - 16:15

Location: Room 5 (ICM, Level 0)

Chairs: F.M.J. Debruyne, Arnhem (NL)
D. Schultheiss, Giessen (DE)

Aims and objectives of this presentation

The 6th International Congress on the History of Urology tries to cover aspects of the development of our speciality in many countries worldwide. Despite the mere medical aspects urology was influenced by political circumstances and also by personal biographies.

08:30 - 08:40

Opening of the congress by the Honorary President

F.M.J. Debruyne, Arnhem (NL)

08:40 - 08:45

A brief history of the International Congress on the History of Urology

D. Schultheiss, Giessen (DE)

08:45 - 10:10

The worldwide roots of Urology

Moderators: M.E. Moran, Linthicum, Maryland (US)
D. Schultheiss, Giessen (DE)

08:45 - 09:00

Urology at the time of the pharaohs

M. Eissa, Cairo (EG)

09:00 - 09:05

Discussion

09:05 - 09:20

Roots of urology in China

W. Wang, Beijing (CN)

09:20 - 09:25

Discussion

09:25 - 09:40

Meredith Campbell and the story behind 'Campbell's Urology'

R. Rabinowitz, Rochester (US)

09:40 - 09:45

Discussion

09:45 - 10:00

Milestones in Canadian urology 1929-2015

J.B. Gajewski, Halifax (CA)

10:00 - 10:05

Discussion

10:05 - 10:10

Closing remarks

M.E. Moran, Linthicum, Maryland (US)
D. Schultheiss, Giessen (DE)

10:10 - 10:30

Coffee break

10:30 - 12:00

Politics and urology

Moderators: P-A. Abrahamsson, Malmö (SE)
P.M. Thompson, London (GB)

10:30 - 10:45

The fall of the urological iron curtain
F.M.J. Debruyne, Arnhem (NL)

10:45 - 10:50

Discussion

10:50 - 11:05

Lelio Olchese Zeno: An Argentinian urologist in the Soviet Union
N.M. Fredotovich, Buenos Aires (AR)

11:05 - 11:10

Discussion

11:10 - 11:25

Urology during the American civil war
M.E. Moran, Linthicum, Maryland (US)

11:25 - 11:30

Discussion

11:30 - 11:45

Urological complications that changed world history
J. Goddard, Leicester (GB)

11:45 - 11:50

Discussion

11:50 - 12:00

Closing remarks
P-A. Abrahamsson, Malmö (SE)
P.M. Thompson, London (GB)

12:00 - 13:00

Lunch break

13:00 - 14:30

Sex around the world

Moderators: N.M. Fredotovich, Buenos Aires (AR)
J. Mattelaer, Kortrijk (BE)

13:00 - 13:15

The prehistoric penis
J. Angulo Cuesta, Madrid (ES)

13:15 - 13:20

Discussion

13:20 - 13:35

When sex came to Germany
D. Schultheiss, Giessen (DE)

13:35 - 13:40

Discussion

13:40 - 13:55

The birth of modern andrology

J.P. Pryor, London (GB)

13:55 - 14:00

Discussion

14:00 - 14:15

Covered, uncovered, discovered

P.E. Van Kerrebroeck, Maastricht (NL)

14:15 - 14:20

Discussion

14:20 - 14:30

Closing remarks

N.M. Fredotovich, Buenos Aires (AR)

J. Mattelaer, Kortrijk (BE)

14:30 - 15:00

Coffee break

15:00 - 16:10

Pioneers in urology

Moderators:

F.M.J. Debruyne, Arnhem (NL)

F.H. Moll, Cologne (DE)

15:00 - 15:15

Salvador Gil Vernet, a pioneer in urological anatomy

J.M. Gil-Vernet Sedo, Barcelona (ES)

15:15 - 15:20

Discussion

15:20 - 15:35

ESWL: A shocking change in urology

C.G. Chaussy, Strasslach (DE)

15:35 - 15:40

Discussion

15:40 - 15:55

Willy Gregoir, a pioneer in European urology

C.C. Schulman, Brussels (BE)

15:55 - 16:00

Discussion

16:00 - 16:10

Closing remarks

F.M.J. Debruyne, Arnhem (NL)

F.H. Moll, Cologne (DE)

16:10 - 16:15

Summary and closure of the 6th International Congress on the History of Urology

F.M.J. Debruyne, Arnhem (NL)

D. Schultheiss, Giessen (DE)

Joint Session of the European Association of Urology (EAU) and World Chinese Urologists

Urology beyond Europe

Friday, 11 March
09:30 - 12:40

Location: Room 14a (ICM, Level 1)

Chairs: H-C. Kuo, Hualien (TW)
J. N'Dow, Aberdeen (GB)
Y-H. Sun, Shanghai (CN)

Aims and objectives of this presentation

1. To help improve the scientific exchange and friendship among Chinese urologists from all around the world.
2. To help improve the scientific exchange and friendship between Chinese urologists and European urologists.
3. To explore scientific collaborations.

09:30 - 09:45

Welcome / Introduction

H-C. Kuo, Hualien (TW)
J. N'Dow, Aberdeen (GB)
Y-H. Sun, Shanghai (CN)

09:45 - 10:25

Urolithiasis (management of renal stones)

Moderators: C-C. Wang, New Taipei City (TW)
J-Y. Wang, Beijing (CN)

09:45 - 09:55

What is the role of retrograde intrarenal surgery (RIRS)?

O. Traxer, Paris (FR)

09:55 - 10:05

Predictors of successful extracorporeal shock wave lithotripsy for radiopaque and radiolucent calculi

B.J. Chiang, New Taipei City (TW)

10:05 - 10:15

The clinical experience of Mr. SUN's ureteroscope

P.Y.H. Peng, Shanghai (CN)

10:15 - 10:25

Discussion

10:25 - 11:05

Men's health

Moderators: T.L. Lin, Taipei (TW)
F. Montorsi, Milan (IT)

10:25 - 10:35

Is it safe to administer testosterone in prostate cancer patients?

A. Salonia, Milan (IT)

10:35 - 10:45

Treatment algorithm of male LUTS in Taiwan

Y-H. Jiang, Hualien (TW)

10:45 - 10:55 **The advancements in underactive bladder**
K-X. Xu, Beijing (CN)

10:55 - 11:05 **Discussion**

11:05 - 11:45 **Prostate cancer**

Moderators: W-J. Wu, Kaohsiung (TW)
F. Montorsi, Milan (IT)

11:05 - 11:15 **Robotic-assisted radical prostatectomy in Taiwan**
C. Yang, Taichung (TW)

11:15 - 11:25 **Ultrasound CT with artificial intelligence for early detection of prostate cancer**
L-P. Xie, Hangzhou (CN)

11:25 - 11:35 **Role of adjuvant vs salvage post-prostatectomy radiotherapy**
F. Montorsi, Milan (IT)

11:35 - 11:45 **Discussion**

11:45 - 12:25 **Small renal mass**

Moderators: T-J. Pan, Wuhan (CN)
W-J. Wu, Kaohsiung (TW)

11:45 - 11:55 **Partial nephrectomy for renal mass**
S.K. Huang, Tainan City (TW)

11:55 - 12:05 **LncRNA-SARCC and AR in renal cell carcinoma**
J. Zheng, Shanghai (CN)

12:05 - 12:15 **Current role of predicting models in kidney cancer surgery**
V. Ficarra, Padova (IT)

12:25 - 12:40 **Conclusion**
H-C. Kuo, Hualien (TW)
J. N'Dow, Aberdeen (GB)
Y-H. Sun, Shanghai (CN)

Joint Session of the European Association of Urology (EAU) and the Confederación Americana de Urología (CAU) - 'Urologic hot topics in 2016'

Urology beyond Europe

Friday, 11 March
09:30 - 13:00

Location: Room 14b (ICM, Level 1)

Chairs: H. Davila Barrios, Caracas (VE)
H. Van Poppel, Leuven (BE)
H. Villavicencio Mavrich, Barcelona (ES)

Aims and objectives of this presentation

This joint session will update the participants on technical and surgical aspects of minimal invasive urological and uro-oncological surgery for stone disease, prostate and kidney cancer. Apart from that, special attention will be drawn to the actual place of randomised clinical trials in urological research, magnetic resonance in prostate cancer and at the same time give perspectives on personalised medicine and stress urinary incontinence.

09:30 - 09:35

Welcome and introduction

H. Davila Barrios, Caracas (VE)
H. Van Poppel, Leuven (BE)
H. Villavicencio Mavrich, Barcelona (ES)

09:35 - 09:50

Where have we got to go with the management of stress incontinence in the female in 2016?

C.R. Chapple, Sheffield (GB)

09:50 - 09:55

Discussion

09:55 - 10:10

Epigenetic in urologic malignancies: New markers for personalised medicine

J. Angulo Cuesta, Madrid (ES)

10:10 - 10:15

Discussion

10:15 - 10:30

Assessment of complications in robotic surgery according to the Clavien-Dindo classification: Where are we?

J. Palou, Barcelona (ES)

10:30 - 10:35

Discussion

10:35 - 10:50

Robotic flexible ureteroscopy (Roboflex)

J. Rassweiler, Heilbronn (DE)

10:50 - 10:55

Discussion

10:55 - 11:10

CAU experience in minimally invasive nephrectomy

F.P. Secin, Buenos Aires (AR)

11:10 - 11:15

Discussion

11:15 - 11:30	The end of randomised clinical trials as we know them today M. Emberton, London (GB)
11:30 - 11:35	Discussion
11:35 - 11:50	Should we stop doing complex elective partial nephrectomies for RCC? H. Van Poppel, Leuven (BE)
11:50 - 11:55	Discussion
11:55 - 12:10	Robotic-assisted kidney transplantation: Our experience A. Breda, Barcelona (ES)
12:10 - 12:15	Discussion
12:15 - 12:30	Magnetic resonance in prostate cancer: Where does the truth lie? J. Walz, Marseille (FR)
12:30 - 12:35	Discussion
12:35 - 12:50	Prevention and management of complications during percutaneous renal surgery and endourology J. Gutierrez, Winston Salem (US)
12:50 - 12:55	Discussion
<hr/>	
12:55 - 13:00	Conclusion H. Davila Barrios, Caracas (VE) H. Van Poppel, Leuven (BE) H. Villavicencio Mavrich, Barcelona (ES)

Joint Session of the European Association of Urology (EAU) and the Federation of ASEAN Urological Associations (FAUA) - 'Challenges in the ASEAN Urology'

Urology beyond Europe

Friday, 11 March
09:30 - 12:15

Location: Room Vienna (Hall B2, level 0)

Chairs: B. Djavan, Vienna (AT)
C.C.M. Lei, Kuching (MY)
J.W. Thüroff, Mainz (DE)

09:30 - 09:35

Welcome and introduction

B. Djavan, Vienna (AT)
C.C.M. Lei, Kuching (MY)
J.W. Thüroff, Mainz (DE)

09:35 - 10:25

Infection and bladder cancer

09:35 - 09:50

Stones and infection problems in Indonesia

D.M. Soebadi, Surabaya (ID)

09:50 - 10:00

Discussion

10:00 - 10:15

High risk superficial bladder cancer

T.Y. Hong, Singapore (SG)

10:15 - 10:25

Discussion

10:25 - 11:15

Prostate cancer I

10:25 - 10:40

PSA-based biopsies: How we apply in Vietnam

V.L. Chuyen, Ho Chi Minh City (VN)

10:40 - 10:50

Discussion

10:50 - 11:05

Treatment options for localised prostate cancer in the Philippines

J. Letran, Manilla (PH)

11:05 - 11:15

Discussion

11:15 - 12:05

Prostate Cancer II

11:15 - 11:30

Outcome of surgery in locally advanced prostate cancer: Thai perspective

S. Leewansangtong, Bangkok (TH)

11:30 - 11:40

Discussion

11:40 - 11:55

Robotic surgery in Malaysia: Past, present and future

G.C. Teh, Kuching (MY)

11:55 - 12:05

Discussion

12:05 - 12:15

Conclusion

B. Djavan, Vienna (AT)

J.W. Thüroff, Mainz (DE)

3rd ESO Prostate Cancer Observatory: Innovation and care in the next 12 months

Special session

Friday, 11 March
09:45 - 11:30

Location: Room 11 (ICM, Level 1)

Chairs: S. Joniau, Leuven (BE)
R. Valdagni, Milan (IT)

Aims and objectives of this presentation

ESO Observatories are high level sessions organised during major international congresses with the aim of providing the audience with updated and unbiased information on a given topic. An ESO Observatory lasts about one hour and concentrates on a forecast given by a panel of experts on what it is expected to happen in their own field in the coming 12 months. The Panel includes distinguished clinicians and/or scientists and a patient advocate. The forecast by each panel member is given in the form of take-home concise messages with a 5 minute slide presentation followed by 3 minutes of discussion for each topic. The forecast will be discussed by the panel.

09:45 - 09:50

Introduction

09:50 - 10:00

The researcher's perspective

F. Claessens, Leuven (BE)

10:00 - 10:10

The urologist's perspective on screening

K. Touijer, New York (US)

10:10 - 10:20

The biostatistician/methodologist's perspective

D. Sjoberg, New York (US)

10:20 - 10:30

The imaging specialist's perspective on MRI

M. Emberton, London (GB)

10:30 - 10:40

The pathologist's perspective

R. Montironi, Torrette di Ancona (IT)

10:40 - 10:50

The radiation oncologist's perspective

G. De Meerleer, Ghent (BE)

10:50 - 11:00

The medical oncologist's perspective

S. Osanto, Leiden (NL)

11:00 - 11:10

The imaging specialist's perspective on PSMA

K. Goffin, Leuven (BE)

11:10 - 11:20

The patient's perspective

K. Mastris, Clayhall Ilford (GB)

11:20 - 11:30

Discussion and take home messages

Leadership and the EAU

Special session

Friday, 11 March
10:00 - 12:00

Location: Room Paris (Hall B2, level 0)

Chair: J.P.M. Sedelaar, Nijmegen (NL)

Aims and objectives of this presentation

To give the participants an insight in how the EAU is structured, how you can get involved in EAU activities and the importance of contemporary medical leadership. The EAU is always looking for new ways to get the members involved in the new development. The development of specific leadership-qualities could be very helpful in the coming future of the EAU.

10:00 - 10:30

The structure of the EAU and possibilities for involvement in the EAU

J.P.M. Sedelaar, Nijmegen (NL)

10:30 - 12:00

Contemporary Medical Leadership, what makes a leader, different leadership styles, specific competences of Medical Leadership

To be confirmed

Joint Session of the European Association of Urology (EAU) and the Korean Urological Association (KUA) - 'Upper tract urothelial cancer and prostate cancer: Is there a difference in the approach in Korea and Europe?'

Urology beyond Europe

Friday, 11 March
10:15 - 13:00

Location: Room London (Hall B2, level 0)

Chairs: A. Stenzl, Tübingen (DE)
G.T. Sung, Busan (KR)

Aims and objectives of this presentation

Members of the Korean Urological Association and the European Association of Urology will give an overview of new approaches to two important topics. The aim of this session is to show both the latest developments in upper tract urothelial cancer and biochemically recurrent prostate cancer, as well as different clinical applications of new developments in Korea and Europe.

10:15 - 10:20

Welcome and introduction

A. Stenzl, Tübingen (DE)
M-S. Choo, Seoul (KR)

10:20 - 11:20

Urothelial cancer of the upper urinary tract

Moderators: S.J. Kim, Suwon (KR)
S. Shariat, Vienna (AT)

10:20 - 10:32

Diagnosis and follow-up of Upper Tract Urothelial Cancer (UTUC): Korean approach
J.S. Cho, Ahnyang (KR)

10:32 - 10:35

Discussion

10:35 - 10:47

Diagnosis and follow-up of Upper Tract Urothelial Cancer (UTUC): European approach
S. Shariat, Vienna (AT)

10:47 - 10:50

Discussion

10:50 - 11:02

Organ-sparing treatment of Upper Tract Urothelial Cancer (UTUC): Korean approach
B.C. Jeong, Seoul (KR)

11:02 - 11:05

Discussion

11:05 - 11:17

Organ-sparing treatment of Upper Tract Urothelial Cancer (UTUC): European approach
J.J.M.C.H. De La Rosette, Amsterdam (NL)

11:17 - 11:20

Discussion

11:20 - 11:35 **State-of-the-art lecture Systemic treatment of metastatic urothelial cancer: Upper tract versus bladder**
M. De Santis, Coventry (GB)

11:35 - 12:35 **Prostate cancer: Biochemical recurrence after radical prostatectomy**

Moderators: A. Briganti, Milan (IT)
 C-S. Kim, Seoul (KR)

11:35 - 11:47 **Role of blood tests and imaging studies in the diagnosis of biochemical recurrence: Korean approach**
S.J. Yun, Cheongju - Chungbuk (KR)

11:47 - 11:50 **Discussion**

11:50 - 12:02 **Role of blood tests and imaging studies in the diagnosis of biochemical recurrence: European approach**
P. Albers, Düsseldorf (DE)

12:02 - 12:05 **Discussion**

12:05 - 12:17 **Optimal management for biochemical recurrence: Korean approach**
W.K. Han, Seoul (KR)

12:17 - 12:20 **Discussion**

12:20 - 12:32 **Optimal Managements for biochemical recurrence: European approach**
A. Briganti, Milan (IT)

12:32 - 12:35 **Discussion**

12:35 - 12:55 **Joint Korean – European case discussion**

P. Albers, Düsseldorf (DE)
A. Briganti, Milan (IT)
J.H. Ku, Seoul (KR)
S.I. Seo, Seoul (KR)

12:35 - 12:45 **Case 1**
J.Y. Joung, Goyang (KR)

12:45 - 12:55 **Case 2**
A. Stenzl, Tübingen (DE)

12:55 - 13:00 **Conclusion**
A. Stenzl, Tübingen (DE)
G.T. Sung, Busan (KR)

Joint Session of the European Association of Urology (EAU) and the Arab Association of Urology (AAU)

Urology beyond Europe

Friday, 11 March
10:30 - 13:00

Location: Room Madrid (Hall B2, level 0)

Chairs: H. Abol-Enein, Mansoura (EG)
C.R. Chapple, Sheffield (GB)

Aims and objectives of this presentation

This interesting session allows colleagues from the EAU and the AAU to compare and contrast views relating to the effective management of a number of pertinent conditions, such as renal, bladder and prostate cancer. A number of functional disorders affecting the lower urinary tract are also reviewed, including overactive bladder, erectile dysfunction, urethral surgery both for anterior urethral strictures and following pelvic fracture injuries, and the appropriate management of benign prostatic hyperplasia.

10:30 - 10:35

Welcome

H. Abol-Enein, Mansoura (EG)
To be confirmed
C.R. Chapple, Sheffield (GB)
Y. Farahat, Tanta (EG)

10:35 - 11:15

Video's: How I do it

Moderators: I. Al-Oraifi, Dammam (SA)
C.R. Chapple, Sheffield (GB)
N. Ramadan, Khartoum (SD)

10:35 - 10:45

Nerve sparing radical cystectomy

A. Mansour, Mansoura (EG)

10:45 - 10:55

Nephron sparing partial nephrectomy

H. Van Poppel, Leuven (BE)

10:55 - 11:05

Posterior urethroplasty

L. Martínez-Piñero, Madrid (ES)

11:05 - 11:15

Discussion

11:15 - 12:05

Bladder disorders

Moderators: H. Abol-Enein, Mansoura (EG)
Y. Farahat, Tanta (EG)
C.R. Chapple, Sheffield (GB)

11:15 - 11:30

Overactive bladder: What is new?

C.R. Chapple, Sheffield (GB)

11:30 - 11:45

NMIBC: When to do cystectomy?

M. Bulbul, Beirut (LB)

11:45 - 12:05

Robotic radical cystectomy: Do we need it?

11:45 - 11:55

Pro:

J. Rassweiler, Heilbronn (DE)

11:55 - 12:05

Con:

H. Abol-Enein, Mansoura (EG)

12:05 - 12:50

Erectile dysfunction, prostate and urethra

Moderators:

C.R. Chapple, Sheffield (GB)

N. Al-Hamdani, Baghdad (IQ)

A.A. Al-Zarooni, Sharjah (AE)

12:05 - 12:20

Treatment of erectile dysfunction when the medication fails

A. Shamsodini Takhtei, Doha - Waab (QA)

12:20 - 12:35

Urethroplasty: Challenges and alternative

S. Orabi, Alexandria (EG)

12:35 - 12:50

Prostatectomy for BPH: Still TUR or laser

A. Tubaro, Rome (IT)

12:50 - 13:00

Closing remarks

Joint Session of the European Association of Urology (EAU) and the Iranian Urological Association (IUA)

Urology beyond Europe

Friday, 11 March
10:30 - 13:00

Location: Room 14c (ICM, Level 1)

Chairs: S.J. Hosseini, Tehran (IR)
M. Wirth, Dresden (DE)

10:30 - 11:20

Session 1: Urethroplasty

10:30 - 10:50

New one-stage and two-stage penile urethroplasty using oral mucosa and glue

G. Barbagli, Sesto Fiorentino (IT)

10:50 - 11:10

Complicated posterior urethroplasty

S.J. Hosseini, Tehran (IR)

11:10 - 11:20

Questions & answers

11:20 - 12:10

Session 2: Prostate Cancer

11:20 - 11:40

What is new in diagnosis and treatment of prostate cancer?

M. Wirth, Dresden (DE)

11:40 - 12:00

CRPC

M.A. Zargar Shoshtari, Tehran (IR)

12:00 - 12:10

Questions & answers

12:10 - 13:00

Session 3: Bladder Cancer

12:10 - 12:30

Treatment of muscle invasive bladder cancer: What is new?

W. Artibani, Verona (IT)

12:30 - 12:50

Surgical modification in standard radical cystectomy

A. Basiri, Tehran (IR)

12:50 - 13:00

Questions & answers

Joint Session of the European Association of Urology (EAU) and the Maghreb Union Countries

Urology beyond Europe

Friday, 11 March
13:15 - 15:45

Location: Room Madrid (Hall B2, level 0)

Chairs: A. Belaidi, Boufarik Blida (DZ)
P. Coloby, Cergy Pontoise (FR)
A. Joual, Casablanca (MA)

Aims and objectives of this presentation

The aims and objectives for this session are to compare and to share the practice for diagnosis and surgical treatment of prostate cancer and epidemiology and surgical treatment of bladder tumours in Maghreb countries with European countries.

13:15 - 13:20

Welcome and introduction

A. Belaidi, Boufarik Blida (DZ)

13:20 - 13:55

Prostate Session: Diagnosis

Moderators: K. Atallah, Tunis (TN)
A. Belaidi, Boufarik Blida (DZ)
P. Coloby, Cergy Pontoise (FR)
H.A. El Alj, Rabat (MA)
A. Ouzzane, Lille (FR)

13:20 - 13:30

The prostate biopsy in Maghreb countries in 2016

K. Hachi, Alger (DZ)

13:30 - 13:45

MRI in the diagnosis of prostate cancer

A. Ouzzane, Lille (FR)

13:45 - 13:55

Clinical case discussion

A. Zribi, Tunis (TN)

13:55 - 14:45

Prostate Session: Surgical treatment

Moderators: Z. Belahnech, Rabat (MA)
To be confirmed
M. Lounici, Alger (DZ)
M. Rouprêt, Paris (FR)
To be confirmed

13:55 - 14:10

Prostatectomy in T3

T. Roumeguere, Brussels (BE)

14:10 - 14:20

The robotic (Da Vinci) prostatectomy: Benefits

M. Rouprêt, Paris (FR)

14:20 - 14:35

Treatment of prostate cancer "high risk"

A. Ammani, Fes (MA)

14:35 - 14:45

Questions and answers

14:45 - 15:40

Muscle Invasive Bladder Cancer (MIBC)

Moderators:

M. Benatmane, Alger (DZ)
N. Ben Rais, Tunis (TN)
C. Djeflal, Annaba (DZ)
A. Joul, Casablanca (MA)
T. Roumeguere, Brussels (BE)
S. Shariat, Vienna (AT)

14:45 - 14:55

Bladder tumours in Maghreb countries in 2016

W. Zakhama, Monastir (TN)

14:55 - 15:05

Urinary diversions after cystoprostatectomy

M. Azli, Annaba (DZ)

15:05 - 15:20

Cystoprostatectomy in PT1 "high risk"

S. Shariat, Vienna (AT)

15:20 - 15:30

Case presentation

C. Djeflal, Annaba (DZ)

15:30 - 15:40

Questions and answers

15:40 - 15:45

Closure

Joint Session of the European Association of Urology (EAU) and the Pan-African Urological Surgeons' Association (PAUSA) - 'Update on uro-Oncology, functional and reconstructive urology'

Urology beyond Europe

Friday, 11 March
13:15 - 15:45

Location: Room 14a (ICM, Level 1)

Chairs: D.M. Castro-Diaz, La Laguna Santa Cruz Tenerife (ES)
E.O. Olapade-Olaopa, Ibadan (NG)

Aims and objectives of this presentation

This meeting seeks to offer an update in the field of onco-Urology, functional and reconstructive urology. Current state and approach of several hot topics will be discussed including prostate and bladder cancer, urodynamics and urethral stricture.

13:15 - 13:20

Welcome and introduction

D.M. Castro-Diaz, La Laguna Santa Cruz Tenerife (ES)
E.O. Olapade-Olaopa, Ibadan (NG)

13:20 - 14:20

Oncology

Moderators: M.J. Grabe, Malmö (SE)
E.O. Olapade-Olaopa, Ibadan (NG)

13:20 - 13:35

Management of prostate cancer in Africans in the Diaspora

L. Ajayi, London (GB)

13:35 - 13:50

Bladder cancer in Africa: An argument for a different staging system for squamous cell carcinoma

K. Bowa, Ndola (ZM)

13:50 - 14:05

Changed epidemiology of bladder cancer in Ibadan, Nigeria and its implications for national health systems policies

A. Takure, Ibadan (NG)

14:05 - 14:20

Current state of bladder cancer therapy

B.J. Schmitz-Dräger, Fürth (DE)

14:20 - 15:40

Functional and reconstructive urology

Moderators: D.M. Castro-Diaz, La Laguna Santa Cruz Tenerife (ES)
E. Kocjancic, Chicago (US)

14:20 - 14:40

Urodynamic studies in urological practice in a resource limited environment

E.O. Olapade-Olaopa, Ibadan (NG)

14:40 - 15:00

Role of minimally invasive therapy in the management of urethral stricture disease

E. Kocjancic, Chicago (US)

15:00 - 15:20

Current state of urethroplasty

C.R. Chapple, Sheffield (GB)

15:20 - 15:40

Urethroplasty: An African perspective

S.M. Gueye, Dakar (SN)

15:40 - 15:45

Conclusion

D.M. Castro-Diaz, La Laguna Santa Cruz Tenerife (ES)

E.O. Olapade-Olaopa, Ibadan (NG)

Joint Session of the European Association of Urology (EAU) and the Société Internationale d'Urologie (SIU) - 'Optimal diagnosis and management of non-muscle invasive bladder cancer and localised renal tumor'

Urology beyond Europe

Friday, 11 March
13:15 - 15:45

Location: Room 14b (ICM, Level 1)

Chairs: S. Naito, Fukuoka (JP)
J. Palou, Barcelona (ES)

Aims and objectives of this presentation

To introduce and discuss the updated concept and technology for the diagnosis and treatment of NMIBC and localised renal tumours.

13:15 - 13:20

Welcome and introduction

S. Naito, Fukuoka (JP)
J. Palou, Barcelona (ES)

13:20 - 14:20

Session 1: Bladder

Moderators: S. Naito, Fukuoka (JP)
J. Palou, Barcelona (ES)
J.A. Witjes, Nijmegen (NL)

13:20 - 13:40

Narrow band imaging and photodynamic diagnosis: Recommended?

J.J.M.C.H. De La Rosette, Amsterdam (NL)

13:40 - 14:00

Transurethral en-bloc resection of NMIBC: Where is the evidence?

T.R.W. Herrmann, Hannover (DE)

14:00 - 14:20

Prognostic factors and optimal selection of aggressive treatment in high-grade T1 bladder cancer: Criteria to decide

P. Gontero, Turin (IT)

14:20 - 15:40

Session 2: Kidney

Moderators: N.W. Clarke, Manchester (GB)
S. Naito, Fukuoka (JP)
J. Palou, Barcelona (ES)

14:20 - 14:40

Renal tumour biopsy: Is it really established?

U. Capitanio, Milan (IT)

14:40 - 15:00

Active surveillance for small renal mass: Is it a really safe initial conservative management?

R.A. Rendon, Halifax (CA)

15:00 - 15:20

Cryoablation for small renal mass: Selection criteria, complication, functional and oncologic outcomes

O. Rodriguez Faba, Barcelona (ES)

15:20 - 15:40

Robot-assisted partial nephrectomy: Optimal indication, technique and limitation

I.S. Gill, Los Angeles (US)

15:40 - 15:45

Conclusion

S. Naito, Fukuoka (JP)

J. Palou, Barcelona (ES)

Joint Session of the European Association of Urology (EAU) and Caucasus - Central Asia countries

Urology beyond Europe

Friday, 11 March
13:15 - 15:45

Location: Room 14c (ICM, Level 1)

Chairs: F. Cruz, Porto (PT)
N. Turmanidze, Tbilisi (GE)
F.A. Akilov, Tashkent (UZ)
A.M. Grabsky, Yerevan (AM)

Aims and objectives of this presentation

The main objective of the session is to strengthen the links between EAU and the National Societies representing the Caucasus and Central Asian countries. Several topics will be discussed, in parallel, by members from EAU, the Caucasus and Central Asian countries. They will include urological education and diseases such as bladder cancer, prostate cancer, BPH or pelvic organ prolapses. Recent advances will be highlighted and possible differences in the management of these diseases among countries discussed in a friendly atmosphere.

13:15 - 13:20

Welcome and introduction

F. Cruz, Porto (PT)
N. Turmanidze, Tbilisi (GE)

13:20 - 13:45

Urology training

13:20 - 13:30

Laparoscopic training in Europe

A. Stenzl, Tübingen (DE)

13:30 - 13:40

Endourology training for residents in Kazakhstan

T. Anafin, Almaty (KZ)

13:40 - 13:45

Discussion

13:45 - 14:10

Bladder cancer

13:45 - 13:55

Quality assessment in bladder TUR

M.J. Ribal, Barcelona (ES)

13:55 - 14:05

Contemporary management of invasive bladder tumours in Georgia

G. Khvadagiani, Tbilisi (GE)

14:05 - 14:10

Discussion

14:10 - 14:35

BPH

14:10 - 14:20

Individualisation of medical treatment in BPH patients

T. Vieira Da Conceição Antunes Lopes, Porto (PT)

14:20 - 14:30

Surgical treatment of BPH patients in Central Asia

S.S. Kariev, Tashkent (UZ)

14:30 - 14:35

Discussion

14:35 - 15:00

Pelvic floor disorders in women

14:35 - 14:45

Contemporary treatment of SUI in the National Center of Urology, Tbilisi, Georgia

A. Khelaia, Tbilisi (GE)

14:45 - 14:55

Do we still need meshes for correction of pelvic organ prolapses

E. Costantini, Perugia (IT)

14:55 - 15:00

Discussion

15:00 - 15:25

Prostate cancer

15:00 - 15:10

First and second line androgen deprivation therapy in Central Asia

N. Kurmanbekov, Bishkek (KG)

15:10 - 15:20

What is changing in metastatic prostate cancer treatment?

B. Tombal, Brussels (BE)

15:20 - 15:25

Discussion

15:25 - 15:40

Clinical case discussion Renal stone: ESWL, PCNL or flexible ureteroscopy?

S. Fanarjyan, Yerevan (AM)

15:40 - 15:45

Conclusion

F. Cruz, Porto (PT)

N. Turmanidze, Tbilisi (GE)

Joint Session of the European Association of Urology (EAU) and the Japanese Urological Association (JUA)

Urology beyond Europe

Friday, 11 March
13:15 - 15:45

Location: Room Paris (Hall B2, level 0)

Chairs: S. Egawa, Tokyo (JP)
D. Jacqmin, Strasbourg (FR)

Aims and objectives of this presentation

This programme is built to nurture mutual interaction and further strengthen relationships between JUA and EAU on an individual basis. This is also to understand and discuss the cutting-edge knowledge and controversial issues in urology. Topics on urological oncology and voiding dysfunction will be discussed by world experts.

13:15 - 13:20

Welcome and introduction

S. Egawa, Tokyo (JP)
D. Jacqmin, Strasbourg (FR)

13:20 - 14:05

Prostate cancer: New horizon in the treatment of metastatic cancer

Moderators: T. Kamoto, Miyazaki (JP)
N. Mottet, Saint-Étienne (FR)

13:20 - 13:30

Chemotherapy for newly diagnostic metastatic prostate cancer

B. Tombal, Brussels (BE)

13:30 - 13:40

Bone targeting therapy in castration sensitive metastatic prostate cancer

T. Kamba, Kyoto (JP)

13:40 - 14:05

Clinical case discussion: How to approach this situation?

K. Mitsuzuka, Sendai (JP)
N. Mottet, Saint-Étienne (FR)
B. Tombal, Brussels (BE)
M. Uemura, Suita Osaka (JP)

14:05 - 14:50

Renal cell carcinoma (RCC)

Moderators: J. Bellmunt, Boston (US)
Y. Tomita, Niigata (JP)

14:05 - 14:15

Back to the future? Re-emerging of immunotherapy

L. Albiges, Villejuif (FR)

14:15 - 14:25

A prospective multicentre biomarker identification trial for sunitinib in Japanese patients with metastatic RCC

R. Mizuno, Tokyo (JP)

14:25 - 14:50

Clinical case discussion: How to approach this situation? Aging male with multiple comorbidities?

L. Albiges, Villejuif (FR)

J. Bellmunt, Boston (US)
K. Saito, Tokyo (JP)
K. Tatsugami, Fukuoka (JP)

14:50 - 15:35

Male LUTS

Moderators: B. Malavaud, Toulouse (FR)
S. Takahashi, Tokyo (JP)

14:50 - 15:00

How to maintain male pelvic health?
S. Takahashi, Tokyo (JP)

15:00 - 15:10

Benefit of laser surgery for BPH. Is it worth it?
C. Llorente, Madrid (ES)

15:10 - 15:35

Clinical case discussion: How do you treat this patient? Difference in approach to male LUTS?

T. Kitta, Sapporo (JP)
C. Llorente, Madrid (ES)
B. Malavaud, Toulouse (FR)
K. Torimoto, Nara (JP)

15:35 - 15:45

Conclusion
M. Fujisawa, Kobe (JP)

Joint Session of the European Association of Urology (EAU) and the Urological Society of India (USI)

Urology beyond Europe

Friday, 11 March
13:15 - 15:45

Location: Room Vienna (Hall B2, level 0)

Chairs: V.G. Mirone, Naples (IT)
R. Sood, New Delhi (IN)

Aims and objectives of this presentation

To provide an updated view on hot and interesting issues in the field of testicular cancer, surgical treatment of BPH and urolithiasis. Recognised experts in these fields working in India and Europe will provide updated reviews and are available to clarify the most conflicting areas.

13:15 - 13:20

Welcome and introduction

V.G. Mirone, Naples (IT)
R. Sood, New Delhi (IN)

13:20 - 13:44

Minimally invasive approach to cystoprostatectomy: Robotic vs mini lap

13:20 - 13:32

European view

N.P. Wiklund, Stockholm (SE)

13:32 - 13:44

Indian view

S. Rawal, Delhi (IN)

13:44 - 14:08

Free PSA & PSA: Should they be discriminated racially and geographically

13:44 - 13:56

European view

J.A. Schalken, Nijmegen (NL)

13:56 - 14:08

Indian view

A. Mandhani, Lucknow (IN)

14:08 - 14:32

The new wave in PCNL

14:08 - 14:20

European view

A. Patel, London (GB)

14:20 - 14:32

Indian view

J. Desai, Ahmedabad (IN)

14:32 - 14:56

Contemporary endoscopic management of Vesico Ureteric Reflux

14:32 - 14:44

European view

M.S. Silay, Istanbul (TR)

14:44 - 14:56

Indian view

D. Ramesh, Bangalore (IN)

14:56 - 15:20

Why men suffer more and die early: ED as sentinel marker, genome and metabolic milieu

14:56 - 15:08

European view

A. Salonia, Milan (IT)

15:08 - 15:20

Indian view

R. Sood, New Delhi (IN)

15:20 - 15:44

Transplant in abnormal bladder and other special situations

15:20 - 15:32

European view

R.P. Djjinovic, Belgrade (RS)

15:32 - 15:44

Indian view

A. Kumar, Noida (IN)

15:44 - 15:45

Conclusion and closing remarks

Meeting of the Young Academic Urologists

Special Session

Friday, 11 March
14:00 - 18:00

Location: Room 4 (ICM, Level 0)

14:00 - 14:10

YAU Overview
M.S. Silay, Istanbul (TR)

14:10 - 14:50

YAU Working parties reports

14:10 - 14:14

Renal cancer
S.D. Brookman-May, Munich (DE)

14:14 - 14:18

Prostate cancer
G. Ploussard, Toulouse (FR)

14:18 - 14:22

Urothelial cancer
E. Xylinas, Paris (FR)

14:22 - 14:26

Men's health
P. Verze, Naples (IT)

14:26 - 14:30

Functional urology
J-N.L. Cornu, Rouen (FR)

14:30 - 14:34

ERUS-Robotic
N. Buffi, Milan (IT)

14:34 - 14:38

Endourology-stone disease
F. Sanguedolce, London (GB)

14:38 - 14:42

Paediatrics
B. Haid, Linz (AT)

14:42 - 14:50

Open discussion

14:50 - 15:10

Panel Establishing a professional career

Panel: S.D. Brookman-May, Munich (DE)
J.P.M. Sedelaar, Nijmegen (NL)

14:50 - 15:00

Tips and tricks in establishing a lifetime successful career
L. Martínez-Piñero, Madrid (ES)

15:00 - 15:10

Establishing a professional career at a European level: How to take the steps as a young urologist to become a key opinion leader
M. Rouprêt, Paris (FR)

15:10 - 15:40

Panel Overview of YAU and EAU Sections

Panel: F. Sanguedolce, London (GB)
E. Xylinas, Paris (FR)

15:10 - 15:20

The current relations of YAU and Sections of EAU

M.S. Silay, Istanbul (TR)

15:20 - 15:30

How to improve the contribution of YAU to the sections of EAU

J. Rassweiler, Heilbronn (DE)

15:30 - 15:40

Open discussion

15:40 - 18:00

Brainstorming of YAU working groups

EAU Opening Ceremony

Friday, 11 March
18:00 - 19:30

Location: eURO Auditorium (Hall C1, Level 0)

Opening addresses
C.R. Chapple, Sheffield (GB)

Announcement of the new EAU Honorary Members

Presentation of the EAU Willy Gregoir Medal 2016

Presentation of the EAU Frans Debruyne Life Time Achievement Award 2016

Presentation of the EAU Crystal Matula Award 2016

Presentation of the EAU Hans Marberger Award 2016

Presentation of the EAU Innovators in Urology Award 2016

Presentation of the EAU Prostate Cancer Research Award 2016

EAU General assembly

Special session

Saturday, 12 March
07:30 - 08:30

Location: Room Madrid (Hall B2, level 0)

Welcome by the EAU Secretary General

Approval minutes General Assembly of 21 March 2015, Madrid, Spain

General report by the EAU Secretary General
C.R. Chapple, Sheffield (GB)

Report by the EAU Treasurer
M. Wirth, Dresden (DE)

Specific reports on the EAU Offices by the EAU Executive

Approval of the new EAU Office Chairman for the Section Office and History Office

Report by the Secretary General on the EAU Membership Office

Approval new EAU members

Approval new Honorary members

Other business

Announcement of the 32nd Annual EAU Congress in London, 24-28 March 2017

Evidence-based medicine vs common practice / challenging the evidence

Plenary Session 1

Saturday, 12 March
08:30 - 10:15

Location: eURO Auditorium (Hall C1, Level 0)

Chairs: J. N'Dow, Aberdeen (GB)
H. Van Poppel, Leuven (BE)

Aims and objectives of this presentation

This session will address challenging clinical scenarios and treatment decisions that urologists have to deal with in daily practice. Whilst there are high quality EAU Guidelines that give generic guidance, this session will highlight how to use evidence and guidelines on the one hand and highlight the importance of tailoring care to the needs of each individual patient on the other, including when it is appropriate to deviate from the EAU Guidelines.

08:30 - 08:40

Introduction The future of guidelines in Europe: Legal implications
J. N'Dow, Aberdeen (GB)

08:40 - 09:15

Case discussion Management of ureteral stones

Moderator: C. Türk, Vienna (AT)

08:40 - 08:45

Medically induced stone passage: Are the EAU guidelines wrong?
C. Türk, Vienna (AT)

08:45 - 09:00

Pro
C.C. Seitz, Vienna (AT)

09:00 - 09:15

Con
S. McClinton, Aberdeen (GB)

09:15 - 09:50

Case discussion Male incontinence after radical prostatectomy: When does experience have to overrule the EAU guidelines?

09:15 - 09:20

Moderator and case presenter
F.C. Burkhard, Berne (CH)

09:20 - 09:35

When, why and which slings to use in moderate urinary incontinence?
V.W. Nitti, New York (US)

09:35 - 09:50

Artificial urinary sphincter - Get it right the first time?
E. Chartier-Kastler, Paris (FR)

09:50 - 10:05

American Urological Association (AUA) lecture Testosterone therapy
A. Morgentaler, Boston (US)

LBA01

Efficacy of Mycobacterium phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG- Unresponsive Patients

By: [Ashish K.](#)², Amrhein J.³, Cohen Z.¹, Champagne M.¹

Institutes:¹Telesta Therapeutics, Inc, Department, Pointe Claire, Canada, ²The University of Texas M.D. Anderson Cancer Center, Dept. of Urology, Houston, United States of America, ³McDougall Scientific Ltd, Department, Toronto, Canada

American Urological Association (AUA) lecture

Aims and objectives of this presentation

To present results of MCNA in patients with BCG Unresponsive NMIBC showing how in this highest risk subgroup of BCG Failures MCNA achieves 1 year DFS of 35% for overall population; 24% for CIS; and 60% for papillary tumors.

10:11 - 10:15

Discussant

J. Palou, Barcelona (ES)

Slings and things in female incontinence

Poster Session 01

Saturday, 12 March
08:30 - 10:00

Location: Room Stockholm (Hall B2, level 0)

Chairs: R. Hamid, London (GB)
A. Vaze, Mumbai (IN)
D. Waltregny, Liège (BE)

Aims and objectives of this presentation

Sling surgery is now the golden standard for stress incontinence in women. This session will deal with innovation, complications and new things in this field.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 1 **Is detrusor contraction really necessary for female micturition?**
By: [Kira S.](#), Kobayashi H., Haneda Y., Sawada N., Mitsui T., Takeda M.
Institutes: University of Yamanashi, Dept. of Urology, Chuo, Japan
- 2 **Three and six month results from a randomized, controlled clinical trial of an intravesical pressure-attenuation balloon system for the treatment of female stress urinary incontinence (SUI)**
By: [De Wachter S.](#)¹, Wyndaele J.-J.¹, Tommaselli G.², Angioli R.³, De Wildt M.⁴, Everaert K.⁵, Michielsen D.⁶, Van Koevering G.⁷
Institutes:¹University of Antwerp, Dept. of Urology, Antwerp, Belgium, ²University Degli Studi Di Napoli "Federico II", Dept. of Obstetrics and Gynecology, Naples, Italy, ³Universita Di Roma Campus Biomedico, Dept. of Obstetrics and Gynecology, Rome, Italy, ⁴Catharina ziekenhuis, Dept. of Urology, Eindhoven, The Netherlands, ⁵Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ⁶UZ Brussel, Dept. of Urology, Brussels, Belgium, ⁷Maastricht University Medical Centre, Dept. of Urology, Maastricht, The Netherlands
- 3 **Mid-term outcomes following sub-urethral synthetic sling removal in women**
By: Foster J., Singla N., Aggarwal H., Alhalabi F., Lemack G., [Zimmern P.](#)
Institutes: Ut Southwestern Medical Center, Dept. of Urology, Dallas, United States of America
- 4 **Treatment satisfaction and patients' perception of pulsed magnetic stimulation for female stress urinary incontinence**
By: [Lim R.](#)¹, Liong M.L.³, Leong W.S.², Abdul Karim Khan N.¹, Yuen K.H.¹
Institutes:¹Universiti Sains Malaysia, School of Pharmaceutical Sciences, Penang, Malaysia, ²Lam Wah Ee Hospital, Dept. of Urology, Penang, Malaysia, ³Island Hospital, Dept. of Urology, Penang, Malaysia
- 5 **Urodynamic examinations performed before stress incontinence surgery in female patients: Cost analysis in Italy**
By: Patruno G.¹, Del Fabbro D.¹, Petta F.¹, Vespasiani G.¹, Serati M.², [Finazzi Agrò E.](#)¹
Institutes:¹Policlinico Tor Vergata Roma, Dept. of Urology, Rome, Italy, ²University of Insubria, Dept. of Gynaecology, Varese, Italy
- 6 **Safety and efficacy of REMEEEX sling system for female urinary incontinence and feasibility of re-adjustment**
By: [Jo J.K.](#)¹, Lee Y.I.², Lee S.W.³, Kim J.H.³, Joeng S.J.¹
Institutes:¹Seoul National University Bundang Hospital, Dept. of Urology, Seongnam-Si, South Korea, ²Daedong Hospital, Dept. of Urology, Busan-Si, South Korea, ³Kangwon National University Hospital, Dept. of Urology, Kangwon, South Korea

- 7 **Sling procedures for female stress incontinence: Does surgical specialty matter?**
By: Löppenberg B.¹, Meyer C.¹, Hanna N.¹, Cole A.¹, Vetterlein M.¹, Menon M.², Sammon J.², Leow J.¹, Kibel A.¹, Trinh Q-D.¹
Institutes:¹Brigham and Women's Hospital, Dept. of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Henry Ford Hospital / Health System, Vattikuti Institute of Urology, Center For Outcomes Research, Analytics and Evaluation, Detroit, United States of America
- 8 **Trends in the diagnosis and management of female urinary incontinence in the United States**
By: Forde J.¹, Chughtai B.¹, Stone B.¹, Cea M.², Te A.¹, Bishop T.²
Institutes:¹Weill Cornell Medical College/New York Presbyterian Hospital, Dept. of Urology, New York, United States of America, ²Weill Cornell Medical College/New York Presbyterian Hospital, Dept. of Healthcare Policy & Research, New York, United States of America
- 9 **Laparoscopic approach for artificial urinary sphincter implantation in women with urinary stress incontinence: 10 Years experience**
By: Ferreira C., Mandron E., Bryckaert P-E.
Institutes:Clinic Du Pré, Dept. of Urology, Le Mans, France
- 11 **Sacrocolpopexy for post-hysterectomy vaginal vault prolapse: Long term follow-up**
By: Illiano E.², Di Biase M.¹, Giannitsas K.³, Zucchi A.¹, Lazzeri M.⁴, Balsamo R.², Costantini E.¹
Institutes:¹University of Perugia, Dept. of Urology, Perugia, Italy, ²University of Napoli Federico II, Dept. of Urology, Naples, Italy, ³Patras University Hospital, Dept. of Urology, Patras, Greece, ⁴Hospital Vita Salute S Raffaele, Dept. of Urology, Milan, Italy
- 12 **Evaluating pad weight gain in asymptomatic women**
By: Duffy M., Nicholls C., Gora A., Hamid R., Ockrim J.L., Greenwell T.J., Pakzad M.H.
Institutes:University College London Hospital, Dept. of Urology, London, United Kingdom
- 13 **Does pelvic floor muscle training help to reduce urinary incontinence in elderly women with mild cognitive impairment and Alzheimer's disease?**
By: Cho S.T.¹, Jung H.B.¹, Choi D.K.¹, Lee Y.G.¹, Kim K.K.¹, Kim H.J.², Na H.R.³
Institutes:¹Kangnam Sacred Heart Hospital, Dept. of Urology, Seoul, South Korea, ²Dankook University College of Medicine, Dept. of Urology, Cheonan, South Korea, ³Bobath Memorial Hospital, Dept. of Neurology, Seoungnam, South Korea
- 14 **Coital incontinence in women with urinary incontinence: Results from an international cross-sectional study**
By: Costantini E.¹, Illiano E.², Tienforti D.³, Athanasopoulos A.⁴, Giannitsas K.⁴, Balsamo R.⁵, Masiello G.⁶, Di Biase M.⁷, Natale F.⁸, Carbone A.⁹, Filocamo M.T.¹⁰, Villari D.¹¹, Mahfouz W.¹², Finazzi Agro' E.¹³, Kocjancic E.¹⁴
Institutes:¹University of Perugia, Dept. of Urology and Andrology Clinic, Department of Surgical and Biomedical Sciences, Naples, Italy, ²University Federico II of Naples, Dept. of Neuroscience, Reproductive Sciences and Dentistry, Naples, Italy, ³Institute of Clinical Sexology, Dept. of Clinical Sexology, Rome, Italy, ⁴University of Patras Patras, Dept. of Urology Unit Medical School, Patras, Greece, ⁵Magna Graecia University, Doctorate Research Program, Catanzaro, Italy, ⁶Don Tonino Bello Hospital, Dept. of Urology, Molfetta, Italy, ⁷University of Perugia, Dept. of Urology and Andrology Clinic, Perugia, Italy, ⁸San Carlo Di Nancy Hospital, Dept. of Urogynecology, Rome, Italy, ⁹Sapienza University of Rome, Faculty of Pharmacy and Medicine, Urology Unit ICOT, Dept. of Medico-Surgical Sciences and Biotechnologies, Latina, Italy, ¹⁰ASL CN1, Dept. of Urology, Savigliano, Italy, ¹¹University of Florence, Dept. of Urology and Andrology, Florence, Italy, ¹²Alexandria University, Dept. of Female Urology, Functional Urology & Voiding Dysfunction, Alexandria, Egypt, ¹³Tor Vergata University Hospital, Dept. of Experimental Medicine and Surgery, Rome, Italy, ¹⁴University of Illinois at Chicago, Dept. of Pelvic Health and Reconstructive Urology, Dept. of Urology, Chicago, Illinois, United States of America

Challenging kidney surgery

Video Session 01

Saturday, 12 March
08:30 - 10:00

Location: Room 1 (ICM, Level 0)
Chairs: A. Carbone, Latina (IT)
A. Mottrie, Aalst (BE)
P-T. Piéchaud, Bordeaux (FR)

All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.

- V1 **Extra-Gerota's fascia partial nephrectomy for angiomyolipoma (AML)**
By: [Kheifets A.](#), Sidi A.A., Tsivian A.
Institutes: Wolfson Medical Center, Dept. of Urology, Holon, Israel
- V2 **A novel technique during laparoscopic partial nephrectomy**
By: Wang M., Yang F., Song L., Kang N., Niu Y., Zhang J., [Xing N.](#)
Institutes: Beijing Chao-Yang Hospital, Capital Medical University, Dept. of Urology, Beijing, China
- V3 **Is laparoscopic partial nephrectomy feasible in complex renal tumours?**
By: [Petrut B.](#), Schiil cu V., Feflea D.
Institutes: The Oncology Institute 'Prof. Dr. I. Chiricută', Dept. of Urology, Cluj Napoca, Romania
- V4 **Tailored ischemia during robot-assisted partial nephrectomy: Initial experience and description of the technique**
By: Rühle A., Grande P., Mordasini L., Danuser H., [Mattei A.](#)
Institutes: Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland
- V5 **Robot-assisted adrenalectomy in case of bulky pheochromocytoma**
By: [Gandaglia G.](#), Capogrosso P., Nini A., Larcher A., Deho' F., Dell'Oglio P., Di Trapani E., Salonia A., Briganti A., Bertini R., Capitanio U., Montorsi F.
Institutes: IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy
- V6 **Contemporary open surgical techniques for intracardiac renal tumours**
By: [Hussain M.](#), Thomas K., Austin C., O'Brien T.S.
Institutes: Guy's Hospital, Dept. of Urology, London, United Kingdom
- V7 **Our experience of laparoscopic thrombectomy and vena cava suture**
By: [Popov S.](#)¹, Orlov I.¹, Chernysheva D.¹, Galliamov E.², Novikov A.³, Sergeev V.⁴, Kochkin A.D.⁶, Sanzharov A.⁵
Institutes: ¹City Hospital Saint Luka / No18, Dept. of Urology, Saint Petersburg, Russia, ²Civil Aviation Central Clinical Hospital, Dept. of Urology, Moscow, Russia, ³Medical Center of Bank of Russia, Dept. of Urology, Moscow, Russia, ⁴Federal Medical Biophysical Center named after A.I. Burnazyan, Dept. of Urology, Moscow, Russia, ⁵City Hospital 40, Dept. of Urology, Ekaterinburg, Russia, ⁶Railroad Clinical Hospital, Dept. of Urology, N. Novgorod, Russia
- V8 **Robotic level II and III IVC thrombectomy: Technical innovations**
By: [Simone G.](#)¹, Abreu A.L.², Kundavaram C.², Ferriero M.¹, Papalia R.³, Mastroianni R.¹, Shin D.², Metcalfe C.², Chopra S.², Ukimura O.², Guaglianone S.¹, Aron M.², Desai M.², Sotelo R.², Gallucci M.¹, Gill I.S.²
Institutes: ¹"Regina Elena" National Cancer Institute, Dept. of Urology, Rome, Italy, ²USC Institute of Urology and Departments of Urology, Keck School of Medicine, University of Southern California, Dept. of Urology, Los Angeles, California, United States of America, ³Campus Biomedico University of

Rome, Dept. of Urology, Rome, Italy

V9

Robot assisted radical nephrectomy and inferior vena cava thrombectomy: Surgical technique, perioperative and early oncologic outcomes

By: Simone G.¹, Ferriero M.¹, Papalia R.², Mastroianni R.², Minisola F.¹, Misuraca L.¹, Tuderti G.¹, Guaglianone S.¹, Costantini M.¹, Pompeo V.¹, De Castro Abreu A.L.³, Aron M.³, Desai M.³, Gill I.S.³, Gallucci M.¹

Institutes:¹"Regina Elena" National Cancer Institute, Dept. of Urology, Rome, Italy, ²Campus Biomedico University of Rome, Dept. of Urology, Rome, Italy, ³USC Institute of Urology and Departments of Urology, Keck School of Medicine, University of Southern, Dept. of Urology, Los Angeles, California, United States of America

Testis cancer: New surgical and medical approaches

Poster Session 02

Saturday, 12 March
08:30 - 10:00

Location: Room Milan (Hall B2, level 0)

Chairs: A. Lorch, Düsseldorf (DE)
N. Nicolai, Milan (IT)
J. Oldenburg, Oslo (NO)

Aims and objectives of this presentation

This session will highlight and discuss controversial topics in the diagnosis and treatment of testicular tumours especially in stage II seminoma and will present new data on drugs used in the salvage chemotherapy setting.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *15 **Minimally invasive RPLND(MI-RPLND): Is this an option for low volume stage 2 seminoma?**
By: Nicol D., Huddart R., Reid A., Mayer E.
Institutes:Royal Marsden Hospital, Dept. of Urology, London, United Kingdom
- *16 **Primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment**
By: Lusch A., Zaum M., Besmens M., Albers P.
Institutes:Düsseldorf University, Dept. of Urology, Düsseldorf, Germany
- *17 **Single center experience with two cycles of PEB chemotherapy for clinical stage IIa or IIB seminoma patients**
By: Kunit T.¹, Törzsök P.¹, Colleselli D.¹, Sievert K.D.²
Institutes:¹Paracelsus Private University, Dept. of Urology, Salzburg, Austria, ²Universitätsklinikum Salzburg, Klinik für Urologie und Andrologie, Salzburg, Austria
- *18 **Long-term oncologic outcomes of post-chemotherapy laparoscopic retroperitoneal lymph node dissection for metastatic testicular germ cell tumours**
By: Perez Reggeti J.J.¹, Vigués F.², Sanchez-Salas R.¹, Linares Espinos E.¹, Bonet X.², Vila H.², Secin F.³, Galiano M.¹, Barret E.¹, Rozet F.¹, Cathelineau X.¹
Institutes:¹Institute Mutualiste Montsouris, Dept. of Urology, Paris, France, ²Hospital Universitari De Bellvitge, Dept. of Urology, Barcelona, Spain, ³CEMIC, Dept. of Urology, Buenos Aires, Argentina
- *19 **Testicle-sparing surgery versus radical orchiectomy in the management of Leydig cell tumors: Results from a multicenter study**
By: Laclergerie F.¹, Mouillet G.², Balssa L.¹, Larré S.³, Eschwege P.⁴, Hubert J.⁴, Saussine C.⁵, Cormier L.⁶, Thiery-Vuillemin A.², Kleinclauss F.¹
Institutes:¹University of Franche-Comté, Dept. of Urology, Besançon, France, ²University of Franche-Comté, Dept. of Oncology, Besançon, France, ³University of Reims Champagne-Ardenne, Dept. of Urology, Reims, France, ⁴University of Lorraine, Dept. of Urology, Nancy, France, ⁵University of Strasbourg, Dept. of Urology, Strasbourg, France, ⁶University of Bourgogne, Dept. of Urology, Dijon, France
- *20 **Pazopanib in patients (pts) with advanced germ cell tumors (GCT): Results from an open-label, single-group, phase 2 trial (Pazotest-01)**
By: Necchi A.¹, Raggi D.¹, Giannatempo P.¹, Calareso G.², Togliardi E.³, Nicolai N.⁴, Crippa F.⁵, Mariani L.⁶, Salvioni R.⁴

Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, ³Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pharmacy, Milan, Italy, ⁴Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, ⁵Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Nuclear Medicine, Milan, Italy, ⁶Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Clinical Epidemiology and Trials Organization, Milan, Italy

*21

An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumours (GCT): Results at the end of first stage (FM12GCT01)

By: Necchi A.¹, Magazzu' D.², Anichini A.³, Raggi D.¹, Giannatempo P.¹, Nicolai N.⁴, Colecchia M.⁵, Paolini B.⁵, Coradeschi E.⁶, Tassi E.³, Grazia G.³, Mortarini R.³, Calareso G.⁷, Togliardi E.⁸, Crippa F.⁹, Salvioni R.⁴, Gianni A.¹, Valagussa P.⁶

Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione Michelangelo, Dept. of Statistics, Milan, Italy, ³Fondazione IRCCS - Istituto Nazionale Dei Tumori, Immunotherapy of Human Tumors, Milan, Italy, ⁴Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, ⁵Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy, ⁶Fondazione Michelangelo, Head Office, Milan, Italy, ⁷Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, ⁸Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pharmacy Unit, Milan, Italy, ⁹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Nuclear Medicine, Milan, Italy

*22

Second-line combination chemotherapy with cisplatin, gemcitabine and paclitaxel for the treatment of advanced germ cell tumours

By: Tatsuro T., Yuasa T., Hagiwara K., Sano M., Uehara S., Ogawa M., Yamasaki M., Sakura M., Masuda H., Yamamoto S., Fukui I.

Institutes:Japanese Foundation For Cancer Research, Dept. of Urology, Koto-Ku, Japan

*23

Risk stratification for venous thromboembolism in patients with testicular germ cell tumours

By: Bezan A.¹, Posch F.¹, Ploner F.¹, Bauernhofer T.¹, Pichler M.¹, Szkandera J.¹, Hutterer G.², Pummer K.², Gary T.³, Samonigg H.¹, Gerger A.¹, Stotz M.¹

Institutes:¹Medical University of Graz, Dept. of Oncology, Graz, Austria, ²Medical University of Graz, Dept. of Urology, Graz, Austria, ³Medical University of Graz, Dept. of Angiology, Graz, Austria

*24

Risk factors for thromboembolic complications in patients undergoing chemotherapy for metastatic germ cell tumors

By: Fankhauser C.¹, Beyer J.², Sander S.¹, Poyet C.¹, Sulser T.¹, Hermanns T.¹

Institutes:¹University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, ²University Hospital Zurich, Dept. of Oncology, Zurich, Switzerland

*25

Impact of bleomycin (BLM) administration on the development of pulmonary toxicity in advanced germ cell tumours (GCT) receiving first-line chemotherapy (CT): A meta-analysis of randomized studies

By: Necchi A.¹, Oualla K.², Miceli R.³, Sonpavde G.⁴, Nicolai N.⁵, Raggi D.¹, Giannatempo P.¹, Boffi R.⁶, Busia A.⁶, Mariani L.³, Salvioni R.⁵

Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Hassan II University Hospital, Dept. of Medical Oncology, Fez, Morocco, ³Fondazione IRCCS - Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, ⁴UAB Comprehensive Cancer Center, Dept. of Medical Oncology, Birmingham, United States of America, ⁵Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, ⁶Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pneumology, Milan, Italy

09:41 - 09:48

Summary and context

N. Nicolai, Milan (IT)

Best Posters EAU Regional Meetings

Poster Session EAU Regional Meetings

Saturday, 12 March
08:30 - 10:00

Location: Room 14a (ICM, Level 1)

Chairs: P. Albers, Düsseldorf (DE)
B. Djavan, Vienna (AT)

08:30 - 10:00

RM01: Autoantibody responses elicited by prostate cancer-possible biomarkers for the aggressiveness of the disease

V. Melne, Riga (LV)

08:30 - 10:00

RM02: Luminex detected antibodies are clinically relevant in pretransplant risk assessment

P. Veskimäe, Tartu (EE)

08:30 - 10:00

RM03: Is there a difference in number of interstitial cells, neurons, presence of fibrosis and inflammation in UPL tissues of patients with UPJ obstruction with and without crossing-vessel and normal subjects in humans?

A.E. Canda, Ankara (TR)

08:30 - 10:00

RM04: Lower ureteric stones treated by expulsive medical therapy: Selective α_1 -adrenergic blockers versus tadalafil plus selective α_1 -adrenergic blockers

To be confirmed

08:30 - 10:00

RM05: Survival rates of hereditary and sporadic prostate cancer patients

K. Mišulis, Mārupe (LV)

08:30 - 10:00

RM06: Evidence of bladder re-innervation following spinal cord injury via vagal nerve- fMRI study

To be confirmed

08:30 - 10:00

RM07: Outcomes following partial nephrectomy for small renal masses

A. Cekauskas, Vilnius (LT)

08:30 - 10:00

RM08: Immediate results of surgical treatment of non-muscle invasive bladder cancer using the new en bloc TURBT

I. Masanski, Minsk (BY)

08:30 - 10:00

RM09: Renal colic: Emergency department diagnostic workout and treatment

L. Redmanis, Riga (LV)

08:30 - 10:00

RM10: Methods of performing a fusion of MR and transrectal ultrasound images in prostate biopsy

J. Stejskal, Praha (CZ)

08:30 - 10:00

RM11: Changes in contemporary perioperative care in patients undergoing radical cystectomy

M. Oszczudlowski, Warsaw (PL)

08:30 - 10:00

RM12: Laparoscopic promontofixation for pelvic organ prolapse: A 3-year single center experience in a series of 60 patients

J. Dér, Budapest (HU)

08:30 - 10:00

RM13: Decision making protocol for the management of complex renal cystic masses according to the 10-years of clinical experience and meta-analysis of the current literature. Lesson learned

from the multi-institutional analysis

To be confirmed

08:30 - 10:00

RM14: Mutation analysis of EGFR signal transduction pathway in urachal carcinoma

O. Modos, Budapest (HU)

08:30 - 10:00

RM15: What urologists should know about the tuberous sclerosis complex

To be confirmed

08:30 - 10:00

RM16: Relationship between of vascular endothelial growth factor A and tumor size, degree of tumor necrosis, degree of tumor hemorrhage in clear cell renal cell carcinoma

F. Veselaj, Prishtina (KOS)

08:30 - 10:00

RM17: Does type-2 diabetes mellitus has an impact on postoperative early, mid-term and late-term urinary continence after robotic radical prostatectomy?

A.E. Canda, Ankara (TR)

08:30 - 10:00

RM18: Stone composition in patients who undergo percutaneous nephrolithotomy: Review of 123 stone analyses in Azerbaijan

V. Ismayil , Baku (AZ)

08:30 - 10:00

RM19: A study of detrusor underactivity in association with age amongst men undergoing urodynamic testing for refractory lower urinary tract symptoms or acute retention

K.V. Mytilekas, Thessaloniki (GR)

08:30 - 10:00

RM20: Results and complications of percutaneous nephrolithotomy (PCNL): Report of over 12,000 cases in Southern Iran

M.M. Hosseini, Shiraz (IR)

08:30 - 10:00

RM21: Current trends in percutaneous nephrolithotomy (PCNL)

A. Ahmed, Salmeya (KW)

Sophisticated imaging in urology

Poster Session 03

Saturday, 12 March
08:30 - 10:00

Location: Room 14b (ICM, Level 1)

Chairs: S. Kruck, Tübingen (DE)
T. Loch, Flensburg (DE)
J. Walz, Marseille (FR)

Aims and objectives of this presentation

New imaging technologies are reshaping the everyday life of urologists by providing new insights into the pathology and new tools for diagnosis and monitoring. This session discusses an abstract about these promising technologies.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *26 **Novel stepwise algorithm using CT and MRI for differential diagnosis of fat-poor angiomyolipoma in small renal masses: Development and external validation**
By: [Tanaka H.](#)¹, Fujii Y.¹, Yoshida S.¹, Yokoyama M.¹, Ishioka J.¹, Matsuoka Y.¹, Numao N.¹, Saito K.¹, Uehara S.², Yuasa T.², Yamamoto S.², Masuda H.², Yonese J.², Kihara K.¹
Institutes:¹Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan, ²Cancer Institute Hospital, Japanese Foundation For Cancer Research, Dept. of Urology, Tokyo, Japan
- *27 **Exploring the potential of fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG PET) to improve clinical decision making in patients with retroperitoneal fibrosis (RPF)?**
By: [Fernando A.](#), Horsfield C., Pattison J., D'Cruz D., O'Brien T.
Institutes:Guy's and St Thomas' NHS Trust, Dept. of Urology, London, United Kingdom
- *28 **Preliminary results of a new tool to evaluate cavernous body fibrosis following radical prostatectomy: Penile elastography**
By: [Hamidi N.](#)¹, Altinbas N.², Gokce M.¹, Süer E.¹, Yagci C.², Baltaci S.¹, Turkolmez K.¹
Institutes:¹Ankara University School of Medicine, Dept. of Urology, Ankara, Turkey, ²Ankara University School of Medicine, Dept. of Radiology, Ankara, Turkey
- *29 **Postoperative recovery of skeletal muscle mass is associated with favorable prognosis in metastatic renal cell carcinoma patients who underwent cytoreductive nephrectomy**
By: Fukushima H., Nakanishi Y., Kataoka M., Tobisu K., [Koga E.](#)
Institutes:Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan
- *30 **Magnetic resonance neurography for residual pelvic pain after synthetic vaginal mesh and/or sling removal**
By: Abraham A.¹, Chhabra A.², Scott K.³, [Zimmern P.](#)¹
Institutes:¹UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ²UT Southwestern Medical Center, Dept. of Radiology, Dallas, United States of America, ³UT Southwestern Medical Center, Dept. of PMR, Dallas, United States of America
- *31 **Generating panoramic images of the urinary bladder for the digital documentation of cystoscopy findings using Endorama®: Development and first clinical experience**
By: [Kriegmair M.](#)¹, Wittenberg T.², Ritter M.¹, Michel M-S.¹, Bolenz C.³, Bergen T.²
Institutes:¹University Medical Center Mannheim, Dept. of Urology, Mannheim, Germany, ²Fraunhofer Institut für Integrierte Schaltungen IIS, Abteilung für Bildverarbeitung und

Medizintechnik, Erlangen, Germany, ³University of Ulm, Dept. of Urology, Ulm, Germany

- *32 **Multispectral imaging allows real time dual-fluorescent guided cystoscopy in a preclinical model**
By: Kriegmair M.¹, Theuring M.², Dimitriadis N.², Grychtol B.², Deliolanis N.², Ritter M.¹
Institutes:¹University Medical Center Mannheim, Dept. of Urology, Mannheim, Germany, ²Fraunhofer-Institut, Projektgruppe für Automatisierung In Der Medizin und Biotechnologie, Mannheim, Germany
- *33 **Performance of multi-frame shear-wave elastography in the diagnostic work-up of the scrotum**
By: Marcon J.¹, Trottman M.¹, D'Anastasi M.², Stief C.G.¹, Reiser M.F.², Buchner A.¹, Clevert D.A.²
Institutes:¹University Hospital of The Ludwig-Maximilians-University of Munich, Dept. of Urology, Munich, Germany, ²University Hospital of The Ludwig-Maximilians-University of Munich, Dept. of Clinical Radiology, Munich, Germany
- *34 **Potential utility of standardized apparent diffusion coefficient value as a biomarker predicting clinical aggressiveness of bladder cancer with various MRI protocols at various institutions**
By: Yoshida S.¹, Koga F.², Fukushima H.², Nakanishi Y.², Yokoyama M.¹, Ishioka J.¹, Matsuoka Y.¹, Numao N.¹, Saito K.¹, Fujii Y.¹, Kihara K.¹
Institutes:¹Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, ²Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan
- *35 **Histogram circle Hounsfield unit assessment of stone composition compared to conventional method? A new gold standard**
By: Di Benedetto A.¹, Durner L.¹, Fan S.², Patel A.¹
Institutes:¹Royal London Hospital, Dept. of Urology, London, Italy, ²Royal London Hospital, Dept. of Nephrology, London, Italy
- *36 **Radiographic manifestations of pubic symphysis osteomyelitis in the prostate cancer survivor: Definitive diagnosis lies in findings on magnetic resonance imaging**
By: Lavien G., Zaid U., Peterson A.
Institutes:Duke University Medical Center, Dept. of Urology, Durham, United States of America
- *37 **Urethral ultrasonography – initial experience and comparison with retrograde urethrography in urethral strictures evaluation**
By: Santos Lopes S., Furtado A., Silva A., Dores J., Cardoso P., Lourenço M., Ferrito F., Carrasquinho Gomes F.
Institutes:Hospital Prof. Doutor Fernando Fonseca, Dept. of Urology, Amadora, Portugal
- 09:45 - 09:52 **Summary and context**
T. Loch, Flensburg (DE)

Experimental therapies with novel compounds in prostate cancer

Poster Session 04

Saturday, 12 March
08:30 - 10:00

Location: Room 14c (ICM, Level 1)

Chairs: F. Claessens, Leuven (BE)
T.B. Lam, Aberdeen (GB)
F.R. Santer, Innsbruck (AT)

Aims and objectives of this presentation

Clinical relevance of experimental therapy studies will be discussed and clinical relevance assessed. Targeting tumour metabolism is a novel innovative strategy for prostate cancer. The potential of novel compounds will be presented in the session.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *38 **Preventing occurrence of metastatic disease in rats with locally advanced prostate cancer by immunomodulation and vascular targeted therapy**
By: [Lindner U.](#)¹, [Preise D.](#)², [Kudinova N.](#)², [Agaronov A.](#)¹, [Salomon Y.](#)³, [Coleman J.](#)⁴, [Leibovich D.](#)¹
Institutes:¹Kaplan Medical Center, Dept. of Urology, Rehovot, Israel, ²The Weizmann Institute of Science, Dept. of Plant and Environmental Sciences, Rehovot, Israel, ³The Weizmann Institute of Science, Dept. of Biological Regulation, Rehovot, Israel, ⁴Memorial Sloan-Kettering Cancer Center, Dept. of Surgery, New York, United States of America
- *39 **Targeting cell metabolism to improve prostate cancer therapeutics**
By: [Bedaj M.](#), [Rao K.](#), [Robson C.](#), [McCracken S.](#)
Institutes:Newcastle University, Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom
- *40 **Efficacy of prostate cancer compound with novel mechanism of action targeting the DNA binding domain of the androgen receptor**
By: [Borgmann H.](#), [Dalal K.](#), [Beraldi E.](#), [Cherkasov A.](#), [Rennie P.](#), [Gleave M.](#)
Institutes:Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada
- *41 **The role of the HER2 and HER3 in prostate cancer and their potential as therapeutic targets**
By: [Rao K.](#), [Alsamrae M.](#), [Gaughan L.](#), [Robson C.](#), [McCracken S.](#)
Institutes:Newcastle University, Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom
- *42 **Targeting clusterin-associated proteins improve cellular sensitivity to taxane in prostate cancer**
By: [Takeuchi A.](#), [Shiota M.](#), [Katsunori T.](#), [Inokuchi J.](#), [Kashiwagi E.](#), [Dejima T.](#), [Yokomizo A.](#), [Eto M.](#)
Institutes:Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan
- *43 **Equol, a metabolite converted from daidzein by enterobacteria, has chemopreventive and inhibitory effects against prostate cancer**
By: [Tatsumi Y.](#)¹, [Miyake M.](#)², [Hori S.](#)², [Morizawa Y.](#)², [Nakai Y.](#)², [Anai S.](#)², [Torimoto K.](#)², [Fujii T.](#)¹, [Konishi N.](#)¹, [Fujimoto K.](#)²
Institutes:¹Nara Medical University, Dept. of Pathology, Kashihara, Japan, ²Nara Medical University, Dept. of Urology, Kashihara, Japan
- *44 **Allyl isothiocyanate induces reactive oxygen species-mediated autophagy through beclin-1 in**

human prostate cancer cells

By: Chen H-E.¹, Lin J-F.², Lin Y-C.¹, Tsai T-F.¹, Chou K-Y.¹, Hwang T.I.S.¹

Institutes:¹Shin Kong Wu Ho-Su Mem. Hospital, Dept. of Urology, Taipei, Taiwan, ²Shin Kong Wu Ho-Su Mem. Hospital, Central Laboratory, Taipei, Taiwan

*45

Simvastatin inhibits the proliferation, migration and invasion of androgen independent human prostate cancer cells via up-regulation of Annexin A10

By: Miyazawa Y., Sekine Y., Kato H., Furuya Y., Koike H., Matsui H., Shibata Y., Ito K., Suzuki K.

Institutes:Gunma University Graduate School of Medicine, Dept. of Urology, Maebashi, Japan

*46

Ability of plant extracts to reactivate epigenetically silenced genes in prostate cancer cells

By: Schagdarsurenin U., Teuchert L., Nesheim N., Wagenlehner F., Dansranjavin T.

Institutes:Justus Liebig University of Giessen, Dept. of Urology, Pediatric Urology and Andrology, Giessen, Germany

*48

Development of the first model of radical prostatectomy in mouse: A feasibility study with biochemical validation

By: Di Trapani E., Nini A., Russo A., Buono R., Dell'Oglio P., Locatelli I., Castiglione F., La Croce G., Benigni F., Montorsi F., Salonia A., Briganti A., Cavarretta I.T.

Institutes:Urological Research Institute, Irccs San Raffaele Scientific Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy

09:43 - 09:50

Summary and context

F. Claessens, Leuven (BE)

Management of trauma and emergencies in urology

Poster Session 05

Saturday, 12 March
08:30 - 10:00

Location: Room Paris (Hall B2, level 0)

Chairs: N. Lumen, Ghent (BE)
D. Ramesh, Bangalore (IN)
D.M. Sharma, London (GB)

Aims and objectives of this presentation

The aim of this session is to discuss contemporary management of trauma and emergencies in urology with a report from the Trauma Guidelines panel at the end. Plus an update on management of anterior urethral injuries or management of renal trauma

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

08:53 - 09:03

Guideline introduction on management of renal trauma

D.M. Sharma, London (GB)

09:03 - 09:13

Update on the guidelines on urethral injuries

N. Lumen, Ghent (BE)

*49

High-grade blunt renal trauma: Who should we operate? Predictors of surgery and long-term outcome of conservative management, a prospective monocentric study

By: Lanchon C., Fiard G., Descotes J-L., Rambeaud J-J., Long J-A.

Institutes: Grenoble University Hospital, Dept. of Urology, Grenoble, France

*50

Factors predicting of failure after conservative treatment in high-grade blunt renal trauma

By: Moudouni S.², Fettouh A.¹, Bounit A.², Dahami Z.², Lakmichi A.², Sarf I.²

Institutes:¹Hôpital Max Fourestier, Dept. of Urology, Nanterre, France, ²CHU MED VI, Dept. of Urology, Marrakech, Morocco

*51

Renal trauma. Analysis in our series of conservative versus surgical treatment: Management and complications

By: Blanco Chamorro C.¹, Garcia Ruiz R.², Tejero Sanchez A.², Suarez Broto M.A.², Serrano Frago P.², Fantova Alonso A.², Cabañuz Plo T.², Muñoz Rivero M.², Gil Sanz M.J.²

Institutes:¹Hospital Universitario Miguel Servet, Zaragoza, Spain, ²Hospital Universitario Miguel Servet, Dept. of Urology, Zaragoza, Spain

*52

Indwelling nephrostomy (PCN) and ureteral stents: Comparing the burden to the patients and the healthcare system

By: Aro T., Mullerad M., Badaan S., Kastin A., Naamne B., Zisman A., Assadi A., Goldin O., Amiel G.

Institutes: Rambam Health Care Campus, Dept. of Urology, Haifa, Israel

*53

Bladder irrigation with aluminum solution and transurethral coagulation would be preferable treatment option for grade 4 hemorrhage radiation cystitis: Multicenter series

By: Sugihara T.¹, Yasunaga H.², Matsui H.², Fushimi K.³, Gondo T.¹, Nakagami Y.¹, Horiguchi Y.¹, Ohno Y.¹, Namiki K.¹, Ohori M.¹, Nakashima J.¹, Tachibana M.¹, Homma Y.⁴

Institutes:¹Tokyo Medical University, Dept. of Urology, Tokyo, Japan, ²The University of Tokyo, Dept. of Clinical Epidemiology and Health Economics, Tokyo, Japan, ³Tokyo Medical and Dental University, Dept. of Health Care Informatics, Tokyo, Japan, ⁴The University of Tokyo, Dept. of Urology, Tokyo, Japan

- *54 **Hemorrhagic cystitis (HC) in patients undergoing allogeneic hematopoietic stem cell transplantation (AloHSCT): Factors involved, clinical approach and outcomes**
By: [Martinez Rodriguez R.](#)¹, [Alves De Oliveira M.J.](#)¹, [Morgades Delafe M.](#)², [Batlle M.](#)², [Calaf Perisé O.](#)¹, [Ibarz Servio L.](#)¹
Institutes:¹Hospital Universitari Germans Trias I Pujol, Dept. of Urology, Badalona, Spain, ²Institut Català D'Oncologia, Hospital Universitari Germans Trias I Pujol, Institut De Recerca Contra, Dept. of Hematology, Badalona, Spain
- *55 **Rendezvous ureteric re-alignment (RUR): Criteria for success**
By: [Philip J.](#)¹, [Collin N.](#)²
Institutes:¹Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom, ²Southmead Hospital, Dept. of Interventional Radiology, Bristol, United Kingdom
- *56 **The value of ultrasonography imaging in early treatment of penile trauma**
By: [Dell'Atti L.](#)
Institutes:University Hospital "St. Anna", Dept. of Urology, Ferrara, Italy
- *57 **Testicular injuries: Experience of 30 years**
By: [Lee Y.](#)¹, [Song Y.S.](#)², [Choi S-K.](#)¹, [Lee D-G.](#)¹, [Min G.E.](#)¹, [Lee H-L.](#)¹, [Lee S.H.](#)¹, [Jeon S.H.](#)¹, [Lee S-J.](#)¹, [Lee C-H.](#)¹, [Chang S-G.](#)¹, [Yoo K.H.](#)¹
Institutes:¹School of Medicine, Kyung Hee University, Dept. of Urology, Seoul, South Korea, ²Soonchunhyang University Hospital, Dept. of Urology, Seoul, South Korea
- *58 **Torsion of the spermatic cord. Does reality correspond with what is written in literature?**
By: [Cabañuz T.](#), [Muñoz M.V.](#), [Blanco C.](#), [Tejero A.](#), [Garcia R.](#), [Reyes A.A.](#), [Gil M.J.](#)
Institutes:Hospital Universitario Miguel Servet, Dept. of Urology, Zaragoza, Spain
- 09:53 - 10:00 **Summary and context**
D.M. Sharma, London (GB)

The importance of survivorship issues in prostate cancer

Poster Session 06

Saturday, 12 March
08:30 - 10:00

Location: Room Vienna (Hall B2, level 0)

Chairs: K. Mastris, Clayhall Ilford (GB)
G. Morgia, San Giovanni La Punta (IT)
M. Plata, Bogota (CO)

Aims and objectives of this presentation

New therapeutic strategies have produced a clear shift toward extended survival of patients with prostate cancer. Interestingly, the long-term consequences of treatments are still poorly understood in the general community. Understanding these better is the topic of this Survivorship session.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*59

Second primary tumors in prostate cancer: Data from two phase III trials

By: [Nabid A.](#)¹, Carrier N.², Vigneault E.³, Martin A-G.³, Bahary J-P.⁴, Souhami L.⁵, Duclos M.⁵, Lemaire C.⁶, Brassard M-A.⁷, Vass S.⁸, Bahoric B.⁹, Archambault R.¹⁰, Vincent F.¹¹, Nguyen-Huynh T-V.⁴

Institutes:¹Centre Hospitalier Universitaire De Sherbrooke, Dept. of Radio-Oncology, Sherbrooke, Canada, ²Centre Hospitalier Universitaire De Sherbrooke, Statistician, M.S.c., Sherbrooke, Canada, ³Centre Hospitalier Universitaire De Québec, Dept. of Radiation Oncology, Québec, Canada, ⁴Centre Hospitalier Universitaire De Montréal, Dept. of Radiation Oncology, Montréal, Canada, ⁵Centre Universitaire De Santé McGill, Dept. of Radiation Oncology, Montréal, Canada, ⁶Hopital Maisonneuve-Rosemont, Dept. of Radiation Oncology, Montréal, Canada, ⁷Centre De Santé Et Services Sociaux De Chicoutimi, Dept. of Radiation Oncology, Chicoutimi, Canada, ⁸Centre De Santé Et Services Sociaux De Chicoutimi, Dept. of Radiation Oncology, Chicoutimi, Canada, ⁹Hopital Général Juif De Montréal, Dept. of Radiation Oncology, Montréal, Canada, ¹⁰Hopital De Gatineau, Dept. of Radiation Oncology, Gatineau, Canada, ¹¹Centre Hospitalier Régional De Trois-Rivières, Dept. of Radiation Oncology, Trois-Rivières, Canada

*60

Secondary bladder cancer after anticancer therapy for prostate cancer; reduced comorbidity after androgen-deprivation therapy and increased comorbidity with smoking history

By: [Shiota M.](#)¹, Yokomizo A.¹, Takeuchi A.¹, Imada K.¹, Kiyoshima K.¹, Inokuchi J.¹, Tatsugami K.¹, Ohga S.², Nakamura K.², Honda H.², Naito S.¹, Eto M.¹

Institutes:¹Kyushu University, Dept. of Urology, Fukuoka, Japan, ²Kyushu University, Dept. of Clinical Radiology, Fukuoka, Japan

*61

Prophylactic irradiation of pelvic lymph-nodal area after prostatectomy does not increase the risk of second neoplasms: A single institution analysis of 1109 patients with 10 years follow-up

By: Sini C.², [Cozzarini C.](#)¹, Fiorino C.², Briganti A.³, Deantoni C.¹, Fodor A.¹, Fossati N.³, Gandaglia G.³, Noris Chiorda B.¹, Perna L.², Montorsi F.³, Calandrino R.², Di Muzio N.¹

Institutes:¹San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy, ²San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy, ³San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy

*62

What is the color of cancer?

By: Tatli V., [Ucer O.](#), Muezzinoglu T.

Institutes:Celal Bayar University Faculty of Medicine, Dept. of Urology, Manisa, Turkey

- *63 **Online support groups offer low-threshold backing for caregivers of patients with prostate cancer**
 By: Renner T.¹, Maatz P.¹, Muck T.¹, Ihrig A.², Huber J.¹
 Institutes:¹Medical Faculty Carl Gustav Carus, Tu Dresden, Dept. of Urology, Dresden, Germany, ²University of Heidelberg, Dept. of General Internal Medicine and Psychosomatic, Heidelberg, Germany
- *64 **When should patients undergo prostate biopsy? Decision analysis using differences in the health-related quality-of-life between pre-biopsy healthy men and patients with castration-resistant prostate cancer**
 By: Ishioaka J.¹, Masuda H.², Inoue M.¹, Itoh M.¹, Yoshida S.¹, Yokoyama M.¹, Matsuoka Y.¹, Numao N.¹, Saito K.¹, Fujii Y.¹, Kihara K.¹
 Institutes:¹Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, ²The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Dept. of Urology, Tokyo, Japan
- *65 **Effect of prostate specific antigen parameters on global quality of life in prostate cancer patients during follow-up**
 By: Kao Y-L.¹, Tsai Y-S.¹, Ou F-Y.¹, Lin Z-Y.², Ou C-H.¹, Yang W-H.¹, Chen H-L.¹, Tzai T-S.¹, Wang J-D.²
 Institutes:¹National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, ²National Cheng Kung University, Dept. of Public Health, Tainan, Taiwan
- *66 **The correlation between retrograde leak point pressure and 24-hour pad weight for men with post prostatectomy incontinence**
 By: Solomon E., Malde S., Pakzad M., Hamid R., Shah J., Greenwell T.J., Ockrim J.
 Institutes:University College London Hospitals, Dept. of Urology, London, United Kingdom
- *67 **The impact of subsequent metastases on survival and medical costs in prostate cancer patients**
 By: Li T.¹, Shore N.D.², Mehra M.³, Todd M.⁴, Saadi R.¹, Leblay G.⁵, Griffiths R.⁶
 Institutes:¹Janssen Global Services, Health Economics and Global Market Access, Raritan, United States of America, ²Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, United States of America, ³Janssen Global Services, Market Access Analytics and Policy, Raritan, United States of America, ⁴Janssen Global Services, Medical Affairs, Raritan, United States of America, ⁵Janssen Global Services, Global Oncology Strategy, Raritan, United States of America, ⁶Boston Health Economics, Health Services Consulting, Waltham, United States of America
- *68 **Initial experience of an algorithm-based protocol for the community follow-up of men with stable prostate cancer**
 By: Goodall P.¹, Little J.¹, Robinson E.¹, Trimble I.², Cole O.³, Walton T.¹
 Institutes:¹Nottingham City Hospital, Dept. of Urology, Nottingham, United Kingdom, ²Nottingham City Clinical Commissioning Group, Dept. of Clinical Commissioning, Nottingham, United Kingdom, ³Medical Specialist Group, Dept. of Urology, Guernsey, United Kingdom
- *69 **Prospective evaluation of erectile function during four years after brachytherapy in men with low risk prostate cancer and baseline IIEF5 > 16**
 By: Schoentgen N.¹, Delage F.¹, Perrouin-Verbe M-A.¹, Coquet J-B.¹, Malhaire J-P.², Fournier G.¹, Valeri A.¹
 Institutes:¹Brest University Hospital, Dept. of Urology, Brest, France, ²Brest University Hospital, Dept. of Radiotherapy, Brest, France
- *70 **Osteoporosis among men with prostate cancer during treatment with androgen deprivation therapy**
 By: Poulsen M.H.¹, Frost M.², Abrahamsen B.³, Gerke O.⁴, Walter S.¹
 Institutes:¹Odense University Hospital, Dept. of Urology, Odense C, Denmark, ²Odense University Hospital, Dept. of Endocrinology and Metabolism, Odense C, Denmark, ³Holbæk Hospital, Dept. of Medicine and Endocrinology, Holbæk, Denmark, ⁴Odense University Hospital, Dept. of Nuclear Medicine, Odense C, Denmark

*71

Morbidity, mortality and costs of treatment for locally advanced prostate cancer: A population-based analysis comparing radical prostatectomy and external beam radiation

By: Meyer C.¹, Feldman A.², Sanchez A.², Reznor G.¹, Hanske J.¹, Hanna N.¹, Kibel A.¹, Sammon J.³, Cole A.¹, Leow J.¹, Sun M.¹, Trinh Q-D.¹

Institutes:¹Brigham and Women's Hospital, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Massachusetts General Hospital, Dept. of Urology, Boston, United States of America, ³Henry Ford Hospital, Vatikutti Urology Institute, Boston, United States of America

Kidney donors: Different types, different surgical approaches

Poster Session 07

Saturday, 12 March
08:30 - 10:00

Location: Room London (Hall B2, level 0)

Chairs: G. Carrieri, Bari (IT)
A. Chkhotua, Tbilisi (GE)
C. Terrone, Novara (IT)

Aims and objectives of this presentation

To review the latest updates on outcomes of kidney transplant from different types of kidney donors with special remarks on surgical approaches.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *72 **Kidney transplantation from donors after circulatory determination of death: Evaluation prognostic factors for delayed graft function and graft survival**
By: [Medina Polo J.](#)¹, [García-González L.](#)¹, [Justo-Quintas J.](#)¹, [Gil-Moradillo J.](#)¹, [Guerrero-Ramos F.](#)¹, [Pamplona-Casamayor M.](#)¹, [De La Rosa-Kehrmann F.](#)¹, [Rodríguez-Antolín A.](#)¹, [Duarte-Ojeda J.M.](#)¹, [Tejido-Sánchez A.](#)¹, [Villacampa-Aubá F.](#)¹, [Andrés-Belmonte A.](#)², [Passas-Martínez J.B.](#)¹
Institutes:¹Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ²Hospital Universitario 12 de Octubre, Dept. of Nephrology, Madrid, Spain
- *73 **Survival of kidney transplants from uncontrolled DCD donors under normothermic preservation: Are they as good as DBD kidneys?**
By: [Guerrero Ramos F.](#)¹, [Cavero Escribano T.](#)², [Rodríguez Antolín A.](#)¹, [Pamplona Casamayor M.](#)¹, [Tejido Sánchez A.](#)¹, [De La Rosa Kehrmann F.](#)¹, [Villacampa Aubá F.](#)¹, [Medina Polo J.](#)¹, [Andrés Belmonte A.](#)², [Passas Martínez J.B.](#)¹
Institutes:¹"12 De Octubre" University Hospital, Dept. of Urology, Madrid, Spain, ²"12 De Octubre" University Hospital, Dept. of Nephrology, Madrid, Spain
- *74 **Maastricht 2 DCD donors with normothermic recirculation: A valuable source for organs to transplant**
By: [Peri Cusi L.](#)¹, [Toranzo F.](#)¹, [Ruiz A.](#)², [Musquera Felipe M.](#)¹, [De Souza E.](#)³, [Alcaraz Asensio A.](#)¹
Institutes:¹Hospital Clínic De Barcelona, Dept. of Urology, Barcelona, Spain, ²Hospital Clínic De Barcelona, Dept. of Transplant Coordination, Barcelona, Spain, ³Hospital Clínic De Barcelona, Dept. of Kidney Transplant, Barcelona, Spain
- *75 **Early results of a controlled non-heart-beating kidney donor programme (Maastricht type III)**
By: [Cámara Moreno C.](#)¹, [Francés Comalat A.](#)¹, [Pérez Sáez M.J.](#)², [Henao Macaya S.](#)¹, [Zapatero Ferrándiz A.](#)³, [Abascal Junquera J.M.](#)¹, [Fumadó Ciutat Ll.](#)¹, [Pascual Santos J.](#)², [Cecchini Rosell Ll.](#)¹
Institutes:¹Hospital Del Mar, Dept. of Urology, Barcelona, Spain, ²Hospital Del Mar, Dept. of Nephrology, Barcelona, Spain, ³Hospital Del Mar, Dept. of Intensive Care, Barcelona, Spain
- *76 **Renal transplantation with donors older than 70 years**
By: [Sousa Dinis P.J.](#), [Marconi L.](#), [Nunes P.](#), [Figueiredo A.](#), [Parada B.](#), [Moreira P.](#), [Bastos C.](#), [Roseiro A.](#), [Dias V.](#), [Rolo F.](#), [Mota A.](#)
Institutes:Hospitais da Universidade de Coimbra, Dept. of Urology and Renal Transplantation, Coimbra, Portugal
- *77 **How old is old? Survival analysis of kidney transplantation from extremely old donors (≥ 80 years-old)**

By: Vila Reyes H.¹, Riera Canals L.¹, Cocera Rodriguez R.¹, Fernandez-Concha Schwalb J.J.¹, Bestard Matamoros O.², Suarez Novo J.F.¹, Vigués Julià F.¹
Institutes:¹Hospital Universitari De Bellvitge, Dept. of Urology, Hospitalet De Llobregat, Spain, ²Hospital Universitari De Bellvitge, Dept. of Nephrology, Hospitalet De Llobregat, Spain

*78

Total laparoscopic donor nephrectomy in 500 consecutive cases: Lessons learnt and future developments

By: Veeratterapillay R., Rogers A., Bryant D., Bailie J., Dosani T., Russel K., Talbot D., Sen G., Page T., Soomro N., Rix D.
Institutes:Freeman Hospital, Dept. of Urology, Newcastle upon Tyne, United Kingdom

*79

Surgical evolution and results in living related kidney donation after 500 cases

By: Peri L., Musquera Felip M., Ribal M.J., Huguet J., Alvarez-Vijande R., Alcaraz A.
Institutes:Hospital Clínic de Barcelona, Dept. of Urology, Barcelona, Spain

*80

Laparoscopic living donor nephrectomy: Predictors of warm ischemia time and consequences for the transplant

By: Benoit T.¹, Roumiguie M.², Beauval J.B.², Doumerc N.², Sallusto F.², Soulie M.², Rischmann P.², Kamar N.², Game X.²
Institutes:¹Dept. of Urology, Toulouse, France, ²CHU Rangueil, Dept. of Urology, Toulouse, France

*82

CT-based renal volume predicts the renal function of post-transplant living donors

By: Yoichi K., Imamura R., Nakazawa S., Yamanaka K., Abe T., Nonomura N.
Institutes:Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Japan

*83

Does CT-measured renal cortex volume influence renal function in living kidney donors?

By: Keito S., Okamoto K., Ozaki K., Tsujioka T., Iio H., Nishimura K., Hujikata S., Tanimoto S., Yamashi S., Kan M.
Institutes:Ehime Prefectural Central Hospital, Dept. of Urology, Matsuyama, Japan

*84

Robotic-assisted laparoscopic donor nephrectomy with transvaginal extraction of the kidney

By: Champy C.¹, Salomon L.¹, Cholley I.¹, Hoznek A.¹, Yiou R.¹, Vordos D.¹, Grimbert P.², Lang P.², De La Taille A.¹
Institutes:¹Hôpitaux Universitaires Henri Mondor, Dept. of Urology, Creteil, France, ²Hôpitaux Universitaires Henri Mondor, Dept. of Nephrology, Creteil, France

*85

Living donor nephrectomy: A multicentric comparative study between standard laparoscopic and robot-assisted laparoscopic donor nephrectomy

By: Pradere B.¹, Benoit T.², Peyronnet B.³, May A.⁴, Beauval J.B.², Roumiguie M.², Sallusto F.², Rischmann P.², Soulié M.², Gamé X.², Bruyère F.⁴
Institutes:¹CHU de Tours, Hospital Bretonneau, Dept. of Urology, Tours, France, ²CHU Toulouse Rangueil, Dept. of Urology, Toulouse, France, ³CHU Rennes, Dept. of Urology, Rennes, France, ⁴CHU Tours, Dept. of Urology, Tours, France

ESU/ESFFU Hands-on training in OnabotulinumtoxinA administration for OAB

HOT 12

Saturday, 12 March
09:00 - 10:30

Location: Room Europe (Hall B0, level 0)

Chair: H. Hashim, Bristol (GB)

Aims and objectives of this presentation

Botulinum toxin type A administration in Urology has become common practice over the last two decades. Following the completion of Phase 3 registration trials in OAB, OnabotulinumtoxinA received marketing approval for this indication and now has a standardised injection paradigm. This course is procedure-focused, and will teach attendees the practicalities of OnabotulinumtoxinA administration through short lectures, videos and hands-on demonstrations using bladder models. Attendees will learn how to reconstitute the product and see different types of equipment available.

R. Bauer, Munich (DE)
A. Sahai, London (GB)
AGM Garcia Mora

ESU/ESUT Hands-on training with Thulium laser for vaporesection of prostate

HOT 53

Saturday, 12 March
09:00 - 10:30

Location: Room Africa (Hall B0, level 0)

Chair: T. Bach, Hamburg (DE)

Aims and objectives of this presentation

This hands on training course is to introduce the trainee into the laser tissue interaction of the Thulium 2 micron continuous wave laser with the use of two different training stations. In the first workstation the trainee will try the laser on cadaver tissue submersed in water. The second setting resembles the Thulium Laser Vaporesection of Prostate on a training device.

Aims and objectives:

- The trainee will understand the tissue vaporization effect by the Thulium 2 micron continuous wave laser, the limited depth of tissue damage and how to vaporize and to perform a cut in tissue.
- The trainee also may cut the sample tissue by cold knife for visual inspection of the tissue damage zone.
- The trainee is challenged to introduce the laser resectoscope into the artificial organ of the training device, maneuver the resectoscope in the artificial prostatic urethra and to vaporize and cut tissue samples.

I. Kyriazis, Athens (GR)

C. Netsch, Hamburg (DE)

ESU/ESFFU Hands-on Training in Urodynamics

HOT 39

Saturday, 12 March
09:00 - 12:00

Location: Room North America (Hall B0, level 0)

Chair: G. Van Koeveringe, Maastricht (NL)

Aims and objectives of this presentation

- The participants will be trained in both indications / applications for urodynamic testing and practical aspects of the Urodynamic tests.
- The emphasis will be on practical aspects including:
 - how to perform a good urodynamic assessment (Good Urodynamic Practice)
 - how to use equipment properly and which equipment can be used.
 - interpretation of traces,
 - quality control and trouble-shooting.

All in an Interactive "hands-on" environment

- Individual needs will be addressed in small groups, recorded tests will be used and access to equipment is provided to be able to simulate the clinical setting as much as possible.
- In a short plenary session the participants will be informed on current and future urodynamic indications and specialized urodynamic tests
- All the speakers are subject matter experts in Urodynamics and have extensive, hands-on Urodynamics teaching experience and numerous publications to their credit.

The course aims to provide the delegates with both knowledge of urodynamic indications and practical experience to be able to recognize and use the additional value of urodynamic measurements.

09:00 - 12:00

Indications for Urodynamics in Males, Females, children and Neurourology

P.E. Van Kerrebroeck, Maastricht (NL)

09:00 - 12:00

Hands on experience

M. Gray, Charlottesville (US)

09:00 - 12:00

Conducting a typical urodynamic study

R. Kirschner-Hermanns, Aachen (DE)

09:00 - 12:00

Physical aspects of UDS Testing

T. Mckinney, Fort Lauderdale (US)

09:00 - 12:00

Urodynamic assessment of voiding

P.F.W.M. Rosier, Nijmegen (NL)

09:00 - 12:00

Additional urodynamic techniques (Video, Mobile)

G. Van Koeveringe, Maastricht (NL)

09:00 - 12:00

The role of urodynamics in clinical decision making

G. Van Koeveringe, Maastricht (NL)

09:00 - 12:00

interactive discussion Q & A

ESU/ESUT Hands-on training in Laparoscopic suturing (anastomosis)

HOT 01

Saturday, 12 March
09:00 - 10:30

Location: Room South America (Hall B0, level 0)

Chair: R.E. Sanchez Salas, Paris (FR)

Aims and objectives of this presentation

The aim of this advanced laparoscopic suturing course is to develop skill and knowledge about laparoscopic suturing.

Supported by experienced laparoscopist and state of the art Laparoscopic technology, you can improve your suturing skills, shorten your learning curve with the help of HD vision and practice an anastomosis. An intermediate level in laparoscopy is mandatory for this course.

- A. Sempere Gutierrez, Murcia (ES)
- E. Gallyamov, Moscow (RU)
- G. Pini, Cologno Monzese (MI) (IT)
- T. Tokas, Hall In Tirol (AT)
- D. Veneziano, Minneapolis (US)

ESU/ERUS Hands-on training in Robotic surgery

HOT 08

Saturday, 12 March
09:30 - 11:00

Location: Room Asia (Hall B0, level 0)

Chair: M. Naudin, Hyon (BE)

Aims and objectives of this presentation

The European School of Urology (ESU) and the EAU Robotic Urology Section (ERUS) offer an intensive hands-on training course. We will provide training using simulators. The main aims of this 90 minutes course are: improving the participants' control-skills and hand-eye-coordination, as well as an objective benchmarking of console performance and an introduction into standardized surgical steps in robot-assisted procedures.

To be confirmed
I.C. Acar, Ankara (TR)

YUORDay16 (EAU Young Urologists Office & European Society of Residents in Urology ESRU)

Special Session

Saturday, 12 March
10:00 - 17:00

Location: Room Madrid (Hall B2, level 0)

Chairs: G. Patruno, Rome (IT)
J.P.M. Sedelaar, Nijmegen (NL)

Aims and objectives of this presentation

This session is intended for residents, a training-based session in which residents are protagonists.

Although main topics have been selected specifically for younger urologists and residents, we believe that they can also be useful for more experienced colleagues.

Moreover, this year is ESRU's 25th anniversary.

10:00 - 10:15

Introduction

G. Patruno, Rome (IT)
J.P.M. Sedelaar, Nijmegen (NL)

10:15 - 11:00

What residents need to know about the EAU organisation

Moderators: T.B. Pedersen, Vejle (DK)
S. Sarikaya, Ankara (TR)

10:15 - 10:25

EAU Regional Office

B. Djavan, Vienna (AT)

10:25 - 10:35

European School of Urology

J. Palou, Barcelona (ES)

10:35 - 10:45

European Research Foundation

P.F.A. Mulders, Nijmegen (NL)

10:45 - 11:00

EAU Patient Information project

T. Bach, Hamburg (DE)

11:00 - 12:30

European Urology Scholarship Programme (EUSP) Session

Moderators: V.G. Mirone, Naples (IT)
J.P.M. Sedelaar, Nijmegen (NL)

11:00 - 11:15

A great research opportunity for young urologists

M.J. Ribal, Barcelona (ES)

11:15 - 11:30

How to write a successful EUSP application

J.A. Schalken, Nijmegen (NL)

11:30 - 11:45

Partnership between EBU & EUSP

S.C. Müller, Bonn (DE)

11:45 - 12:00 **How YAU can assist in increasing young urologists' interest in research**
M.S. Silay, Istanbul (TR)

12:00 - 12:15 **Experience of an EUSP Scholar**
M.A. Behrendt, Basel (CH)

12:15 - 12:30 **Best Scholar Award winner**
V.G. Mirone, Naples (IT)

12:30 - 13:00 **Campbell Team Challenge Quiz**

Quizmasters: Á.C. Rosecker, Budapest (HU)
M. Schmid, Göttingen (DE)
M.J. Ribal, Barcelona (ES)

13:00 - 14:40 **Surgery: Tips and tricks**

Moderators: P. Uvin, Leuven (BE)
J.L. Vasquez, Copenhagen (DK)

13:00 - 13:25 **Minimal invasive male urinary incontinence surgery**
E. Finazzi Agrò, Rome (IT)

13:25 - 13:50 **TURP**
L. Martínez-Piñeiro, Madrid (ES)

13:50 - 14:15 **TRUS and MR guided prostate biopsy**
N. Nørgaard, Virum (DK)

14:15 - 14:40 **Penile emergencies: fractures and priapism**
A. Kadioglu, Istanbul (TR)

14:40 - 14:55 **Celebrating 25 years of ESRU**
C.R. Chapple, Sheffield (GB)

14:55 - 16:00 **Old school versus new school, which is the best?**

Moderators: D. Duijvesz, Rotterdam (NL)
J. Gómez Rivas, Madrid (ES)

14:55 - 15:30 **Treatment of benign large prostates**

Panel: F.M.J. Debruyne, Arnhem (NL)
P. Schatteman, Dilbeek (BE)

15:30 - 16:00 **Radical cystectomy**

Panel: J. Bjerggaard Jensen, Århus N (DK)
J. Palou, Barcelona (ES)

16:00 - 16:45

We are not supermen: "Scrubs" session

Moderators: M. Stepanchenko, Chernivtsi (UA)
A. Urkmez, Istanbul (TR)

16:00 - 16:15

Delivering bad news

N.W. Clarke, Manchester (GB)

16:15 - 16:30

Novel therapies in mCRPC

P. Sooriakumaran, Oxford (GB)

16:30 - 16:45

Practise, practise, practise: Latest developments in simulation training

D. Veneziano, Reggio Calabria (RC) (IT)

16:45 - 17:00

Prizes and awards

Moderator: G. Patruno, Rome (IT)

17:00 - 17:00

Residents group picture

Andrology: Today and tomorrow

Joint meeting of the EAU Section of Andrological Urology (ESAU) and the European Academy of Andrology (EAA)

Saturday, 12 March
10:15 - 14:00

Location: Room Stockholm (Hall B2, level 0)

Chairs: C. Krausz, Florence (IT)
W. Weidner, Giessen (DE)

Aims and objectives of this presentation

This joint ESAU section and EAA (European Academy of Andrology) session will provide a comprehensive update on topics interesting for andrologist world-wide. Furthermore, selected items identified as hot topics for the future andrological clinical work, will be presented by different European experts.

The session offers as highlight a state-of-the-art presentation on the role of genetics in the management of the infertile couple and an interdisciplinary sub session on the treatment of azoospermia in an infertile partnership. A different aspect is the role of infertility and hypogonadism as cofactor for morbidity and mortality of the male. All these topics will be addressed by key international experts and opinion leaders, separate moderators will debate important questions from the audience which are thoroughly discussed.

The session will be completed by lectures on medical and surgical developments in the treatment of sexual dysfunction, local therapy of Peyronie's disease and the use of robotics in andrological surgery.

To complete this joint ESAU-EAA session, the delegates will be informed on current issues in andrology and relevant future aspects for men's health, sexual dysfunction and infertility.

10:15 - 10:25

Welcome and introduction: Two organisations, one issue

C. Krausz, Florence (IT)
W. Weidner, Giessen (DE)

10:25 - 11:05

Morbidity and mortality in infertility and hypogonadism

Moderators: H. Behre, Halle (DE)
G.R. Dohle, Rotterdam (NL)

10:25 - 10:40

Infertility as marker of morbidity and mortality

A. Giwercman, Malmö (SE)

10:40 - 10:45

Discussion

10:45 - 11:00

Hypogonadism as marker of morbidity and mortality

M. Dinkelman-Smit, Rotterdam (NL)

11:00 - 11:05

Discussion

11:05 - 11:45

Optimised treatment of azoospermia: A couple's problem

Moderators: Z. Kopa, Budapest (HU)
N. Sofikitis, Ioannina (GR)

11:05 - 11:20 **Refertilisation and sperm retrieval: State-of-the-art and future improvement**
S.S. Minhas, London (GB)

11:20 - 11:25 **Discussion**

11:25 - 11:40 **Aspects of a reproductive specialist**
H. Tournaye, Brussels (BE)

11:40 - 11:45 **Discussion**

11:45 - 12:05 **State-of-the-art lecture Does genetics improve the management of the infertile couple?**

Moderator: A. Giwercman, Malmö (SE)

11:45 - 12:05 **State-of-the-art lecture**
C. Krausz, Florence (IT)

12:05 - 13:05 **Highlights in the treatment of sexual dysfunction**

Moderators: A. Kadioglu, Istanbul (TR)
E.J.H. Meuleman, Amsterdam (NL)

12:05 - 12:20 **New Drugs**
F. Fusco, Naples (IT)

12:20 - 12:25 **Discussion**

12:25 - 12:40 **Surgical therapy**
D.J. Ralph, London (GB)

12:40 - 12:45 **Discussion**

12:45 - 13:00 **Penile elongation: Do conservative methods work?**
C. Bettocchi, Bari (IT)

13:00 - 13:05 **Discussion**

13:05 - 13:55 **Hot topics in andrology: New developments, snapshots and breaking news**

Moderators: C. Bettocchi, Bari (IT)
A. Kadioglu, Istanbul (TR)

13:05 - 13:20 **Sexuality in adolescents with congenital urological diseases**
D.N. Wood, London (GB)

13:20 - 13:25 **Discussion**

13:25 - 13:35 **Collagenase in Peyronie's disease**
P. Verze, Naples (IT)

13:35 - 13:40 **Discussion**

13:40 - 13:50 **Robotics in andrological surgery**
S. Elzanaty

13:50 - 13:55 **Discussion**

13:55 - 14:00 **Closure**
C. Krausz, Florence (IT)
W. Weidner, Giessen (DE)

Management of stones: How did advancing technology, better evaluation and increased collaboration change our traditional approach?

Meeting of the EAU Section of Urolithiasis (EULIS)

Saturday, 12 March
10:15 - 14:00

Location: Room 1 (ICM, Level 0)

Chair: K. Sarica, Istanbul (TR)

Aims and objectives of this presentation

Contemporary management concepts of stone disease have changed significantly as a result of the enormous technological developments in the last 10-15 years. The main management concept remains bringing the patients into a completely stone-free status by using minimally invasive management alternatives. However, a well-planned treatment strategy which includes accurate imaging studies and recurrent prophylaxis based on a well-planned metabolic evaluation are also important steps to be considered for a successful and complication-free outcome.

Moreover, close collaboration between the disciplines involved (among which the nephrologic approach to stone-forming patients is the most crucial) is essential in obtaining the desired ultimate success, particularly in recurrent and complex cases.

Thus, in this EULIS session we will take a close look at recent developments in the field, particularly in imaging of stone disease. In addition, we will try to focus on the importance of close collaboration with other disciplines, particularly with regard to the changing concepts in both medical and surgical management of urolithiasis, from nephrologists' as well as urologists' perspectives.

10:15 - 10:20

Introduction

K. Sarica, Istanbul (TR)

10:20 - 11:05

Non-surgical management of stones: Neglected, underestimated but highly important!

Moderators

J. Galan, Elche (ES)
P. Honeck, Bensheim (DE)
S. Oehlschläger, Dresden (DE)

10:20 - 10:35

Recurrence metaphylaxis: Are we successful?

M. Straub, Munich (DE)

10:35 - 10:50

Is any special beverage likely to matter apart from water?

R. Siener, Bonn (DE)

10:50 - 11:05

Herbal medicine in the management of stones

R.J. Unwin, London (GB)

11:05 - 11:45

Difficult cases in stone management: Tips and tricks from the experts

Moderator:

C. Türk, Vienna (AT)

G. Gambaro, Rome (IT)
P.A. Geavlete, Bucharest (RO)

S. Hayek, Cambridge (GB)
T. Knoll, Sindelfingen (DE)
A.Y. Muslumanoglu, Istanbul (TR)

11:45 - 12:25

1-2 cm medium sized lower pole stone: How I do it? Tips and tricks with video presentations

Moderators: A. Hoznek, Creteil (FR)
I. Saltirov, Sofia (BG)
A. Trinchieri, Lecco (IT)

11:45 - 11:55

Flexible URS

O. Traxer, Paris (FR)

11:55 - 12:05

Mini-PNL

S. Lahme, Pforzheim (DE)

12:05 - 12:15

Ultra-mini PNL

J. Desai, Ahmedabad (IN)

12:15 - 12:25

Micro-PNL

E. Montanari, Milan (IT)

12:25 - 13:10

Evolving modalities in imaging and evaluation of stone disease: From preoperative evaluation to decision making and follow-up

Moderators: K.H. Andreassen, Frederiksberg (DK)
T. Bach, Hamburg (DE)
G. Wendt-Nordahl, Sindelfingen (DE)

12:25 - 12:40

From plain X-ray to Micro-CT in stone disease: A critical evaluation from practical aspects

A. Neisius, Mainz (DE)

12:40 - 12:50

Role of the new endoscopes in the metabolic evaluation of renal stone formers

A. Papatsoris, Athens (GR)

12:50 - 13:00

"Definition of success" after stone removal procedures: Methods for assessment and follow-up

C.C. Seitz, Vienna (AT)

13:00 - 13:10

Assessment of metabolic risk index: It is more practical and reliable than ever!

D.J. Kok, Rotterdam (NL)

13:10 - 13:40

Management of staghorn stones: Are endourological approaches sufficient in all cases?

Moderators: J.M. Reis Santos, Lisbon (PT)
A. Skolarikos, Athens (GR)
A. Szendrői, Budapest (HU)

13:10 - 13:20

PNL: Satisfactory results are possible in all cases!

E. Liatsikos, Filothei, Athens (GR)

13:20 - 13:30

ECIRS: The best way for a completely stone free status with a smaller number of punctures

C.M. Scoffone, Turin (IT)

13:30 - 13:40	Open surgery: Somehow forgotten but efficient for a better stone free status in selected cases! H-M. Fritsche, Regensburg (DE)
13:40 - 14:00	Nephro-urology "collaboration" panel Moderators: P.J.S. Osther, Fredericia (DK) K. Sarica, Istanbul (TR)
13:40 - 13:50	What do the nephrologists expect from urologists G. Gambaro, Rome (IT)
13:50 - 14:00	What do the urologists expect from nephrologists N.N-P. Buchholz, Ilford (GB)
14:00 - 14:00	Announcements and final remarks K. Sarica, Istanbul (TR)

Uro-genital reconstructive surgery: Personal tips and tricks

Meeting of the EAU Section of Genito-Urinary Reconstructive Surgeons (ESGURS)

Saturday, 12 March
10:15 - 15:45

Location: Room Milan (Hall B2, level 0)

Chair: R.P. Djinovic, Belgrade (RS)

Aims and objectives of this presentation

In the time when the most "classical" urological procedures become widely standardized, uro-genital reconstructive surgery still remains at the developing level and present challenge throughout the world.

In our session we will try to show the experience of leading experts through presentation of their tips and tricks and panel discussions of challenging cases. We are welcoming all colleagues interested in this field and hope that our session will help them to improve every-day work and the level of patient-care.

10:15 - 10:20

Welcome and introduction

R.P. Djinovic, Belgrade (RS)

10:20 - 11:25

Urethral reconstruction: Tips and tricks

Moderators: D.E. Andrich, Kingston upon Thames (GB)
E. Palminteri, Arezzo (IT)

10:20 - 10:35

Anterior urethra reconstruction: Tips and tricks

G. Barbagli, Sesto Fiorentino (IT)

10:35 - 10:50

Bulbar urethra reconstruction: Tips and tricks

M. Fisch, Hamburg (DE)

10:50 - 11:05

Posterior urethra reconstruction: Tips and tricks

A.R. Mundy, London (GB)

11:05 - 11:25

Urethral stricture: Case presentations

D.E. Andrich, Kingston upon Thames (GB)
R. Dahlem, Hamburg (DE)
R. Olianas, Voegelsen (DE)
E. Palminteri, Arezzo (IT)

11:25 - 12:15

Penile implant surgery: Tips and tricks

Moderators: R.P. Djinovic, Belgrade (RS)
F. Colombo, Milan (IT)

11:25 - 11:40

Penile implant: Tips and tricks

I. Moncada, Madrid (ES)

11:40 - 11:55

Re-Do penile implants: Tips and tricks

D.J. Ralph, London (GB)

11:55 - 12:15

Implant complications: Case presentations

C. Bettocchi, Bari (IT)
F. Colombo, Milan (IT)
A. Faix, Montpellier (FR)
O.R. Sedigh, Castleroy, Limerick (IE)

12:15 - 13:05

Incontinence surgery: Tips and tricks

Moderators: E. Kocjancic, Chicago (US)
I. Moncada, Madrid (ES)

12:15 - 12:25

AUS: Tips and tricks

K-D. Sievert, Salzburg (AT)

12:25 - 12:35

Re-Do AUS: Tips and tricks

R. Dahlem, Hamburg (DE)

12:35 - 12:50

Male sling - primary and re-do: Tips and tricks

O. Shenfeld, Jerusalem (IL)

12:50 - 13:05

Incontinence surgery: Case presentations

E. Kocjancic, Chicago (US)
J. Romero-Otero, Madrid (ES)
O. Shenfeld, Jerusalem (IL)

13:05 - 14:00

Peyronies surgery: Tips and tricks

D.J. Ralph, London (GB)
A. Shamsodini Takhtei, Doha - Waab (QA)

13:05 - 13:15

Peyronies - plicating surgery: Tips and tricks

N. Tomada, Porto (PT)

13:15 - 13:30

Peyronies - grafting surgery: Tips and tricks

C. Bettocchi, Bari (IT)

13:30 - 13:40

Peyronies: Conservative treatment

J.I. Martínez Salamanca, Madrid (ES)

13:40 - 14:00

Peyronies surgery: Case presentations

C. Bettocchi, Bari (IT)
G. Garaffa, London (GB)
S. Sansalone, Rome (IT)

N. Tomada, Porto (PT)

14:00 - 14:40

Congenital anomalies and penile cancer: Tips and tricks

Moderators: R. Olianas, Voegelsen (DE)
D.N. Wood, London (GB)

14:00 - 14:15

Primary hypospadias in adults: Tips and tricks

P. Hoebeke, Gent (BE)

14:15 - 14:30

Re-Do hypospadias in adults: Tips and tricks

S. Sansalone, Rome (IT)

14:30 - 14:40

Penile cancer – organ preserving surgery: Tips and tricks

M. Sohn, Frankfurt (DE)

14:40 - 15:15

Gender dysphoria: Tips and tricks

Moderators: N. Morel Journal, Lyon (FR)
M. Sohn, Frankfurt (DE)

14:40 - 14:55

M2F: Tips and tricks

C. Trombetta, Trieste (IT)

14:55 - 15:05

F2M: Radial forearm flap total phalloplasty

N. Lumen, Ghent (BE)

15:05 - 15:15

F2M: Latissimus dorsi flap total phalloplasty

R.P. Djjinovic, Belgrade (RS)

15:15 - 15:40

Upper tract reconstruction: Tips and tricks

Moderators: K.G.W. Månsson, Lund (SE)
V. Pansadoro, Rome (IT)

15:15 - 15:25

Ureteral reconstruction: Robotic and laparoscopic approach

S. Deger, Ostfildern (DE)

15:25 - 15:40

Neobladder formation: Tips and tricks

H. Abol-Enein, Mansoura (EG)

15:40 - 15:45

Conclusion

R.P. Djjinovic, Belgrade (RS)

Oligometastatic cancer: Yet another disease stage?

Joint meeting of the EAU Section of Urological Imaging (ESUI), the EAU Section of Uropathology (ESUP) and the EAU Section of Urological Research (ESUR)

Saturday, 12 March
10:15 - 14:00

Location: Room 14a (ICM, Level 1)

Chairs: K. Junker, Homburg (DE)
R. Montironi, Torrette di Ancona (IT)
J. Walz, Marseille (FR)

Aims and objectives of this presentation

Metastases to lymph nodes (LNs) represent an unfavorable prognostic factor in patients with prostate cancer. The metastatic detection rate can vary according to the approach adopted in the microscopic analysis, which includes frozen section examination, total inclusion of the tissue with and without whole mount sections, serial sectioning, and application of immunohistochemistry. The aims & objectives for this session are an update on the histopathological evaluation of LND specimens, and focus is made on their clinical and prognostic significance.

10:15 - 10:20

Introduction

K. Junker, Homburg (DE)
R. Montironi, Torrette di Ancona (IT)
J. Walz, Marseille (FR)

10:20 - 11:26

What is oligometastatic disease?

Moderators: H.U. Ahmed, London (GB)
A. Bjartell, Malmö (SE)
R. Montironi, Torrette di Ancona (IT)

10:20 - 10:28

Metastatic disease equals non metastatic disease: Definition of oligometastatic disease

A. Briganti, Milan (IT)

10:28 - 10:31

Discussion

10:31 - 10:39

Why should we consider oligometastatic disease as a different disease stage?

G. De Meerleer, Ghent (BE)

10:39 - 10:42

Discussion

10:42 - 10:50

The "dormant" metastasis: Myth or truth?

L.R. Languino, Philadelphia (US)

10:50 - 10:53

Discussion

10:53 - 11:01

Exosomes in metastatic urological cancers: What is their prognostic meaning?

G. Jenster, Rotterdam (NL)

11:01 - 11:04

Discussion

- 11:04 - 11:12 **Was PET imaging the door opener for oligometastatic disease?**
J. Walz, Marseille (FR)
- 11:12 - 11:15 **Discussion**
- 11:15 - 11:23 **Hype or true need ? The EAU Guidelines Office point of view on oligometastatic cancer**
J. N'Dow, Aberdeen (GB)
- 11:23 - 11:26 **Discussion**
-

- 11:26 - 12:10 **Oligometastatic bladder cancer**
- Moderators:** A. Hartmann, Erlangen (DE)
M. Knowles, Leeds (GB)
J. Walz, Marseille (FR)

- 11:26 - 11:34 **Case of oligometastatic bladder cancer**
F. Algaba, Barcelona (ES)
- 11:34 - 11:37 **Discussion**
- 11:37 - 11:45 **How to detect oligometastatic bladder cancer with imaging?**
L. Mertens, Amsterdam (NL)
- 11:45 - 11:48 **Discussion**
- 11:48 - 11:56 **Prognostic factors in metastatic bladder cancer**
R. Knüchel Clarke, Aachen (DE)
- 11:56 - 11:59 **Discussion**
- 11:59 - 12:07 **Treatment options for oligometastatic bladder cancer**
P. Gontero, Turin (IT)
- 12:07 - 12:10 **Discussion**
-

- 12:10 - 12:25 **ESUI Vision Award 2016**
-

- 12:25 - 13:09 **Oligometastatic renal cell cancer**
- Moderators:** Y. Allory, Creteil (FR)
K. Junker, Homburg (DE)
S. Siracusano, Trieste (IT)
- 12:25 - 12:33 **Case of oligometastatic renal cell cancer**
-

Y. Allory, Creteil (FR)

12:33 - 12:36

Discussion

12:36 - 12:44

How to detect oligometastatic renal cell cancer with imaging?

O. Boerman, Nijmegen (NL)

12:44 - 12:47

Discussion

12:47 - 12:55

Prognostic factors for oligometastatic renal cancer

A. Hartmann, Erlangen (DE)

12:55 - 12:58

Discussion

12:58 - 13:06

Scientific basis for treatment options for oligometastatic renal cell cancer

G. Yousef , Toronto (CA)

13:06 - 13:09

Discussion

13:09 - 13:53

Oligometastatic prostate cancer

Moderators:

S. Bettuzzi, Parma (IT)

T. Loch, Flensburg (DE)

S. Perner, Lübeck (DE)

13:09 - 13:17

Case of oligometastatic prostate cancer

R. Montironi, Torrette di Ancona (IT)

13:17 - 13:20

Discussion

13:20 - 13:28

How to detect oligometastatic prostate cancer with imaging?

R. Schiavina, Bologna (IT)

13:28 - 13:31

Discussion

13:31 - 13:39

Prognosticators of metastatic prostate cancer: Genetic alterations as predictors of treatment of oligometastatic prostate cancer

G. Bova, Tampere (FI)

13:39 - 13:42

Discussion

13:42 - 13:50

Treatment options for metastatic prostate cancer, resistance and perspectives

M. Saar, Homburg (DE)

13:50 - 13:53

Discussion

13:53 - 14:00

Summary

K. Junker, Homburg (DE)

R. Montironi, Torrette di Ancona (IT)

J. Walz, Marseille (FR)

GU cancer in the elderly (>Age 75)

Meeting of the EAU Section of Oncological Urology (ESOU) in cooperation with the European Organisation for Research and Treatment of Cancer Genito-Urinary Cancer Group (EORTC GUCCG), The European Uro-Oncology Group (EUOG), The European Society of Surgical Oncology (ESSO) and the European Society for Radiotherapy & Oncology (ESTRO)

Saturday, 12 March
10:15 - 14:30

Location: Room 14b (ICM, Level 1)

Chairs: M. Brausi, Modena (IT)
G.N. Thalmann, Bern (CH)

10:15 - 10:35

The European Uro-Oncology Group (EUOG)

Moderator: S. Osanto, Leiden (NL)

10:15 - 10:30

Molecular tumour boards: Molecular diagnostic in clinical practice
J.A. Schalken, Nijmegen (NL)

10:30 - 10:35

Discussion

10:35 - 10:55

The European Society of Surgical Oncology (ESSO)

10:35 - 10:50

3rd evaluation before planning pelvic oncological surgery
P. Tekkis, London (GB)

10:50 - 10:55

Discussion

10:55 - 13:40

Meeting of the EAU Section of Oncological Urology (ESOU)

10:55 - 11:00

Welcome and introduction
M. Brausi, Modena (IT)

11:00 - 11:10

Evaluating the elderly and frail patients
A. Hohn, Köln (DE)

11:10 - 11:40

Prostate cancer in the elderly

11:10 - 11:25

Who is the appropriate candidate for definitive therapy?
S. Joniau, Leuven (BE)

11:25 - 11:40

Alternative treatments: Are they more appropriate?
M. Emberton, London (GB)

11:40 - 12:15

Debate: Radical cystectomy in muscle invasive TCC of the bladder

11:40 - 11:55

Pro: It should be performed more often
A. Stenzl, Tübingen (DE)

11:55 - 12:10	Con: Bladder sparing surgery with trimodality treatment is the new avenue R.A. Huddart, Sutton (GB)
12:10 - 12:15	Discussion
<hr/>	
12:15 - 13:05	Debate Localised renal cancer in the elderly
12:15 - 12:30	Yes: Surgery is preferable O. Rodriguez Faba, Barcelona (ES)
12:30 - 12:45	Alternative treatments are the standard J.J.M.C.H. De La Rosette, Amsterdam (NL)
12:45 - 13:00	Expectant management is a good option A. Volpe, Torino (IT)
13:00 - 13:05	Discussion
<hr/>	
13:05 - 13:40	Complications of uro-onco surgery: How to avoid them
13:05 - 13:15	Prostate C. Surcel, Bucharest (RO)
13:15 - 13:25	Bladder E. Xylinas, Paris (FR)
13:25 - 13:35	Kidney S.D. Brookman-May, Munich (DE)
13:35 - 13:40	Discussion
<hr/>	
13:40 - 14:00	The European Society for Radiotherapy & Oncology (ESTRO)
13:40 - 13:55	Role of adjuvant hormonal treatment together with salvage radiation therapy for local recurrence after prostatectomy P. Pommier, Lyon (FR)
13:55 - 14:00	Discussion
<hr/>	
14:00 - 14:20	The European Organisation for Research and Treatment of Cancer Genito-Urinary Cancer Group (EORTC GUCCG)
14:00 - 14:15	Designing the next generation of studies in germ cell cancers S. Gillissen, St. Gallen (CH)
14:15 - 14:20	Discussion

14:20 - 14:30

Summary and closure
M. Brausi, Modena (IT)

Lower urinary tract function and urogenital infections

Joint meeting of the EAU Section of Female and Functional Urology (ESFFU) and the EAU Section of Infections in Urology (ESIU)

Saturday, 12 March
10:15 - 14:00

Location: Room 14c (ICM, Level 1)

Chairs: T.E. Bjerklund Johansen, Oslo (NO)
J.P.F.A. Heesakkers, Nijmegen (NL)

Aims and objectives of this presentation

This joint ESFFU and ESIU session will provide a comprehensive update on topics common to both specialist sections and offers state of the art presentations in the overlapping fields of functional disorders, reconstructive operations and infective complications.

Delegates will be given deep insight into basic aspects including the importance of the urine microbiome and the myth that normal urine is sterile. Speakers will address infectious complications related to diversions and reservoirs, catheters and implants. All topics will be addressed by key international experts and opinion leaders and separate moderators will ensure that important questions from the audience are thoroughly discussed and answered. The session is organised in three parts: Basic aspects, functional disorders and reconstruction.

To complete this joint ESFFU-ESIU session, the delegates will obtain deep insight into recent knowledge about the relationship between function, foreign bodies and infection. He or she will be updated on how to prevent and treat urological infections in pregnancy and neurological disorders, as well as complications of all kind of implants and reconstructive surgery in urology.

10:15 - 10:20

Welcome and introduction

T.E. Bjerklund Johansen, Oslo (NO)

10:20 - 11:20

Session I: Basic aspects

Moderators: D.M. Castro-Diaz, La Laguna Santa Cruz Tenerife (ES)
F.M.E. Wagenlehner, Gießen (DE)

10:20 - 10:35

Who is to blame in UTI, the host, the microorganisms or both?

B. Wullt, Lund (SE)

10:35 - 10:50

The role of the microbiome in the development of urinary tract problems

V. Smelov, Lyon (FR)

10:50 - 11:05

The role of brush cells in the urinary tract and the development of UTI

W. Kummer, Giessen (DE)

11:05 - 11:20

Is UTI in a neurogenic patient different from UTI in a non-neurogenic patient and should it be treated differently?

M.J. Drake, Bristol (GB)

11:20 - 12:35

Session II: Functional disorders and infection

Moderators: M. Porena, Perugia (IT)
P. Tenke, Budapest (HU)

11:20 - 11:35

Is OAB an UTI?

Z. Tandoi du, Newcastle Upon Tyne (GB)

11:35 - 11:50

How to treat urinary tract infections in pregnancy?

T. Cai, Trento (IT)

11:50 - 12:05

Does UTI worsen neurological diseases like MS?

R. Hamid, London (GB)

12:05 - 12:20

Catheters and UTI: Indwelling, intermittent or reusable?

B. Köves, Budapest (HU)

12:20 - 12:35

Prevention and treatment of infective complications of diversions and reservoirs

J. Bjerggaard Jensen, Århus N (DK)

12:35 - 13:50

Session III: Reconstructive urology and infection

Moderators:

R. Bartoletti, Pistoia (IT)

S. Charalampous, Limassol (CY)

12:35 - 12:50

Is infection the only cause of erosion in urological implants?

F. Bruyere, Tours (FR)

12:50 - 13:05

Prevention and treatment of infective complications of implants for SUI and pelvic organ prolapse

F. Van Der Aa, Leuven (BE)

13:05 - 13:20

Prevention and treatment of infections related to AUS and other male incontinence devices

K-D. Sievert, Salzburg (AT)

13:20 - 13:35

Prevention and treatment of infections related to penile implants

K-D. Sievert, Salzburg (AT)

13:35 - 13:50

How much time is needed before we can re-implant safely without risk of a new infection?

E. Chartier-Kastler, Paris (FR)

13:50 - 14:00

Discussion and closure

J.P.F.A. Heesakkers, Nijmegen (NL)

Infections and lithiasis in kidney transplantation

Meeting of the EAU Section of Transplantation Urology (ESTU), in cooperation with the EAU Section of Infections in Urology (ESIU) and the EAU Section of Urolithiasis (EULIS)

Saturday, 12 March
10:15 - 14:00

Location: Room Vienna (Hall B2, level 0)

Chair: A.J. Figueiredo, Coimbra (PT)

Aims and objectives of this presentation

The aim of this meeting is to review and discuss the recent advances in prevention, diagnosis and treatment of infections and lithiasis in renal transplantation.

It will also include the extended presentation of the winner of the 2015 René Küss prize.

10:15 - 10:20

Welcome and introduction

A.J. Figueiredo, Coimbra (PT)

E. Lledo García, Madrid (ES)

10:20 - 11:20

Infections: How to avoid?

Moderators: A.J. Figueiredo, Coimbra (PT)

E. Lledo García, Madrid (ES)

10:20 - 10:35

Impact of infections on transplant results

F. Friedersdorff, Berlin (DE)

10:35 - 10:50

Stents and drains: A problem?

V. Díez Nicolás, Madrid (ES)

10:50 - 11:05

Ureteral reflux: How relevant is it?

P.T. Coelho Nunes, Coimbra (PT)

11:05 - 11:20

Vaccination in kidney transplant recipients

J. Fortún, Madrid (ES)

11:20 - 12:05

Infections: How to deal with?

Moderators: M. Musquera Felip, Barcelona (ES)

C. Terrone, Turin (IT)

11:20 - 11:35

Viral infections: Beyond the infection themselves

T. Cai, Trento (IT)

11:35 - 11:50

Infections in the cadaveric donor: How to deal with them?

U. Sester, Homburg (DE)

11:50 - 12:05

Infectious calculi in the graft

Z. Tandođ du, Newcastle Upon Tyne (GB)

12:05 - 12:50

Lithiasis

Moderators: A. Chkhotua, Tbilisi (GE)
P. Ditonno, Bari (IT)

12:05 - 12:20

Lithiasis in transplantation: How common is it?

J.D.J.M. Branchereau, Nantes (FR)

12:20 - 12:35

Stones in kidney grafts: Are they different?

M. Billia, Burolo (TO) (IT)

12:35 - 12:50

Stones in native kidneys: A concern?

J. Galan, Alicante (ES)

12:50 - 13:35

Lithiasis: How to deal with

Moderators: F.J. Burgos Revilla, Madrid (ES)
O. Rodriguez Faba, Barcelona (ES)

12:50 - 13:05

Stones in the donor kidney: What to do?

J.D. Olsburgh, London (GB)

13:05 - 13:20

Treatment of ureteral stones in transplantation

P.A. Geavlete, Bucharest (RO)

13:20 - 13:35

Treatment of graft lithiasis: Are there any particularities?

A. Trinchieri, Lecco (IT)

13:35 - 13:50

Rene Küss lecture: Creation of a bank of kidney precursors for transplantation

C.D. Vera Donoso, Valencia (ES)

13:50 - 14:00

Award of the Rene Küss Prize 2016 and conclusion

Moderators: A.J. Figueiredo, Coimbra (PT)
E. Lledo García, Madrid (ES)

Projects from the EAU History Office

Special session

Saturday, 12 March
10:15 - 11:45

Location: Room London (Hall B2, level 0)

Chairs: D. Schultheiss, Giessen (DE)
P.E. Van Kerrebroeck, Maastricht (NL)

Aims and objectives of this presentation

The EAU History Office is involved in a variety of different projects to preserve and popularize the history of urology. This session will present the latest achievements and still ongoing works of the EAU History Office to all members of the EAU.

10:15 - 10:25

The historian is a prophet in reverse

D. Schultheiss, Giessen (DE)

10:25 - 10:45

Urology under the Swastika

H. Fangerau, Ulm (DE)

10:45 - 11:00

Historical library and collections of the EAU in Arnhem

J. Mattelaer, Kortrijk (BE)

11:00 - 11:15

Oral history

R. Sosnowski, Warsaw (PL)

11:15 - 11:30

EAU History Office online

L.W. Keizer, Arnhem (NL)

11:30 - 11:45

Closing remarks

P.E. Van Kerrebroeck, Maastricht (NL)

ESU/ESUT Hands-on training in Laparoscopic suturing (anastomosis)

HOT 02

Saturday, 12 March
10:45 - 12:15

Location: Room South America (Hall B0, level 0)

Chair: D. Veneziano, Minneapolis (US)

Aims and objectives of this presentation

The aim of this advanced laparoscopic suturing course is to develop skill and knowledge about laparoscopic suturing.

Supported by experienced laparoscopist and state of the art Laparoscopic technology, you can improve your suturing skills, shorten your learning curve with the help of HD vision and practice an anastomosis. An intermediate level in laparoscopy is mandatory for this course.

A. Sempere Gutierrez, Murcia (ES)
C.S. Biyani, Leeds (GB)
G. Pini, Cologno Monzese (MI) (IT)
T. Tokas, Hall In Tirol (AT)
P.J. Zondervan, Amsterdam (NL)

Robots, video technology and smart instruments

Meeting of the EAU Section of Uro-Technology (ESUT), in cooperation with the EAU Robotic Urology Section (ERUS) and the EAU Section of Urolithiasis (EULIS)

Saturday, 12 March
11:00 - 17:30

Location: eURO Auditorium (Hall C1, Level 0)

Chair: J. Rassweiler, Heilbronn (DE)

Aims and objectives of this presentation

Following a more than 10-year tradition of Live-surgery sessions, the EAU-section of Uro-Technology (ESUT) presents an ambitious programme focussing on novel techniques in percutaneous, endourological, laparoscopic, and robotic-assisted procedures. This year, with "Robots, video technology and smart instruments" we want to focus on novel technology improving the performance of video-assisted surgery and diagnostics in all fields of Endourology. This session is conducted in collaboration with the EAU Robotic Urology Section (ERUS) and the EAU Section of Urolithiasis (EULIS). In the laparoscopic and robot-assisted cases, we will focus on the developments of imaging (3D-HD, iso-cynine-green) as well as new instruments and devices (laser) improving the ergonomics of laparoscopy and endourology. The latest digital developments for flexible endoscopy of the upper urinary tract for diagnosis and treatment of tumours and calculi are demonstrated.

ESUT-faculty consists of internationally well-known experts serving as surgeons and moderators. The different surgical procedures will be transmitted from Klinikum Rechts der Isar Technical University Munich (Chairman: Prof. Dr. J. Gschwend) in high-definition and 3D-quality. Some of the robot-assisted procedures are transmitted also from Klinikum Grosshadern University of Munich (Chairman: Prof. Dr. C. Stief). A split-screen will allow the delegates to follow the uncommented procedures. Traditionally, the format of ESUT-Live Surgery will allow all delegates to directly communicate with the surgeons to ask questions and to discuss every aspect of the procedure. Moreover, the ESUT session will be available on-line.

11:00 - 17:30

Live broadcasts from Klinikum 'Rechts der Isar' and Klinikum 'Grosshadern', Munich (DE)

11:00 - 17:30

Coordinators at Klinikum 'Rechts der Isar', Munich (DE)

C-C. Abbou, Vincennes (FR)

A. Bachmann, Basel (CH)

M. Straub, Munich (DE)

Coordinator at Klinikum 'Grosshadern', Munich (DE)

C. Gratzke, Munich (DE)

11:00 - 17:30

Coordinators at eURO Auditorium

T. Frede, Müllheim (DE)

E. Liatsikos, Filothei, Athens (GR)

R. Muschter, Rotenburg (DE)

11:00 - 11:05

Welcome and introduction

J. Rassweiler, Heilbronn (DE)

11:05 - 11:10

Ethics of live surgery: Cases from last year

M.I. Galante Romo, Madrid (ES)

11:10 - 13:05

Live surgery: Part I

Moderators: T. Knoll, Sindelfingen (DE)
M.P. Laguna, Amsterdam (NL)
R.F. Van Velthoven, Brussels (BE)
N.P. Wiklund, Stockholm (SE)

11:10 - 11:35

3D-HD: Laparoscopic partial nephrectomy with flexible telescope
A. Alcaraz, Barcelona (ES)

11:35 - 12:00

Robotic partial nephrectomy: With isocyanine green using Da Vinci XI
A. Mottrie, Aalst (BE)

12:00 - 12:25

Robotic partial nephrectomy: Extraperitoneal access using Da Vinci SI
J. Porter, Seattle (US)

12:25 - 12:45

SPIES-assisted RIRS for diagnosis of upper tract TCC
A. Breda, Barcelona (ES)

12:45 - 13:05

NBI-assisted RIRS for diagnosis of upper tract TCC
M. Brehmer, Aarhus N (DK)

13:05 - 15:15

Live surgery: Part II

Moderators: E. Barret, Paris (FR)
A.J. Gross, Hamburg (DE)
F. Montorsi, Milan (IT)
A. Skolarikos, Athens (GR)

13:05 - 13:45

Flexible URS (FURS) using digital Cobra (pre-recorded)
M. Straub, Munich (DE)
J. Rassweiler, Heilbronn (DE)
R. Saglam, Ankara (TR)

13:45 - 14:05

Green light laser enucleation of the prostate (pre-recorded)
F. Gomez Sancha, Madrid (ES)

14:05 - 14:30

3D-laparoscopic extraperitoneal radical prostatectomy
J-U. Stolzenburg, Leipzig (DE)

14:30 - 14:50

Bipolar enucleation of prostate (pre-recorded)
T.R.W. Herrmann, Hannover (DE)

14:50 - 15:15

Robotic nerve-sparing radical prostatectomy using Da Vinci XI
S. Siemer, Homburg (DE)

15:15 - 17:25

Live surgery: Part III

Moderators: M. Burchardt, Greifswald (DE)
M.S. Michel, Mannheim (DE)
C-H. Rochat, Geneva (CH)
C.M. Scoffone, Turin (IT)

15:15 - 15:35

Combined management (supine PCNL plus FURS) of a renal stone using digital endoscopic technology (pre-recorded)

P.J.S. Osther, Fredericia (DK)
S.S. Osther, Fredericia (DK)
O. Traxer, Paris (FR)

15:35 - 15:55

MIP-L: A new concept of PCNL

U. Nagele, Hall in Tirol (AT)

15:55 - 16:20

Robotic nerve-sparing radical prostatectomy using Da Vinci Xi

B. Rocco, Milan (IT)

16:20 - 16:45

Laparoscopic radical prostatectomy using new technology

C. Schwentner, Stuttgart (DE)

16:45 - 17:05

BipolarTUR-B with PDD

J.E. Gschwend, Munich (DE)

17:05 - 17:25

NBI-assisted en-bloc TURis B

B. Malavaud, Toulouse (FR)

17:25 - 17:30

Conclusion

J. Rassweiler, Heilbronn (DE)

An introduction to social media: Why this is important for urologists

ESU Course 01

Saturday, 12 March
11:00 - 14:00

Location: Room 13a (ICM, Level 1)

Chair: J.W.F. Catto, Sheffield (GB)

Aims and objectives of this presentation

Social media are important for practicing urologists to keep up to date and for communication. These web based interfaces allow rapid transfer of knowledge, interaction and facilitate a community of science. In this course we will introduce the audience to the Why, How, When and When not to, of social media. We will cover different tools (such as Twitter and Facebook), advise practice (offer professional guidance). We will introduce aspects of European Urology and how we will adapt to social media in the future. Dear Jim,

- To understand the role of social media in modern medicine
- To understand how best to interact with social media
- To understand how European Urology fits into these media

11:00 - 14:00

Introduction to social media

J.W.F. Catto, Sheffield (GB)

11:00 - 14:00

Social media for beginners

M.R. Cooperberg, San Francisco (US)

11:00 - 14:00

Why social media matters

D. Murphy, Melbourne (AU)

11:00 - 14:00

Using social media in medicine

A. Kutikov

11:00 - 14:00

Examples of best practice

M.R. Cooperberg, San Francisco (US)

11:00 - 14:00

Trends and developments in social media

D. Murphy, Melbourne (AU)

11:00 - 14:00

www.europeanurology.com

A. Kutikov

11:00 - 14:00

Questions and answers

J.W.F. Catto, Sheffield (GB)

Paediatric urology for the adult urologist: A practical update

ESU Course 02

Saturday, 12 March
11:00 - 14:00

Location: Room 13b (ICM, Level 1)

Chair: J.M. Nijman, Groningen (NL)

Aims and objectives of this presentation

Many children with congenital anomalies will present to the adult urologist with long-term sequelae. It is important to know what has been done in terms of surgical procedures so that the adult urologist knows what he can do in the future. It is also important to know how the urological follow-up of these patients should be done. The most common pediatric conditions will be reviewed, while long-term complications will be explored by short interactive case presentations.

- Many children born with hydronephrosis may not require surgical intervention, but need close follow-up until after puberty
- Penile and urethral reconstruction, such as hypospadias may have serious implications for transurethral procedures in the future
- The clinical presentation of congenital anomalies of the urinary tract is changing but some of these may still present in the adult patient
- Obstructive uropathy and VUR are not always surgical anomalies, but may be functional in nature: the treatment modalities and long-term outcomes depend on the pathophysiology

11:00 - 14:00

Obstructive uropathy: What to do when, from neonate till puberty

G. Bogaert, Leuven (BE)

11:00 - 14:00

How to deal with congenital malformations of the external genitalia, when is surgery indicated and how to do it

S. Tekgül, Ankara (TR)

11:00 - 14:00

Urinary infection, reflux and voiding dysfunction: New insights in pathology, diagnostic work-up and management

J.M. Nijman, Groningen (NL)

Robot-assisted laparoscopic prostatectomy

ESU Course 04

Saturday, 12 March
11:00 - 14:00

Location: Room 12 (ICM, Level 1)

Chair: P-T. Piéchaud, Bordeaux (FR)

11:00 - 14:00

Introduction

P-T. Piéchaud, Bordeaux (FR)

11:00 - 14:00

General principles of robotic radical prostatectomy

W. Artibani, Verona (IT)

P. Dasgupta, London (GB)

11:00 - 14:00

Anatomical and oncological supports of radical prostatectomy

11:00 - 14:00

Bladder neck preservation: Useful? Dangerous?

P-T. Piéchaud, Bordeaux (FR)

11:00 - 14:00

Neurovascular bundle dissection: Anatomical reminders of the peri prostatic fascia and space of dissection

P. Dasgupta, London (GB)

11:00 - 14:00

Tips and tricks around vesico uretral anastomosis (Rocco, anterior suspension...)

W. Artibani, Verona (IT)

11:00 - 14:00

Step by step operative procedure; How I do it

W. Artibani, Verona (IT)

P. Dasgupta, London (GB)

P-T. Piéchaud, Bordeaux (FR)

11:00 - 14:00

Questions from participants about operative protocols

11:00 - 14:00

Lymphadenectomy

W. Artibani, Verona (IT)

11:00 - 14:00

Specific situations

P-T. Piéchaud, Bordeaux (FR)

11:00 - 14:00

Postoperative complications

P. Dasgupta, London (GB)

11:00 - 14:00

Anatomical and functional results

W. Artibani, Verona (IT)

11:00 - 14:00

Conclusion

P-T. Piéchaud, Bordeaux (FR)

Adrenalectomy

ESU Course 06

Saturday, 12 March
11:00 - 14:00

Location: Room 22 (ICM, Level 2)

Chair: A.S. Gözen, Heilbronn (DE)

Aims and objectives of this presentation

To teach all about the adrenal gland minimal invasive approach; starting with the correct indications for surgery and preoperative medical preparation. The different approaches and new equipment will be shown including special instructions. The operations will be given step by step in high quality videos in detail with tips and tricks. The complication videos and intraoperative management will be discussed interactively with the experts.

11:00 - 14:00

Indications and patient preparation (medical and surgical)

H. Langenhuijsen, Nijmegen (NL)

11:00 - 14:00

Surgical anatomy

F. Porpiglia, Turin (IT)

11:00 - 14:00

How I do it; step by step operative procedure, technical tips and tricks

11:00 - 14:00

Transperitoneal

H. Langenhuijsen, Nijmegen (NL)

11:00 - 14:00

Retroperitoneal and prone

A.S. Gözen, Heilbronn (DE)

11:00 - 14:00

Mini-laparoscopic

F. Porpiglia, Turin (IT)

11:00 - 14:00

Complications and management

A.S. Gözen, Heilbronn (DE)

11:00 - 14:00

Discussion and interaction

A.S. Gözen, Heilbronn (DE)
H. Langenhuijsen, Nijmegen (NL)
F. Porpiglia, Turin (IT)

ESU/ESFFU Hands-on training in OnabotulinumtoxinA administration for OAB

HOT 13

Saturday, 12 March
11:00 - 12:30

Location: Room Europe (Hall B0, level 0)

Chair: H. Hashim, Bristol (GB)

Aims and objectives of this presentation

Botulinum toxin type A administration in Urology has become common practice over the last two decades. Following the completion of Phase 3 registration trials in OAB, OnabotulinumtoxinA received marketing approval for this indication and now has a standardised injection paradigm. This course is procedure-focused, and will teach attendees the practicalities of OnabotulinumtoxinA administration through short lectures, videos and hands-on demonstrations using bladder models. Attendees will learn how to reconstitute the product and see different types of equipment available.

R. Bauer, Munich (DE)
R. Inman, Sheffield (GB)
A. Sahai, London (GB)

ESU/ESUT Hands-on training with Thulium laser for vaporesection of prostate

HOT 54

Saturday, 12 March
11:00 - 12:30**Location:** Room Africa (Hall B0, level 0)**Chair:** I. Kyriazis, Athens (GR)**Aims and objectives of this presentation**

This hands on training course is to introduce the trainee into the laser tissue interaction of the Thulium 2 micron continuous wave laser with the use of two different training stations. In the first workstation the trainee will try the laser on cadaver tissue submersed in water. The second setting resembles the Thulium Laser Vaporesection of Prostate on a training device.

Aims and objectives:

- The trainee will understand the tissue vaporization effect by the Thulium 2 micron continuous wave laser, the limited depth of tissue damage and how to vaporize and to perform a cut in tissue.
- The trainee also may cut the sample tissue by cold knife for visual inspection of the tissue damage zone.
- The trainee is challenged to introduce the laser resectoscope into the artificial organ of the training device, maneuver the resectoscope in the artificial prostatic urethra and to vaporize and cut tissue samples.

L. Carmignani, Milan (IT)

C. Netsch, Hamburg (DE)

ESU/ERUS Hands-on training in Robotic surgery

HOT 09

Saturday, 12 March
11:30 - 13:00

Location: Room Asia (Hall B0, level 0)

Chair: M. Naudin, Hyon (BE)

Aims and objectives of this presentation

The European School of Urology (ESU) and the EAU Robotic Urology Section (ERUS) offer an intensive hands-on training course. We will provide training using simulators. The main aims of this 90 minutes course are: improving the participants' control-skills and hand-eye-coordination, as well as an objective benchmarking of console performance and an introduction into standardized surgical steps in robot-assisted procedures.

To be confirmed
I.C. Acar, Ankara (TR)

How to proceed with hematuria

ESU Course 03

Saturday, 12 March
12:00 - 14:00

Location: Room 11 (ICM, Level 1)

Chair: S. Boorjian, Rochester (US)

Aims and objectives of this presentation

Hematuria is one of the most common indications for urologic evaluation, and is recognized as a sign of potentially important illness. Therefore, knowledge of the differential diagnosis, principles of evaluation, and strategies for management of hematuria is critical. This course is designed for the practicing urologist, to provide a guidelines-based and case-oriented approach to the evaluation and management of hematuria.

After attending the course, participants will:

- Understand guideline recommendations for initial evaluation of asymptomatic microscopic hematuria
- Describe existing data regarding hematuria screening
- Recognize intravesical treatment regimens and associated side effect profiles for hemorrhagic cystitis
- Create strategies for treating refractory hemorrhagic cystitis, upper urinary tract, and prostate-related bleeding

12:00 - 14:00

Course introduction and background to hematuria

S. Boorjian, Rochester (US)

12:00 - 14:00

Review of microscopic hematuria

H. Mostafid, Guildford (GB)

12:00 - 14:00

AUA guidelines on microscopic hematuria

S. Boorjian, Rochester (US)

12:00 - 14:00

Cases and questions focusing on microhematuria

S. Boorjian, Rochester (US)

H. Mostafid, Guildford (GB)

12:00 - 14:00

Evaluation and management of gross hematuria and hemorrhagic cystitis

S. Boorjian, Rochester (US)

H. Mostafid, Guildford (GB)

12:00 - 14:00

Prostate/Urethral/Upper urinary tract bleeding

H. Mostafid, Guildford (GB)

12:00 - 14:00

Cases and questions focusing on gross hematuria

S. Boorjian, Rochester (US)

H. Mostafid, Guildford (GB)

Surgery for renal cancer beyond minimally invasive approaches: Opportunities and limits

ESU Course 05

**Saturday, 12 March
12:00 - 14:00**

Location: Room 21 (ICM, Level 2)

Chair: M. Kuczyk, Hanover (DE)

Aims and objectives of this presentation

Addressing patients with locally advanced renal cell cancer with / without intraval tumour thrombosis usually not being considered candidates for laparoscopy, the current course presents tips and tricks for the surgical management of these cases. In addition, the indication for and the potential clinical value of metastasectomy, cytoreductive nephrectomy and lymph node dissection in the aforementioned clinical situation is revisited.

- Tips and tricks for the surgical management of locally advanced renal cancer with / without intracaval tumor thrombosis
- What is the indication for and the value of metastasectomy in renal cancer patients?
- Can we define the ideal candidate for cytoreductive nephrectomy?
- Is there any value of a more extended lymph node dissection during nephrectomy?

12:00 - 14:00

The role of metastasectomy in metastatic renal cancer

M. Kuczyk, Hanover (DE)

12:00 - 14:00

The role of cytoreductive nephrectomy in metastatic renal cancer

M. Kuczyk, Hanover (DE)

12:00 - 14:00

Tips and tricks for the surgical management of patients with advanced renal cell cancer not suitable for a minimally invasive approach

A. Bex, Amsterdam (NL)

12:00 - 14:00

The surgical strategy for the management of renal cancer with intracaval thrombosis

A. Bex, Amsterdam (NL)

12:00 - 14:00

The role of lymphadenectomy during the surgical treatment of RCC patients

M. Kuczyk, Hanover (DE)

ESU/ESUT Hands-on training in Laparoscopic suturing (anastomosis)

HOT 03

Saturday, 12 March
12:30 - 14:00

Location: Room South America (Hall B0, level 0)

Chair: D. Veneziano, Minneapolis (US)

Aims and objectives of this presentation

The aim of this advanced laparoscopic suturing course is to develop skill and knowledge about laparoscopic suturing.

Supported by experienced laparoscopist and state of the art Laparoscopic technology, you can improve your suturing skills, shorten your learning curve with the help of HD vision and practice an anastomosis. An intermediate level in laparoscopy is mandatory for this course.

E. Gallyamov, Moscow (RU)
M. Arslan, Izmir (TR)
G. Pini, Cologno Monzese (MI) (IT)
T. Tokas, Hall In Tirol (AT)
P. Macek, Prague (CZ)

ESU/ESFFU Hands-on Training in Urodynamics

HOT 40

Saturday, 12 March
13:00 - 16:00

Location: Room North America (Hall B0, level 0)

Chair: G. Van Koeveringe, Maastricht (NL)

Aims and objectives of this presentation

- The participants will be trained in both indications / applications for urodynamic testing and practical aspects of the Urodynamic tests.
- The emphasis will be on practical aspects including:
 - how to perform a good urodynamic assessment (Good Urodynamic Practice)
 - how to use equipment properly and which equipment can be used.
 - interpretation of traces,
 - quality control and trouble-shooting.

All in an Interactive "hands-on" environment

- Individual needs will be addressed in small groups, recorded tests will be used and access to equipment is provided to be able to simulate the clinical setting as much as possible.
- In a short plenary session the participants will be informed on current and future urodynamic indications and specialized urodynamic tests
- All the speakers are subject matter experts in Urodynamics and have extensive, hands-on Urodynamics teaching experience and numerous publications to their credit.

The course aims to provide the delegates with both knowledge of urodynamic indications and practical experience to be able to recognize and use the additional value of urodynamic measurements.

13:00 - 16:00

Indications for Urodynamics in Males, Females, children and Neurourology
P.E. Van Kerrebroeck, Maastricht (NL)

13:00 - 16:00

Hands on experience
M. Gray, Charlottesville (US)

13:00 - 16:00

Conducting a typical urodynamic study
E. Finazzi Agrò, Rome (IT)

13:00 - 16:00

Physical aspects of UDS Testing
T. Mckinney, Fort Lauderdale (US)

13:00 - 16:00

Urodynamic assessment of voiding
P.F.W.M. Rosier, Nijmegen (NL)

13:00 - 16:00

The role of urodynamics in clinical decision making
G. Van Koeveringe, Maastricht (NL)

13:00 - 16:00

Additional urodynamic techniques (Video, Mobile)
G. Van Koeveringe, Maastricht (NL)

13:00 - 16:00

Interactive discussion Q & A

ESU/ESFFU Hands-on training in OnabotulinumtoxinA administration for OAB

HOT 14

**Saturday, 12 March
13:30 - 15:00****Location:** Room Europe (Hall B0, level 0)**Chair:** R. Hamid, London (GB)**Aims and objectives of this presentation**

Botulinum toxin type A administration in Urology has become common practice over the last two decades. Following the completion of Phase 3 registration trials in OAB, OnabotulinumtoxinA received marketing approval for this indication and now has a standardised injection paradigm. This course is procedure-focused, and will teach attendees the practicalities of OnabotulinumtoxinA administration through short lectures, videos and hands-on demonstrations using bladder models. Attendees will learn how to reconstitute the product and see different types of equipment available.

R. Bauer, Munich (DE)

A. Sahai, London (GB)

M.S. Rahnama'i, Heerlen (NL)

ESU/ERUS Hands-on training in Robotic surgery

HOT 10

Saturday, 12 March
13:30 - 15:00

Location: Room Asia (Hall B0, level 0)

Chair: J.S. Schraml, Usti Nad Labem (CZ)

Aims and objectives of this presentation

The European School of Urology (ESU) and the EAU Robotic Urology Section (ERUS) offer an intensive hands-on training course. We will provide training using simulators. The main aims of this 90 minutes course are: improving the participants' control-skills and hand-eye-coordination, as well as an objective benchmarking of console performance and an introduction into standardized surgical steps in robot-assisted procedures.

To be confirmed

A. Ploumidis, Athens (GR)

Prostate cancer screening and early detection

Poster Session 08

Saturday, 12 March
14:15 - 15:45

Location: Room Stockholm (Hall B2, level 0)

Chairs: S.V. Carlsson, New York (US)
F.K-H. Chun, Hamburg (DE)
O. Yossepowitch, Petah-Tikva (IL)

Aims and objectives of this presentation

The session is focused on prostate cancer screening and early detection.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*86

The STHLM3 model improves prostate cancer testing in men 50-69 years - further health economic and clinic evaluation

By: Grönberg H.¹, Adolfsson J.², Aly M.¹, Nordström T.¹, Wiklund P.³, Brandberg Y.⁴, Thompson J.⁵, Wiklund F.¹, Lindberg J.¹, Clements M.¹, Egevad L.⁴, Eklund M.¹

Institutes:¹Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ²Karolinska Institutet, Dept. of Clinical Science, Intervention and Technology (CLINTEC), Stockholm, Sweden, ³Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ⁴Karolinska Institutet, Dept. of Oncology-Pathology, Stockholm, Sweden, ⁵Karolinska Institutet, Biobank, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden

*87

18-year follow up of the Gothenburg randomized population-based prostate cancer screening trial

By: Arnsrud Godtman R.¹, Carlsson S.¹, Grenabo Bergdahl A.¹, Holmberg E.², Stranne J.¹, Lilja H.³, Hugosson J.¹

Institutes:¹Institute of Clinical Sciences, Sahlgrenska Academy at The University of Gothenburg, Dept. of Urology, Gothenburg, Sweden, ²Institute of Clinical Sciences, Sahlgrenska Academy at The University of Gothenburg, Dept. of Oncology, Gothenburg, Sweden, ³Memorial Sloan-Kettering Cancer Center/Nuffield Dept. of Surgical Sciences/Lund University Hospital, Dept. of Laboratory Medicine, Surgery (Urology), and Medicine (GU Oncology), Malmö, Sweden

*88

Correlation between stage shift and differences in mortality between the two study arms of the ERSPC

By: Roobol M.J.¹, Auvinen A.², Carlsson S.V.³, Kwiatkowski M.⁴, Denis L.J.⁵, Zappa M.⁶, Paez A.⁷, Hugosson J.⁸, Moss S.M.⁹, Bokhorst L.P.¹

Institutes:¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²University of Tampere, School of Medicine, Tampere, Finland, ³Sahlgrenska Academy At University of Gothenburg/Memorial Sloan-Kettering Cancer Center, Dept. of Urology, Gothenburg, Sweden, ⁴Kantonsspital Aarau, Dept. of Urology, Aarau, Switzerland, ⁵Europa Uomo, Antwerp, Belgium, ⁶ISPO, Unit of Clinical and Descriptive Epidemiology, Florence, Italy, ⁷Hospital Universitario De Fuenlabrada, Dept. of Urology, Madrid, Spain, ⁸Sahlgrenska Academy At University of Gothenburg, Dept. of Urology, Gothenburg, Sweden, ⁹Centre For Cancer Prevention, Queen Mary University of London, Cancer Prevention, London, United Kingdom

*89

The association between family history and prostate-specific antigen from a large group of 45-year old men embarking on prostate cancer screening: Results from the PROBASE trial

By: Herkommer K.¹, Laenger N.¹, Klorek T.¹, Ankerst D.², Grill S.², Schulwitz H.¹, Albers P.³, Arsov C.³, Hadaschik B.⁴, Hohenfellner M.⁴, Kuczyk M.⁵, Imkamp F.⁵, Gschwend J.¹

Institutes:¹Technical University of Munich, Dept. of Urology, Munich, Germany, ²Technical University of Munich, Dept. of Mathematics, Munich, Germany, ³University Dusseldorf, Medical

Faculty, Dept. of Urology, Dusseldorf, Germany, ⁴University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ⁵Hanover Medical School, Dept. of Urology, Hanover, Germany

- *90 **Differences in prostate specific antigen testing among urologists and primary care providers in the United States following the 2011 USPSTF recommendations**
By: Meyer C.¹, Zavaski M.¹, Hanske J.¹, Friedlander D.¹, Cheng P.¹, Menon M.², Kibel A.¹, Cole A.¹, Leow J.¹, Abdollah F.², Sun M.¹, Sammon J.², Trinh Q-D.¹
Institutes:¹Brigham and Women's Hospital, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Henry Ford Hospital, Vatikutti Urology Institute, Detroit, United States of America
- *91 **The impact of 2012 United States Preventive Services Task Force (USPSTF) panel update on PSA screening practice: A nationwide, and state-by-state level analyses**
By: Abdollah F.F.H.¹, Dalela D.¹, Sood A.¹, Meyer C.², Sun M.², Trinh Q.D.², Menon M.¹, Sammon J.¹
Institutes:¹Henry Ford Hospital / Health System, Dept. of Urology, Detroit, United States of America, ²Brigham and Women's Hospital / Dana-Farber Cancer Institute, Harvard Medical School, Dept. of Urologic Surgery and Center for Surgery and Public Health, Detroit, United States of America
- *92 **Swiss prostate-check: A population based risk-calculator for next generation prostate cancer screening**
By: Kwiatkowski M.¹, Wyler S.F.¹, Prause L.¹, Möltgen T.¹, Huber A.², Grobholz R.³, Manka L.⁴, Seifert B.⁵, Randazzo M.⁶, Recker F.¹
Institutes:¹Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland, ²Cantonal Hospital Aarau, Dept. of Laboratory Medicine, Aarau, Switzerland, ³Cantonal Hospital Aarau, Dept. of Pathology, Aarau, Switzerland, ⁴Academic Hospital Braunschweig, Dept. of Urology, Braunschweig, Germany, ⁵University of Zurich, Institute for Biostatistics, Zürich, Switzerland, ⁶University of Zurich, Dept. of Urology, Zürich, Switzerland
- *93 **A nationwide survey of prostate specific antigen based screening and counseling for prostate cancer**
By: Meyer C.¹, Friedlander D.¹, Choi K.¹, Cole A.¹, Abdollah F.², Hanske J.¹, Zavaski M.¹, Sammon J.³, Leow J.¹, Menon M.³, Sun M.¹, Kibel A.¹, Trinh Q-D.¹
Institutes:¹Brigham and Women's Hospital, Dept. of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Henry Ford Hospital, Dept. of Urology, Detroit, United States of America, ³Henry Ford Hospital, Vatikutti Urology Institute, Detroit, United States of America
- *94 **Informed decision-making for prostate-specific antigen screening**
By: Hanna N.¹, Zavaski M.¹, Gelpi-Hammerchmidt F.¹, Meyer C.¹, Sammon J.², Kibel A.¹, Menon M.², Leow J.¹, Sun M.¹, Abdollah F.², Trinh Q-D.¹
Institutes:¹Brigham and Women's Hospital, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Henry Ford Hospital, Vatikutti Urology Institute, Detroit, United States of America
- *95 **Detection of asymptomatic locally advanced and high-risk prostate cancer through PSA testing: Clinical outcomes in men excluded from the ProtecT Trial**
By: Johnston T.¹, Shaw G.¹, Lamb A.², Gnanapragasam V.¹, Greenberg D.³, Parashar D.⁴, Xiong T.¹, Moore A.¹, Holding P.⁵, Herbert P.¹, Davis M.⁶, Down E.⁶, Lane J.A.⁶, Donovan J.⁶, Hamdy F.⁷, Neal D.¹
Institutes:¹Cambridge University and Cambridge University Hospitals NHS Trust, Surgical Academic Urological Grou, Dept. of Surgery, Cambridge, United Kingdom, ²Cambridge University and Cambridge University Hospitals NHS Trust, Cambridge, Uk, Dept. of Urology, Cambridge, United Kingdom, ³National Cancer Registration Service - Eastern Office, Dept. of Public Health, Cambridge, United Kingdom, ⁴Cancer Research UK Cambridge Institute, Dept. of Urology, Cambridge, United Kingdom, ⁵Academic Urology Unit, Royal Hallamshire Hospital,, Dept. of Surgery, Sheffield, United Kingdom, ⁶School of Social and Community Medicine, Dept. of Urology, Bristol, United Kingdom, ⁷Nuffield Department of Surgical Sciences, Dept. of Surgery, Oxford,

United Kingdom

*96

Comorbidities and concomitant medications at time of diagnosis of prostate cancer: Data from the PROS-IT CNR study

By: Gacci M.¹, Artibani W.², Bassi P.³, Bertoni F.⁴, Bracarda S.⁵, Conti G.⁶, Corvò R.⁷, Graziotti P.⁸, Maggi S.⁹, Magrini S.M.¹⁰, Maurizi Enrici R.¹¹, Mirone V.¹², Montironi R.¹³, Muto G.¹⁴, Noale M.⁹, Pecoraro S.¹⁵, Porreca A.¹⁶, Ricardi U.¹⁷, Tubaro A.¹⁸, Zagonel V.¹⁹, Zattoni F.²⁰

Institutes:¹University of Florence, Dept. of Urology, Florence, Italy, ²Azienda Ospedaliera Universitaria Integrata and University of Verona, Dept. of Urology and Oncological and Surgical Sciences, Verona, Italy, ³University of Rome La Cattolica, Dept. of Urology, Rome, Italy, ⁴Italian Association For Radiation Oncology, Referent For The Prostate Group of AIRO, Rome, Italy, ⁵Ospedale San Donato, Azienda USL8, Dept. of Medical Oncology, Arezzo, Italy, ⁶St. Anna Hospital, Dept. of Urology, Como, Italy, ⁷AOU IRCCS San Martino - IST National Cancer Research Institute and University, Dept. of Radiation Oncology, Genoa, Italy, ⁸Ospedale S. Giuseppe, Dept. of Urology, Milan, Italy, ⁹CNR, Neuroscience Institute, Dept. of Aging Branch, Padua, Italy, ¹⁰University of Brescia and Spedali Civili Hospital, Dept. of Radiation Oncology Unit, Brescia, Italy, ¹¹University "La Sapienza", Dept. of Radiation Oncology, Rome, Italy, ¹²University Federico II, Dept. of Urology, Naples, Italy, ¹³Polytechnic University of The Marche Region, Section of Pathological Anatomy, Ancona, Italy, ¹⁴Campus Bio-Medico University of Rome, Dept. of Urology, Rome, Italy, ¹⁵Malzoni Center, Dept. of Nephrourology, Avellino, Italy, ¹⁶Abano Terme General Hospital, Dept. of Urology, Padua, Italy, ¹⁷University of Turin, Dept. of Oncology, Radiation Oncology, Turin, Italy, ¹⁸Sant'Andrea Hospital, Sapienza University of Rome, Dept. of Urology, Rome, Italy, ¹⁹Istituto Oncologico Veneto IOV – IRCCS, Dept. of Medical Oncology, Padua, Italy, ²⁰University of Padua, Dept. of Urology, Padua, Italy

*97

Repeat prostate-specific antigen (PSA) tests before biopsy decisions: Results from the STHLM3 diagnostic trial

By: Nordström T.¹, Adolfsson J.², Grönberg H.¹, Eklund M.¹

Institutes:¹Karolinska Institute, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ²Karolinska Institute, Dept. of Clinical Science, Intervention and Technology, Stockholm, Sweden

15:30 - 15:37

Summary and context

S.V. Carlsson, New York (US)

Improvements in prostate cancer diagnosis and treatment

Video Session 02

Saturday, 12 March
14:15 - 15:45

Location: Room 1 (ICM, Level 0)

Chairs: F. Gómez Veiga, Salamanca (ES)
P.C. Mozer, Paris (FR)
C. Stief, Munich (DE)

Aims and objectives of this presentation

This video session aims at highlighting the latest advancements in the prostate biopsy technique and specific aspects of robot-assisted lymphadenectomy and prostatectomy.

All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.

- *V10 **Technique and outcomes of transperineal prostate biopsy: The Victorian Transperineal Biopsy Collaboration**
By: [Murphy D.](#)¹, Huang S.², Zargar H.¹, Tjandra D.¹, Ong W.³, Weerakoon M.⁴, Van Bruwaene S.¹, Van Den Bergh R.¹, Moon D.¹, Lawrentschuk N.¹, Frydenberg M.⁵, Grummet J.⁶
Institutes:¹Peter Mac Callum Cancer Institute, Dept. of Cancer Surgery, Melbourne, Australia, ²Australian Urology Associates, Dept. of Urology, Melbourne, Australia, ³Monash University, Dept. of Cancer Surgery, Melbourne, Australia, ⁴Austin Health, Dept. of Urology, Melbourne, Australia, ⁵Monash Health, Dept. of Urology, Melbourne, Australia, ⁶Alfred Hospital, Dept. of Urology, Melbourne, Australia
- *V11 **USG and MP-MRI fused images for guiding HIFU in the focal treatment of prostate cancer**
By: [De Gracia-Nieto A.E.](#)¹, Sánchez-Salas R.¹, Barret E.¹, Sivaraman A.¹, Fregeville A.², Renard-Penna R.³, Rozet F.¹, Galiano M.¹, Cathelineau X.¹
Institutes:¹Institute Mutualiste Montsouris, Dept. of Urology, Paris, France, ²Institute Mutualiste Montsouris, Dept. of Imaging and Radiology, Paris, France, ³Hopital Pitie-Salpetriere, Dept. of Polyvalent and Oncologic Imaging, Paris, France
- *V12 **Robotic laparoendoscopic single-site (r-LESS) radical prostatectomy: IDEAL phase 1**
By: Gaboardi F., [Pini G.](#), Suardi N., Smelzo S., Passaretti G., Rosso M., Gadda G.
Institutes:San Raffaele Hospital, Turro, Dept. of Urology, Milan, Italy
- *V13 **The usefulness of a new laparoscopic needle driver with robotic tip to make vesico-urethral anastomosis**
By: [Varca V.](#)¹, Pietrantuono F.², Gregori A.¹, Gaboardi F.³
Institutes:¹G. Salvini Hospital, Dept. of Urology, Garbagnate Milanese, Italy, ²L. Sacco Hospital, Dept. of Urology, Milan, Italy, ³Ville Turro Hospital, Dept. of Urology, Milan, Italy
- *V15 **Early experience of robotic salvage pelvic lymph node dissection in the Ga-68 PSMA PET scanning era**
By: [Murphy D.](#)¹, Zargar H.¹, Van Den Bergh R.¹, Van Bruwaene S.¹, Goad J.¹, Coughlin G.², Harewood L.³, Dundee P.³
Institutes:¹Peter Mac Callum Cancer Institute, Dept. of Cancer Surgery, Melbourne, Australia, ²Wesley Hospital, Dept. of Urology, Brisbane, Australia, ³Epworth Hospital, Dept. of Urology, Melbourne, Australia
- *V16 **Salvage robotic-assisted laparoscopic prostatectomy (sRARP)**
By: Syed J., Chew C., Mouraviev V., Samavedis S., [Ogaya Pinies G.](#), Ganapathi H., Kumar A., Coelho R., Rocco B., Patel V.

Institutes: Global Robotic Institute, Dept. of Urology, Celebration, United States of America

New diagnostic tools in male LUTS

Poster Session 09

Saturday, 12 March
14:15 - 15:45

Location: Room 14a (ICM, Level 1)

Chairs: M. Oelke, Hannover (DE)
A. Tubaro, Rome (IT)

Aims and objectives of this presentation

New diagnostic tools are being developed to allow us better screening and patient selection. These tools are being scrutinized in this session.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *98 **Lower urinary tract symptoms, depression and adverse life events: Data from the European Male Ageing Study**
By: [Cocci A.](#)¹, Gacci M.¹, Drake M.², Castellini G.³, Ricca V.⁴, Forti G.⁴, Wu F.⁵, Maggi M.³
Institutes:¹University of Florence, Dept. of Urology, Florence, Italy, ²University of Bristol, Dept. of Urology, Bristol, United Kingdom, ³Sexual Medicine and Andrology Unit, Dept. of Experimental, Clinical and Biomedical Sciences, Florence, Italy, ⁴Psychiatric Unit, University of Florence, Dept. of Neuropsychiatric Sciences, Florence, Italy, ⁵Andrology Research Unit, Endocrinology and Diabetes Research Group, Institute of Human Development, Manchester, United Kingdom
- *99 **Correlation between uroflowmetry and a new visual pictogram in patients with lower urinary tract symptoms: Analogical uroflowmetry (ANUF)**
By: [Rogel R.](#), Lorenzo L., Avargues A., Lujan S., Broseta E., Boronat F.
Institutes:Hospital Universitari I Politècnic La Fe, Dept. of Urology, Valencia, Spain
- *100 **A prostate cancer risk polymorphism (rs12500426) of the PDLIM5 gene is a strong determinant of age related benign prostate hypertrophy**
By: [Audouin M.](#)¹, Barkatz J.¹, Cox D.⁸, Roupert M.², Cormier L.³, Valeri A.⁴, Azzouzi A-R.⁵, Ondet V.⁶, Gaffory C.⁷, Cancel-Tassin G.⁷, Cussenot O.¹
Institutes:¹Assistance Publique-Hopitaux De Paris, Tenon Hospital, Dept. of Urology, Paris, France, ²Assistance Publique-Hopitaux De Paris, Pitie-Salpetriere Hospital, Dept. of Urology, Paris, France, ³CHU Dijon, Dept. of Urology, Dijon, France, ⁴CHU Brest, Dept. of Urology, Brest, France, ⁵CHU Angers, Dept. of Urology, Angers, France, ⁶UPMC Univ Paris 06, GRC N°5 ONCOTYPE-URO, Paris, France, ⁷CeRePP, GRC N°5 ONCOTYPE-URO, Paris, France, ⁸INSERM, U1052, Lyon, France
- *101 **Developing a clinical nomogram for detection of bladder outlet obstruction in non-neurogenic male patients with overactive bladder symptoms**
By: [Chen W.J.](#), Fan Y.H., Lin A.T.L., Chen K.K.
Institutes:Taipei Veterans General Hospital, Dept. of Urology, Taipei City, Taiwan
- *102 **Methylation of CpG islands in promoter of type 2 5- α reductase and implications of finasteride resistance for BPH therapy**
By: Jin S., Fan D., Liu Z., Sun J., Xing N., [Niu Y.](#)
Institutes:Beijing Chao-Yang Hospital, Dept. of Urology, Beijing, China
- *103 **Serum vitamin D level in benign prostatic hyperplasia and hypogonadism has different correlations according to metabolic status**
By: [Park M.G.](#)¹, Dae Yeon C.¹, Jeong Kyun Y.¹, Jeong Woo L.², Sung Yong C.³, Min Chul C.³
Institutes:¹Inje University, Seoul Paik Hospital, Dept. of Urology, Seoul, South Korea, ²Dongguk University, Dept. of Urology, Seoul, South Korea, ³Seoul University, Dept. of Urology, Seoul, South

Korea

- *104 **Prospective evaluation of quality of information provided to patients before a transurethral resection of the prostate**
By: [Dominique I.](#)¹, Meyer V.², Terrier J-E.¹, Badet L.², Paparel P.¹, Ruffion A.¹, Champetier D.¹
Institutes:¹CHU Lyon Sud, Dept. of Urology, Rhones Alpes, Pierre Benite, France, ²CHU Edouard Herriot, Dept. of Urology, Rhones Alpes, Lyon, France
- *105 **Impact of treatment with statin on prostate volume and lower urinary tract symptoms: 3-Year follow-up**
By: Han J-Y., [Jeong S.C.](#), Lee S.S., Park S-W., Chung M.K.
Institutes:Pusan National University Hospital, Dept. of Urology, Yangsan, South Korea
- *106 **Impairment of autophagy in prostatic inflammation**
By: Vecchione A.¹, [De Nunzio C.](#)², Cirombella R.³, Lombardo R.⁴, Stoppacciaro A.³, Tubaro A.⁴
Institutes:¹Sant' Andrea Hospital - Sapienza University, Dept. of Molecular Pathology, Rome, Italy, ²Sant' Andrea Hospital - Sapienza, Dept. of Urology, Rome, Italy, ³Sant' Andrea Hospital 'la Sapienza', Dept. of Molecular Pathology, Rome, Italy, ⁴Sant' Andrea Hospital 'la Sapienza', Dept. of Urology, Rome, Italy
- *107 **Intravesical prostatic protrusion can predict postoperative outcomes in patients with benign prostatic hyperplasia who undergo trans urethral resection of prostate (TURP)**
By: [Nur Budaya T.](#)¹, Daryanto B.², Soetojo S.¹
Institutes:¹Dr. Soetomo Hospital, Faculty of Medicine Airlangga University, Dept. of Urology, Surabaya, Indonesia, ²Dr. Saiful Anwar Hospital, Faculty of Medicine Brawijaya University, Dept. of Urology, Malang, Indonesia
- *108 **The relationship between body mass index and benign prostate hyperplasia in large scale community based cohort**
By: [Choi S.M.](#), Yoon S., Seo D.H., Jeh S.U., Kam S.C., Hwa J.S., Chung K.H., Hyun J.S.
Institutes:Gyeongsang National University Hospital, Dept. of Urology, Jinju, South Korea
- *109 **A preoperative nomogram to predict functional outcomes of Greenlight® XPS 180 W photoselective vaporization of the prostate**
By: [Peyronnet B.](#)¹, Hupertan V.², Pradère B.³, Phé V.⁴, Zorn K.⁵, Rouprêt M.⁴, Misrai V.⁶
Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²Bichat Hospital, Dept. of Urology, Paris, France, ³CHU Tours, Dept. of Urology, Tours, France, ⁴Pitié Salpêtrière Hospital, Dept. of Urology, Paris, France, ⁵McGill University, Dept. of Urology, Montreal, France, ⁶Clinique Pasteur, Dept. of Urology, Toulouse, France

Basic research in renal tumours: Looking for the right treatment for the right patient

Poster Session 10

Saturday, 12 March
14:15 - 15:45

Location: Room 14c (ICM, Level 1)

Chairs: T. Klatte, Vienna (AT)
I. Mincik, Presov (SK)
G. Stewart, Cambridge (GB)

Aims and objectives of this presentation

To explore the molecular mechanism of resistance of the different drugs available to treat advanced RCC as well as to select patients sensitive or resistant to the different drugs.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *110 **Combination therapy using molecular-targeted drugs inhibiting platelet-derived growth factor receptors in the tumor microenvironment of renal cell carcinoma**
By: [Kitano H.](#)¹, Teishima J.¹, Yuge R.², Shinmei S.¹, Nagamatsu H.¹, Goto K.³, Syoji K.¹, Inoue S.¹, Hayashi T.¹, Sentani K.³, Kitadai Y.², Yasui W.³, Matsubara A.¹
Institutes:¹Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Hiroshima University, Dept. of Gastroenterology, Hiroshima, Japan, ³Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan
- *111 **Netrin-1 protein responsible for disease progression in renal cell carcinoma sunitinib resistant tumors**
By: [Frees S.K.](#), Chavez-Munoz C., Zhou B., Wong A., Raven P., So A.I.
Institutes:Vancouver Prostate Centre, Dept. of Urological Sciences, Vancouver, Canada
- *112 **Acquired resistance to tyrosine kinase inhibitor sunitinib is associated with functional alterations in renal cell carcinoma cell lines**
By: [Vynnytska-Myronovska B.](#), Schendel D., Unteregger G., Stöckle M., Junker K.
Institutes:Saarland University Medical Center, Dept. of Urology, Homburg/Saar, Germany
- *113 **Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo**
By: [Imai S.](#), Tei H., Miyake H., Fujisawa M.
Institutes:Kobe University Graduate School of Medicine, Dept. of Urology, Kobe, Japan
- *114 **Clonal mTOR pathway activation as a predictive biomarker for mTOR inhibitor therapy in clear cell renal cell carcinoma**
By: [Stares M.](#)¹, Nicol D.², O'Brien T.³, Challacombe B.³, Rowan A.¹, Horswell S.⁴, Salm M.⁴, Soutati A.⁵, Hazell S.⁶, Chandra A.⁷, López J.⁸, Fisher R.⁹, Chowdhury S.⁵, Rudman S.⁵, Gore M.⁹, Matthews N.¹⁰, Fotiadis N.¹¹, Larkin J.⁹, Turajlic S.¹, Swanton C.¹
Institutes:¹The Francis Crick Institute, Translational Cancer Therapeutics Laboratory, London, United Kingdom, ²The Royal Marsden Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁴The Francis Crick Institute, Bioinformatics and Biostatistics, London, United Kingdom, ⁵Guy's and St Thomas' NHS Foundation Trust, Dept. of Medicine, London, United Kingdom, ⁶The Royal Marsden Hospital NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ⁷Guy's and St Thomas' NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ⁸Cruces University Hospital, Dept. of Pathology, Bilbao, Spain, ⁹The Royal Marsden Hospital NHS Foundation Trust, Dept. of Medicine, London, United Kingdom, ¹⁰The Francis Crick Institute, Advanced Sequencing Facility, London, United Kingdom, ¹¹The Royal Marsden Hospital NHS

Foundation Trust, Dept. of Interventional Radiology, London, United Kingdom

- *115 **CMG-101: Novel selective mTOR 1/2 inhibitor for renal cell carcinoma**
By: Park D.S., Seo J.B., Lee S.R., Hong Y.K., Hong J.Y., Choi K.H.
Institutes:Cha University, Dept. of Urology, Seongnam, South Korea
- *116 **Acceleration of proteinuria without significant impact on renal function and its protection by angiotensin II receptor blocker in rats treated with axitinib**
By: Imai S., Miyake H., Fujisawa M.
Institutes:Kobe University Graduate School Of Medicine, Dept. of Urology, Kobe, Japan
- *117 **Predicting clinical response based on ex vivo drug treatment in renal cell carcinoma using kinase activity profiling**
By: Oosterwijk-Wakka J.¹, Ruijtenbeek R.², Houkes L.², Mulders P.¹, Oosterwijk E.¹
Institutes:¹Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ²Pamgene International, Research & Development, 's Hertogenbosch, The Netherlands
- *118 **Patient-derived avatar mouse models predicts prognosis in advanced renal cell carcinoma**
By: Trilla E.¹, Regis L.¹, Lorente D.¹, Servián P.¹, Celma A.¹, Salvador C.¹, Planas J.¹, Placer J.¹, Suarez C.², Martinez M.², Jimenez-Valerio G.², Detorres I.³, Morales R.², Jimenez J.⁴, Vivancos A.⁴, Nuciforo P.⁵, Carles J.², Casanovas O.⁵, Morote J.¹
Institutes:¹Hospital Universitari Vall d'Hebron, Dept. of Urology, Barcelona, Spain, ²Hospital Universitari Vall d'Hebron, Dept. of Oncology, Barcelona, Spain, ³Hospital Universitari Vall d'Hebron, Dept. of Pathology, Barcelona, Spain, ⁴Vall D'Hebron Institute of Oncology, Cancer Genomic Group, Barcelona, Spain, ⁵Vall D'Hebron Institute of Oncology, Molecular Pathology Group, Barcelona, Spain
- *119 **Interleukin-22 (IL-22), a T-cell secreted cytokine, contributes to renal cell carcinoma (RCC) progression and is associated with poor outcome in RCC patients**
By: Rodler S.², Shangqing S.³, Weidenbusch M.², Staehler M.⁵, Seliger B.⁴, Stief C.G.⁵, Anders H-J.², Nuhn P.¹
Institutes:¹University Medical Centre Mannheim, University of Heidelberg, Dept. of Urology, Mannheim, Germany, ²Klinikum Universität München, Nephrologisches Zentrum, Medizinische Klinik Und Poliklinik IV, Munich, Germany, ³Klinikum Der Universität München, Nephrologisches Zentrum, Medizinische Klinik Und Poliklinik IV, Munich, Germany, ⁴Martin-Luther-University Halle-Wittenberg Institute of Medical Immunology, Institute of Medical Immunology, Halle, Germany, ⁵Klinikum Universität München, Dept. of Urology, Munich, Germany
- *120 **The Mediator complex subunit MED8 is implicated in the progression of papillary renal cell carcinoma**
By: Syring L.¹, Klümper N.², Shaikhibrahim Z.², Offermann A.², Braun M.², Deng M.², Böhm D.², Queisser A.², Von Mässenhausen A.², Ellinger J.³, Müller S.³, Perner S.⁴
Institutes:¹University Hospital of Bonn, Dept. of Urology and Pediatric Urology; Dept. of Prostate Cancer Research, Institute of Pathology, Bonn, Germany, ²University Hospital of Bonn, Dept. of Prostate Cancer Research, Institute of Pathology, Bonn, Germany, ³University Hospital of Bonn, Clinic For Urology and Pediatric Urology, Bonn, Germany, ⁴University Hospital of Bonn, Department of Prostate Cancer Research, Institute of Pathology; Pathology Network of The University Hospital of Luebeck and Leibniz Research Center Borstel, Bonn, Germany
- *121 **TSPAN8 expression in renal cell carcinoma is a poor prognostic factor and a novel therapeutic target**
By: Hayashi T.¹, Sentani K.², Black P.³, Goto K.¹, Shinmei S.¹, Anami K.², Oo H.Z.², Teishima J.¹, Yasui W.², Matsubara A.¹
Institutes:¹Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan, ³Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada
- *122 **Ritonavir and delanzomib inhibit renal cancer growth in vitro and in vivo by inducing endoplasmic**

reticulum stress synergistically

By: Isono M.¹, Sato A.¹, Asano T.¹, Okubo K.¹, Ito K.¹, Schulz W.², Asano T.¹

Institutes:¹National Defense Medical College, Dept. of Urology, Tokorozawa, Japan, ²Heinrich Heine University, Dept. of Urology, Düsseldorf, Germany

*123

Experimental imaging in orthotopic xenograft models of renal cell carcinoma: Comparative evaluation of high-resolution ultrasonography, in-vivo micro-CT and 9.4T MRI

By: Linxweiler J.¹, Körbel C.², Müller A.³, Jung V.¹, Jünger E.⁴, Siemer S.¹, Junker K.¹, Menger M.D.², Saar M.¹

Institutes:¹Saarland University Medical Center, Dept. of Urology, Homburg/Saar, Germany, ²Saarland University Medical Center, Dept. of Clinical-Experimental Surgery, Homburg/Saar, Germany, ³Saarland University Medical Center, Dept. of Diagnostic and Interventional Radiology, Homburg/Saar, Germany, ⁴Frankfurt University Medical Center, Dept. of Urology, Frankfurt am Main, Germany

Benign problems in the upper urinary tract: 'Not cancer but not easy'

Poster Session 11

Saturday, 12 March
14:15 - 15:45

Location: Room Paris (Hall B2, level 0)

Chairs: M. Bultitude, London (GB)
M. Frydenberg, Melbourne (AU)
M.I. Kogan, Rostov On Don (RU)

Aims and objectives of this presentation

Incorporating the most upto date techniques into the management of a myriad of complex non-malignant problems in the upper urinary tract.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *124 **Comparison of insertion forces during ureteral access sheath placement in an experimental model with different commercially available access sheaths**
By: [Tefik T.](#)¹, Buttice S.², Marson F.², Sanli O.¹, Oktar T.¹, Villa L.², Traxer O.²
Institutes:¹Istanbul University, Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ²Pierre Et Marie Curie University, Paris VI, Tenon University Hospital, Dept. of Urology, Paris, France
- *125 **Segmental spiral stent with nanostructured coatings for surgical treatment of obstruction of ureteropelvic junction**
By: Shkodkin S.², [Kogan M.I.](#)¹, Idashkin Y.², Lyubushkin A.², Miroshnichenko O.²
Institutes:¹Rostov State Medical University, Dept. of Urology, Rostov on Don, Russia, ²Belgorod National Research University, Dept. of Urology, Belgorod, Russia
- *126 **Diagnostic accuracy of urinary α 2-microglobulin, CA19-9, NGAL and KIM-1 in the setting of ureteropelvic junction obstruction in adults**
By: Miranda E., De Bessa Jr J., Lopes R., Bandeira R., Srougi V., Andrade H., Arap M., Mitre A., Dos Reis S., Viana N., Leite K., Srougi M., [Duarte R.](#)
Institutes:University of Sao Paulo School of Medicine, Dept. of Urology, Sao Paulo, Brazil
- *127 **Laparoscopic management of ureteropelvic junction obstruction in horseshoe kidneys**
By: [Guliev B.](#), Komyakov B., Aliev R.
Institutes:Mechnikov Saint Petersburg State Medical Academy, Dept. of Urology, Saint-Petersburg, Russia
- *128 **High-grade hydronephrosis is sustained even in patients with improved renal function after laparoscopic pyeloplasty for ureteropelvic junction obstruction**
By: [Nishi M.](#), Matsumoto K., Tabata K., Ishii D., Tsumura H., Hirayama T., Fujita T., Iwamura M.
Institutes:Kitasato University School of Medicine, Dept. of Urology, Sagamihara, Japan

14:58 - 15:02

Associated video presentation P.Robo.S.C.I.S.: A novel non-dismembered technique for robotic pyeloplasty

F. Dal Moro, Padova (IT)

*129

What are factors that influence ureteral stent obstruction in patients with ureteral stricture?

By: [Ko Y.H.](#), Song P.H., Lee K.S., Choi J.Y., Jung H.C., Moon K.H.

Institutes:Yeungnam University, College of Medicine, Dept. of Urology, Daegu, South Korea

Associated video presentation

*130

Balloon dilatation of ureteric and ureteroileal strictures

By: [Yam W.L.](#)¹, Lim S.K.T.¹, Teo J.K.¹, Ng K.S.², Ng F.C.¹

Institutes:¹Changi General Hospital, Dept. of Urology, Singapore, Singapore, ²Changi General Hospital, Dept. of Radiology, Singapore, Singapore

Associated video presentation

*131

Ureteral endometriosis associated with hydronephrosis

By: [Fernandez Ramon C.](#)¹, Peri Cusi L.¹, Costa Grau M.¹, Melnick A.¹, Martínez-Zamora M.A.², Franco De Castro A.¹, Alcaraz Asensio A.¹, Carmona F.²

Institutes:¹Hospital Clinic of Barcelona, Dept. of Urology, Barcelona, Spain, ²Hospital Clinic of Barcelona, Dept. of Gynecology, Barcelona, Spain

Associated video presentation

*132

Comparison of initial experiences between full-length metallic stent and segmental metallic stent in malignant ureteral obstruction

By: [Han J.-Y.](#), Lee S.S., Jeong S.C., Park S-W., Chung M.K.

Institutes:Pusan National University Hospital, Dept. of Urology, Yangsan, South Korea

Associated video presentation

*133

Glyphosate-based herbicide effects on rat's kidney

By: Hamdaoui L.², [Naifar M.](#)¹, Chtrourou A.³, Fourati M.⁴, Mhiri N.⁴, Ayedi F.³, Rebai T.²

Institutes:¹Sfax Medicine College, Dept. of Research «molecular Bases of Human Diseases» 12es17, Sfax, Tunisia, ²Sfax Medicine College, Histology Embryology Laboratory, Sfax, Tunisia, ³Habib Bourguiba Hospital, Dept. of Biochemistry, Sfax, Tunisia, ⁴Habib Bourguiba Hospital, Dept. of Urology, Sfax, Tunisia

Associated video presentation

*134

Clinical management of spontaneous perirenal hematomas without renal causes: A new urological challenge

By: [La Falce S.](#), Sekulovic S., Morlacco A., Gigli F., Zattoni F., Mancini M.

Institutes:University of Padua, Dept. of Oncological and Surgical Sciences, Urology Clinic, Padua, Italy

Associated video presentation

*135

Benign lesions of upper urinary tract with nephroureterectomy: The preoperative characteristics

By: [Lu Z.](#), Ou C.

Institutes:National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan

Associated video presentation

15:30 - 15:37

Summary and context

M. Bultitude, London (GB)

Novel models for studying prostate cancer biology

Poster Session 12

Saturday, 12 March
14:15 - 15:45

Location: Room Vienna (Hall B2, level 0)

Chairs: M. Puhr, Innsbruck (AT)
J.A. Schalken, Nijmegen (NL)
G. Van Der Pluijm, Leiden (NL)

Aims and objectives of this presentation

Novel animal and cellular models have been extensively used in prostate cancer research. Because of the heterogeneity of human prostate cancer, it is particularly important to demonstrate applicability of these novel models to address clinically relevant questions. Mediators of stromal epithelial interactions and respective signaling pathways will be discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

14:38 - 14:48

Introduction

G. Van Der Pluijm, Leiden (NL)

*136

Periprostatic adipose tissue acts as a driving force for the local invasion of prostate cancer in obesity: Role of the CCR3/CCL7 axis

By: Roumiguie M.¹, Laurent V.², Toulet A.², Zaidi F.³, Valet P.⁴, Mazerolles C.³, Malavaud B.¹, Muller C.²

Institutes:¹Institut Universitaire Du Cancer, Dept. of Urology, Toulouse, France, ²Institut De Pharmacologie Et Biologie Structurale Du CNRS, Dept. of Oncology, Toulouse, France, ³Institut Universitaire Du Cancer, Dept. of Pathology, Toulouse, France, ⁴INSERM, U1048, Toulouse, France

*137

The neurosteroidogenic potential of metastatic prostate cancer cell lines under starvation treatment with abiraterone

By: Gomes De Mello Martins A.G.¹, Allegretta G.¹, Haupenthal J.¹, Eberhard J.¹, Van Der Zee J.², Unteregger G.², Stöckle M.², Junker K.², Hartmann R.W.¹, Ohlmann C-H.²

Institutes:¹Helmholtz Institute For Pharmaceutical Research Saarland, Dept. of Drug Design and Optimization, Saarbrücken, Germany, ²Saarland University Medical Center, Dept. of Urology, Homburg-Saar, Germany

*138

Exploring a novel therapeutic target for neuroendocrine prostate cancer using a xenograft model of trans-differentiation

By: Akamatsu S.¹, Wyatt A.², Lin D.², Lysakowski S.², Zhang F.², Kawai Y.², Fazli L.², Ogawa O.¹, Lotan T.³, Rubin M.⁴, Beltran H.⁵, Zoubeidi A.², Wang Y.², Gleave M.², Collins C.²

Institutes:¹Kyoto University Graduate School of Medicine, Dept. of Urology, Kyoto, Japan, ²Vancouver Prostate Centre, Dept. of Urologic Sciences, Vancouver, Canada, ³Johns Hopkins School of Medicine, Dept. of Pathology, Baltimore, United States of America, ⁴Weil Cornell Medical College, Dept. of Pathology and Laboratory Medicine, New York, United States of America, ⁵Weil Cornell Medical College, Dept. of Medicine, New York, United States of America

*139

Prostate cancer xenograft in vitro culture using organoid technology

By: Nicholson C.², Williams E.², Vela L.¹

Institutes:¹Princess Alexandra Hospital/Australian Prostate Cancer Research Centre-Queensland, Dept. of Urology, Woolloongabba, Australia, ²Queensland University of Technology, Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia

- *140 **Orthotopic xenografts using LuCaP136 spheroid cultures provide a versatile preclinical model of prostate cancer**
By: Linxweiler J.¹, Körbel C.², Valta M.³, Müller A.⁴, Junker K.¹, Stöckle M.¹, Menger M.D.², Peehl D.M.⁵, Saar M.¹
Institutes:¹Saarland University Medical Center, Dept. of Urology, Homburg/Saar, Germany, ²Saarland University Medical Center, Dept. of Clinical-Experimental Surgery, Homburg/Saar, Germany, ³Turku University Hospital and University of Turku, Dept. of Medicine, Turku, Finland, ⁴Saarland University Medical Center, Dept. of Diagnostic and Interventional Radiology, Homburg/Saar, Germany, ⁵Stanford University School of Medicine, Dept. of Urology, Stanford, United States of America
- *141 **Development of prostate intra-epithelial neoplasia in an aging series of PolgA mutator mice suggests a role for mitochondrial DNA mutations in prostate carcinogenesis**
By: Sachdeva A.¹, El-Sherif A.², Turnbull D.³, Greaves L.³, Heer R.¹
Institutes:¹Newcastle University, Northern Institute of Cancer Research, Newcastle upon Tyne, United Kingdom, ²Newcastle-Upon-Tyne NHS Foundation Trust, Dept. of Histopathology, Newcastle upon Tyne, United Kingdom, ³Newcastle University, Wellcome Trust Centre For Mitochondrial Research, Newcastle upon Tyne, United Kingdom
- *142 **Next generation sequencing to determine the clonal origin of lymph node metastasis in multifocal prostate cancer: Defining the biologically dominant nodule**
By: Salami S.¹, Hovelson D.², Mathieu R.³, Susani M.⁴, Rioux-Leclercq N.⁵, Tracey J.¹, Shariat S.³, Tomlins S.², Palapattu G.¹
Institutes:¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, ³Medical University Vienna, Dept. of Urology, Vienna, Austria, ⁴Medical University Vienna, Dept. of Pathology, Vienna, Austria, ⁵Rennes University Hospital, Dept. of Pathology, Rennes, France
- *143 **MED15 overexpression arises during androgen deprivation therapy via PI3K/mTOR signaling**
By: Offermann A.¹, Shaikhibrahim Z.¹, Syring I.², Vogel W.¹, Ruiz C.³, Zellweger T.⁴, Rentsch C.A.⁵, Bubendorf L.³, Perner S.¹
Institutes:¹University Hospital of Luebeck and Leibniz Research Center Borstel, Dept. of Pathology, Lübeck, Germany, ²University Hospital of Bonn, Dept. of Urology and Pediatric Urology, Bonn, Germany, ³University Hospital Basel, Institute for Pathology, Basel, Switzerland, ⁴St. Claraspital Basel, Dept. of Urology, Basel, Switzerland, ⁵University Hospital Basel, Dept. of Urology, Basel, Switzerland
- *144 **Expression of glucocorticoid receptors, androgen receptors and its splice variants in prostate cancer: Comparison between hormone dependent and castrate-resistant prostate cancer**
By: Shim M.¹, Choi S.K.², Kim Y.², Ahn T.Y.², Ahn H.²
Institutes:¹Hallym University Sacred Heart Hospital, Dept. of Urology, Anyang-Si, South Korea, ²Asan Medical Center, University of Ulsan College of Medicine, Dept. of Urology, Seoul, South Korea
- *145 **Tumour-stromal architecture influences prognosis and response to docetaxel in prostate cancer**
By: Bokobza S.², Hiew K.¹, Huby R.², Davies E.², Brown M.¹, Barry S.², Davies B.², Elliott T.³, Clarke N.⁴, Smith N.²
Institutes:¹Cancer Research UK Manchester Institute, The University of Manchester, Genito Urinary Cancer Research Group, Manchester, United Kingdom, ²AstraZeneca, R & D, Oncology IMed, Macclesfield, United Kingdom, ³Christie Hospital NHS Foundation Trust, Dept. of Oncology, Manchester, United Kingdom, ⁴Christie Hospital NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom
- *146 **Patient-derived three-dimensional spheroid cultures provide an innovative tool for comprehensive in-vitro studies on organ-confined prostate cancer**
By: Saar M.¹, Linxweiler J.¹, Muhs S.¹, Ohlmann C.H.¹, Jung V.¹, Pryalukhin A.², Junker K.¹, Stöckle M.¹
Institutes:¹Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Homburg/Saar, Germany, ²Saarland University Medical Center, Dept. of Pathology, Homburg/Saar,

Germany

*147

The C-Myc and TNF α /NF- κ B pathways are critically involved in the regulatory network between the undifferentiated prostate basal stem cell state and the more differentiated luminal prostate epithelial cells

By: Höfner T.¹, Klein C.², Eisen C.², Rigo-Watermeier T.², Haferkamp A.³, Trumpp A.², Sprick M.²

Institutes:¹University Hospital Frankfurt, Heidelberg Institute for Stem Cell Research and Experimental Medicine (HI-STEM), German Cancer Research Center (DKFZ), Frankfurt am Main, Germany, ²German Cancer Research Center (DKFZ), Heidelberg Institute for Stem Cell Research and Experimental Medicine (HI-STEM), Heidelberg, Germany, ³University Hospital Frankfurt, Dept. of Urology, Frankfurt am Main, Germany

Urological infections

Poster Session 13

Saturday, 12 March
14:15 - 15:45

Location: Room London (Hall B2, level 0)

Chairs: F. Bruyere, Tours (FR)
T. Cai, Trento (IT)

Aims and objectives of this presentation

Infectious urological diseases overview of current clinical and research state-of-the-art.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *148 **Four-year prospective study evaluating healthcare-associated infections (HAIs) in a urology ward: Risk factors, microbiological characteristics, and temporal evolution**
By: Medina Polo J., Sopeña-Sútil R., Arrébola-Pajares A., Pérez-Cadavid S., Benítez-Sala R., Lara-Isla A., Alonso-Isa M., Gil-Moradillo J., Justo-Quintas J., García-Rojo E., González-Padilla D.A., Aguilar-Gisbert L., Miranda-Utrera N., Passas-Martínez J.B., Tejido-Sánchez A.
Institutes:Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain
- *149 **Recommended initial antimicrobial therapy for emphysematous pyelonephritis: 51 cases and 14-year-experience of a tertiary referral center**
By: Lu Y-C.¹, Wang S-M.¹, Huang C-Y.²
Institutes:¹National Taiwan University Hospital Yun-Lin Branch, Dept. of Urology, Douliou City, Taiwan, ²National Taiwan University Hospital, Dept. of Urology, Taipei, Taiwan
- *150 **Is pre-operative urine culture sufficient to predict septic complications of percutaneous nephrolithotomy?**
By: Chakroun M., Kerkeni W., Bouzouita A., Saadi A., Ayed H., Cherif M., Derouiche A., Ben Slama M.R., Chebil M.
Institutes:Charles Nicolle Hospital, Dept. of Urology, Tunis, Tunisia
- *151 **Antibiotic prophylaxis is avoidable in minimally invasive clean surgery for renal or adrenal tumors: A prospective study of 678 cases**
By: Fujiwara M., Inoue M., Yokoyama M., Nakayama T., Ito M., Kijima T., Yoshida S., Ishioka J., Matsuoka Y., Numao N., Saito K., Fujii Y., Kihara K.
Institutes:Tokyo Medical And Dental University, Dept. of Urology, Tokyo, Japan
- *152 **Infections in patients with catheters into the upper urinary tract**
By: Medina Polo J., Lara-Isla A., Pérez-Cadavid S., Arrébola-Pajares A., Benítez-Sala R., Sopeña-Sutil R., Alonso-Isa M., Justo-Quintas J., Gil-Moradillo J., González-Padilla D.A., García-Rojo E., Aguilar-Gisbert L., Miranda-Utrera N., Passas-Martínez J.B., Tejido-Sánchez A.
Institutes:Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain
- *153 **Saving lives: Reducing the risk of catheter-associated urinary tract infections**
By: Clarke L.¹, Taylor J.¹, Rowbotham D.², Grayson S.², Morris F.³, Blears C.⁴, Hunt C.², Murphy P.⁵, Simpson R.¹, Kadler B.¹, O'Flynn K.¹, Shackley D.¹
Institutes:¹Salford Royal NHS Foundation Trust, Dept. of Urology, Salford, United Kingdom, ²Salford Royal NHS Foundation Trust, Dept. of Quality Improvement, Salford, United Kingdom, ³Salford Royal NHS Foundation Trust, Nursing and Corporate Services, Salford, United Kingdom, ⁴Salford Royal NHS Foundation Trust, Community Bladder and Bowel Service, Salford, United Kingdom, ⁵Salford Royal NHS Foundation Trust, Dept. of Nursing, Salford, United Kingdom

- *154 **Preoperative hospital stay would be risks of resistant bacteria emergence after radical cystectomy: Analysis of 11,410 cases**
 By: [Sugihara T.](#)¹, Yasunaga H.², Matsui H.², Fushimi K.³, Gondo T.⁴, Nakagami Y.⁴, Horiguchi Y.⁴, Ohno Y.⁴, Namiki K.⁴, Ohori M.⁴, Nakashima J.⁴, Tachibana M.¹, Homma Y.⁴
 Institutes:¹Tokyo Medical University, Dept. of Urology, Tokyo, Japan, ²The University of Tokyo, Dept. Clinical Epidemiology and Health Economics, Tokyo, Japan, ³Tokyo Medical and Dental University, Dept. Health Care Informatics, Tokyo, Japan, ⁴The University of Tokyo, Dept. of Urology, Tokyo, Japan
- *155 **Is targeted antibiotic prophylaxis for transrectal prostate biopsy based on rectal swab cultures still effective to prevent infective complications?**
 By: [Nasu Y.](#)¹, Murata T.¹, Kosaka N.²
 Institutes:¹Okayama Rosai Hospital, Dept. of Urology, Okayama, Japan, ²Okayama Rosai Hospital, Dept. of Clinical Laboratory, Okayama, Japan
- *156 **Increasing incidence of blood-culture positive infectious complications following transrectal prostate biopsies**
 By: Lahdensuo M.K.¹, [Rannikko A.](#)¹, Anttila V-J.², Erickson A.³, Pätäri-Sampo A.⁴, Rautio M.⁴, Santti H.¹, Tarkka E.⁴, Vaara M.⁴, Huotari K.²
 Institutes:¹Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ²Helsinki University Hospital, Dept. of Infectious Diseases, Helsinki, Finland, ³FIMM, Institute for Molecular Medicine, Helsinki, Finland, ⁴Helsinki University Hospital, Dept. of Clinical Microbiology, Helsinki, Finland
- *157 **Non-antibiotic strategies for reducing infective complications in men undergoing prostate biopsy: A systematic review and meta-analysis**
 By: [Pilatz A.](#)¹, Pradere B.², Yuan Y.³, Adewuyi T.⁴, Cek M.⁵, Pickard R.⁶, Bruyere F.²
 Institutes:¹Justus Liebig University of Giessen, Dept. of Urology, Pediatric Urology and Andrology, Gießen, Germany, ²University Hospital of Tours, Dept. of Urology, Tours, France, ³McMaster University, Faculty of Health Sciences, Hamilton, Canada, ⁴University of Aberdeen, Dept. of Academic Urology, Aberdeen, United Kingdom, ⁵Trakya University, Dept of Urology, Edirne, Turkey, ⁶Newcastle University, Dept. of of Cellular Medicine, Edirne, United Kingdom
- *158 **Targeted antibiotic prophylaxis reduces infectious complications following transrectal ultrasound guided prostate biopsy: Data from a developing country**
 By: [Singh P.](#)¹, Kumar A.¹, Kapil A.², Dogra P.N.¹
 Institutes:¹All India Institute of Medical Sciences, Dept. of Urology, New Delhi, India, ²All India Institute of Medical Sciences, Dept. of Microbiology, New Delhi, India
- *159 **Screening for fluoroquinolone resistant E coli in rectal flora prior to transrectal ultrasound guided prostate biopsy reduces the risk of post biopsy sepsis**
 By: [Holmes M.A.](#)¹, Lyons M.¹, Leyland J.¹, Devcich G.¹, Davies A.¹, Smit L.¹, Mansell C.²
 Institutes:¹Waikato Hospital, Dept. of Urology, Hamilton, New Zealand, ²Waikato Hospital, Dept. of Microbiology, Hamilton, New Zealand
- *160 **Accuracy of dipstick urine analysis and urine flow cytometry to predict bacteriuria prior to GreenLight laservaporisation of the prostate**
 By: [Bonkat G.](#)¹, Halla A.¹, Seifert H.¹, Müller G.¹, Egli A.², Regeniter A.³, Gasser T.¹, Bachmann A.¹, Rieken M.¹
 Institutes:¹University Hospital Basel, Dept. of Urology, Basel, Switzerland, ²University Hospital Basel, Dept. of Medical Microbiology, Basel, Switzerland, ³University Hospital Basel, Dept. of Laboratory Medicine, Basel, Switzerland
- *161 **Evaluation of risk factors for chronic bacterial prostatitis**
 By: [Lee G.](#)¹, Kim C.S.², Seo Y.¹
 Institutes:¹Dankook University Medical College, Dept. of Urology, Cheonan, ChungNam, South Korea, ²Chosun University Hospital, Dept. of Urology, Gwangju, South Korea
- *162 **Pharmacokinetics of fluoroquinolones into human epididymis**

By: Sadahira T., Wada K., Araki M., Ebara S., Watanabe M., Watanabe T., Nasu Y.

Institutes: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Dept. of Urology, Okayama, Japan

E-BLUS Exam

HOT 04

Saturday, 12 March
14:15 - 15:00

Location: Room South America (Hall B0, level 0)

Aims and objectives of this presentation

The European training in basic laparoscopic urological skills (E-BLUS) is a programme offered to residents and urologists who want to improve the basic skills in laparoscopy. It is a unique opportunity to train with international experts in laparoscopy. The E-BLUS programme includes:

- Hands-on training (HOT) sessions of different levels carried out under the guidance of experienced tutors
- A set of training-box exercises developed and validated by the Dutch project Training in Urology (TiU) to train basic skills needed in urological laparoscopy
- E-BLUS examination and certification
- An online theoretical course

M. Arslan, Izmir (TR)
A. Sempere Gutierrez, Murcia (ES)
T. Tokas, Hall In Tirol (AT)
P.J. Zondervan, Amsterdam (NL)
T. Kalogeropoulos, Athens (GR)
C. Wagner, Gronau (DE)

Screening and active surveillance – where are we now

ESU Course 07

Saturday, 12 March
14:30 - 17:30

Location: Room 13a (ICM, Level 1)

Chair: A.R. Zlotta, Toronto (CA)

Aims and objectives of this presentation

- Prostate cancer presents a global public. While the ERSPC has showed a reduction in prostate cancer mortality, the potential for negative effects from over-diagnosis and treatment cannot be ignored. This is why the evidence for and against prostate cancer screening remains controversial.
- Today's challenges include the age when to start screening, screening intervals and the optimal use of "intelligent screening" which would incorporate many factors other than PSA such as Family history, Ethnicity and Genetic factors.
- Active surveillance is now widely accepted as a management strategy for low risk prostate cancer with definitive treatment used if there is evidence that the patient is at increased risk for disease progression. Multiple studies consistently found a low rate of progression to metastatic disease or death from prostate cancer with active surveillance; in addition, the majority of patients did not require definitive therapy.
- Clinical and pathological factors influencing the risk of disease progression in patients with low risk prostate cancer under active surveillance, surveillance strategy, role of repeat biopsy, inclusion criteria, use of MRI will be discussed.

14:30 - 17:30

Screening

J.E. Hugosson, Göteborg (SE)

14:30 - 17:30

Active surveillance

A.R. Zlotta, Toronto (CA)

Advanced course on urethral stricture surgery

ESU Course 08

Saturday, 12 March
14:30 - 17:30

Location: Room 13b (ICM, Level 1)

Chair: R. Inman, Sheffield (GB)

Aims and objectives of this presentation

To update on latest advances and evidence for treatment for male urethral stricture disease including

- Investigations and assessment
- Minimally invasive and endoscopic treatment
- Urethroplasty for anterior urethral strictures (Penile and bulbar strictures)
- Surgery for posterior urethral strictures (Pelvic fracture injuries)

The course will consist of lectures, reviews of the evidence regarding treatment of strictures and interactive case discussions to illustrate decision making.

14:30 - 17:30

Introduction

R. Inman, Sheffield (GB)

14:30 - 17:30

Basic principles, anatomy and minimally invasive management of urethral stricture disease

P. Nyirády, Budapest (HU)

14:30 - 17:30

Management of anterior urethral stricture disease

R. Inman, Sheffield (GB)

14:30 - 17:30

Urethroplasty for posterior urethral injuries

L. Martínez-Piñeiro, Madrid (ES)

14:30 - 17:30

Female strictures

R. Inman, Sheffield (GB)

14:30 - 17:30

Interesting cases and final questions

R. Inman, Sheffield (GB)

L. Martínez-Piñeiro, Madrid (ES)

P. Nyirády, Budapest (HU)

Management of BPO: From medical to surgical treatment

ESU Course 09

Saturday, 12 March
14:30 - 17:30

Location: Room 11 (ICM, Level 1)

Chair: V.A.C. Ramani, Manchester (GB)

Aims and objectives of this presentation

- To help delegates understand the principles and evidence behind the assessment and medical management of a BPO patient.
- To summarise / review the evidence base for electro surgery and lasers for surgical management of BPO.
- Tips and Tricks to improve outcomes and avoid complications.
- To help delegates understand the factors that influence the patient's and surgeon's choice of treatment modalities

14:30 - 17:30

Introduction/scene setting BPO 2016

V.A.C. Ramani, Manchester (GB)

14:30 - 17:30

Assessment and medical management

V.A.C. Ramani, Manchester (GB)

14:30 - 17:30

Surgical management – Electrosurgery

A.G. Martov, Moscow (RU)

14:30 - 17:30

Surgical management – Lasers and less invasive options

S.A. Ahyai, Göttingen (DE)

14:30 - 17:30

Case presentations

S.A. Ahyai, Göttingen (DE)

A.G. Martov, Moscow (RU)

Retropubic radical prostatectomy – Tips, tricks and pitfalls

ESU Course 10

Saturday, 12 March
14:30 - 17:30

Location: Room 12 (ICM, Level 1)

Chair: H. Van Poppel, Leuven (BE)

Aims and objectives of this presentation

In many parts of Europe, open retropubic radical prostatectomy is still the gold standard for treating localised prostate cancer. The competition with radiotherapy and novel techniques like cryosurgery and HIFU, should encourage urologists to optimally perform the surgical resection .

This teaching course is a must for the elder resident and the younger urologist but well trained urologists who do not treat many patients with localised prostate cancer, will benefit.

14:30 - 17:30

Introduction

H. Van Poppel, Leuven (BE)

14:30 - 17:30

Surgical anatomy

O.W. Hakenberg, Rostock (DE)

14:30 - 17:30

Step by step radical retropubic prostatectomy

H. Van Poppel, Leuven (BE)

14:30 - 17:30

Tips, tricks and pitfalls

O.W. Hakenberg, Rostock (DE)

14:30 - 17:30

Treatment of complications

H. Van Poppel, Leuven (BE)

14:30 - 17:30

Discussion and interaction

Urinary tract and genital trauma

ESU Course 11

Saturday, 12 March
14:30 - 17:30

Location: Room 21 (ICM, Level 2)

Chair: D.M. Sharma, London (GB)

Aims and objectives of this presentation

Trauma is a leading cause of death and morbidity in civilian populations. All Urologists will have to manage trauma patients and need to understand basic principles. The EAU Guidelines Group prepare guidelines in order to assist in the management of urological trauma and these principles will be followed for the specific organ systems and in the context of polytrauma.

- Urological trauma is usually associated with other injuries. The role of the urologist in polytrauma is important to understand.
- Modern diagnostic imaging and interventional radiology techniques has resulted in a greater understanding of organ injury and treatment
- Increasing use is made of non-operative or delayed surgical intervention with a resulting higher rate of organ preservation.
- Minimising long term morbidity is an important role for injuries that are usually not life threatening.

14:30 - 17:30

Introduction

D.M. Sharma, London (GB)

14:30 - 17:30

General trauma considerations

D.M. Sharma, London (GB)

14:30 - 17:30

Blunt and penetrating renal trauma

P. Macek, Prague (CZ)

14:30 - 17:30

Ureteric injuries – diagnosis and treatment

D.M. Sharma, London (GB)

14:30 - 17:30

Bulbar and bulbomembranous urethral trauma

P. Macek, Prague (CZ)

14:30 - 17:30

Bladder, penile and testicular trauma

D.M. Sharma, London (GB)

14:30 - 17:30

Case presentations

D.M. Sharma, London (GB)

P. Macek, Prague (CZ)

Prolapse management and female pelvic floor problems

ESU Course 12

Saturday, 12 March
14:30 - 17:30

Location: Room 22 (ICM, Level 2)

Chair: D.J.M.K. De Ridder, Leuven (BE)

Aims and objectives of this presentation

This course gives practical information about prolapse management by urologists. From anatomy to mesh implant, the recent revival of native tissue repairs and the management of complications. Also laparoscopic and robotic approaches will be evaluated.

14:30 - 17:30

Vaginal surgical anatomy for urologists

E. Kocjancic, Chicago (US)

14:30 - 17:30

Investigations and imaging for POP

D.J.M.K. De Ridder, Leuven (BE)

14:30 - 17:30

Vaginal Native tissue repair

D.J.M.K. De Ridder, Leuven (BE)

14:30 - 17:30

Vaginal Mesh repair

E. Kocjancic, Chicago (US)

14:30 - 17:30

Open/laparoscopic/robotic repair

H. Hashim, Bristol (GB)

14:30 - 17:30

Classification and Management of complications & case discussion

H. Hashim, Bristol (GB)

E. Kocjancic, Chicago (US)

EAU Research Foundation Meeting

Special session

Saturday, 12 March
14:45 - 17:00

Location: Room 3 (ICM, Level 0)

Chair: P.F.A. Mulders, Nijmegen (NL)

14:45 - 14:55

Welcome

P.F.A. Mulders, Nijmegen (NL)

14:55 - 15:10

Do cancer stem cells play a role in resistance to conventional therapies in PCa? EAU Research Foundation career track fellow

J. Ceder, Malmö (SE)

15:10 - 15:25

PCa: The use of image guidance for diagnosis. EAU Research Foundation project 'PRECISION'

M. Emberton, London (GB)

15:25 - 15:40

Can we optimize adjuvant treatment of intermediate/high risk NMIBC from a patients' perspective?

M-O. Grimm, Jena (DE)

15:40 - 15:55

Adjuvant Treatment of MIBC: The unmet clinical need. Lessons from EAU Research Foundation project 'MAGNOLIA'

P.F.A. Mulders, Nijmegen (NL)

15:55 - 16:10

Patient selection for pharmacological treatment of LUTS due to BPH. EAU Research Foundation project 'EVOLUTION'

A. Tubaro, Rome (IT)

16:10 - 16:25

Individual management of patients with incidental small renal masses. EAU Research Foundation project 'EASE'

A. Volpe, Torino (IT)

16:25 - 16:40

Antibiotic resistance in UTI. A current or future issue for the urologist? EAU Research Foundation project 'GPIU/SERPENS'

T.E. Bjerklund Johansen, Oslo (NO)

16:40 - 16:50

Patient selection for minimal invasive therapy of stress urinary incontinence, ESFFU/EAU Research Foundation project

R. Hamid, London (GB)

16:50 - 17:00

Closure and farewell

P.F.A. Mulders, Nijmegen (NL)

E-BLUS Exam

HOT 05

Saturday, 12 March
15:15 - 16:00

Location: Room South America (Hall B0, level 0)

Aims and objectives of this presentation

The European training in basic laparoscopic urological skills (E-BLUS) is a programme offered to residents and urologists who want to improve the basic skills in laparoscopy. It is a unique opportunity to train with international experts in laparoscopy. The E-BLUS programme includes:

- Hands-on training (HOT) sessions of different levels carried out under the guidance of experienced tutors
- A set of training-box exercises developed and validated by the Dutch project Training in Urology (TiU) to train basic skills needed in urological laparoscopy
- E-BLUS examination and certification
- An online theoretical course

To be confirmed

W. Brinkman, Rotterdam (NL)

B.S.E.P. Van Cleynenbreugel, Wolfsdonk (BE)

T. Tokas, Hall In Tirol (AT)

T. Kalogeropoulos, Athens (GR)

To be confirmed

ESU/ESFFU Hands-on training in OnabotulinumtoxinA administration for OAB

HOT 15

Saturday, 12 March
15:30 - 17:00**Location:** Room Europe (Hall B0, level 0)**Chair:** M.J. Drake, Bristol (GB)**Aims and objectives of this presentation**

Botulinum toxin type A administration in Urology has become common practice over the last two decades. Following the completion of Phase 3 registration trials in OAB, OnabotulinumtoxinA received marketing approval for this indication and now has a standardised injection paradigm. This course is procedure-focused, and will teach attendees the practicalities of OnabotulinumtoxinA administration through short lectures, videos and hands-on demonstrations using bladder models. Attendees will learn how to reconstitute the product and see different types of equipment available.

E. Chartier-Kastler, Paris (FR)

A. Sahai, London (GB)

M.S. Rahnama'i, Heerlen (NL)

ESU/ERUS Hands-on training in Robotic surgery

HOT 11

Saturday, 12 March
15:30 - 17:00

Location: Room Asia (Hall B0, level 0)

Chair: J.S. Schraml, Usti Nad Labem (CZ)

Aims and objectives of this presentation

The European School of Urology (ESU) and the EAU Robotic Urology Section (ERUS) offer an intensive hands-on training course. We will provide training using simulators. The main aims of this 90 minutes course are: improving the participants' control-skills and hand-eye-coordination, as well as an objective benchmarking of console performance and an introduction into standardized surgical steps in robot-assisted procedures.

To be confirmed

A. Ploumidis, Athens (GR)

The changing landscape of surgery for prostate cancer

Poster Session 14

Saturday, 12 March
16:00 - 17:30

Location: Room Stockholm (Hall B2, level 0)

Chairs: R. Khaulil, Beirut (LB)
R.E. Sanchez Salas, Paris (FR)
T. Sulser, Zürich (CH)

Aims and objectives of this presentation

During this session the trends in surgically treated patients profiles, in morbidity of surgical approaches, in risk of death after radical prostatectomy and in new subclassification systems for our patients will be discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*163

Historical trends in high-risk prostate cancer patients characteristics: A 27 years old observational study from the European multicenter prostate cancer clinical and translational research group (EMPaCT) data base

By: Bianchi M.¹, Briganti A.², Karnes J.³, Gandaglia G.², Fossati N.², Spahn M.⁴, Gontero P.⁵, Tosco L.⁶, Kneitz B.⁷, Chun F.⁸, Zaffuto E.², De Ridder D.⁶, Sun M.⁹, Graefen M.¹⁰, Marchioro G.¹¹, Frohneberg D.¹², Guilloneau B.¹³, Giona S.⁵, Sanchez-Salas R.¹⁴, Cathelineau X.¹⁴, Karakiewicz P.⁹, Van Poppel H.⁶, Montorsi F.², Joniau S.⁶

Institutes:¹Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology; URI, Milan, Italy, ³Mayo Medical School and Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁴University of Berne, Dept. of Urology, Berne, Switzerland, ⁵University of Turin, Molinette Hospital, Dept. of Urology, Turin, Italy, ⁶University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁷University Hospital Wurzburg, Dept. of Urology and Pediatric Urology, Wurzburg, Germany, ⁸University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁹University of Montreal Health Center, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Quebec, Canada, ¹⁰University Medical Center Hamburg-Eppendorf, Martini-Clinic, Prostate Cancer Centre, Hamburg, Germany, ¹¹University of Piemonte Orientale, Dept. of Urology, Novara, Italy, ¹²Community Hospital Karlsruhe, Dept. of Urology, Karlsruhe, Germany, ¹³Memorial Sloan-Kettering Cancer Center, Dept. of Urology Service and Surgery, New York, United States of America, ¹⁴Institut Mutualiste Montsouris, Dept. of Urology, Paris, France

*164

Restratification of high risk prostate cancer according to NCCN guideline for patients who underwent radical prostatectomy: Analysis from K-CaP registry

By: Lee K.S.¹, Koo K.C.¹, Choi I.Y.², Lee J.Y.³, Hong J.H.⁴, Kim C-S.⁴, Lee H.M.⁵, Hong S.K.⁶, Rha K.H.⁷, Chung B.H.⁷

Institutes:¹Urological Science Institute, Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Graduate School of Management and Policy, The Catholic University of Korea, Dept. of Urology, Seoul, South Korea, ³Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Dept. of Urology, Seoul, South Korea, ⁴Asan Medical Center, University of Ulsan College of Medicine, Dept. of Urology, Seoul, South Korea, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea, ⁶Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, South Korea, ⁷Urological Science Institute, Yonsei University College of Medicine, Dept. of Urology, Seongnam, South Korea

*165

National trends and differences in morbidity among surgical approaches for radical prostatectomy in Germany

By: Stolzenburg J.U., [Kyriazis L.](#), Gilfrich C., Popken G., Weißbach L., Von Zastrow C., Fahlenbrach C., Günster C., Jeschke E., Leicht H.

Institutes:University of Leizig, Dept. of Urology, Leipzig, Germany

*166 **Trend of global quality of life in localized or metastatic prostate cancer patients after treatment: A 5-year Kernel smoothing curve analysis**

By: [Kao Y-L.](#)¹, Tsai Y-S.¹, Ou F-Y.¹, Lin Z-Y.², Ou C-H.¹, Yang W-H.¹, Cheng H-L.¹, Tzai T-S.¹, Wang J-D.²

Institutes:¹National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, ²National Cheng Kung University, Dept. of Public Health, Tainan, Taiwan

*167 **Prostate cancer death after radical prostatectomy or radiotherapy: Nationwide population-based study**

By: [Robinson D.](#)¹, Garmo H.², Franck Lissbrant I.³, Nilsson P.⁴, Widmark A.⁵, Stattin P.⁶

Institutes:¹Ryhov County Hospital, Dept. of Urology, Eksjö, Sweden, ²Uppsala University Hospital, Dept. of Cancer, Uppsala, Sweden, ³Sahlgrenska Academy, Dept. of Oncology, Gothenburg, Sweden, ⁴Skåne University Hospital, Dept. of Oncology and Radiation Physics, Lund, Sweden, ⁵Umeå University, Dept. of Radiation Sciences, Umeå, Sweden, ⁶Umeå University, Dept. of Surgery and Perioperative Sciences, Urology and Andrology, Umeå, Sweden

*168 **Pathologic outcomes using different extended templates for lymph node dissection at radical prostatectomy**

By: Maderthaner L., [Furrer M.](#), Burkhard F., Thalmann G., Studer U., Nguyen D.

Institutes:University Hospital Berne, Dept. of Urology, Berne, Switzerland

*169 **Pathological analysis of patients undergoing radical prostatectomy who were potential candidates for focal therapy**

By: Oliveira Soares R.M.¹, Haagsma B.², Laing R.³, Patil K.¹, [Eden C.](#)¹, Langley S.¹

Institutes:¹Royal Surrey County Hospital, Dept. of Urology, Guildford, United Kingdom, ²Royal Surrey County Hospital, Dept. of Pathology, Guildford, United Kingdom, ³St. Luke's Cancer Centre, Dept. of Oncology, Guildford, United Kingdom

*170 **Hypogonadism independently predicts pathological Gleason pattern 5 at the time of radical prostatectomy**

By: [Moschini M.](#)¹, Dell'Oglio P.¹, Fossati N.¹, Gandaglia G.¹, Larcher A.¹, Stabile A.¹, Saitta G.¹, Ventimiglia E.¹, Barbagli G.², Shariat S.³, Bollens R.⁴, Montorsi F.¹, Briganti A.¹

Institutes:¹IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy, ²Centro Chirurgico Toscano, Dept. of Urology, Arezzo, Italy, ³Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁴Jules Bordet Institute, Université Libre De Bruxelles, Dept. of Urology, Brussels, Belgium

*171 **Factors improving lymph node invasion detection during pelvic lymph node dissection for prostate cancer: Outcomes of 2160 lymph node dissections**

By: [Kyriazis L.](#)¹, Do M.¹, Dietel A.¹, Ganzer R.¹, Alloussi S.¹, Kallidonis P.², Liatsikos E.², Stolzenburg J.U.¹

Institutes:¹University of Leizig, Dept. of Urology, Leipzig, Germany, ²University of Patras, Dept. of Urology, Patras, Greece

*172 **A new sub-classification system for decision making with intermediate risk prostate cancer patients treated by radical prostatectomy: A multicenter study**

By: [Beauval J.B.](#)¹, Ploussard G.², Ouzzane A.³, Gougeon A.¹⁶, Cabarro B.¹⁷, Gas J.¹, Marcq G.⁴, Mathieu R.⁵, Fromont G.⁶, Hennequin C.⁷, Vincendeau S.⁵, Renard Penna R.⁸, Azria D.⁹, Beuzeboc P.¹⁰, Cormier L.¹¹, Mongiat Artus P.¹², De La Taille A.¹³, Roupret M.¹⁴, Salomon L.¹³, Soulié M.¹, Mejean A.¹⁵, Rozet F.¹⁶

Institutes:¹CHU Rangueil, Dept. of Urology, Toulouse, France, ²St Jean Hospital, Dept. of Urology, Toulouse, France, ³CHU Lille, Dept. of Urology, Lille, France, ⁴CHU, Dept. of Urology, Lille, France, ⁵CHU, Dept. of Urology, Rennes, France, ⁶CHU, Dept. of Pathology, Tours, France, ⁷CHU St Louis, Dept. of Radiotherapy, Paris, France, ⁸CHU La Pitié Salpêtrière, Dept. of Radiology, Paris, France, ⁹

ICM, Dept. of Radiotherapy, Montpellier, France, ¹⁰Curie Institute, Dept. of Oncology, Paris, France, ¹¹CHU, Dept. of Urology, Dijon, France, ¹²CHU St Louis, Dept. of Urology, Paris, France, ¹³CHU Mondor, Dept. of Urology, Créteil, France, ¹⁴CHU La Pitié Salpêtrière, Dept. of Urology, Paris, France, ¹⁵HEGP, Dept. of Urology, Paris, France, ¹⁶IMM, Dept. of Urology, Paris, France, ¹⁷IUCT-O, Dept. of Statistics, Toulouse, France

*173

Prognostic significance of vas deferens invasion after radical prostatectomy in patients with pathological stage T3b prostate cancer

By: Jang W.S.¹, Han J.H.¹, Kang Y.J.¹, Yoon C.Y.¹, Kwon J.K.¹, Lee J.Y.¹, Cho K.S.¹, Ham W.S.¹, Kim W.T.³, Kim Y.S.², Choi Y.D.¹

Institutes:¹Urological Science Institute, Yonsei University College Of Medicine, Dept. of Urology, Seoul, South Korea, ²National Health Insurance Corporation Ilsan Hospital, Dept. of Urology, Goyang, South Korea, ³Chungbuk National University College of Medicine, Dept. of Urology, Cheongju, South Korea

*174

Level of education and mortality after radical prostatectomy

By: Fröhner M.¹, Koch R.², Propping S.¹, Hübler M.³, Wirth M.³

Institutes:¹Technical University Dresden, Dept. of Urology, Dresden, Germany, ²Technical University Dresden, Dept. of Medical Informatics, Dresden, Germany, ³Technical University Dresden, Dept. of Anesthesiology, Dresden, Germany

*175

Does neoadjuvant hormonal therapy stimulate cancer cell dissemination via increasing of lymph vessel size in prostate cancer patients?

By: Miyata Y., Hakariya T., Shida Y., Asai A., Yasuda T., Matsuo T., Ohba K., Sakai H.

Institutes:Nagasaki University Graduate School Of Biomedical Sciences, Nagasaki, Japan

How to improve functional outcome in robot-assisted radical prostatectomy

Video Session 03

Saturday, 12 March
16:00 - 17:30

Location: Room 1 (ICM, Level 0)

Chairs: B.H. Chung, Seoul (KR)
B. Rocco, Milan (IT)
R.F. Van Velthoven, Brussels (BE)

Aims and objectives of this presentation

With regard to what is today considered as state-of-the-art in the fields of RARP, this session could emphasize some new technical contributions to improve continence and potency after surgery. Participants should be able to distinguish relevant contributions from anecdotal reports.

All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.

- *V17 **Early NVBs release in RARP: The technique**
By: [Ferrari M.](#), Fabbri F., Zaroni M., Ghezzi M., Sangalli M., Sozzi F., Lolli C., Dell'Acqua V., Rigatti P., Cestari A.
Institutes: Istituto Auxologico Italiano, Dept. of Urology, Milan, Italy
- *V18 **Full neurovascular preservation in radical prostatectomy**
By: Mearini E., [Boni A.](#), Pohja S., Barillaro F., Cochetti G.
Institutes: University of Perugia, Dept. of Surgical and Biomedical Sciences, Perugia, Italy
- *V19 **A novel technique of dynamic lateral suspension of posterior reconstruction suture (DLSPRS) after vesico-urethral anastomosis during robotic radical prostatectomy - improves early continence**
By: [Thyaviahally Y.](#), Pednekar A., Kaushik T., Kalyan C., Waigaonkar S.
Institutes: Kokilaben Dhirubhai Ambani Hospital, Dept. of Uro-oncology, Mumbai, India
- *V20 **Bladder neck sparing (BNS) robot assisted laparoscopic prostatectomy (RALP): Does it improve continence?**
By: [Zakri R.H.](#), Vedanayagam M., John B., Hearnden B., Simpson P., Eddy B.
Institutes: Kent & Canterbury Hospital, East Kent Nhs University Foundation Trust, Dept. of Urology, Canterbury, United Kingdom
- *V21 **Robot-assisted functional reconstruction of urethral support during radical prostatectomy**
By: [Student Jr. V.](#), Hartmann I., Vidlar A., Grepl M., Student V.
Institutes: University Hospital Olomouc, Dept. of Urology, Olomouc, Czech Republic
- *V22 **Six-branches suburethral autologous sling placed during robotic radical prostatectomy to improve early urinary continence recovery: A technical evolution in the sling concept**
By: [Cestari A.](#), Sangalli M., Fabbri F., Ferrari M., Zaroni M., Ghezzi M., Sozzi F., Dell'Acqua V., Lolli C., Rigatti P.
Institutes: Istituto Auxologico Italiano, Dept. of Urology, Milan, Italy
- *V23 **The use of scaffolding tissue biografts to bolster the vesicourethral anastomosis during salvage robot-assisted radical prostatectomy reduces leak rates and catheter times**
By: Kadakia Y., [Ogaya Pinies G.](#), Samavedi S., Mouraviev V., Coelho R., Rocco B., Anup K., Ganapathi H., Marquinez J., Patel V.
Institutes: Global Robotic Institute, Dept. of Urology, Celebration, United States of America

*V24

A new single barbed bidirectional suture (Filbloc, Assut SPA) for posterior muscolofascial reconstruction and knotless urethrovesical anastomosis during RARP

By: Schiavina R.¹, Bianchi L.¹, Salvaggio A.², Borghesi M.¹, Cappa E.², Dente D.², Brunocilla E.¹, Dababneh H.¹, Chessa F.¹, Caffarelli A.², Vagnoni V.¹, Pultrone C.V.¹, Giampaoli M.¹, Martorana G.¹, Porreca A.²

Institutes:¹University of Bologna-S. Orsola-Malpighi Hospital, Dept. of Urology, Bologna, Italy, ²Policlinic of Abano Terme, Dept. of Urology, Abano Terme, Italy

Infertility: Clinical

Poster Session 15

Saturday, 12 March
16:00 - 17:30

Location: Room Milan (Hall B2, level 0)

Chairs: G.R. Dohle, Rotterdam (NL)
A. Kadioglu, Istanbul (TR)

Aims and objectives of this presentation

The aim of the session is to provide the audience with up-to-date knowledge on the treatment of common etiologies of male factor infertility such as varicoceles and azoospermia and the latest results of Micro-TESE. The session will include a variety of research spanning from the role of semen analysis in evaluation of male infertility to clinical implication of genetic testing which can be readily implemented in the andrology clinic.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*176

Varicocele is negatively associated with semen quality and hormone levels: A study of 7067 men from six European countries

By: Damsgaard J.², Joensen U.N.¹, Carlsen E.³, Erenpreiss J.⁴, Jensen M.B.², Matulevicius V.⁵, Olesen I.A.², Perheentupa A.⁶, Punab M.⁷, Salzbrunn A.⁸, Toppari J.⁹, Virtanen H.⁹, Zilaitiene B.⁵, Juul A.², Skakkebaek N.E.², Jørgensen N.²

Institutes:¹Roskilde Hospital, Dept. of Urology, Roskilde, Denmark, ²University Hospital of Copenhagen, Rigshospitalet, Dept. of Growth and Reproduction, Copenhagen, Denmark, ³University Hospital of Copenhagen, Rigshospitalet, Dept. of Fertility, Copenhagen, Denmark, ⁴Biomedicine Study and Research Center, Biomedicine Study and Research Center, Riga, Latvia, ⁵Lithuanian University of Health Sciences, Medical Academy, Institute of Endocrinology, Kaunas, Lithuania, ⁶Turku University Hospital, Dept. of Obstetrics and Gynecology, Turku, Finland, ⁷Tartu University Hospital, Dept. of Andrology, Tartu, Estonia, ⁸Universitätsklinikum Hamburg-Eppendorf, Dept. of Andrology, Hamburg, Germany, ⁹University of Turku, Dept. of Physiology and Department of Paediatrics, Turku, Finland

*177

Evolution of the therapeutic management of varicoceles: Analysis of French national coding database (2006-2014)

By: Forzini T.¹, Alezra E.¹, Demailly M.¹, Lewandowski E.², Saint F.¹

Institutes:¹Amiens University Hospital, Dept. of Urology and Transplantation, Amiens, France, ²Amiens University Hospital, Dept. of Medical Information, Amiens, France

*179

Retrospective study of multiple factors affecting surgical outcomes and patency rates in use of single-armed two-suture technique for microsurgical vasoepididymostomy: A single surgeon's experience with 81 patients

By: Hong K.¹, Zhao L.¹, Xu S.¹, Tang W.¹, Mao J.², Liu D.², Lin H.¹, Zhang H.², Jiang H.¹, Ma L.¹, Qiao J.²

Institutes:¹Peking University Third Hospital, Dept. of Urology, Beijing, China, ²Peking University Third Hospital, Dept. of Obstetrics and Gynecology, Beijing, China

*181

CFTR gene polymorphisms are associated with reduced sperm progressive motility in Caucasian-European men with idiopathic infertility: Clinical implication in genetic testing

By: Ventimiglia E.¹, Capogrosso P.¹, Boeri L.¹, Ippolito S.¹, Scano R.¹, Moretti D.¹, La Croce G.¹, Dehò F.¹, Rocco D.², Briganti A.¹, Montorsi F.¹, Salonia A.¹

Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Magna Graecia University, Research Doctorate Program In Urology, Catanzaro, Italy

- *182 **Validation of the European Association of Urology guidelines for couple's infertility in terms of genetic assessment in a cohort of Caucasian-European men with primary infertility in the real-life setting**
By: Ventimiglia E.¹, Capogrosso P.¹, Boeri L.¹, Ippolito S.¹, La Croce G.¹, Pederzoli F.¹, Scano R.¹, Dehò F.¹, Briganti A.¹, Mirone V.², Montorsi F.¹, Salonia A.¹
Institutes:¹Irccs Ospedale San Raffaele, Division of Experimental Oncology/unit of Urology; Uri, Milan, Italy, ²University of Naples Federico,II, Dept. of Urology, Milan, Italy
- *183 **Male infertility problems of patients with sperm morphology between 5-14%**
By: Jensen C.¹, Khan O.², Nagras Z.¹, Sonksen J.¹, Fode M.¹, Shah T.³, Ohl D.²
Institutes:¹Herlev Hospital, Dept. of Urology, Herlev, Denmark, ²University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ³University of Michigan, Dept. of Obstetrics and Gynecology, Ann Arbor, United States of America
- *184 **The early and late effects of cancer on semen parameters in men**
By: Poullis C.¹, Abumelha S.¹, Almashat F.¹, Williamson E.¹, Yap T.², Ralph D.¹, Minhas S.¹
Institutes:¹University College London Hospitals, Dept. of Urology, London, United Kingdom, ²St. George's Hospital, Dept. of Urology, London, United Kingdom
- *185 **Microdissection onco-TESE in men with azoospermia and cancer**
By: Abumelha S.¹, Poullis C.¹, Almashat F.¹, Yap T.², Williamson E.¹, Ralph D.J.¹, Minhas S.¹
Institutes:¹University College London Hospitals, Dept. of Urology, London, United Kingdom, ²St George's Hospital, Dept. of Urology, London, United Kingdom
- *186 **Microdissection TESE in men with maturation arrest: An outcome analysis**
By: Yap T.¹, Abumelha S.², Poullis C.², Almashat F.², Williamson E.², Ralph D.², Minhas S.²
Institutes:¹St George's Hospital, Dept. of Urology, London, United Kingdom, ²University College London Hospitals, Dept. of Urology, London, United Kingdom
- *187 **From clinical presentations of NOA males to predict the outcome of microdissection TESE**
By: Ku M-H., Huang W.J-S., Huang I.S., Lin T.L., Chen K-K.
Institutes:Taipei Veterans General Hospital, Dept.of Urology, Taipei, Taiwan
- *188 **Live birth rates in men undergoing microdissection TESE in non-obstructive azoospermia (NOA)**
By: Abumelha S.¹, Poullis C.¹, Almashat F.A.¹, Yap T.L.³, Rushwan N.², Thum Y.², Abdallah H.², Minhas S.¹
Institutes:¹University College London Hospitals, Dept. of Urology, London, United Kingdom, ²Lister Fertility Clinic, Dept. of Assisted Reproduction, London, United Kingdom, ³St George's Hospital, Dept. of Urology, London, United Kingdom
- *189 **The effect of alcohol, smoking and male age on semen parameters and IVF/ICSI outcomes – is there a correlation?**
By: Almashat F.¹, Abumelha S.¹, Poullis C.¹, Yap T.², Rushwan N.³, Abdalla H.³, Thum M.Y.³, Minhas S.¹
Institutes:¹University College Hospital, Dept. of Andrology, London, United Kingdom, ²St. Georges Hospital-NHS Foundation Trust, Dept. of Andrology, London, United Kingdom, ³Lister Fertility Clinic, Dept. of Assisted Reproduction, London, United Kingdom

Sphincters and slings in the male

Poster Session 16

Saturday, 12 March
16:00 - 17:30

Location: Room 14a (ICM, Level 1)

Chairs: R. Bauer, Munich (DE)
C. Gozzi, Bressanone (IT)
J.P.F.A. Heesakkers, Nijmegen (NL)

Aims and objectives of this presentation

Post-prostatectomy incontinence has a high impact on the QoL. This session reviews some new data on this topic.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*190

Long-term functional outcomes and durability of artificial urinary sphincter

By: Suh Y.S.¹, Ko K.J.¹, Yoo J.H.¹, Sung H.H.¹, Jeong J.², Lee K-S.¹

Institutes:¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Center for Health Promotion, Seoul, South Korea

*191

Complications and short-term explantation rate following single-cuff vs double-cuff artificial urinary sphincter implantation

By: Kretschmer A.¹, Hüscher T.², Thomsen F.², Kronlachner D.², Obaje A.³, Anding R.⁴, Pottke T.⁵, Rose A.⁶, Olianias R.⁷, Friedl A.⁸, Hübner W.⁹, Homberg R.¹⁰, Pfitzenmaier J.¹¹, Grein U.¹², Queissert F.¹³, Naumann C.M.¹⁴, Schweiger J.¹⁵, Wotzka C.¹⁶, Nyarangi-Dix J.¹⁷, Hofmann T.¹⁸, Seiler R.¹⁹, Haferkamp A.², Bauer R.¹

Institutes:¹LMU-Klinikum der Universität München, Dept. of Urology, Munich, Germany, ²University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ³University Hospital Jena, Dept. of Urology, Jena, Germany, ⁴University Hospital Bonn, Dept. of Urology, Bonn, Germany, ⁵Asklepios Hospital West Hamburg, Dept. of Urology, Hamburg, Germany, ⁶Helios Hospital Duisburg, Dept. of Urology, Duisburg, Germany, ⁷Hospital Lüneburg, Dept. of Urology, Lüneburg, Germany, ⁸Hospital Göttlicher Heiland Vienna, Dept. of Urology, Vienna, Austria, ⁹Hospital Weinviertel Korneuburg, Dept. of Urology, Korneuburg, Austria, ¹⁰St. Barbara Hospital Hamm, Dept. of Urology, Hamm, Germany, ¹¹Evangelic Hospital Bielefeld, Dept. of Urology, Bielefeld, Germany, ¹²Helios Hospital Schwelm, Dept. of Urology, Schwelm, Germany, ¹³University Hospital Münster, Dept. of Urology, Münster, Germany, ¹⁴University Hospital Kiel, Dept. of Urology, Kiel, Germany, ¹⁵Catholic Hospital St. Johann Nepomuk, Dept. of Urology, Erfurt, Germany, ¹⁶Diakonie Hospital Stuttgart, Dept. of Urology, Stuttgart, Germany, ¹⁷University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ¹⁸Diakonie Hospital Schwäbisch Hall, Dept. of Urology, Schwäbisch Hall, Germany, ¹⁹Vancouver Prostate Centre, Dept. of Urological Sciences, Vancouver, Canada

*192

Impact of antibiotic coating (InhibiZone®) on infection and explantation rates of the artificial urinary sphincter AMS 800®

By: Hüscher T.¹, Kretschmer A.², Thomsen F.¹, Kronlachner D.¹, Kurosch M.¹, Obaje A.³, Anding R.⁴, Pottke T.⁵, Rose A.⁶, Olianias R.⁷, Friedl A.⁸, Hübner W.⁹, Homberg R.¹⁰, Pfitzenmaier J.¹¹, Grein U.¹², Queissert F.¹³, Naumann C.M.¹⁴, Schweiger J.¹⁵, Wotzka C.¹⁶, Nyarangi-Dix J.¹⁷, Hofmann T.¹⁸, Ulm K.¹⁹, Bauer R.M.², Haferkamp A.¹

Institutes:¹University Hospital Frankfurt, Dept. of Urology and Paediatric Urology, Frankfurt, Germany, ²Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, ³University Hospital Jena, Dept. of Urology, Jena, Germany, ⁴University Hospital Bonn, Dept. of Urology and Paediatric Urology, Bonn, Germany, ⁵Asklepios Hospital West Hamburg, Dept. of Urology,

Hamburg, Germany, ⁶Helios Hospital Duisburg, Dept. of Urology and Paediatric Urology, Duisburg, Germany, ⁷Hospital Lüneburg, Dept. of Urology, Lüneburg, Germany, ⁸Göttlicher Heiland Vienna, Dept. of Urology, Vienna, Austria, ⁹Hospital Weinviertel Korneuburg, Dept. of Urology, Korneuburg, Austria, ¹⁰St. Barbara Hospital Hamm GmbH, Dept. of Urology and Paediatric Urology, Hamm, Germany, ¹¹Evangelic Hospital Bielefeld, Dept. of Urology, Bielefeld, Germany, ¹²Helios Hospital Schwelm, Dept. of Urology and Paediatric Urology, Schwelm, Germany, ¹³University Hospital Muenster, Dept. of Urology and Paediatric Urology, Muenster, Germany, ¹⁴University Hospital Kiel, Dept. of Urology and Paediatric Urology, Kiel, Germany, ¹⁵Catholic Hospital St. Johann Nepomuk, Dept. of Urology and Paediatric Urology, Erfurt, Germany, ¹⁶Diakonie Hospital Stuttgart, Dept. of Urology, Stuttgart, Germany, ¹⁷University Hospital Heidelberg, Dept. of Urology and Paediatric Urology, Heidelberg, Germany, ¹⁸Diakonie Hospital Schwäbisch Hall, Dept. of Urology, Schwäbisch Hall, Germany, ¹⁹Technical University Munich, Institute For Medical Statistic and Epidemiology, Munich, Germany

- *193 **Can artificial sphincter satisfaction be reached by adjustable bulbourethral suspension?**
 By: [Baier P.](#), Kuhn D., Förster B., Haab A., John H.
 Institutes: Kantonsspital Winterthur, Dept. of Urology, Winterthur, Switzerland
- *194 **Long-term quality of life and functional outcomes among primary and secondary artificial urinary sphincter implantations in men with stress urinary incontinence**
 By: [Viers B.](#), Linder B., Rivera M., Rangel L., Ziegelmann M., Elliott D.
 Institutes: Mayo Clinic, Dept. of Urology, Rochester, United States of America
- *195 **Artificial urinary sphincter mechanical failures: Is it better to replace the entire device or just the malfunctioning component?**
 By: Linder B., [Viers B.](#), Ziegelmann M., Rivera M., Rangel L., Elliott D.
 Institutes: Mayo Clinic, Dept. of Urology, Rochester, United States of America
- *196 **Outcome of the artificial urinary sphincter with double cuff as a primary and secondary treatment option of urinary stress incontinence**
 By: [Sayed Ahmed K.](#), Kaftan B., Aragona M., Ekrutt J., Olianias R.
 Institutes: Lüneburg Hospital, Dept. of Urology, Lüneburg, Germany
- *197 **Treatment of post-prostatectomy urinary incontinence by implantation of a transobturator male sling (ISTOP-TOMS™): 5 Years results**
 By: Malval B.¹, Rebibo J-D.¹, Tzebia C.¹, Vautherin R.², Saussine C.³, Nouhaud F-X.¹, Grise P.¹, [Cornu J-N.](#)¹
 Institutes: ¹Rouen University Hospital, Dept. of Urology, Rouen, France, ²Clinique Ternel, Dept. of Urology, Sainte Colombe, France, ³NHC, Dept. of Urology, Strasbourg, France
- *198 **Outcomes of transobturator sling placement in men with incontinence secondary to radical prostatectomy and radiotherapy for prostate cancer: A systematic review and meta-analysis**
 By: [Ajay D.](#)¹, Potts B.¹, Feltner C.², Peterson A.C.¹
 Institutes: ¹Duke University Medical Center, Dept. of Surgery, Division of Urology, Durham, United States of America, ²University of North Carolina, Chapel Hill, Dept. of Internal Medicine, Chapel Hill, United States of America
- *199 **Treatment of complications after ProACT® implantation in men with stress urinary incontinence following radical prostatectomy: A retrospective analysis of 252 implants in a single centre**
 By: Abbinante M., Rossanese M., Crestani A., Calandriello M., Ficarra V., [Giannarini G.](#)
 Institutes: Academic Medical Centre Hospital Santa Maria Della Misericordia, Dept. of Urology, Udine, Italy
- *200 **Continence results, acute retention of urine and postoperative urgency after AdVance® male sling surgery: Assessing predictive factors**
 By: [Collado Serra A.](#)¹, Ramirez-Backhaus M.¹, Ortiz Rodriguez I.M.², Dominguez-Escrig J.¹, Gomez-Ferrer A.¹, Rubio-Briones J.¹, Casanova Ramón-Borja J.¹, Iborra Juan I.¹, Ricos Torrent J.V.¹, Monrós Lliso J.L.¹, Dumont Martinez R.¹, Rodríguez Torreblanca C.², Solsona Narbón E.¹

Institutes:¹Fundación Instituto Valenciano De Oncología, Dept. of Urology, Valencia, Spain, ²Universidad De Almería, Dept. of Mathematics, Almería, Spain

*201

A proposed external urethral sphincter contraction grading system for the algorithmic approach to post prostatectomy stress urinary incontinence

By: Lavien G., Zaid U., Le N-B., Lentz A., Peterson, A.

Institutes:Duke University Medical Center, Dept. of Urology, Durham, United States of America

*202

Can filling phase urodynamic parameters predict the success of the bulbar artificial urinary sphincter in treating post-prostatectomy incontinence?

By: Solomon E.¹, Veeratterapillay R.², Harding C.², Greenwell T.¹

Institutes:¹University College London Hospital, Dept. of Urology, London, United Kingdom, ²Freeman Hospital, Dept. of Urology, Newcastle upon Tyne, United Kingdom

17:21 - 17:28

Summary and context

R. Bauer, Munich (DE)

Improvement in the management of non muscle-invasive bladder cancer

Poster Session 17

Saturday, 12 March
16:00 - 17:30

Location: Room 14b (ICM, Level 1)

Chairs: M. Babjuk, Prague (CZ)
P. Gontero, Turin (IT)
G. Simone, Rome (IT)

Aims and objectives of this presentation

After primary transurethral resection of the bladder tumour (TURBT), adjuvant intravesical instillations are most commonly used to manage intermediate – high risk NMIBC. However, whether a preventive radical cystectomy (RC) should be performed in selected cases of high-grade T1 remains a moot point. The purpose of the session is to discuss current strategies according to recognised challenges in the field: increase the detection of bladder cancer and flat lesions, reduce residual tumours, reduce recurrence rate, prolongation of follow-up cystoscopies.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *203 **Modelling the burden of bladder cancer and monitoring cystoscopies in Europe**
By: Vecino Ortiz A.I., Glover R., [Adams E.J.](#)
Institutes: Aquarius Population Health, Health Economics, London, United Kingdom
- *204 **Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle invasive bladder cancer**
By: Onishi T.¹, Sibahara T.¹, Masui S.¹, [Sugino Y.](#)¹, Sasaki T.²
Institutes:¹Ise Red Cross Hospital, Dept. of Urology, Ise, Japan, ²Mie University Hospital, Dept. of Urology, Tsu, Japan
- *205 **Intravesical Bacillus Calmette-Guérin (BCG) versus combination of epirubicin and interferon- γ 2a (EPI+INF) instillations in prevention of frequently recurrent non-muscle-invasive bladder carcinoma (NMIBC) - FinnBladder-6 study**
By: [Marttila T.](#)², Järvinen R.¹, Seppänen M.³, Liukkonen T.⁴, Raitanen M.², Boström P.⁵, Kaasinen E.⁶
Institutes:¹Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, ²Seinäjoki Central Hospital, Dept. of Urology, Seinäjoki, Finland, ³Satakunta Central Hospital, Dept. of Urology, Pori, Finland, ⁴Mikkeli Central Hospital, Dept. of Urology, Mikkeli, Finland, ⁵Turku University Hospital, Dept. of Urology, Turku, Finland, ⁶Hyvinkää Hospital, Dept. of Urology, Hyvinkää, Finland
- *206 **Cancer-specific survival in patients with primary bladder CIS**
By: [Jancke G.](#)
Institutes: Skånes Universitetssjukhus, Dept. of Urology, Malmö, Sweden
- *207 **3rd course of BCG instillation to the patients with primary CIS of bladder: Is it safe?**
By: [Kim S.J.](#)¹, Hong S.², Kim H.J.², You D.¹, Jeong I.G.¹, Song C.¹, Hong B.S.¹, Kim C.S.¹, Ahn H.¹, Hong J.H.¹
Institutes:¹Asan Medical Center, Dept. of Urology, Seoul, South Korea, ²Dankook University College of Medicine, Dept. of Urology, Cheonan, South Korea
- *208 **Transurethral resection guided by photodynamic diagnosis can prevent progression in non-muscle invasive bladder cancer patients**
By: [Rolevich A.I.](#)¹, Zhegalik A.G.¹, Minich A.A.¹, Nabeбина T.I.², Polyakov S.A.¹, Krasny S.A.¹,

Sukonko O.G.¹

Institutes:¹N.N. Alexandrov National Cancer Centre of Belarus, Dept. of Urology, Minsk, Belarus, ²N.N. Alexandrov National Cancer Centre of Belarus, Dept. of Pathology, Minsk, Belarus

*209

A phase 1 clinical trial assessing an intravesical administered second-generation antisense oligonucleotide targeting heat shock protein 27 in bladder cancer

By: Frees S., Beraldi E., Chi K., Fazli L., Black P., Gleave M., So A.

Institutes:Vancouver Prostate Centre, Dept. of Urological Sciences, Vancouver, Canada

*210

Randomized study of intravesical chemotherapy using pirarubicin in low- and intermediate risk non-muscle-invasive bladder cancer in Japan - comparison one immediate postoperative intravesical chemotherapy with short-term adjuvant intravesical chemotherapy after TURBT

By: Naya Y.¹, Shiraishi T.¹, Oishi M.¹, Ueda T.¹, Nakanishi H.¹, Nakamura T.¹, Hongo F.¹, Iwata T.², Kanazawa M.³, Mikami K.⁴, Kamoi K.¹, Okihara K.¹, Ukimura O.¹

Institutes:¹Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan, ²Nantan Hospital, Dept. of Urology, Nantan, Japan, ³Matsushita Memorial Hospital, Dept. of Urology, Moriguchi, Japan, ⁴Kyoto First Red-Cross Hospital, Dept. of Urology, Kyoto, Japan

*211

Decrease in rate of Tx histology after transurethral resection of bladder tumours following implementation of an institutional quality improvement programme

By: Giannarini G., Crestani A., Palumbo V., Calandriello M., Abbinante M., Ficarra V.

Institutes:Academic Medical Centre Hospital Santa Maria Della Misericordia, Dept. of Urology, Udine, Italy

*212

White light imaging vs Storz Professional Image Enhancement System (SPIES) cystoscopy during follow up of patients submitted to WLI-transurethral resection of non-muscle-invasive bladder cancer: Preliminary results of a bicenter randomized diagnostic trial

By: Chondros K.¹, Kazoulis S.², Chrysanthakopoulos G.², Tamiolakis D.³, Kalogeraki A.³, Tzardi M.³, Heretis I.¹, Mavromanolakis E.¹, Chondros N.¹, Zoras O.⁴, Chalkiadakis G.⁵, Mamoulakis C.¹

Institutes:¹University General Hospital of Heraklion, Dept. of Urology, Heraklion, Greece, ²General Hospital of Chania St. George, Dept. of Urology, Chania, Greece, ³University General Hospital of Heraklion, Dept. of Pathology-Cytopathology, Heraklion, Greece, ⁴University General Hospital of Heraklion, Dept. of Surgical Oncology, Heraklion, Greece, ⁵University General Hospital of Heraklion, Dept. of General Surgery, Heraklion, Greece

*213

Visualizing the muscularis propria via narrow band imaging during transurethral en bloc dissection for non-muscle-invasive bladder cancer

By: Okada Y., Kawakami S., Takeshita H., Yano A., Chou E., Sugiyama H., Morozumi M., Yamada T.

Institutes:Saitama Medical Center, Dept. of Urology, Saitama, Japan

*214

Prognostic significance of markers of systemic inflammatory response in patients with non-muscle invasive bladder cancer

By: Mbeutcha A.¹, Shariat S.², Rieken M.³, Rink M.⁴, Xylinas E.⁵, Seitz C.², Lucca I.⁶, Mathieu R.⁷, Rouprêt M.⁸, Briganti A.⁹, Karakiewicz P.¹⁰, Klatte T.²

Institutes:¹University Hospital of Nice, Dept. of Urology, Nice, France, ²Medical University of Vienna, Dept. of Urology, Vienna, Austria, ³University Hospital of Basel, Dept. of Urology, Basel, Switzerland, ⁴University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁵Cochin Hospital, APHP, Paris Descartes University, Dept. of Urology, Paris, France, ⁶Centre Hospitalier Universitaire Vaudois, Dept. of Urology, Lausanne, Switzerland, ⁷Rennes University Hospital, Dept. of Urology, Rennes, France, ⁸Pitié- Salpêtrière, APHP, University Paris VI, Dept. of Urology, Paris, France, ⁹Università Vita-Salute, Ospedale S. Raffaele, Dept. of Urology, Milan, Italy, ¹⁰University of Montréal, Dept. of Urology, Montréal, Canada

*215

A phase II trial of an oral methionine aminopeptidase II (MetAP2) inhibitor for patients with high-risk non-muscle invasive bladder cancer (NMIBC) who relapsed after intravesical therapies: Preliminary results

By: Yao X.², Wang G.³, Pu J.⁴, Yao X.⁵, Zhou F.⁶, Qi J.⁷, Ye Z.⁸, Xie L.⁹, Chen J.¹⁰, Xie K.¹¹, Zhao X.¹², Xu Z.¹³, Guo H.¹⁴, Yang Y.¹⁵, Cao D.¹, Yang B.², Zhang C.³, Lu Y.⁴, Du J.⁵, Ye Y.⁶, Gu Z.⁷, Song X.⁸, Liu

B.⁹, Wen J.¹⁰, Deng X.¹¹, Zhong Z.¹², Liao G.¹³, Liu T.¹⁴, Zhao Q.¹⁵, Jia Y.¹⁶, Liu J.¹⁷, Pan K.¹⁶, Ye D.¹
Institutes:¹Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ²Shanghai The Tenth People's Hospital of Tongji University, Dept. of Urology, Shanghai, China, ³The First Affiliated Hospital of Nanchang University, Dept. of Urology, Nanchang, China, ⁴The First Affiliated Hospital of Soochow University, Dept. of Urology, Suzhou, China, ⁵Tianjin Medical University Cancer Institute & Hospital, Dept. of Urology, Tianjin, China, ⁶Sun Yat-Sen University Cancer Center, Dept. of Urology, Guangzhou, China, ⁷Xin Hua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China, ⁸Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Dept. of Urology, Wuhan, China, ⁹The First Affiliated Hospital, Zhejiang University, Dept. of Urology, Hangzhou, China, ¹⁰The Second Affiliated Hospital of Zhejiang University School of Medicine, Dept. of Urology, Hangzhou, China, ¹¹Guangzhou The First People's Hospital, Dept. of Urology, Guangzhou, China, ¹²The Second Xiangya Hospital of Central South University, Dept. of Urology, Changsha, China, ¹³Zhejiang Provincial People's Hospital, Dept. of Urology, Hangzhou, China, ¹⁴Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Dept. of Urology, Nanjing, China, ¹⁵Beijing Cancer Hospital, Dept. of Urology, Beijing, China, ¹⁶Jiangsu Yahong MediTech Co., Ltd., Dept. of Clinical Research, Taizhou, China, ¹⁷Jiangsu Yahong MediTech Co., Ltd., Pharmaceutical Sciences, Taizhou, China

*216

Discrepancy between guidelines and daily practice in the management of non-muscle-invasive bladder cancer (NMIBC): Results of a European survey

By: Aziz A.², Bes P.¹², Chun F.K.², Dobruch J.³, Kluth L.A.², Gontero P.⁴, Necchi A.⁵, Noon A.⁶, Van Rhijn B.WG⁷, Rink M.², Roghmann F.⁸, Roupret M.⁹, Seiler R.¹⁰, Shariat S.F.¹¹, Qvick B.¹², Xylinas E.N.¹
Institutes:¹Cochin Hospital, Paris Descartes University, Dept. of Urology, Paris, France, ²University Medical Center Hamburg-Eppendorf, Hamburg, Dept. of Urology, Hamburg, Germany, ³Centre of Postgraduate Medical Education, Dept. of Urology, Warsaw, Poland, ⁴Città Della Salute E Della Scienza Di Torino, Dept. of Urology, Turin, Italy, ⁵Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, ⁶Division of Urology, University of Toronto, Dept. of Urology, Toronto, Canada, ⁷Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ⁸Marien Hospital, Ruhr-University Bochum, Dept. of Urology, Herne, Germany, ⁹Pitié-Salpêtrière APHP, Dept. of Urology, Paris, France, ¹⁰University of Berne, Dept. of Urology, Berne, Switzerland, ¹¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹²Ipsen, Dept. of Pharma, Paris, France

Basic research in renal tumours: Gene profiling and molecular markers

Poster Session 18

Saturday, 12 March
16:00 - 17:30

Location: Room 14c (ICM, Level 1)

Chairs: L. Mengual, Barcelona (ES)
A. Vuksanovic, Belgrade (RS)

Aims and objectives of this presentation

To show and discuss latest advances in gene profiling as well as molecular markers of prognosis.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *217 **Identifying the metastatic subclone by exhaustive sampling of primary and metastasis in clear cell renal cell carcinoma (ccRCC) pair**
By: [Soultati A.](#)¹, O'Brien T.², Challacombe B.J.², Nicol D.³, Horswell S.⁴, Xu H.⁵, Rowan A.J.⁵, Lopez J.I.⁶, Stares M.⁵, Chandra A.⁷, Chowdhury S.⁸, Rudman S.⁸, Matthews N.⁹, Larkin J.¹⁰, Turajlic S.⁵, Swanton C.⁵
Institutes:¹Guy's and St' Thomas NHS Foundation Trust, Dept. of Oncology, London, United Kingdom, ²Guy's and St' Thomas NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³Royal Marsden Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁴The Francis Crick Institute, Dept. of Bioinformatics and Biostatistics, London, United Kingdom, ⁵The Francis Crick Institute, Translational Cancer Therapeutics Laboratory, London, United Kingdom, ⁶Cruces University Hospital, Dept. of Pathology, Bilbao, Spain, ⁷Guy's and St' Thomas NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ⁸Guy's and St' Thomas NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ⁹The Francis Crick Institute, Advanced Sequencing Facility, London, United Kingdom, ¹⁰Royal Marsden Hospital NHS Foundation Trust, Dept. of Medicine, London, United Kingdom
- *218 **Intermittent hypoxia increases tumor angiogenesis in a mouse model of kidney cancer**
By: [Vilaseca Cabo A.](#)¹, Musquera M.¹, Torres M.², Campillo N.², Gozal D.³, Montserrat J.⁴, Touijer K.⁵, Farré R.², Almendros I.², Alcaraz A.¹
Institutes:¹Hospital Clínic De Barcelona, Dept. of Urology, Barcelona, Spain, ²Universitat De Barcelona, Dept. of Biophysics and Bioengineering, Barcelona, Spain, ³University of Chicago, Dept. of Sleep Disorders, Chicago, United States of America, ⁴Hospital Clínic De Barcelona, Dept. of Pneumology, Barcelona, Spain, ⁵Memorial Sloan-Kettering Cancer Center, Dept. of Urology, New York, United States of America
- *219 **Quantification, culture and characterization of circulating endothelial progenitor cells in patients with renal cell carcinoma**
By: [Yang B.](#), Gu W., Sun W., Guo C., Yao X., Zheng J.
Institutes:Shanghai Tenth People's Hospital, Tongji University School Of Medicine, Dept. of Urology, Shanghai, China
- *220 **Tumour-derived vascular endothelial growth factor mobilizes circulating endothelial progenitor cells and contributes to vasculogenesis of renal cell carcinoma**
By: [Yang B.](#), Gu W., Guo C., Sun W., Che J., Liu M., Yao X., Zheng J.
Institutes:Shanghai Tenth People's Hospital, Tongji University School of Medicine, Dept. of Urology, Shanghai, China
- *221 **Multi-region whole exome sequencing reveals monoclonal nature of inferior vena cava tumour thrombus extension in clear cell renal cell carcinoma**

By: [Stares M.](#)¹, Nicol D.², O'Brien T.³, Challacombe B.³, Rowan A.¹, Horswell S.⁴, Salm M.⁴, Soutati A.⁵, Hazell S.⁶, Chandra A.⁷, López J.⁸, Fisher R.⁹, Chowdhury S.⁵, Rudman S.⁵, Gore M.⁹, Larkin J.⁹, Matthews N.¹⁰, Turajlic S.¹, Swanton C.¹

Institutes:¹The Francis Crick Institute, Translational Cancer Therapeutics Laboratory, London, United Kingdom, ²Royal Marsden Hospital NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ³Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁴The Francis Crick Institute, Dept. of Bioinformatics and Biostatistics, London, United Kingdom, ⁵Guy's and St Thomas' NHS Foundation Trust, Dept. of Medicine, London, United Kingdom, ⁶Royal Marsden Hospital NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ⁷Guy's and St Thomas' NHS Foundation Trust, Dept. of Pathology, London, United Kingdom, ⁸Cruces University Hospital, Dept. of Pathology, Bilbao, Spain, ⁹Royal Marsden Hospital NHS Foundation Trust, Dept. of Medicine, London, United Kingdom, ¹⁰The Francis Crick Institute, Advanced Sequencing Facility, London, United Kingdom

*222

Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells is associated with poor prognosis in clear cell renal cell carcinoma

By: [Füssel S.](#)¹, Toma M.², Erdmann K.¹, Wehner R.³, Kloß A.³, Baretton G.², Wirth M.P.¹, Schmitz M.³

Institutes:¹Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dept. of Urology, Dresden, Germany, ²Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dept. of Pathology, Dresden, Germany, ³Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dept. of Immunology, Dresden, Germany

*223

Identification and validation of soluble carrier family expression signature for predicting poor outcome of renal cell carcinoma

By: [Wan F.](#), Ma C., Zhang H., Shi G., Zhu Y., Ye D.

Institutes:Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

*224

Genetic alterations in specific chromosomal regions indicate metastatic potential in ccRCC patients

By: [Grimm J.](#)¹, Janssen M.¹, Hartmann A.², Kunath F.³, Stöhr C.², Stöckle M.¹, Junker K.¹

Institutes:¹UKS Universitätsklinikum des Saarlandes, Dept. of Urology and Pediatric Urology, Homburg/Saar, Germany, ²University Hospital Erlangen, Dept. of Pathology, Erlangen, Germany, ³University Hospital Erlangen, Dept. of Urology, Erlangen, Germany

*225

Identification and validation of an 8-gene expression signature for predicting high Fuhrman grade renal cell carcinoma

By: [Wan F.](#)¹, Zhu Y.², Han C.², Xu Q.³, Zhang H.², Shi G.², Gu W.², Ye D.²

Institutes:¹Shanghai Medical College, Fudan University, Dept. of Oncology, Shanghai, China, ²Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ³Fudan University Shanghai Cancer Center, Dept. of Pathology, Shanghai, China

*226

Myopodin methylation correlates to tumour progression and predicts antiangiogenic response in kidney cancer

By: Perez-Lonzac A.², Pompas-Veganzones N.², Beltran M.³, Beardo P.⁴, Vazquez F.⁵, Cozar J.M.⁵, Alvarez-Ossorio J.L.⁶, [Sanchez-Carbayo M.](#)¹

Institutes:¹University of the Basque Country, Bladder Cancer Group, Vitoria-Gasteiz, Spain, ²University of the Basque Country, Translational Oncology Lab, Vitoria-Gasteiz, Spain, ³Hospital Puerta Del Mar, Dept. of Pathology, Cadiz, Spain, ⁴Hospital De Jerez, Dept. of Urology, Cadiz, Spain, ⁵Hospital Virgen De Las Nieves, Dept. of Urology, Cadiz, Spain, ⁶Hospital Puerta Del Mar, Dept. of Urology, Cadiz, Spain

*227

Circulating free genomic and mitochondrial DNA fragments and their diagnostic and prognostic potential in clear cell renal cell carcinoma patients

By: [Ralla B.](#)¹, Hongbiao L.¹, Jung M.¹, Rabenhorst S.¹, Kilic E.¹, Budach N.², Fendler A.¹, Jung K.¹, Busch J.¹

Institutes:¹Charité - Universitätsmedizin Berlin, Dept. of Urology, Berlin, Germany, ²Charité - Universitätsmedizin Berlin, Dept. of Radiology, Berlin, Germany

*228

Predictive molecular biomarkers of renal clear cell carcinoma

By: Trevisani F.¹, Cascione L.², Ghidini M.³, Lampis A.⁴, Fassan M.⁵, Hanhe J.K.⁴, Dell'Antonia G.⁶, Rigotti P.⁷, Larcher A.¹, Capitanio U.¹, Benigni F.¹, Briganti A.¹, Bertini R.¹, Salonia A.¹, Montorsi F.¹, Valeri N.⁴

Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Oncology, Department of Urology, URI, Milan, Italy, ²IOR - Institute of Oncology Research, Lymphoma and Genomics Research Program Bioinformatics Core Unit, Bellinzona, Switzerland, ³Hospital of Cremona, Dept. of Oncology, Cremona, Italy, ⁴Institute of Cancer Research, Laboratory of Gastrointestinal Cancer Biology and Genomics, London, United Kingdom, ⁵University of Padua, Dept. of Pathology, Padua, Italy, ⁶IRCCS Ospedale San Raffaele, Division of Pathology, Milan, Italy, ⁷University of Padua, Dept. of Surgical Science, Milan, Italy

*229

Significance of TERT variants in renal cell carcinoma

By: Casuscelli J.¹, Manley B.¹, Redzematovic A.¹, Becerra M.¹, Tennenbaum D.¹, Arcila M.¹, Voss M.², Feldman D.², Motzer R.², Coleman J.³, Russo P.³, Hsieh J.¹, Hakimi A.A.³

Institutes:¹Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York City, United States of America, ²Memorial Sloan Kettering Cancer Center, Dept. of Medicine, New York City, United States of America, ³Memorial Sloan Kettering Cancer Center, Dept. of Surgery, New York City, United States of America

*230

Blood based exosomal miRNAs as biomarkers for diagnosis and prognosis of clear cell renal cell cancer

By: Heinzelmann J.¹, Baumgart S.², Hoelters S.², Janssen M.², Stöckle M.², Junker K.²

Institutes:¹Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Hamburg, Germany, ²Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Homburg, Germany

Penile cancer: New drugs and molecular insights on the horizon

Poster Session 19

Saturday, 12 March
16:00 - 17:30

Location: Room Paris (Hall B2, level 0)

Chairs: S.S. Minhas, London (GB)
S. Osanto, Leiden (NL)
C. Protzel, Rostock (DE)

Aims and objectives of this presentation

This session presents results of local surgical laser treatment and new insights into molecular pathogenesis of penile cancer as well as new drugs to treat metastatic penile cancer.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *231 **Role of penile Doppler US in the preoperative assessment of penile squamous cell carcinoma patients: Results from a large prospective multicenter European study**
By: [Bozzini G.](#)¹, [Provenzano M.](#)², [Romero Otero J.](#)³, [Margreiter M.](#)⁴, [Garcia Cruz E.](#)⁵, [Osmolorski B.](#)⁶, [Verze P.](#)⁷, [Pavan N.](#)⁸, [Sanguedolce F.](#)⁹, [Buffi N.](#)², [Guazzoni G.](#)², [Taverna G.](#)¹
Institutes:¹Humanitas Mater Domini, Dept. of Urology, Castellanza, Italy, ²Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy, ³Hospital Universitario 12 De Octubre, Dept. of Urology, Madrid, Spain, ⁴Vienna General Hospital, Dept. of Urology, Vienna, Austria, ⁵Hospital Clinic De Barcelona, Dept. of Urology, Barcelona, Spain, ⁶Lomonosov University Hospital, Dept. of Urology, Moscow, Russia, ⁷University Federico II, Dept. of Urology, Naples, Italy, ⁸University of Trieste, Dept. of Urology, Trieste, Italy, ⁹Londo King's College Hospital, Dept. of Urology, London, United Kingdom
- *232 **Malignancy in biopsy proven penile lichen sclerosus**
By: [Zaid U.](#), [Lavien G.](#), [Potts B.](#), [Peterson A.](#)
Institutes:Duke University, Dept. of Urology, Durham, United States of America
- *233 **Carbon dioxide laser treatment of penile intraepithelial neoplasia**
By: [Vint R.](#)¹, [Zreik A.](#)¹, [Rewhorn M.](#)¹, [Khan R.](#)², [Hendry D.](#)¹
Institutes:¹Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, ²Wishaw General Hospital, Dept. of Urology, Wishaw, United Kingdom
- *234 **Outcomes of CO2 laser treatment for penile carcinoma in situ at a UK tertiary centre**
By: [McGuinness L.](#)¹, [Veeratterapillay R.](#)¹, [Conaway D.](#)², [Teo L.](#)², [Asterling S.](#)², [Greene D.](#)², [Keegan P.](#)²
Institutes:¹Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, ²Sunderland Royal Hospital, Dept. of Urology, Sunderland, United Kingdom
- *235 **Clinical usefulness of SPECT/CT during dynamic sentinel lymph node mapping in penile cancer**
By: [Omorpos S.](#)¹, [Saad Z.](#)², [Malone P.](#)¹, [Nigam R.](#)¹, [Bomanji J.](#)², [Muneer A.](#)¹
Institutes:¹University College London Hospitals, Dept. of Urology, London, United Kingdom, ²University College London Hospitals, Dept. of Nuclear Medicine, London, United Kingdom
- *236 **Surgical and oncological outcomes after video endoscopic inguinal lymphadenectomy (VEIL): Single institute series**
By: [Thyavihally Y.](#), [Rao H.](#), [Pednekar A.](#), [Kaushik T.](#), [Kalyan C.](#), [Parab M.](#), [Dharmadhikari N.](#), [Gulavani N.](#), [Patil A.](#), [Waigaonkar S.](#)
Institutes:Kokilaben Dhirubhai Ambani Hospital, Dept. of Uro-oncology, Mumbai, India
- *237 **Programmed death ligand 1 (PDL1) as a target for immunotherapy in penile carcinoma**

By: Ottenhof S.¹, Djajadiningrat R.¹, De Jong J.², Horenblas S.¹, Jordanova K.²
Institutes:¹Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Dept. of Urologic Oncology, Amsterdam, The Netherlands, ²Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Dept. of Pathology, Amsterdam, The Netherlands

*238

PIK3CA gene copy number and mRNA expression in invasive penile cancer

By: Adimonye A.¹, Stankiewicz E.¹, Kudahetti S.¹, Rajab R.², Corbishley C.², Lu Y-J.¹, Watkin N.³, Berney D.¹

Institutes:¹Barts Cancer Institute, Dept. of Molecular Oncology, London, United Kingdom, ²St George's Hospital, Dept. of Histopathology, London, United Kingdom, ³St George's Hospital, Dept. of Urology, London, United Kingdom

*239

Pan-HER trosine-kinase inhibitors (TKI) dacomitinib and afatinib in penile squamous cell carcinoma (PSCC): Results from an ongoing open-label, single-group, phase 2 trial of dacomitinib in chemo-naïve patients (pts)

By: Necchi A.¹, Raggi D.¹, Giannatempo P.¹, Nicolai N.², Colecchia M.³, Calareso G.⁴, Togliardi E.⁵, Crippa F.⁶, Mariani L.⁷, Perrone F.³, Pelosi G.³, Salvioni R.², Sonpavde G.⁸

Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, ³Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy, ⁴Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, ⁵Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pharmacy, Milan, Italy, ⁶Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Nuclear Medicine, Milan, Italy, ⁷Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Clinical Epidemiology and Trials Organization, Milan, Italy, ⁸UAB Comprehensive Cancer Center, Dept. of Medical Oncology, Birmingham, United States of America

*240

Distinct patterns of copy number aberrations in penile cancer

By: Rodney S.¹, Feber A.¹, Arya M.², De Winter P.¹, Saqib M.¹, Nigam R.¹, Malone P.¹, Tan S.¹, Christodoulidou M.¹, Sahdev V.¹, Lechner M.³, Freeman A.⁴, Jameson C.¹, Muneer A.², Beck S.⁵, Kelly J.¹

Institutes:¹University College London, Dept. of Surgery and Interventional Sciences, London, United Kingdom, ²University College London Hospital, Dept. of Urology, London, United Kingdom, ³University College London Hospitals, Dept. of Histopathology, London, United Kingdom, ⁴University College London Hospital, Dept. of Histopathology, London, United Kingdom, ⁵University College London, UCL Cancer Institute, London, United Kingdom

*241

Prognostic factors of adjuvant chemotherapy with taxane, cisplatin, and 5FU combination (TPF) in patients (pts) with nodal metastases of penile squamous cell carcinoma (PSCC)

By: Necchi A.¹, Lo Vullo S.², Nicolai N.³, Raggi D.¹, Giannatempo P.¹, Colecchia M.⁴, Torelli T.³, Catanzaro M.³, Piva L.³, BIASONI D.³, Stagni S.³, Mariani L.², Salvioni R.³

Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS - Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, ³Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, ⁴Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy

*242

Comparison of survival outcomes for African-American and Caucasian men with advanced penile cancer in Florida

By: Ritch C.², Pavan N.¹, Rai S.², Soodana-Prakash N.², Balise R.³, Parekh D.², Gonzalzo M.²

Institutes:¹University of Trieste, Dept. of Urology, Trieste, Italy, ²University of Miami Leonard M. Miller School of Medicine, Dept. of Urology, Miami, Florida, United States of America, ³University of Miami Leonard M. Miller School of Medicine, Dept. of Biostatistics, Department of Public Health Sciences, Miami, Florida, United States of America

*243

Penile cancer cell lines of primary tumors and lymph node metastases are resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cell death

By: Naumann C.M.¹, Hamann M.F.¹, Van Der Horst C.¹, Colberg C.¹, Osmonov D.¹, Engelmann D.², Jünemann K.P.¹, Kalthoff H.³, Trauzold A.³

Institutes:¹University Hospital Schleswig-Holstein, Dept. of Urology, Kiel, Germany, ²Institute of Experimental Gene Therapy and Cancer Research, Biomedical Research Center Rostock University Medical Center, Rostock, Germany, ³Institute For Experimental Cancer Research, Dept. of Molecular Oncology, Kiel, Germany

17:15 - 17:22

Summary and context

S.S. Minhas, London (GB)

Signalling networks in prostate cancer

Poster Session 20

Saturday, 12 March
16:00 - 17:30

Location: Room Vienna (Hall B2, level 0)

Chairs: H.G. Lilja, New York (US)
G. Jenster, Rotterdam (NL)
S. Perner, Bonn (DE)

Aims and objectives of this presentation

Novel oncogenic and tumour suppressive miRNA have been discovered in prostate cancer. Recent studies focused on identification of their targets and regulation of cellular events. In this session, signaling pathways regulated by miRNA and androgen receptors in cancerous prostate will be discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *244 **MiR-130a modulates high-fat diet-induced tumour progression through the activation of MET in prostate cancer**
By: Narita S.¹, Matsuda Y.¹, Nara T.¹, Huang M.¹, Yoshioka T.², Takayama K.¹, Numakura K.¹, Tsuruta H.¹, Maeno A.¹, Saito M.¹, Inoue T.¹, Satoh S.³, Habuchi T.¹
Institutes:¹Akita University School of Medicine, Dept. of Urology, Akita, Japan, ²Akita University School of Medicine, Dept. of Molecular Pathology and Tumor Pathology, Akita, Japan, ³Akita University Hospital, Dept. of Center For Kidney Disease and Transplantation, Akita, Japan
- *245 **MicroRNA-145 mediates the inhibitory effect of adipose-derived stem cells on androgen-independent prostate cancer**
By: Takahara K., Inamoto T., Ibuki N., Uchimoto T., Saito K., Takai T., Tanda N., Hirano H., Nomi H., Kiyama S., Azuma H.
Institutes:Osaka Medical College, Dept. of Urology, Takatsuki, Japan
- *246 **The castration-resistant prostate cancer-associated miRNAs, miR-3687 and miR-4417, are involved in tumour cell hypoxia response and tumour cell migration**
By: Fussek S.¹, Rönnau C.², Span P.N.³, Burchardt M.², Verhaegh G.W.¹, Schalken J.A.¹
Institutes:¹Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ²University Medicine Greifswald, Dept. of Urology, Greifswald, Germany, ³Radboud University Medical Center, Dept. of Radiation Oncology, Nijmegen, The Netherlands
- *247 **MicroRNA-660 is down-regulated in prostate cancer and directly regulates prostate-specific membrane antigen**
By: Erdmann K., Bienert F., Füssel S., Wirth M.
Institutes:TU Dresden, Dept. of Urology, Dresden, Germany
- *248 **Up-regulation of androgen receptor expression in enzalutamide-resistant prostate cancer cells**
By: Höfer J., Akbor M., Ofer P., Culig Z., Klocker H., Heidegger I.M.
Institutes:Medizinische Universität Innsbruck, Dept. of Urology, Innsbruck, Austria
- *249 **Cell surface branching glycan regulates prostate cancer invasiveness by enhancing $\alpha 5 \beta 1$ integrin signaling**
By: Tobisawa Y.¹, Mikami J.¹, Yoneyama T.¹, Hatakeyama S.¹, Mori K.¹, Hashimoto Y.¹, Koie T.¹, Ohyama C.¹, Fukuda M.²
Institutes:¹Hirosaki University, Dept. Of Urology, Hirosaki, Japan, ²Sanford Burnham Prebys Medical Discovery Institute, Tumour Microenvironment and Metastasis Program, NCI-Designated

Cancer Center, La Jolla, United States of America

- *250 **Role of anti-metastatic laminin-binding O-glycan on α -dystroglycan regulated by miR-X in prostate cancer**
By: [Yoneyama T.](#)¹, Fujita N.², Imamura H.², Okamoto A.², Yamamoto H.², Mori K.², Hatakeyama S.², Hashimoto Y.¹, Koie T.², Tobisawa Y.², Fukuda M.³, Ohyama C.²
Institutes:¹Hirosaki University Graduate School of Medicine, Dept. of Advanced Transplantation & Regenerative Medicine, Hirosaki, Japan, ²Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ³Sanford-Burnham Prebys Medical Discovery Institute, Dept. of Tumor Microenvironment Program, La Jolla, United States of America
- *251 **Down-regulation of CDKN3 inhibited prostate cancer proliferation in vitro and in vivo via regulating cell cycle and DNA replication signaling**
By: [Yiping Z.](#), Dingwei Y., Hailiang Z., Bo D.
Institutes:Fudan University Shanghai Cancer Center, Dept. of Urology, Shang Hai, China
- *252 **Characterisation of immune infiltrates in malignant and benign prostate tissues**
By: [Woon D.T.S.](#)¹, Whitty G.², Saxena M.², Bolton D.¹, Davis I.²
Institutes:¹Austin Health, Dept. of Urology, Melbourne, Australia, ²Ludwig Institute For Cancer Research, Dept. of Uro-Oncology Laboratory, Melbourne, Australia
- *253 **Induction of prostate-specific membrane antigen expression (PSMA) expression and internalization of anti-PSMA monoclonal antibodies in human endothelial cells**
By: [Nguyen T.P.D.](#), Xiong P., Pan S., Liu H., Guo M., Leconet W., Navarro V., Kim S., Bander N.
Institutes:Weill Medical College of Cornell University, Dept. of Urology, New York, United States of America
- *254 **The α 1-adrenoceptor antagonist prazosin, but not tamsulosin, suppresses hypoxia inducible factor-1 α and radio-sensitises hypoxic prostate cancer cells**
By: Forbes A.¹, Mc Dermott C.¹, Anoopkumar-Dukie S.², Christie D.³, [Chess-Williams R.](#)¹
Institutes:¹Bond University, Dept. of Urology Research, Gold Coast, Australia, ²Griffith University, School of Pharmacy, Gold Coast, Australia, ³Genesis CancerCare, Dept. of Radiation Oncology, Gold Coast, Australia
- *255 **PD-L1 expression in prostate cancer**
By: [Hashimoto Y.](#), Iwamura H., Imai A., Hatakeyama S., Yoneyama T., Koie T., Ohyama C.
Institutes:Hirosaki University, Dept. of Urology, Hirosaki, Japan
- 17:11 - 17:18 **Summary and context**
 G. Jenster, Rotterdam (NL)

Infectious diseases of the urinary tract

Poster Session 21

Saturday, 12 March
16:00 - 17:30

Location: Room London (Hall B2, level 0)

Chairs: R. Bartoletti, Pisa (IT)
H.M. Çek, Edirne (TR)
H. Davila Barrios, Caracas (VE)

Aims and objectives of this presentation

Overview of current state-of-the-art clinical and research in the field of urological infections.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *256 **Use of a novel electronic health records reporting tool to assess the most common bacterial strains in urine cultures in Jordan and their resistance to common antibiotics: A population based study**
By: [Abughosh Z.M.](#), Alsadi M.R., Ayoub F., Alhakim M., Alnawaji T.
Institutes: Electronic Health Solutions, Dept. of Health Analytics, Amman, Jordan
- *257 **Accuracy of dipstick urine analysis and urine flow cytometry to predict bacteriuria in patients with indwelling ureteral stents**
By: [Bonkat G.](#)¹, Halla A.¹, Seifert H.¹, Müller G.¹, Braissant O.¹, Egli A.², Regeniter A.³, Gasser T.¹, Bachmann A.¹, Rieken M.¹
Institutes:¹University Hospital Basel, Dept. of Urology, Basel, Switzerland, ²University Hospital Basel, Medical Microbiology, Basel, Switzerland, ³University Hospital Basel, Laboratory Medicine, Basel, Switzerland
- *258 **The impact of sex hormones on microbiome in female urinary tract**
By: Cao M.¹, Hu Z.H.¹, Liu F.², Xu Z.M.¹, Yang Y.Y.¹, Cao J.J.¹, Wu H.S.¹, [Jin X-D.](#)¹
Institutes:¹The First Affiliated Hospital of Zhejiang University, Dept. of Urology, Hangzhou, China, ²D'Youville College School of Pharmacy, , Buffalo, United States of America
- *259 **Increased mRNA expression of connexins in the urothelium of patients with interstitial cystitis: Possible biomarkers**
By: [Mitsui T.](#), Tsuchiya S., Sawada N., Miyamoto T., Nakagomi H., Kira S., Takeda M.
Institutes: University of Yamanashi, Dept. of Urology, Chuo-City, Japan
- *260 **Hyaluronic acid enhances innate immune defences in an in vitro model of female urinary tract infection**
By: Mowbray C.², Shams S.¹, Stanton A.², Suchenko A.², [Ali A.](#)¹, Pickard R.¹, Hall J.²
Institutes:¹Newcastle University, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom, ²Newcastle University, Institute for Cell and Molecular Biosciences, Newcastle upon Tyne, United Kingdom
- *261 **Efficacy of ultra-violet light on bacterial growth and biofilm production of selected strains of uropathogenic Escherichia coli and pseudomonas aeruginosa**
By: Lin C-J., Gandee L., Hseish J., [Zimmermann P.](#)
Institutes: UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America
- *262 **Canephron® N reduces pain in experimental cystitis and prostatitis putatively by inhibition of PGE2 production**

By: Nausch B.¹, Koeberle A.², Werz O.², Ammendola A.¹, Künstle G.¹
Institutes:¹Bionorica SE, Preclinical R&D, Neumarkt, Germany, ²Friedrich Schiller University Jena, Institute of Pharmacy, Jena, Germany

- *263 **HPV infection in male sexual partners of women diagnosed of high grade cervical lesions and concordance in couples**
 By: Lopez Diez E.¹, Carballo Quintá M.¹, Almuster S.¹, Perez S.², Iñarrea A.³, Tortolero L.¹, Rodríguez Socarrás M.E.¹, Montero R.¹, Castro M.¹, Ojea A.¹
Institutes:¹Alvaro Cunqueiro Hospital, Dept. of Urology, Vigo, Spain, ²Alvaro Cunqueiro Hospital, Dept. of Microbiology, Vigo, Spain, ³Alvaro Cunqueiro Hospital, Dept. of Gynaecology, Vigo, Spain
- *264 **Healthcare-associated infections by multidrug-resistant bacteria in a tertiary urology department**
 By: Marques V., Rolo F., Tavares Silva E., Torres A., Figueiredo A., Mota A.
Institutes:University and Hospital Centre of Coimbra, Dept. of Urology and Renal Transplantation, Coimbra, Portugal
- *265 **Phage therapy for the treatment for urinary tract infection: Results of in-vitro screenings and in-vivo application using commercially available bacteriophage cocktails**
 By: Ujmajuridze A.¹, Jvania G.¹, Chanishvili N.², Goderdzishvili M.², Sybesma W.³, Managadze L.¹, Chkhotua A.¹, Kessler T.⁴
Institutes:¹National Center of Urology, Dept. of Urology, Tbilisi, Georgia, ²The Eliava Institute of Bacteriophage, Dept. of Microbiology and Virology, Tbilisi, Georgia, ³University of Zürich, Institute of Medical Microbiology, Zürich, Switzerland, ⁴Balgrist University Hospital, Dept. of Neuro-Urology, Spinal Cord Injury Center & Research, Zürich, Switzerland
- *266 **Validation of the index of severity in Fournier's gangrene in large contemporary series of 60 cases**
 By: Moudouni S., Fettouh A., Arza S., Lakmichi A., Dahami Z., Sarf I.
Institutes:Chu Med Vi, Dept. of Urology, Marrakech, Morocco
- *267 **Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: Fosfomycin trometamol is an attractive strategy**
 By: Cai T.¹, Tiscione D.¹, Malossini G.¹, Rizzo M.², Verze P.³, Gacci M.⁴, Cocci A.⁴, Pisano F.⁹, Carini M.⁴, Liguori G.², Gontero P.⁹, Trombetta C.², Bartoletti R.⁵, Mirone V.³, Wagenlehner F.⁶, Naber K.⁷, Bjerklund Johansen T.E.⁸
Institutes:¹Santa Chiara Hospital, Dept. of Urology, Trento, Italy, ²University of Trieste, Dept. of Urology, Trieste, Italy, ³University of Naples, Dept. of Urology, Naples, Italy, ⁴University of Florence, Dept. of Urology, Florence, Italy, ⁵University of Pisa, Dept. of Urology, Pisa, Italy, ⁶University of Giessen, Dept. of Urology, Giessen, Germany, ⁷Technical University of Munich, Dept. of Urology, Munich, Germany, ⁸Oslo University Hospital, Dept. of Urology, Oslo, Norway, ⁹University of Turin, Dept. of Urology, Turin, Norway
- *268 **The role of indoleamine 2,3-dioxygenase in epididymitis**
 By: Ohira S.¹, Hara R.¹, Tone S.², Fujii T.¹, Miyaji Y.¹, Kuribayashi F.², Nagai A.¹
Institutes:¹Kawasaki Medical School, Dept. of Urology, Kurashiki City, Japan, ²Kawasaki Medical School, Dept. of Biochemistry, Kurashiki City, Japan
- *269 **First results of a prospective study on urological complications under allogenic stem cell transplantation (aSCT) – analysis focused on viral urological infections**
 By: Schneidewind L.¹, Neumann T.², Krueger W.², Burchardt M.¹
Institutes:¹University Medicine Greifswald, Dept. of Urology, Greifswald, Germany, ²University Medicine Greifswald, Dept. of Hematology/Oncology, Greifswald, Germany
- *270 **The acetowhite test in genital human papillomavirus infection in men**
 By: Lopez Diez E.¹, Carballo Quintá M.¹, Almuster S.¹, Perez S.², Iñarrea A.³, Rodríguez Socarrás M.E.¹, Tortolero L.¹, Castro M.¹, Ojea A.¹
Institutes:¹Alvaro Cunqueiro Hospital, Dept. of Urology, Vigo, Spain, ²Alvaro Cunqueiro Hospital, Dept. of Microbiology, Vigo, Spain, ³Alvaro Cunqueiro Hospital, Dept. of Gynaecology, Vigo, Spain

E-BLUS Exam

HOT 06

Saturday, 12 March
16:15 - 17:00

Location: Room South America (Hall B0, level 0)

Aims and objectives of this presentation

The European training in basic laparoscopic urological skills (E-BLUS) is a programme offered to residents and urologists who want to improve the basic skills in laparoscopy. It is a unique opportunity to train with international experts in laparoscopy. The E-BLUS programme includes:

- Hands-on training (HOT) sessions of different levels carried out under the guidance of experienced tutors
- A set of training-box exercises developed and validated by the Dutch project Training in Urology (TiU) to train basic skills needed in urological laparoscopy
- E-BLUS examination and certification
- An online theoretical course

To be confirmed

T. Tokas, Hall In Tirol (AT)

To be confirmed

O. Rodriguez Faba, Barcelona (ES)

F.C.H. d'Ancona, Nijmegen (NL)

A. Sempere Gutierrez, Murcia (ES)

E-BLUS Exam

HOT 07

Saturday, 12 March
17:15 - 18:00

Location: Room South America (Hall B0, level 0)

Aims and objectives of this presentation

The European training in basic laparoscopic urological skills (E-BLUS) is a programme offered to residents and urologists who want to improve the basic skills in laparoscopy. It is a unique opportunity to train with international experts in laparoscopy. The E-BLUS programme includes:

- Hands-on training (HOT) sessions of different levels carried out under the guidance of experienced tutors
- A set of training-box exercises developed and validated by the Dutch project Training in Urology(TiU) to train basic skills needed in urological laparoscopy
- E-BLUS examination and certification
- An online theoretical course

T. Tokas, Hall In Tirol (AT)

To be confirmed

T. Kalogeropoulos, Athens (GR)

O. Rodriguez Faba, Barcelona (ES)

A. Sempere Gutierrez, Murcia (ES)

B.S.E.P. Van Cleynenbreugel, Wolfsdonk (BE)

Prostate cancer

Plenary Session 2

Sunday, 13 March
07:30 - 10:55

Location: eURO Auditorium (Hall C1, Level 0)

Chairs: D. Jacqmin, Strasbourg (FR)
M. Wirth, Dresden (DE)

Aims and objectives of this presentation

The session deals with diagnosis and classification of patients with prostate cancer. One topic is whether genomics help us define patients with high risk disease with higher certainty and thus improve active surveillance. The other lectures deal with early diagnosis of prostate cancer, the role of multiparametric MRI and when a biopsy is indicated. Adjuvant radiotherapy is another hot topic of this session. We will learn when it should be applied.

07:30 - 08:00

Highlight session Highlight session 1

07:30 - 07:40

Lower urinary tract dysfunction

N. Thiruchelvam, Cambridge (GB)

07:40 - 07:50

Stones

A. Papatsoris, Athens (GR)

07:50 - 08:00

Andrology

C. Jensen, Herlev (DK)

Aims and objectives of this presentation

The aim of the presentation is to provide an overview of the newest discoveries and best research presented within the field of Andrology at EAU 2016.

*LBA02

TOOKAD SolubleTM versus active surveillance in men with low risk prostate cancer – a randomized phase 3 clinical trial

By: Alcaraz A.¹², Azzouzi A.R.², Barret E.⁴, Benzaghou F.¹⁶, Cicco A.⁵, Debruyne F.M.J.¹⁵, Emberton M.¹, Gaillac B.¹⁶, Gratzke C.⁸, Kleinclauss F.⁶, Rassweiler J.⁹, Ahlgren G.M.¹⁴, Salomon G.¹⁰, Solsona E.¹¹, Stief C.⁸, Tammela T.¹³, Van Der Poel H.⁷, Vincendeau S.³

Institutes:¹University College London, Dept. of Surgery and Interventional Science, London, United Kingdom, ²Angers University Hospital, Dept. of Urology, Angers, France, ³Rennes University Hospital, Dept. of Urology, Rennes, France, ⁴Université Paris-Descartes, Dept. of Urology, Paris, France, ⁵Centre Catalan Urologie Andrologie, Dept. of Urology, Cabestany, France, ⁶Besançon University Hospital, Saint Jacques Hospital, Dept. of Urology and Renal Transplantation, Besançon, France, ⁷Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ⁸LMU-Klinikum der Universität München, Dept. of Urology, Munich, Germany, ⁹SLK Kliniken, Dept. of Urology, Heilbronn, Germany, ¹⁰Martini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ¹¹Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain, ¹²Hospital Clínic de Barcelona, Dept. of Urology, Barcelona, Spain, ¹³Tampere University Hospital, Dept. of Urology, Tampere, Finland, ¹⁴Skåne University Hospital, Dept. of Urology, Malmö, Sweden, ¹⁵Andros Clinic, Dept. of Urology, Arnhem, The Netherlands, ¹⁶, Medical department, Paris, France

08:06 - 08:10

Discussant

D. Murphy, Melbourne (AU)

08:10 - 08:20

State-of-the-art lecture **Is genomics going to help us find high risk disease?**

T. Schlomm, Hamburg (DE)

08:20 - 08:50

Debate **Is there a role for pre-biopsy MRI?**

J. Walz, Marseille (FR)

08:20 - 08:35

Challenger

E. Baco, Oslo (NO)

08:35 - 08:50

Discussant **European Society of Urogenital Radiology (ESUR)**

H. Thoeny, Berne (CH)

08:50 - 09:05

State-of-the-art lecture **Prevention and management of biopsy complications**

T. Cai, Trento (IT)

Aims and objectives of this presentation

Even if prostate biopsy is generally considered a safe procedure, it may be accompanied by several clinical complications, like bleeding or, more frequently, infective complications ranging from asymptomatic bacteriuria to symptomatic UTI and sepsis. Today, the infective complications after prostate biopsy represent an important challenge for the urologist and a life-threatening risk for the patient, in particular due to the increased rate of antibiotic resistant bacteria. We need to find novel approaches and strategies for the prevention of infective complications.

09:05 - 09:35

Debate **Timing of radiotherapy after radical prostatectomy**

J. Irani, Le Kremlin-Bicetre (FR)

09:05 - 09:20

Adjuvant

T. Wiegel, Ulm (DE)

09:20 - 09:35

Salvage

R.J. Karnes, Rochester (US)

09:35 - 09:50

State-of-the-art lecture **Long term quality of life in survivors**

E.M. Johansson, Uppsala (SE)

Aims and objectives of this presentation

Due to early detection the life expectancy for men with localized prostate cancer can be two decades or more, emphasizing the importance of long-term quality of life data. I will present long-term data focusing on the SPCG-4 study.

09:50 - 10:30

Debate **When is chemotherapy indicated in hormone-naïve prostate cancer in 2016?**

Moderator:

K. Miller, Berlin (DE)

09:50 - 09:55

Introduction

K. Miller, Berlin (DE)

- 09:55 - 10:05 **Results of the STAMPEDE trial: Game, set and match**
N.W. Clarke, Manchester (GB)
- 10:05 - 10:15 **Will hormone therapy be lost for urologists in these cases?**
N. Mottet, Saint-Étienne (FR)
- 10:15 - 10:30 **Discussion**
-

- 10:30 - 10:55 **Case discussion Rising PSA after curative therapy: What to do?**
-

K. Touijer, New York (US)

- 10:30 - 10:40 **Pro surgery**
S. Joniau, Leuven (BE)

- 10:40 - 10:50 **Pro radiotherapy**
P. Ost, Ghent (BE)

- 10:50 - 10:55 **Discussion**

Office management of male sexual dysfunction

ESU Course 13

Sunday, 13 March
08:30 - 11:30

Location: Room 13a (ICM, Level 1)

Chair: C. Stief, Munich (DE)

Aims and objectives of this presentation

The course is aimed at providing practical advice on how to diagnose and treat a patient with Premature ejaculation or ED. It will allow

- An up-to-date understanding of the aetiology of ED and EP
- An adequate work up enabling an individually adopted regimen
- Currently available treatment options as topical and oral drugs, testosterone and devices
- Post-prostatectomy ED with various approaches

08:30 - 11:30

Introduction

C. Stief, Munich (DE)

08:30 - 11:30

Diagnostics - What is necessary?

O. Kayes, Leeds (GB)

08:30 - 11:30

Testosterone replacement

C. Stief, Munich (DE)

08:30 - 11:30

Oral therapy for ED

O. Kayes, Leeds (GB)

08:30 - 11:30

Therapy of ED when pills fail

D.J. Ralph

08:30 - 11:30

Medical therapy for premature ejaculation

O. Kayes, Leeds (GB)

08:30 - 11:30

Surgical topics: Penile implants, priapism, Peyronie's

D.J. Ralph

08:30 - 11:30

What to do after radical prostatectomy?

C. Stief, Munich (DE)

Update on stone disease

ESU Course 14

Sunday, 13 March
08:30 - 11:30

Location: Room 13b (ICM, Level 1)

Chair: A. Patel, London (GB)

Aims and objectives of this presentation

The previously devastating burden of urinary tract urolithiasis has been reduced by modern stone therapy. Complex branched stones are rare, and therapy has moved largely to the outpatient setting. Nevertheless, successful management requires competence in all aspects of stone management. After a brief review of new developments in present treatment strategies, these will be further explored by interactive case presentations.

- Stone disease aetiology is multi-factorial, relating in large part to genetics, diet (salt, calorie and protein intake), hydration status factors and ageing.
- The clinical presentation is changing with a growing base of elderly and obese patient cohorts in developed nations.
- Today's challenge is employing the ideal initial and salvage approaches for specific situations – individuals, including judicious selection of prevention strategies.
- Patients should be given choices and counselled about the risk benefits and potential outcomes of all appropriate reasonable approaches.

08:30 - 11:30

Introduction

A. Patel, London (GB)

08:30 - 11:30

Medical aspects of urinary stones

M. Straub, Munich (DE)

08:30 - 11:30

SWL

M. Straub, Munich (DE)

08:30 - 11:30

Uretero-Renoscropy

A. Breda, Barcelona (ES)

08:30 - 11:30

Percutaneous nephrolithotomy and questions and answers

A. Patel, London (GB)

08:30 - 11:30

Interactive case discussion

A. Patel, London (GB)

Focal treatment in prostate cancer

ESU Course 15

Sunday, 13 March
08:30 - 11:30

Location: Room 11 (ICM, Level 1)

Chair: T.E. Bjerklund Johansen, Oslo (NO)

Aims and objectives of this presentation

Focal treatment is about eradicating the cancer lesion within the prostate while preserving genitourinary function. This interactive course offers delegates

- understanding of the rationale for focal treatment and patient selection criteria
- update on principles, outcome and side effects of focal technologies
- a thorough discussion of biopsy strategies and imaging in diagnostic work-up and follow-up
- information about existing registries

As men with prostate cancer are getting younger the side effects of whole gland treatment are getting more important. With several new technologies available a significant development of focal treatment is expected in the coming years.

08:30 - 11:30

Welcome and introduction

T.E. Bjerklund Johansen, Oslo (NO)

08:30 - 11:30

Diagnostic work-up

08:30 - 11:30

The role of prostate biopsies for ruling in and ruling out prostate cancer in different parts of the gland; The need for biopsy tracking and image fusion systems

D. Greene, Sunderland (GB)

08:30 - 11:30

The role of MRI for ruling in and ruling out prostate cancer in different parts of the gland; The role of N and M-staging by node dissection, PET CT, MRI and bone scan

J.P.M. Sedelaar, Nijmegen (NL)

08:30 - 11:30

Focal treatment methods, outcome and side effects

08:30 - 11:30

Cryosurgical ablation

T.E. Bjerklund Johansen, Oslo (NO)

08:30 - 11:30

High intensity focused ultrasound

D. Greene, Sunderland (GB)

08:30 - 11:30

Other technologies

J.P.M. Sedelaar, Nijmegen (NL)

08:30 - 11:30

Follow up after focal therapy

08:30 - 11:30

The role of PSA; When to do biopsies

D. Greene, Sunderland (GB)

08:30 - 11:30

The role of MRI; Indications for whole gland treatment; Focal treatment in a salvage setting

J.P.M. Sedelaar, Nijmegen (NL)

08:30 - 11:30

The need for research guidelines and registries (EUCAP; Alpha registry and ECLIPSE)
T.E. Bjerklund Johansen, Oslo (NO)

How to write a manuscript and get it published in European Urology

ESU Course 16

Sunday, 13 March
08:30 - 11:30

Location: Room 12 (ICM, Level 1)

Chair: J.W.F. Catto, Sheffield (GB)

Aims and objectives of this presentation

In this course we will explain the role the European Urology and European Urology Focus in learning and Evidence based medicine. We will focus upon our interaction with authors and how we can encourage high quality medical reports. We will explain in details the review process, focus upon the importance of statistical design and reporting guidelines. We will use practical examples to educate.

- To understand the role of European Urology in the field of urology
- To understand what makes a successful submission for publication
- To learn about statistical design and robust reporting styles
- To understand the review process and how best to address this
- To understand how we handle and review submissions

08:30 - 11:30

Surgery in Motion: How to combine the best possible manuscript and video for the Surgery in Motion Section

A. Mottrie, Aalst (BE)

08:30 - 11:30

Why publishing (and publishing on European Urology) is important for you

C. Gratzke

08:30 - 11:30

Clinical research original article: How to write an article and get it published in European Urology

M.R. Cooperberg, San Francisco (US)

08:30 - 11:30

Common problems and potential solutions

J.W.F. Catto, Sheffield (GB)

08:30 - 11:30

The importance of statistical design and analysis

D. Sjoberg, New York (US)

08:30 - 11:30

How to write a basic research article to be relevant for the readers of European Urology

J-N.L. Cornu, Rouen (FR)

08:30 - 11:30

How to write the perfect Twitter text

A. Kutikov, Philadelphia (US)

08:30 - 11:30

How to review a paper for European Urology

S. Boorjian, Rochester (US)

08:30 - 11:30

Questions and answers

J.W.F. Catto, Sheffield (GB)

Lower urinary tract dysfunction and urodynamics

ESU Course 17

Sunday, 13 March
08:30 - 11:30

Location: Room 21 (ICM, Level 2)

Chair: P. Abrams, Bristol (GB)

Aims and objectives of this presentation

Having attended the course, the attendee should:

- Understand the basic physical principles referable to urodynamics
- Be able to assess the quality of a urodynamic trace
- Recognise common artefacts and know how to correct them
- Know the indications for urodynamic studies in children, men, women and neurological patients.

08:30 - 11:30

The scientific basics of urodynamics

P. Abrams, Bristol (GB)

08:30 - 11:30

Urodynamics - getting philosophy and technique correct

P. Abrams, Bristol (GB)

08:30 - 11:30

Urodynamics in neurourology

J.L.H.R. Bosch, Utrecht (NL)

08:30 - 11:30

Urodynamics in female urology

P. Abrams, Bristol (GB)

08:30 - 11:30

Urodynamics in the child and in men

J.L.H.R. Bosch, Utrecht (NL)

Advanced course on laparoscopic nephrectomy

ESU Course 18

Sunday, 13 March
08:30 - 11:30

Location: Room 22 (ICM, Level 2)

Chair: V. Pansadoro, Rome (IT)

Aims and objectives of this presentation

Minimally invasive surgery has steadily improved over the last years. Today one can approach with confidence new, difficult and challenging situations.

The course is structured to evaluate and explore the increasing indications and possible complications of Laparoscopic and Robotic kidney surgery.

This course will focus upon common and uncommon complications and how to manage and prevent them.

In addition, special situations such as single port inguinal approach, zero ischemia time, cava thrombus, accidental splenectomy and living donor nephrectomy will be presented.

08:30 - 11:30

Introduction

R. Bollens, Lomme (FR)

V. Pansadoro, Rome (IT)

08:30 - 11:30

Transperitoneal approach

V. Pansadoro, Rome (IT)

08:30 - 11:30

Retroperitoneal approach

R. Bollens, Lomme (FR)

V. Pansadoro, Rome (IT)

08:30 - 11:30

Single port inguinal approach

R. Bollens, Lomme (FR)

08:30 - 11:30

Intraoperative complications

R. Bollens, Lomme (FR)

V. Pansadoro, Rome (IT)

08:30 - 11:30

Difficult nephrectomies

R. Bollens, Lomme (FR)

08:30 - 11:30

Partial nephrectomy

R. Bollens, Lomme (FR)

V. Pansadoro, Rome (IT)

08:30 - 11:30

Special cases

R. Bollens, Lomme (FR)

V. Pansadoro, Rome (IT)

New horizons in LUTS

Poster Session 22

Sunday, 13 March
08:45 - 10:15

Location: Room Madrid (Hall B2, level 0)

Chairs: F. Cruz, Porto (PT)
M.J. Drake, Bristol (GB)
A. Ruffion, Pierre-Bénite (FR)

Aims and objectives of this presentation

Recent advances in the area of bladder pathophysiology, pharmacology and stem cell therapy will be presented and discussed

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *271 **Sphingosine-1-phosphate, a new biomarker of detrusor overactivity in patients with multiple sclerosis**
By: Sanson S.¹, Roumiguié M.¹, Ballouhey Q.², Castel-Lacanal E.³, Jaafar A.⁴, Tack Y.⁴, Game X.¹
Institutes:¹CHU Rangueil, Dept. of Urology, Toulouse, France, ²CHU, Dept. of Pediatric Surgery, Limoges, France, ³CHU Rangueil, Dept. of Physical Medicine and Rehabilitation, Toulouse, France, ⁴CHU Rangueil, Dept. of Physiological Functional Exploration, Toulouse, France
- *272 **Differences in organisation and phenotypes of interstitial cells in bladder lamina propria between human and laboratory animals**
By: Gevaert T.¹, Steiner C.², Vanstreels E.³, Pintelon I.⁴, Timmermans J-P.⁴, Neuhaus J.², De Ridder D.¹
Institutes:¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²University of Leipzig, Dept. of Urology, Leipzig, Germany, ³KU Leuven, Dept. of Laboratory of Virology and Chemotherapy (Rega Institute), Leuven, Belgium, ⁴University of Antwerp, Dept. of Veterinary Sciences, Antwerp, Belgium
- *273 **Altered muscarinic signalling in the urinary bladder of mouse models of Alzheimer's disease**
By: Hohnen R.¹, Zare A.¹, Stevens J.¹, Losen M.¹, Meriaux C.¹, Rahnama'i M.S.², Van Koeveringe G.²
Institutes:¹Maastricht University, Dept. of Neuroscience, Maastricht, The Netherlands, ²Maastricht University Medical Centre, Dept. of Urology, Maastricht, The Netherlands
- *274 **Measurement of endocannabinoids levels during treatment of bladder hyperactivity induced by cystitis with FAAH inhibitors and evaluation of the cannabinoid receptor and TRPV1 roles**
By: Charrua A.¹, Matos R.¹, Marczylo T.², Nagy I.³, Cruz E.¹
Institutes:¹Faculty of Medicine of University of Porto, Dept. of Experimental Biology, Porto, Portugal, ²Public Health England, Chilton, United Kingdom, ³Faculty of Medicine, Imperial College of London, Dept. of Surgery & Cancer, London, United Kingdom
- *275 **Up-regulation of prostatic cannabinoid receptor type 2 following capsaicin-induced prostatitis in castrated and non-castrated rats**
By: Lin T.L.
Institutes:National Yang-Ming University Taipei Veterans Gen Hospital, Dept. of Urology, Taipei, Taiwan
- *276 **Does TRP channel play a role of extracellular calcium sensing in urethral smooth muscle?**
By: Kajioka S., Hayashi M., Maki T., Takahashi R., Etoh M.
Institutes:Kyushu University, Dept. of Urology, Fukuoka, Japan

- *277 **Mouse model with ketamine-induced voiding dysfunction demonstrates intact urothelial barrier function**
By: [Rajandram R.](#)¹, Ong T.A.¹, Razack A.¹, Maciver I.B.², Zeidel M.², Yu W.²
Institutes:¹University of Malaya, Dept. of Surgery, Kuala Lumpur, Malaysia, ²Beth Israel Deaconess Medical Center and Harvard Medical School, Dept. of Medicine, Boston, United States of America
- *278 **Safety and effectiveness of mirabegron in patients with overactive bladder (OAB): Results of two Japanese post-marketing surveys**
By: [Kato D.](#)¹, Katoh T.², Kuwamoto K.¹, Nozawa Y.¹, Tabuchi H.¹, Kuroishi K.¹
Institutes:¹Astellas Pharma Inc, Medical Affairs, Tokyo, Japan, ²International University of Health and Welfare, Mita Hospital, Cardiovascular Centre, Tokyo, Japan
- *279 **Bladder acellular matrix grafts seeded with adipose-derived stem cells and incubated intraperitoneally promote the regeneration of bladder smooth muscle in a rat model of bladder augmentation**
By: Zhou Z.², Da J.², Zhao Y.², Zhang M.², Xiao D.², Wang Q.², Wang Z.², [Lu M.](#)¹
Institutes:¹Shanghai 9th People's Hospital, Shanghai, China, ²Shanghai 9th People's Hospital, Dept. of Urology, Shanghai, China
- *280 **Advanced properties of urine derived stem cells compared to adipose tissue derived stem cells in terms of cell proliferation, immune modulation and multi differentiation**
By: [Choi S.H.](#)¹, Chung J-W.¹, Lee J.N.¹, Ha Y-S.¹, Kim B.S.¹, Kim H.T.¹, Kim T-H.¹, Yoo E.S.¹, Kwon T.G.¹, Chung S.K.¹, Kim B.W.¹, Cho D-H.², Kim J.S.³
Institutes:¹Kyungpook University Hospital, Dept. of Urology, Daegu, South Korea, ²CHA Gumi Medical Center, Dept. of Urology, Gumi-Si, South Korea, ³Daegu Fatima Hospital, Dept. of Urology, Daegu, South Korea
- *281 **Functional smooth muscle cells differentiated from adipose derived stem cells: The importance of autophagy**
By: Salemi S., Mortezaei A., Sulser T., [Eberli D.](#)
Institutes:University Hospital Zürich, Dept. of Urology, Zurich, Switzerland
- 10:00 - 10:07 **Summary and context**
F. Cruz, Porto (PT)

Control of cellular events in urothelial tumours

Poster Session 23

Sunday, 13 March
08:45 - 10:15

Location: Room Stockholm (Hall B2, level 0)

Chairs: E. Comp rat, Paris (FR)
K. Junker, Homburg (DE)
N. Malats, Madrid (ES)

Aims and objectives of this presentation

In this session, miRNA and long coding RNA in urothelial cancer will be highlighted. Their involvement in oncogenic and tumour suppressive regulation of carcinogenesis will be presented. The session will also focus on innovative therapy applications in this malignancy.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *283 **Intravesical instillation of exogenous microRNA-145 as a therapy for mouse orthotopic human bladder cancer xenograft**
By: [Inamoto T.](#)¹, Taniguchi K.², Takahara K.¹, Iwatsuki A.², Takai T.¹, Komura K.¹, Yoshikawa Y.¹, Uchimoto T.¹, Saito K.¹, Tanda N.¹, Kouno J.¹, Minami K.¹, Uehara H.¹, Hirano H.¹, Nomi H.¹, Kiyama S.¹, Akao Y.², Azuma H.¹
Institutes:¹Osaka Medical College, Dept. of Urology, Osaka, Japan, ²Gifu University, United Graduate School of Drug Discovery and Medical Information Sciences, Gifu, Japan
- *284 **Intravesical delivery of hydrophobic drug using mucoadhesive cationic serum albumin nanoparticle as a carrier for bladder cancer therapy**
By: [Chiong E.](#)¹, Lu S.², Tan C.³, Rahmat J.³, Kang E.T.², Mahendran R.³, Neoh K.G.²
Institutes:¹National University Health System, Dept. of Urology, Singapore, Singapore, ²National University of Singapore, Dept. of Engineering, Singapore, Singapore, ³National University of Singapore, Dept. of Surgery, Singapore, Singapore
- *285 **MRNA expression levels and prognostic value of PD1/PDL1 and CTLA4 pathways genes in a large series of 155 bladder tumors**
By: [Le Goux C.](#)¹, Bieche I.¹, Barry De Longchamps N.², Vacher S.¹, Sibony M.³, Zerbib M.², Damotte D.³, Pignot G.⁴
Institutes:¹Institut Curie, Dept. of Pharmacog nomique, Paris, France, ²Hopital Cochin, Dept. of Urology, Paris, France, ³Hopital Cochin, Dept. of Anatomopathology, Paris, France, ⁴Institut Paoli-Calmettes, Dept. of Urology, Marseille, France
- *286 **Long noncoding RNAs in bladder cancer. Expression and quantification of MALAT1 in low and high risk tumors**
By: [Virsedo Rogriguez A.J.](#)¹, Garcia Hernandez J.L.³, Garcia Garcia J.¹, Salvatierra Perez C.¹, N nuez Otero J.J.¹, Coderque Mejia M.P.¹, Hernandez Sanchez T.¹, Hernandez Rivas J.M.², Herrero Polo M.¹, Martin Parada A.¹, Cruz J.J.⁴, G mez Veiga F.¹
Institutes:¹Salamanca University Hospital, Dept. of Urology IBSAL-GITUR, Salamanca, Spain, ²Cancer Investigation Center of University of Salamanca, IBMCC, Salamanca, Spain, ³Resarch Unit of The University Hospital of Salamanca, Spain Center For Cancer Research (CIC-IBMCC;CSIC/USAL; IBSAL), Salamanca, Spain, ⁴Universitary and Hospitalary Salamanca's Complex, Dept. of Oncology, Salamanca, Spain
- *287 **Targeting protein kinase CK2 suppresses bladder cancer cell survival via glucolysis pathway**
By: Tao T., Zhang X., Yang C., Cheng Y., Li P., Yang X., Deng X., [Lu Q.](#)

Institutes:The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology And Kidney Transplantation, Nanjing, China

- *288 **Is two protein immunohistochemistry assay able to identify the basal subtype of bladder cancer?**
By: Masson-Lecomte A.¹, Sirab N.², De Reyniès A.³, Maillé P.², Soyeux-Porte P.², Vordos D.¹¹, Lebret T.⁴, Benhamou S.⁵, Carrato A.⁶, Malats N.⁷, Real F.⁸, De La Taille A.¹¹, Radvanyi F.⁹, Allory Y.¹⁰
Institutes:¹Hôpitaux Universitaires Henri Mondor, Dept. of Urology, Créteil, France, ²IMRB, Translational Research In Genito-Urinary Cancers, Créteil, France, ³Ligue Nationale Contre Le Cancer, Carte D'identité des Tumeurs Program, Paris, France, ⁴Foch Hospital, Dept. of Urology, Suresnes, France, ⁵INSERM, INSERM U946, Paris, France, ⁶Ramon Y Cajal Hospital, Dept. of Oncology, Madrid, Spain, ⁷CNIO, Genetic and Molecular Epidemiology Group, Madrid, Spain, ⁸CNIO, Epithelial Carcinogenesis Group, Madrid, Spain, ⁹CNRS, Institut Curie, UMR 144, Paris, France, ¹⁰Henri Mondor Hospital, Dept. of Pathology, Créteil, France, ¹¹Henri Mondor Hospital, Dept. of Urology, Créteil, France
- *289 **Sulfated hyaluronic acid: A novel antitumor agent for bladder cancer**
By: Hennig M.¹, Jordan A.², Chipollini J.³, Hupe M.¹, Kramer M.¹, Lopez L.⁴, Merseburger A.¹, Lokeshwar V.⁴
Institutes:¹University of Lübeck, Dept. of Urology, Lübeck, Germany, ²Sylvester Comprehensive Cancer Center, University of Miami - Miller School of Medicine, Dept. of Urology, Miami, United States of America, ³University of Miami - Miller School of Medicine, Dept. of Urology, Miami, United States of America, ⁴Medical College of Georgia, Augusta University, Dept. of Biochemistry & Molecular Biology, Augusta, United States of America
- *290 **Topical and systemic immunoreaction induced by intravesical instillation of chemotherapeutic agents in a BBN-induced bladder cancer mouse model**
By: Shunta H., Miyake M., Tatsumi Y., Ohnishi S., Morizawa Y., Nakai Y., Anai S., Tanaka N., Fujimoto K.
Institutes:Nara Medical University, Dept. of Urology, Nara, Japan
- *291 **Efficacy of recombinant bacille Calmette-Guérin secreting interleukin-15 against bladder cancer**
By: Takeuchi A., Tatsugami K., Shiota M., Yokomizo A., Inokuchi J., Kashiwagi E., Takashi D., Eto M.
Institutes:Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan
- *292 **Circulating tumour cells in patients with advanced urothelial carcinoma of the bladder and correlation with tumour stage, lymph node metastases and FDG-PET-findings**
By: Abrahamsson J.¹, Aaltonen K.², Engilbertsson H.¹, Liedberg F.¹, Patschan O.¹, Rydén L.², Sjö Dahl G.¹, Gudjonsson S.¹
Institutes:¹Lund University, Dept. of Translational Medicine, Dept. of Urology, Skåne University Hospital, Malmö, Sweden, ²Lund University, Dept. of Clinical Sciences, Dept. of Oncology, Lund, Sweden
- *293 **UroMark - a highly multiplex biomarker for the detection of bladder cancer**
By: Feber A.¹, De Winter P.², Dhami P.³, Martinez-Fernande M.⁴, Paul D.⁵, Hynes-Allen A.³, Tan W.², Gurung P.², Rodney S.², Mehmood A.², Jameson C.⁶, Paramio J.⁴, Bryan R.⁷, James N.⁷, Freeman A.⁶, Beck S.³, Kelly J.²
Institutes:¹Ucl Cancer Institute, Dept. of Cancer Biology, London, United Kingdom, ²UCL Medical School, Dept. of Surgery & Interventional Science, London, United Kingdom, ³UCL Cancer Institute, Dept. of Cancer Biology, London, United Kingdom, ⁴CIEMAT, Molecular Oncology Unit, Madrid, Spain, ⁵UCL Cancer Insitute, Dept. of Cancer Biology, London, United Kingdom, ⁶University College London Hospital, Dept. of Histopathology, London, United Kingdom, ⁷University of Birmingham, School of Cancer Sciences, London, United Kingdom
- *294 **Hormonal receptor and Her2 status correlates independently of gender with staging and grading in non muscle-invasive urothelial bladder carcinoma**
By: Breyer J.¹, Wirtz R.², Denzinger S.¹, Erben P.³, Burger M.¹, Hartmann A.⁴, Otto W.¹

Institutes:¹University of Regensburg, Dept. of Urology, Regensburg, Germany, ²Stratifyer Molecular Pathology, Dept. of Pathology, Cologne, Germany, ³University of Mannheim, Dept. of Urology, Mannheim, Germany, ⁴University of Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany

Advanced robotic reconstruction

Video Session 04

Sunday, 13 March
08:45 - 10:15

Location: Room 1 (ICM, Level 0)

Chairs: W. Artibani, Verona (IT)
P. Dasgupta, London (GB)
R.J.A. Van Moorselaar, Amsterdam (NL)

All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.

- *V25 **Residents and robots: Learning the value of teamwork**
By: Dal Moro E.¹, Zattoni F.²
Institutes:¹Università' di Padova, Azienda Ospedaliera, Dept. of Surgery, Oncology and Gastroenterology, Padua, Italy, ²Università' di Padova, Azienda Ospedaliera, Dept. of Surgery, Oncology and Gastroenterology - Urology, Padua, Italy
- *V26 **Robotic assisted Boari flap with ureteroneocystostomy (RA-BFUR): Replicating the techniques of open surgery in robotics**
By: Kallidonis P.¹, Stolzenburg J-U.², Raia B.², Doa M.², Liatsikos E.², Dietel A.², Ganzer R.², Qazi H.², Meneses A.²
Institutes:¹University of Patras, Dept. of Urology, Patras, Greece, ²University of Leipzig, Dept. of Urology, Leipzig, Germany
- *V27 **Robotic bilateral ureteric reimplantation in an ileal conduit**
By: Campos Juanatey E., Ballester Diego R., Portillo Martín J.A., Fuentes Pastor J., Carrión Ballardo C.J., Velilla Díez G., Herrero Blanco E., Gutiérrez Baños J.L.
Institutes:Hospital Universitario Marqués de Valdecilla, Dept. of Urology, Santander, Spain
- *V28 **Wallace versus Bricker ureteroileal anastomoses during robot assisted radical cystectomy with totally intracorporeal ileal conduit**
By: Simone G.¹, Tuderti G.¹, Papalia R.², Ferriero M.¹, Mastroianni R.², Minisola F.¹, Misuraca L.¹, Guaglianone S.¹, Gallucci M.¹
Institutes:¹"Regina Elena" National Cancer Institute, Dept. of Urology, Rome, Italy, ²Campus Biomedico University of Rome, Dept. of Urology, Rome, Italy
- *V29 **Robotic intracorporeal Indiana pouch: Replicating open surgery**
By: Simone G.¹, Abreu A.L.², Ferriero M.³, Chopra S.², Papalia R.⁴, Park D.², Mastroianni R.³, Ahmadi N.², Sotelo R.², Guaglianone S.³, Aron M.², Gill I.², Desai M.², Gallucci M.³
Institutes:¹Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²USC Institute of Urology and Departments of Urology, Keck School of Medicine, University of Southern, Dept. of Urology, Los Angeles, United States of America, ³"Regina Elena" National Cancer Institute, Dept. of Urology, Rome, Italy, ⁴Campus Biomedico University of Rome, Dept. of Urology, Rome, Italy
- *V30 **IAI (intuitive anatomical intracorporeal) neobladder technique after robotic assisted radical cystectomy**
By: Sangalli M.N., Ferrari M., Zanoni M., Fabbri F., Ghezzi M., Sozzi F., Lolli C., Dell'Acqua V., Rigatti P., Cestari A.
Institutes:Istituto Auxologico Italiano, Dept. of Urology, Milan, Italy
- *V31 **Robot-assisted ureteral reimplantation on Studer neobladder**
By: Palou J., Gaya J.M., Schwartzmann I., Moncada E., Gausa L., Villavicencio H.
Institutes:Universitat Autònoma de Barcelona - Fundació Puigvert, Dept. of Urology, Barcelona,

Spain

*V32

Robot-assisted partial cystectomy for the treatment of urachus acinar adenocarcinoma

By: Dababneh H.¹, Gandaglia G.², De Groote R.³, Geurts N.³, Schatteman P.³, D'Hondt F.³, De Naeyer G.³, Zazzara M.², Novara G.², Schiavina R.¹, Mottrie A.²

Institutes:¹Sant'Orsola Malpighi, Dept. of Urology, Bologna, Italy, ²OLV Vattikuti Robotic Surgery Institute (ORSI), Dept. of Urology, Melle, Belgium, ³OLV Hospital, Dept. of Urology, Aalst, Belgium

Renal tumours: All about imaging

Poster Session 24

Sunday, 13 March
08:45 - 10:15

Location: Room Milan (Hall B2, level 0)

Chairs: U. Capitanio, Milan (IT)
E. Herrmann, Münster (DE)

Aims and objectives of this presentation

To discuss different aspects of imaging modalities in renal tumours.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *295 **Systematic review on the effectiveness of the Bosniak system for complex renal cysts**
By: [Verhagen P.](#)¹, Zaccai K.³, Schoots I.²
Institutes:¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, ³University College London Hospital, Dept. of Urology, London, United Kingdom
- *296 **Diagnosis performance of contrast-enhanced ultrasonography and magnetic resonance imaging for the assessment of complex renal cysts: A prospective study**
By: Defortescu G.¹, Cornu J.N.¹, Giwerc A.¹, Werquin C.², Gobet F.³, Béjar S.², Pfister C.¹, [Nouhaud F.X.](#)¹
Institutes:¹Rouen University Hospital, Dept. of Urology, Rouen, France, ²Rouen University Hospital, Dept. of Radiology, Rouen, France, ³Rouen University Hospital, Dept. of Pathology, Rouen, France
- *297 **Diffusion weighted MRI to discriminate the histological subtype of renal tumours**
By: [Van Oostenbrugge T.](#)¹, Langenhuijsen J.¹, Van Amerongen M.², Fütterer J.², Mulders P.¹
Institutes:¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²Radboudumc, Dept. of Radiology, Nijmegen, The Netherlands
- *298 **Percutaneous needle based optical coherence tomography for the differentiation of renal masses**
By: Wagstaff P.¹, Ingels A.¹, De Bruin D.², [Buijs M.](#)¹, Zondervan P.¹, Savci Heijink D.³, Van Delden O.⁴, Faber D.², Van Leeuwen T.², Van Moorselaar R.⁵, De La Rosette J.¹, Laguna Pes P.¹
Institutes:¹Academic Medical Center Amsterdam, Dept. of Urology, Amsterdam, The Netherlands, ²Academic Medical Center Amsterdam, Dept. of Biomedical Engineering and Physics, Amsterdam, The Netherlands, ³Academic Medical Center Amsterdam, Dept. of Pathology, Amsterdam, The Netherlands, ⁴Academic Medical Center Amsterdam, Dept. of Radiology, Amsterdam, The Netherlands, ⁵VU University Medical Center, Dept. of Urology, Amsterdam, The Netherlands
- *299 **A new quantitative method for characterizing small renal masses: MRI intensity ratio curve analysis**
By: [Moriyama S.](#), Yoshida S., Tanaka H., Inoue M., Ito M., Yokoyama M., Ishioka J., Matsuoka Y., Numao N., Saito K., Fujii Y., Kihara K.
Institutes:Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan
- *300 **When to perform a staging chest-CT scan before surgical treatment for kidney cancer**
By: [Larcher A.](#)¹, Nini A.¹, Fossati N.¹, Corti S.¹, Dell'Oglio P.¹, Trevisani F.¹, Nicoletti R.², De Cobelli F.², Dehò F.¹, Montorsi F.¹, Salonia A.¹, Briganti A.¹, Bertini R.¹, Capitanio U.¹
Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy
- *301 **When to perform preoperative bone scan for kidney cancer staging**

By: [Larcher A.](#)¹, Nini A.¹, Dell'Oglio P.¹, Fossati N.¹, Di Trapani E.¹, Suardi N.¹, Stabile A.¹, Trevisani F.¹, Picchio M.², Salonia A.¹, Briganti A.¹, Montorsi F.¹, Bertini R.¹, Capitanio U.¹

Institutes:¹IRCCS Ospedale San Raffaele, Milan, Italy, Dept. of Oncology and Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy

*302

Could perirenal fat be more important than the tumor itself? The MAP score better predicts perioperative morbidity than the RENAL score

By: [Khene Z-E.](#), Peyronnet B., Robert C., Prader B., Rohou T., Mathieu R., Verhoest G., Rioux-Leclercq N., Bensalah K.

Institutes: Pontchaillou University Hospital (Rennes), Dept. of Urology, Rennes, France

*303

Functional lower urinary tract symptoms: Innovation in innervation

Poster Session 25

Sunday, 13 March
08:45 - 10:15

Location: Room 14a (ICM, Level 1)

Chairs: S. De Wachter, Edegem (BE)
A. Giannantoni, Perugia (IT)
T.L.J. Tammela, Tampere (FI)

Aims and objectives of this presentation

This session will review innovative research in innervation and function of the lower urinary tract.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *305 **Supraspinal lower urinary tract control in spinal cord injury patients: A structural and functional MRI study**
By: [Leitner L.](#)¹, Walter M.², Liechti M.³, Michels L.⁴, Kollias S.⁴, Freund P.², Mehnert U.², Kessler T.²
Institutes:¹Balgrist University Hospital and University Hospital of Basel, Dept. of Neuro-Urology and Urology, Zürich and Basel, Switzerland, ²Balgrist University Hospital, Dept. of Neuro-Urology, Zürich, Switzerland, ³University College London, Dept. of Brain Repair and Rehabilitation, London, United Kingdom, ⁴University Hospital Zürich, Institute of Neuro-Radiology, Zürich, Switzerland
- *306 **Different supraspinal responses to automated, repetitive bladder filling in OAB patients compared to healthy subjects - an fMRI study**
By: [Walter M.](#)¹, [Leitner L.](#)¹, [Michels L.](#)², [Kollias S.](#)², [Freund P.](#)³, [Liechti M.](#)¹, [Kessler T.M.](#)¹, [Mehnert U.](#)¹
Institutes:¹Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital, Dept. of Neuro-Urology, Zürich, Switzerland, ²University of Zürich, University Hospital Zürich, Dept. of Neuro-Radiology, Zürich, Switzerland, ³Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital, Dept. of Neurology, Zürich, Switzerland
- *307 **Levator ani muscle innervation**
By: [Nyangoh Timoh K.](#)¹, [Lebacqz C.](#)², [Bessede T.](#)², [Martinovic J.](#)³, [Zaitouna M.](#)¹, [Diallo D.](#)¹, [Creuze M.](#)¹, [Benoit G.](#)¹, [Moszkowicz D.](#)¹
Institutes:¹U1195, Univ. Paris Sud, Inserm, Université Paris-Saclay, MRSNA, Le Kremlin Bicetre, France, ²U1195, Univ. Paris Sud, Inserm, AP-HP, Université Paris-Saclay, Dept. of Urology, Le Kremlin Bicetre, France, ³AP-HP, Antoine Beclere Hospital, University Paris-Sud, Dept. of Foetal Pathology, Clamart, France
- *308 **Beta-3 adrenoceptor expression in the human urinary bladder nerve fibers**
By: [Coelho A.](#)¹, [Gillespie J.](#)², [Cruz F.](#)¹
Institutes:¹University of Porto, Dept. of Renal, Urologic and Infectious Diseases, and Instituto De Investigação E Inovação Em Saúde, Porto, Portugal, ²The Medical and Dental Schools, Newcastle University, Dept. of Uro-Physiology Research, Newcastle, United Kingdom
- *309 **Ageing-related bladder dysfunction in mice: A possible animal model of detrusor hyperactivity with impaired contractility**
By: [Kamei J.](#)¹, [Ito H.](#)², [Aizawa N.](#)², [Akiyama Y.](#)¹, [Hotta H.](#)³, [Kojima T.](#)⁴, [Fujita Y.](#)⁵, [Ito M.](#)⁵, [Andersson K-E.](#)⁶, [Homma Y.](#)⁷, [Igawa Y.](#)²
Institutes:¹The University of Tokyo graduate school of Medicine, Dept. of Continence Medicine and Urology, Tokyo, Japan, ²The University of Tokyo graduate school of Medicine, Dept. of Continence

Medicine, Tokyo, Japan, ³Tokyo Metropolitan institute of Gerontology, Dept. of Autonomic Neuroscience, Tokyo, Japan, ⁴Toyohashi University of Technology, Health care center, Aichi, Japan, ⁵Tokyo Metropolitan institute of Gerontology, Research team for mechanism of aging, Tokyo, Japan, ⁶Aarhus University, Aarhus institute of advanced studies, Aarhus, Denmark, ⁷The University of Tokyo graduate school of Medicine, Dept. of Urology, Tokyo, Japan

- *310 **Crucial roles of nitric oxide synthases in α -adrenoceptor-mediated bladder relaxation in mice**
By: [Satake Y.](#)¹, [Kaiho Y.](#)¹, [Satoh K.](#)², [Yamashita S.](#)¹, [Tsutsui M.](#)³, [Shimokawa H.](#)², [Arai Y.](#)¹
Institutes:¹Tohoku University Graduate School of Medicine, Dept. of Urology, Sendai, Japan, ²Tohoku University Graduate School of Medicine, Dept. of Cardiovascular Medicine, Sendai, Japan, ³University of Ryukyus, Dept. of Pharmacology, Okinawa, Japan
- *311 **Properties of spontaneous activity in the muscularis mucosae of the guinea pig bladder**
By: [Lee K.](#), [Mitsui R.](#), [Hashitani H.](#)
Institutes:Nagoya City University, Dept. of Cell Physiology, Nagoya, Japan
- *312 **Cannabinoid receptors 1 and 2 promote proliferation of prostate stromal cells, while cytoskeletal reorganization underlies specific regulation by cannabinoid receptor 2**
By: [Hennenberg M.](#), [Ciotkowska A.](#), [Rutz B.](#), [Strittmatter F.](#), [Waidelich R.](#), [Stief C.G.](#), [Gratzke C.](#)
Institutes:LMU Munich, Dept. of Urology, Munich, Germany
- *313 **The cation channel TRPV4 mediates responses to LPS in urothelial cells**
By: [Alpizar Y.](#)², [Uvin P.](#)¹, [Franken J.](#)¹, [Gevaert T.](#)¹, [Voets T.](#)², [De Ridder D.](#)¹, [Talavera K.](#)²
Institutes:¹Faculty of Medicine, KU Leuven, Dept. of Development and Regeneration, Leuven, Belgium, ²Faculty of Medicine, KU Leuven, Dept. of Cellular and Molecular Medicine, Leuven, Belgium
- *314 **Metabotropic glutamate receptor subtypes 1 and 5 synergistically modulate bladder filling function in mice**
By: [Yoshiyama M.](#), [Takeda M.](#)
Institutes:University of Yamanashi, Dept. of Urology, Chuo, Japan
- *315 **Alterations of muscarinic induced bladder contractions in a regenerative animal model for neurogenic detrusor underactivity**
By: [Dewulf K.](#)¹, [Weyne E.](#)¹, [Deruyver Y.](#)¹, [Van Bree R.](#)², [De Ridder D.](#)¹, [Everaerts W.](#)¹, [Albersen M.](#)¹
Institutes:¹Ku Leuven, Dept. of Development and Regeneration, Lab of Experimental Urology, Leuven, Belgium, ²Ku Leuven, Dept. of Development and Regeneration, Leuven, Belgium
- *316 **Clock genes regulate circadian rhythm of Piezo1 and TRPV4 expressions and intracellular Ca²⁺ influx after stretch stimulation in the cultured urothelial cells**
By: [Ihara T.](#)¹, [Kira S.](#)¹, [Miyamoto T.](#)¹, [Sawada N.](#)¹, [Nakagomi H.](#)¹, [Mitsui T.](#)¹, [Kobayashi H.](#)¹, [Yoshiyama M.](#)¹, [Takeda M.](#)¹, [Nakamura Y.](#)², [Nakao A.](#)², [Shigetomi E.](#)³, [Shibata K.](#)³, [Shinozaki Y.](#)³, [Koizumu S.](#)³
Institutes:¹University of Yamanashi, Dept. of Urology, Yamanashi, Japan, ²University of Yamanashi, Dept. of Immunology, Yamanashi, Japan, ³University of Yamanashi, Dept. of Pharmacology, Yamanashi, Japan

10:00 - 10:07

Summary and context
 S. De Wachter, Edegem (BE)

Urogenital reconstructions

Poster Session 26

Sunday, 13 March
08:45 - 10:15

Location: Room 14b (ICM, Level 1)

Chairs: K-D. Sievert, Salzburg (AT)
R.P. Djinic, Belgrade (RS)
M. Sohn, Frankfurt (DE)

Aims and objectives of this presentation

Overview of clinical and research aspects in urogenital reconstructions.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *317 **Extravesical uretero-vesical anastomosis effectiveness for distal ureteral strictures and obliterations surgical treatment in adults**
By: Poliakov N.V., Keshishev N., Kachmazov A., Bekiev Y., Verzin A., Prokhorov S., Alekseev B., Apolikhin O., Kaprin A.
Institutes:Scientific Research Institute of Urology and Interventional Radiology Named After N.A.Lopatkin, Dept. of Innovations, Moscow, Russia
- *318 **Functional results in laparoscopic colposacropexy: Continence and sexual function**
By: Conde Redondo M.C., Castroviejo Royo F., Rodriguez Toves L.A., Garcia Viña A., Amon Sesmero J., Alonso Villalba A., Martinez Sagarra J.
Institutes:Hospital Universitario Río Hortega, Dept. of Urology, Valladolid, Spain
- *319 **What constitutes complexity in the surgical reconstruction of pelvic fracture-related urethral injuries?**
By: Bugeja S., Ivaz S., Frost A., Fes E., Campos F., Andrich D., Mundy A.
Institutes:University College London Hospitals, Dept. of Reconstructive Urology, London, United Kingdom
- *320 **Total phallic reconstruction using radial artery based forearm free flap after penile loss secondary to trauma**
By: Falcone M., Garaffa G., Raheem A., De Luca F., Christopher A.N., Ralph D.J.
Institutes:University College London Hospital (uclh), St.Peter's Andrology and The Institute of Urology, London, United Kingdom
- *321 **Management of sphincter weakness incontinence (SWI) in patients with concomitant bladder neck contractures (BNC) after the treatment of prostate cancer**
By: Bugeja S., Ivaz S., Frost A., Campos F., Fes E., Andrich D., Mundy A.
Institutes:University College London Hospitals, Dept. of Reconstructive Urology, London, United Kingdom
- *322 **Ambulatory outpatient urethroplasty is safe and produces good outcomes**
By: Zaid U., Lavien G., Granieri M., Peterson A.
Institutes:Duke University, Dept. of Urology, Durham, United States of America
- *323 **Self-perception and sexual function after distal urethra transposition**
By: Gvozdev M., Tupikina N., Popova A., Pushkar D.
Institutes:Moscow State University of Medicine and Dentistry Named After A. I. Evdokimov, Dept. of Urology, Moscow, Russia

- *324 **Non-transecting urethroplasty using buccal mucosa for bulbar urethral strictures**
By: Bugeja S., Ivaz S., Frost A., Fes E., Campos F., Andrich D., Mundy A.
Institutes: University College London Hospitals, Dept. of Reconstructive Urology, London, United Kingdom
- *325 **Transperineal reanastomosis for treatment of recurrent anastomotic strictures**
By: Schüttfort V.M.¹, Reiss C.P.S.¹, Pfalzgraf D.², Fisch M.¹, Dahlem R.¹
Institutes:¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²Medical Faculty Mannheim at Heidelberg University, Dept. of Urology, Mannheim, Germany
- *326 **Complications following male re-constructive urologic surgery**
By: Eleswarapu S.¹, Sood A.¹, Abdollah F.¹, Sammon J.¹, Jeong W.¹, Dalela D.¹, Klett D.¹, Peabody J.¹, Eswara J.², Menon M.¹, Trinh Q.D.², Dabaja A.¹
Institutes:¹Henry Ford Hospital / Health System, Dept. of Urology, Detroit, United States of America, ²Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America
- *327 **Lateral vaginal wall flap for the treatment of female urethral stricture. An alternative technique**
By: Romero Maroto J., Verdú Verdú L., López López A.I., Pérez Tomás C., Pacheco Bru J.J., Gómez Pérez L.
Institutes: San Juan de Alicante University Hospital, Dept. of Urology, Alicante, Spain
- *328 **How to harvest and use lingual mucosa grafts for the repair of long anterior urethral strictures**
By: Qiang F., Zhang K., Jin S., Sa Y., Zhang J., Xu Y.
Institutes: Shanghai 6th Hospital, Dept. of Urology, Shanghai, China
- *329 **Surgical repair of long anterior urethral stricture: Skin versus buccal mucosal grafts**
By: Riad A.M., Hammady A., Mamdouh A.
Institutes: Sohag University Hospital, Dept. of Urology, Sohag, Egypt
- *330 **Buccal mucosal graft urethroplasty in men – risk factors for stricture recurrence and complications**
By: Spilotros M., Sihra N., Pakzad M.H., Hamid R.H., Ockrim J.L., Greenwell T.J.
Institutes: University College London Hospital, Dept. of Urology, London, United Kingdom
- *331 **Collagen cell carriers seeded with human urothelial cells for urethral reconstructive surgery first results in a xenograft mini-pig model**
By: Aufderklamm S.¹, Maurer S.¹, Kelp A.¹, Gustafsson L.¹, Mundhenk J.², Busch S.³, Vaegler M.⁴, Stenzl A.¹, Sievert K-D.⁵, Amend B.¹
Institutes:¹Eberhard Karls University, Dept. of Urology, Tübingen, Germany, ²Diakonie Hospital Stuttgart, Dept. of Urology, Stuttgart, Germany, ³Viscofan, Dept. of BioEngineering, Weinheim, Germany, ⁴University Clinic Charité, Dept. of Experimental and Clinical Research, Berlin, Germany, ⁵University Clinic of Salzburg, Dept. of Urology, Salzburg, Austria

Enhanced recovery after surgery: What's new in urology

Poster Session 27

Sunday, 13 March
08:45 - 10:15

Location: Room 14c (ICM, Level 1)

Chairs: J.E. Hugosson, Göteborg (SE)
F. Bagheri, Dubai (AE)
D. Murphy, Melbourne (AU)

Aims and objectives of this presentation

This session focusses on strategies to speed up recovery after surgery and thus reduce the length of hospitalisation.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *332 **Exercise-based prehabilitation is feasible and effective in radical cystectomy pathways - secondary results from a randomized controlled trial**
By: [Jensen B.T.](#)¹, Laustsen S.², Jensen J.¹, Petersen A.K.³, Borre M.¹
Institutes:¹Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ²Aarhus University Hospital, Dept. of Cardiothoracic and Vascular Surgery, Aarhus, Denmark, ³Aarhus University Hospital, Dept. of Physio- and Occupational Therapy, Aarhus, Denmark
- *333 **Slow gait speed and rapid renal function decline are risk factors for postoperative delirium after urological surgery**
By: [Hatakeyama S.](#), Sato T., Okamoto T., Hosogoe S., Yamamoto H., Tobisawa Y., Yoneyama T., Yoneyama T., Koie T., Ohyama C.
Institutes:Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan
- *334 **Is cardiopulmonary exercise testing in patients undergoing radical cystectomy a useful preoperative tool?**
By: [Khan R.](#)¹, Elhage O.¹, Chidi A.¹, Ismail F.¹, Ahmed K.¹, Gan C.¹, Thomas K.², O'Brien T.², Thurairaja R.², Khan M.²
Institutes:¹Guy's And St Thomas' Hospital, Dept. of Urology, London, United Kingdom, ²Guy's and St Thomas' Hospital, Dept. of Urology, London, United Kingdom
- *335 **Nutritional status and major abdominal surgeries: 30-Day postoperative complications**
By: [Pavan N.](#)¹, Mir C.², Ritch C.², Rai S.², Soodana-Prakash N.², Balise R.³, Trombetta C.¹, Parekh D.², Gonzalgo M.²
Institutes:¹University of Trieste, Dept. of Urology, Trieste, Italy, ²University of Miami Leonard M. Miller School of Medicine, Dept. of Urology, Miami, Florida, United States of America, ³University of Miami Leonard M. Miller School of Medicine, Dept. of Biostatistics and Public Health Sciences, Miami, Florida, United States of America
- *336 **Renal arterial infusion of adipose tissue-derived stromal vascular fraction protects the renal function against acute kidney injury induced by ischemia-reperfusion injury**
By: Lee C.², Ahn T.Y.², Jang M.J.¹, [Kim B.H.](#)², You D.², Jeong I.G.², Kim C-S.²
Institutes:¹Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Dept. of Urology, Seoul, South Korea, ²Asan Medical Center, University of Ulsan College of Medicine, Dept. of Urology, Seoul, South Korea
- *338 **Impairment in activities of daily living after radical cystectomy among elderly aged over 80. Assessment based on 6778 cases**
By: [Hirasawa Y.](#)¹, Sugihara T.¹, Yasunaga H.², Gondo T.¹, Nakagami Y.¹, Horiguchi Y.¹, Ohno Y.¹,

Namiki K.¹, Nakashima J.¹, Ohori M.¹, Matsui H.², Fushimi K.³, Tachibana M.¹, Homma Y.⁴
Institutes:¹Tokyo Medical University, Dept. of Urology, Tokyo, Japan, ²The University of Tokyo, Dept. of Clinical Epidemiology and Health Economics, Tokyo, Japan, ³Tokyo Medical and Dental University, Dept. of Health Care Informatics, Tokyo, Japan, ⁴The University of Tokyo, Dept. of Urology, Tokyo, Japan

- *339 **Peri-incisional infiltration and intraperitoneal instillation of local anesthetic for management of early postoperative pain following laparoscopic nephrectomy: A prospective, randomized, double-blind controlled trial**
By: Choi S.¹, Hong S-H.², Ha U-S.¹, Hong S-H.¹, Lee J.Y.¹, Kim S.W.¹, Cho H.J.¹
Institutes:¹Seoul St. Mary's Hospital, Dept. of Urology, Seoul, South Korea, ²Seoul St. Mary's Hospital, Dept. of Anesthesiology, Seoul, South Korea
- *340 **Applying fast-track protocols in bladder cancer patients undergoing radical cystectomy with ileal urinary diversions - early results of a prospective randomised controlled single center study**
By: Olaru V., Gingu C., Baston C., Manea I., Preda A., Voinea S., Stefan B., Dudu C., Sinescu I.
Institutes:Fundeni Clinical Institute, Dept. of Urology and Renal Transplantation, Bucharest, Romania
- *341 **The effectiveness of acupuncture for the relief perioperative pain and anxiety in patients undergoing endourologic interventions**
By: Meyer G.¹, Halachmi S.¹, Attias S.², Stopelman N.², Avshalomov D.², Schiff E.², Nativ O.¹
Institutes:¹Bnai-Zion Medical Center, Dept. of Urology, Haifa, Israel, ²Bnai-Zion Medical Center, Dept. of Integrative Medicine, Haifa, Israel
- *342 **Correlation of preoperative co-morbidity indices with perioperative metrics in urological patients undergoing major open procedures**
By: Sarri I.¹, Fragkiadis E.², Anastasiou I.², Constantinides C.², Mitropoulos D.²
Institutes:¹Laiko General Hospital, Dept. of Anesthesiology, Athens, Greece, ²Medical School, National and Kapodestrian University of Athens, Dept. of Urology, Athens, Greece
- *343 **Effects of pipemidic acid, phenazopyridine HCl and sodium diclofenac on pain perception after endoscopic urology surgery: A prospective, randomized, double-blinded, placebo-controlled trial**
By: Yuri P.¹, Ali Z.²
Institutes:¹University of Indonesia, Cipto Mangunkusumo Hospital, Dept. of Urology, Jakarta, Indonesia, ²Kardinah Hospital Tegal, Dept. of Urology, Central Java, Indonesia
- 09:56 - 10:03 **Summary and context**
 J.E. Hugosson, Göteborg (SE)

New technologies in incontinence and laser

Poster Session 28

Sunday, 13 March
08:45 - 10:15

Location: Room Paris (Hall B2, level 0)

Chairs: G. De Naeyer, Aalst (BE)
V. Ficarra, Padova (IT)
G. Novara, Padova (IT)

Aims and objectives of this presentation

In this session on new technologies, several abstracts will be presented with ideas and concepts that will perhaps be our future: new adjustable transobturator male system for incontinence in male, simulation of artificial urinary bladder, laser for upper tract or prostate tumours and telemedicine in outpatient urology.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *344 **Six-branches vs two-branches retropubic intracorporeal suburethral autologous sling placed during robotic radical prostatectomy to improve early urinary continence recovery**
By: Cestari A., Ferrari M., Zannoni M., Sozzi F., Dell'Acqua V., Sangalli M., Fabbri F., Ghezzi M., Lolli C., Rigatti P.
Institutes: Istituto Auxologico Italiano, Dept. of Urology, Milan, Italy
- *345 **Long-term efficacy and safety of the Adjustable Transobturator Male System (ATOMS): 6-year results of a European multi-institutional study**
By: Friedl A.¹, Mühlstädt S.², Zchoval R.³, Kivaranovic D.⁴, Rom M.⁵, Mohammed N.², Fornara P.², Brössner C.¹
Institutes:¹Hospital Göttlicher Heiland, Dept. of Urology, Vienna, Austria, ²Martin Luther-Medical School, Dept. of Urology and Kidney Transplantation, Halle, Germany, ³Thomayer Hospital, Charles University, Dept. of Urology and 1st and 3rd Medical Faculty, Prague, Czech Republic, ⁴Medical University Vienna, Dept. of Medical Statistics, Informatics and Intelligent Systems, Vienna, Austria, ⁵Vienna General Hospital, Medical University of Vienna, Dept. of Urology, Vienna, Austria
- *346 **Computational model for the simulation of artificial urinary bladder**
By: Monteiro V.¹, Onate E.¹, Oller S.², Gasser C.³
Institutes:¹Universitat Politècnica De Catalunya, Dept. of Structures, Barcelona, Spain, ²Universitat Politècnica De Catalunya, Dept. of Structures, Barcelona, Spain, ³The Royal Institute of Technology, Dept. of Solid Mechanics, Stockholm, Sweden
- *348 **Developing a long-term implantable system to accurately measure real-time bladder wall movements: A feasibility study in the rat**
By: Weydts T.¹, Deruyver Y.², Brancato L.¹, Dewulf K.², Soebadi Y.², Weyne E.², De Ridder D.², Puers R.¹
Institutes:¹KU Leuven, Dept. of Electrical Engineering, Leuven, Belgium, ²KU Leuven, Dept. of Urology, Leuven, Belgium
- *349 **Topical urethral anesthesia in patients undergoing rigid cystoscopy: Results from a prospective study comparing lidocaine-based anesthetic gel and mepivacaine-based anesthetic gel combined with lidocaine-prilocaine cream**
By: Creta M.¹, Di Meo S.¹, Buonopane R.¹, Fusco F.², Imperatore V.¹
Institutes:¹Ospedale Buon Consiglio Fatebenefratelli, Dept. of Urology, Naples, Italy, ²University Federico II of Naples, Dept. of Urology, Naples, Italy

- *350 **High power (200W) thulium laser vaporization of the prostate with the Oyster technique: Initial experience and early postoperative outcomes**
By: [Kallidonis P.](#), Panagopoulos V., Vasilas M., Kyriazis I., Kemal W., Liatsikos E.
Institutes: University of Patras, Dept. of Urology, Patras, Greece
- *351 **Thulium (Tm:YAG) laser in the upper urinary tract: Does the heat generation by the laser in the irrigation fluid pose a risk? Evidence from an in vivo experimental study**
By: [Kamal W.](#), Kallidonis P., Liatsikos E., Panagopoulos V., Vrettos T., Lefteris A.
Institutes: University of Patras, Dept. of Patras, Patras, Greece
- *352 **ESO-Prost 9: A new era in non-invasive automatic detection of prostate cancer: Preliminary results on 314 patients**
By: Bellorofonte C.¹, Cesana C.¹, Vercesi A.¹, [Morselli L.](#)²
Institutes: ¹Columbus Clinic, Dept. of Urology, Milan, Italy, ²Kimea Pte Ltd, Dept. of Research and Development, Singapore, Singapore
- *353 **A new era of data extraction: Example of automated extraction PSA values from electronic health records**
By: [Leyh-Bannurah S-R.](#)¹, Dell'Oglio P.², Tian Z.³, Graefen M.¹, Huland H.¹, Budäus L.¹
Institutes: ¹Martini-Clinic, Prostate Cancer Center, Hamburg, Germany, ²URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ³McGill University, Dept. of Epidemiology, Biostatistics and Occupational Health, Montreal, Canada
- *354 **Assessing the potential for telemedicine in outpatient urology**
By: [Dukic I.](#)¹, Matthews A.², Pillai M.²
Institutes: ¹Derriford Hospital, Dept. of Urology, Plymouth, United Kingdom, ²East Lancashire Hospitals NHS Trust, Dept. of Urology, Blackburn, United Kingdom
- *355 **Which of the spies modalities could be the best working tool?**
By: [Emiliani E.](#), Orosa A., Baghdadi M., Barreiro A., Talso M., Servan P., Proietti S., Traxer O.
Institutes: Tenon Hospital, Université Pierre et Marie Curie - Paris Vi, Dept. of Urology, Paris, France

What's new in the field of urological education and training

Poster Session 29

Sunday, 13 March
08:45 - 10:15

Location: Room Vienna (Hall B2, level 0)

Chairs: L. Marconi Serra De Oliveira, Coimbra (PT)
S.C. Müller, Bonn (DE)
I. Pearce, Manchester (GB)

Aims and objectives of this presentation

This session addresses hot topics from technical skills training to the changing landscape of social media in education for the next generation.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

09:08 - 09:18

Standardisation of urology training across Europe

S.C. Müller, Bonn (DE)

*356

Does regional audit improve practice in the management of urological cancers?

By: Dyer J.¹, Hartley S.², Thompson A.¹

Institutes:¹Royal Albert Edward Infirmary, Dept. of Urology, Wigan, United Kingdom, ²North West Regional Audit, North West Regional Audit, Wigan, United Kingdom

*357

First Urology Simulation Boot Camp: Education value and impact on improving trainees' confidence in common urological procedures

By: Hanchanale V., Rajpal S., Reeves F., Jain S., Garthwaite M., Cartledge J., Somani B., Gowda R., Koenig P., Rogawski K., Cordford P., Eardley I., Terry T., Myatt A., Biyani C.

Institutes: St. James's University Hospital, Leeds Institute for Minimally Invasive Therapy (LIMIT), Leeds, United Kingdom

*358

Experimental 3D-printed kidney model based on medical imaging data of human cadavers for educational and surgery planning purposes

By: Adams F.¹, Qiu T.², Fritz B.³, Pollak S.⁴, Miernik A.¹, Wetterauer U.¹, Fischer P.²

Institutes:¹University Medical Centre Freiburg, Dept. of Urology, Freiburg, Germany, ²Max Planck Institute Stuttgart, Intelligent Systems, Stuttgart, Germany, ³University Medical Centre Freiburg, Dept. of Radiology, Freiburg, Germany, ⁴University Medical Centre Freiburg, Dept. of Forensic Medicine, Freiburg, Germany

*359

Quality of online health information on prostate cancer – adherence to EAU guidelines?

By: Breyer J.¹, Rothbauer C.¹, Ludwig B.², Dotzler B.², Wolff C.², Reimann S.², Borgmann H.³, Burger M.¹

Institutes:¹University of Regensburg, Dept. of Urology, Regensburg, Germany, ²University of Regensburg, Institute of Information, Media, Language and Culture, Regensburg, Germany, ³University of Frankfurt, Dept. of Urology, Frankfurt, Germany

*360

Direct comparison of an ergonomic laparoscopic system with robotic surgery, in terms of operating speed, in an inanimate experimental laparoscopic radical prostatectomy setting

By: Tokas T.¹, Gözen A.S.², Avgeris M.³, Tschada A.⁴, Rassweiler J.²

Institutes:¹Hall in Tirol General Hospital, Dept. of Urology, Hall in Tirol, Austria, ²SLK-Kliniken Heilbronn GmbH, Dept. of Urology, Heilbronn, Germany, ³University of Athens, Dept. of Molecular Biology and Biochemistry, Athens, Greece, ⁴Mannheim University, Mannheim, Germany

*361

Training in high intensity centres allows urological residents to attain sufficient volume and

competence at transurethral resection of the prostate surgery

By: Kelly B.¹, Mak D.¹, Thompson B.¹, Ord J.¹, Jha A.¹, Sole G.¹, Lundon D.², Akhtar M.¹

Institutes:¹Hereford County Hospital, Dept. of Urology, Hereford, United Kingdom, ²University College Dublin, Dept. of Medical Informatics, Dublin, Ireland

*362

Live surgery: Harmful or helpful? Experience of the "Challenge in Laparoscopy and Robotics" meeting

By: De Lorenzis E.¹, Grasso A.A.C.¹, Mistretta F.A.¹, Cozzi G.¹, Spinelli M.G.¹, Rocco B.¹, Pansadoro V.²

Institutes:¹Fondazione IRCCS - Ca' Granda Ospedale Maggiore Policlinico, Dept. of Urology, Milan, Italy, ²Vincenzo Pansadoro Foundation, Dept. of Urology, Rome, Italy

*363

Learning curve in robot-assisted radical prostatectomy: Practice makes perfect, but what practice?

By: Lovegrove C.E.¹, Novara G.², Guru K.³, Mottrie A.⁴, Challacombe B.⁵, Raza J.³, Van Der Poel H.⁶, Peabody J.⁷, Popert R.⁵, Dasgupta P.¹, Ahmed K.¹

Institutes:¹King's College London, Dept. of Urology, London, United Kingdom, ²University of Padua, Dept. of Urology, Padua, Italy, ³Roswell Park Cancer Institute, Dept. of Urology, Buffalo, United States of America, ⁴OLV Clinic, Dept. of Urology, Aalst, Belgium, ⁵Guy's Hospital, Dept. of Urology, London, United Kingdom, ⁶Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ⁷Henry Ford Hospital, Dept. of Urology, Detroit, United States of America

*364

Assessment of surgical competency for robot-assisted radical prostatectomy: Development and validation of Prostatectomy Assessment and Competency Evaluation (PACE)

By: Ghani K.R.¹, Aly A.², Peabody J.³, Lane B.⁴, Sarle R.⁵, Abaza R.⁶, Montgomery J.¹, Hu J.⁷, Eun D.⁸, Fumo M.⁹, Comstock B.¹⁰, Linsell S.¹, Miller D.C.¹, Guru K.²

Institutes:¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²Roswell Park Cancer Center, Dept. of Urology, Buffalo, United States of America, ³Henry Ford Hospital, Vattikuti Urology Institute, Detroit, United States of America, ⁴Spectrum Health, Dept. of Urology, Grand Rapids, United States of America, ⁵Michigan Institute Urology, Dept. of Urology, Dearborn, United States of America, ⁶OhioHealth, Dept. of Urology, Columbus, United States of America, ⁷Cornell University, Dept. of Urology, New York, United States of America, ⁸Temple University, Dept. of Urology, Philadelphia, United States of America, ⁹Rockford Urological Associates, Dept. of Urology, Rockford, United States of America, ¹⁰University of Washington, Dept. of Biostatistics, Seattle, United States of America

*365

Evaluation of European Association of Urology guidelines on male infertility: Adherence through urology residents

By: Luján S.¹, Ordaz G.¹, Rogel R.¹, Escudero-Fontano E.², Gavrillov P.³, Broseta E.¹, Boronat F.¹

Institutes:¹Hospital Universitari i Politècnic La Fe, Dept. of Urology, Valencia, Spain, ²Consortio Hospital General Universitario De Valencia, Dept. of Urology, Valencia, Spain, ³Fundació Puigvert, Dept. of Urology, Barcelona, Spain

*366

Professional use of internet, social media, and mobile media by urology residents in Europe and North America

By: Borgmann H.¹, Salem J.², Baunacke M.³, MacNeily A.⁴, Parnham A.⁵, Huber J.³

Institutes:¹University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ²St.-Josef Hospital Dortmund, Dept. of Urology, Dortmund, Germany, ³TU Dresden, Dept. of Urology, Dresden, Germany, ⁴University of British Columbia, Dept. of Urology, Vancouver, Canada, ⁵Manchester Royal Infirmary/Edgehill University, Dept. of Urology, Manchester, United Kingdom

*367

Influence of social media on urologic knowledge acquisition among young urologists across Europe

By: Gómez Rivas J.A.¹, Uvin P.², Rodríguez Socarras M.E.³, Patrino G.⁴, Esperto F.⁵, Dinis P.J.⁶, Borgmann H.⁷

Institutes:¹La Paz University Hospital, Dept. of Urology, Madrid, Spain, ²University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ³Complejo Hospitalario Universitario de Vigo, Dept. of Urology, Vigo, Spain, ⁴University of Rome "Tor Vergata", Dept. of Urology, Rome, Italy, ⁵University of

Rome "La Sapienza", Dept. of Urology, Rome, Italy, ⁶Centro Hospitalar e Universitário de Coimbra, Dept. of Urology, Coimbra, Portugal, ⁷University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany

History of urology

Poster Session 30

Sunday, 13 March
08:45 - 10:15

Location: Room London (Hall B2, level 0)
Chairs: J. Mattelaer, Kortrijk (BE)
D. Schultheiss, Giessen (DE)
P.E. Van Kerrebroeck, Maastricht (NL)

Aims and objectives of this presentation

The session will present new aspects from recent research looking at the history of urology.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *368 **Vasectomy: A journey down a blind ending tube**
By: [Gill N.W.](#)
Institutes: Morriston Hospital, Dept. of Urology, Swansea, United Kingdom
- *369 **Codex de la Cruz-Badiano, the Aztec herbal manuscript: Its influence on Spanish medicine and the treatment of urological diseases**
By: [Moreno Palacios J.](#)¹, Torres-Anguiano J.¹, Moreno-Aranda J.², Ugarte-Romano F.²
Institutes:¹Hospital de Especialidades Centro Medico Nacional Siglo XXI, Dept. of Urology, Mexico City, Mexico, ²Hospital Angeles Del Pedregal, Dept. of Urology, Mexico City, Mexico
- *370 **The European Association of Urology and the Cold War: Observations, interests and influence of East German delegates 1972-1989**
By: Halling T.², [Moll F.H.](#)¹, Krischel M.², Fangerau H.²
Institutes:¹Cologne Medical Center, Dept. of Urology, Cologne, Germany, ²University of Düsseldorf, Institute for The History and Ethics of Medicine, Düsseldorf, Germany
- *371 **Female orgasmic emission in Galen and Aristotle**
By: [Musitelli S.](#), Bossi M.C.
Institutes: , Zibido San Giacomo, Italy
- *372 **The contribution of Sir Thomas Spencer Wells to urology**
By: [Wanis M.](#), Goddard J. C.
Institutes: Leicester General Hospital, Dept. of Urology, Leicester, United Kingdom
- *373 **The living witness programme - a review of the first six years**
By: [Hodgson D.](#)¹, Thompson P.²
Institutes:¹Queen Alexandra Hospital, Dept. of Urology, Portsmouth, United Kingdom, ²King's College Hospital, Dept. of Urology, London, United Kingdom
- *374 **The history of establishment of Ottoman urological society in connection with European ones**
By: [Verit A.](#)¹, Ürkmez A.¹, Tellaloglu S.²
Institutes:¹Fatih Sultan Mehmet Eğitim Ve Araştırma Hastanesi, Dept. of Urology, Istanbul, Turkey, ²Istanbul University, Dept. of Urology, Istanbul, Turkey
- *375 **First autoptic studies on vesico-vaginal fistulas: Discovery of aetiopathogenesis due to female masturbation**
By: [Mancini M.](#), Righetto M., Dal Moro F., Zattoni F.
Institutes: Urological Clinic, University of Padua, Dept. of Surgical and Oncological Sciences,

Padua, Italy

- *376 **The imaginary dialogues of Carlo Diano with Epicurus and their impact on his cancer suffering**
By: [Stamatiou K.](#)¹, Mexis D.², Sgouridou M.³, Themou A.³, Zoras G.³
Institutes:¹General Hospital of Piraeus, Dept. of Urology, Piraeus, Greece, ²University of Athens, Dept. of Philosophy, Athens, Greece, ³University of Athens, Dept. of Italian Literature, Athens, Greece
- *377 **A Spanish treatise on urinary lithiasis of the late 16th century: "Discourse to find out what urine disease Diego Leon Anriquez his friend and compadre is suffering" by Francisco Sánchez de Oropesa (1594)**
By: [Fariña-Pérez L.A.](#)¹, Otero-Tejero I.O.T.²
Institutes:¹Hospital Povisa, Dept. of Urology, Vigo, Spain, ²Hospital Guadalajara, Dept. of Urology, Guadalajara, Spain
- *378 **John Wickham – the "godfather" of robotic surgery: A pioneer urologist**
By: [Kailavasan M.](#), Hanchanale V., Cross W., Prescott S.
Institutes:Leeds Teaching Hospital, Dept. of Urology, Leeds, United Kingdom
- *379 **Showmen in urology**
By: [Auer A.](#), Hodgson D.
Institutes:Queen Alexandra Hospital, Dept. of Urology, Portsmouth, United Kingdom

ESU/ESUT Hands-on training in GreenLight Laser Vaporisation

HOT 20

Sunday, 13 March
09:00 - 10:30

Location: Room North America (Hall B0, level 0)

Chair: N. Barber, Camberley (GB)

Aims and objectives of this presentation

The European School of Urology (ESU) and the European Section of Uro-Technology (ESUT) offer an intensive hands-on training course with different models focussing on the endoscopic management of LUTS. The delegates will be taken through a sequential programme of GreenLight-laservaporisation using virtual reality models. A video demonstrating the different steps and tasks of the procedures will be presented and afterwards the delegates will be instructed according to their level of experience in small teams at the models. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

J.H. Roelink, Almelo (NL)

W.C. Loidl, Linz (AT)

M. Rieken, Basel (CH)

H. Langenhuisen, Nijmegen (NL)

ESU/ESUT Hands-on training in Laparoscopic suturing (anastomosis)

HOT 64

Sunday, 13 March
09:00 - 10:30

Location: Room South America (Hall B0, level 0)

Chair: D. Veneziano, Minneapolis (US)

Aims and objectives of this presentation

The aim of this advanced laparoscopic suturing course is to develop skill and knowledge about laparoscopic suturing.

Supported by experienced laparoscopist and state of the art Laparoscopic technology, you can improve your suturing skills, shorten your learning curve with the help of HD vision and practice an anastomosis. An intermediate level in laparoscopy is mandatory for this course.

C.S. Biyani, Leeds (GB)

Y. Akin, Sanliurfa (TR)

F. Greco, Crotone (IT)

A. Sempere Gutierrez, Murcia (ES)

G. Pini, Cologno Monzese (MI) (IT)

ESU Social Media Training

HOT 41

Sunday, 13 March
09:00 - 09:45

Location: Room 0.305

Chair: M. Rouprêt, Paris (FR)

Aims and objectives of this presentation

- EAU Congress Attendees will be instructed on how to harness professional Social Media to augment experience of professional meetings, follow urologic news feeds, and engage with the world-wide urologic community.
- Urologists who are expert in the use of Social Media will provide 45 minute small group hands-on workshops on the use of professional Social Media.
- Current Social Media users will have the opportunity to exchange expertise with other Social Media users during small group sessions.

A. Cebulla, Ulm (DE)

ESU/ESUT Hands-on training in Transurethral therapy of LUTS - Bipolar TURP

HOT 55

Sunday, 13 March
09:30 - 11:00

Location: Room Europe (Hall B0, level 0)

Chair: T.R.W. Herrmann, Hannover (DE)

Aims and objectives of this presentation

The European School of Urology (ESU) and the EAU Section of Uro-Technology (ESUT) offer an intensive hands-on training course with different models focussing on the endoscopic management of LUTS. The delegates will be taken through a sequential programme of Bipolar TURP using normal endoscopic instruments in different models. A video demonstrating the different steps and tasks of the procedures will be presented and afterwards the delegates will be instructed according to their level of experience in small teams at the models. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

A. De La Taille, Créteil (FR)

A. Bachmann, Basel (CH)

T. Bach, Hamburg (DE)

ESU/ERUS Hands-on training in Robotic surgery

HOT 16

Sunday, 13 March
09:30 - 11:00

Location: Room Asia (Hall B0, level 0)

Chair: C. Wagner, Gronau (DE)

Aims and objectives of this presentation

The European School of Urology (ESU) and the EAU Robotic Urology Section (ERUS) offer an intensive hands-on training course. We will provide training using simulators. The main aims of this 90 minutes course are: improving the participants' control-skills and hand-eye-coordination, as well as an objective benchmarking of console performance and an introduction into standardized surgical steps in robot-assisted procedures.

To be confirmed
W. Brinkman, Rotterdam (NL)

ESU/ESUT/ESUI Hands-on training in MRI Fusion Biopsy

HOT 29

Sunday, 13 March
10:00 - 12:00

Location: Room Africa (Hall B0, level 0)

Chair: L. Budäus, Hamburg (DE)

Aims and objectives of this presentation

MRI is increasingly used in patients undergoing prostate biopsies. Different MRI Ultrasound fusion devices allow integrating the MRI information into the daily clinical workflow.

The course will provide an overview on MRI reading, technical basics and different prostate biopsy approaches. Technical considerations, the transrectal or transperineal approach will be critically reviewed and discussed. During the second half of the course, the participants are able to try out 5 different Fusion biopsy machines in small groups, changing every 10 min.

Aims and objectives

o At the end of the course, the participants understand the advantages, handling and limitations of MRI Ultrasound fusion biopsies.

Target audience:

Urologists, interested in the diagnostic ability of MRI use for transrectal and perineal prostate biopsies

A. Rannikko, Helsinki (FI)
W. Picker, Oslo (NO)
S. Kruck, Tübingen (DE)
C. Kastner, Cambridge (GB)
M. Ritter, Mannheim (DE)

ESU Social Media Training

HOT 42

Sunday, 13 March
10:00 - 10:45

Location: Room 0.305

Chair: S. Loeb, New York (US)

Aims and objectives of this presentation

- EAU Congress Attendees will be instructed on how to harness professional Social Media to augment experience of professional meetings, follow urologic news feeds, and engage with the world-wide urologic community.
- Urologists who are expert in the use of Social Media will provide 45 minute small group hands-on workshops on the use of professional Social Media.
- Current Social Media users will have the opportunity to exchange expertise with other Social Media users during small group sessions.

M. Rouprêt, Paris (FR)

Complications: Trouble shooting during and after TUR/Laser enucleation

Thematic Session 02

Sunday, 13 March
10:30 - 12:00

Location: Room Madrid (Hall B2, level 0)

Chair: J. Rassweiler, Heilbronn (DE)

Aims and objectives of this presentation

Transurethral resection of the prostate (TURP) and laser enucleation of the prostate (HoLEP, ThuLEP) represent the standard operations for minimally invasive management of the benign prostatic syndrome (BPS). Due to technological progress and improvement of armamentarium both techniques have become safe and reproducible. Nevertheless, both can lead to significant intra-operative and postoperative complications. This thematic session focuses on the main pitfalls of TURP and HoLEP/ThuLEP using video-assisted illustration of intra-operative situations and providing tips and tricks for prevention and management. We are happy to present a high-lighted faculty for this session, which should be as interactive as possible to discuss all main issues with the delegates.

10:30 - 10:40

Video presentation TUR-syndrome

T. Sulser, Zürich (CH)

Aims and objectives of this presentation

In this presentation you will have the possibility to learn how dangerous situations leading to a TUR-syndrome can be recognized early during the transurethral intervention, how to prevent such situations, what are the clinical signs and implications for the patient and how does the treatment look like.

10:40 - 10:45

Discussion

10:45 - 10:55

Video presentation Bleeding

M. Fiedler, Erlenbach (DE)

10:55 - 11:00

Discussion

11:00 - 11:10

Video presentation Extravasation

K-D. Sievert, Salzburg (AT)

11:10 - 11:15

Discussion

11:15 - 11:25

Video presentation Urethral and prostatic strictures

A. Tasca, Vicenza (IT)

11:25 - 11:30

Discussion

11:30 - 11:40

Video presentation Laser enucleation: Bleeding and the wrong layer

S.A. Ahyai, Göttingen (DE)

11:40 - 11:45

Discussion

11:45 - 11:55

Video presentation Morcellation problems

F. Gomez Sancha, Madrid (ES)

Aims and objectives of this presentation

This video presentation reviews common problems that arise with morcellation and how to tackle them for a safe outcome of enucleation and morcellation.

11:55 - 12:00

Discussion

The changing landscape in the management of prostate cancer recurrence

Thematic Session 03

Sunday, 13 March
10:30 - 12:00

Location: Room Stockholm (Hall B2, level 0)

Chair: A. Briganti, Milan (IT)

Aims and objectives of this presentation

The approach to recurrent prostate cancer (PCa) after curative treatment has dramatically changed over the recent years due to significant advances in imaging technologies and a better understanding of disease biology. This has opened new horizons in the context of administration of individualised treatments which include systemic and metastasis-directed therapies. The aim of this session is to update the biology knowledge of PCa recurrence and to assess the optimal use of individualised imaging and therapeutic approaches for recurrent disease.

10:30 - 10:45

State-of-the-art lecture **The genomic picture of recurrent prostate cancer**

G. Bova, Tampere (FI)

Aims and objectives of this presentation

- Review current knowledge and recent advances in the genomics of metastatic prostate cancer
- Discuss genomic and other molecular analyses in relation to potential "precision medicine" for prostate cancer
- Discuss how clinicians and researchers can come together to accelerate development of effective precision medicine

10:45 - 11:00

European Association of Nuclear Medicine (EANM) lecture **How to optimise the use of imaging in the recurrent setting: The role of PET/CT**

S. Fanti, Bologna (IT)

11:00 - 11:15

State-of-the-art lecture **Early use of hormonal therapy: Evidence or conventional wisdom?**

N.W. Clarke, Manchester (GB)

Aims and objectives of this presentation

To introduce the concept of communication in difficult circumstances in urology both between patients and between professionals

11:15 - 11:30

State-of-the-art lecture **Imaging guided approaches: A new treatment option for oligometastatic disease**

M. Graefen, Hamburg (DE)

11:30 - 12:00

Associated video and abstract presentations

*V15

Early experience of robotic salvage pelvic lymph node dissection in the Ga-68 PSMA PET scanning era

By: [Murphy D.](#)¹, [Zargar H.](#)¹, [Van Den Bergh R.](#)¹, [Van Bruwaene S.](#)¹, [Goad J.](#)¹, [Coughlin G.](#)², [Harewood L.](#)³, [Dundee P.](#)³

Institutes:¹Peter Mac Callum Cancer Institute, Dept. of Cancer Surgery, Melbourne, Australia, ²

Wesley Hospital, Dept. of Urology, Brisbane, Australia, ³Epworth Hospital, Dept. of Urology, Melbourne, Australia

State-of-the-art lecture

Aims and objectives of this presentation

68Ga-PSMA PET/CT has recently been introduced and shows much promise for the assessment of recurrence following radical prostatectomy. Our aim was to assess the utility of salvage pelvic lymph node dissection in men with biochemical recurrence after radical prostatectomy selected by 68Ga-PSMA PET/CT.

*142

Next generation sequencing to determine the clonal origin of lymph node metastasis in multifocal prostate cancer: Defining the biologically dominant nodule

By: Salami S.¹, Hovelson D.², Mathieu R.³, Susani M.⁴, Rioux-Leclercq N.⁵, Tracey J.¹, Shariat S.³, Tomlins S.², Palapattu G.¹

Institutes:¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, ³Medical University Vienna, Dept. of Urology, Vienna, Austria, ⁴Medical University Vienna, Dept. of Pathology, Vienna, Austria, ⁵Rennes University Hospital, Dept. of Pathology, Rennes, France

State-of-the-art lecture

Aims and objectives of this presentation

Although prostate cancer is often multifocal, the clonal origin of multifocal disease is controversial. In addition, it is currently unknown what characterizes the biologically dominant nodule. The objective of this presentation to showcase our data which demonstrate i) that different foci of prostate cancer exhibit molecular heterogeneity suggesting independent clonal origin; and ii) that a biologically dominant nodule possesses the capability to metastasize to lymph node (s).

*435

Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk

By: Ross A.¹, Den R.², Yousefi K.³, Trock B.¹, Davicioni E.⁴, Tosoian J.¹, Thompson D.⁵, Choerung V.³, Haddad Z.³, Tran P.⁶, Trabulsi E.⁷, Gomella L.⁸, Lallas C.⁸, Abdollah F.⁹, Feng F.¹⁰, Dicker A.², Freedland S.¹¹, Karnes J.¹², Schaeffer E.¹

Institutes:¹Johns Hopkins Hospital, James Buchanan Brady Urological Institute, Baltimore, United States of America, ²Sidney Kimmel Medical College at Thomas Jefferson University, Dept. of Radiation Oncology, Philadelphia, United States of America, ³GenomeDx Biosciences, Dept. of Biostatistics, Vancouver, Canada, ⁴GenomeDx Biosciences, Dept. of Research and Development, Vancouver, Canada, ⁵Emmes Canada, Dept. of Biostatistics, Burnaby, Canada, ⁶Johns Hopkins Hospital, Dept. of Radiation Oncology, Baltimore, United States of America, ⁷Sidney Kimmel Medical College at Thomas Jefferson University, Dept. of Urology, Epidemiology, Oncology, Environmental Health, Philadelphia, United States of America, ⁸Sidney Kimmel Medical College at Thomas Jefferson University, Dept. of Urology, Philadelphia, United States of America, ⁹Henry Ford Hospital, Dept. of Vattikuti Urology Institute, Detroit, United States of America, ¹⁰University of Michigan, Dept. of Radiation Oncology, Ann Arbor, United States of America, ¹¹Cedars-Sinai Medical Center, Dept. of Surgery, Division of Urology, Los Angeles, United States of America, ¹²Mayo Clinic, Dept. of Urology, Rochester, United States of America

State-of-the-art lecture

Aims and objectives of this presentation

To determine the therapeutic impact of postoperative radiation in the adjuvant and salvage settings after controlling for both genomic and clinico-pathologic risk

*843

Phase III study of intermittent monotherapy versus continuous combined androgen deprivation

By: Calais Da Silva Junior E.¹, Calais Da Silva Senior F.E.², Gonçalves F.³, Kliment J.⁴, Santos A.⁵, Spyros P.⁶, Queimadelos A.⁷, Robertson C.⁸

Institutes:¹CHLC - Hospital De São José, Dept. of Urology, Lisbon, Portugal, ²CHLC - H.S.José, Dept. of Urology, Lisbon, Portugal, ³CUIMED A Saint Michal Hospital, Dept. of Urology, Bratislava, Slovakia, ⁴Jessenius School of Medicine, Dept. of Urology, Martin, Slovakia, ⁵Hospital De Braga, Dept. of Urology, Braga, Portugal, ⁶Amalia Fleming Hospital, Dept. of Urology, Athens, Greece, ⁷Policlinica La Rosaleda, Dept. of Urology, Santiago Compostela, Spain, ⁸University of Strathclyde, Dept. of Statistics, Glasgow, United Kingdom

State-of-the-art lecture

Aims and objectives of this presentation

Intermittent androgen deprivation mono therapy is evaluated in 918 patients with M1 and local advance prostate cancer with a median follow up 5.5 years. Metastatic status PSA and age are all prognostic factors for survival. + 75 years and PSA that falls to 2-4 at randomization have an increase hazard of dying 1.63 ,1.95 , 2.01.

The inicial results shoed no survival diference,but now there is a poor survival in continuos therapy than intermittent principally associated with an excess CDV deaths 119 int 137 cont and the same prostate deaths 96.

Surgery in motion

European Urology Session

Sunday, 13 March
10:30 - 12:30

Location: Room 1 (ICM, Level 0)

J.W.F. Catto, Sheffield (GB)
A. Mottrie, Aalst (BE)
H.G. Van Der Poel, Amsterdam (NL)

10:30 - 10:35

Introduction

J.W.F. Catto, Sheffield (GB)
A. Mottrie, Aalst (BE)

10:35 - 10:55

Robot-assisted radical cystectomy and urinary diversion: Technical recommendations from the Pasadena consensus panel

K. Chan, Duarte (US)

10:55 - 11:15

Robotic unclamped "Minimal-margin" partial nephrectomy: Ongoing refinement of the anatomic zero-ischemia concept

R. Satkunasivam, Toronto (CA)

11:15 - 11:35

Robot-assisted simple prostatectomy for treatment of lower urinary tract symptoms secondary to benign prostatic enlargement: Surgical technique

Z.S. Dovey, Oxford (GB)

11:35 - 11:55

Robot-assisted, single-site, dismembered pyeloplasty for ureteropelvic junction obstruction with the New da Vinci platform: A stage 2a study

N. Buffi, Milan (IT)

11:55 - 12:15

Surgical tips and tricks during urethroplasty for bulbar urethral strictures focusing on accurate localisation of the stricture: Results from a tertiary centre

T.L.C. Kuo, Singapore (SG)

12:15 - 12:30

Discussion

J.W.F. Catto, Sheffield (GB)
A. Mottrie, Aalst (BE)

Andrology update 2016

Thematic Session 05

Sunday, 13 March
10:30 - 12:00

Location: Room Milan (Hall B2, level 0)

Chairs: V.G. Mirone, Naples (IT)
J.O.R. Sonksen, Herlev (DK)

Aims and objectives of this presentation

The objective of the session is to give the urologist insight into current gold standards, controversies and future developments within andrology. The session will include basic research as well as clinical recommendations in erectile dysfunction (ED), Peyronies disease, hypogonadism and infertility. With a series of state-of-the-art and practical oriented lectures from some of the sharpest brains in andrology, this thematic session aims to both inform and inspire established -andro-urologists as well as the talents of the future.

10:30 - 10:45

State-of-the-art lecture From bench to bed: Do our ideas on sexual dysfunction research reach our patients?

M. Albersen, Leuven (BE)

10:45 - 11:00

State-of-the-art lecture Erectile dysfunction (ED) treatment choice after radical prostatectomy: How to choose the right method for the right patient

G. Gandaglia, Milan (IT)

Aims and objectives of this presentation

Despite excellent oncologic outcomes, radical prostatectomy (RP) is associated with disability functional impairments, such as urinary incontinence and erectile dysfunction (ED). Despite the continuous effort in the improvement of surgical technique, nowadays up to 70% of patients still experience postoperative ED, even when a bilateral nerve-sparing approach is performed. This led to the development of several treatment options designed to improve erectile function recovery. The aim of this lecture is to provide insight into the management of patients experiencing ED after RP.

11:00 - 11:15

State-of-the-art lecture Peyronies disease - what is the optimal management?

E. Zacharakis, London (GB)

11:15 - 11:30

State-of-the-art lecture Hypogonadism: Where do we stand in 2016?

S. Arver, Stockholm (SE)

11:30 - 11:45

State-of-the-art lecture How do I do it: Diagnosis of male infertility

Z. Kopa, Budapest (HU)

Aims and objectives of this presentation

Aims and objectives

Diagnosis of male infertility has been revolutionary improved resulting the significant decrease of idiopathic cases. Detailed medical history, detecting life style factors, general physical examination and semen analysis using the WHO V. criteria mean the base of the diagnostic work-up followed by imaging techniques, endocrine and genetic testing. Clarification of infectious

agents and auto-immune alterations are essential part of this work. Recently developed specialized sperm functional tests and the seminal biochemical markers will lead to more precise evaluation of male infertility. The aim of this lecture is to guide the audience into the current recommendations and future directions to find therapeutic consequences treating male infertility and predict the chances of infertile couples to achieve a pregnancy.

11:45 - 12:00

State-of-the-art lecture Cancer and preservation of fertility

M. Fode, Herlev (DK)

Resistance to novel endocrine therapy in prostate cancer

Thematic Session 04

Sunday, 13 March
10:30 - 12:00

Location: Room 14a (ICM, Level 1)

Chairs: Z. Culig, Innsbruck (AT)
B. Tombal, Brussels (BE)

Aims and objectives of this presentation

Various mechanisms of resistance have been proposed for different anti-androgens. Specific mutations have been discovered in patients treated with hydroxyflutamide, bicalutamide, or more recently, enzalutamide. Importantly, appearance of truncated, constitutively active androgen receptors during therapy with enzalutamide or abiraterone and clinical implications will be discussed in this session.

10:30 - 10:35

Introduction The current status of AR research
Z. Culig, Innsbruck (AT)

10:35 - 10:50

State-of-the-art lecture Truncated androgen receptor and intracrine androgen synthesis in resistant prostate cancer
A. Gao, Sacramento (US)

10:50 - 11:05

State-of-the-art lecture Imaging of primary and secondary resistance to new AR pathways inhibitors
N. Tunariu, London (GB)

Aims and objectives of this presentation

The presentation aims to present a concise review of the emerging modern imaging techniques with emphasis on 1) improved assessment of response to therapy in bone metastases and 2) depiction of intra-patient heterogeneity as potential tools for a better understanding of the new AR pathways inhibitors resistance mechanisms.

11:05 - 11:20

State-of-the-art lecture Will new AR pathways inhibitors reshape the early prostate cancer landscape?
G. Kramer, Vienna (AT)

11:20 - 11:30

Late breaking news A Randomized Trial of Abiraterone Acetate (AA) Administered With 1 of 4 Glucocorticoid (GC) Regimens in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients (its)
A.S. Merseburger, Lübeck (DE)

11:30 - 11:45

State-of-the-art lecture Abiraterone acetate resistance and plasma androgen receptor
D. Gasi Tandefelt, Sutton, Surrey (GB)

Aims and objectives of this presentation

By using next-generation sequencing on circulating tumor DNA obtained from plasma through a minimally invasive blood test, we have demonstrated the capacity to identify genomic aberrations

that associate with resistance to abiraterone.

*LBA03

Trop-2 expression is driven by epithelial-to-mesenchymal transition in prostate cancer cells

By: Binó L.², Fedr R.², Kozubík A.³, Pernicová Z.², Remíšík J.¹, Šimešková S.¹, Souček K.¹

Institutes:¹Institute of Biophysics, Academy of Sciences, Dept. of Cytokinetics, Brno, Czech Republic, ²International Clinical Research Center, St. Anne's University Hospital Brno, Center of Biomolecular and Cellular Engineering, Brno, Czech Republic, ³Masaryk University, Department of Experimental Biology, Faculty of Science, Brno, Czech Republic

State-of-the-art lecture

11:53 - 12:00

Associated abstract presentation

*136

Periprostatic adipose tissue acts as a driving force for the local invasion of prostate cancer in obesity: Role of the CCR3/CCL7 axis

By: Roumiguie M.¹, Laurent V.², Toulet A.², Zaidi F.³, Valet P.⁴, Mazerolles C.³, Malavaud B.¹, Muller C.²

Institutes:¹Institut Universitaire Du Cancer, Dept. of Urology, Toulouse, France, ²Institut De Pharmacologie Et Biologie Structurale Du CNRS, Dept. of Oncology, Toulouse, France, ³Institut Universitaire Du Cancer, Dept. of Pathology, Toulouse, France, ⁴INSERM, U1048, Toulouse, France

State-of-the-art lecture

Aims and objectives of this presentation

The prostate is surrounded by adipose tissue (PPAT), an active endocrine organ able to secrete chemokines, referred to as adipokines. Compared to benign epithelium, cancer cells overexpress receptors for adipokines suggesting a crosstalk between PPAT and cancer.

We hypothesized that this could be instrumental in the increased aggressiveness reported in obese cancer patients and in extracapsular disease.

The ability of PPAT to attract cancer cells away from the prostate gland is dependent on an original CCR3/CCL7 axis. Up-regulation of CCL7 secretion in obesity facilitates extra-prostatic extension and local dissemination, which is abrogated when the CCR3/CCL7 axis is inhibited. Attention is driven towards CCR3 antagonists, which are being developed in other medical conditions.

Quality of care for patients with recurrent stone formation

Thematic Session 01

Sunday, 13 March
10:30 - 12:00

Location: Room 14b (ICM, Level 1)

Chair: T. Knoll, Sindelfingen (DE)

Aims and objectives of this presentation

This thematic session will give a comprehensive overview on the pathogenesis of urinary stone formation, its implication on our patients' life and concepts for prevention of stone recurrences. This controversy on the efficacy of metabolic evaluation will be addressed in a point-counter-point discussion.

10:30 - 10:45

State-of-the-art lecture **How do stones form?**

G. Gambaro, Rome (IT)

Aims and objectives of this presentation

Recent studies have confirmed what was hypothesised for many years, i.e. that crystals to become a stone generally need to be anchored to the renal tissue. This is certainly the case for the common CaOx and apatite crystals, and for some rare crystal kind. They need Randall's plaque or ductal plugs as an anchor. However, the possibility exists of lithogenesis in the liquid phase without any anchoring cannot be ruled out in some conditions.

10:45 - 11:05

State-of-the-art lecture **Quality of life in stone formers**

M. Monga, Cleveland (US)

Aims and objectives of this presentation

The goal of this lecture will be to discuss

- A. What is quality of life?
- B. How does it apply to the impact of both acute renal colic and stone prevention?
- C. What tools have been developed to assess QOL in stone patients?
- D. What do we know and where do we go?

11:05 - 11:25

State-of-the-art lecture **Practical recommendations for metabolic evaluation and stone prevention**

O. Traxer, Paris (FR)

Aims and objectives of this presentation

To learn about stone composition and diet
To learn about the basics for 24h urine collection
To learn about basics for diet and stones

11:25 - 11:55

Debate **Do we need specific work-up for our stone patients?**

11:25 - 11:40

Pro

A. Skolarikos, Athens (GR)

11:40 - 11:55

Con

T. Bach, Hamburg (DE)

Aims and objectives of this presentation

The premise of metabolic workup and identification of risk factors is based on the assumption, that the identification of individual risk factors will allow individualized and tailored preventive measures and treatment for the individual patient. But although the concept of metabolic testing and prevention is tempting the database supporting this concept is at least in part rather weak and further research is needed to identify the best way of preventive measures.

11:55 - 12:00

Summary

Challenges in incontinence treatment

Thematic Session 07

Sunday, 13 March
10:30 - 12:00

Location: Room 14c (ICM, Level 1)

Chair: D.J.M.K. De Ridder, Leuven (BE)

Aims and objectives of this presentation

Incontinence after radiotherapy or failed artificial sphincter can be a real challenge. Refractory stress incontinence, OAB symptoms will need an appropriate approach. And how do we deal with complex prolapse problems, now that the use of meshes has been banned? This session will tackle some difficult but very relevant questions in the field of functional urology.

10:30 - 10:50

State-of-the-art lecture Incontinence after radiation therapy: What works?

E. Chartier-Kastler, Paris (FR)

Aims and objectives of this presentation

Radiotherapy may be used as an oncological treatment dedicated to urological malignancies (prostate, urethra, bladder) or colorectal malignancies (rectal cancer). The side effects on urethral and/or bladder function are unpredictable and may be of high level of quality of life and continence impairment.

Management of incontinence after radiation therapy must check bladder alteration first. None stress urinary treatment may be done without the best control (information at least) of the bladder compliance and capacity. A review of the best combination will be done.

10:50 - 11:10

State-of-the-art lecture Bladder neck closure in adolescents and adults: Options and outcomes

F. Van Der Aa, Leuven (BE)

Aims and objectives of this presentation

In this presentation, the indications for bladder neck closure in adults and adolescents will be presented and some points of technique will be discussed. Also, attention will be given to patient counselling and expected outcomes.

11:10 - 11:30

State-of-the-art lecture OAB and incontinence after prostate surgery: What's out, what's in, what's coming?

M. Plata, Bogota (CO)

Aims and objectives of this presentation

This is an evidence based approach for the management of urinary incontinence after prostatic surgery for malignant disease. At the end the audience will get data addressing the rates for urinary complications after the different surgical options for prostate cancer and how to avoid, prevent and deal with them. New technologies will be updated and also procedures that did not stand the prove of time will be discussed.

11:30 - 11:50

State-of-the-art lecture Prolapse: The mess with the mesh - What now?

S. Salvatore, Milan (IT)

11:50 - 12:00

Conclusion and discussion

Neuro-urology

Thematic Session 06

Sunday, 13 March
10:30 - 12:00

Location: Room Paris (Hall B2, level 0)

Chair: P. Radziszewski, Warsaw (PL)

Aims and objectives of this presentation

More treatment possibilities appear in modern neuro-urology, but do we really know how to use them? The session is an attempt to answer this question. Also the problem of bladder cancer in neurogenic bladder will be discussed during the state-of-the-art lecture.

10:30 - 10:45

State-of-the-art lecture Optimal sequencing of treatment in neurogenic bladder

J.P.F.A. Heesakkers, Nijmegen (NL)

Aims and objectives of this presentation

In this presentation the goal of neurourological control and intervention will be discussed. Especially the timing of intervention and the sequence of type of intervention in relationship with patients's characteristics will be discussed.

10:45 - 11:00

State-of-the-art lecture What to do when Botox doesn't work?

A. Giannantoni, Perugia (IT)

Aims and objectives of this presentation

While the efficacy and safety of intradetrusorial Botox injection for the treatment of neurogenic detrusor overactivity and idiopathic overactive bladder are well-established, there are still several methodological issues which need to be solved. Indeed, the injection's technique during cystoscopy may be accompanied by several unwanted mistakes that produce loss of the solution into the bladder and reduce the amount of the administered neurotoxin. This may account for the reduced efficacy of the neurotoxin, particularly along repeat treatments. Avoiding these mistakes may improve the efficacy of Botox treatment.

11:00 - 11:30

Case discussion The complicated, previously treated, neurogenic bladder

11:00 - 11:10

Case presenter

P. Radziszewski, Warsaw (PL)

11:10 - 11:20

Minimally invasive options

F. Cruz, Porto (PT)

Aims and objectives of this presentation

A quick overview of the options that might be used in cases that do not respond to bladder administration of botulinum toxin will be addressed. Emphasis will be put on the rapid diagnosis of NDO and a swift introduction of effective treatments before terminal bladder wall fibrosis develops. Prevention may also be the case for MS and Parkinson patients. New routes for administration of old drugs and electrical stimulation of spinal centers and roots will be briefly mentioned.

11:20 - 11:30

Surgical options

J-N.L. Cornu, Rouen (FR)

Aims and objectives of this presentation

Surgical management of neurogenic bladder is mainly based on enterocystoplasty, bladder reconstruction, and urinary diversion techniques. The most popular techniques and surgical tips and tricks as well as innovations in surgical approach are reviewed.

11:30 - 11:45

State-of-the-art lecture Cancer in neurogenic bladder

T.M. Kessler, Zürich (CH)

Aims and objectives of this presentation

Patients with neurogenic lower urinary tract dysfunction seem to have an increased risk for bladder cancer, but the literature is conflicting. The aim of this lecture is to explain the underlying pathomechanisms involved, to show typical differences between neurological and non-neurological patients and to provide a guide for the management of cancer in the neurogenic bladder in daily clinical practice.

11:45 - 12:00

Associated abstract presentations

*648

Lower urinary tract dysfunction is the major concern of adult patients with spina bifida: Data from a prospective cohort of 371 patients

By: Peyronnet B.¹, Brochard C.², Jezequel M.³, Ménard H.³, Dampousse M.⁴, Bonan I.⁴, Kerdraon J.⁴, Siproudhis L.², Gamé X.⁵, Manunta A.¹

Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²CHU Rennes, Dept. of Gastrology, Rennes, France, ³CHU Rennes, Referral Center For Spina Bifida, Rennes, France, ⁴CHU Rennes, Dept. of Physical Medicine, Rennes, France, ⁵CHU Toulouse, Dept. of Urology, Toulouse, France

State-of-the-art lecture

Aims and objectives of this presentation

During their first visit to the French national referral center for spina bifida, patients were asked about their major concern in daily living. Three hundred seventy-one patients were included. The distribution of spina bifida types was: myelomeningocele (66%) and closed spinal dysraphism (34%). The most frequent major concern was lower urinary tract dysfunction (32.8%). The other major concerns were mostly musculoskeletal disorders (24.4%) and anorectal dysfunction. The average Qualiveen score was 2.6 (± 0.9) and 227 patients had a score ≥ 3 (61.1%).

*649

Bacteriuria in patients undergoing intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity: Do we need antibiotic prophylaxis?

By: Leitner L.¹, Sammer U.², Walter M.², Knüpfer S.², Schneider M.P.³, Seifert B.⁴, Mehnert U.², Kessler T.M.²

Institutes:¹Balgrist University Hospital and University Hospital of Basel, Dept. of Neuro-Urology and Urology, Zürich and Basel, Switzerland, ²Balgrist University Hospital, Dept. of Neuro-Urology, Zürich, Switzerland, ³ETH Zürich, Brain Research Institute, Zürich, Switzerland, ⁴University of Zürich, Dept. of Biostatistics and Prevention, Zürich, Switzerland

State-of-the-art lecture

Aims and objectives of this presentation

Intradetrusor onabotulinumtoxinA injections is a highly effective, minimally invasive and well-tolerated therapy for refractory neurogenic detrusor overactivity. Many of these patients rely on some type of catheterisation and present with chronic bacteriuria. In these patients, antibiotic prophylaxis has been widely recommended since bacteriuria might impair efficacy and cause urinary tract infection, but the evidence is very limited. Thus, the aim of the present study was to evaluate if antibiotic prophylaxis is needed in patients with bacteriuria undergoing intradetrusor onabotulinumtoxinA injections.

Paediatric urology 2016

Thematic Session 08

Sunday, 13 March
10:30 - 12:00

Location: Room Vienna (Hall B2, level 0)

Chair: W.F.J. Feitz, Nijmegen (NL)

Aims and objectives of this presentation

Paediatric urology 2016 will give an overview of new clinical, research and educational developments in the field of urological care for children and families. The session is directed to practical aspects for general urologists, residents in urology, paediatric urologists and those interested. Key note speakers and experts in the field will present the newest information to you in an understanding way.

10:30 - 10:45

Introduction Paediatric urology 2016: European expertise and continuation of care

W.F.J. Feitz, Nijmegen (NL)

Aims and objectives of this presentation

Paediatric urology and the latest european expertise network developments will be presented and discussed. The policy of the European Union on network developments for rare diseases has led to the formation of european reference networks. These networks and the continuation of care depends on share, care and cure for the best medical treatments for our patients.

10:45 - 11:00

State-of-the-art lecture Hypospadias: Clinical practice and improvements

J. Seibold, Tübingen (DE)

Aims and objectives of this presentation

Hypospadias and the surgical correction of hypospadias are a challenge in the search for new and better solutions. This overview will provide the insight in therapy from very mild forms, to complex hypospadias as well to hypospadias cripples. Different techniques are highlighted.

11:00 - 11:15

State-of-the-art lecture Robot and children: Special care

M. De Gennaro, Rome (IT)

Aims and objectives of this presentation

Robot-assisted surgery has been one of the major innovations introduced to pediatric surgeons. The first series was published in 2001. The more frequent procedures are Pyeloplasty and Funduplication (collectively 46% of overall volume). The robot is definitely more helpful than laparoscopy for complex reconstructive procedures: ileocystoplasty with Mitrofanoff appendicovesicostomy are feasible, even if the instrument isn't suited for pediatric patients in its current form. It has been calculated that in pediatric urology a volume of 100-150 procedures/year is needed to balance revenues and costs.

11:15 - 11:30

State-of-the-art lecture Complex congenital anomalies and transition of care

W.H. Roesch, Regensburg (DE)

11:30 - 11:45

State-of-the-art lecture Urological reconstructions and regenerative methods

R. Subramaniam, Leeds (GB)

Aims and objectives of this presentation

This presentation looks at status of Regenerative medicine with regards to urinary bladder. I will try and explore the rationale of various strategies employed to develop a tissue engineered bladder and the challenges in realising this goal.

11:45 - 12:00

State-of-the-art lecture The urine microbiome, relations to urinary tract infection, hormonal status, gender and age

D.J. Kok, Rotterdam (NL)

Lessons from transplantation surgery applied to general urology

Thematic Session 09

Sunday, 13 March
10:30 - 12:00

Location: Room London (Hall B2, level 0)

Chair: L. Peri Cusi, Barcelona (ES)

Aims and objectives of this presentation

Kidney transplantation benefits from urological surgical techniques and vice versa. The present session gives us three examples. Laparoscopic living donor nephrectomy, is a nephrectomy that should preserve the kidney anatomy carefully and needs to use a short warm ischemia time. Several issues related to safety in the management of the pedicle must be updated including, the debate on the use of hem-O-locks. Robotic surgery in urology was developed mainly in the field of radical prostatectomy. New indications have been developed, probably the most amazing one being complex reconstructive surgery such as kidney transplant. An open debate about their benefits and risks is taking place currently and during the session. Finally the most paradigmatic application of kidney transplant, autotransplantation, will be reviewed in order to define when to use it for severe urological disorders.

10:30 - 10:45

State-of-the-art lecture **Laparoscopic living donor nephrectomy: Safety issues. How to best secure the pedicle?**

A.J. Figueiredo, Coimbra (PT)

Aims and objectives of this presentation

"Safety first" is nowhere as fundamental as in living donor nephrectomy. During surgery, the control of the pedicle is the one that encompasses the biggest danger. The aim of this lecture is to provide a critical review of the different ways of controlling the pedicle. It will include the presentation of the results of an online survey on the methods that urologists use to clamp the artery and on their position regarding the controversial use of "Hem-o-Loks" in this setting.

10:45 - 11:20

Debate **Is robotic assisted transplantation the future?**

10:45 - 11:05

Laparoscopic and robotic transplantation

R. Ahlawat, Gurgaon (IN)

Aims and objectives of this presentation

Aim of the presentation is to present the basics of technique and the potential advantages of the minimally invasive approach. Like all other areas of surgery, minimally invasive approach is likely to prove its value in transplantation.

11:05 - 11:20

Challenger

E. Lledo García, Madrid (ES)

11:20 - 11:35

State-of-the-art lecture **What urologists can learn from transplant surgeons**

F.J. Burgos Revilla, Madrid (ES)

Aims and objectives of this presentation

The aim of the presentation is to show technical details of kidney transplantation surgery that are useful for the general urologists to resolve different surgical challenges in conventional practice.

Additionally techniques used for resolution of kidney transplant surgical complications are showed and translocated to conventional urologic settings.

11:35 - 11:50

Discussion

11:50 - 12:00

Associated video abstract presentation

*V47

A new surgical area opened in renal transplantation: A pure robot-assisted approach for both living donor nephrectomy and kidney transplantation using transvaginal route

By: Doumerc N.¹, Beauval J.B.², Roumigué M.², Game X.², Kamar N.³, Sallusto F.², Soulié M.², Rischmann P.²

Institutes:¹CHU Rangueil, Dept. of Urology, Toulouse, France, ²CHU Rangueil, Dept. of Urology, Andrology and Renal Transplantation, Toulouse, France, ³CHU Rangueil, Dept. of Nephrology and Renal Transplantation and Andrology, Toulouse, France

State-of-the-art lecture

Aims and objectives of this presentation

To show a new way to perform a kidney transplantation using exclusively robotics for both donor and recipient.

ESU/ESUT Hands-on training in GreenLight Laser Vaporisation

HOT 21

Sunday, 13 March
10:45 - 12:15

Location: Room North America (Hall B0, level 0)

Aims and objectives of this presentation

The European School of Urology (ESU) and the European Section of Uro-Technology (ESUT) offer an intensive hands-on training course with different models focussing on the endoscopic management of LUTS. The delegates will be taken through a sequential programme of GreenLight-laservaporisation using virtual reality models. A video demonstrating the different steps and tasks of the procedures will be presented and afterwards the delegates will be instructed according to their level of experience in small teams at the models. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

S. Shariat, Vienna (AT)
J.H. Roelink, Almelo (NL)
N. Barber, Camberley (GB)
To be confirmed
M. Rieken, Basel (CH)

ESU/ESUT Hands-on training in Basic laparoscopic skills

HOT 65

Sunday, 13 March
10:45 - 12:15

Location: Room South America (Hall B0, level 0)

Chair: A.S. Gözen, Heilbronn (DE)

Aims and objectives of this presentation

In this course basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme.

Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporeal suturing.

This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

A. Sempere Gutierrez, Murcia (ES)

To be confirmed

G. Pini, Cologno Monzese (MI) (IT)

T. Kalogeropoulos, Athens (GR)

D. Veneziano, Minneapolis (US)

ESU Social Media Training

HOT 43

Sunday, 13 March
11:00 - 11:45

Location: Room 0.305

Chair: C.J. Wijburg, Arnhem (NL)

Aims and objectives of this presentation

- EAU Congress Attendees will be instructed on how to harness professional Social Media to augment experience of professional meetings, follow urologic news feeds, and engage with the world-wide urologic community.
- Urologists who are expert in the use of Social Media will provide 45 minute small group hands-on workshops on the use of professional Social Media.
- Current Social Media users will have the opportunity to exchange expertise with other Social Media users during small group sessions.

M.J. Ribal, Barcelona (ES)

ESU/ESUT Hands-on training in Transurethral therapy of LUTS - Bipolar TURP

HOT 56

Sunday, 13 March
11:30 - 13:00

Location: Room Europe (Hall B0, level 0)

Chair: A. De La Taille, Créteil (FR)

Aims and objectives of this presentation

The European School of Urology (ESU) and the EAU Section of Uro-Technology (ESUT) offer an intensive hands-on training course with different models focussing on the endoscopic management of LUTS. The delegates will be taken through a sequential programme of Bipolar TURP using normal endoscopic instruments in different models. A video demonstrating the different steps and tasks of the procedures will be presented and afterwards the delegates will be instructed according to their level of experience in small teams at the models. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

S. Gravas, Larissa (GR)
A.G. Martov, Moscow (RU)
A. Meneghini, Adria (IT)

ESU/ERUS Hands-on training in Robotic surgery

HOT 17

Sunday, 13 March
11:30 - 13:00

Location: Room Asia (Hall B0, level 0)

Chair: C. Wagner, Gronau (DE)

Aims and objectives of this presentation

The European School of Urology (ESU) and the EAU Robotic Urology Section (ERUS) offer an intensive hands-on training course. We will provide training using simulators. The main aims of this 90 minutes course are: improving the participants' control-skills and hand-eye-coordination, as well as an objective benchmarking of console performance and an introduction into standardized surgical steps in robot-assisted procedures.

To be confirmed
W. Brinkman, Rotterdam (NL)

Practical aspects of cancer pathology for urologists. The 2016 WHO novelties

ESU Course 19

Sunday, 13 March
12:00 - 14:00

Location: Room 13a (ICM, Level 1)

Chair: E. Compérat, Paris (FR)

Aims and objectives of this presentation

This course treats urogenitary pathology. We want to improve the urologist-pathologist interaction, understanding of the whole diagnostic spectrum and to update urologists with the new WHO classification 2016.

- Optimal handling of pathology specimen
- When ask for frozen sections, surgical margins
- Pathology report. Read and understand all included information
- Novelties in Uro-Onco Pathology. Applications in daily practice

F. Algaba, Barcelona (ES)

12:00 - 14:00

Consensus conference on Gleason Grading: Proposal for a new grading system

E. Compérat, Paris (FR)

12:00 - 14:00

Bladder cancer classification: What is new in 2016, Classical grading and molecular grading, how to integrate?

E. Compérat, Paris (FR)

12:00 - 14:00

Kidney tumours with the 2016 WHO eyes

F. Algaba, Barcelona (ES)

12:00 - 14:00

Testis tumours: New insights with clinical impact

F. Algaba, Barcelona (ES)

Ultrasound in urology

ESU Course 20

Sunday, 13 March
12:00 - 14:00

Location: Room 13b (ICM, Level 1)

Chair: T. Loch, Flensburg (DE)

Aims and objectives of this presentation

Ultrasound is the basic imaging tool of the urologist and almost all urologists are using ultrasound in daily practice. Despite this, training and teaching of urological ultrasound is not provided in a satisfactory manner. The aim of the course is to provide the technical basics and standards for the use of ultrasound in urology. After the course the delegate should know the ideal settings for reliable and informative urological ultrasound as well as the normal and pathological findings.

- Covering urological organs: kidney, ureter, bladder, testis and penis
- Standard patient positioning
- Best choice of transducers and settings
- Standard operating procedures (SOP)
- Normal, benign and malignant pathologic findings
- Interventional and intraoperative ultrasound.

12:00 - 14:00

Technical basics and new technologies

T. Loch, Flensburg (DE)

12:00 - 14:00

Standardisation, tuning, acquisition and reporting of ultrasound exams

M. Ritter, Mannheim (DE)

12:00 - 14:00

Ultrasound of the kidney and ureter

M. Ritter, Mannheim (DE)

12:00 - 14:00

Ultrasound of the bladder

T. Loch, Flensburg (DE)

12:00 - 14:00

Ultrasound of the testis

T. Loch, Flensburg (DE)

12:00 - 14:00

Ultrasound of the penis

M. Ritter, Mannheim (DE)

Laparoscopy for beginners

ESU Course 21

Sunday, 13 March
12:00 - 14:00

Location: Room 11 (ICM, Level 1)

Chair: X. Cathelineau, Paris (FR)

Aims and objectives of this presentation

With the large widespread of mini-invasive surgery, improving knowledge of practical aspects of laparoscopy is mandatory.

Knowledge of:

- Indications and contra-indications of laparoscopic approach
- How to choose and use the instrumentation, in order to optimize the procedure and minimize adverse effects
- Air insufflations parameters and optimal access in laparoscopic urology
- How to prevent, recognize and manage complications

This course aims to provide all this knowledge in an interactive and practical way (video clip, open discussion), in order to assist beginners in laparoscopy shortening their learning curve and optimizing the success of their laparoscopic procedures.

- Laparoscopic surgery: For which patients and which procedures?
- Masterize the armentarium
- Tips and tricks to optimize the procedure
- New potential and future evolutions

12:00 - 14:00

Indications for laparoscopy

B.S.E.P. Van Cleynenbreugel, Wolfsdonk (BE)

12:00 - 14:00

Instrumentation and haemostatis

X. Cathelineau, Paris (FR)

12:00 - 14:00

Peritoneal access and effects of pneumoperitoneum

B.S.E.P. Van Cleynenbreugel, Wolfsdonk (BE)

12:00 - 14:00

Avoiding complications

X. Cathelineau, Paris (FR)

Basic surgical and endo urological skills

ESU Course 22

Sunday, 13 March
12:00 - 14:00

Location: Room 12 (ICM, Level 1)

Chair: L. Henningsohn, Stockholm (SE)

Aims and objectives of this presentation

The course is designed to apply basic surgical knowledge and principles in the initial development of urological training. It aims to provide learners with valuable basic skills in developing a safe and methodological approach to application of surgical knowledge.

- To familiarize oneself with all the basic surgical and endourological procedures.
- To understand the importance of previous medical history, anatomy and surgical technique for basic Urological procedures.
- To review indications, technical details and possible complications and management in basic surgical and endourological procedures.

12:00 - 14:00

Physical examination of the genitourinary tract

L. Henningsohn, Stockholm (SE)
R.E. Sanchez Salas, Paris (FR)

12:00 - 14:00

Penile surgery

L. Henningsohn, Stockholm (SE)

12:00 - 14:00

Scrotal surgery

R.E. Sanchez Salas, Paris (FR)

12:00 - 14:00

Basic endoscopic procedures (urethral catheterization, cystoscopy, nephrostomy)

L. Henningsohn, Stockholm (SE)
R.E. Sanchez Salas, Paris (FR)

Management and outcome in invasive and locally advanced bladder cancer

ESU Course 23

Sunday, 13 March
12:00 - 14:00

Location: Room 21 (ICM, Level 2)

Chair: B. Malavaud, Toulouse (FR)

Aims and objectives of this presentation

MIBC is a multifaceted entity where one size no longer fits all, supporting the development of personalized and, in selected cases, organ-preserving strategies.

Are the advances in imaging, molecular biology, conservative surgery; medical oncology and radiotherapy strong enough to shift the current pre-eminence of the ablative approach toward a more integrated and conservative perspective? If yes, what are the ideal candidates?

- One size does not fit all and urologists are central to the development of personalized treatment in MIBC
- Patients selection is critical and based on advances in imaging, resection techniques and pathology
- Organ preservation is feasible in a significant proportion of patients
- Radical cystectomy and pre-emptive chemotherapy are essential to optimize results in aggressive conditions.

12:00 - 14:00

Cystectomy in the management of bladder invasive and locally advanced bladder cancer

M. Burger, Regensburg (DE)

12:00 - 14:00

Case discussion on cystectomy in the management of bladder invasive and locally advanced bladder cancer

B. Malavaud, Toulouse (FR)

12:00 - 14:00

Bladder sparing approaches to muscle invasive bladder cancer

M. Burger, Regensburg (DE)

12:00 - 14:00

Case discussion on bladder sparing approaches to muscle invasive bladder cancer

B. Malavaud, Toulouse (FR)

12:00 - 14:00

Cytotoxic chemotherapy in bladder cancer: Neoadjuvant and adjuvant setting and treatment of metastatic disease

B. Malavaud, Toulouse (FR)

General neuro-urology

ESU Course 24

Sunday, 13 March
12:00 - 14:00

Location: Room 22 (ICM, Level 2)

Chair: F. Cruz, Porto (PT)

Aims and objectives of this presentation

The course aims at introducing the basic principles of the diagnostic work-up and of the management of the most common neurological micturition dysfunctions to urologists and residents. The early identification of common neurological micturition dysfunctions will contribute to increase the longevity and the quality of life of neurological patients.

The main aims are:

- To refresh the terminology and the specific methods of investigation in Neuro-Urology
- To review the most important urodynamics patterns found in patients with neurogenic micturition dysfunction
- To analyse the pharmacological and surgical options available for the management of the neuro-urological patient
- To update the indications of botulinum toxin type A in the management of the neuro-urological patient.

12:00 - 14:00

Introduction

F. Cruz, Porto (PT)

12:00 - 14:00

Diagnostics

M.J. Drake, Bristol (GB)

12:00 - 14:00

Therapy

F. Cruz, Porto (PT)

12:00 - 14:00

Case discussions

Complex robotic partial nephrectomy

Video Session 05

Sunday, 13 March
12:15 - 13:45

Location: eURO Auditorium (Hall C1, Level 0)

Chairs: R. Autorino, Cleveland (US)
I.S. Gill, Los Angeles (US)
N.P. Wiklund, Stockholm (SE)

Aims and objectives of this presentation

Robot assisted partial nephrectomy (RAPN) is becoming the new gold standard for minimally invasive nephron sparing surgery. Surgical techniques have been refined and indications have rapidly expanded over the past 5 years. The aim of this video session will be to focus on challenging indications of RAPN. Technical nuances will be discussed and details of the procedure in this specific setting will be critically scrutinized.

All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.

- *V33 **Robot-assisted partial nephrectomy: The anatomical tumour devascularization concept**
By: [Grassano Y.](#), Michiels C., Vuong N-S, Cornelis F., Tran P., Simeon H., Pierquet G., Ginot R., Capon G., Tricaud E., Rouget B., Susperregui J., Pasticier G., Robert G., Bensadoun H., Ferriere J-M., Bernhard J-C.
Institutes: University Hospital of Bordeaux, Dept. of Urology, Bordeaux, France
- *V34 **Robotic partial nephrectomy for hilar tumours: Zero ischemia or early unclamping?**
By: [Peyronnet B.](#), Pradère B., Alimi Q., Khene Z., Fardoun T., Mathieu R., Verhoest G., Bensalah K.
Institutes: CHU Rennes, Dept. of Urology, Rennes, France
- *V35 **Robotic partial nephrectomy (RAPN) for highly complex renal masses (PADUA 10)**
By: [Ohlmann C-H.](#), Saar M., Siemer S., Stöckle M., Janssen M.
Institutes: UKS Universitätsklinikum des Saarlandes, Dept. of Urology, Homburg, Germany
- *V36 **Feasibility of robotic partial nephrectomy for cystic tumour**
By: [Pradere B.](#)¹, Peyronnet B.², Fardoun T.², Verhoest G.², Mathieu R.², Bensalah K.²
Institutes: ¹CHU de Tours, Hospital Bretonneau, Dept. of Urology, Tours, France, ²CHU Rennes, Dept. of Urology, Rennes, France
- *V37 **Retro-peritoneal approach for robotic assisted laparoscopic partial nephrectomy of a clinical T2a renal mass**
By: Hamilton Z., Patel N., Woo J., [Derweesh I.](#)
Institutes: University of California, Dept. of Urology, San Diego, United States of America
- *V38 **Robot-assisted partial nephrectomy with super-selective clamping for complex hilar tumour**
By: [Michiels C.](#), Capon G., Grassano Y., Queruel V., Susperregui J., Robert G., Pasticier G., Bensadoun H., Ferrière J-M., Bernhard J-C.
Institutes: Bordeaux University Hospital, Dept. of Urology, Bordeaux, France
- *V39 **Extending the limits: Fluorescence guided selective arterial control for a zero ischemia robotic partial nephrectomy in a t1b central hilar tumour**
By: Zambrano N.¹, Vera Veliz A.I.¹, Susaeta R.¹, Mercado A.¹, Hinrichs A.¹, [Guzman S.](#)²
Institutes: ¹Clinica Las Condes, Dept. of Urology, Santiago, Chile, ²Clinica Las Condes, Technical Director Centro De Robotica; Urology Department, Santiago, Chile

*V40

Zero-ischemia robot-assisted partial nephrectomy using near-infrared fluorescence

By: Lanchon C., Fiard G., Descotes J-L., Rambeaud J-J., Long J-A.

Institutes: Grenoble University Hospital, Dept. of Urology, Grenoble, France

Novel biomarkers for prostate cancer prediction

Poster Session 31

Sunday, 13 March
12:15 - 13:45

Location: Room Madrid (Hall B2, level 0)

Chairs: P-A. Abrahamsson, Malmö (SE)
P. Cornford, Liverpool (GB)
N. Suardi, Milan (IT)

Aims and objectives of this presentation

The session focuses on performance characteristics of novel biomarkers and multivariable models to predict prostate cancer and its grading

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*380

Novel long non-protein coding RNAs as biomarkers and potential therapeutic targets for prostate cancer

By: [Christ-Breulmann S.](#)¹, Horn F.², Puppel S-H.¹, Buschmann T.¹, Reiche K.¹, Specht M.¹, Bertram C.¹, Friedrich M.¹, Blumert C.¹, Binder S.¹, Hackermüller J.³, Kreuz M.⁴, Löffler M.⁴, Toma M.I.⁵, Muders M.⁵, Baretton G.B.⁵, Fröhner M.⁶, Füssel S.⁶, Wirth M.⁶

Institutes:¹Fraunhofer Institute for Cell Therapy and Immunology, Dept. of Diagnostics, Leipzig, Germany, ²University of Leipzig, Institute of Clinical Immunology, Leipzig, Germany, ³Helmholtz Centre for Environmental Research, Young Investigator Group Bioinformatics & Transcriptomics, Leipzig, Germany, ⁴University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology, Leipzig, Germany, ⁵University Hospital "Carl Gustav Carus", Technical University Dresden, Institute of Pathology, Dresden, Germany, ⁶University Hospital "Carl Gustav Carus", Technical University Dresden, Dept. of Urology, Dresden, Germany

*381

The 4Kscore predicts the grade and stage of prostate cancer in the radical prostatectomy specimen: Results from a multi-institutional prospective trial

By: Punnen S.¹, Nahar B.¹, [Pavan N.](#)¹, Sjoberg D.², Zappala S.³, Parekh D.¹

Institutes:¹University of Miami Miller School of Medicine, Dept. of Urology, Miami, United States of America, ²Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, ³Andover Urology, Dept. of Urology, Andover, United States of America

*382

The 4kscore® test is comparable to biopsy in accurately predicting high-grade cancer in radical prostatectomy specimens with potential implications for active surveillance

By: [Alcaraz A.](#)¹, Newmark J.², Casariego J.³, Dong Y.², Sant G.², Mathur M.², Steiner M.²

Institutes:¹Hospital Clinic, Dept. of Urology, Barcelona, Spain, ²OPKO Health, Inc., Dept. of Medical Affairs and Diagnostics, Miami, United States of America, ³OPKO Health Europe, Dept. of Medical, Barcelona, Spain

*383

Multicenter validation study of a urine-based molecular biomarker algorithm to predict high-grade prostate cancer

By: [Hendriks R.J.](#)¹, Dijkstra S.¹, Trooskens G.⁹, Van Criekinge W.⁹, Cornel E.B.², Jannink S.A.³, De Jong H.³, Hessels D.³, Smit F.P.³, Melchers W.J.G.¹, Leyten G.H.J.M.¹, De Reijke T.M.⁴, Vergunst H.⁵, Kil P.⁶, Knipscheer B.C.⁷, Hulsbergen-Van De Kaa C.A.⁸, Mulders P.F.A.¹, Van Oort I.M.¹, Van Neste L.¹⁰, Schalken J.A.¹

Institutes:¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²ZGT Hospital, Dept. of Urology, Hengelo, The Netherlands, ³Noviogendix, Dept. of Research and Development, Nijmegen, The Netherlands, ⁴AMC University Medical Centre, Dept. of Urology, Amsterdam, The Netherlands, ⁵CWZ Hospital, Dept. of Urology, Nijmegen, The Netherlands, ⁶St Elisabeth Hospital, Dept. of

Urology, Tilburg, The Netherlands, ⁷Scheper Hospital, Dept. of Urology, Emmen, The Netherlands, ⁸Radboudumc, Dept. of Pathology, Nijmegen, The Netherlands, ⁹Ghent University, Laboratory of Bioinformatics and Computational Genomics, Ghent, Belgium, ¹⁰Maastricht University Medical Center, GROW - School for Oncology and Developmental Biology, Dept. of Pathology, Maastricht, The Netherlands

- *384 **The Prostate Health Index (PHI) predicts positive cancer biopsies in men with a negative mpMRI in a repeat biopsy population**
By: Gnanapragasam V.J.¹, Burling K.⁶, George A.¹, Kastner C.², Doble A.², Barret T.³, Koo B.⁴, Gallagher F.³, Warren A.⁵, Ragab M.²
Institutes:¹University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, ²Cambridge University Hospitals NHS Foundation Trust, Dept. of Urology, Cambridge, United Kingdom, ³University of Cambridge, Dept. of Radiology, Cambridge, United Kingdom, ⁴Cambridge University Hospitals NHS Foundation Trust, Dept. of Radiology, Cambridge, United Kingdom, ⁵Cambridge University Hospitals NHS Foundation Trust, Dept. of Pathology, Cambridge, United Kingdom, ⁶Cambridge University Hospitals NHS Foundation Trust, Core Biochemical Assay Laboratory, Cambridge, United Kingdom
- *385 **The ERSPC risk calculator significantly outperforms the PCPT 2.0 in the prediction of prostate cancer: A multi-institutional study**
By: Foley R.W.¹, Gorman L.², Murphy K.³, Lunden D.², Durkan G.⁴, Power R.⁵, O'Brien F.⁶, O'Malley K.J.⁷, Galvin D.J.⁸, Murphy B.³, Watson R.W.²
Institutes:¹University College Dublin, UCD School of Medicine, Dublin, Ireland, ²University College Dublin, UCD Conway Institute of Biomolecular and Biomedical Research, Dublin, Ireland, ³University College Dublin, UCD School of Mathematics, Dublin, Ireland, ⁴University College Galway, Department of Urology, Galway, Ireland, ⁵Beaumont Hospital, Department of Urology, Dublin, Ireland, ⁶University Hospital Waterford, Department of Urology, Waterford, Ireland, ⁷Mater Misericordiae University Hospital, Department of Urology, Dublin, Ireland, ⁸St. Vincent's University Hospital, Department of Urology, Dublin, Ireland
- *386 **PCA3 and T2-ERG add further predictive and clinical benefit to the detection of prostate cancer in men of various ages in the early detection research network (EDRN)**
By: O'Malley P.¹, Golombos D.¹, Lewicki P.¹, Al Hussein Al Awamlh B.¹, Christos P.², Sanda M.³, Thompson IM⁴, Wei J.⁵, Rubin M.⁶, Barbieri C.¹, Scherr D.¹
Institutes:¹Weill Cornell Medical College, Dept. of Urology, New York, United States of America, ²Weill Cornell Medical College, Dept. of Healthcare Policy and Research, New York, United States of America, ³Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America, ⁴University of Texas Health Science Center At San Antonio, Dept. of Urology, San Antonio, United States of America, ⁵University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ⁶Weill Cornell Medical College, Dept. of Pathology and Laboratory Medicine, New York, United States of America
- *387 **Identification of population-specific genetic risk profiles in young individuals with or without family history of prostate cancer**
By: Cucchiara V.¹, Zoccolillo M.², Vizziello D.³, Lazarevic D.², Cittaro D.², Ferrara A.M.¹, Gandaglia G.¹, Fossati N.¹, Benigni F.¹, Bianchi M.E.⁴, Montorsi F.¹, Briganti A.¹
Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Center For Translational Genomics and Bioinformatics, Milan, Italy, ³IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, ⁴IRCCS Ospedale San Raffaele, Dept. of Genetics and Cell Biology, Milan, Italy
- *388 **Genetic variations in the OPG and RANKL genes are associated with prostate cancer risk**
By: Ney J.², Saar M.¹, Juhasz-Boess I.², Assmann G.³, Kasoha M.², Solomayer E-F.², Stöckle M.¹, Jung V.¹
Institutes:¹UKS Universitätsklinikum des Saarlandes, Dept. of Urology & Paediatric, Homburg/Saar, Germany, ²UKS Universitätsklinikum des Saarlandes, Dept. of Gynaecology, Obstetrics and Reproductive Medicine, Homburg/Saar, Germany, ³UKS Universitätsklinikum des Saarlandes, Internal Medicine I, Jose-Carreras-Center For Immuno- and Gene Therapy, Homburg/Saar, Germany

- *389 **Performance of a validated urine-exosome gene signature on initial biopsy in the 4-10ng/mL PSA gray zone: Assessment of avoided biopsies and impact of an adjusted cut-point**
By: [Donovan M.](#)¹, Bentink S.², Noerholm M.³, O'Neill V.⁴, Skog J.⁵
Institutes:¹Icahn School Of Medicine At Mt. Sinai, Dept. of Pathology, New York City, United States of America, ²Exosome Diagnostics GmbH, Dept. of Biostatistics, Martinsreid, Germany, ³Exosome Diagnostics GmbH, Dept. of Product Development, Martinsreid, Germany, ⁴Exosome Diagnostics, Clinical, Cambridge, United States of America, ⁵Exosome Diagnostics, Dept. of R&D, Cambridge, United States of America
- *390 **Micromechanical biomarkers are superior to conventional DRE and TRUS biopsy in the detection of prostate cancer**
By: [Good D.](#)¹, Hammer S.², Scanlan P.², Stewart G.¹, Phipps S.³, Shu W.², Reuben R.², McNeill A.³
Institutes:¹University of Edinburgh, Edinburgh Urological Cancer Group, Edinburgh, United Kingdom, ²Heriot Watt University, Dept. of Engineering, Edinburgh, United Kingdom, ³NHS Lothian, Dept. of Urology, Edinburgh, United Kingdom
- *391 **How accurate is the PSA test? A prevalence study of disturbed PSA values in a tertiary referral hospital**
By: [Poyet C.](#)¹, Saba K.¹, Lautenbach N.¹, Saleh L.², Umbehr M.³, Sulser T.¹, Müntener M.³, Von Eckardstein A.²
Institutes:¹Universitätsspital Zürich, Dept. of Urology, Zürich, Switzerland, ²Universitätsspital Zürich, Institut Für Klinische Chemie, Zürich, Switzerland, ³Stadtspital Triemli Zürich, Dept. of Urology, Zürich, Switzerland
- 13:28 - 13:35 **Summary and context**
N. Suardi, Milan (IT)

Current tools for modern staging of urothelial tumours

Poster Session 32

Sunday, 13 March
12:15 - 13:45

Location: Room Stockholm (Hall B2, level 0)

Chairs: M.J. Ribal, Barcelona (ES)
P. Black, Vancouver (CA)
M. Roscigno, Vignate (IT)

Aims and objectives of this presentation

Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous entity including different substages of superficial tumours with specific evolution and prognosis. The risks of recurrence and progression in NMIBC are largely influenced by well-known risk factors, such as stage, grade, multifocality, tumour size and concomitant CIS. Thus, risk tables and scoring systems have been developed by the EORTC group to adapt the treatment to the aggressiveness of the disease. The current session is dedicated to current staging of urothelial tumours.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*392

New pathological features predicting prognosis of early-invasive urothelial carcinoma: Quantitative substaging and tumour invasion pattern should assist WHO 1973 grading classification in predicting cancer-specific survival of stage pT1 bladder cancer

By: Breyer J.¹, Bertz S.², Müller A.², Lausenmeyer E-M.¹, Mayr R.¹, Gierth M.¹, Burger M.¹, Denzinger S.¹, Hartmann A.², Otto W.¹

Institutes:¹University of Regensburg, Dept. of Urology, Regensburg, Germany, ²University of Erlangen-Nuremberg, Institute of Pathology, Erlangen, Germany

*393

Associations of mutation heterogeneity in 20 cancer-related genes with the progression in T1G3 bladder cancers

By: Salomo K.¹, Hübner D.¹, Hahm J.², Meinel J.³, Novotny V.¹, Boehme M.², Füssel S.¹, Wirth M.¹

Institutes:¹Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dept. of Urology, Dresden Johannstadt Nord, Germany, ²Biotype Diagnostic GmbH, Dept. of Research and Development, Dresden, Germany, ³Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dept. of Pathology, Dresden Johannstadt Nord, Germany

*394

MRNA-based subtype classification of bladder cancer and patient outcome after radical cystectomy

By: Sjö Dahl G.¹, Kollberg P.², Liedberg F.¹, Höglund M.³

Institutes:¹Lund University, Dept. of Translational Medicine, Malmö, Sweden, ²Lund University, Dept. of Translational Medicine, Helsingborg, Sweden, ³Dept. of Clinical Sciences Lund University, Dept. of Oncology, Lund, Sweden

*395

Novel circulating tumour cell enumeration and epithelial/mesenchymal probe marking technique in bladder cancer

By: Chen H., Zhang R., Jin D., Dong L., Yang G., Cao M., Zhang L., Xue W., Huang Y.

Institutes: Shanghai Renji Hospital, Dept. of Urology, Shanghai, China

*396

Impact of stage migration on bladder cancer: A slow but steady improvement in the long term survival rates after radical cystectomy in the last 25 years

By: Moschini M.¹, La Croce G.¹, Bianchi M.¹, Cucchiara V.¹, Freschi M.², Burgio G.³, Shariat S.⁴, Serretta V.⁵, Damiano R.⁶, Briganti A.¹, Montorsi F.¹, Colombo R.¹, Gallina A.¹

Institutes:¹Uri, Irccs San Raffaele Scientific Institute, Dept. of Oncology and Urology, Milan, Italy, ²Uri, Irccs San Raffaele Scientific Institute, Dept. of Pathology, Milan, Italy, ³Uri, Irccs San Raffaele Scientific Institute, Dept. of Urology and Experimental Oncology, Milan, Italy, ⁴Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁵Università Degli Studi Di Palermo, Dept. of Discipline and Surgical Oncology, Palermo, Italy, ⁶Magna Græcia University of Catanzaro, Dept. of Urology and Doctorate Research Program, Catanzaro, Italy

- *397 **Change of perioperative lymphocyte–monocyte ratio is good predictor of prognosis in patients with bladder cancer undergoing radical cystectomy**
By: Kinoshita H., Yoshida T., Matsuda T.
Institutes:Kansai Medical University, Dept. of Urology and Andrology, Hirakata, Japan
- *398 **Pelvic lymph node staging by combined 18F-FDG-PET/CT in bladder cancer following radical cystectomy**
By: Pichler R.¹, De Zordo T.², Fritz J.³, Kroiss A.⁴, Heidegger I.¹, Virgolini I.⁴, Aigner F.², Uprimny C.⁴, Horninger W.¹
Institutes:¹Medical University Innsbruck, Dept. of Urology, Innsbruck, Austria, ²Medical University Innsbruck, Dept. of Radiology, Innsbruck, Austria, ³Medical University Innsbruck, Dept. of Medical Statistics, Informatics and Health Economics, Innsbruck, Austria, ⁴Medical University Innsbruck, Dept. of Nuclear Medicine, Innsbruck, Austria
- *399 **The timing of the TURBT and accuracy of bladder cancer staging**
By: Robinson S.¹, Bryan R.², Maudgil D.³, Motiwala H.⁴, Montgomery B.⁴
Institutes:¹Frimley Park Hospital, Dept. of Urology, Henley on Thames, United Kingdom, ²University of Birmingham, The Institute of Cancer & Genomic Sciences, Birmingham, United Kingdom, ³Frimley Park Hospital, Dept. of Radiology, Frimley, United Kingdom, ⁴Frimley Park Hospital, Dept. of Urology, Frimley, United Kingdom
- *400 **Preoperative platelet/leukocyte ratio and platelet count - impact on cancer-specific survival in patients undergoing radical cystectomy for bladder cancer**
By: Schulz G.B., Grimm T., Buchner A., Schneevoigt B-S., Kretschmer A., Apfelbeck M., Grabbert M., Jokisch F., Stief C.G., Karl A.
Institutes:Ludwig-Maximilians University Munich, Dept. of Urology, Munich, Germany
- *401 **MRI-based spatially resolved quantitative diffusivity measurements reflect proliferative activity of bladder cancer**
By: Sevcenco S.¹, Haitel A.², Shariat S.³, Rauchenwald M.¹, Klingler H-C.⁴, Susani M.², Ponhold L.⁵, Baltzer P.⁵
Institutes:¹Sozialmedizinisches Zentrum Ost - Donauspital, Dept. of Urology, Vienna, Austria, ²Medical University of Vienna, Dept. of Histopathology, Vienna, Austria, ³Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁴Wilhelminenspital, Dept. of Urology, Vienna, Austria, ⁵Medical University of Vienna, Dept. of Radiology, Vienna, Austria
- *402 **FDG PET-CT vs CT scan in the staging of urothelial neoplasms**
By: Gaya Sopena J.M.¹, Rodríguez O.¹, Maroto P.², Carrió I.³, Kanashiro A.¹, Gómez De Liaño A.², Palou J.¹
Institutes:¹Universitat Autònoma de Barcelona - Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²Hospital De Sant Pau I La Santa Creu, Dept. of Oncology, Barcelona, Spain, ³Hospital De Sant Pau I La Santa Creu, Dept. of Nuclear Medicine, Barcelona, Spain
- *403 **Apparent diffusion coefficient values obtained by unenhanced MRI predicts disease-specific survival in bladder cancer**
By: Sevcenco S.¹, Klingler H-C.², Rauchenwald M.³, Haitel A.⁴, Shariat S.F.⁵, Maj-Hes A.⁵, Baltzer P.⁶
Institutes:¹Sozialmedizinisches Zentrum Ost - Donauspital, Dept. of Urology, Vienna, Austria, ²Wilhelminenspital, Dept. of Urology, Vienna, Austria, ³Sozialmedizinisches Zentrum Ost - Donauspital, Dept. of Urology, Vienna, Austria, ⁴Medical University of Vienna, Dept. of Histopathology, Vienna, Austria, ⁵Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁶Medical University of Vienna, Dept. of Radiology, Vienna, Austria

13:30 - 13:37

Summary and context

P. Black, Vancouver (CA)

Is robot-assisted partial nephrectomy the new standard?

Poster Session 33

Sunday, 13 March
12:15 - 13:45

Location: Room Milan (Hall B2, level 0)

Chairs: K. Bensalah, Rennes (FR)
F. Porpiglia, Turin (IT)
G.T. Sung, Busan (KR)

Aims and objectives of this presentation

To discuss the current role of RAPN

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *404 **Is robotic partial nephrectomy really safe? Analysis of >300 consecutive procedures**
By: Song W., Ko K.J., Kim T.H., Yoo J.H., Jeong B.C., Jeon S.S., Lee H.M., Choi H.Y., Seo S.I.
Institutes: Samsung Medical Center, Dept. of Urology, Seoul, South Korea
- *405 **Comparison of 1,800 robotic and open partial nephrectomies for renal tumors**
By: Peyronnet B.¹, Vaessen C.², Grassano Y.³, Benoit T.⁴, Carrouget J.⁵, Pradère B.¹, Giwerc A.⁶, Beauval J-B.⁴, Seisen T.², Nouhaud F.⁶, Bigot P.⁵, Doumerc N.⁴, Bernhard J-C.³, Mejean A.⁷, Patard J-J.⁸, Roupret M.², Bensalah K.¹
Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²Pitié-Salpêtrière Hospital, Dept. of Urology, Paris, France, ³CHU Bordeaux, Dept. of Urology, Bordeaux, France, ⁴CHU Toulouse, Dept. of Urology, Toulouse, France, ⁵CHU Angers, Dept. of Urology, Angers, France, ⁶CHU Rouen, Dept. of Urology, Rouen, France, ⁷Georges Pompidou Hospital, Dept. of Urology, Paris, France, ⁸Kremlin-Bicetre Hospital, Dept. of Urology, Paris, France
- *406 **1:1 Exact matched comparison of robot-associated partial nephrectomy and open partial nephrectomy on postoperative renal function**
By: Yoo S.¹, Choi S.Y.¹, Jung J.¹, Hong S.², Kim H.J.², Kwon T.³, Moon K.H.³, Han J.H.¹, You D.¹, Jeong I.G.¹, Ahn T.Y.¹, Kim C-S.¹
Institutes:¹Asan Medical Center, Dept. of Urology, Seoul, South Korea, ²Dankook University College of Medicine, Dept. of Urology, Cheonan, South Korea, ³Ulsan University Hospital, Dept. of Urology, Ulsan, South Korea
- *407 **Robotic versus laparoscopic approach for retroperitoneal partial nephrectomy**
By: Gambachidze D., Cholley I., Masson-Lecomte A., Moroch J., Vordos D., Salomon L., De La Taille A.
Institutes: Henri Mondor Academic Hospital, Dept. of Urology, Creteil, France
- *408 **Robotic vs open partial nephrectomy for patients with pre-existing chronic kidney disease**
By: Hamilton Z.¹, Ristau B.², Lane B.³, Berquist S.¹, Hassan A.R.¹, Defour C.¹, Wan F.¹, Proudfoot J.¹, Tobert C.⁴, Lee H.¹, Uzzo R.², Derweesh I.¹
Institutes:¹University of California, San Diego, Dept. of Urology, San Diego, United States of America, ²Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, ³Spectrum Health, Dept. of Urology, Michigan, United States of America, ⁴Spectrum Health, Dept. of Urology, Grand Rapids, United States of America
- *409 **Preoperative predictors of renal failure after robot-assisted partial nephrectomy: Analysis of the Vattikuti Global Quality Initiative in Robotic Urologic Surgery (GQI-RUS) database**
By: Gandaglia G.¹, Zazzara M.², Abaza R.³, Adsheed J.⁴, Ahlawat R.⁵, Buffi N.M.⁶, Challacombe B.⁷, Dasgupta P.⁷, Moon D.A.⁸, Parekh D.J.⁹, Porpiglia F.¹⁰, Rawal S.¹¹, Novara G.², Rogers C.¹², Bhandari

M.^{1,2}, Mottrie A.²

Institutes:¹Irccs Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, ²OLV Vattikuti Robotic Surgery Institute, Dept. of Urology, Melle, Belgium, ³Ohio Health Dublin Methodist Hospital, Dept. of Urology, Dublin, United States of America, ⁴Hertfordshire and South Bedfordshire Urological Cancer Centre, Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, ⁵Medanta Kidney and Urology Institute, Dept. of Urology and Renal Transplantation, Medanta, India, ⁶Humanitas Clinical and Research Center, Dept. of Urology, Rozzano Milan, Italy, ⁷MRC Centre For Transplantation, King's College London, Dept. of Urology, London, United Kingdom, ⁸Peter MacCallum Cancer Centre, Dept. of Urology, Melbourne, Australia, ⁹University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Dept. of Urology, Miami, United States of America, ¹⁰San Luigi Gonzaga Hospital, University of Turin, Dept. of Urology, Orbassano, Italy, ¹¹Rajiv Gandhi Cancer Hospital, Dept. of Urology, New Delhi, India, ¹²Vattikuti Urology Institute, Henry Ford Hospital, Dept. of Urology, Detroit, United States of America

*410

Association between better renal function preservation and lower volume loss between robotic partial nephrectomy and laparoscopic partial nephrectomy: A propensity score matched analysis

By: Tachibana H., Takagi T., Iizuka J., Kondo T., Tanabe K.

Institutes: Tokyo Women's Medical University, Dept. of Urology, Tokyo, Japan

*411

Predictive factors of TRIFECTA accomplishment during robotic partial nephrectomy: Results of a retrospective multi-institutional study

By: Benoit T., Peyronnet B., Roumiguié M., Doumerc N., Soulie M., Rischmann P., Roupret M., Vaessen C., Bensalah K., Beauval J.B.

Institutes: Chu Rangueil Toulouse, Dept. of Urology, Toulouse, France

*412

Outcomes of robot-assisted partial nephrectomy in patients with complex renal tumours and pre-existing chronic kidney disease in a multi-institutional, multinational database

By: Dalela D.¹, Barod R.¹, Gandaglia G.², Abaza R.³, Adshead J.⁴, Ahlawat R.⁵, Buffi N.⁶, Challacombe B.⁷, Dasgupta P.⁷, Moon D.⁸, Parekh D.⁹, Porpiglia F.¹⁰, Rawal S.¹¹, Novara G.², Bhandari M.¹, Rogers C.¹, Mottrie A.²

Institutes:¹Henry Ford Hospital/health System, Dept. of Urology, Detroit, United States of America, ²OLV Vattikuti Robotic Surgery Institute, Dept. of Urology, Melle, Belgium, ³Ohio Health Dublin Methodist Hospital, Dept. of Urology, Dublin, United States of America, ⁴Lister Hospital, Hertfordshire and South Bedfordshire Urological Cancer Centre, Stevenage, United Kingdom, ⁵Medanta - The Medicity, Dept. of Urology and Renal Transplantation, Gurgaon, India, ⁶Humanitas Clinical and Research Center, Dept. of Urology, Rozzano Milan, Italy, ⁷King's College London, MRC Centre For Transplantation, London, United Kingdom, ⁸Peter MacCallum Cancer Centre, Dept. of Urology, Melbourne, Australia, ⁹University of Miami, Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, United States of America, ¹⁰University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy, ¹¹Rajiv Gandhi Cancer Center, Dept. of Urology, New Delhi, India

*413

Results of robot-assisted partial nephrectomy (RPN) – trifecta analysis of 145 consecutive patients

By: Zimmermanns V., Paramythelli I., Lahme S.

Institutes: Siloah St. Trudpert Hospital, Dept. of Urology, Pforzheim, Germany

*414

Short- and mid-term impact of RAPN on renal function as assessed by renal scan

By: Luciani L.G.¹, Chiodini S.¹, Vattovani V.¹, Tiscione D.¹, Cai T.¹, Giusti G.², Malossini G.¹

Institutes:¹Santa Chiara Hospital, Dept. of Urology, Trento, Italy, ²Humanitas Research Hospital, Dept. of Urology, Milan, Italy

*415

Endoscopic robot-assisted simple enucleation (ERASE) vs open simple enucleation (OSE) for the treatment of clinical T1 renal masses: Analysis of predictors of trifecta outcome

By: Mari A., Bonifazi M., Campi R., Sessa F., Chini T., Siena G., Tuccio A., Masieri L., Vignolini G., Gacci M., Lapini A., Serni S., Carini M., Minervini A.

Institutes: Careggi University Hospital, Dept. of Urology, Florence, Italy

- *416 **Comparative study of optimal outcomes on robot-assisted partial nephrectomy for T1a and T1b renal masses: Propensity score matched study**
By: Kim D.K.², Alabdulaali I.², Sheikh A.², Alatawi A.², Yoon Y.E.², Koo K.C.², Han W.K.², Abdel Raheem A.¹, Rha K.H.²
Institutes:¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Yonsei University College of Medicine, Dept. of Urology and Urological Science Institute, Seoul, South Korea
- *417 **Robot-assisted partial nephrectomy in tumors ≤ pT1b – a feasibility study according to the MIC system**
By: Harke N.N.¹, Godes M.¹, Wagner C.¹, Trabs G.², Schiefelbein F.², Schoen G.², Witt J.¹
Institutes:¹St. Antonius-Hospital Gronau GmbH, Dept. of Urology, Pediatric Urology and Urologic Oncology, Gronau, Germany, ²Missionsaerztliche Klinik Wuerzburg, Dept. of Urology, Würzburg, Germany

Bladder pain syndrome: Evolving strategies

Poster Session 34

Sunday, 13 March
12:15 - 13:45

Location: Room 14a (ICM, Level 1)

Chairs: P. Dinis Oliveira, Porto (PT)
D.S. Engeler, St. Gallen (CH)
H-C. Kuo, Hualien (TW)

Aims and objectives of this presentation

New and old treatment options

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *418 **Immunotherapy to treat bladder painful syndrome**
By: Augé C.², Lluet P.², Vergnolle N.¹, Dietrich G.¹
Institutes:¹Purpan Hospital, Inserm Umr1043, Toulouse, France, ²UROsphere, Dept. of Pharmacology, Toulouse, France
- *419 **Toll like receptor 7 is overexpressed in the bladder mucosa of Hunner type interstitial cystitis and its activation in the mouse bladder induces cystitis and pain**
By: Ichihara K.¹, Aizawa N.¹, Sugiyama R.¹, Ito H.¹, Kamei J.¹, Akiyama Y.¹, Masumori N.², Andersson K-E.⁴, Homma Y.³, Igawa Y.¹
Institutes:¹The University of Tokyo Graduate School of Medicine, Dept. of Continence Medicine, Tokyo, Japan, ²Sapporo Medical University School of Medicine, Dept. of Urology, Sapporo, Japan, ³The University of Tokyo Graduate School of Medicine, Dept. of Urology, Tokyo, Japan, ⁴Aarhus University, Aarhus Institute of Advanced Studies, Aarhus, Denmark
- *420 **Development and validation of a clinically-relevant chronic model of interstitial cystitis/bladder painful syndrome**
By: Chabot S.¹, Augé C.¹, Meen M.¹, Guilloteau V.¹, Vergnolle N.², Gamé X.³, Lluet P.¹
Institutes:¹Urosphere, Dept. of Urology, Toulouse, France, ²INSERM UMR1043, Purpan University Hospital, Toulouse, France, ³INSERM I2MC-U1048, Rangueil University Hospital, Dept. of Urology, Toulouse, France
- *421 **Comparison of Cystistat®, iAluril®, and Whitmore Cocktail for treatment of patients with bladder pain syndrome/interstitial cystitis**
By: Cocci A.¹, Alowidah I.², Skews R.², Hashim H.²
Institutes:¹University of Florence, Dept. of Urology, Florence, Italy, ²Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom
- *422 **Pelvic inflammatory disease is associated with bladder pain syndrome/interstitial cystitis: A population-based case-control study**
By: Tan J-S.
Institutes:Far Eastern Memorial Hospital, Dept. of Urology, New Taipei City, Taiwan
- *423 **The effect of intravesical liposome-based NGF antisense therapy on bladder overactivity and nociception in a rat model of cystitis induced by hydrogen peroxide**
By: Majima T.¹, Tyagi P.², Dogishi K.³, Kashyap M.², Gotoh M.¹, Chancellor M.B.⁴, Yoshimura N.²
Institutes:¹Nagoya University School of Medicine, Dept. of Urology, Nagoya, Japan, ²University of Pittsburgh, Dept. of Urology, Pittsburgh, United States of America, ³University of Kyoto, Dept. of Molecular Pharmacology, Kyoto, Japan, ⁴Oakland University William Beaumont School of

Medicine, Dept. of Urology, Royal Oak, United States of America

*424 **Chronic pelvic pain syndrome is similar as features and symptoms of occlusive lesions of common and internal iliac arteries**

By: Belousov I., [Kogan M.I.](#)

Institutes:Rostov State Medical University, Dept. of Urology, Rostov on Don, Russia

*425 **Analysis of multiple urine markers for the detection of interstitial cystitis/bladder pain syndrome in patients with lower urinary tract symptoms**

By: [Furuta A.](#)¹, Yamamoto T.², Koike Y.¹, Suzuki Y.³, Gotoh M.², Egawa S.⁴, Yoshimura N.⁵

Institutes:¹Jikei University School Of Medicine, Dept. of Urology, Tokyo, Japan, ²Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan, ³Tokyo Metropolitan Rehabilitation Hospital, Dept. of Urology, Tokyo, Japan, ⁴Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ⁵University of Pittsburgh School of Medicine, Dept. of Urology, Pennsylvania, United States of America

*426 **Possible role of matrix metalloproteinase-8 in pathophysiology of interstitial cystitis/painful bladder syndrome**

By: [Piecha T.](#)¹, Poletajew S.¹, Wyczałowska-Tomasik A.², Gala K.², Burdzińska A.², Pączek L.², Radziszewski P.¹

Institutes:¹Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, ²Medical University of Warsaw, Dept. of Immunology, Transplantation and Internal Diseases, Warsaw, Poland

*427 **Plasma and urinary pharmacokinetics of the novel, oral SHIP1 activator, AQX-1125 in interstitial cystitis/bladder pain syndrome (IC/BPS): Results of the phase2 LEADERSHIP trial**

By: Nickel C.², Evans R.³, Tam P.⁴, Toews J.⁴, MacKenzie L.⁴, Biagi H.¹, [Shrewsbury S.](#)¹

Institutes:¹Aquinox Pharmaceuticals, Dept. of Clinical Development, Vancouver, Canada, ²Queen's University, Dept. of Urology, Kingston, Canada, ³Wake Forest University Health Sciences, Dept. of Urology, Winston Salem, United States of America, ⁴Aquinox Pharmaceuticals, Dept. of Technical Operations, Vancouver, Canada

*429 **5-HT in the rat prefrontal cortex controls the micturition reflex via 5-HT2A and 5-HT7**

By: [Hiroki C.](#)¹, Mitsui T.², Kitta T.¹, Ohmura Y.³, Moriya K.¹, Kanno Y.¹, Yoshioka M.³, Shinohara N.¹

Institutes:¹Hokkaido University, Dept. of Urology, Sapporo, Japan, ²Yamanashi University, Dept. of Urology, Yamanashi, Japan, ³Hokkaido University, Dept. of Neuropharmacology, Sapporo, Japan

13:30 - 13:37

Summary and context

P. Dinis Oliveira, Porto (PT)

How to manage recurrence after radical prostatectomy

Poster Session 35

Sunday, 13 March
12:15 - 13:45

Location: Room 14b (ICM, Level 1)

Chairs: A. Bossi, Villejuif (FR)
A.S. Merseburger, Lübeck (DE)
R. Sood, New Delhi (IN)

Aims and objectives of this presentation

PSA recurrence after curative treatments is a common problem. During this session we will discuss the patient profile in this situation and 2 adjuvant or salvage modalities with either radiation or PSMA radio guided surgery.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *430 **Patterns of clinical recurrence and predictors of systemic progression of prostate cancer patients with PSA persistence after radical prostatectomy**
By: Gandaglia G.¹, Fossati N.², Dell'Oglio P.², Damiano R.³, Bianchi M.³, Picozzi M.², Farina E.², Cucchiara V.², Bertini R.², Dehò F.², Montorsi F.², Briganti A.²
Institutes:¹Irccs Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ³Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy
- *431 **External validation of a model predicting survival of men with recurrent prostate cancer after radical prostatectomy**
By: Dell'Oglio P.¹, Suardi N.¹, Boorjian S.², Fossati N.¹, Gandaglia G.¹, Tian Z.³, Moschini M.¹, Capitanio U.¹, Karakiewicz P.³, Montorsi F.¹, Karnes J.², Briganti A.¹
Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³University of Montreal Health Center, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Canada
- *432 **A novel model to estimate a patient's individual risk of biochemical recurrence after radical prostatectomy**
By: Røder M.A.¹, Berg K.D.¹, Thomsen F.B.¹, Kurbegovic S.¹, Rytgaard H.C.², Gruschy L.¹, Brasso K.¹, Gerds T.A.², Iversen P.¹
Institutes:¹Rigshospitalet, University of Copenhagen, Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen, Denmark, ²University of Copenhagen, Dept. of Biostatistics, Copenhagen, Denmark
- *433 **Long-term oncological outcomes of salvage radical prostatectomy for radio-recurrent/persistent prostate cancer after radiation therapy**
By: Vilaseca Cabo A.¹, Nguyen D.¹, Tin A.², Corradi R.¹, Martin-Malburet A.¹, Sandhu J.¹, Leddy L.¹, Sjoberg D.², Eastham J.¹, Scardino P.¹, Touijer K.¹
Institutes:¹Memorial Sloan-Kettering Cancer Center, Dept. of Urology, New York, United States of America, ²Memorial Sloan-Kettering Cancer Center, Dept. of Epidemiology and Biostatistics, New York, United States of America
- *434 **Early or delayed radiotherapy in high risk prostate cancer patients treated with radical prostatectomy? Long term results of a multicenter prospective study**
By: Maurizi F.¹, Antognoni P.², Bonetta A.³, Bonetto E.M.⁴, Bortolus R.⁵, Colombo A.⁶, Frezza G.⁷, Gabriele P.⁸, Giacobazzi P.⁹, Marcenaro M.¹⁰, Mattana F.¹¹, Moro G.¹², Rocchi M.B.L.¹³, Signor M.¹⁴,

Malinverni G.¹⁵

Institutes:¹Az. Osp. Ospedali Riuniti Marche Nord, Dept. of Radiotherapy, Pesaro, Italy, ²Ospedale Di Circolo E Fondazione Macchi, Dept. of Radiotherapy, Varese, Italy, ³Istituti Ospitalieri Di Cremona, Dept. of Radiotherapy, Cremona, Italy, ⁴Azienda Ospedaliera San Gerardo, Dept. of Radiotherapy, Monza, Italy, ⁵Centro Di Riferimento Oncologico, Dept. of Radiotherapy, Pesaro, Italy, ⁶Ospedale "Alessandro Manzoni", Dept. of Radiotherapy, Lecco, Italy, ⁷Ospedale Bellaria, Dept. of Radiotherapy, Bologna, Italy, ⁸IRCCS, Dept. of Radiotherapy, Candiolo, Italy, ⁹Policlinico Di Modena, Dept. of Radiotherapy, Modena, Italy, ¹⁰Istituto Nazionale Per La Ricerca Sul Cancro, Dept. of Radiotherapy, Genova, Italy, ¹¹Policlinico Di Monza, Dept. of Radiotherapy, Monza, Italy, ¹²Ospedale Degli Infermi ASL BI, Dept. of Radiotherapy, Biella, Italy, ¹³Università Degli Studi Di Urbino Carlo Bo, Dept. of Biomolecular Science, Urbino, Italy, ¹⁴Azienda Ospedaliera Universitaria S. Maria Della Misericordia, Dept. of Radiotherapy, Udine, Italy, ¹⁵Az. Osped. "Ordine Mauriziano", Dept. of Radiotherapy, Turin, Italy

*435

Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk

By: Ross A.¹, Den R.², Yousefi K.³, Trock B.¹, Davicioni E.⁴, Tosoian J.¹, Thompson D.⁵, Choerung V.³, Haddad Z.³, Tran P.⁶, Trabulsi E.⁷, Gomella L.⁸, Lallas C.⁸, Abdollah F.⁹, Feng F.¹⁰, Dicker A.², Freedland S.¹¹, Karnes J.¹², Schaeffer E.¹

Institutes:¹Johns Hopkins Hospital, James Buchanan Brady Urological Institute, Baltimore, United States of America, ²Sidney Kimmel Medical College at Thomas Jefferson University, Dept. of Radiation Oncology, Philadelphia, United States of America, ³GenomeDx Biosciences, Dept. of Biostatistics, Vancouver, Canada, ⁴GenomeDx Biosciences, Dept. of Research and Development, Vancouver, Canada, ⁵Emmes Canada, Dept. of Biostatistics, Burnaby, Canada, ⁶Johns Hopkins Hospital, Dept. of Radiation Oncology, Baltimore, United States of America, ⁷Sidney Kimmel Medical College at Thomas Jefferson University, Dept. of Urology, Epidemiology, Oncology, Environmental Health, Philadelphia, United States of America, ⁸Sidney Kimmel Medical College at Thomas Jefferson University, Dept. of Urology, Philadelphia, United States of America, ⁹Henry Ford Hospital, Dept. of Vattikuti Urology Institute, Detroit, United States of America, ¹⁰University of Michigan, Dept. of Radiation Oncology, Ann Arbor, United States of America, ¹¹Cedars-Sinai Medical Center, Dept. of Surgery, Division of Urology, Los Angeles, United States of America, ¹²Mayo Clinic, Dept. of Urology, Rochester, United States of America

*436

The time elapsed between radical prostatectomy and postoperative radiotherapy has a significant impact on the subsequent recovery of erectile function

By: Gandaglia G.¹, Fossati N.², Bianchi M.³, Picozzi M.², Farina E.², Cucchiara V.², Larcher A.², Karakiewicz P.⁴, Mirone V.⁵, Cozzarini C.⁶, Montorsi F.², Briganti A.²

Institutes:¹Irccs Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ³Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, ⁴University of Montreal Health Center, Dept. of Urology, Montreal, Canada, ⁵University Federico II, Dept. of Urology, Naples, Italy, ⁶IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy

*437

Detrimental role of pre-prostatectomy neoadjuvant androgen deprivation in node-negative patients treated with adjuvant RT

By: Cozzarini C.¹, Noris Chiorda B.¹, Deantoni C.¹, Briganti A.², Fiorino C.³, Gandaglia G.², Fossati N.², Freschi M.⁴, Sini C.³, Montironi R.⁵, Montorsi F.², Di Muzio N.¹

Institutes:¹San Raffaele Scientific Institute, Department of Radiotherapy, Milan, Italy, ²San Raffaele Scientific Institute, Department of Urology, Milan, Italy, ³San Raffaele Scientific Institute, Department of Medical Physics, Milan, Italy, ⁴San Raffaele Scientific Institute, Department of Pathology, Milan, Italy, ⁵Polytechnic University of The Marche Region, School of Medicine, AOU Ospedali Riuniti, Department of Pathology, Ancona, Italy

*438

PSMA-radioguided surgery for recurrent prostate cancer – mid-term follow-up and novel developments

By: Maurer T.¹, Eiber M.³, Wirtz M.², Robu S.², Schottelius M.², Rauscher I.³, Schwaiger M.³, Gschwend J.¹, Wester H.-J.²

Institutes:¹Technical University of Munich, Dept. of Urology, Munich, Germany, ²Technical University of Munich, Dept. of Pharmaceutical Radiochemistry, Munich, Germany, ³Technical

University of Munich, Dept. of Nuclear Medicine, Munich, Germany

- *439 **When is tumour volume an exclusion criteria for focal therapy? Results from a radical prostatectomy series**
By: Fossati N., Gandaglia G., Suardi N., Capitanio U., Zaffuto E., Cucchiara V., Larcher A., Stabile A., Farina E., Salonia A., Montorsi F., Briganti A.
Institutes: IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy
- *440 **Expression of steroid hormone receptors in residual cancer and stromal cells after neoadjuvant chemohormonal therapy with docetaxal for high-risk localized prostate cancer**
By: Narita N.¹, Nara T.¹, Huang M.¹, Numakura K.¹, Tsuruta H.¹, Maeno A.¹, Saito M.¹, Inoue T.¹, Nanjo H.³, Satoh S.², Habuchi T.¹
Institutes:¹Akita University School of Medicine, Dept. of Urology, Akita, Japan, ²Akita University Hospital, Enter For Kidney Disease and Transplantation, Akita, Japan, ³Akita University Hospital, Dept. of Pathology, Akita, Japan
- *441 **Neutrophil-to-lymphocyte ratio is associated with survival after radical prostatectomy in prostate cancer**
By: Jang W.S.¹, Kang Y.J.¹, Han J.H.¹, Lee J.Y.¹, Cho K.S.¹, Ham W.S.¹, Oh C.K.⁴, Kim Y.S.², Lee J.S.³, Cho I.R.⁴, Choi Y.D.¹
Institutes:¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²National Health Insurance Corporation Ilsan Hospital, Dept. of Urology, Goyang, South Korea, ³Cheil General Hospital & Women's Healthcare Center, Dept. of Urology, Seoul, South Korea, ⁴Inje University College of Medicine, Dept. of Urology, Gimhae, South Korea
- 13:32 - 13:39 **Summary and context**
A.S. Merseburger, Lübeck (DE)

Evaluation in radical prostatectomy

Poster Session 36

Sunday, 13 March
12:15 - 13:45

Location: Room 14c (ICM, Level 1)

Chairs: C.G. Eden, Odiham (GB)
G. Janetschek, Salzburg (AT)
H.G. Van Der Poel

Aims and objectives of this presentation

Several urological teams will present their radical prostatectomy results in terms of positive margins, erectile function and continence rates but will also compare their surgical techniques such as retropubic space-sparing approach and importance of neurovascular bundle thickness.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*442

Four-year outcome of a prospective randomised trial comparing laparoscopic versus robot-assisted radical prostatectomy

By: Fiori C.¹, Morra I.¹, Manfredi M.², Mele F.², Bertolo R.², Cattaneo G.², Poggio M.², Ragni F.², Amparore D.², De Cillis S.², Checcucci E.², De Luca S.², Porpiglia F.²

Institutes:¹San Luigi Hospital, Dept. of Urology, University of Turin, Orbassano, Italy, ²San Luigi Hospital, Dept. of Urology, University of Turin, Orbassano, Italy

*443

Minimally invasive vs open radical prostatectomy: An analysis of 30-day postoperative complications, unplanned readmissions, and mortality

By: Meyer C.¹, Sood A.², Abdollah F.², Sammon J.², Vetterlein M.¹, Lööpberg B.¹, Hanske J.¹, Leow J.¹, Cole A.¹, Sun M.¹, Menon M.², Trinh Q-D.¹

Institutes:¹Brigham and Women's Hospital, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America, ²Henry Ford Hospital / Health System, Vattikuti Institute of Urology, Center for Outcomes Research, Analytics and Evaluation, Detroit, United States of America

*444

Variation between experienced surgeons in oncological and functional outcome after prostatectomy. A comparison between open and robotic surgeons in the Swedish LAPPRO study

By: Nyberg M.², Carlsson S.³, Wilderäng U.⁴, Vickers A.⁵, Stranne J.¹, Steineck G.⁶, Wiklund P.⁷, Haglund E.⁸, Bjartell A.², Hugosson J.¹

Institutes:¹Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Dept. of Urology, Gothenburg, Sweden, ²Skåne University Hospital, Lund University, Dept. of Urology, Malmö, Sweden, ³Sahlgrenska Academy at University of Gothenburg/Memorial Sloan-Kettering Cancer Center, New York, Dept. of Urology, Gothenburg, Sweden, ⁴Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Division of Clinical Cancer Epidemiology, Department of Oncology, Gothenburg, Sweden, ⁵Memorial Sloan-Kettering Cancer Center, Dept. of Epidemiology and Biostatistics, New York, United States of America, ⁶Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Division of Clinical Cancer Epidemiology, Department of Oncology/Department of Oncology and Pathology, Gothenburg, Sweden, ⁷Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Section of Urology, Stockholm, Sweden, ⁸Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Dept. of Surgery, Gothenburg, Sweden

*445

Time to catheter removal after radical prostatectomy has no adverse effect on intermediate- and long-term continence rates

By: Preisser E., Tilki D., Graefen M., Huland H., Chun F.K.
Institutes:University Hospital Hamburg-Eppendorf, Martini-Clinic Prostate Cancer Center, Hamburg, Germany

*446 **Positive surgical margins after nerve sparing during robot-assisted radical prostatectomy (RARP) in intermediate and high-risk prostate cancer**

By: Godes M., Harke N., Addali M., Schütte A., Wagner C., Witt J.
Institutes:St. Antonius-Hospital Gronau GmbH, Dept. of Urology and Pediatric Urology, Gronau, Germany

*447 **Late recovery of erectile function in men treated with robotic-assisted laparoscopic radical prostatectomy (RALP): A novel nomogram development and validation**

By: Abdollah F.F.H.¹, Dalela D.¹, Sammon J.¹, Sood A.¹, Fossati N.², Gandaglia G.², Suardi N.², Gaboardi F.², Pini G.², Jeong W.¹, Rogers C.¹, Peabody J.¹, Montorsi F.², Briganti A.², Menon M.¹
Institutes:¹Henry Ford Hospital / Health System, Dept. of Urology, Detroit, United States of America, ²Vita Salute San Raffaele University, Dept. of Urology, Milan, Italy

*448 **Is a well-performed robot-assisted radical prostatectomy the real focal therapy for the treatment of clinically localized prostate cancer?**

By: Gandaglia G.¹, Fossati N.², Gallina A.², Di Trapani E.³, Dehò F.², Mottrie A.⁵, Larcher A.², Bianchi M.⁴, Picozzi M.², Farina E.², Gaboardi F.², Montorsi F.², Briganti A.²
Institutes:¹Irccs Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy, ³Diaconesses-Croix Saint Simon Hospital, Dept. of Urology, Paris, France, ⁴Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, ⁵OLV Vattikuti Robotic Surgery Institute, ORSI, Melle, Belgium

*449 **Extended vs limited pelvic lymph node dissection during bilateral nerve-sparing radical prostatectomy and its effect on continence and erectile function recovery: Long-term results and trifecta rates of a comparative analysis**

By: Hatzichristodoulou G.¹, Wagenpfeil S.², Wagenpfeil G.³, Gschwend J.¹, Kübler H.¹
Institutes:¹Technical University of Munich, University Hospital Klinikum Rechts Der Isar, Dept. of Urology, Munich, Germany, ²Saarland University Hospital, Institute For Medical Biometry and Dept. of Epidemiology and Medical Informatics, Homburg, Germany, ³Saarland University Hospital, Institute For Medical Biometry and Dept. of Epidemiology and Medical Informatics, Homburg, Germany

*450 **Comparative peri-operative, oncologic and continence study after 300 cases of Retzius-sparing robot-assisted radical prostatectomy**

By: Kim D.K.², Alabdulaali I.², Alatawi A.², Sheikh A.², Abdel Raheem A.¹, Choi Y.D.², Rha K.H.²
Institutes:¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Yonsei University College of Medicine, Dept. of Urology and Urological Science Institute, Seoul, South Korea

*451 **Relationship between immediate continence and early potency recovery after PERUSIA radical prostatectomy**

By: Boni A.¹, Cochetti G.¹, Lepri E.¹, Lepri L.¹, D'Amico F.E.², Mearini E.¹
Institutes:¹University of Perugia, Dept. of Surgical and Biomedical Sciences, Division of Urologic, Andrologic Surgery and Minimally Invasive Techniques, Perugia, Italy, ²University of Perugia, Dept. of Surgical and Biomedical Sciences, Division of Urologic, Andrologic Surgery and Minimally Invasive Techniques, Terni, Italy

*452 **Impact of thickness of spared neurovascular bundle on postoperative urinary and sexual outcomes after robot-assisted radical prostatectomy: An ongoing prospective study**

By: Yoo S.¹, Choi S.Y.¹, Jung J.¹, Nam W.¹, Han J.H.¹, Hong S.², Kim H.J.², Kwon T.³, Moon K.H.³, You D.¹, Jeong I.G.¹, Ahn T.Y.¹, Kim C-S.¹
Institutes:¹Asan Medical Center, Dept. of Urology, Seoul, South Korea, ²Dankook University College of Medicine, Dept. of Urology, Seoul, South Korea, ³Ulsan University Hospital, Dept. of Urology, Ulsan, South Korea

*453

Posterior reconstruction of the rhabdosphincter improves early recovery of urinary continence after robot-assisted radical prostatectomy

By: Pushkar D.¹, Govorov A.¹, Rasner P.¹, Kolontarev K.¹, Rocco B.²

Institutes:¹Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia,

²Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Università Degli Studi Di Milano, Dept. of Urology, Milan, Italy

ESWL: Any news?

Poster Session 37

Sunday, 13 March
12:15 - 13:45

Location: Room Paris (Hall B2, level 0)

Chairs: A.A. Al-Zarooni, Sharjah (AE)
A. Neisius, Mainz (DE)
R.D. Smith, London (GB)

Aims and objectives of this presentation

ESWL was applied to most stones in the kidney and ureter for decades, but today improvements of endourological procedures led to a significant decrease in ESWL frequency. Since a few years, however, the interest in ESWL seems to rise again and interesting new developments are seen.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *455 **Emergency extracorporeal shockwave lithotripsy (eESWL) for acute renal colic due to ureteral stones**
By: [Umari P.](#), Bucci S., Rizzo M., Pavan N., Liguori G., Marega D., Trombetta C.
Institutes: Azienda Ospedaliero Universitaria di Trieste, Dept. of Urology, Trieste, Italy
- *456 **A retrospective comparative analysis between emergency and elective shockwave lithotripsy for acutely obstructing ureteral stones**
By: [Durner L.](#)¹, Bourdoumis A.², Dibenedetto A.³, Roberts J.³, Patel A.³
Institutes:¹Harnsteinzentrum München, Fachkliniken München AG, Planegg, Germany, ²Torbay Hospital, Dept. of Urology, Torquay, United Kingdom, ³Royal London Hospital, Dept. of Urology, London, United Kingdom
- *457 **Primary ESWL is an efficient and cost-effective treatment for lower pole renal stones between 10-20mm in size: A prospective large single centre study**
By: [Good D.W.](#), Chan L.H., Phipps S., Thomas B.G., Keanie J.Y., Tolley D.A., Cutress M.L.
Institutes: Western General Hospital, NHS Lothian, The Scottish Lithotripter Centre, Department of Urology, Edinburgh, United Kingdom
- *458 **Concomitant tamsulosin and silodosin treatment is not associated with a better clinical outcome or an increased stone free rate in patients treated with ESWL: A randomized-placebo controlled study**
By: [De Nunzio C.](#), Brassetti A., Bellangino M., Lombardo R., Presicce F., Voglino O., Tubaro A.
Institutes: Sant' Andrea Hospital 'La Sapienza', Dept. of Urology, Rome, Italy
- *459 **In vitro assessment of the influence of focus size on stone comminution in shock wave lithotripsy**
By: [Heers H.](#)¹, Turney B.¹, Cleveland R.²
Institutes:¹University of Oxford, Oxford Stone Group, Dept. of Urology, Nuffield Department of Surgical Sciences, Oxford, United Kingdom, ²University of Oxford, Institute of Biomedical Engineering, Department of Engineering Science, Oxford, United Kingdom
- *460 **Do stones that fail lithotripsy require treatment?**
By: [Pullar B.](#), Collie J., Shah N., Hayek S., Wiseman O.
Institutes: Addenbrookes Hospital, Dept. of Urology, Cambridge, United Kingdom
- *461 **Stone volume and stone attenuation: Significant predictors for extracorporeal shock wave lithotripsy success in ureteric stones**

By: Dukic I., Ellison J., Collin N., Timoney A., Philip J.

Institutes: North Bristol NHS Trust, Bristol Urological Institute, Bristol, United Kingdom

*462

Computed tomography-based novel prediction model for the outcome of SWL in proximal ureteral stone

By: Yoon C.Y.¹, Kong M.K.¹, Ahn H.G.¹, Kang S.G.¹, Han J.H.¹, Kang Y.J.¹, Jang W.S.¹, Lee J.S.², Kim Y.S.³, Park H.S.⁴, Cho I.R.⁵, Cheon J.⁴, Choi Y.D.¹

Institutes:¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Cheil General Hospital and Women's Healthcare Center, Dankook University, College of Medicine, Dept. of Urology, Seoul, South Korea, ³National Health Insurance Service Ilsan Hospital, Dept. of Urology, Ilsan, South Korea, ⁴Korea University, College of Medicine, Dept. of Urology, Seoul, South Korea, ⁵Korea University, College of Medicine, Dept. of Urology, Ilsan, South Korea

*463

Stone heterogeneity index defined as the standard deviation of Hounsfield units on non-contrast computed tomography is a novel predictor for shock-wave lithotripsy outcomes in ureteral calculi

By: Kang D.H.¹, Lee J.Y.¹, Chung D.Y.¹, Song Y.S.³, Kang Y.J.¹, Jung H.D.², Kwon J.K.¹, Lee S.H.¹, Choi Y.D.¹, Cho K.S.¹

Institutes:¹Yonsei University College of Medicine, Dept. of Urology, Urological Science Institute, Seoul, South Korea, ²Incheon Red Cross Hospital, Dept. of Urology, Incheon, South Korea, ³Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Dept. of Urology, Seoul, South Korea

*464

Predicting successful shockwave lithotripsy using CT texture analysis: A potential novel biomarker

By: Cui H.¹, Stevens D.¹, Ganeshan B.², Turney B.¹

Institutes:¹University of Oxford, Oxford Stone Group, Oxford, United Kingdom, ²University College London, Institute of Nuclear Medicine, London, United Kingdom

*465

Does lithotripsy increase stone recurrence? A comparative study between extracorporeal shock wave lithotripsy and non-fragmenting percutaneous nephrolithotomy

By: El-Assmy A., El Demerdash Y., Elkhamesy M., El-Nahas A., Harraz A., Elshal A., Muhamad Abdullateef M., Sheir K.

Institutes: Urology And Nephrology Center, Dept. of Urology, Mansoura, Egypt

*466

Past and present of ESWL in the era of modern endourology – a single center experience

By: Manu R.¹, Constantiniu R.², Manu M.A.², Parlitanu B.¹, Sinescu I.²

Institutes:¹Fundeni Clinical Institute, Dept. of Urology and Renal Transplantation, Bucharest, Romania, Bucharest, Romania, ²Fundeni Clinical Institute, University of Medicine and Pharmacy 'Carol Davila', Dept. of Urology and Renal Transplantation, Bucharest, Romania, Bucharest, Romania

*467

Is an increase of focal shock wave energy through an expanded number of shockwaves per session efficient and safe in extracorporeal lithotripsy? A cost-effectiveness analysis

By: Betancourt J.¹, Budía Alba A.¹, Caballer V.², López-Acón J.D.¹, Vivas-Consuelo D.², Bahílo P.¹, Trassierra-Villa M.¹, Boronat F.¹

Institutes:¹Hospital Universitari i Politènic La Fe, Dept. of Endourology and Lithotripsy, Valencia, Spain, ²Universitat Politècnica De València, Research Centre For Health Economics and Management, Valencia, Spain

*468

Comparison of extracorporeal shock wave lithotripsy versus retrograde intrarenal surgery in the management of small moderated-sized renal stones: A cost-effectiveness analysis

By: Bahílo P.¹, Caballer V.², López-Acón D.³, Budía A.³, Vivas-Consuelo D.², Trassierra M.³, Boronat F.³

Institutes:¹La Fe University and Polytechnic Hospital, Valencia, Dept. of Urology, Valencia, Spain, ²Politechnic University of Valencia, Research Centre For Health Economics and Management, Valencia, Spain, ³La Fe University and Polytechnic Hospital, Valencia, Dept. of Urology, Valencia, Spain

13:34 - 13:41

Summary and context

A. Neisius, Mainz (DE)

Paediatric urology 1

Poster Session 38

Sunday, 13 March
12:15 - 13:45

Location: Room Vienna (Hall B2, level 0)

Chairs: M. Eissa, Cairo (EG)
Y. Tanidir, Istanbul (TR)

Aims and objectives of this presentation

Paediatric urology update on the latest clinical and research aspects.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *469 **Stone disease in children: An endourological challenge**
By: Beltrami P., Bettin L., Zattoni E., Iannetti A., Guttilla A., Castagnetti M., Dal Moro F., Zattoni F.
Institutes: University of Padua, Dept. of Surgical, Oncological and Gastroenterological Sciences - Urology Clinic, Padua, Italy
- *470 **Shockwave lithotripsy vs PCNL for treatment of (1-2) cm renal stones in children with a solitary kidney: A prospective randomized study**
By: Gamal Saad W., Mmdouh A.
Institutes: Sohag University Hospital, Dept. of Urology, Sohag, Egypt
- *471 **What happens to the asymptomatic lower calyx kidney stones smaller than 10 mm in children during watchful waiting?**
By: Telli O.¹, Hamidi N.², Hacıyev P.¹, Bağcı U.², Demirbas A.³, Karakan T.³, Soygur T.¹, Burgu B.¹
Institutes:¹Ankara University, School of Medicine, Dept. of Pediatric Urology, Ankara, Turkey, ²Ankara University, School of Medicine, Dept. of Urology, Ankara, Turkey, ³Ankara Training and Research Hospital, Dept. of Urology, Ankara, Turkey
- *472 **Endoscopic therapy for pediatric stone disease – our experience in more than 100 cases**
By: Kurtz F., Schütz V., Hauner K., Gschwend J.E., Straub M.
Institutes: Rechts Der Isar, Medical Center, Technical University of Munich, Dept. of Urology, Munich, Germany
- *473 **The efficacy and safety of transurethral holmium:YAG laser cystolithotripsy in the management of urinary bladder stones in children**
By: Almail J.A.
Institutes: Kufa University, Dept. of Urology, Najaf, Iraq
- *474 **Pediatric renal cell carcinoma – descriptive analysis of prospective single-center series**
By: Riechardt S.¹, Aziz H.², Fisch M.¹
Institutes:¹University Hamburg, Dept. of Urology, Hamburg, Germany, ²Medical Practice, Dept. of Dentology, Hamburg, Germany
- *475 **Xanthogranulomatous pyelonephritis in children: A 24 case series**
By: Mseddi M.A.¹, Jallouli M.², Mejdoub B.¹, Ammar S.², Bouassida M.¹, Abid I.², Rebai N.¹, Ben Dhaw M.², Hadjslimane M.¹, Mhiri R.², Mhiri M.N.¹
Institutes:¹Chu Habib Bourguiba Sfax, Dept. of Urology, Sfax, Tunisia, ²Chu Hédi Chaker Sfax, Dept. of Pediatric Surgery, Sfax, Tunisia
- *476

Surgical management of adrenals

Poster Session 39

Sunday, 13 March
12:15 - 13:45

Location: Room London (Hall B2, level 0)

Chairs: P. Sebe, Paris (FR)
A.Z. Vinarov, Moscow (RU)

Aims and objectives of this presentation

Adrenal tumours are a heterogeneous group of rare tumours. The aim of this session is to critically review specific differences in the incidence, prognosis and symptoms of the different surgical strategies in the management of different subtypes of adrenal tumours.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *484 **Renal dysfunction manifestation in patients with adrenal Cushing's syndrome after adrenalectomy**
By: [Nakamura Y.](#)¹, Yoshida S.¹, Minami I.², Uchida Y.¹, Yokoyama M.¹, Ishioka J.¹, Matsuoka Y.¹, Numao N.¹, Saito K.¹, Yoshimoto T.², Fujii Y.¹, Ogawa Y.², Kihara K.¹
Institutes:¹Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, ²Tokyo Medical and Dental University, Dept. of Molecular Endocrinology and Metabolism, Tokyo, Japan
- *485 **Complications after adrenalectomy – does the speciality matter?**
By: Sood A.¹, Sammon J.¹, Abdollah F.¹, Klett D.¹, Dalela D.¹, [Löppenberg B.](#)², Kibel A.², Pucheril D.¹, Schmid M.², Jeong W.¹, Dabaja A.¹, Rogers C.¹, Peabody J.¹, Menon M.¹, Trinh Q.²
Institutes:¹Henry Ford Hospital / Health System, Dept. of Urology, Detroit, United States of America, ²Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America
- *486 **The implication of aortic calcification on persistent hypertension after laparoscopic adrenalectomy in patients with primary aldosteronism**
By: [Fujita N.](#), Hatakeyama S., Yamamoto H., Imai A., Yoneyama T., Hashimoto Y., Koie T., Ohyama C.
Institutes:Hirosaki University School of Medicine, Dept. of Urology, Hirosaki, Japan
- *487 **A novel laparoscopic adrenalectomy via transumbilical approach: Focus on technique**
By: [Zou X.](#), Zhang G., Xu H., Yuan Y., Xiao R., Wu G.
Institutes:First Affiliated Hospital of Gannan Medical University, Dept. of Urology, Ganzhou, China
- *489 **Impact of primary histology on oncologic outcomes after minimally invasive adrenalectomy for metastatic cancer**
By: [Ferriero M.C.](#), Simone G., Papalia R., Mastroianni R., Guaglianone S., Gallucci M.
Institutes:"Regina Elena" National Cancer Institute, Dept. of Urology, Rome, Italy
- *490 **Laparoscopic adrenalectomy: Can single-port replace conventional laparoscopy?**
By: [Sousa Dinis P.J.](#), Figueiredo A., Nunes P., Freire M.J., Lourenço M., Castelo D., Parada B., Mota A.
Institutes:Hospitais da Universidade de Coimbra, Dept. of Urology and Renal transplant, Coimbra, Portugal
- *491 **Oncological outcomes of radical nephroureterectomy with and without synchronous ipsilateral adrenalectomy**

By: Peyronnet B., Alimi Q., Verhoest G., Mathieu R., Vincendeau S., Guillé F., Rioux-Leclercq N., Bensalah K., Manunta A.
Institutes: CHU Rennes, Dept. of Urology, Rennes, France

*492 **Predictive ability of preoperative CT scan in determining whether the adrenal gland is spared at radical nephrectomy**

By: Nason G., Aslam A., Giri S.
Institutes: University Hospital Limerick, Dept. of Urology, Limerick, Ireland

*493 **Longitudinal evaluation of patient-reported cosmesis outcome following laparoscopic adrenalectomy: Laparoendoscopic single-site adrenalectomy vs conventional laparoscopic adrenalectomy**

By: Inoue S., Hayashi T., Fujii S., Kobatake K., Kitano H., Hieda K., Shinmei S., Nagamatsu H., Shoji K., Teishima J., Matsubara A.
Institutes: Hiroshima University, Dept. of Urology, Hiroshima, Japan

*494 **Heat shock protein 90 interactome is highly altered in adrenocortical carcinoma**

By: Prince T.², Williams H.¹
Institutes:¹Geisinger Medical Center, Dept. of Urology, Danville, United States of America, ²National Cancer Institute, Dept. of Urologic Oncology, Bethesda, United States of America

*495 **Incidental adrenal nodules: Do our results support the guidelines?**

By: Sousa Dinis P.J.¹, Nunes P.², Figueiredo A.², Freire M.J.², Lourenço M.², Parada B.², Mota A.²
Institutes:¹Hospitais da Universidade de Coi Dept. of Urology and Transplantation Renal mbra, Dept. of Urology and Transplantation Renal, Coimbra, Portugal, ²Hospitais da Universidade de Coimbra, Dept. of Urology and Transplantation Renal, Coimbra, Portugal

*496 **Elevation of urinary metanephrine/normetanephrine and impairment of glucose tolerance predict the development of hypoglycemia after resection of pheochromocytoma**

By: Waseda Y.¹, Moriyama S.¹, Nakayama T.¹, Tanaka H.¹, Inoue M.¹, Ito M.¹, Komai Y.², Yoshida S.¹, Kawamura N.¹, Yokoyama M.¹, Ishioka J.¹, Matsuoka Y.¹, Numao N.¹, Saito K.¹, Fujii Y.¹, Kihara K.¹
Institutes:¹Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, ²National Cancer Center Hospital East, Dept. of Urology, Chiba, Japan

ESU/ESUT Hands-on training in GreenLight Laser Vaporisation

HOT 22

Sunday, 13 March
12:30 - 14:00

Location: Room North America (Hall B0, level 0)

Chair: J.A. Thomas, Bridgend (GB)

Aims and objectives of this presentation

The European School of Urology (ESU) and the European Section of Uro-Technology (ESUT) offer an intensive hands-on training course with different models focussing on the endoscopic management of LUTS. The delegates will be taken through a sequential programme of GreenLight-laservaporisation using virtual reality models. A video demonstrating the different steps and tasks of the procedures will be presented and afterwards the delegates will be instructed according to their level of experience in small teams at the models. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

U. Witzsch, Bad Soden am Taunus (DE)
S. Shariat, Vienna (AT)
A. Tubaro, Rome (IT)
J.H. Roelink, Almelo (NL)
F. D'Ancona, Nijmegen (NL)

ESU/ESUT Hands-on training in Basic laparoscopic skills

HOT 66

Sunday, 13 March
12:30 - 14:00

Location: Room South America (Hall B0, level 0)

Chair: D. Veneziano, Minneapolis (US)

Aims and objectives of this presentation

In this course basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme.

Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporeal suturing.

This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- G. Pini, Cologno Monzese (MI) (IT)
- A. Sempere Gutierrez, Murcia (ES)
- A. Papatsoris, Athens (GR)
- T. Tokas, Hall In Tirol (AT)
- T. Kalogeropoulos, Athens (GR)

ESU Social Media Training

HOT 44

Sunday, 13 March
13:00 - 13:45

Location: Room 0.305

Chair: C.J. Wijburg, Arnhem (NL)

Aims and objectives of this presentation

- EAU Congress Attendees will be instructed on how to harness professional Social Media to augment experience of professional meetings, follow urologic news feeds, and engage with the world-wide urologic community.
- Urologists who are expert in the use of Social Media will provide 45 minute small group hands-on workshops on the use of professional Social Media.
- Current Social Media users will have the opportunity to exchange expertise with other Social Media users during small group sessions.

I.M. Van Oort, Nijmegen (NL)

ESU/ERUS Hands-on training in Robotic surgery

HOT 18

Sunday, 13 March
13:30 - 15:00

Location: Room Asia (Hall B0, level 0)

Chair: A.E. Canda, Ankara (TR)

Aims and objectives of this presentation

The European School of Urology (ESU) and the EAU Robotic Urology Section (ERUS) offer an intensive hands-on training course. We will provide training using simulators. The main aims of this 90 minutes course are: improving the participants' control-skills and hand-eye-coordination, as well as an objective benchmarking of console performance and an introduction into standardized surgical steps in robot-assisted procedures.

To be confirmed
H. Zecha, Stuttgart (DE)

ESU/ESUT/EULIS Hands-on training in Ureterorenoscopy

HOT 57

Sunday, 13 March
13:45 - 15:15

Location: Room Europe (Hall B0, level 0)

Chair: To be confirmed

Aims and objectives of this presentation

Ureteroscopy is an essential tool in the management of stone disease for all Endourologists. This course will provide hands-on-training with tutor guided practical tips and tricks of doing ureteroscopy. Participants will get a chance to perform Semirigid and Flexible ureteroscopy in the models with a chance to navigate the pelvicalyceal system, stone manipulation and extraction.

Aims and objectives

- At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models
- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.

B. Geavlete, Bucharest (RO)

A. Ploumidis, Athens (GR)

N. Macchione, Milan (IT)

S. Proietti, Perugia (IT)

S.A. Ahyai, Göttingen (DE)

Urothelial tumours and awards

Video Session 06

Sunday, 13 March
14:00 - 15:30

Location: eURO Auditorium (Hall C1, Level 0)

Chairs: F. Gaboardi, Milan (IT)
A. Messas, Paris (FR)

Aims and objectives of this presentation

The videos of the session propose new approaches in the treatment of upper urinary tract tumours or bladder tumours and new technical details in robotic-assisted partial nephrectomy and renal transplantation.

All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.

- *V41 **Confocal laser endomicroscopy in the management of endoscopically treated upper urinary tract urothelial cell carcinoma (UTUC): Preliminary data**
By: Villa L.¹, Cloutier J.², Coté J-F.³, Salonia A.⁴, Montorsi F.⁴, Traxer O.²
Institutes:¹Tenon Hospital, Pierre and Marie Curie University, Paris, France; Division of Experimental Oncology/, Dept. of Urology, Milan, Italy, ²Tenon Hospital, Pierre and Marie Curie University, Dept. of Urology, Paris, France, ³Tenon Hospital, Pierre and Marie Curie University, Dept. of Pathology, Paris, France, ⁴Division of Experimental Oncology/unit of Urology; Uri; Irccs Ospedale San Raffaele; Università Vita, Dept. of Urology, Milan, Italy
- *V42 **Conservative treatment of the upper urinary tract carcinoma**
By: Laso I.M., Orosa-Andrada A., Duque-Ruiz G., Donis-Canet F., Fabuel-Alcañiz J.J., Ruiz-Hernandez M., Arias-Fúnez F., Gomez-Dos-Santos V., Burgos-Revilla F.J.
Institutes:Ramón Y Cajal University Hospital. Alcalá University., Dept. of Urology, Madrid, Spain
- *V43 **En bloc thulium laser resection of bladder tumours: Indications, surgical tips, and 3-yr oncologic outcomes**
By: Simone G.¹, Giacobbe A.², Papalia R.³, Collura D.², Rosso R.², D'Urso L.², Castelli E.², Muto G.L.³, Gallucci M.¹, Muto G.³
Institutes:¹Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²San Giovanni Bosco Hospital, Dept. of Urology, Turin, Italy, ³Campus Biomedico University of Rome, Dept. of Urology, Rome, Italy
- *V44 **En bloc holmium laser resection of UTUC by percutaneous approach**
By: Angeri Feu O., Salas D., Lopez J.M., Palou J., Villavicencio H.
Institutes:Universitat Autònoma de Barcelona - Fundació Puigvert, Dept. of Urology, Barcelona, Spain
- *V45 **Benefit of the superselective clamping technique for multiple robot assisted tumorectomies**
By: Vuong N-S., Michiels C., Grassano Y., Cornelis F., Tran P., Siméon H., Pierquet G., Yacoub M., Pasticier G., Robert G., Bensadoun H., Grenier N., Ferrière J-M., Bernhard J-C.
Institutes:University Hospital of Bordeaux, Dept. of Urology and Kidney Transplant, Bordeaux, France
- *V46 **Prospective evaluation of the Surface-Intermediate-Base (SIB) margin score for standardized reporting of resection technique during robot-assisted partial nephrectomy (RAPN) in a high-volume center: A step-by-step tutorial**
By: Minervini A.¹, Campi R.¹, Mari A.¹, Sessa F.¹, Martini A.¹, Smaldone M.C.², Serni S.¹, Uzzo R.², Carini M.¹, Kutikov A.²
Institutes:¹University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, ²Fox Chase

Cancer Center, Dept. of Urologic Oncology, Philadelphia, United States of America

*V47

A new surgical area opened in renal transplantation: A pure robot-assisted approach for both living donor nephrectomy and kidney transplantation using transvaginal route

By: Doumerc N.¹, Beauval J.B.², Roumigué M.², Game X.², Kamar N.³, Sallusto F.², Soulié M.², Rischmann P.²

Institutes:¹CHU Rangueil, Dept. of Urology, Toulouse, France, ²CHU Rangueil, Dept. of Urology, Andrology and Renal Transplantation, Toulouse, France, ³CHU Rangueil, Dept. of Nephrology and Renal Transplantation and Andrology, Toulouse, France

Prostate MRI: When do we really need it?

Poster Session 40

Sunday, 13 March
14:00 - 15:30

Location: Room Madrid (Hall B2, level 0)

Chairs: C.L. Dickinson, London (GB)
M. Emberton, London (GB)
B.A. Hadaschik, Heidelberg (DE)

Aims and objectives of this presentation

Prostate MRI is gaining more importance in diagnosis of prostate cancer but the exact indication is still unclear. This session will highlight new data on the indication for an MRI before the first and second biopsy and in active surveillance patients.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*497

Blinded comparison of MRI targeted TRUS guided prostate biopsy and TRUS guided biopsy in the 5th screening round of the European Randomized study of Screening for Prostate Cancer Rotterdam

By: [Alberts A.](#)¹, Roobol M.¹, Bokhorst L.¹, Drost F-J.², Van Leenders G.³, Dwarkasing R.², Barentsz J.⁴, Schröder F.¹, Bangma C.¹, Schoots I.²

Institutes:¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, ³Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ⁴Radboudumc, Dept. of Radiology, Nijmegen, The Netherlands

*498

The UCL PICTURE trial: A prospective cohort validating study evaluating the accuracy of multi-parametric MRI and prostate HistoScanning compared to transperineal template mapping biopsies in patients requiring risk stratification after prior transrectal prostate biopsy

By: Simmons L.¹, [Kanthabalan A.](#)¹, Hu Y.², Barrat D.², Punwani S.³, Ramachandran N.³, Jameson C.⁴, Freeman A.⁴, McCartan N.¹, Briggs T.⁵, Gelister J.⁵, Charman S.⁶, Van Der Muelen J.⁶, Moore C.¹, Ahmed H.¹, Emberton M.¹

Institutes:¹University College Hospitals London, Dept. of Surgery and Interventional Science, London, United Kingdom, ²University College London, Centre For Medical Imaging and Computing, London, United Kingdom, ³University College Hospitals London, Dept. of Radiology, London, United Kingdom, ⁴University College Hospital London, Dept. of Pathology, London, United Kingdom, ⁵Barnet Hospital, The Royal Free London NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁶London School of Hygiene and Tropical Medicine, Dept. of Health Services Research and Policy, London, United Kingdom

*499

A prospective randomized study comparing standard prostate biopsy and a new diagnostic path with MRI and fusion biopsy: Preliminary results

By: [Porpiglia F.](#)¹, Mele F.¹, Manfredi M.¹, Aimar R.¹, Checcucci E.¹, Cossu M.¹, Bollito E.², Russo F.³, Gned D.⁴, De Pascale A.⁴, Cirillo S.⁵, Fiori C.¹

Institutes:¹San Luigi Gonzaga Hospital, Dept. of Urology, University of Turin, Orbassano, Turin, Italy, ²San Luigi Gonzaga Hospital, Dept. of Pathology, University of Turin, Orbassano, Turin, Italy, ³Candiolo Cancer Institute, Division of Radiology, Candiolo, Turin, Italy, ⁴San Luigi Gonzaga Hospital, Division of Radiology, University of Turin, Orbassano, Turin, Italy, ⁵Mauriziano Hospital, Division of Radiology, Turin, Italy

*500

Multiparametric magnetic resonance imaging and MRI/TRUS-fusion-biopsy for index tumor detection: Correlation with radical prostatectomy specimen

By: [Radtke J.P.](#)¹, Schwab C.¹, Wolf M.², Freitag M.², Alt C.³, Kesch C.¹, Popeneciu I.V.¹, Huettnerbrink

C.¹, Gasch C.¹, Klein T.¹, Duensing S.⁴, Roth W.⁵, Schueler S.⁶, Stock C.⁶, Schlemmer H-P.², Roethke M.C.², Hohenfellner M.¹, Hadaschik B.¹

Institutes:¹University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ²German Cancer Research Center, Dept. of Radiology, Heidelberg, Germany, ³Heinrich-Heine University Düsseldorf, Dept. of Radiology, Düsseldorf, Germany, ⁴University Hospital Heidelberg, Dept. of Urology, Section of Molecular Urooncology, Heidelberg, Germany, ⁵University of Heidelberg, Dept. of Pathology, Heidelberg, Germany, ⁶University of Heidelberg, Dept. of Medical Biometry and Informatics, Heidelberg, Germany

*501

Is a negative mpMRI really able to rule out significant prostate cancer?

By: Branger N.¹, Maubon T.¹, Traumann M.¹, Thomassin J.², Paciona M.², Brunelle S.³, Salem N.⁴, Gravis G.⁵, Walz J.¹

Institutes:¹Institut Paoli-Calmettes, Dept. of Urology, Marseille, France, ²Institut Paoli-Calmettes, Dept. of Pathology, Marseille, France, ³Institut Paoli-Calmettes, Dept. of Radiology, Marseille, France, ⁴Institut Paoli-Calmettes, Dept. of Radiotherapy, Marseille, France, ⁵Institut Paoli-Calmettes, Dept. of Oncology, Marseille, France

*502

Multiparametric MRI and MRI-TRUS fusion-biopsy in patients with prior negative prostate biopsy

By: Kesch C.¹, Radtke J.P.¹, Roth W.², Roethke M.³, Schlemmer H.P.³, Hohenfellner M.¹, Hadaschik B.¹

Institutes:¹University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ²University Hospital Heidelberg, Dept. of Pathology, Heidelberg, Germany, ³German Cancer Research Center, Dept. of Radiology, Heidelberg, Germany

*503

Evaluation of PI-RADS classification in prediction of tumor-aggressiveness in targeted biopsy

By: Borkowetz A.¹, Platzek I.², Toma M.³, Renner T.¹, Fröhner M.¹, Koch R.⁴, Zastrow S.¹, Wirth M.¹

Institutes:¹University Hospital, TU Dresden, Dept. of Urology, Dresden, Germany, ²University Hospital, TU Dresden, Dept. of Radiology, Dresden, Germany, ³University Hospital, TU Dresden, Dept. of Pathology, Dresden, Germany, ⁴University Hospital, TU Dresden, Institute For Medical Informatics and Biometry, Dresden, Germany

*504

Poor reproducibility of PI-RADS score in 2 multiparametric MRIs before biopsy in men with elevated PSA

By: Müller S., Løfsgaard L., Estop-Garanto M., Sand T.E., Helgø D., Sund P., Mygland V.

Institutes:Akershus University Hospital, Dept. of Urology, Lørenskog, Norway

*505

Targeted PET/TRUS software fusion-guided biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy: A feasibility study and preliminary results

By: Lopci E.², Lazzeri M.¹, Lughezzani G.¹, Pasini L.¹, Hurle R.¹, Leonardi L.², Casale P.¹, Buffi N.¹, Peschechera R.¹, Rodari M.², Zandegiacomo S.¹, Benetti A.¹, Fiorini G.¹, Chiti A.³, Guazzoni G.⁴

Institutes:¹Istituto Clinico Humanitas IRCCS, Dept. of Urology, Milan, Italy, ²Istituto Clinico Humanitas IRCCS, Dept. of Nuclear Medicine, Milan, Italy, ³Istituto Clinico Humanitas IRCCS-Humanitas University, Dept. of Nuclear Medicine, Milan, Italy, ⁴Istituto Clinico Humanitas IRCCS-Humanitas University, Dept. of Urology, Milan, Italy

*506

MRI guided prostate biopsy: What is the place of PCA3 score?

By: Roumiguie M.¹, Beauval J.B.¹, Nogueira L.², Portalez D.³, Soulie M.¹, Rischmann P.¹, Malavaud B.¹

Institutes:¹CHU Rangueil, Dept. of Urology, Toulouse, France, ²CHU Purpan, Dept. of Biology, Toulouse, France, ³CHU Rangueil, Dept. of Radiology, Toulouse, France

*507

Low apparent diffusion coefficient (ADC) value is associated with biochemical recurrence in high risk prostate cancer patients

By: Park J., Yoon M.Y., Kim J.K., Kim H.S., Jeong C.W., Ku J.H., Kim H.H., Kwak C.

Institutes:Seoul National University Hospital, Dept. of Urology, Seoul, South Korea

15:13 - 15:20

Summary and context

B.A. Hadaschik, Heidelberg (DE)

Cystectomy: Optimising perioperative care

Poster Session 41

Sunday, 13 March
14:00 - 15:30

Location: Room Stockholm (Hall B2, level 0)

Chairs: J.L. Boormans, Rotterdam (NL)
O. Rodriguez Faba, Barcelona (ES)
A.R. Zlotta, Toronto (CA)

Aims and objectives of this presentation

Understand how to judge risks and how to minimise them in patients undergoing cystectomy.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

*508

The impact of cigarette smoking and smoking cessation on oncological aggressiveness at radical cystectomy – a prospective, European, multicenter study of the EAU Young Academic Urologists (YAU) bladder cancer working group

By: Gild P.¹, Schmid M.¹, Cumberbatch M.², Dobruch J.³, Gontero P.⁴, Mertens L.S.⁵, Necchi A.⁶, Noon A.², Preto M.⁴, Van Rhijn B.⁵, Roupret M.⁷, Seiler R.⁸, Seisen T.⁷, Shariat S.F.⁹, Aziz A.¹, Chun F.K.¹, Xylinas E.¹⁰, Rink M.¹

Institutes:¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²Sheffield Teaching Hospitals NHS Trust, Dept. of Urology, Sheffield, United Kingdom, ³Centre of Postgraduate Medical Education, Dept. of Urology, Warsaw, Poland, ⁴University of Turin, Dept. of Surgical Sciences, Urology Clinic, Turin, Italy, ⁵Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ⁶National Cancer Institute, Dept. of Medical Oncology, Milan, Italy, ⁷Hôpital Pitié-Salpêtrière, AP-HP, Université Paris 6, Dept. of Urology, Paris, France, ⁸University Hospital Berne, Dept. of Urology, Berne, Switzerland, ⁹Medical University Vienna, Dept. of Urology, Vienna, Austria, ¹⁰Cochin Hospital, Paris Descartes University, Dept. of Urology, Paris, France

*509

Simplified Charlson Comorbidity Index for assessment of perioperative mortality after radical cystectomy

By: Dell'Oglio P.¹, Tian Z.², Leyh-Bannurah S-R.³, Larcher A.⁴, Moschini M.⁴, Gandaglia G.⁴, Fossati N.⁴, Suardi N.⁴, Capitanio U.⁴, Briganti A.⁴, Montorsi F.⁴, Karakiewicz P.¹

Institutes:¹Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Dept. of Urology, Montreal, Canada, ²McGill University, Dept. of Epidemiology, Biostatistics and Occupational Health, Montreal, Canada, ³Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁴Ircss Ospedale San Raffaele, Division of Oncology, Unit of Urology, URI, Milan, Italy

*510

An easily applicable single condition-based mortality index for patients undergoing radical cystectomy or radical prostatectomy

By: Fröhner M.¹, Koch R.², Heberling U.¹, Novotny V.¹, Hübler M.³, Wirth M.¹

Institutes:¹Technical University Dresden, Dept. of Urology, Dresden, Germany, ²Technical University Dresden, Dept. of Medical Informatics, Dresden, Germany, ³Technical University Dresden, Dept. of Anaesthesiology, Dresden, Germany

*511

Preoperative systemic inflammation may predict severe complications after radical cystectomy

By: Ryndzin A., Rolevich A., Minich A., Zelenkevich I., Polyakov S., Krasny S., Sukonko O.

Institutes:N.N. Alexandrov National Cancer Center, Dept. of Urology, Minsk, Belarus

*512

The choice of perioperative crystalloid solution enhances recovery of gastrointestinal function after radical cystectomy: Results of a randomized clinical trial

By: Loeffel L.M.¹, Burkhard F.C.², Wüthrich P.Y.¹

Institutes:¹University Hospital Berne, Dept. of Anesthesiology and Pain Medicine, Berne, Switzerland, ²University Hospital Berne, Dept. of Urology, Berne, Switzerland

*513 **Sarcopenia as a novel preoperative prognostic predictor for survival in patients with bladder cancer undergoing radical cystectomy**

By: Hirasawa Y., Nakashima J., Tatsuo G., Shimizu Y., Tokuyama N., Shimodaira K., Nakagami Y., Horiguchi Y., Ohno Y., Namiki K., Ohori M., Tachibana M.

Institutes: Tokyo Medical University, Dept. of Urology, Tokyo, Japan

*514 **Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for non-metastatic bladder cancer: Results from a single high-volume institution**

By: Moschini M.¹, Gandaglia G.¹, Cucchiara V.¹, Burgio G.¹, Mattei A.², Shariat S.³, Cantiello F.⁴, Damiano R.⁴, Salonia A.¹, Briganti A.¹, Montorsi F.¹, Colombo R.¹, Gallina A.¹

Institutes:¹Uri, Irccs San Raffaele Scientific Institute, Dept. of Oncology and Urology, Milan, Italy, ²Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, ³Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁴Magna Graecia University of Catanzaro, Doctorate Research Program, Catanzaro, Italy

*515 **Does postoperative parenteral nutrition after radical cystectomy impact oncological and functional outcomes in bladder cancer patients?**

By: Vidal Faune A., Arnold N., Vartolomei M., Kiss B., Burkhard F.C., Thalmann G.N., Roth B.

Institutes: University Hospital Berne, Dept. of Urology, Berne, Switzerland

*516 **Hospital but not surgical volume predicts 30- and 90-day complications in radical cystectomy (RC) – results from the prospective multicenter radical cystectomy series (PROMETRICS 2011) study group**

By: Meyer C.P.¹, Leyh-Bannurah S-R.¹, Vetterlein M.W.¹, Mayr R.², Gierth M.², Fritsche H-M.², Burger M.², Keck B.³, Wullich B.³, Martini T.⁴, Bolenz C.⁴, Pycha A.⁵, Hanske J.⁶, Roghmann F.⁶, Noldus J.⁶, Gilfrich C.⁷, Bastian P.J.⁸, May M.⁷, Rink M.¹, Chun F.K.H.¹, Dahlem R.¹, Fisch M.¹, Aziz A.¹

Institutes:¹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²Caritas St. Josef Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, ³University Medical Center Erlangen, Dept. of Urology, Erlangen, Germany, ⁴University Medical Center Ulm, Dept. of Urology, Ulm, Germany, ⁵Central Hospital Bolzano, Dept. of Urology, Bolzano, Italy, ⁶Marienhospital Herne, Ruhr-University Bochum, Dept. of Urology, Herne, Germany, ⁷St. Elisabeth Medical Center Straubing, Dept. of Urology, Straubing, Germany, ⁸Paracelsus Medical Center Golzheim, Dept. of Urology, Düsseldorf, Germany

*517 **Contemporary surgical outcomes of radical cystectomy in a decentralized health system. Does volume matter?**

By: Llorente C.¹, Hernández V.¹, Pérez-Fernández E.², Elze M.C.³, López B.¹, Pocock S.³

Institutes:¹Hospital Universitario Fundación Alcorcón, Dept. of Urology, Madrid, Spain, ²Hospital Universitario Fundación Alcorcón, Dept. of Research, Madrid, Spain, ³London School of Hygiene and Tropical Medicine, Dept. of Medical Statistics, London, United Kingdom

*518 **Contemporary analysis of comorbid diseases used to define Charlson comorbidity index score among radical cystectomy candidates**

By: Dell'Oglio P.¹, Tian Z.², Leyh-Bannurah S-R.³, Larcher A.⁴, Moschini M.⁴, Trudeau V.¹, Capitanio U.⁴, Briganti A.⁴, Montorsi F.⁴, Karakiewicz P.¹

Institutes:¹Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Dept. of Urology, Montreal, Canada, ²McGill University, Dept. of Epidemiology, Biostatistics and Occupational Health, Montreal, Canada, ³Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁴Irccs Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy

*519 **The impact of a minimum cystectomy volume policy on the centralization and quality of bladder**

cancer care in the Netherlands

By: Bruins H.M.¹, Fransen Van De Putte E.², Verhoeven R.³, Van Oort I.¹, Horenblas S.²

Institutes: ¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Dept. of Urology, Nijmegen, The Netherlands, ³Comprehensive Cancer Organisation The Netherlands, Nijmegen, The Netherlands

Education, Innovation and Surgery sessions endorsed by the European School of Urology and EAU Congress Scientific Committee

Live surgery

Sunday, 13 March
14:00 - 17:00

Location: Room 1 (ICM, Level 0)

Moderators: C. Gratzke, Munich (DE)
J. Porter, Seattle (US)
S. Siemer, Homburg (DE)

1st Live 3DHD da Vinci® Xi Partial Nephrectomy Surgery with Firefly™ Fluorescence Imaging and Integrated Table Motion at EAU

To be confirmed

Live 3DHD da Vinci® Si Advanced Prostatectomy with Extended Lymphnode Dissection
A. Mottrie, Aalst (BE)

Surgical treatment of renal tumours

Poster Session 42

Sunday, 13 March
14:00 - 15:30

Location: Room Milan (Hall B2, level 0)

Chairs: A. Bex, Amsterdam (NL)
B. Peyronnet, Rennes (FR)

Aims and objectives of this presentation

To review the latest releases on patients submitted to nephrectomy for the treatment of renal tumours, including outcomes, surgical tricks and predictive factors of renal functioning after nephrectomy.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*520

Perioperative 30-day mortality rates are dependent on hospital surgical volume - results from a Norwegian population based study on surgical treatment for renal cell carcinoma

By: Hjelle K.¹, Johannesen T.², Beisland C.¹

Institutes:¹Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ²Cancer Registry of Norway, Oslo, Norway

*521

Impact of surgical volume on perioperative outcomes after nephrectomy with tumor thrombectomy

By: Linares Espinós E.¹, Martinez-Salamanca J.I.², Carballido J.², Gonzalez J.³, Capitanio U.⁴, Chantada V.⁵, Chromecki T.⁶, Ciancio G.⁷, Daneshmand S.⁸, Evans C.P.⁹, Gontero P.¹⁰, Haferkamp A.¹¹, Hohenfellner M.¹², Huang W.¹³, Koppie T.M.¹⁴, Lorentz A.¹⁵, Master V.¹⁵, McKiernan J.¹⁶, Montorsi F.⁴, O'Malley P.¹⁷, Pahernik S.¹², Palou J.¹⁸, Pontones J.L.¹⁹, Pruthi R.²⁰, Rodriguez Faba O.¹⁸, Russo P.²¹, Scherr D.S.¹⁷, Spahn M.²², Terrone C.²³, Tilki D.⁹, Vázquez-Martul, D.⁵, Vera Donoso C.¹⁹, Vergho D.²², Wallen E.²⁰, Zigeuner R.⁶, Libertino J.²⁴

Institutes:¹Hospital Universitario Infanta Sofia, Dept. of Urology, Madrid, Spain, ²Hospital Universitario Puerta De Hierro-Majadahonda, Dept. of Urology, Madrid, Spain, ³Hospital Central De La Cruz Roja San José Y Santa Adela, Dept. of Urology, Madrid, Spain, ⁴Hospital San Raffaele, University Vita-Salute, Dept. of Urology, Milan, Italy, ⁵Complejo Hospitalario Universitario A Coruña, Dept. of Urology, Coruña, Spain, ⁶Medical University of Graz, Dept. of Urology, Graz, Austria, ⁷Miami Transplant Institute, University of Miami, Dept. of Urology, Miami, United States of America, ⁸USC/Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, ⁹UC Davis Medical Center, Dept. of Urology, Sacramento, United States of America, ¹⁰A.O.U. San Giovanni Battista, University of Turin, Dept. of Urology, Turin, Italy, ¹¹University of Frankfurt, Dept. of Urology, Frankfurt, Germany, ¹²University of Heidelberg, Dept. of Urology, Heidelberg, Germany, ¹³New York University School of Medicine, Dept. of Urology, New York, United States of America, ¹⁴Oregon Health & Science University, Dept. of Urology, Portland, United States of America, ¹⁵Emory University, Dept. of Urology, Atlanta, United States of America, ¹⁶Columbia University, Dept. of Urology, New York, United States of America, ¹⁷Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, ¹⁸Fundación Puigvert, Dept. of Urology, Barcelona, Spain, ¹⁹Hospital Universitario Y Politécnico La Fe, Dept. of Urology, Valencia, Spain, ²⁰UNC At Chappel Hill, Dept. of Urology, Chappel Hill, United States of America, ²¹Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, ²²University of Würzburg, Dept. of Urology, Würzburg, Germany, ²³Maggiore Della Carita Hospital, University of Eastern Piedmont, Dept. of Urology, Novara, Italy, ²⁴Lahey Clinic, Dept. of Urology, Burlington, United States of America

*522

Temporal trends in the rate of lymph node dissection for renal cell carcinoma

By: Capitanio U.¹, Stewart G.², Klatte T.³, Volpe A.⁴, Akdogan B.⁵, Roscigno M.⁶, Langenhuijsen H.⁷, Marszalek M.⁸, Rodriguez Faba O.⁹, Salagierski M.¹⁰, Minervini A.¹¹, Brookman-May S.¹²

Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Western General Hospital, Dept. of Urology, Edinburgh, United Kingdom, ³Vienna Medical University, Dept. of Urology, Vienna, Austria, ⁴Maggiore Della Carità Hospital, Dept. of Urology, Novara, Italy, ⁵Hacettepe University, Dept. of Urology, Ankara, Turkey, ⁶Papa Giovanni XXIII Hospital, Dept. of Urology, Bergamo, Italy, ⁷Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ⁸Donauspital, Dept. of Urology, Vienna, Austria, ⁹Fundacio-Puigvert, Dept. of Urology, Barcelona, Spain, ¹⁰Kent & Canterbury Hospital, Dept. of Urology, Canterbury, United Kingdom, ¹¹Azienda Ospedaliero Universitaria Careggi, Dept. of Urology, Florence, Italy, ¹²LMU-Klinikum der Universität München, Dept. of Urology, Munich, Germany

*523

Impact of lymph node dissection at the time of radical nephrectomy and tumour thrombectomy on oncological outcomes of patients with renal cell carcinoma and tumour thrombus

By: Tilki D.², Terrone C.¹, Chandrasekar T.², Ciancio G.³, Daneshmand S.⁴, Martinez-Salamanca J.⁵, Montorsi F.⁶, Rodriguez-Faba O.⁷, Zigeuner R.⁸, Libertino J.⁹, Evans C.²

Institutes:¹Maggiore Della Carita Hospital, University of Eastern Piedmont, Division of Urology, Novara, Italy, ²University of California, Davis, School of Medicine, Dept. of Urology, Sacramento, United States of America, ³University of Miami, Miami Transplant Institute, Miami, United States of America, ⁴USC/Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, ⁵Hospital Universitario Puerta De Hierro-Majadahonda, Universidad Autónoma De Madrid, Dept. of Urology, Madrid, Spain, ⁶Hospital San Raffaele, University Vita-Salute, Dept. of Urology, Milan, Italy, ⁷Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁸Medical University of Graz, Dept. of Urology, Graz, Austria, ⁹Lahey Clinic, Dept. of Urology, Burlington, United States of America

*524

Preoperative renal artery embolization in renal carcinoma with venous thrombus: Preliminary results of a multicenter study

By: Vazquez-Martul Pazos D.¹, Chantada V.C.¹, Capitanio U.², Carballido J.A.³, Chromecki T.⁴, Ciancio G.⁵, Daneshmand S.⁶, Evans C.P.⁷, Gontero P.⁸, González J.⁹, Haferkamp A.¹⁰, Hohenfellner M.¹¹, Huang W.C.¹², Koppie T.M.¹³, Linares Espinós E.¹⁴, Lorentz A.¹⁵, Martínez-Salamanca J.I.³, Mass A.Y.¹², Master V.A.¹⁵, McKiernan J.M.¹⁶, Montorsi F.², O'Malley P.¹⁷, Pahernik S.¹¹, Palou J.¹⁸, Pontones Moreno J.L.¹⁹, Pruthi R.S.²⁰, Rodriguez Faba O.¹⁸, Russo P.²¹, Scherr D.S.¹⁷, Shariat S.F.²², Spahn M.²³, Terrone C.²⁴, Tilki D.⁷, Vera Donoso C.D.¹⁹, Vergho D.²³, Wallen E.M.²⁰, Zigeuner R.⁴, Libertino J.A.²⁵

Institutes:¹Complejo Hospitalario Universitario A Coruña, Dept. of Urology, A Coruña, Spain, ²Hospital San Raffaele, University Vita-Salute, Dept. of Urology, Milan, Italy, ³Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, Dept. of Urology, Madrid, Spain, ⁴Medical University of Graz, Dept. of Urology, Graz, Austria, ⁵Miami Transplant Institute, University of Miami, Dept. of Urology, Miami, United States of America, ⁶USC/Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, ⁷UC Davis Medical Center, Dept. of Urology, Sacramento, United States of America, ⁸A.O.U. San Giovanni Battista, University of Turin, Dept. of Urology, Turin, Italy, ⁹Hospital Central de la Cruz Roja San José y Santa Adela, Dept. of Urology, Madrid, Spain, ¹⁰University of Frankfurt, Dept. of Urology, Frankfurt, Germany, ¹¹University of Heidelberg, Dept. of Urology, Heidelberg, Germany, ¹²New York University School of Medicine, Dept. of Urology, New York, United States of America, ¹³Oregon Health & Science University, Dept. of Urology, Portland, United States of America, ¹⁴Hospital Universitario Infanta Sofía, Dept. of Urology, Madrid, Spain, ¹⁵Emory University, Dept. of Urology, Atlanta, United States of America, ¹⁶Columbia University College of Physicians and Surgeons, Dept. of Urology, New York, United States of America, ¹⁷Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, ¹⁸Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ¹⁹Hospital Universitario y Politécnico La Fe, Dept. of Urology, Valencia, Spain, ²⁰UNC at Chapel Hill, Dept. of Urology, Chapel Hill, United States of America, ²¹Memorial Sloan Kettering Cancer Center, Dept. of Surgery, Urology Service, New York, United States of America, ²²Medical University of Vienna, Dept. of Urology, Vienna, Austria, ²³University of Würzburg, Dept. of Urology, Würzburg, Germany, ²⁴Maggiore della Carita Hospital, University of Eastern Piedmont, Division of Urology, Novara, Italy, ²⁵Lahey Clinic, Dept. of Urology, Burlington, United States of America

*525

Control of the renal artery after removal of tumor thrombus from the inferior vena cava: Analysis

of the efficacy and safety of a new surgical approach

By: Lesovoy V., Shchukin D., Garagatiy I., Khareba G., Polyakov M.

Institutes:Kharkiv National Medical University, Dept. of Urology, Nephrology and Andrology, Kharkiv, Ukraine

*526

Robotic radical nephrectomy with inferior vena cava tumor thrombectomy: Initial series

By: Simone G.¹, Ferriero M.¹, Papalia R.², Abreu A.L.³, Guaglianone S.¹, Minisola F.¹, Tuderti G.¹, Misuraca L.¹, Pompeo V.¹, Mastroianni R.², Aron M.³, Desai M.³, Gill I.S.³, Gallucci M.¹

Institutes:¹"Regina Elena" National Cancer Institute, Dept. of Urology, Rome, Italy, ²Campus Biomedico University of Rome, Dept. of Urology, Rome, Italy, ³USC Institute of Urology and Departments of Urology, Keck School of Medicine, University of Southern, Dept. of Urology, Los Angeles, United States of America

*527

Incidence of cardiovascular events after tumour nephrectomy in young patients – a single center, matched pair analysis between donor nephrectomy and radical tumour nephrectomy comprising a long term follow-up

By: Levien P., Nestler S., Jäger W., Neisius A., Thomas C., Kamal M.M., Hampel C., Thüroff J., Roos F.C.

Institutes:Medical Center, University of Mainz, Mainz, Germany

*528

Tumour size is associated with compensatory hypertrophy in the contra-lateral kidney after radical nephrectomy in patients with renal cell carcinoma

By: Park B.H.¹, Kim J.I.², Jeong B.C.³, Seo S.I.³, Jeon S.S.³, Lee H.M.³, Choi H.Y.³, Jeon H.G.³

Institutes:¹Uijeongbu St. Mary's Hospital, Dept. of Urology, Uijeongbu-Si, South Korea, ²Kyung Hee University Hospital At Gangdong, Dept. of Radiology, Seoul, South Korea, ³Samsung Medical Center, Dept. of Urology, Seoul, South Korea

*529

Longitudinal changes in renal function after radical nephrectomy and risk factors for postoperative severe renal impairment: A Japanese multicenter study using a linear mixed model analysis

By: Yokoyama M.¹, Kawamura N.¹, Fujii Y.¹, Inoue M.¹, Ishioka J.¹, Numao N.¹, Matsuoka Y.¹, Saito K.¹, Arisawa C.², Okuno T.³, Noro A.⁴, Morimoto S.⁵, Kihara K.¹

Institutes:¹Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, ²Tobu Chiiki Hospital, Dept. of Urology, Tokyo, Japan, ³JA Toride Medical Center, Dept. of Urology, Toride, Japan, ⁴Saitama Red Cross Hospital, Dept. of Urology, Saitama, Japan, ⁵Tsuchiura Kyodo General Hospital, Dept. of Urology, Tsuchiura, Japan

*530

The effect of time elapsed from surgery on the subsequent risk of cancer specific mortality in renal cell carcinoma patients

By: Dell'Oglio P.¹, Larcher A.¹, Capogrosso P.¹, Nini A.¹, La Croce G.¹, Stabile A.¹, Di Trapani E.¹, Karakiewicz P.², Briganti A.¹, Montorsi F.¹, Capitanio U.¹, Bertini R.¹

Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Dept. of Urology, Montreal, Canada

*531

How did we obtain complete remission with patients who have metastatic renal cancer using targeted therapies?

By: Brecheteau F., Carrouget J., Lebdaï S., Azzouzi A.R., Bigot P.

Institutes:Angers University Hospital, Dept. of Urology, Angers, France

*532

Metastatic renal cell carcinoma with cytoreductive nephrectomy. Risk model of cancer-specific survival

By: Velis Campillo J.M., Ancizu Marckert F.J., Hevia Suárez M., Merino Narro I., García Cortés A., Tienza Fernández A., Algarra Navarro R., Pascual Piédrola I., Robles García J.E.

Institutes:Clínica Universidad de Navarra, Dept. of Urology, Pamplona, Spain

Advances in nocturia

Poster Session 43

Sunday, 13 March
14:00 - 15:30

Location: Room 14a (ICM, Level 1)

Chairs: J.L.H.R. Bosch, Utrecht (NL)
H. Hashim, Bristol (GB)
C.G. Roehrborn, Dallas (US)

Aims and objectives of this presentation

xxx

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*533

Effects of altering fluid intake time on nocturia

By: Kim J.W.¹, Chi B.H.¹, Moon Y.T.¹, Kim K.D.¹, Kim T-H.¹, Myung S.C.¹, Chang I.H.¹, Kim M.S.², Lee S.Y.², Ahn S.H.³, Choi J.D.³, Kim J.H.³

Institutes:¹Chung-Ang University Hospital, Dept. of Urology, Seoul, South Korea, ²Seoul Medical Center, Dept. of Urology, Seoul, South Korea, ³KEPCO Medical Center, Dept. of Urology, Seoul, South Korea

*534

Enuresis and urinary infections in childhood: Bad "news" for young women?

By: Illiano E.¹, Appignani A.³, Giannitsas K.⁴, Balsamo R.⁵, Giannantoni A.², Mirone V.¹, Natale F.⁶, Mariuccia S.⁷, Salvini E.⁸, Carbone A.⁹, Pastore A.⁹, Bevacqua M.¹⁰, Prestipino M.¹¹, Fragalà E.¹², Filocamo M.T.¹³, Villari D.¹⁴, Bini V.¹⁵, Costantini E.²

Institutes:¹University Federico II of Naples, Dept. of Neuroscience, Reproductive Sciences and Dentistry, Naples, Italy, ²University of Perugia, Dept. of Surgical and Biomedical Sciences, Section of Urology and Andrology, Perugia, Italy, ³University of Perugia, Dept. of Pediatric Surgery, University of Perugia, Perugia, Italy, ⁴Patras University Hospital, Dept. of Urology, Patras, Greece, ⁵Doctorate Research Program, Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, ⁶IDI-Hospital, Urogynecology San Carlo, Rome, Italy, ⁷Umberto I Hospital, Sapienza University, Dept. of Urology U Bracci, Rome, Italy, ⁸University of Perugia, Dept. of Surgical and Biomedical Sciences, Section of Urology and Andrology, Perugia, Italy, ⁹Sapienza University, Dept. of Medical-Surgical Sciences and Biotechnologies, Latina, Italy, ¹⁰Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, ¹¹University of Perugia, Dept. of Pediatric Surgery, Perugia, Italy, ¹²Romolo Hospital, Dept. of Urology, Rocca Di Neto, Italy, ¹³ASL CN1, Dept. of Urology, Savigliano, Italy, ¹⁴University of Florence, Dept. of Urology, Florence, Italy, ¹⁵University of Perugia, Dept. of Medicine Section of Internal Medicine Endocrine and Metabolic Sciences, Perugia, Italy

*535

The obesity paradox in nocturia? Lower body mass index is a risk factor of mortality in outpatients with nocturia in Japan

By: Negoro H.¹, Sugino Y.¹, Nishizawa K.², Soda T.², Shimizu Y.¹, Yoshimura K.³, Ogawa O.¹, Yoshimura K.¹

Institutes:¹Kyoto University Hospital, Dept. of Urology, Kyoto, Japan, ²Kurashiki Central Hospital, Dept. of Urology, Okayama, Japan, ³Kyoto University Hospital, Dept. of Clinical Trial Design and Management, Kyoto, Japan

*536

Diagnosing nocturnal polyuria (NP)-based on self-reported nocturnal void volume and fluid intake in clinical practice: Results from a real-world treatment survey in Europe and the USA

By: Weiss J.¹, Andersson F.², Juul K.V.²

Institutes:¹SUNY Downstate College of Medicine, Dept. of Urology, Brooklyn, United States of America, ²International PharmaScience Center, Ferring Pharmaceuticals A/S, Copenhagen,

Denmark

- *537 **Nocturia due to nocturnal polyuria (NP) in women with overactive bladder (OAB) may be better managed by adding a low-dose desmopressin to tolterodine therapy**
By: Rovner E.S.¹, Andersson F.², Raymond K.², Juul K.V.²
Institutes:¹Medical University of South Carolina, Dept. of Urology, Charleston, United States of America, ²International PharmaScience Center, Ferring Pharmaceuticals A/S, Copenhagen, Denmark
- *538 **Mirabegron improves nocturia and nocturia associated QoL and sleep quality**
By: Yoshida M.¹, Gotoh M.², Kageyama S.³, Kato K.⁴, Matsukawa Y.², Narushima M.⁵
Institutes:¹National Center For Geriatrics and Gerontology, Dept. of Urology, Obu, Aichi, Japan, ²Nagoya University School of Medicine, Dept. of Urology, Nagoya, Japan, ³Kageyama Clinic, Dept. of Urology, Shizuoka, Japan, ⁴Nagoya 1st Red Cross Hospital, Dept. of Urology, Nagoya, Japan, ⁵Meitetsu Hospital, Dept. of Urology, Nagoya, Japan
- *539 **Copeptin in nocturics: A posthoc explorative analysis**
By: Bruneel E.¹, Goessaert A-S.¹, Denys M-A.¹, Vande Walle J.², Juul K.V.³, Rittig S.⁴, Nørgaard J.P.³, Everaert K.¹
Institutes:¹University Hospital Ghent, Dept. of Urology, Ghent, Belgium, ²University Hospital Ghent, Dept. of Pediatrics, Ghent, Belgium, ³Ferring, Dept. of International PharmaScience Center, Copenhagen, Denmark, ⁴Aarhus University Hospital, Dept. of Pediatrics, Aarhus, Denmark
- *540 **Mental and psychological characteristics of young adult males with primary nocturnal enuresis: A case-control observational study**
By: Guragac A., Yilmaz S., Aydur E.
Institutes:Gülhane Military Medical Academy, Dept. Of Urology, Ankara, Turkey
- *541 **Metabolic abnormalities linked to an increased cardiovascular risk are associated with higher storage lower urinary tract symptoms**
By: De Nunzio C.¹, Truscelli G.², Lombardo R.¹, Gacci M.³, Presicce F.³, Leonardo C.¹, Gaudio C.², Lopes Mendes A.L.¹, Tubaro A.¹
Institutes:¹Sant' Andrea Hospital 'La Sapienza', Dept. of Urology, Rome, Italy, ²Policlinico Umberto I, "Sapienza" University, Dept. of Cardiology, Rome, Italy, ³Ospedale Careggi, University of Florence, Dept. of Urology, Florence, Italy
- *542 **Obstructive sleep apnea increases the risk of urinary incontinence**
By: Fan Y-H., Chung H.J., Huang Y.H., Lin C.C., Lin T.L., Chen K.K.
Institutes:Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan
- *543 **Efficacy and safety of desmopressin "add-on" therapy in men with persistent nocturia under alpha blocker monotherapy for lower urinary tract symptoms: A randomized, double-blind, placebo-controlled study**
By: Cho K.J.¹, Lee Z.Z.², Lee J.G.³, Seo J.T.⁴, Kim D.Y.⁵, Oh S-J.⁶, Lee K-S.⁷, Choo M-S.⁸, Kim J.C.¹, Choi Y.S.¹
Institutes:¹The Catholic University of Korea, Dept. of Urology, Bucheon City, South Korea, ²Pusan National University, School of Medicine, Dept. of Urology, Pusan, South Korea, ³College of Medicine, Korea University, Dept. of Urology, Seoul, South Korea, ⁴Cheil General Hospital and Women's Healthcare Center, Dankook University, Dept. of Urology, Seoul, South Korea, ⁵Daegu Catholic University, College of Medicine, Dept. of Urology, Daegu, South Korea, ⁶Seoul National University, College of Medicine, Dept. of Urology, Seoul, South Korea, ⁷Samsung Medical Center, Sungkyunkwan University, Dept. of Urology, Seoul, South Korea, ⁸Asan Medical Center, University of Ulsan, Dept. of Urology, Seoul, South Korea
- 15:11 - 15:18 **Summary and context**
 J.L.H.R. Bosch, Utrecht (NL)

Management of recurrent prostate cancer

Poster Session 44

Sunday, 13 March
14:00 - 15:30

Location: Room 14b (ICM, Level 1)

Chairs: A. Bjartell, Malmö (SE)
A. Ponholzer, Vienna (AT)
J. Rubio Briones, Valencia (ES)

Aims and objectives of this presentation

Managing PSA recurrence after radical treatment remains one of the more difficult challenges in modern urology. That implies early identification and correct prognostication of individual risk. This session will present the latest update on the topic.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*544

Long-term impact of adjuvant versus early salvage radiation therapy on clinical recurrence in pT3N0 prostate cancer patients treated with radical prostatectomy: Results of a multi-institutional analysis

By: Fossati N.¹, Karnes J.², Morlacco A.³, Moschini M.¹, Boorjian S.², Seisen T.³, Bossi A.³, Cozzarini C.⁴, Fiorino C.⁴, Noris Chiorda B.⁴, Gandaglia G.¹, Tosco L.⁵, De Ridder D.⁵, Joniau S.⁵, Goldner G.⁶, Shariat S.⁷, Hinkelbein W.⁸, Haustermans K.⁹, Tombal B.¹⁰, Montorsi F.¹, Van Poppel H.⁵, Wiegel T.¹¹, Briganti A.¹

Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Oncology/Unit of Urology; URI, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, ⁴IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁵University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁶Medical University of Vienna, Dept. of Radio oncology, Vienna, Austria, ⁷Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁸Charité Universita`tsmedizin, Campus Benjamin Franklin, Dept. of Radiation Oncology, Berlin, Germany, ⁹University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, ¹⁰Universite´ Catholique De Louvain, Dept. of Urology, Brussels, Belgium, ¹¹University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany

*545

Early salvage radiotherapy gives favorable results in unfavorable prostate cancer patient subgroups

By: Wiegel T.¹, Bartkowiak D.¹, Bottke D.¹, Siegmann A.², Böhmer D.², Budach V.²

Institutes:¹University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ²University Hospital Berlin, Dept. of Radiation Oncology, Berlin, Germany

*546

Patterns of recurrence and long-term cancer-specific mortality of prostate cancer patients treated with salvage radical prostatectomy for radio-recurrent prostate cancer

By: Gandaglia G.¹, Fossati N.², Suardi N.², Gallina A.², Colombo R.², Bertini R.², Dehò F.², Scattoni V.², Stabile A.², Cozzarini C.³, Rigatti P.⁴, Montorsi F.², Briganti A.²

Institutes:¹Irccs Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Oncology/Unit of Urology; URI, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁴Advanced Urotechnology Center, Istituto Auxologico Italiano, Dept. of Urology, Milan, Italy

*547

Clinical utility of PET-PSMA in decision-making for prostate cancer patients: Preliminary analysis of 42 consecutive patients

By: Albisinni S.¹, Artigas C.², Aoun F.¹, Biaou I.¹, Limani K.¹, Hawaux E.¹, Peltier A.¹, Flamen P.², Van

Velthoven R.¹

Institutes:¹Institut Jules Bordet, Dept. of Urology, Brussels, Belgium, ²Institut Jules Bordet, Dept. of Nuclear Medicine, Brussels, Belgium

*548

68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment

By: Van Leeuwen P.J.¹, Emmett L.², Hruby G.³, Kneebone A.³, Stricker P.¹

Institutes:¹St Vincent's Prostate Cancer Centre, Dept. of Urology, Sydney, Australia, ²St Vincent's Public Hospital, Dept. of Diagnostic Imaging, Sydney, Australia, ³Northern Sydney Cancer Centre, Royal North Shore Hospital, Dept. of Radiation Oncology, Sydney, Australia

*549

Results of a prospective phase I/II randomized trial of peptide-specific vaccination in HLA-A*0201 positive prostate carcinoma patients with biochemical recurrence after radical prostatectomy

By: Bedke J.¹, Gouttefangeas C.², Feyerabend S.¹, Hennenlotter J.¹, Avilés Escobar C.M.¹, Laske K.², Widenmeyer M.², Griesemann H.², Stevanovic S.², Rammensee H-G.², Stenzl A.¹

Institutes:¹University of Tübingen, Dept. of Urology, Tübingen, Germany, ²University of Tübingen, Dept. of Immunology, Tübingen, Germany

*550

Oncologic outcomes and biochemical predictors following salvage lymph node dissection for prostate cancer

By: Zattoni F.¹, Nehra A.¹, Lowe V.², Rangel L.¹, Mynderse L.¹, Kwon E.¹, Karnes J.¹

Institutes:¹Mayo Clinic, Dept. of Urology, Rochester, United States of America, ²Mayo Clinic, Dept. of Radiology, Rochester, United States of America

*551

Feasibility of ¹¹¹In-PSMA-guided surgery for treatment of nodal prostate cancer relapse

By: Schaal K.¹, Stoykow C.², Mix M.², Bartholomä M.², Drendel V.³, Mäcke H.², Gourni E.², Wetterauer U.¹, Schultze-Seemann W.¹, Meyer P.², Jilg C.A.¹

Institutes:¹University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany, ²University Medical Center Freiburg, Dept. of Nuclear Medicine, Freiburg, Germany, ³University Medical Center Freiburg, Dept. of Pathology, Freiburg, Germany

*552

Predicting the 5-year risk of biochemical relapse after post-prostatectomy radiotherapy in pT2 patients with a comprehensive radiobiological model

By: Fiorino C.¹, Broggi S.¹, Fossati N.², Cozzarini C.³, Goldner G.⁴, Wiegel T.⁵, Hinkelbein W.⁶, Karnes J.⁷, Hausermans K.⁸, Joniau S.⁹, De Ridder D.⁹, Shariat S.¹⁰, Montorsi F.², Van Poppel H.⁹, Di Muzio N.³, Calandrino R.¹, Briganti A.²

Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Medical Physics, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁴Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, ⁵University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ⁶Charité Universitätsmedizin, Campus Benjamin Franklin, Dept. of Radiation Oncology, Berlin, Germany, ⁷Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁸University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, ⁹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ¹⁰Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria

*553

Salvage tomotherapy choline PET/CT guided for prostate cancer lymph nodal recurrence

By: Fodor A.¹, Genoveffa B.¹, Fiorino C.², Picchio M.³, Busnardo E.³, Kirienko M.⁴, Incerti E.³, Cozzarini C.¹, Dell'Oca I.¹, Mangili P.², Pasetti M.¹, Calandrino R.², Gianolli L.³, Di Muzio N.G.¹

Institutes:¹San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy, ²San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy, ³San Raffaele Scientific Institute, Dept. of Nuclear Medicine, Milan, Italy, ⁴University Milano-Bicocca, Dept. of Nuclear Medicine, Milan, Italy

*554

Does salvage lymphadenectomy for biochemical progression following radical prostatectomy and additional radiotherapy has an impact on overall survival? Initial results from a case-control study

By: Jilg C.A.¹, Tennstedt P.², Heinzer H.², Wetterauer U.¹, Grosu A.³, Budaeus L.², Schultze-Seemann W.¹, Steuber T.²

Institutes:¹University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany, ²Martini-Clinic,

University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ³University Medical Center Freiburg, Dept. of Radiation Oncology, Freiburg, Germany

*555

Long-term oncological outcomes of salvage cryotherapy for radio-recurrent prostate cancer

By: Siddiqui K.¹, Billia M.¹, Violette P.², Arifin A.¹, Tran K.¹, Chin J.¹

Institutes:¹University of Western Ontario, Dept. of Urology, London, Canada, ²Woodstock Hospital, Dept. of Urology, Woodstock, Canada

*556

A prospective phase II clinical trial of salvage whole gland high intensity focused ultrasound for radio-recurrent prostate: Intermediate term results

By: Siddiqui K.¹, Billia M.¹, Violette P.², Chin J.²

Institutes:¹University of Western Ontario, Dept. of Urology, London, Canada, ²Woodstock Hospital, Dept. of Urology, London, Canada

15:17 - 15:24

Summary and context

J. Rubio Briones, Valencia (ES)

Gallium-PSMA and other tracers for prostate cancer: Do they really help?

Poster Session 45

Sunday, 13 March
14:00 - 15:30

Location: Room 14c (ICM, Level 1)

Chairs: F. Abdollah, Royal Oak (US)
G. Ploussard, Toulouse (FR)
T. Wiegel, Ulm (DE)

Aims and objectives of this presentation

Gallium-PSMA PET is suggested to be an emerging tool in staging of prostate cancer. Conflicting data, however, have been published concerning its use for lymph node staging or diagnosis of prostate cancer relapse. This session will highlight the most recent data on new PET tracers for prostate cancer.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

14:23 - 14:33

Is seeing more enough to do more?

T. Wiegel, Ulm (DE)

*557

Localization of primary prostate cancer by simultaneous ⁶⁸Gallium-HBED-CC-PSMA PET and multiparametric MRI

By: Eiber M.¹, Weirich G.², Nguyen N.³, Holzapfel K.⁴, Souvatzoglou M.¹, Haller B.⁵, Rauscher I.¹, Beer A.⁶, Wester H.-J.⁷, Westenfelder K.³, Gschwend J.³, Schwaiger M.¹, Maurer T.³

Institutes:¹Technical University of Munich, Dept. of Nuclear Medicine, Munich, Germany, ²Technical University of Munich, Dept. of Pathology, Munich, Germany, ³Technical University of Munich, Dept. of Urology, Munich, Germany, ⁴Technical University of Munich, Dept. of Radiology, Munich, Germany, ⁵Technical University of Munich, Dept. of Medical Statistics and Epidemiology, Munich, Germany, ⁶University of Ulm, Dept. of Nuclear Medicine, Ulm, Germany, ⁷Technical University of Munich, Dept. of Pharmaceutical Radiopharmacy, Munich, Germany

*558

Diagnostic efficacy of ⁶⁸Ga-PSMA PET for lymph node staging and metastatic distribution in patients with intermediate to high-risk prostate cancer

By: Maurer T.¹, Gschwend J.¹, Pähr L.¹, Rauscher I.², Souvatzoglou M.², Haller B.³, Weirich G.⁴, Wester H.-J.⁵, Heck M.¹, Hacker C.¹, Kübler H.¹, Beer A.⁶, Schwaiger M.², Eiber M.²

Institutes:¹Technical University of Munich, Dept. of Urology, Munich, Germany, ²Technical University of Munich, Dept. of Nuclear Medicine, Munich, Germany, ³Technical University of Munich, Institute for Medical Statistics and Epidemiology, Munich, Germany, ⁴Technical University of Munich, Institute of Pathology, Munich, Germany, ⁵Technical University of Munich, Dept. of Pharmaceutical Radiochemistry, Munich, Germany, ⁶University of Ulm, Dept. of Nuclear Medicine, Ulm, Germany

*559

Prospective evaluation of ⁶⁸Ga-PSMA positron emission tomography/computerized tomography for preoperative lymph node staging in prostate cancer

By: Van Leeuwen P.¹, Emmett L.², Ho B.², Delprado W.³, Stricker P.¹

Institutes:¹St. Vincent's Prostate Cancer Centre, Dept. of Urology, Sydney, Australia, ²St. Vincent's Public Hospital, Dept. of Diagnostic Imaging, Sydney, Australia, ³University of Notre Dame, Dept. of Histopathology, Sydney, Australia

*560

⁶⁸Ga-PSMA PET/CT provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer

By: Herlemann A.¹, Wenter V.², Kretschmer A.¹, Bartenstein P.², Stief C.¹, Gratzke C.¹, Fendler W.²

Institutes:¹Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, ²Ludwig-Maximilians-University Munich, Dept. of Nuclear Medicine, Munich, Germany

- *561 **Evaluation of detection rate of 68Ga-PSMA PET/CT for biochemical recurrence after radical prostatectomy**
By: Paffen M.L.J.E.¹, Murphy D.², Costello A.², Hicks R.³, Hoffman M.³
Institutes:¹Royal Melbourne Hospital, Dept. of Urology, Wodonga, Australia, ²Royal Melbourne Hospital, Dept. of Urology, Melbourne, Australia, ³Peter MacCallum Cancer Centre, Dept. of Nuclear Medicine, Melbourne, Australia
- *562 **Accuracy of 18f-facbc (anti1-amino-3-18f-fluorocyclobutane-1-carboxylic acid) in prostate cancer relapse: Results of a prospective trial**
By: Pultrone C.V.¹, Bianchi L.¹, Brunocilla E.¹, Fanti S.², Nanni C.², Zanoni L.², Matti A.², Borghesi M.³, Bravi C.¹, Martorana G.¹, Schiavina R.¹
Institutes:¹St Orsola Hospital, University of Bologna, Dept. of Urology, Bologna, Italy, ²St Orsola Hospital, University of Bologna, Dept. of Nuclear Medicine, Bologna, Italy, ³St Orsola Hospital, University of Bologna, Dept. of Urology and Medical and Surgical Sciences, Bologna, Italy
- *563 **The diagnostic accuracy of 68Ga-PSMA-PET/CT for detection of lymph node metastases in the setting of salvage lymph node dissection**
By: Jilg C.A.¹, Drendel V.², Beck T.³, Rischke C.³, Grosu A.⁴, Werner M.², Wetterauer U.¹, Meyer P.³, Schultze-Seemann W.¹
Institutes:¹University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany, ²University Medical Center Freiburg, Dept. of Pathology, Freiburg, Germany, ³University Medical Center Freiburg, Dept. of Nuclear Medicine, Freiburg, Germany, ⁴University Medical Center Freiburg, Dept. of Radiation Oncology, Freiburg, Germany
- *564 **The role of 68Ga-PSMA PET/CT in the diagnosis and therapeutic decision making of oligometastatic recurrence after radical prostatectomy**
By: Tosco L.¹, Gheysens O.², Deroose C.², De Meerleer G.³, Haustermans K.⁴, Everaerts W.¹, Cromphout L.¹, Van Poppel H.¹, Van Laere K.², Joniau S.¹, Goffin K.²
Institutes:¹UZ Leuven, Dept. of Development and Regeneration, Leuven, Belgium, ²UZ Leuven, Dept. of Nuclear Medicine, Leuven, Belgium, ³University Hospitals Ghent, Dept. of Radiotherapy, Ghent, Belgium, ⁴UZ Leuven, Dept. of Radiotherapy, Leuven, Belgium
- *565 **Probability of positive PET imaging with a [68Ga]-labelled PSMA ligand based on PSA value in patients with biochemical recurrent prostate cancer after radical prostatectomy**
By: Cromphout L.¹, Tosco L.¹, Everaerts W.¹, Albersen M.¹, Gheysens O.², Deroose C.², Van Laere K.², Goffin K.², Joniau S.¹
Institutes:¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²UZ Leuven, Dept. of Nuclear Medicine, Leuven, Belgium
- *566 **68Gallium-HBED-CC-PSMA PET compared to conventional bone scintigraphy for evaluation of bone metastases in prostate cancer patients**
By: Eiber M.¹, Pyka T.¹, Okamoto S.¹, Rauscher I.¹, Dahlbender M.², Tauber R.², Retz M.², Gschwend J.², Schwaiger M.¹, Maurer T.²
Institutes:¹Technical University of Munich, Dept. of Nuclear Medicine, Munich, Germany, ²Technical University of Munich, Dept. of Urology, Munich, Germany
- *567 **PET imaging of therapy-naïve primary prostate cancer patients using the GRPr-targeting ligand Sarabesin 3**
By: Bakker I.L.¹, Fröberg A.C.¹, Busstra M.B.², Van Leenders G.J.L.H.³, De Blois E.¹, Schoots I.⁴, Veenland J.⁴, Maina T.⁵, Van Weerden W.M.², Nock B.A.⁵, De Jong M.¹
Institutes:¹Erasmus MC, Dept. of Nuclear Medicine, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ³Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ⁴Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, ⁵NCSR "Demokritos", Dept. of Radiochemistry, Athens, Greece

*568

PSMA pet improves diagnostic accuracy of mpMRI in localised prostate cancer as confirmed by whole mount histopathology: Implications for selection and assessment for active surveillance and focal therapy

By: Rhee H.¹, Thomas P.², Shepherd B.³, Greenslade S.⁴, Vela L.¹, Russell P.⁵, Nelson C.⁵, Chung E.⁶, Wood G.⁷, Malone G.⁸, Wood S.⁸, Heathcote P.⁸

Institutes:¹Princess Alexandra Hospital/ Queensland University of Technology, Dept. of Urology and Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia, ²Royal Brisbane and Women's Hospital, Dept. of Nuclear Medicine, Brisbane, Australia, ³Princess Alexandra Hospital, Dept. of Anatomical Pathology, Woolloongabba, Australia, ⁴Princess Alexandra Hospital, Dept. of Radiology, Woolloongabba, Australia, ⁵Queensland University of Technology, Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia, ⁶Princess Alexandra Hospital, Dept. of Urology, Woolloongabba, Australia, ⁷Greenslopes Private Hospital, Dept. of Urology, Brisbane, Australia, ⁸Princess Alexandra Hospital/Greenslopes Private Hospital, Dept. of Urology, Brisbane, Australia

PCNL: Imaging and access

Poster Session 46

Sunday, 13 March
14:00 - 15:30

Location: Room Paris (Hall B2, level 0)

Chairs: E.K. Bres-Niewada, Warsaw (PL)
P.J. Chibber, Mumbai (IN)
S. McClinton, Aberdeen (GB)

Aims and objectives of this presentation

Preoperative imaging, correct planning and perfect access are the key factors of PNL. This session will address several aspects and controversies on how to achieve best results in PNL.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*569

Antibiotic prescribing pre-PCNL: What affects clinical decision making and what effect do pre-operative antibiotics have on post-operative infection rates: Data from the BAUS national PCNL registry

By: Wiseman O.², Withington J.¹, Finch W.³, Fowler S.⁴, Armitage J.², Glass J.⁵, Irving S.³, Burgess N.³

Institutes:¹Whittington Hospital Nhs Trust, Dept. of Urology, London, United Kingdom, ²Cambridge University Teaching Hospitals NHS Trust, Dept. of Urology, Cambridge, United Kingdom, ³Norfolk and Norwich University Hospitals NHS Trust, Dept. of Urology, Norwich, United Kingdom, ⁴British Association of Urological Surgeons, Dept. of Audit, London, United Kingdom, ⁵Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom

*570

The significance of preoperative neutrophil-lymphocyte count ratio on predicting postoperative sepsis after percutaneous nephrolithotomy

By: En V.¹, Bozkurt I.H.¹, Aydogdu O.¹, Yonguc T.¹, Yarimoglu S.¹, Sen P.², Koras O.³, Degirmenci T.¹

Institutes:¹Izmir Bozyaka Research and Training Hospital, Dept. of Urology, Izmir, Turkey, ²Izmir Katip Celebi University Ataturk Training and Research Hospital, Dept. of Infectious Diseases and Clinical Microbiology, Izmir, Turkey, ³Mardin Midyat State Hospital, Dept. of Urology, Mardin, Turkey

*571

Investigation of the ideal position for endoscopic combined intrarenal surgery: Prone position vs modified Valdivia position

By: Hamamoto S., Unno R., Taguchi K., Ando R., Okada A., Tozawa K., Yasui T.

Institutes: Nagoya City University, Dept. Of Nephro-urology, Nagoya, Japan

*572

Feasibility of supracostal access in supine percutaneous renal surgery

By: Al-Dessoukey A., Mousa A., Abdallah R., Gamal A., Abdolbary A., Massoud A.

Institutes: Beni Suef University, Dept. of Urology, Cairo, Egypt

*573

Development of an ultrasound-guided renal puncture assisting flexible ureteroscope for ECIRS

By: Unno R., Hamamoto S., Taguchi K., Ando R., Okada A., Tozawa K., Kohri K., Yasui T.

Institutes: Nagoya City University, Dept. of Nephro-urology, Nagoya, Japan

*574

Percutaneous nephrolithotomy under X-ray control and totally ultrasound-guided percutaneous nephrolithotomy: The outcome comparison

By: Atduev V.¹, Ledyayev D.¹, Dyrdik M.², Abramov D.², Sevryukov F.³, Yudeev I.², Shevelev I.²,

Geyushov I.¹, Bochkareva O.¹

Institutes:¹Nizhni Novgorod State Medical Academy, Dept. of Surgical Diseases, Nizhny Novgorod, Russia, ²Volga District Medical Centre, Dept. of Urology, Nizhny Novgorod, Russia, ³Railway Clinical Hospital At The Gorky Station, Dept. of Urology, Nizhny Novgorod, Russia

*575

PCNL access by urologist or radiologist: An analysis of the BAUS PCNL Registry

By: Armitage J.N.¹, Fowler S.², Finch W.³, Burgess N.A.³, Irving S.O.³, Withington J.⁴, Glass J.⁵, Wiseman O.J.¹

Institutes:¹Addenbrooke's Hospital, Dept. of Urology, Cambridge, United Kingdom, ²British Association of Urological Surgeons, , London, United Kingdom, ³Norfolk and Norwich University Hospitals Foundation Trust, Dept. of Urology, Norwich, United Kingdom, ⁴Whittington Hospital, Dept. of Urology, London, United Kingdom, ⁵Guy's Hospital, Dept. of Urology, London, United Kingdom

*576

Assessing whether morphometric and anatomic measurements interferes with the accessibility of upper calyx through a lower calyx in supine PCNL

By: Barguti Y.¹, Mintz I.¹, Giusti G.², Proietti S.³, Matzkin H.¹, Sofer M.¹

Institutes:¹Tel-Aviv Sourasky Medical Center, Dept. of Urology, Tel-Aviv, Israel, ²Ospedale San Raffaele-Turro, Dept. of Urology, Milan, Italy, ³Tenon Hospitalm Pierre and Marie Curie University, Dept. of Urology, Paris, France

*577

Questioning the wisdom of puncture at the calyceal fornix in percutaneous nephrolithotripsy: Our experience with 137 patients operated via a non calyceal percutaneous track

By: Kyriazis L., Kallidonis P., Vasilas M., Panagopoulos V., Liatsikos E.

Institutes:General University Hospital of Patras, Dept. of Urology, Patras, Greece

*578

IPad assisted PCNL - clinical study to compare to the standard puncturing technique

By: Rassweiler M-C.¹, Klein J.T.², Mueller M.³, Meinzer H-P.³, Rassweiler J.J.⁴

Institutes:¹University Medicine Mannheim, Mannheim, Germany, ²Universityhospital, Dept. of Urology, Ulm, Germany, ³German Cancer Research Center (DKFZ), Dept. of Medical and Biological Informatics, Heidelberg, Germany, ⁴SLK-Kliniken Heilbronn, Dept. of Urology, Heilbronn, Germany

*579

Caliceal stone distribution is better than Guy's stone score in predicting outcome after percutaneous nephrolithotomy

By: Osman Y., El-Nahas A., Harraz A., Diao-Eldin T., Elsayy A., El-Kappany H.

Institutes:Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt

*580

Pediatric PCNL: Can we consider the lower calyx as a universal calyx?

By: Gamal Saad W., Mmdouh A.

Institutes:Sohag University Hospital, Dept. of Urology, Sohag, Egypt

15:15 - 15:22

Summary and context

S. McClinton, Aberdeen (GB)

Paediatric urology 2

Poster Session 47

Sunday, 13 March
14:00 - 15:30

Location: Room Vienna (Hall B2, level 0)

Chairs: To be confirmed
F. O'Kelly, Dublin (IE)

Aims and objectives of this presentation

Update on paediatric urology reconstructions.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *581 **Prevalence of hypospadias in South-America. 30 year analysis. Effect of altitude as a risk factor**
By: [Fernandez Bonilla J.N.](#)¹, Perez J.¹, Zarante I.²
Institutes:¹Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogota, Colombia, ²Pontificia Universidad Javeriana, Instituto De Genetica Humana, Bogota, Colombia
- *582 **SIGHT - a novel psychometric evaluation of psychosexual satisfaction after hypospadias repair**
By: [Ardelt P.](#)¹, Cederqvist M.², Barth M.³, Frankenschmidt A.²
Institutes:¹University Hospital Basel, Dept. of Urology, Basel, Switzerland, ²Albert-Ludwigs-University of Freiburg, Dept. of Pediatric Urology, Freiburg, Germany, ³Albert-Ludwigs-University of Freiburg, Dept. of Pediatric Psychology, Freiburg, Germany
- *583 **Short- and long-term results of surgical correction for buried penis**
By: [Hayashi Y.](#), Mizuno K., Nishio H., Moritoki Y., Kamisawa H., Nakane A., Kurokawa S., Maruyama T., Yasui T.
Institutes:Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-urology, Nagoya, Japan
- *584 **Dorsal inlay buccal mucosal graft (Asopa technique) for the repair of large post hypospadias urethrocutaneous fistula**
By: [Elgamal S.](#)¹, Gameel T.¹, Ghalwash M.¹, Abdelhameed H.², Radwan M.¹, Nagla S.¹, Lotfy M.¹
Institutes:¹Tanta University Hospitals, Dept. of Urology, Tanta, Egypt, ²Fayoum University Hospitals, Dept. of Urology, Fayoum, Egypt
- *585 **Repair of distal penile hypospadias with and without dartos fascia flap, a comparative study**
By: Fathy M., [Elbadry M.S.B.](#), Elsayed A., Nagy O.
Institutes:Minia University, Dept. of Pediatric Surgery, Minia, Egypt
- *586 **In-situ glanulplasty: A modified technique for glans approximation in tubularised incised plate procedure**
By: [Hussein M.M.](#), Gamal W., Mamdouh A., Rashed E.
Institutes:Sohag University Hospital, Dept. of Urology, Sohag, Egypt
- *587 **Long-term outcome of dorsal approach in the treatment of congenital ventral penile curvature**
By: Stojanovic B.², [Bizic M.](#)¹, Djordjevic M.¹
Institutes:¹Medical School, University of Belgrade, Dept. of Urology, Belgrade, Serbia, ²University Children's Hospital, Dept. of Urology, Belgrade, Serbia
- *588 **Ventral buccal mucosa grafting for simultaneous curvature repair and urethroplasty in the treatment of proximal hypospadias: A novel technique**

By: Djordjevic M.L.¹, Bizic M.², Stojanovic B.², Vukadinovic V.¹, Radojicic Z.¹, Krstic Z.¹
Institutes:¹School of Medicine, University of Belgrade, Dept. of Urology, Belgrade, Serbia, ²University Children's Hospital, Dept. of Urology, Belgrade, Serbia

- *589 **A novel technique for repair of mid-penile hypospadias using a preputial skin flap: Results of 110 patients**
By: El-Moghazy H.¹, Alsagheer G.A.²
Institutes:¹Sohag University Hospital, Dept. of Urology, Sohag, Egypt, ²Quena University Hospital, Dept. of Urology, Quena, Egypt
- *590 **Prognostic factors for complications following primary hypospadias repair**
By: Dokter E.M.J.¹, Van Der Zanden L.F.M.¹, De Gier R.P.E.², Kortmann B.B.M.², Ulrich D.J.O.³, Roeleveld N.⁴, Feitz W.F.J.², Van Rooij I.A.L.M.¹
Institutes:¹Radboud Institute For Health Sciences, Radboud University Medical Center, Dept. of Health Evidence, Nijmegen, The Netherlands, ²Radboudumc Amalia Children's Hospital, Radboud University Medical Center, Dept. of Urology, Paediatric Urology, Nijmegen, The Netherlands, ³Radboud University Medical Center, Dept. of Plastic Surgery, Nijmegen, The Netherlands, ⁴Radboudumc Amalia Children's Hospital, Radboud University Medical Center, Dept. of Health Evidence, Nijmegen, The Netherlands
- *591 **Median raphe anomalies as an indicator of megameatus intact prepuce anomaly in children undergoing routine circumcision**
By: Fahmy M.A.B.
Institutes:Al Azhar, Cairo, Egypt
- *592 **Bleeding after circumcision is more likely in children with Lichen Sclerosus (Balanitis Xerotica Obliterans)**
By: Somov P., Chan B.K.Y., Wild C., Corbett H.
Institutes:Alder Hey Children's Hospital, Dept. of Paediatric Surgery, Liverpool, United Kingdom
- *593 **Laparoscopic versus open orchiopexy in the management of peeping testis: A multi-institutional prospective randomized study**
By: Abolyosr A.¹, Elderwy A.¹, Kurkar A.², Abdel-Kader M M.¹, Al-Hazmi H.³, Neel F.³, Hammouda H.², Elanany F.²
Institutes:¹Qena University Hospital, Dept. of Urology, Qena, Egypt, ²Assiut University Hospital, Dept. of Urology, Assiut, Egypt, ³College of Medicine and King Khalid University Hospital, Dept. of Urology, Riyadh, Saudi Arabia
- *594 **Low ambient temperature and midnight to early morning period onset highly predict testicular torsion among acute scrotums in Japanese male patients younger than 30**
By: Takeshita H., Kawakami S., Tachibana K., Hiranuma S., Sugiyama H., Cho E., Yano A., Okada Y., Morozumi M., Yamada T.
Institutes:Saitama Medical Center, Saitama Medical University, Dept. of Urology, Saitama, Japan
- *595 **A comparative analysis of the effects of spermatic cord hydroceles and testicular hydroceles on the testes of children**
By: Kurokawa S., Mizuno K., Kamisawa H., Moritoki Y., Nishio H., Nakane A., Maruyama T., Hayashi Y., Yasui T.
Institutes:Nagoya City University School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan

Kidney transplant: From bench to clinical practice

Poster Session 48

Sunday, 13 March
14:00 - 15:30

Location: Room London (Hall B2, level 0)

Chairs: A. Breda, Barcelona (ES)
A.J. Figueiredo, Coimbra (PT)

Aims and objectives of this presentation

To review the latest advances in kidney preservation as well as molecular basis of transplant.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *596 **Five-year clinical effects of donor bone marrow cells infusions in kidney allograft recipients**
By: Pourmand G.¹, Solgi G.², Gadi V.³, Paul B.³, Mytilineos J.⁴, Mehrsai A.¹, Ranjbar M.¹, Mohammadnia M.⁵, Nikbin B.⁶, Amirzargar A.A.⁶
Institutes:¹Tehran University of Medical Sciences, Urology Research Center, Tehran, Iran, ²Hamadan University of Medical Sciences, Dept. of Immunology, Hamadan, Iran, ³Fred Hutchinson Cancer Research Center, Dept. of Clinical Research, Seattle, United States of America, ⁴University Hospital Ulm, Dept. of Transplantation Immunology, Ulm, Germany, ⁵Torbiat Modares University, Dept. of Immunology, Faculty of Medical Sciences, Tehran, Iran, ⁶Tehran University of Medical Sciences, Modares University, Dept. of Molecular Immunology Research, Tehran, Iran
- *597 **What should be moved, graft or machine? Travel strategy in an Expanded Criteria Donor Program. Organ Procurement and Transplant Organizations (OPO) perspective**
By: Burgos Revilla F.J.¹, Gómez V.¹, Díez-Nicolás V.¹, Alvarez S.¹, Hevia V.¹, Martínez A.², Martínez L.¹, Fernández A.¹, Jiménez S.³, Arias F.¹, Rodríguez-Patrón R.¹, Jiménez M.¹
Institutes:¹Hospital Universitario Ramón y Cajal, Dept. of Urology, Madrid, Spain, ²Hospital Universitario Ramón y Cajal, Transplantation Coordination, Madrid, Spain, ³Hospital Universitario Ramón y Cajal, Dept. of Nephrology, Madrid, Spain
- *598 **Is a short pulsatile hypothermic perfusion just before the transplant beneficial for the graft in the setting of warm ischemic kidneys?**
By: Lledo García E.¹, Humanes Sanchez B.², Agra Pujol C.³, Hernandez Fernandez C.¹, Del Cañizo Lopez J.F.⁴, Tejedor Jorge A.⁵, Lazaro Fernandez A.²
Institutes:¹Instituto De Investigacion Sanitaria Gregorio Marañón, Dept. of Urology, Madrid, Spain, ²Instituto De Investigacion Sanitaria Gregorio Marañón, Dept. of Experimental Nephrology, Madrid, Spain, ³Instituto De Investigacion Sanitaria Gregorio Marañón, Dept. of Pathology, Madrid, Spain, ⁴Instituto De Investigacion Sanitaria Gregorio Marañón, Dept. of Experimental Bio-Engineering, Madrid, Spain, ⁵Instituto De Investigacion Sanitaria Gregorio Marañón, Dept. of Experimental Nephrology-CHAIR, Madrid, Spain
- *599 **MicroRNAs in kidney graft hypothermic machine perfusion fluid as novel biomarkers for graft function: Panel validation**
By: Gomez Dos Santos V.¹, Rodríguez-Serrano M.², Carracedo D.¹, Orosa A.¹, García-Bermejo L.², Ramos E.², Díez-Nicolás V.¹, Alvarez S.¹, Hevia V.¹, Martínez A.³, Jiménez S.⁴, Torres A.M.⁵, Martínez L.¹, Fernández A.¹, Burgos F.J.¹
Institutes:¹Hospital Universitario Ramón y Cajal, Dept. of Urology, Madrid, Spain, ²Hospital Universitario Ramón y Cajal, Biomarkers and Therapeutic Targets Group, Madrid, Spain, ³Hospital Universitario Ramón y Cajal, Transplantation Coordination, Madrid, Spain, ⁴Hospital Universitario Ramón y Cajal, Dept. of Nephrology, Madrid, Spain, ⁵Hospital Universitario Ramón y Cajal, Biobank, Madrid, Spain

- *600 **Association of early kidney allograft failure with preformed IgA antibodies to α 2-glycoprotein I**
By: De La Rosa Kehrmann E.¹, García González L.¹, Martínez-Flores J.A.², Duarte Ojeda J.M.¹, Pamplona Casamayor M.¹, Rodríguez Antolín A.¹, Passas Martínez J.¹
Institutes:¹Hospital Universitario 12 de Octubre, Dept. of Urology, Madrid, Spain, ²Hospital Universitario 12 de Octubre, Dept. of Immunology, Madrid, Spain
- *601 **Similarities between remote ischemic postconditioning and ischemic postconditioning in canine models undergoing warm ischemic and renal autotransplantation**
By: Jiang B.T.¹, Chen Q.², Liu X.³
Institutes:¹Xianning Central Hospital, Hubei Province, Dept. of Urology, Xianning, China, ²Xianning Central Hospital, Hubei Province, Dept. of Respiratory Medicine, Xianning, China, ³Renmin Hospital of Wuhan University, Dept. of Urology, Wuhan, China
- *602 **Syringic acid preconditioning improves kidney ischemia-reperfusion**
By: Sancak E.B.¹, Akbas A.¹, Silan C.², Cakir D.Ü.³, Sidika Seyma O.⁴
Institutes:¹Canakkale Onsekiz Mart University, Faculty of Medicine, Dept. of Urology, Canakkale, Turkey, ²Canakkale Onsekiz Mart University, Faculty of Medicine, Dept. of Pharmacology, Canakkale, Turkey, ³Canakkale Onsekiz Mart University, Faculty of Medicine, Dept. of Biochemistry, Canakkale, Turkey, ⁴Göztepe Training and Research Hospital, Dept. of Pathology, Canakkale, Turkey
- *603 **Myeloid heme oxygenase-1 controls renal ischemia reperfusion injury**
By: Rossi M.¹, Thierry A.², Preyat N.³, Delbauve S.², Leo O.³, Roumeguère T.¹, Flamand V.², Le Moine A.⁴, Hougardy J-M.⁴
Institutes:¹Erasmus Hospital, Dept. of Urology, Brussels, Belgium, ²Université Libre De Bruxelles, Institute for Medical Immunology, Gosselies, Belgium, ³Université Libre De Bruxelles, Institute for Molecular Biology and Medicine, Gosselies, Belgium, ⁴Erasmus Hospital, Dept. of Nephrology, Brussels, Belgium
- *604 **Serum N-glycan profiling predict antibody mediated rejection in patients undergoing living kidney transplantation**
By: Noro D.¹, Yoneyama T.², Tobisawa Y.¹, Hatakeyama S.¹, Saito M.³, Hashimoto Y.², Koie T.¹, Sato S.³, Ohyama C.¹
Institutes:¹Hirosaki University School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Hirosaki University School of Medicine, Dept. of Advanced Transplantation & Regenerative Medicine, Hirosaki, Japan, ³Akita University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan
- *605 **Reno-protective effect of local sildenafil administration in canine model of renal ischemia reperfusion injury**
By: Zahran M., Mosbah A., Nabeeh A., Shokeir A.A.
Institutes:Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt
- *607 **Analysis of factors that prescribes the compensatory hypertrophy ratio of the transplanted kidney**
By: Kato M., Fujita T., Funahashi Y., Ishida S., Gotoh M.
Institutes:Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan
- 15:13 - 15:20 **Summary and context**
A.J. Figueiredo, Coimbra (PT)

ESU/ESUT/ESUI Hands-on training in MRI Fusion Biopsy

HOT 30

Sunday, 13 March
14:00 - 16:00

Location: Room Africa (Hall B0, level 0)

Chair: L. Budäus, Hamburg (DE)

Aims and objectives of this presentation

MRI is increasingly used in patients undergoing prostate biopsies. Different MRI Ultrasound fusion devices allow integrating the MRI information into the daily clinical workflow.

The course will provide an overview on MRI reading, technical basics and different prostate biopsy approaches. Technical considerations, the transrectal or transperineal approach will be critically reviewed and discussed. During the second half of the course, the participants are able to try out 5 different Fusion biopsy machines in small groups, changing every 10 min.

Aims and objectives

o At the end of the course, the participants understand the advantages, handling and limitations of MRI Ultrasound fusion biopsies.

Target audience:

Urologists, interested in the diagnostic ability of MRI use for transrectal and perineal prostate biopsies

W. Picker, Oslo (NO)

M. Ritter, Mannheim (DE)

S. Kruck, Tübingen (DE)

C. Kastner, Cambridge (GB)

A. Rannikko, Helsinki (FI)

ESU Social Media Training

HOT 45

Sunday, 13 March
14:00 - 14:45

Location: Room 0.305

Chair: I.M. Van Oort, Nijmegen (NL)

Aims and objectives of this presentation

- EAU Congress Attendees will be instructed on how to harness professional Social Media to augment experience of professional meetings, follow urologic news feeds, and engage with the world-wide urologic community.
- Urologists who are expert in the use of Social Media will provide 45 minute small group hands-on workshops on the use of professional Social Media.
- Current Social Media users will have the opportunity to exchange expertise with other Social Media users during small group sessions.

A. Cebulla, Ulm (DE)

E-BLUS Exam

HOT 35

Sunday, 13 March
14:15 - 15:00

Location: Room South America (Hall B0, level 0)

Aims and objectives of this presentation

The European training in basic laparoscopic urological skills (E-BLUS) is a programme offered to residents and urologists who want to improve the basic skills in laparoscopy. It is a unique opportunity to train with international experts in laparoscopy. The E-BLUS programme includes:

- Hands-on training (HOT) sessions of different levels carried out under the guidance of experienced tutors
- A set of training-box exercises developed and validated by the Dutch project Training in Urology(TiU) to train basic skills needed in urological laparoscopy
- E-BLUS examination and certification
- An online theoretical course

To be confirmed

To be confirmed

A. Papatsoris, Athens (GR)

T. Tokas, Hall In Tirol (AT)

D. Veneziano, Minneapolis (US)

To be confirmed

Advanced course on upper tract laparoscopy (UPJ, adrenal and stones)

ESU Course 25

Sunday, 13 March
14:30 - 17:30

Location: Room 13a (ICM, Level 1)

Chair: G. Janetschek, Salzburg (AT)

Aims and objectives of this presentation

Surgery of the kidney and adrenal gland by means of laparoscopy is standard of care.

Approach: Transperitoneal, retroperitoneoscopy, posterior approach, direct approach through the mesentery of the colon. Each has specific advantages.

Procedures: Virtually all ablative procedures concerning the adrenal, kidney and ureter, but also reconstruction. Rarely but effectively stone surgery.

Presentation: power-point, interactive, videos, analysis of complications.

- For surgery of the kidney and adrenal, the da Vinci robot is often overkill. Therefore standard laparoscopy should be mastered in addition.
- Choice of the perfect approach makes the respective surgery easier and safer.
- Standard laparoscopy is greatly facilitated by 3D vision.
- When mastering both laparoscopic surgical skills and the surgical concept of the respective procedure complications can either be avoided or managed appropriately.

14:30 - 17:30

Transperitoneal approach to the kidney and retroperitoneum, nephrectomy

G. Janetschek, Salzburg (AT)

14:30 - 17:30

Retroperitoneoscopy: Lateral and posterior approach, nephrectomy

A. Alcaraz, Barcelona (ES)

14:30 - 17:30

Dismembered and nondismembered pyeloplasty: Indication - technique – problems – complications

H. Baumert, Paris (FR)

14:30 - 17:30

Nephroureterectomy

G. Janetschek, Salzburg (AT)

14:30 - 17:30

Adrenalectomy and partial adrenalectomy

H. Baumert, Paris (FR)

14:30 - 17:30

Stone surgery

A. Alcaraz, Barcelona (ES)

14:30 - 17:30

Questions and discussions

A. Alcaraz, Barcelona (ES)

H. Baumert, Paris (FR)

G. Janetschek, Salzburg (AT)

Flexible ureterorenoscopy and retrograde intrarenal surgery: Instrumentation, technique, tips and tricks, indications

ESU Course 26

Sunday, 13 March
14:30 - 17:30

Location: Room 13b (ICM, Level 1)

Chair: O. Traxer, Paris (FR)

Aims and objectives of this presentation

The aims and objectives of this course is to provide a complete overview of instruments, endoscopes, indications, technique and special tips and tricks concerning Retrograde IntraRenal Surgery (RIRS) using flexible ureterorenoscopes and Holmium YAG lasers. At the end the participants will know the equipment and the technique to perform flexible ureterorenoscopy in the best conditions.

- To learn about equipment
- To learn about technique and indications
- To learn how to use an Holmium Laser
- To learn tips and tricks for special circumstances

14:30 - 17:30

Welcome message and introduction of the course

O. Traxer, Paris (FR)

14:30 - 17:30

Instrumentation: Endoscopes

O. Traxer, Paris (FR)

14:30 - 17:30

Instrumentation: Laser and lithotripsy devices

M. Grasso, New York (US)

14:30 - 17:30

Instrumentation: Disposable (wires, retrieving devices, UAS, irrigation devices and others)

P.J.S. Osther, Fredericia (DK)

14:30 - 17:30

Technique: Stones

O. Traxer, Paris (FR)

14:30 - 17:30

Technique: Urothelial tumours and strictures

M. Grasso, New York (US)

14:30 - 17:30

Tips and tricks and special circumstances

O. Traxer, Paris (FR)

14:30 - 17:30

Indications (guidelines) and clinical cases

P.J.S. Osther, Fredericia (DK)

14:30 - 17:30

Conclusions

O. Traxer, Paris (FR)

Penile diseases

ESU Course 27

Sunday, 13 March
14:30 - 17:30

Location: Room 11 (ICM, Level 1)

Chair: S.S. Minhas, London (GB)

Aims and objectives of this presentation

This novel course will give a state of the art update on the variety of penile diseases that Urologists will encounter in everyday clinical practice. The faculty consists of a group of internationally renowned experts in this field.

A spectrum of pathologies can affect the penis including benign disorders to cancers. There will be particular focus on interactive case based discussions highlighting the pit falls and controversies in management of penile diseases;

- The aetiology, diagnosis and medical management of the common penile diseases including inflammatory conditions of the penis.
- The medical and surgical management of HPV, BXO and pre-malignant conditions of the penis.
- The course will also deal with the surgical management of these diseases including the surgical indications and surgical techniques used in penile reconstructive surgery.
- The management of penile carcinoma including the aetiopathogenesis, techniques/outcome of organ sparing surgery and surgical management of advanced disease including lymphadenectomy will be discussed.

14:30 - 17:30

Penile dermatology for the urologist

C. Bunker, London (GB)

14:30 - 17:30

Surgical management of penile diseases

S.S. Minhas, London (GB)

14:30 - 17:30

HPV, Premalignant lesions and penile cancer

S.S. Minhas, London (GB)

14:30 - 17:30

Management of penile cancer and lymph nodes

C. Protzel, Rostock (DE)

Surgery or radiotherapy for localised and locally advanced prostate cancer

ESU Course 28

Sunday, 13 March
14:30 - 17:30

Location: Room 12 (ICM, Level 1)

Chair: B. Djavan, Vienna (AT)

Aims and objectives of this presentation

The decision process towards surgery/active surveillance or radiation is a constantly evolving matter that requires a multitude of various information and inputs. In localised disease old habits have been jeopardised and surgical management seems to be fused with active surveillance in an increasing number of patients with good prognosticators. This course will summarise the decision process and indications for patients with clinically localised disease and help select the optimal treatment based on most recent oncological and functional data.

In locally advanced disease, growing evidence supports the notion of radical surgery to improve outcome. US and European data endorse this policy in a selected group of patients. New radiation protocols and strategies combined with hormone therapy offer as much adequate alternatives. In the second part of this course, controversies regarding the optimal management of locally advanced prostate cancer patients will be discussed and clear recommendations made to facilitate patient counselling and treatment.

14:30 - 17:30

Localised prostate cancer

14:30 - 17:30

Introduction

B. Djavan, Vienna (AT)

14:30 - 17:30

Treatment options and strategies in localised prostate cancer

B. Djavan, Vienna (AT)

14:30 - 17:30

How and when to use nomograms and networks

R.J.A. Van Moorselaar, Amsterdam (NL)

14:30 - 17:30

Oncology results of radiation therapy

G. De Meerleer, Ghent (BE)

14:30 - 17:30

Oncological and functional results of radical prostatectomy

B. Djavan, Vienna (AT)

14:30 - 17:30

Advanced prostate cancer

14:30 - 17:30

Radiotherapy with or without hormonal treatment in advanced PCA

G. De Meerleer, Ghent (BE)

14:30 - 17:30

Adjuvant therapies following radical prostatectomy: What is the standard and what is new?

R.J.A. Van Moorselaar, Amsterdam (NL)

14:30 - 17:30

Results of radical prostatectomy for T3 disease

B. Djavan, Vienna (AT)

14:30 - 17:30

Take home messages

B. Djavan, Vienna (AT)

Advanced vaginal reconstruction

ESU Course 29

Sunday, 13 March
14:30 - 17:30

Location: Room 21 (ICM, Level 2)

Chair: D. Pushkar, Moscow (RU)

Aims and objectives of this presentation

Clinicians involved in the care of female patients should know vaginal surgery. A specific goal of the faculty is to employ scientific principles, published information and clinical experience to describe and position newly developed techniques in current management of urinary incontinence. Special attention will be given to new techniques that use synthetic tapes in SUI surgery. This course will also cover the management of complications of surgery for stress incontinence and mesh complications. Treatment of recurrent urinary incontinence and incontinence with mixed symptoms also will be under discussion.

Management of vesicovaginal fistulas, urethral diverticulae and some rare conditions will be shown both during podium and video presentations. An interactive course means active participation by the audience and participants are encouraged to prepare and present interesting and challenging clinical cases for consultation by the faculty. After this course, participants should know how to apply the newest technique in patients with stress incontinence, urethral loss and iatrogenic injuries of lower urinary tract. This course will facilitate the decision making process for those who are just starting their careers and for advanced surgeons.

14:30 - 17:30

Introduction: Female Urology – improving functional outcome

D. Pushkar, Moscow (RU)

14:30 - 17:30

Stress urinary incontinence – approaching patient's expectations

D. Waltregny, Liège (BE)

14:30 - 17:30

Obstructive slings: What to do?

F.C. Burkhard, Berne (CH)

D. Pushkar, Moscow (RU)

14:30 - 17:30

Autologous sling in 2015

D. Waltregny, Liège (BE)

14:30 - 17:30

Management of mesh complications

F.C. Burkhard, Berne (CH)

D. Pushkar, Moscow (RU)

D. Waltregny, Liège (BE)

14:30 - 17:30

Urethral diverticulae surgery – tips and tricks

D. Waltregny, Liège (BE)

14:30 - 17:30

Urethral loss in females

D. Pushkar, Moscow (RU)

14:30 - 17:30

Vesico-vaginal fistulae repair from simple to complicated

D. Pushkar, Moscow (RU)

14:30 - 17:30

New slings for SUI – do you need one?

F.C. Burkhard, Berne (CH)

D. Waltregny, Liège (BE)

14:30 - 17:30

Adjournment

Nerve-sparing cystectomy and orthotopic bladder substitution - Surgical tricks and management of complications

ESU Course 30

Sunday, 13 March
14:30 - 17:30

Location: Room 22 (ICM, Level 2)

Chair: A. Stenzl, Tübingen (DE)

Aims and objectives of this presentation

This course has over many years dealt with the technique of urethra- and nerve-sparing cystectomy and subsequent orthotopic bladder substitution in male and female patients. It will deal with indications, technique, possible complications and their prevention. Urologists with a vast experience in cystectomy and urinary diversion will present technical tips using videoclips, results in the literature as well as own data.

- Technique of nerve-sparing cystectomy
- Optimization of sphincter preservation for optimal continence results
- Technical tips and tricks in orthotopic neobladder surgery
- What to observe in male and female patients

14:30 - 17:30

Preoperative investigations and selection of patients for orthotopic bladder substitution

J.E. Gschwend, Munich (DE)

14:30 - 17:30

Arguments for nerve sparing cystectomy with orthotopic bladder substitution

A. Stenzl, Tuebingen (DE)

14:30 - 17:30

How to do a nerve-sparing cystectomy in male patients

H. Abol-Enein, Mansoura (EG)

14:30 - 17:30

Surgical tricks to avoid complications with orthotopic bladder substitution

J.E. Gschwend, Munich (DE)

14:30 - 17:30

Video on how to obtain good functional results in female patients

A. Stenzl, Tuebingen (DE)

14:30 - 17:30

Tips and Tricks: Male/female orthotopic urinary diversion

H. Abol-Enein, Mansoura (EG)

14:30 - 17:30

How to treat complications during follow-up

J.E. Gschwend, Munich (DE)

ESU/ESFFU Hands-on training in Women's health

HOT 23

Sunday, 13 March
15:00 - 16:30

Location: Room North America (Hall B0, level 0)

Chair: J.P.F.A. Heesakkers, Nijmegen (NL)

Aims and objectives of this presentation

The European School of Urology (ESU) and the EAU Section of Female and Functional Urology (ESFFU) offer a practical hands-on training course with female pelvic models focusing on the placement of slings for the treatment of stress urinary incontinence. The delegates will be taken through a step-by-step programme of surgical treatment of stress urinary incontinence with retropubic, transobturator, and single-incision slings. The programme will begin with a discussion of patient selection and relevant clinical data. Videos demonstrating the different techniques will be presented, and afterwards the delegates will be instructed in small teams on the pelvic trainers. Finally, all remaining questions can be answered and discussed with the tutors, including the demonstration of tips and tricks.

D.M. Castro-Diaz, La Laguna Santa Cruz Tenerife (ES)

F. Van Der Aa, Leuven (BE)

ESU Social Media Training

HOT 46

Sunday, 13 March
15:00 - 15:45

Location: Room 0.305

Chair: V. Misrai, Toulouse (FR)

Aims and objectives of this presentation

- EAU Congress Attendees will be instructed on how to harness professional Social Media to augment experience of professional meetings, follow urologic news feeds, and engage with the world-wide urologic community.
- Urologists who are expert in the use of Social Media will provide 45 minute small group hands-on workshops on the use of professional Social Media.
- Current Social Media users will have the opportunity to exchange expertise with other Social Media users during small group sessions.

M.J. Ribal, Barcelona (ES)

E-BLUS Exam

HOT 36

Sunday, 13 March
15:15 - 16:00

Location: Room South America (Hall B0, level 0)

Aims and objectives of this presentation

The European training in basic laparoscopic urological skills (E-BLUS) is a programme offered to residents and urologists who want to improve the basic skills in laparoscopy. It is a unique opportunity to train with international experts in laparoscopy. The E-BLUS programme includes:

- Hands-on training (HOT) sessions of different levels carried out under the guidance of experienced tutors
- A set of training-box exercises developed and validated by the Dutch project Training in Urology (TiU) to train basic skills needed in urological laparoscopy
- E-BLUS examination and certification
- An online theoretical course

A. Papatsoris, Athens (GR)
W. Brinkman, Rotterdam (NL)
To be confirmed
T. Kalogeropoulos, Athens (GR)
T. Tokas, Hall In Tirol (AT)
D. Veneziano, Minneapolis (US)

ESU/ESUT/EULIS Hands-on training in Ureterorenoscopy

HOT 58

Sunday, 13 March
15:30 - 17:00

Location: Room Europe (Hall B0, level 0)

Chair: To be confirmed

Aims and objectives of this presentation

Ureteroscopy is an essential tool in the management of stone disease for all Endourologists. This course will provide hands-on-training with tutor guided practical tips and tricks of doing ureteroscopy. Participants will get a chance to perform Semirigid and Flexible ureteroscopy in the models with a chance to navigate the pelvicalyceal system, stone manipulation and extraction.

Aims and objectives

- At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models
- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.

L. Villa, Milan (IT)
D. Djordjevic, Belgrade (RS)
B.K. Somani, Southampton (GB)
S. Proietti, Perugia (IT)
S.A. Ahyai, Göttingen (DE)

ESU/ERUS Hands-on training in Robotic surgery

HOT 19

Sunday, 13 March
15:30 - 17:00

Location: Room Asia (Hall B0, level 0)

Chair: A.E. Canda, Ankara (TR)

Aims and objectives of this presentation

The European School of Urology (ESU) and the EAU Robotic Urology Section (ERUS) offer an intensive hands-on training course. We will provide training using simulators. The main aims of this 90 minutes course are: improving the participants' control-skills and hand-eye-coordination, as well as an objective benchmarking of console performance and an introduction into standardized surgical steps in robot-assisted procedures.

To be confirmed
N. Fossati, Milan (IT)

Innovation in nephrectomy and transplantation

Video Session 07

Sunday, 13 March
15:45 - 17:15

Location: eURO Auditorium (Hall C1, Level 0)

Chairs: F.J. Burgos Revilla, Madrid (ES)
A. Mattei, Lucerne (CH)
J-U. Stolzenburg, Leipzig (DE)

Aims and objectives of this presentation

The aim of the session is to show the advances and surgical challenges in the field of robotic kidney transplant and laparoscopic nephron sparing surgery. Mini-invasive techniques for resolution of kidney transplant complications will be updated.

All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.

- *V48 **PRESIRES: Preoperative simulation of renal surgery**
By: Von Rundstedt F-C., Scovell J., Zaneveld J.E., Von Rundstedt F-C.E., Link R.E.
Institutes: Baylor College of Medicine, Dept. of Urology, Houston, United States of America
- *V49 **Minimally ischemic partial nephrectomy: Surgical technique, perioperative and long term oncologic and functional outcomes of more than 1000 patients**
By: Simone G.¹, Misuraca L.¹, Papalia R.², Mastroianni R.², Tuderti G.¹, Ferriero M.¹, Minisola F.¹, Costantini M.¹, Pompeo V.¹, Guaglianone S.¹, Gallucci M.¹
Institutes:¹Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, ²Campus Biomedico University of Rome, Dept. of Urology, Rome, Italy
- *V51 **A novel approach for LESS nephroureterectomy for upper urinary tract urothelial carcinoma**
By: Huang Y-H.¹, Fan Y-H.¹, Kuo J-Y.¹, Chiu A.W.², Chang Y-H.³, Lin A.T.I.³, Chen K-K.³
Institutes:¹Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, ²Taipei City Hospital, Dept. of Surgery, Taipei, Taiwan, ³Taipei Veterans Hospital, Dept. of Urology, Taipei, Taiwan
- *V52 **Laparoscopic management of renal tumour in a horseshoe kidney**
By: Al Salhi Y., Palleschi G., Pastore A.L., Autieri D., Al Rawashdah S., Fuschi A., Leto A., Ripoli A., Carbone A.
Institutes: Sapienza University of Rome, Faculty of Pharmacy and Medicine, Dept. of Medico-Surgical Sciences and Biotechnologies, Urology Unit, ICOT, Latina, Italy
- *V53 **Robotic kidney transplantation: Our first case**
By: Breda A., Gausa L., Territo A., Schwartzmann I., Rodríguez Faba O., Caffaratti J., Ponce De León J., Villavicencio H.
Institutes: Universitat Autònoma de Barcelona - Fundació Puigvert, Dept. of Urology, Barcelona, Spain
- *V54 **Robotic kidney transplantation with transvaginal graft insertion**
By: Alcaraz A., Peri L., Vilaseca A., Izquierdo L., Mateu L., Musquera M.
Institutes: Hospital Clínic de Barcelona, Dept. of Urology, Barcelona, Spain
- *V55 **Endoscopic resolution of surgical challenges after kidney transplantation**
By: Laso I.M., Gómez-Dos-Santos V, Duque-Ruiz G., Fabuel-Alcañiz J.J., Martínez-Arcos L., Díez-Nicolás V, Fernández-Alcalde A.A., Hevia-Palacios V., Álvarez-Rodríguez S., Arias-Fúnez F., Burgos-Revilla F.J.
Institutes: Ramón Y Cajal University Hospital, Alcalá University, Dept. of Urology, Madrid, Spain

Making more of prostate biopsies

Poster Session 49

Sunday, 13 March
15:45 - 17:15

Location: Room Madrid (Hall B2, level 0)

Chairs: C. Beisland, Bergen (NO)
C. Surcel, Bucharest (RO)
G. Van Leenders, Rotterdam (NL)

Aims and objectives of this presentation

To address the role of prostatic biopsies in the diagnosis of early prostate cancer, how to make use of their diagnostic and prognostic value in clinical decision making, and how to improve their diagnostic yield.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *608 **Needle disinfectant technique during prostate biopsy is associated with less infection-related hospitalization: Results from a surgical collaborative**
By: [Ghani K.](#)¹, [Auffenberg G.](#)¹, [Brachulis A.](#)¹, [Linsell S.](#)¹, [Gao Y.](#)¹, [Ye Z.](#)¹, [Kraklau D.](#)², [Montie J.](#)¹, [Miller D.](#)¹
Institutes:¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²Lakeland Health, Dept. of Urology, St Joseph, United States of America
- *609 **Are all pathologic Gleason scores 8 created equal? Implications for the applicability of new prostate cancer grading system**
By: [Gandaglia G.](#)¹, [Fossati N.](#)², [Bianchi M.](#)³, [Freschi M.](#)⁴, [Doglioni C.](#)⁴, [Farina E.](#)², [Gallina A.](#)², [Stabile A.](#)², [Capitanio U.](#)², [Salonia A.](#)², [Montorsi F.](#)², [Briganti A.](#)²
Institutes:¹Irccs Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ³Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, ⁴IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy
- *610 **Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy**
By: [Qi R.](#), [Moul J.](#)
Institutes:Duke University Medical Center, Dept. of Urologic Surgery and Duke Cancer Institute, Durham, United States of America
- *611 **Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy**
By: [Kweldam C.F.](#)¹, [Kümmerlin I.P.](#)¹, [Nieboer D.](#)², [Verhoef E.I.](#)¹, [Steyerberg E.W.](#)², [Van Der Kwast T.H.](#)³, [Roobol M.J.](#)⁴, [Van Leenders G.J.L.H.](#)¹
Institutes:¹Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands, ³University Health Network, Laboratory Medicine Program, Toronto, Canada, ⁴Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands
- *613 **An improved clinical risk stratification system to better predict cancer specific mortality at diagnosis in primary non-metastatic prostate cancer**
By: [Gnanapragasam V.](#)¹, [Lophatananon A.](#)², [Muir K.](#)³, [Gavin A.](#)⁴, [Wright K.](#)⁵, [Greenberg D.](#)⁵
Institutes:¹University of Cambridge, Dept. of Academic Urology, Cambridge, United Kingdom, ²University of Warwick, Dept. of Health Science, Warwick, United Kingdom, ³University of Manchester, Dept. of Public Health, Manchester, United Kingdom, ⁴Queen's University Belfast, Northern Ireland Cancer Registry, Belfast, United Kingdom, ⁵Public Health England, Cambridge, United Kingdom

- *614 **Morphological and molecular pathway-based analysis of Gleason score 7 prostate cancer using a 17-gene expression assay**
By: [Bonham M.](#)¹, McCullough D.², Lu R.², Bennet J.³, Febbo P.⁴, Tsiatis A.⁵
Institutes:¹Genomic Health, Dept of Pathology, Redwood City, United States of America, ²Genomic Health, Dept. of Biostatistics, Redwood City, United States of America, ³Genomic Health, Dept. of Data Management, Redwood City, United States of America, ⁴Genomic Health, Dept. of Translational Sciences, Redwood City, United States of America, ⁵Genomic Health, Dept. of Pathology, Redwood City, United States of America
- *615 **Pathological outcomes after radical prostatectomy in men eligible for active surveillance, multi-institutional study**
By: [Mizuno K.](#)¹, Inoue T.², Kinoshita H.³, Yano T.⁴, Kawanishi H.⁵, Kanda H.⁶, Terada N.², Kamba T.², Okumura K.⁵, Kawakita M.⁴, Ogura K.¹, Sugimura Y.⁶, Matsuda T.³, Ogawa O.²
Institutes:¹Japanese Red Cross Otsu Hospital, Dept. of Urology, Otsu, Japan, ²Kyoto University Graduate School of Medicine, Dept. of Urology, Kyoto, Japan, ³Kansai Medical University, Dept. of Urology and Andrology, Hirakata, Japan, ⁴Kobe Medical Center General Hospital, Dept. of Urology, Kobe, Japan, ⁵Tenri Hospital, Dept. of Urology, Tenri, Japan, ⁶Mie University Graduate School of Medicine, Dept. of Nephro-Urologic Surgery and Andrology, Tsu, Japan
- *616 **Routine use of magnetic resonance imaging in prostate cancer facilitates better candidate selection for active surveillance**
By: [Sivaraman A.](#), Ahallal Y., Sanchez-Salas R., Barret E., Linares Ospinos E., Perez Regetti J., Russo A., Armando Hernandez Palacios G., Galiano M., Rozet F., Cathelineau X.
Institutes:Institute Mutualiste Montsouris, Dept. of Urology, Paris, France
- *617 **The value of PSA density in combination with PI-RADS scoring for prostate cancer prediction**
By: [Distler F.](#)¹, Radtke J.P.¹, Bonekamp D.², Roethke M.², Schlemmer H-P.², Roth W.³, Hohenfellner M.¹, Hadaschik B.A.¹
Institutes:¹University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ²German Cancer Research Center, Heidelberg, Dept. of Radiology, Heidelberg, Germany, ³University Hospital Heidelberg, Dept. of Pathology, Heidelberg, Germany
- *618 **Impact of targeted prostate biopsy using magnetic resonance imaging – ultrasound elastic fusion in men with suspicion of prostate cancer**
By: [Fourcade A.](#)¹, Perrouin-Verbe M-A.¹, Tissot V.², Serey-Effeil S.¹, Callerot P.¹, Cuvelier G.³, Coquet J-B.⁴, Doucet L.⁵, Delage F.⁴, Deruelle C.⁴, Joulin V.⁴, Fournier G.⁴, Valéri A.⁴
Institutes:¹University Hospital Of Brest, Department of Urology, Brest, France, ²University Hospital Of Brest, Department of Radiology, Brest, France, ³Hospital of Quimper, Department of Urology, Brest, France, ⁴University Hospital of Brest, Department of Urology, Brest, France, ⁵University Hospital of Brest, Department of Anatomic-Pathology, Brest, France
- *619 **A non-inferiority multicentric controlled trial comparing three MRI-TRUS targeted biopsies to systematic TRUS biopsies for the detection of prostate cancer in patients with a single suspicious focus on prostate MRI: Results of the MURIELLE study**
By: [Delongchamps N.B.](#)¹, Portalez D.², Bruguière E.³, Escourrou C.¹, Casanova J.M.⁴, Roumiguié M.⁵, Hohn N.⁶, Bratan F.⁷, Sanzalone T.⁷, Rouvière O.⁷, Fiard G.⁶, Thoulouzan M.⁵, Malavaud B.⁵, Bordier B.³, Guillotreau J.³, Bouazza N.¹, De Gorski A.⁸, Mozer P.⁸, Aziza R.⁹, Renard-Penna R.⁸, Misrai V.³, Descotes J.L.⁶, Cornud F.¹
Institutes:¹Cochin Hospital, Paris Descartes University, Dept. of Urology, Paris, France, ²Rangueil University Hospital, Dept. of Radiology, Toulouse, France, ³Clinique Pasteur, Dept. of Urology, Toulouse, France, ⁴Clinique Saint Jean de Dieu, Dept. of Urology, Paris, France, ⁵Rangueil University Hospital, Dept. of Urology, Toulouse, France, ⁶Grenoble University Hospital, Dept. of Urology, Grenoble, France, ⁷Hospices Civils de Lyon, Edouard Herriot Hospital, University Lyon 1, Dept. of Urinary and Vascular Radiology, Lyon, France, ⁸Pitié Salpêtrière University Hospital, Pierre et Marie Curie University, Dept. of Urology, Paris, France, ⁹Institut Universitaire du Cancer de Toulouse – Oncopole, Dept. of Urology, Toulouse, France

16:56 - 17:03

Summary and context

G. Van Leenders, Rotterdam (NL)

Cystectomy in 2016: Have we reached the limits

Poster Session 50

Sunday, 13 March
15:45 - 17:15

Location: Room Stockholm (Hall B2, level 0)

Chairs: P. Anderson, Melbourne (AU)
M. Burger, Regensburg (DE)
P. Zehnder, Luzern (CH)

Aims and objectives of this presentation

Understand the state-of-the-art in cystectomy technique.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

*620

Complication rates after radical cystectomy following any previous abdominal-pelvic-perineal radiotherapy: An international, multicenter retrospective study on 609 cases

By: Gontero P.¹, Pisano F.¹, Joniau S.², Albersen M.², Battaglia A.¹, Destefanis P.¹, Colombo R.³, Briganti A.³, Pellucchi F.³, Burgio G.³, Van Rhijn B.⁴, Van De Putte E.F.⁴, Esquena S.⁵, Palou J.⁵, Babjuk M.⁶, Fritsche H.M.⁷, Mayr R.⁷, Albers P.⁸, Niegisch G.⁸, De La Taille A.⁹, Masson-Lecomte A.⁹, Roupret M.¹⁰, Cai T.¹¹, Witjes J.A.¹², Bruins M.¹², Baniel J.¹³, Mano R.¹³, Brausi M.¹⁴, Lapini A.¹⁵, Sessa F.¹⁵, Irani J.¹⁶, Stenzl A.¹⁷, Gakis G.¹⁷, Karnes J.¹⁸, Zattoni F.¹⁸, Scherr D.¹⁹, O'Malley P.¹⁹, Shariat S.²⁰, Black P.²¹, Abdi H.²¹, Matveev V.B.²², Samuseva O.²², Peters M.²², Parekh D.²³, Gonzalgo M.²³, Fish M.²⁴, Atiquallah A.²⁴, Rink M.²⁴

Institutes:¹A.o Città Della Salute E Della Scienza, University of Turin, Dept. of Urology, Turin, Italy, ²University Hospitals Leuven, Dept. of Oncologic and Reconstructive Urology, Leuven, Belgium, ³URI, IRCCS Ospedale San Raffaele, Milan, Italy, Dept. of Urology, Milan, Italy, ⁴Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Dept. of Surgical Oncology (Urology), Amsterdam, The Netherlands, ⁵Fundació Puigvert, Universitat Autònoma De Barcelona, Dept. of Uro Oncology, Barcelona, Spain, ⁶Hospital Motol and 2nd Faculty of Medicine, Charles University, Dept. of Urology, Prague, Czech Republic, ⁷Regensburg University, Dept. of Urology, Regensburg, Germany, ⁸Heinrich-Heine-University, Medical Faculty, Dept. of Urology, Dusseldorf, Germany, ⁹CHU Mondor, Assistance Publique Des Hopitaux De Paris, Dept. of Urology, Paris, France, ¹⁰Hopital Pitié-Salpêtrière, Paris 6 University, Dept. of Urology, Paris, France, ¹¹Osp. S. Chiara, Dept. of Urology, Trento, Italy, ¹²Radboud University Nijmegen Medical Centre, Dept. of Urology, Nijmegen, The Netherlands, ¹³Rabin Medical Centre, Dept. of Urology, Tel Aviv, Israel, ¹⁴Ospedale Di Carpi-Modena, Dept. of Urology, Carpi, Italy, ¹⁵AOU Careggi, University of Florence, Dept. of Urology, Florence, Italy, ¹⁶Centre Hospitalier Universitaire La Milétrie, University of Poitiers, Dept. of Urology, Poitiers, France, ¹⁷University Clinic of Tübingen, Dept. of Urology, Tübingen, Germany, ¹⁸Mayo Clinic, Rochester, MN, Dept. of Urology, Rochester, United States of America, ¹⁹Weill Medical College of Cornell University, New York, Dept. of Urology, New York, United States of America, ²⁰Comprehensive Cancer Center Medical University Vienna, Dept. of Urology, Vienna, Austria, ²¹Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada, ²²Dept of Urology and N.N. Blokhin Cancer Research Center, Dept. of Urology, Moscow, Russia, ²³University of Miami Miller School of Medicine, Dept. of Urology, Miami, United States of America, ²⁴Hamburg-Eppendor University Hospital, Dept. of Urology, Hamburg, Germany

*621

Increased use of neoadjuvant chemotherapy for muscle invasive bladder cancer does not affect the rate of postoperative complications – results from the Swedish cystectomy registry

By: Jerlström T.¹, Gårdmark T.², Ströck V.³, Aljabery F.A-S.⁴, Hosseini A.A.⁵, Sherif A.⁶, Malmström P-U.⁷, Liedberg F.⁸, Jahnson S.⁴, Carringer M.¹

Institutes:¹Faculty of Medicine and Health, Dept. of Urology, Örebro, Sweden, ²Danderyd Hospital, Karolinska Institutet, Dept. of Clinical Sciences, Stockholm, Sweden, ³Sahlgrenska University Hospital, Dept. of Urology, Gothenburg, Sweden, ⁴Linköping University Hospital, Dept. of Clinical

and Experimental Medicine, Linköping, Sweden, ⁵Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Section of Urology, Stockholm, Sweden, ⁶Umeå University, Dept. of Surgical and Perioperative Sciences, Urology and Andrology, Umeå, Sweden, ⁷Uppsala University, Dept. of Surgical Sciences, Urology, Uppsala, Sweden, ⁸Skåne University Hospital, Lund University, Dept. Translational Medicine, Malmö, Sweden

- *622 **Excellent continence and renal function outcomes can be maintained in patients who survived >10 yrs after diversion with an ileal orthotopic bladder substitute**
By: Furrer M., Roth B., Nguyen D.P., Kiss B., Boxler S., Burkhard F.C., Thalmann G.N., Studer U.E.
Institutes: University Hospital Berne, Dept. of Urology, Berne, Switzerland
- *623 **Validating the Bladder Utility Symptom Scale (BUSS): A multi attribute health state classification system for bladder cancer**
By: Perlis N.¹, Boehme K.¹, Jamal M.², Bremner K.³, Alibhai S.⁴, Finelli A.⁵, Ritvo P.⁶, Krahn M.³, Kulkarni G.¹
Institutes:¹University of Toronto and University Health Network, Dept. of Surgical Oncology and Urology, Toronto, Canada, ²University of Toronto and Trillium Health Partners, Dept. of Urology, Toronto, Canada, ³University Health Network, Toronto Health Economics and Technology Assessment Collaborative, Toronto, Canada, ⁴University Health Network, Dept. of Geriatrics, Toronto, Canada, ⁵University of Toronto and University Health Network, Dept. of Surgical Oncology, Division of Urology, Toronto, Canada, ⁶York University and Cancer Care Ontario, Dept. of Psychology, Toronto, Canada
- *624 **Orthotopic ileal versus sigmoid neobladder in female patients, which is better regarding continence rates?**
By: El-Hilaly H.², El-Adawy M.², Abdel Latif A.¹, Metwally M.³, Mourad M.³, Mousa E.³
Institutes:¹Beni Suef, Dept. of Urology, Beni Suef, Egypt, ²Fayoum University, Dept of Urology, Fayoum, Egypt, ³El-Azhar University, Dept of Urology, Cairo, Egypt
- *625 **What is the evidence for unusual recurrence patterns following totally intracorporeal robotic-assisted radical cystectomy? Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group**
By: Collins J.¹, Hosseini A.¹, Adding C.¹, Nyberg T.¹, Koupparis A.², Rowe E.², Perry M.³, Issa R.³, Schumacher M.⁴, Wijburg C.⁵, Guru K.⁶, Canda A.E.⁷, Balbay M.D.⁸, Decaestecker K.⁹, Schwentner C.¹⁰, Stenzl A.¹⁰, Edeling S.¹¹, Pokupić S.¹¹, Mottrie A.¹², Wiklund P.¹
Institutes:¹Karolinska University Hospital, Dept. of Urology, Stockholm, Sweden, ²Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom, ³St Georges Hospital, Dept. of Urology, London, United Kingdom, ⁴Hirslanden Klinik, Dept. of Urology, Aarau, Switzerland, ⁵Rijnstate Hospital, Dept. of Urology, Arnhem, The Netherlands, ⁶Roswell Park Cancer Institute, Dept. of Urology, Buffalo, United States of America, ⁷Yildirim Beyazit University, Dept. of Urology, Ankara, Turkey, ⁸Memorial Sisli Hospital, Dept. of Urology, Istanbul, Turkey, ⁹Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ¹⁰Tubingen University Hospital, Dept. of Urology, Tubingen, Germany, ¹¹Da Vinci Zentrum, Dept. of Urology, Hanover, Germany, ¹²O.L.V, Dept. of Urology, Aalst, Belgium
- *626 **Bladder-sparing protocol consisting of low-dose chemoradiotherapy and consolidative partial cystectomy against muscle-invasive bladder cancer: Oncological and functional outcome in elderly patients**
By: Fujii Y., Kihara K., Tanaka H., Saito K., Yoshida S., Yokoyama M., Ishioka J., Matsuoka Y., Numao N.
Institutes: Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan
- *627 **Preoperative favourable characteristics in bladder cancer patients cannot substitute the necessity of extended lymphadenectomy during radical cystectomy: A sensitivity curve and a survival analysis**
By: Moschini M.¹, Suardi N.¹, Di Trapani E.¹, Cucchiara V.¹, Burgio G.¹, Mirone V.², Serretta V.³, Guido B.⁵, Shariat S.⁴, Briganti A.¹, Montorsi F.¹, Colombo R.¹, Gallina A.¹
Institutes:¹Uri, Irccs San Raffaele Scientific Institute, Dept. of Oncology and Urology, Milan, Italy, ²University Federico II, Dept. of Urology, Naples, Italy, ³Università Degli Studi Di Palermo, Dept. of

Discipline and Surgical Oncology, Palermo, Italy, ⁴Medical University Vienna, Dept. of Urology, Vienna, Austria, ⁵Center For Reconstructive Urethral Surgery,, Dept. of Surgery, Arezzo, Italy

- *628 **How to manage bowel division easily, cheaply and safely during intracorporeal robotic urinary diversion? LUCS: Lighting from Urethral (Cystoscope) Side!**
By: Dal Moro E., Zattoni F.
Institutes:Universita' di Padova - Azienda Ospedaliera, Dept. of Surgery, Oncology and Gastroenterology - Urology, Padua, Italy
- *629 **Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer**
By: Gakis G.¹, Morgan T.², Daneshmand S.³, Keegan K.A.⁴, Mischinger J.⁵, Schubert T.⁵, Zaid H.⁴, Hrbacek J.⁶, Clayman R.⁷, Ali-El-Dein B.⁸, Galland S.⁷, Olugbade K.², Rink M.⁹, Fritsche H-M.¹⁰, Burger M.¹⁰, Chang S.⁴, Babjuk M.⁶, Thalmann G.¹¹, Stenzl A.⁵, Efstathiou J.⁷
Institutes:¹University Hospital Tuebingen, Dept. of Urology, Tuebingen, Germany, ²University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ³University of Southern California, Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, ⁴Vanderbilt University Medical Center, Dept. of Urologic Surgery, Nashville, United States of America, ⁵University Hospital Tübingen, Dept. of Urology, Tübingen, Germany, ⁶2nd Medical School, Charles University, Dept. of Urology, Prague, Czech Republic, ⁷Massachusetts General Hospital, Harvard Medical School, Dept. of Radiooncology, Boston, United States of America, ⁸Mansoura Clinic, Dept. of Urology and Nephrology, Mansoura, Egypt, ⁹University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ¹⁰University of Regensburg, Dept. of Urology, Regensburg, Germany, ¹¹University of Berne, Dept. of Urology, Berne, Switzerland
- *630 **Factors impacting local, distant and unusual recurrences after robot-assisted radical cystectomy: A detailed analysis from a tertiary referral center**
By: Nguyen T.P.D., Al Hussein Al Awamlh B., Golombos D., O'Malley P., Khan F., Lewicki P., Scherr D.
Institutes:Weill Medical College of Cornell University, Dept. of Urology, New York, United States of America
- *631 **Comparative effectiveness of robot-assisted and open radical cystectomy**
By: Gandaglia G.¹, Karl A.², Novara G.³, De Groot R.⁴, Buchner A.², D' Hondt F.⁴, Montorsi F.⁵, Stief C.², Motttrie A.⁶, Gratzke C.²
Institutes:¹Irccs Ospedale San Raffaele, Dept. of Oncology and Urology, Urological Research Institute, Milan, Italy, ²Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, ³OLV Vattikuti Robotic Surgery Institute, ORSI, Melle, Belgium, ⁴OLV Hospital, Dept. of Urology, Aalst, Belgium, ⁵IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Urological Research Institute, Milan, Italy, ⁶OLV Hospital, OLV Vattikuti Robotic Surgery Institute, Dept. of Urology, ORSI, Aalst, Melle, Belgium
- *632 **Radical cystectomy for bladder cancer vs non-malignant indications: Preoperative predictors of perioperative outcomes in a sample of 3269 patients**
By: Vetterlein M.¹, Meyer C.¹, Löppenber B.¹, Sammon J.², Hanske J.¹, Menon M.², Preston M.¹, Chun F.³, Kibel A.¹, Fisch M.³, Trinh Q-D.¹
Institutes:¹Brigham and Women's Hospital, Dept. of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Henry Ford Hospital / Health System, Vattikuti Institute of Urology, Center For Outcomes Research, Analytics and Evaluation, Detroit, United States of America, ³University Medical Center Hamburg-Eppendorf, Dept. of Urologic Surgery and Center For Surgery and Public Health, Hamburg, Germany

Partial nephrectomy: Improving surgical outcomes

Poster Session 51

Sunday, 13 March
15:45 - 17:15

Location: Room Milan (Hall B2, level 0)

Chairs: A. Minervini, Florence (IT)
M. Oya, Tokyo (JP)
G. Palapattu, Ann Arbor (US)

Aims and objectives of this presentation

This session includes several Abstracts addressing surgical outcomes.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *633 **Oncologic outcome of an incidental pathological T3a stage after partial nephrectomy in small renal cell carcinoma**
By: [Yoo S.](#)¹, [Ahn T.Y.](#)¹, [Han J.H.](#)¹, [Shin J.](#)¹, [Jung J.](#)¹, [Lee C.](#)¹, [You D.](#)¹, [Jeong I.G.](#)¹, [Hong J.H.](#)¹, [Song C.](#)¹, [Hong B.](#)¹, [Kwon T.](#)², [Moon K.H.](#)², [Kim H.J.](#)³, [Sungwoo H.](#)³, [Ahn H.](#)¹, [Kim C-S.](#)¹
Institutes:¹Asan Medical Center, Ulsan University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Ulsan University Hospital, University of Ulsan College of Medicine, Dept. of Urology, Ulsan, South Korea, ³Dankook University College of Medicine, Dept. of Urology, Cheonan, South Korea
- *634 **Does an unexpected final pathology of pT3a renal tumour undermine cancer control in clinically T1N0M0 patients who were initially treated with nephron sparing surgery?**
By: [Capitanio U.](#)¹, [Stewart G.](#)², [Larcher A.](#)¹, [Klatte T.](#)³, [Volpe A.](#)⁴, [Akdogan B.](#)⁵, [Roscigno M.](#)⁶, [Lingard J.](#)², [Langenhuijsen H.](#)⁷, [Marszalek M.](#)⁸, [Rodriguez Faba O.](#)⁹, [Salagierski M.](#)¹⁰, [Carini M.](#)¹¹, [Stief C.](#)¹², [Minervini A.](#)¹¹, [Da Pozzo L.F.](#)⁶, [Brookman-May S.](#)¹²
Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Western General Hospital, Dept. of Urology, Edinburgh, United Kingdom, ³Vienna Medical University, Dept. of Urology, Vienna, Austria, ⁴Maggiore Della Carità Hospital, Dept. of Urology, Novara, Italy, ⁵Hacettepe University, Dept. of Urology, Ankara, Turkey, ⁶Papa Giovanni XXIII Hospital, Dept. of Urology, Bergamo, Italy, ⁷Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ⁸Donauspital, Dept. of Urology, Vienna, Austria, ⁹Fundacio-Puigvert, Dept. of Urology, Barcelona, Spain, ¹⁰Kent & Canterbury Hospital, Dept. of Urology, Canterbury, United Kingdom, ¹¹Azienda Ospedaliera Universitaria Careggi, Dept. of Urology, Florence, Italy, ¹²Lmu Grosshadern, Dept. of Urology, Munich, Germany
- *635 **Survival outcomes for localized renal cell carcinoma according to tumor location and operation method (radical versus partial nephrectomy): A propensity matched analysis**
By: [Shim M.](#)¹, [Choi S.K.](#)², [Park M.](#)², [Song C.](#)², [Ahn T.Y.](#)², [Ahn H.](#)²
Institutes:¹Hallym University Sacred Heart Hospital, Dept. of Urology, Anyang-Si, South Korea, ²Asan Medical Center, University of Ulsan College of Medicine, Dept. of Urology, Seoul, South Korea
- *636 **Centrally located solitary kidney tumors – partial nephrectomy, an imperative indication**
By: [Gingu C.](#), [Crasneanu M.](#), [Dick A.](#), [Baston C.](#), [Cerempei V.](#), [Surcel C.](#), [Ianiotescu S.](#), [Andresanu A.](#), [Voinea S.](#), [Preda A.](#), [Iordache A.](#), [Domnisor L.](#), [Sinescu I.](#)
Institutes:Fundeni Clinical Institute, Center of Urological Surgery and Renal Transplantation, Bucharest, Romania
- *637 **Oncologic outcomes between partial and radical nephrectomy for pT3a renal cell carcinoma: A propensity score matched analysis**
By: [Minich A.](#), [Mirylenka L.](#), [Zelenkevich I.](#), [Ryndzin A.](#), [Rolevich A.](#), [Polyakov S.](#)

Institutes:N.N. Alexandrov National Cancer Centre of Belarus, Dept. of Urology, Minsk, Belarus

*638 **Oncological outcomes of partial versus radical nephrectomy for cT1-2/Nx clear cell RCC: Propensity score matched analysis**

By: Simone G.¹, Papalia R.², Ferriero M.¹, Tuderti G.¹, Mastroianni R.², Minisola F.¹, Misuraca L.¹, Costantini M.¹, Guaglianone S.¹, Pompeo V.¹, Muto G.², Gallucci M.¹

Institutes:¹"Regina Elena" National Cancer Institute, Dept. of Urology, Rome, Italy, ²Campus Biomedico University of Rome, Dept. of Urology, Rome, Italy

*639 **External validation of four nephrometry scores for trans-peritoneal robotic partial nephrectomy - do we have a winner?**

By: Rai B.P.¹, Patel A.², Abroaf A.¹, King C.², Suleyman N.¹, Vasdev N.¹, Adshead J.¹

Institutes:¹Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, ²Lister Hospital, Dept. of Radiology, Stevenage, United Kingdom

*640 **A novel and simple "3S" nephrometry score system to evaluate the technical complexity of nephron-sparing surgery**

By: Zhang S., Ma L., Huang Y., Liu K., Tian Y., Zhang H.

Institutes:Peking University Third Hospital, Dept. of Urology, Beijing, China

*641 **Defining nephrometry: Prospective comparison of R.E.N.A.L, PADUA, NePhRO and C-index score**

By: Kriegmair M.¹, Mandel P.², Moses A.¹, Lenk J.³, Rothamel M.³, Budjan J.⁴, Wagener N.¹, Michel M-S.¹, Pfalzgraf D.¹

Institutes:¹University Medical Center Mannheim, Dept. of Urology, Mannheim, Germany, ²University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ³Urological Hospital Munich-Planegg, Dept. of Urology, Munich-Planegg, Germany, ⁴University Medical Center M Nuclear Medicineannheim, Dept. of Radiology and Nuclear Medicine, Mannheim, Germany

*642 **Modified C index is a novel predictor of the renal functional change following laparoscopic partial nephrectomy**

By: Ito H., Makiyama K., Kawahara T., Osaka K., Izumi K., Yokomizo Y., Nakaigawa N., Yao M.

Institutes:Yokohama City University School of Medicine, Dept. of Urology, Kanagawa, Japan

*643 **Clamp vs clampless endoscopic robot-assisted simple enucleation (ERASE) for the treatment of clinical T1 renal masses: Analysis of surgical and functional outcomes from a matched-paired comparison**

By: Mari A., Minervini A., Sessa F., Campi R., Bonifazi M., Chini T., Salvi M., Siena G., Tuccio A., Masieri L., Vignolini G., Gacci M., Serni S., Carini M.

Institutes:Careggi University Hospital, Dept. of Urology, Florence, Italy

*644 **Medical risk factors for chronic kidney disease are not independent predictors of worse renal function outcome following robotic partial nephrectomy in patients with a normal baseline kidney function**

By: Reddy B.N.¹, Paulucci D.¹, Abaza R.², Eun D.³, Moshier E.¹, Badani K.¹

Institutes:¹Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America, ²Ohio Health Dublin Methodist Hospital, Dept. of Urology, Dublin, United States of America, ³Temple University, Dept. of Urology, Philadelphia, United States of America

*645 **Functional and oncological outcomes of open nephron-sparing surgery for complex renal masses**

By: Bahouth Z., Halachmi S., Barbara Y., Braz Y., Ishak E., Moskovitz B., Nativ O.

Institutes:Bnai-zion Medical Center, Dept. of Urology, Haifa, Israel

17:00 - 17:07

Summary and context

A. Minervini, Florence (IT)

The practical approach to neurogenic LUTD

Poster Session 52

Sunday, 13 March
15:45 - 17:15

Location: Room 14a (ICM, Level 1)
Chairs: T.M. Kessler, Zürich (CH)
A.M.M.S. Tayib, Jeddah (SA)
G. Van Koeveringe, Maastricht (NL)

Aims and objectives of this presentation

Overview of new approaches and longterm outcome in neurogenic patients.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *646 **Effect of early sacral and pudendal neuromodulation on lower urinary tract and spinal cord in spinal cord injury mini pigs**
By: [Foditsch E.E.](#)¹, [Patras I.](#)², [Hutu I.](#)², [Bauer S.](#)¹, [Roider K.](#)¹, [Sievert K-D.](#)¹, [Zimmermann R.](#)¹
Institutes:¹Paracelsus Medical University, Dept. of Urology and Andrology, Salzburg, Austria, ²Banat University of Agronomical Sciences and Veterinary Medicine, Dept. of Animal Productions and Veterinary Public Health, Timisoara, Romania
- *647 **Efficacy and safety of onabotulinumtoxinA 100U for treatment of urinary incontinence due to neurogenic detrusor overactivity in non-catheterising multiple sclerosis patients**
By: [Chartier-Kastler E.](#)¹, [Denys P.](#)², [Keppenne V.](#)³, [Brucker B.](#)⁴, [Egerdie B.](#)⁵, [Magyar A.](#)⁶, [Nicando J.P.](#)⁷, [Jenkins B.](#)⁷, [Kohan A.](#)⁸
Institutes:¹Université Paris-VI, Dept. of Urology, Paris, France, ²Hôpital Raymond Poincaré, Dept. of Neuro-Urology, Garches, France, ³Université De Liège, Dept. of Urology, Liège, Belgium, ⁴New York University, Dept. of Urology and Obstetrics and Gynaecology, New York, United States of America, ⁵Urology Associates/Urologic Med Research, Dept. of Urology, Ontario, Canada, ⁶Allergan Plc, Dept. of Biostatistics, Bridgewater, United States of America, ⁷Allergan Plc, Dept. of Urology, Irvine, United States of America, ⁸Advanced Urology Centers of New York, Dept. of Urology, Bethpage, United States of America
- *648 **Lower urinary tract dysfunction is the major concern of adult patients with spina bifida: Data from a prospective cohort of 371 patients**
By: [Peyronnet B.](#)¹, [Brochard C.](#)², [Jezequel M.](#)³, [Ménard H.](#)³, [Dampousse M.](#)⁴, [Bonan I.](#)⁴, [Kerdran J.](#)⁴, [Siproudhis L.](#)², [Gamé X.](#)⁵, [Manunta A.](#)¹
Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²CHU Rennes, Dept. of Gastrology, Rennes, France, ³CHU Rennes, Referral Center For Spina Bifida, Rennes, France, ⁴CHU Rennes, Dept. of Physical Medicine, Rennes, France, ⁵CHU Toulouse, Dept. of Urology, Toulouse, France
- *649 **Bacteriuria in patients undergoing intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity: Do we need antibiotic prophylaxis?**
By: [Leitner L.](#)¹, [Sammer U.](#)², [Walter M.](#)², [Knüpfer S.](#)², [Schneider M.P.](#)³, [Seifert B.](#)⁴, [Mehnert U.](#)², [Kessler T.M.](#)²
Institutes:¹Balgrist University Hospital and University Hospital of Basel, Dept. of Neuro-Urology and Urology, Zürich and Basel, Switzerland, ²Balgrist University Hospital, Dept. of Neuro-Urology, Zürich, Switzerland, ³ETH Zürich, Brain Research Institute, Zürich, Switzerland, ⁴University of Zürich, Dept. of Biostatistics and Prevention, Zürich, Switzerland
- *651 **Urodynamic findings in amiotrophic lateral sclerosis patients with lower urinary tract symptoms**
By: [Arlandis S.](#)¹, [Vazquez-Costa J.F.](#)², [Martinez-Cuenca E.](#)¹, [Sevilla T.](#)², [Boronat F.](#)¹, [Broseta E.](#)¹
Institutes:¹Hospital Universitari i Politècnic La Fe, Dept. of Urology, Valencia, Spain, ²Hospital

Universitari i Politècnic La Fe, Dept. of Neurology, Valencia, Spain

- *652 **Intradetrusor injections of onabotulinum toxin A (Botox®) 300 u or 200 u versus abobotulinum toxin A (Dysport®) 750 u in the management of neurogenic detrusor overactivity: A case control study**
 By: Peyronnet B.¹, Castel-Lacanal E.², Roumiquié M.³, Even L.³, Guillotreau J.³, Marque P.², Soulié M.⁴, Rischmann P.⁴, Gamé X.⁴
 Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²CHU Toulouse, Dept. of Physical Medicine, Toulouse, France, ³CHU Toulouse, Dept. of Urology, Toulouse, France, ⁴CHU Toulouse, Dept. of Urology, Toulouse, France
- *653 **Urinary and sexual dysfunction in patients affected by Parkinson's disease**
 By: Gubbiotti M.¹, Rossi De Vermandois J.A.¹, Boni A.¹, Proietti S.², Conte A.³, Berardelli A.³, Giannantoni A.¹
 Institutes:¹University of Perugia, Dept. of Surgical and Biomedical Sciences, Perugia, Italy, ²Pierre and Marie Curie University, Tenon Hospital, Dept. of Urology, Paris, France, ³Sapienza University of Rome, Dept. of Neurology and Psychiatry, Rome, Italy
- *654 **Is an early anticholinergic treatment able to prevent detrusor overactivity after spinal cord transection in rats?**
 By: Biardeau X., Aharony S., Loutochin O., Campeau L., Corcos J.
 Institutes: Jewish General Hospital, Dept. of Urology, Montreal, Canada
- *655 **Impairment of sensory nerves by onabotulinumtoxinA improves neurogenic detrusor overactivity following spinal cord injury**
 By: Coelho A.¹, Oliveira R.², Cruz E.¹, Cruz C.²
 Institutes:¹University of Porto, Dept. of Renal, Urologic and Infectious Diseases, Porto, Portugal, ²University of Porto, Dept. of Experimental Biology, Porto, Portugal
- *656 **Mirabegron and refractory neurogenic urinary incontinence**
 By: Andretta E.¹, Virdone S.², Filocamo M.T.³, Zuliani C.⁴, Artuso G.¹
 Institutes:¹General Hospital Ulss 13 Veneto, Dept. of Urology, Dolo, Italy, ²CRO National Cancer Institute, Dept. of Epidemiology, Aviano, Italy, ³General Hospital, Dept. of Urology, Savigliano, Italy, ⁴General Hospital Ulss 13 Veneto, Dept. of Neurology, Mirano, Italy
- *657 **More than 15 years experience with intradetrusor onabotulinumtoxinA injections for treating refractory neurogenic detrusor overactivity: Lessons to be learned**
 By: Tornic J.¹, Leitner L.², Guggenbühl S.¹, Walter M.¹, Knüpfer S.¹, Schneider M.P.³, Mehnert U.¹, Kessler T.M.¹
 Institutes:¹Balgrist University Hospital, Dept. of Neuro-Urology, Zürich, Switzerland, ²Balgrist University Hospital and University Hospital of Basel, Dept. of Neuro-Urology/Urology, Zürich and Basel, Switzerland, ³ETH Zürich, Brain Research Institute, Zürich, Switzerland
- *658 **Risks factors for recurrent urinary tract infections in patients with multiple sclerosis**
 By: Phé V.¹, Curtis C.², Neha S.¹, Porter B.³, Chataway J.³, Panicker J.¹, Pakzad M.¹
 Institutes:¹The National Hospital For Neurology and Neurosurgery, Dept. of Uro-Neurology and UCL Institute of Neurology, London, United Kingdom, ²University College London Hospital, Dept. of Microbiology, London, United Kingdom, ³The National Hospital For Neurology and Neurosurgery, Dept. of Neurology and UCL Institute of Neurology, London, United Kingdom
- *659 **Pudendal nerve neuromodulation: Where do we stand? Trends after analysis of a ten year experience**
 By: Renard J.E.E.¹, Citeri M.², Zanollo L.², Guerrer C.², Rizzato L.², Frediani L.², Iselin C.¹, Spinelli M.²
 Institutes:¹Hôpitaux Universitaires de Genève, Dept. of Urology, Genève, Switzerland, ²Niguarda Hospital, Spinal Unit, A. Zanollo Center for Sacral Area Dysfunctions, Milan, Italy
- 17:04 - 17:11 **Summary and context**
 T.M. Kessler, Zürich (CH)

Outcomes in radical prostatectomy

Poster Session 53

Sunday, 13 March
15:45 - 17:15

Location: Room 14b (ICM, Level 1)

Chairs: B.J. Challacombe, London (GB)
E.M. Johansson, Uppsala (SE)
Q-D. Trinh, Boston (US)

Aims and objectives of this presentation

During this session, results of radical prostatectomy will be discussed including the impact of surgical expertise and learning curves.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *660 **A population based analysis of complications after radical prostatectomy – results from the German DRG database**
By: Schmitges J.¹, Rose J.¹, Pollmanns J.², Graefen M.³, Neukirch B.², Friedrich M.G.¹, Droesler S.², Weyermann M.²
Institutes:¹Helios Hospital Krefeld, Dept. of Urology, Krefeld, Germany, ²Niederrhein University of Applied Sciences, Faculty of Health Care, Krefeld, Germany, ³Martini-Clinic, Prostate Cancer Centre, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- *661 **Surgical expertise represents a strong determinant of early continence recovery after robot-assisted radical prostatectomy**
By: Suardi N., Fossati N., Gandaglia G., Dell'Oglio P., Gallina A., Zaffuto E., Farina E., Picozzi M., Pini G., Gaboardi F., Montorsi F., Briganti A.
Institutes:IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy
- *662 **Prospective randomized trial comparing the use of titan clips versus bipolar coagulation to seal lymphatic vessels during robot-assisted extended pelvic lymph node dissection and radical prostatectomy**
By: Grande P., Di Pierro G.B., Mordasini L., Ferrari M., Danuser H., Mattei A.
Institutes:Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland
- *663 **Scoring surgical skill in robotic prostatectomy as adherence to the surgical plan: Proposal for a new tool (ScAPSA)**
By: Dal Moro E.¹, Gardiman M.P.², Zattoni F.¹
Institutes:¹Universita' di Padova - Azienda Ospedaliera, Dept. of Surgery, Oncology and Gastroenterology and Dept. of Urology, Padua, Italy, ²Universita' di Padova - Azienda Ospedaliera, Dept. of Pathology, Padua, Italy
- *664 **Robot assisted laparoscopic radical prostatectomy: An old but new method to draw learning curves**
By: Okano M.¹, Ivanovic R.², Nomelini Q.S.S.⁵, Morais H.¹, Jr. Pontes J.¹, Salles M.¹, Reis S.¹, Savio L.¹, Srougi M.³, Vuolo C.¹, Passerotti C.⁴
Institutes:¹German Hospital Oswaldo Cruz, Robotic Surgery Center, Sao Paulo, Brazil, ²German Hospital Oswaldo Cruz, Dept. of Robotic Surgery, Sao Paulo, Brazil, ³University of São Paulo, Dept. of Urology, Sao Paulo, Brazil, ⁴German Hospital Oswaldo Cruz, University of São Paulo, Sao Paulo, Brazil, ⁵Federal University of Uberlândia, Dept. of Urology, Minas Gerais, Brazil
- *665 **Do functional outcomes correlate with long-term quality of life 5-years after radical**

prostatectomy?

By: Löppenberg B., Bach P., Von Bodman C., Roghmann F., Noldus J., Palisaar J.

Institutes: Marien Hospital Herne, Ruhr-Universität Bochum, Dept. of Urology, Herne, Germany

*666

Single surgeon perioperative and early functional results of initial 64 RARPs after graduating "ERUS robotic urology curriculum fellowship (pilot study II)" for robot-assisted radical prostatectomy (RARP)

By: Salwa P., Wagner C., Schuette A., Harke N., Witt J.

Institutes: St. Antonius-Hospital Gronau GmbH, Dept. of Urology, Pediatric Urology and Urologic Oncology – Prostate Center Northwest, Ebu Certified Sub-Speciality Centre, Gronau, Germany

*667

Factors influencing recovery of erectile function following robot assisted laparoscopic radical prostatectomy (RALP)

By: Palayapalayam Ganapathi H., Ogaya G., Woodlief T., Rogers T., Mouraviev V., Patel V.

Institutes: Global Robotics Institute, Center For Urologic Cancer, Celebration, United States of America

*668

A total population analysis of in-hospital outcomes of radical prostatectomy in Germany from 2006 to 2013: Impact of surgical approach and the degree of specialisation

By: Groeben C.¹, Koch R.², Baunacke M.¹, Wirth M.¹, Huber J.¹

Institutes:¹Medical Faculty Carl Gustav Carus, TU Dresden, Dept. of Urology, Dresden, Germany, ²Medical Faculty Carl Gustav Carus, TU Dresden, Dept. of Medical Statistics and Biometry, Dresden, Germany

*669

Surgeon and hospital variation in the costs of robot-assisted radical prostatectomy in the United States

By: Meyer C.¹, Cole A.¹, Leow J.¹, Chang S.¹, Kibel A.¹, Menon M.², Sammon J.², Chung B.³, Sun M.¹, Trinh Q-D.¹

Institutes:¹Brigham and Women's Hospital, Dept. of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Henry Ford Hospital, Vatikutti Urology Institute, Detroit, United States of America, ³Stanford University Medical Center, Dept. of Urology, Palo Alto, United States of America

*670

Single positive lymph node prostate cancer can be surgically cured in selective cases

By: Kim D.K.², Alatawi A.², Alabdulaali I.², Sheikh A.², Abdel Raheem A.¹, Ham W.S.², Chung B.H.², Rha K.H.²

Institutes:¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Yonsei University College of Medicine, Department of Urology and Urological Science Institute, Seoul, South Korea

*671

Results of surgical treatment of patients with high and very high risk prostate cancer: Is there a chance of curative operation?

By: Nyushko K.¹, Alekseev B.², Krasheninnikov A.³, Sergienko S.³, Kalpinskiy A.³, Vorobyev N.³, Kaprin A.⁴

Institutes:¹P.A. Herzen Moscow Oncological Research Institute, Dept. of Oncourology, Moscow, Russia, ²P.A. Herzen Moscow Oncological Research Institute, Deputy Director for Scientific Work, Moscow, Russia, ³P.A. Herzen Moscow Oncological Research Institute, Dept. of Urology, Moscow, Russia, ⁴P.A. Herzen Moscow Oncological Research Institute, Head of the Institution, Moscow, Russia

17:00 - 17:07

Summary and context

E.M. Johansson, Uppsala (SE)

Radiation therapy for prostate cancer

Poster Session 54

Sunday, 13 March
15:45 - 17:15

Location: Room 14c (ICM, Level 1)

Chairs: D. Basic, Nis (RS)
R. Ganzer, Leipzig (DE)
R.J. Karnes, Rochester (US)

Aims and objectives of this presentation

Radiation therapy, its outcome and its morbidity for localised prostate cancer patients will be discussed in this session. An interesting prospective randomised trial comparing robotic prostatectomy and brachytherapy will be discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*672

Long term outcomes of prostate brachytherapy in Japan and recurrence predictors

By: [Yagi Y.](#)¹, Aoki K.¹, Nakamura K.¹, Hasegawa M.¹, Ozu C.¹, Nishiyama T.¹, Shiraishi Y.², Toya K.³, Yorozu A.⁴, Saito S.¹

Institutes:¹Tokyo Medical Center, Dept. of Urology, Tokyo, Japan, ²Keio University, Dept. of Radiation Oncology, Tokyo, Japan, ³International University of Health and Welfare, Mita Hospital, Dept. of Radiation Oncology, Tokyo, Japan, ⁴Tokyo Medical Center, Dept. of Radiation Oncology, Tokyo, Japan

*673

Long term 15 years disease free data of LDR brachytherapy in 1700 consecutive men

By: [Matzkin H.](#)¹, Agai R.¹, Strauss N.², Meir Y.², Mabjeesh N.¹

Institutes:¹Tel-Aviv Medical Center, Dept. of Urology, Tel Aviv, Israel, ²Tel-Aviv Medical Center, Dept. of Oncology, Tel Aviv, Israel

*674

Quality of Life (QoL) in patients with locally advanced prostate cancer treated with neoadjuvant endocrine, external beam radiation and adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase III trial

By: [Yokomizo A.](#)¹, Koga H.², Ito K.³, Suzuki K.³, Yamanaka H.⁴, Naito S.²

Institutes:¹Kyushu University Graduate School of Medical Sciences, Dept. of Urology, Fukuoka, Japan, ²Harasanshin Hospital, Dept. of Urology, Fukuoka, Japan, ³Gunma University Graduate School of Medicine, Dept. of Urology, Maebashi, Japan, ⁴Kurosawa Hospital, Dept. of Urology, Takasaki, Japan

*675

Urethral strictures after radiotherapy for prostate cancer - 5 year data of a certified prostate-cancer-centre

By: [Kranz J.](#)¹, Maurer G.², Maurer U.², Deserno O.¹, Steffens J.¹

Institutes:¹St.-Antonius-Hospital, Dept. of Urology, Eschweiler, Germany, ²MVR RNR Eschweiler, Eschweiler, Germany

*676

Prospective evaluation of urinary function in patients with prostate cancer treated with external beam radiation therapy

By: [Badenchini F.](#)², [Cozzarini C.](#)¹, Avuzzi B.², Fodor A.¹, Noris Chiorda B.¹, Rancati T.², Sini C.³, Valdagni R.², Di Muzio N.¹, Fiorino C.³

Institutes:¹San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy, ²Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Radiotherapy, Milan, Italy, ³San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy

- *677 **Oncological outcomes in patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase III trial**
 By: [Ito K.](#)¹, Suzuki K.¹, Yamanaka H.²
 Institutes:¹Gunma University Graduate School of Medicine, Dept. of Urology, Maebashi, Japan, ²Kurosawa Hospital, Institute for Preventive Medicine, Takasaki, Japan
- *678 **External beam radiotherapy with or without androgen deprivation therapy in very elderly patients with high metastatic risk prostate cancer**
 By: [Dell'Oglio P.](#)¹, Leyh-Bannurah S-R.², Tian Z.³, Trudeau V.¹, Larcher A.⁴, Fossati N.⁴, Moschini M.⁴, Sosa J.¹, Capitanio U.⁴, Briganti A.⁴, Graefen M.², Montorsi F.⁴, Saad F.⁵, Karakiewicz P.¹
 Institutes:¹Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Dept. of Urology, Montreal, Canada, ²Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ³McGill University, Dept. of Epidemiology, Biostatistics and Occupational Health, Montreal, Canada, ⁴Irccs Ospedale San Raffaele, Dept. of Oncology, Unit of Urology, Uri, Milan, Italy, ⁵University of Montreal Health Center, Dept. of Urology, Montreal, Canada
- *679 **The incidence and risk of biochemical recurrence following radical radiotherapy for prostate cancer in men on angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARB)**
 By: Alashkham A., Paterson C., [Nabi G.](#)
 Institutes:Ninewells Hospital, Dundee, United Kingdom
- *680 **Whole pelvis intensity-modulated arc therapy for lymph node metastasized prostate cancer: Oncologic outcomes and prognostic factors**
 By: [Poelaert F.](#)¹, Fonteyne V.², Claeys T.¹, Ost P.², Decaestecker K.¹, De Meerleer G.², D'Hondt B.¹, De Visschere P.³, Lumen N.¹
 Institutes:¹Universitair Ziekenhuis Gent, Dept. of Urology, Ghent, Belgium, ²Universitair Ziekenhuis Gent, Dept. of Radiation Oncology, Ghent, Belgium, ³Universitair Ziekenhuis Gent, Dept. of Radiology, Ghent, Belgium
- *681 **Risk of second malignancies after iodine-125 prostate brachytherapy as monotherapy in a single institution**
 By: Fernandez A.¹, [Bucci J.](#)¹, Malouf D.², Wong K.¹, Chin Y.¹, Browne L.³
 Institutes:¹St George Hospital Cancer Care Centre, Dept. of Radiation Oncology, Kogarah, Australia, ²St George Hospital Cancer Care Centre, Dept. of Urology, Kogarah, Australia, ³St George Hospital Cancer Care Centre, Dept. of Statistics, Kogarah, Australia
- *682 **Clinico-dosimetric factors predicting long-term severe urinary incontinence after post-prostatectomy RT: Results of a longitudinal observational study**
 By: Noris Chiorda B.¹, Sini C.², Fiorino C.², Briganti A.³, Chiara A.¹, Deantoni C.¹, Fossati N.³, Gandaglia G.³, Suardi N.³, Montorsi F.³, Di Muzio N.¹, [Cozzarini C.](#)¹
 Institutes:¹San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy, ²San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy, ³San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy
- *683 **Prospective randomized study comparing robotic prostatectomy versus brachytherapy for the treatment of low risk prostate cancer**
 By: Giberti C., [Gallo F.](#), Schenone M., Cortese P., Gastaldi E., Becco D.
 Institutes:San Paolo Hospital, Dept. of Urology, Savona, Italy
- *684 **Could "radical" RT be a reasonable therapeutic option in bone oligometastatic prostate cancer patients?**
 By: Deantoni C.L.¹, [Cozzarini C.](#)¹, Fodor A.¹, Noris Chiorda B.¹, Mangili P.², Picchio M.³, Incerti E.³, Dell'Oca I.¹, Passoni P.¹, Fiorino C.², Calandrino R.², Di Muzio N.¹
 Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Medical Physics, Milan, Italy, ³IRCCS Ospedale San Raffaele, Dept. of Nuclear Medicine, Milan, Italy

*685

Evaluation of outcomes of salvage robotic prostatectomy: Single surgeon experience

By: Syed J., Christopher C., Kumar A., Samavedi S., Jenson C., Ogaya Pinies G., Ganapathi H., Bates A., Doss J., Rocco B., Coelho R., Mouraviev V., Patel V.

Institutes: Global Robotic Institute, Dept. of Urology, Celebration, United States of America

PCNL: Intraoperative management and outcome

Poster Session 55

Sunday, 13 March
15:45 - 17:15

Location: Room Paris (Hall B2, level 0)

Chairs: M. Monga, Shaker Heights (US)
C.M. Scoffone, Turin (IT)
M. Sofer, Tel-Aviv (IL)

Aims and objectives of this presentation

PCNL remains the gold standard for larger renal stones. Although a technique that came of age, frequency is rising again due to its high efficacy and low morbidity in experienced hands.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *686 **Demographics and comorbidities of 5000 patients undergoing PCNL from a national database**
By: Derbyshire L.F., Fowler S., Armitage J.N., Glass J., Withington J., Irving S.O., Burgess N.A., Wiseman O.J.
Institutes:The British Association of Urological Surgeons, Section of Endourology, London, United Kingdom
- *687 **Minimal invasive PCNL (MPCNL) - update on efficacy and safety after 1196 consecutive patients**
By: Anudu J.¹, Zimmermanns V.², Lahme S.²
Institutes:¹Siloah St.Trudpert, Dept. of Urology, Pforzheim, Germany, ²Siloah St.Trudpert Hospital, Dept. of Urology, Pforzheim, Germany
- *688 **RIRS, regular and small size PCNL in the treatment of 1-2 cm renal stones: EULIS survey in 30 European stone centers**
By: Zanetti S.P.¹, Catellani M.¹, Trinchieri A.², Sarica K.³, Montanari E.¹
Institutes:¹San Paolo Teaching Hospital, Dept. of Urology, Milan, Italy, ²Alessandro Manzoni Hospital, Dept. of Urology, Lecco, Italy, ³University of Yeditepe, Medical School, Dept. of Urology, Ankara, Turkey
- *689 **A prospective randomized comparison among SWL, PCNL and RIRS for lower calyceal stones less than 2 cm: A multicenter experience**
By: Bozzini G.¹, Provenzano M.², Buffi N.², Guazzoni G.², Montanari E.³, Macchione N.³, Verze P.⁴, Mirone V.⁴, Dal Piaz O.⁵, Pummer K.⁵, Sanguedolce F.⁶, Osmolorskji B.⁷, Seveso M.¹, Taverna G.¹
Institutes:¹Humanitas Mater Domini, Dept. of Urology, Castellanza, Italy, ²Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy, ³Ospedale San Paolo, Dept. of Urology, Milan, Italy, ⁴University Federico II, Dept. of Urology, Naples, Italy, ⁵Graz University Hospital, Dept. of Urology, Graz, Austria, ⁶London King's College Hospital, Dept. of Urology, London, United Kingdom, ⁷Lomonosov University Hospital, Dept. of Urology, Moscow, Russia
- *690 **Comparison of flexible ureteroscopy with holmium laser lithotripsy and percutaneous nephrolithotomy for 2 to 3cm pelvic stones: A randomized controlled study**
By: Li G.
Institutes:Zhejiang University, Dept. Of Medicine, Hangzhou, China
- *691 **Randomised controlled trial of ultra mini percutaneous nephrolithotomy versus retrograde intrarenal surgery in the treatment of 10-30mm calculi**
By: Datta S.¹, Ng K-W.¹, Solanki R.², Desai J.²

Institutes:¹Colchester Hospital University NHS Foundation Trust, Dept. of Urology, Colchester, United Kingdom, ²Samved Hospital, Dept. of Urology, Ahmedabad, India

*692

Systematic review of tract sizes in miniaturized percutaneous nephrolithotomy

By: Ruhayel Y.¹, Tepeler A.², Dabestani S.¹, MacLennan S.³, Petík A.⁴, Sarica K.⁵, Seitz C.⁶, Skolarikos A.⁷, Straub M.⁸, Türk C.⁹, Yuan Y.C.¹⁰, Knoll T.¹¹

Institutes:¹Skåne University Hospital, Dept. of Urology, Malmö, Sweden, ²Bezmialem Vakif University, Faculty of Medicine / Dept. of Urology, Istanbul, Turkey, ³University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, ⁴Region Hospital, Dept. of Urology, Pécs, Hungary, ⁵Dr. Lutfi Kırdar Kartal Research and Training Hospital, Dept. of Urology, Istanbul, Turkey, ⁶Medical University Vienna, Dept. of Urology, Vienna, Austria, ⁷Sismanoglio Hospital, Athens Medical School, Dept. of Urology, Athens, Greece, ⁸Technical University Munich, Dept. of Urology, Munich, Germany, ⁹Rudolfstiftung Hospital, Dept. of Urology, Vienna, Austria, ¹⁰McMaster University, Dept. of Gastroenterology, Hamilton Health Sciences, Hamilton, Canada, ¹¹Sindelfingen-Boeblingen Medical Center, University of Tübingen, Dept. of Urology, Sindelfingen, Germany

*693

Assessing the volume-outcome relationship for PCNL in 2014: Analysis using national registry data of over 2000 cases

By: Whittington J.¹, Finch W.², Fowler S.³, Armitage J.⁴, Glass J.⁵, Irving S.², Burgess N.², Thomas K.⁵, Wiseman O.⁴

Institutes:¹Whittington Hospital NHS Trust, Dept. of Urology, London, United Kingdom, ²Norfolk and Norwich Hospitals NHS Trust, Dept. of Urology, London, United Kingdom, ³British Association of Urological Surgeons, Audit and Data Manager, London, United Kingdom, ⁴Addenbrooke's Hospital, Cambridge, Dept. of Urology, London, United Kingdom, ⁵Guy's and St Thomas' NHS Hospitals Foundation Trust, Dept. of Urology, London, United Kingdom

*694

Comparison of scoring systems used to predict stone free status after percutaneous nephrolithotomy: A single centre study with 208 cases

By: Lim B.T.Y., Yam W.L., Lim S.K., Teo J.K., Goh D., Ng F.C.

Institutes:Changi General Hospital, Dept. of Urology, Singapore, Singapore

*695

An analysis of factors influencing length of stay after percutaneous nephrolithotomy

By: Dale R., Mazzon G., Bolgeri M., Pal P., Longhorn S., Choong S., Philp T., Smith R., Allen S.

Institutes:University College Hospital, Dept. of Urology, London, United Kingdom

*696

Ambulatory percutaneous nephrolithotomy: Single center prospective study

By: Agudelo J.A.¹, Arias E.¹, Chirinos J.¹, Katch N.¹, Riveros M.², Sanchez L.², Montiel R.²

Institutes:¹Hospital Coromoto De Maracaibo, Dept. of Urology, Maracaibo, Venezuela, ²Clinica Sucre De Maracaibo, Dept. of Urology, Maracaibo, Venezuela

*697

External validation of Guy's stone score in children treated with PCNL for renal stones

By: Ozman O.¹, Erdal F.S.¹, Yener S.¹, Gulu T.², Erozcenci A.¹, Onal B.¹

Institutes:¹Cerrahpasa Medical Faculty, Dept. of Urology, Istanbul, Turkey, ²Boston Children's Hospital, Dept. of Developmental Medicine, Boston, United States of America

17:00 - 17:07

Summary and context

C.M. Scoffone, Turin (IT)

Paediatric urology 3

Poster Session 56

Sunday, 13 March
15:45 - 17:15

Location: Room Vienna (Hall B2, level 0)

Chairs: M.A.B. Fahmy, Cairo (EG)
M.S. Silay, İstanbul (TR)
A-F. Spinoit, Ghent (BE)

Aims and objectives of this presentation

Paediatric urology update on clinical and research topics.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *698 **Crossed fused renal ectopia: Diagnosis and prognosis as a single center experience**
By: [Sarhan O.](#), Al Bedaiwi K., Al Harbi B., Al Ghanbar M., Al Otay A., Nakshabandi Z.
Institutes: Prince Sultan Military Medical City, Riyadh, Dept. of Urology, Riyadh, Saudi Arabia
- *699 **Stentless pediatric flexible renoureteroscopy with laser disintegration for renal stone less than 2cm, how safe is it?**
By: [Hammady A.R.](#)¹, Elbadry M.²
Institutes:¹Sohag University Hospital, Dept. of Urology, Sohag, Egypt, ²Elmenia University Hospital, Dept. of Urology, Elmenia, Egypt
- *700 **Comparison of robot-assisted, laparoscopic, and open pyeloplasty with a minimally invasive incision in children**
By: [Nakane A.](#), Mizuno K., Hayashi Y., Nishio H., Moritoki Y., Kamisawa H., Kurokawa S., Maruyama T., Yasui T.
Institutes: Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan
- *701 **Unilateral renal agenesis: Necessity of postnatal evaluation in a contemporary series**
By: [Sarhan O.](#), Albedaiwi K., Al Harbi B., Al Otay A., Al Ghanbar M., Nakshabandi Z.
Institutes: Prince Sultan Military Medical City, Riyadh, Dept. of Urology, Riyadh, Saudi Arabia
- *702 **Quality of life in male extrophy-epispadias patients: Long term follow up**
By: Centeno C., [Bujons A.](#), Enrike M., Jose B., Caffaratti J., Villavicencio S.
Institutes: Fundació Puigvert, Dept. of Paediatric Urology, Barcelona, Spain
- *703 **Complications of the efferent segment in a long-term outcome analysis after urinary diversion using the ileocecal segment in children and adolescents**
By: [Deuker M.](#)¹, Stein R.²
Institutes:¹Johannes Gutenberg University Mainz, School Of Medicine, Dept. of Urology, Mainz, Germany, ²University Medical Center Mannheim, Dept. of Paediatric and Adolescent Urology, Mainz, Germany
- *704 **Management of pouch stones in a pediatric cohort: Single center experience**
By: [Nabeeh H.](#)¹, Helmy T.¹, Abdelhaleem A.¹, Ghanem W.¹, Nageib M.¹, Dwaba M.¹, Hafez A.¹, Ali M.²
Institutes:¹Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt, ²Urology and nephrology center Mansoura , Urology, Mansoura , Egypt
- *705 **Erectile function is preserved in some children after treatment for rhabdomyosarcoma of prostate**

and bladder

By: [Frees S.](#)¹, Rubenwolf P.², Grossmann A.¹, Ziesel C.¹, Gutjahr P.³, Faber J.³, Thüroff J.¹, Stein R.²
Institutes:¹University Medical Center, Dept. of Urology, Mainz, Germany, ²University Medical Center, Dept. of Pediatric Urology, Mainz, Germany, ³University Medical Center, Dept. of Pediatrics, Mainz, Germany

*706 **Impact of de novo vesicoureteral reflux on transurethral surgery outcomes in pediatric patients with ureteroceles**

By: Song S.H., Kim S.J., Nam W., Choi W.S., Han J.H., Shin J.H., [Kim K.S.](#)
Institutes:Asan Medical Center, Dept. of Urology, Seoul, South Korea

*707 **Comparative study between vesicostomy and posterior urethral valve fulguration in uraemic infants**

By: [Zoheiry M.](#), Shoukry A., Abdelraouf H., Eissa M.
Institutes:Cairo University Hospitals, Dept. of Urology, Cairo, Egypt

*708 **Effect of adrenal androgens during prenatal periods in the second to fourth digit ratio in school-aged children**

By: [Mitsui T.](#)¹, Araki A.², Miyashita C.², Ito S.², Kitta T.³, Moriya K.³, Cho K.⁴, Morioka K.⁴, Kishi R.², Shinohara N.³, Takeda M.¹, Nonomura K.³
Institutes:¹University of Yamanashi, Dept. of Urology, Chuo-City, Japan, ²Hokkaido University, Dept. of Center for Environmental and Health Sciences, Sapporo, Japan, ³Hokkaido University, Dep. of Urology, Sapporo, Japan, ⁴Hokkaido University, Dep. of OB-GYN, Sapporo, Japan

*709 **Feminizing genitoplasty in patients with congenital adrenal hyperplasia**

By: [Ardelean M.A.](#), Schimke C., Brandtner G., Metzger R.
Institutes:Paracelsus Medical University, Dept. of Paediatric Surgery, Salzburg, Austria

*710 **Ultrastructural analysis of the foreskin in patients with true phimosis treated or not-treated with topical betamethasone and hyaluronidase ointment**

By: [Favorito L.A.](#), Gallo C., Silva Costa W., Sampaio F.J.
Institutes:State University of Rio de Janeiro, Dept. of Anatomy, Rio de Janeiro, Brazil

*711 **Biofeedback as a first line treatment for overactive bladder syndrome refractory to standard urotherapy in children**

By: [Ebilo İ. T.](#)¹, Kaya E.², Kopru B.², Topuz B.², Irkilata H.C.², Kibar Y.²
Institutes:¹Etimesgut Military Hospital, Dept. of Urology, Ankara, Turkey, ²Gulhane Military Medical Academy, Dept. of Urology, Ankara, Turkey

*712 **Feasibility and efficacy of a urologic profession campaign on cryptorchidism using internet and social media**

By: [Borgmann H.](#)¹, Kliesch S.², Roth S.³, Roth M.⁴, Degener S.³
Institutes:¹University Hospital Frankfurt, Dept. of Urology, Frankfurt, Germany, ²University Hospital of Münster, Centre of Reproductive Medicine and Andrology, Münster, Germany, ³University of Witten/Herdecke, Dept. of Urology, Wuppertal, Germany, ⁴Park 7 GmbH, -, Cologne, Germany

Kidney transplantation: Outcomes and management

Poster Session 57

Sunday, 13 March
15:45 - 17:15

Location: Room London (Hall B2, level 0)

Chairs: F. Greco, Crotone (IT)
M. Musquera Felip
I. Sinescu, Bucharest (RO)

Aims and objectives of this presentation

To show contemporary outcomes on kidney transplant as well as present trends on the management of urological tumours.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *713 **Kidney transplant activity in Europe during 2014: Differences among countries**
By: [Díez Nicolás V.](#)¹, Gómez Dos Santos V.¹, Hevia Palacios V.¹, Álvarez Rodríguez S.¹, Martínez Arcos L.¹, Rodríguez Patrón R.¹, Lledó García E.³, Alcaraz Asensio A.⁵, Figueiredo A.⁴, Burgos Revilla F.J.²
Institutes:¹Hospital Ramón Y Cajal, Dept. of Urology, Madrid, Spain, ²Hospital Ramón Y Cajal, Universidad De Alcalá, Dept. of Urology, Madrid, Spain, ³Hospital Gregorio Marañón, ESTU Board, Madrid, Spain, ⁴Centro Hospitalar E Universitario De Coimbra, ESTU Board, Coimbra, Portugal, ⁵Hospital Clinic, ESTU Board, Barcelona, Spain
- *714 **Comparative costs of different renal replacement therapies in low- and middle-income countries on the example of Georgia**
By: [Managadze G.](#)¹, Beglarishvili L.², Tataradze A.², Managadze L.², Chkhotua A.²
Institutes:¹Tulane University, Dept. of Cell and Molecular Biology, New Orleans, United States of America, ²National Center of Urology, Dept. of Urology, Tbilisi, Georgia
- *715 **Robotic kidney transplantation with regional hypothermia: Results from a prospective two-arm non-randomized controlled trial (Ideal phase 2b)**
By: [Sood A.](#)¹, [Dalela D.](#)¹, Ghosh P.², Jeong W.¹, Bhandari M.¹, Ahlawat R.², Menon M.¹
Institutes:¹Henry Ford Hospital / Health System, Dept. of Urology, Detroit, United States of America, ²Medanta- The Medicity, Vattikuti Institute of Robotic Surgery, Kidney and Urology Institute, Gurgaon, India
- *716 **Effect of recipient's body mass index at time of transplantation on renal transplant outcome: Retrospective analysis of 400 patients**
By: [Yehia Abdelaziz A.](#), Elshiekh M.G., Aboelela A.A., Morsi A.A.
Institutes:Cairo University, Dept. of Urology, Cairo, Egypt
- *717 **Risk factors for urological complications following living donor renal transplantation in children**
By: [Elsheemy M.S.](#), [Shouman A.](#), [Shoukry A.I.](#), [Aboulela W.](#), Daw K, El Ghoneimy M, Morsi H.A., Badawy H
Institutes:Cairo University, Dept. of Urology, Cairo, Egypt
- *718 **Doppler ultrasound and endovascular approach in the management of transplant renal artery stenosis**
By: [Li Marzi V.](#), Bigazzi B., Siena G., Mari A., Tuccio A., Caroassai S., Villari D., Dattolo E., Serni S., Marzocco M., Nicita G.
Institutes:University of Florence, Dept. of Urology, Florence, Italy

- *719 **Percutaneous transluminal angioplasty for treatment of transplant renal artery stenosis**
By: Massmann A.², Marchal C.³, Niklas C.¹, Seiler-Musler S.⁴, Sester U.⁴, Schneider G.K.², Siemer S.¹, Bücken A.², Stöckle M.¹, Janssen M.¹
Institutes:¹UKS Universitätsklinikum des Saarlandes, Dept. of Urology and Paediatric Urology, Homburg/Saar, Germany, ²UKS Universitätsklinikum des Saarlandes, Dept. of Diagnostic and Intervention Radiology, Homburg/Saar, Germany, ³UKS Universitätsklinikum Des Saarlandes, Dept. of Diagnostic and Intervention Radiology, Homburg/Saar, Germany, ⁴UKS Universitätsklinikum des Saarlandes, Dept. of Internal Medicine IV, Nephrology, Homburg/Saar, Germany
- *720 **Analysis of de novo urologic cancer in kidney transplant recipients: Single center study of 3,951 cases**
By: Yoo S.¹, Lee C.¹, Jung J.¹, Nam W.¹, Choi W.¹, Kim Y.H.², You D.¹, Jeong I.G.¹, Hong B.¹, Ahn T.Y.², Han D.J.², Kim C.S.²
Institutes:¹Asan Medical Center, Dept. of Urology, Seoul, South Korea, ²Asan Medical Center, Dept. of Surgery, Seoul, South Korea
- *721 **Treatment options and predictive factors for recurrence and cancer specific mortality in bladder cancer after renal transplantation: A multiinstitutional analysis**
By: Rodriguez Faba O.¹, Palou J.¹, Palazzetti A.², Gontero P.², García-Olaverri J.³, Fernández Gómez J.M.⁴, Olsburg J.⁵, Terrone C.⁶, Figueiredo A.⁷, Vigués F.⁸, Burgos J.⁹, Lledó E.¹⁰, Breda A.¹
Institutes:¹Universitat Autònoma de Barcelona - Fundació Puigvert, Dept. of Oncology, Barcelona, Spain, ²University of Turin, Dept. of Oncology, Turin, Italy, ³Hospital Cruces, Dept. of Urology, Barakaldo, Spain, ⁴Hospital Central de Asturias, Dept. of Urology, Oviedo, Spain, ⁵Guy's and St. Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ⁶University of Novara, Dept. of Urology, Novara, Italy, ⁷University of Coimbra, Dept. of Urology, Coimbra, Portugal, ⁸Hospital of Bellvitge, Dept. of Urology, Barcelona, Spain, ⁹Hospital Ramón Y Cajal, Dept. of Urology, Madrid, Spain, ¹⁰Hospital Gregorio Marañón, Dept. of Urology, Madrid, Spain
- *722 **Conservative treatments of de novo kidney graft tumours**
By: Tillou X.¹, Guleryuz K.¹, Bensadoun H.³, Bessede T.²¹, Boutin J-M.⁴, Bouyé S⁵, Chambade D.⁶, Codas R.⁷, Coffin G.⁸, Devonec M.⁷, Erauso A.⁹, Hubert J.¹⁰, Karam G.¹¹, Lechevallier E.¹², Salomon L.¹³, Sénéchal C¹⁴, Sallusto F.¹⁵, Terrier N.¹⁶, Timsit M-O.¹⁷, Thuret R.¹⁸, Verhoest G.¹⁹, Viart L.²⁰, Doerfler A.²
Institutes:¹Centre Hospitalier Universitaire De Caen, Dept. of Urology and Transplantation, Caen, France, ²Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Caen, France, ³Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Bordeaux, France, ⁴Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Tours, France, ⁵Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Lille, France, ⁶Centre Hospitalier Universitaire Saint Louis, Dept. of Urology and Transplantation, Paris, France, ⁷Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Lyon, France, ⁸Centre Hospitalier Universitaire De La Pitié Salpêtrière, Dept. of Urology and Transplantation, Paris, France, ⁹Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Brest, France, ¹⁰Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Nancy, France, ¹¹Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Nantes, France, ¹²Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Marseille, France, ¹³Centre Hospitalier Universitaire Henri Mondor, Dept. of Urology and Transplantation, Paris-Créteil, France, ¹⁴Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Fort De France - Guadeloupe, France, ¹⁵Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Toulouse, France, ¹⁶Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Grenoble, France, ¹⁷HEGP, Dept. of Urology and Transplantation, Paris, France, ¹⁸Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Montpellier, France, ¹⁹Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Rennes, France, ²⁰Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Amiens, France, ²¹Centre Hospitalier Universitaire Kremlin Bicêtre, Dept. of Urology and Transplantation, Paris, France
- *723 **De novo bladder urothelial neoplasm in renal transplant recipients: A retrospective multicentric study**
By: Bosio A.¹, Palazzetti A.¹, Dalmasso E.¹, Alessandria E.¹, Peretti D.¹, Destefanis P.¹, Lillaz B.¹, Pasquale G.¹, Sedigh O.¹, Fop F.², Volpe A.³, Di Domenico A.⁴, Iesari S.⁵, Todeschini P.⁶, Famulari

A.⁷, Scolari M.⁶, Stratta P.⁴, Terrone C.³, Segoloni G.P.², Biancone L.², Gontero P.¹, Frea B.¹
Institutes:¹A.O.U. Città Della Salute E Della Scienza - Molinette Hospital, Dept. of Urology, Turin, Italy, ²A.O.U. Città Della Salute E Della Scienza - Molinette Hospital, Dept. of Nephrology and Renal Transplantation, Turin, Italy, ³Maggiore Della Carità Hospital, Dept. of Urology, Novara, Italy, ⁴Maggiore Della Carità Hospital, Dept. of Nephrology and Renal Transplantation, Novara, Italy, ⁵San Salvatore Hospital, Dept. of Nephrology and Dialysis, L'Aquila, Italy, ⁶Alma Mater Hospital, Dept. of Nephrology and Dialysis, Bologna, Italy, ⁷San Salvatore Hospital, Dept. of Nephrology and Dialysis, L'aquila, Italy

*724

Prostate cancer before renal transplantation: A multicenter study

By: Tillou X.¹, Chahwan C.¹, Brichtart N.², Bouyé S³, Culty T.⁴, Iselin C.¹⁰, Pfister C.⁵, Sallusto F.⁶, Salomon L.⁷, Verhoest G⁸, Viart L.⁹, Doerfler A.¹

Institutes:¹Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Caen, France, ²Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Tours, France, ³Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Lille, France, ⁴Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Angers, France, ⁵Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Rouen, France, ⁶Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Toulouse, France, ⁷Centre Hospitalier Universitaire Henri Mondor, Dept. of Urology and Transplantation, Paris - Créteil, France, ⁸Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Rennes, France, ⁹Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Amiens, France, ¹⁰Centre Hospitalier Universitaire, Dept. of Urology and Transplantation, Geneve, Switzerland

*725

Is Retzius-sparing approach for robot-assisted laparoscopic radical prostatectomy the ideal technique for renal transplant recipients?

By: Secco S., Galfano A., Di Trapani D., Sampogna G., Strada E., Petralia G., Bocciardi A.

Institutes:Niguarda Ca' Granda Hospital, Dept. of Urology, Milan, Italy

17:00 - 17:07

Summary and context

F. Greco, Crotone (IT)

How to set standards in urological training throughout Europe

Special Session

Sunday, 13 March
15:45 - 16:45

Location: Room 3 (ICM, Level 0)

Chairs: J.D. Nawrocki, Newick (GB)
J. Palou, Barcelona (ES)
A. Papatsoris, Athens (GR)

Aims and objectives of this presentation

Training of Urologist is a common objective of both the EBU and the ESU. Cooperation between EBU and ESU will contribute to set standards in urological training throughout Europe.

15:45 - 15:55

What is a "good" hospital: Accreditation and certification by EBU
M. Aitchison , Glasgow (GB)

15:55 - 16:05

Structured training: The EBU-Medbook idea
S.C. Müller, Bonn (DE)

16:05 - 16:15

How can The European School of Urology (ESU) be supportive
J. Palou, Barcelona (ES)

16:15 - 16:25

Objective evaluation of knowledge: The EBU examinations
A. Antoniewicz, Warsaw (PL)

16:25 - 16:35

What do the Young Urologists (YUO) want?
J.P.M. Sedelaar, Nijmegen (NL)

16:35 - 16:45

Interactive discussion

E-BLUS Exam

HOT 37

Sunday, 13 March
16:15 - 17:00

Location: Room South America (Hall B0, level 0)

Aims and objectives of this presentation

The European training in basic laparoscopic urological skills (E-BLUS) is a programme offered to residents and urologists who want to improve the basic skills in laparoscopy. It is a unique opportunity to train with international experts in laparoscopy. The E-BLUS programme includes:

- Hands-on training (HOT) sessions of different levels carried out under the guidance of experienced tutors
- A set of training-box exercises developed and validated by the Dutch project Training in Urology (TiU) to train basic skills needed in urological laparoscopy
- E-BLUS examination and certification
- An online theoretical course

To be confirmed

W. Brinkman, Rotterdam (NL)

T. Tokas, Hall In Tirol (AT)

T. Kalogeropoulos, Athens (GR)

To be confirmed

D. Veneziano, Minneapolis (US)

ESU/ESFFU Hands-on training in Women's Health

HOT 24

Sunday, 13 March
16:45 - 18:15

Location: Room North America (Hall B0, level 0)

Chair: J.P.F.A. Heesakkers, Nijmegen (NL)

Aims and objectives of this presentation

The European School of Urology (ESU) and the EAU Section of Female and Functional Urology (ESFFU) offer a practical hands-on training course with female pelvic models focusing on the placement of slings for the treatment of stress urinary incontinence. The delegates will be taken through a step-by-step programme of surgical treatment of stress urinary incontinence with retropubic, transobturator, and single-incision slings. The programme will begin with a discussion of patient selection and relevant clinical data. Videos demonstrating the different techniques will be presented, and afterwards the delegates will be instructed in small teams on the pelvic trainers. Finally, all remaining questions can be answered and discussed with the tutors, including the demonstration of tips and tricks.

F. Van Der Aa, Leuven (BE)

D.M. Castro-Diaz, La Laguna Santa Cruz Tenerife (ES)

E-BLUS Exam

HOT 38

Sunday, 13 March
17:15 - 18:00

Location: Room South America (Hall B0, level 0)

Aims and objectives of this presentation

The European training in basic laparoscopic urological skills (E-BLUS) is a programme offered to residents and urologists who want to improve the basic skills in laparoscopy. It is a unique opportunity to train with international experts in laparoscopy. The E-BLUS programme includes:

- Hands-on training (HOT) sessions of different levels carried out under the guidance of experienced tutors
- A set of training-box exercises developed and validated by the Dutch project Training in Urology(TiU) to train basic skills needed in urological laparoscopy
- E-BLUS examination and certification
- An online theoretical course

W. Brinkman, Rotterdam (NL)

To be confirmed

P. Macek, Prague (CZ)

F.C.H. d'Ancona, Nijmegen (NL)

To be confirmed

D. Veneziano, Minneapolis (US)

Ageing and the lower urinary tract

Plenary Session 3

Monday, 14 March
07:30 - 10:55

Location: eURO Auditorium (Hall C1, Level 0)

Chairs: D.J.M.K. De Ridder, Leuven (BE)
F. Montorsi, Milan (IT)

Aims and objectives of this presentation

Urological patients become older and older. Surgery in octogenarians is no longer uncommon. This session will discuss specific points on diagnosis and treatment of a variety of diseases in the ageing male and female patient.

07:30 - 08:00

Highlight Session Highlight Session 2

07:30 - 07:40

Prostate disease

C. De Nunzio, Rome (IT)

Aims and objectives of this presentation

To identify and highlight the key abstracts on lower urinary tract symptoms and prostatic disease presented during the current EAU congress. To highlight abstracts that change or significantly progress urological practise and to discuss and comment what is in the pipeline.

07:40 - 07:50

Oncology

R. Sosnowski, Warsaw (PL)

07:50 - 08:00

Reconstruction

N. Lumen, Ghent (BE)

Aims and objectives of this presentation

Numerous abstracts on reconstructive urology will be presented during the EAU congress. Some of these abstracts might have practice-changing consequences or might provide new evidence. These abstracts will be highlighted and discussed with the current evidence in literature.

08:00 - 08:15

State-of-the-art lecture Healthy LUT and ageing: A contradiction?

A.J. Wein, Philadelphia (US)

Aims and objectives of this presentation

A review of the changes which occur with ageing in the physiology and pharmacology of the lower urinary tract (bladder, urethra and surrounding structures) and the clinical implications.

08:15 - 08:30

State-of-the-art lecture Drug therapy in the elderly: Which are the good drugs?

A. Wagg, Edmonton (CA)

Aims and objectives of this presentation

Attendees will be able to: assess the relative advantages and disadvantages of oral pharmacotherapy; gain an insight into the cognitive safety of antimuscarinic therapy and understand the potential advantages and disadvantages of newer therapies for lower urinary tract symptoms in older persons

08:30 - 08:45

State-of-the-art lecture Invasive treatment over 75: What does the literature say?

J-N.L. Cornu, Rouen (FR)

Aims and objectives of this presentation

Surgery of the lower urinary tract (particularly benign prostatic obstruction) are daily challenges for the urologist. This lecture will point out the results of these techniques in elderly people according to the most recent data of the literature.

08:45 - 09:15

Case discussion Surgery for BPO in the elderly

C. Gratzke, Munich (DE)

08:45 - 09:00

Yes

A. Bachmann, Basel (CH)

09:00 - 09:15

No

M. Gacci, Florence (IT)

09:15 - 09:55

Case discussion How and when to stop anticoagulation in surgical intervention

H-M. Fritsche, Regensburg (DE)

09:15 - 09:25

Urologist

D. Eberli, Zurich (CH)

09:25 - 09:35

Cardiologist

F. Szymanski, Warsaw (PL)

09:35 - 09:45

Anesthesiologist

P.M. Sandset, Oslo (NO)

09:45 - 09:55

Discussion

09:55 - 10:10

State-of-the-art lecture Do we treat recurrent UTI differently in young vs older women?

G. Bonkat, Basel (CH)

10:10 - 10:25

State-of-the-art lecture Long-term catheterisation and its problems

F.M.E. Wagenlehner, Gießen (DE)

Aims and objectives of this presentation

Urinary catheters are amongst the most frequently used foreign materials in medicine. The catheters are on the one hand used as acute care management tools, such as in acute urinary retention and on the other hand as long-term catheters as urinary diversion. Problems of long term catheters include infections, biofilm infection being the predominant form, and local problems at the insertion sites of urethra, bladder, ureters or kidneys, causing erosions, chronic inflammation and other long term sequelae.

10:25 - 10:40

Confederación Americana de Urología (CAU) lecture Sexual dysfunctions in the elderly couple

N. Cruz, Seville (ES)

Aims and objectives of this presentation

The objective of this talk is to show the real frequency and different types of sexual activity in the ageing population, the prevalence of the different sexual dysfunctions, risk factors and specific correlates in this population.

A short review of the evaluation and treatment will be presented

10:40 - 10:55

State-of-the-art lecture The effect of patients ageing on the offspring

A. Bisgaard Pinborg, Hvidovre (DK)

The infertile couple - Urological aspects

ESU Course 31

Monday, 14 March
08:30 - 11:30

Location: Room 13a (ICM, Level 1)

Chair: W. Aulitzky, Vienna (AT)

Aims and objectives of this presentation

This course provides state-of-the-art information on urological aspects of diagnosis and therapy of modern reproductive medicine. Diagnostic procedures should be standardised and coordinated in a timely fashion for both partners, focusing on the possible urological, hormonal and genetic causes of male infertility. In terms of therapy, this course will provide updated information on evidence based data and will discuss the importance of varicoceles in male infertility. We will show microsurgical techniques on video and explain why proper training and skills perfection is key to successful case management. A successful IVF/ICSI outcome depends upon the use of state-of-the-art techniques for sperm retrieval and sperm preparation. We will also provide information on genetic aspects and stress the responsibility of the urologist as an adviser and gatekeeper for the treatment of the infertile couple.

08:30 - 11:30

Diagnostic work-up, medical treatment

W. Weidner, Giessen (DE)

08:30 - 11:30

Pathophysiology, diagnosis and treatment of varicocele

W. Aulitzky, Vienna (AT)

08:30 - 11:30

Microsurgical refertilisation

W. Aulitzky, Vienna (AT)

08:30 - 11:30

Sperm retrieval techniques and genetic aspects of IVF/ICSI

W. Weidner, Giessen (DE)

Prostate cancer imaging: When and how to use it

ESU Course 32

Monday, 14 March
08:30 - 11:30

Location: Room 13b (ICM, Level 1)

Chair: J. Walz, Marseille (FR)

Aims and objectives of this presentation

Recently new imaging technologies have been developed to improve the diagnosis and management of prostate cancer. These are multiparametric MRI, choline PET and new ultrasound based technologies.

The course's aim is to provide:

- An overview on the currently available imaging tools for prostate cancer
- Practical information about their use
- A critical assessment of their clinical performance and their limitations.

08:30 - 11:30

Introduction and objective of course

J. Walz, Marseille (FR)

08:30 - 11:30

Diagnosis of prostate cancer:

08:30 - 11:30

Standardization, acquisition and reporting of multiparametric MRI

To be confirmed

08:30 - 11:30

Reading of a prostate MRI and use of MRI for diagnosis of prostate cancer

To be confirmed

08:30 - 11:30

MRI guided biopsy and image fusion (mp MRI and Ultrasound)

J. Walz, Marseille (FR)

08:30 - 11:30

What are possible alternatives to multiparametric MRI?

J. Walz, Marseille (FR)

08:30 - 11:30

Staging of prostate cancer:

08:30 - 11:30

Staging with CT, MRI and bone scintigraphy

G. Villeirs, Ghent (BE)

08:30 - 11:30

MRI in local staging of prostate cancer

G. Villeirs, Ghent (BE)

08:30 - 11:30

Recurrent disease:

08:30 - 11:30

Use of PET in the management of prostate cancer (initial staging and recurrence)

J. Walz, Marseille (FR)

08:30 - 11:30

MRI in detection of locally recurrent prostate cancer

G. Villeirs, Ghent (BE)

08:30 - 11:30

When to do imaging of the prostate? Case discussion and current practical questions

To be confirmed

G. Villeirs, Ghent (BE)
J. Walz, Marseille (FR)

08:30 - 11:30

Closure and evaluation

Practical management of non-muscle invasive bladder

ESU Course 33

Monday, 14 March
08:30 - 11:30

Location: Room 11 (ICM, Level 1)

Chair: J.A. Witjes, Nijmegen (NL)

Aims and objectives of this presentation

- Remaining topics: (1) diagnosis NMIBC; (2) risk adapted (new) treatment modalities; (3) abnormal cytology.
- New topics: (1) TUR technique (en bloc resection, difficult TUR's etc) with video's; (2) complications of intravesical therapy;
- The course remains practical with feedback and Q&A.
- The objective is updated and practical knowledge, also in difficult cases

08:30 - 11:30

Introduction

J.A. Witjes, Nijmegen (NL)

08:30 - 11:30

Diagnosis, markers and innovations

J. Palou, Barcelona (ES)

08:30 - 11:30

TUR technique: Tips and tricks, problems and bloc resection, TUR at difficult places, Re-TUR: Enhanced imaging

M. Babjuk, Prague (CZ)

08:30 - 11:30

Risk groups and guideline treatment: What is clearly established

J.A. Witjes, Nijmegen (NL)

08:30 - 11:30

Comments on guideline treatment including BCG shortage and new treatment modalities

M. Babjuk, Prague (CZ)

08:30 - 11:30

Complications of intravesical therapy

J.A. Witjes, Nijmegen (NL)

08:30 - 11:30

How to deal with abnormal cytology including locations outside the bladder (UUT and urethra) and its limitations

J. Palou, Barcelona (ES)

08:30 - 11:30

Open questions

Small renal masses: From concepts to tips and tricks in daily management

ESU Course 34

Monday, 14 March
08:30 - 11:30

Location: Room 12 (ICM, Level 1)

Chair: P. Gontero, Turin (IT)

Aims and objectives of this presentation

- The course aims to address the multiplicity of treatment options for small renal masses.
- Essential concepts to guide the clinical decision making process will be interactively discussed with the help of clinical cases.
- Practical tips for a safe and effective treatment delivery will be provided on the current standard of ablative therapies and minimally invasive surgery.
- Attendees should become familiar on when and how to propose active surveillance in their daily clinical practice.

08:30 - 11:30

Introduction

P. Gontero, Turin (IT)

08:30 - 11:30

Active surveillance and discussion clinical cases

P. Gontero, Turin (IT)

08:30 - 11:30

Ablative therapies: Which technique and why?

J.J.M.C.H. De La Rosette, Amsterdam (NL)

08:30 - 11:30

Minimally invasive surgery in SRMs: How to safely do it when you get started

F. Keeley, Bristol (GB)

08:30 - 11:30

Indications for surgery vs ablative therapies

P. Gontero, Turin (IT)

08:30 - 11:30

Clinical case discussion

J.J.M.C.H. De La Rosette, Amsterdam (NL)

P. Gontero, Turin (IT)

F. Keeley, Bristol (GB)

Robot renal surgery

ESU Course 35

Monday, 14 March
08:30 - 11:30

Location: Room 21 (ICM, Level 2)

Chair: A. Mottrie, Aalst (BE)

Aims and objectives of this presentation

This course will cover all principal indications for robotic surgery of the upper urinary tract. The standard techniques will be explained on a video-based fashion and will be followed by discussing advanced cases as well as troubleshooting and complication management. On top of that, technical innovations and new applications will be discussed as well.

Don't miss this course, a must for all robotic surgeons!:

- Videobased step-by-step approach
- Standard techniques
- Complex cases
- Troubleshooting and complication management
- Technical innovations: What's new in robotics?

08:30 - 11:30

Introduction

A. Mottrie, Aalst (BE)

08:30 - 11:30

Patient positioning, trocar positioning, trans- and retroperitoneal access in renal robotic surgery

B.J. Challacombe, London (GB)

08:30 - 11:30

Robotic pyeloplasty: Multichannel or single technique

N. Buffi, Milan (IT)

08:30 - 11:30

Renal surgery: Nephrectomy and nephroureterectomy: How I do it

B.J. Challacombe, London (GB)

08:30 - 11:30

Partial nephrectomy I: Step 1: Isolation of renal hilum; Step II: Mobilisation of the kidney; Step III: Clamping of renal pedicle: Different techniques

N. Buffi, Milan (IT)

08:30 - 11:30

Partial nephrectomy II: Step IV: Different tumouresection techniques

A. Mottrie, Aalst (BE)

08:30 - 11:30

Partial nephrectomy III: Step V: Different renorrhaphy techniques

B.J. Challacombe, London (GB)

08:30 - 11:30

Partial nephrectomy IV: Special & difficult indications

A. Mottrie, Aalst (BE)

08:30 - 11:30

Partial nephrectomy V: Complication management and new tools

A. Mottrie, Aalst (BE)

08:30 - 11:30

Wrap up and conclusions

B.J. Challacombe, London (GB)

Update renal, bladder and prostate Guidelines 2016, what is changed?

ESU Course 36

Monday, 14 March
08:30 - 11:30

Location: Room 22 (ICM, Level 2)

Chair: H.G. Van Der Poel, Amsterdam (NL)

Aims and objectives of this presentation

During the course recent practice changing alterations in the guidelines will be discussed. Based on the clinical recommendations the highlights of the guidelines on prostate, renal and bladder cancer as changed in the 2016 updates will be presented and illustrated by clinical cases. A basic knowledge of the guidelines information is assumed for participating trainees.

08:30 - 11:30

Introduction

H.G. Van Der Poel, Amsterdam (NL)

08:30 - 11:30

Update renal cancer: Localized

A. Volpe, Novara (IT)

08:30 - 11:30

Discussion

08:30 - 11:30

Update renal cancer: Metastasized

A. Volpe, Novara (IT)

08:30 - 11:30

Discussion

08:30 - 11:30

Update bladder cancer: Non-muscle invasive

B.W.G. Van Rhijn, Amsterdam (NL)

08:30 - 11:30

Discussion

08:30 - 11:30

Update bladder cancer: Muscle invasive

B.W.G. Van Rhijn, Badhoevedorp (NL)

08:30 - 11:30

Discussion

08:30 - 11:30

Update prostate cancer: Localized

H.G. Van Der Poel, Amsterdam (NL)

08:30 - 11:30

Discussion

08:30 - 11:30

Update prostate cancer: Metastasized

H.G. Van Der Poel, Amsterdam (NL)

Molecular markers for prostate cancer: An update

Poster Session 58

Monday, 14 March
08:45 - 10:15

Location: Room Madrid (Hall B2, level 0)

Chairs: S. Loeb, New York (US)
D. Sjoberg, New York (US)
G.N. Thalmann, Bern (CH)

Aims and objectives of this presentation

There are at least three different sets of molecular markers for the diagnosis and aggressiveness of prostate cancer on the market. Are the currently available data sufficient for clinical use in the setting of active surveillance or clinical decision making for or against adjuvant treatment? This session will present the latest data on molecular markers for prostate cancer. In addition high quality data on conventional prognostic markers will be discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

09:08 - 09:18

Molecular markers in prostate cancer: What is currently available?

S. Loeb, New York (US)

*736

Validation of the novel 5-group Gleason grading system: 3+5 disease risk may be overestimated

By: Van den Bergh R.C.N.¹, Van Der Kwast T.², De Jong J.³, Zargar H.⁴, Murphy D.G.⁴, Van Der Poel H.G.⁵

Institutes:¹Royal Melbourne Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Toronto, Dept. of Pathology, Toronto, Canada, ³NKI, Dept. of Pathology, Amsterdam, The Netherlands, ⁴Royal Melbourne Hospital, Dept. of Urology, Melbourne, Australia, ⁵Amsterdam, Dept. of Urology, Amsterdam, The Netherlands

*726

Temporal trends in prostate cancer (PCa) risk group stratification following the 2008 United States preventive services task force recommendations

By: Abdollah F.F.H.¹, Dalela D.¹, Sood A.¹, Sammon J.¹, Karabon P.¹, Meyer C.², Sun M.², Choueiri T.³, Menon M.¹, Trinh Q.D.²

Institutes:¹Henry Ford Hospital / Health System, Dept. of Urology, Detroit, United States of America, ²Brigham and Women's Hospital / Dana-Farber Cancer Institute, Harvard Medical School, Dept. of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America, ³Brigham and Women's Hospital / Dana-Farber Cancer Institute, Harvard Medical School, Dept. of Medical Oncology, Boston, United States of America

*727

Inverse stage migration: Contemporary results of 140.253 North American prostate cancer patients treated with radical prostatectomy from 2004 to 2012

By: Leyh-Bannurah S-R.¹, Dell'Oglio P.², Fisch M.³, Graefen M.¹, Karakiewicz P.⁴, Briganti A.², Montorsi F.², Budäus L.¹

Institutes:¹Martini-Clinic, Prostate Cancer Center, Hamburg, Germany, ²Urological Research Institute, IRCCS San Raffaele Scientific Institute, Dept. of Urology and Division of Experimental Oncology, Milan, Italy, ³University Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁴University of Montreal Health Center, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Canada

*728

Transcriptome-wide expression study reveals biomarker signature with prognostic potential for prostate cancer

By: Horn E.¹, Christ-Breulmann S.², Puppel S-H.², Buschmann T.², Reiche K.², Specht M.², Bertram C.², Friedrich M.², Binder S.², Blumert C.², Hackermüller J.³, Kreuz M.⁴, Löffler M.⁴, Toma M.I.⁵, Muders M.⁵, Baretton G.B.⁵, Fröhner M.⁶, Füssel S.⁶, Wirth M.⁶

Institutes:¹University of Leipzig, Institute of Clinical Immunology, Leipzig, Germany, ²Fraunhofer Institute of Cell Therapy and Immunology, Dept. of Diagnostics, Leipzig, Germany, ³Helmholtz Centre For Environmental Research, Young Investigator Group Bioinformatics & Transcriptomics, Leipzig, Germany, ⁴University of Leipzig, Institute For Medical Informatics, Statistics and Epidemiology, Leipzig, Germany, ⁵University Hospital "Carl Gustav Carus", Technical University Dresden, Institute of Pathology, Dresden, Germany, ⁶University Hospital "Carl Gustav Carus", Technical University Dresden, Dept. of Urology, Dresden, Germany

*729

Utilization of a genomic classifier for prediction of metastasis following postoperative salvage radiation therapy

By: Karnes J.B.¹, Choerung V.², Howard L.³, De Hoedt A.³, Du Plessis M.², Yousefi K.², Lam L.², Buerki C.², Trabulsi E.J.⁴, Dicker A.P.⁴, Davicioni E.², Freedland S.J.³, Den R.B.⁴

Institutes:¹Mayo Clinic, Dept. of Urology, Rochester, United States of America, ²GenomeDx Biosciences, Dept. of Clinical Operations, Vancouver, Canada, ³Duke University, Dept. of Urology, Durham, United States of America, ⁴Thomas Jefferson University, Sidney Kimmel Medical College, Philadelphia, United States of America

*730

Decipher genomic classifier measured on prostate biopsy predicts 10 year metastasis risk

By: Klein E.¹, Neumann S.⁵, Yousefi K.², Haddad Z.², Lam L.², Wang Q.², Choerung V.², Palmer-Aronsten B.², Buerki C.², Davicioni E.², Li J.³, Kattan M.W.³, Stephenson A.J.¹, Magi-Galluzzi C.⁴

Institutes:¹Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, United States of America, ²GenomeDx Biosciences, Dept. of Clinical Operations, Vancouver, Canada, ³Cleveland Clinic, Dept. of Quantitative Health Sciences, Cleveland, United States of America, ⁴Cleveland Clinic, Dept. of Anatomic Pathology, Cleveland, United States of America, ⁵Genomedx Biosciences, Dept. of Marketing, Vancouver, Canada

*731

The power of a genomic classifier to assess cancer persistence and biochemical failure in patients post-prostatectomy

By: Woodlief T., Rocco B., Ganapathi H., Ogaya G., Mouraviev V., Patel V.

Institutes:Florida Hospital, Global Robotics Institute, Celebration, United States of America

*732

CCP-score improves the current risk assessment in newly diagnosed prostate cancer patients

By: Oderda M.¹, Cozzi G.², Barale M.¹, Garelli G.¹, Gurioli A.¹, Daniele L.³, Sapino A.³, Renne G.⁴, De Cobelli O.², Gontero P.¹

Institutes:¹University of Turin, Dept. of Surgical Sciences/Urology, Turin, Italy, ²Istituto Europeo Di Oncologia, Dept. of Urology, Milan, Italy, ³A.O.U. Città Della Salute E Della Scienza, Dept. of Pathology, Turin, Italy, ⁴Istituto Europeo Di Oncologia, Dept. of Pathology, Milan, Italy

*733

Heterogeneity in circulating tumor cells (CTCs) in blood samples of metastatic castration-resistant prostate cancer (mCRPC) patient: Comparison of isolation techniques

By: Theil G., Weiß C., Fischer K., Schumann A., Fornara P.

Institutes:UKH Universitätsklinikum Halle (Saale), Dept. of Urology and Kidney Transplantation, Halle/Saale, Germany

*734

Highly-trained dogs' olfactory system for detecting biochemical recurrence following radical prostatectomy

By: Taverna G.², Tidu L.³, Grizzi F.¹, Stork B.⁴, Seveso M.², Bozzini G.², Sardella P.³, Latorre G.³, Lughezzani G.⁵, Buffi N.⁵, Guazzoni G.⁵, Mandressi A.²

Institutes:¹Humanitas Research Hospital, Dept. of Immunology and Inflammation, Rozzano, Italy, ²Humanitas Mater Domini, Dept. of Urology, Castellanza, Italy, ³Italian Ministry of Defense, Dept. of Veterinary Center, Grosseto, Italy, ⁴West Shore Urology, Dept. of Urology, Michigan, United States of America, ⁵Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy

*735

What is the prognostic impact of nodal tumour burden in patients with a single positive node at final pathology?

By: Nini A.¹, Lucianò R.², Freschi M.², Fossati N.¹, Gandaglia G.¹, Castiglione F.³, La Croce G.¹, Saitta G.¹, Bertini R.¹, Doglioni C.², Montorsi F.¹, Briganti A.¹

Institutes:¹IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Pathology, Milan, Italy, ³University Hospitals Leuven, Dept. of Urology, Leuven, Belgium

*737

Prognostic value of lymphovascular invasion in robot-assisted radical prostatectomy patients with prostate confined, resection margin negative tumour

By: Kang Y.J.¹, Jang W.S.¹, Kwon J.K.¹, Yoon C.Y.¹, Lee J.Y.¹, Cho K.S.¹, Ham W.S.¹, Cho I.R.², Choi Y.D.¹

Institutes:¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Inje University, College of Medicine, Dept. of Urology, Goyang, South Korea

Diagnosing TCC - has the cystoscope had its day?

Poster Session 59

Monday, 14 March
08:45 - 10:15

Location: Room Stockholm (Hall B2, level 0)

Chairs: R.T. Bryan, Birmingham (GB)
A. Miernik, Freiburg (DE)
L-P. Xie, Hangzhou (CN)

Aims and objectives of this presentation

Understand the potential of innovations in endoscopy and urine-based diagnostics.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *738 **The feasibility and safety evaluation of the pressure monitored air cystoscopy during active hematuria**
By: Yu E., Yao L., Wang Y., Yu W., Zhang Q., Wu S., Zhang X., He Z., Zhou L., Jin J.
Institutes: Peking University First Hospital, Dept. of Urology, Beijing, China
- *739 **Comparison of white light, photodynamic diagnosis (PDD) and narrow band imaging (NBI) in detection of flat dysplasia and CIS at transurethral resection of the bladder – the DaBlaCa-8 study**
By: Drejer D.¹, Beji S.², Lam G.W.², Jensen J.B.¹
Institutes:¹Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ²Herlev Hospital, Dept. of Urology, Herlev, Denmark
- *740 **A new compound for photodynamic diagnosis of non-muscle invasive bladder cancer – results of a multi-centre phase 2 study with PVP-Hypericin**
By: Straub M.¹, Steiner R.², Schiefelbein F.³, Garlonta V.⁴, Deger S.⁵, Lusuardi L.⁶, Von Pokrzywnitzki W.⁷, Knüchel R.⁸, Schmidbauer J.⁹
Institutes:¹Klinikum Rechts der Isar der Technischen Universität Muenchen, Dept. of Urology, Munich, Germany, ²Sindelfingen-Böblingen Medical Centre, Dept. of Urology, Sindelfingen, Germany, ³Missionsaerztliche Klinik, Dept. of Urology, Würzburg, Germany, ⁴Community Hospital Karlsruhe, Dept. of Urology, Karlsruhe, Germany, ⁵Paracelsus Krankenhaus Ruit, Dept. of Urology, Ruit, Germany, ⁶Paracelsus Medical University, Dept. of Urology, Salzburg, Austria, ⁷Vivantes Klinikum Am Urban, Dept. of Urology, Berlin, Germany, ⁸University Hospital RWTH, Dept. of Pathology, Aachen, Germany, ⁹Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria
- *741 **Does hexaminolevulinate detect chromosomal aberrations in the false-positive bladder biopsies?**
By: D'Andrea D.¹, Martini T.², Mian C.³, Palermo S.M.¹, Comploj E.¹, Pycha A.¹
Institutes:¹General Hospital of Bolzano, Dept. of Urology, Bolzano, Italy, ²Ulm University Medical Center, Dept. of Urology, Ulm, Germany, ³General Hospital of Bolzano, Dept. of Pathology, Bolzano, Italy
- *742 **Urothelial tumor and dual band imaging: New concept in confocal laser endomicroscopy**
By: Bonnal J.L.¹, Yakoubi R.¹, Rock A.¹, El Maadarani K.¹, Marien A.¹, Mauroy B.¹, Gosset P.²
Institutes:¹Hôpital Saint-Philibert, Dept. of Urology, Lomme Cedex, France, ²Hôpital Saint-Vincent, Dept. of Anatomopathology, Lille Cedex, France
- *743 **Measuring the depth of tumor invasion may have greater prognostic value than AJCC/UICC staging of bladder cancer**
By: Nishikimi T.¹, Tsuzuku T.², Mori Y.³, Kashiwagi Y.⁴, Sassa N.⁵, Kimura T.⁶, Fukatsu A.⁷, Tanaka K.⁸, Hattori R.⁹, Takahashi S.³, Gotoh M.⁵

Institutes:¹Nagoya Daini Red Cross Hospital, Dept. of Urology, Nagoya, Japan, ²Nagoya Daini Red Cross Hospital, Dept. of Pathology, Nagoya, Japan, ³Nagoya City University, Dept. of Pathology, Nagoya, Japan, ⁴Okazaki Municipal Hospital, Dept. of Urology, Okazaki, Japan, ⁵Nagoya University, Dept. of Urology, Nagoya, Japan, ⁶JCHO,Cyukyo Hospital, Dept. of Urology, Nagoya, Japan, ⁷Komaki Municipal Hospital, Dept. of Urology, Komaki, Japan, ⁸Komaki Municipal Hospital, Dept. of Urology, Kariya, Japan, ⁹Nagoya Daiichi Red Cross Hospital, Dept. of Urology, Nagoya, Japan

*744

Indolent clinical outcomes of carcinoma in situ-associated pTa bladder tumour after bacillus Calmette-Guérine: Need for a new classification of carcinoma in situ

By: Kim S.J.¹, Hong S.², Kim H.J.², You D.¹, Jeong I.G.¹, Song C.¹, Hong B.S.¹, Kim C.S.¹, Ahn H.¹, Hong J.H.¹

Institutes:¹Asan Medical Center, Dept. of Urology, Seoul, South Korea, ²Dankook University College of Medicine, Dept. of Urology, Cheonan, South Korea

*745

Prognostic performance of different pathological grading schemes in non-muscle invasive transitional-cell carcinoma

By: Nabebina T.², Rolevich A.¹, Dubrowski A.², Polyakov S.¹, Krasny S.¹

Institutes:¹N.N.Alexandrov National Cancer Centre, Dept. of Urology, Minsk, Belarus, ²N.N.Alexandrov National Cancer Centre, Dept. of Pathology, Minsk, Belarus

*746

Molecular tumour grading of non muscle invasive bladder cancer based on whole transcriptome analysis

By: Shen J.², Noon A.³, Aguiar Cabeza E.², Kuk C.⁴, Ilczynski C.⁵, Ni R.⁵, Sukhu B.⁵, Chan K.², Gunaratne A.², Erlich A.⁴, Cremer C.⁶, Morris Q.⁶, Barbosa-Morais N.⁶, Roupert M.⁹, Compérat E.¹⁰, Sweet J.⁸, Fleshner N.⁷, Kulkarni G.⁷, Blencowe B.⁶, Azad A.⁵, Van Der Kwast T.⁸, Zlotta A.R.¹, Wrana J.²

Institutes:¹Mount Sinai Hospital & Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, ²Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada, ³University of Sheffield, Dept. of Urology, Sheffield, United Kingdom, ⁴Mount Sinai Hospital, Dept. of Urology, Toronto, Canada, ⁵Mount Sinai Hospital, Dept. of Pathology and Laboratory Medicine, Toronto, Canada, ⁶University of Toronto, Terrence Donnelly Centre for Cellular and Biomolecular Research, Toronto, Canada, ⁷Princess Margaret Cancer Centre, Dept. of Surgical Oncology, Division of Urology, University Health Network, Toronto, Canada, ⁸University Health Network, Dept. of Pathology, Toronto, Canada, ⁹Group Hospitalier La Pitié-Salpêtrière, Université Pierre et Marie Curie, Dept. of Urology, Paris, France, ¹⁰Group Hospitalier La Pitié-Salpêtrière, Université Pierre et Marie Curie, Dept. of Pathology, Paris, France

*747

Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: The Spanish bladder cancer study

By: Garcia-Rojo D.¹, Robles C.², Viscidi R.³, Malats N.⁴, Silverman D.⁵, Gelabert-Mas A.⁶, Ibarz L.⁷, Cecchini L.⁶, Kogevinas M.⁸, Garcia-Closas R.⁹, Prera A.¹, Lloreta J.¹⁰, Consol S.¹¹, Carrato A.¹², Abascal R.¹³, Fernandez J.M.¹³, Rodriguez De Vera J.M.¹⁴, Rivas M.¹⁵, Guate J.L.¹⁶, Malet J.M.¹⁷, Muntañola P.¹⁸, Gonzalez-Huergo J.¹⁹, Mosquera J.²⁰, Cespedes M.²¹, Prats J.²², Real F.X.²³

Institutes:¹Consorci Hospitalari Parc Tauli, Dept. of Urology, Sabadell, Spain, ²Catalan Institute of Oncology, Dept. of Infections and Cancer, Hospitalet De Llobregat, Spain, ³Johns Hopkins University School of Medicine, Stanley Division of Developmental Neurovirology, Baltimore, United States of America, ⁴Spanish National Cancer Research Centre (CNIO), Dept. of Genetic and Molecular Epidemiology, Madrid, Spain, ⁵National Cancer Institute, Dept. of Cancer Epidemiology and Genetics, Bethesda, United States of America, ⁶Hospital Del Mar, Dept. of Urology, Barcelona, Spain, ⁷Hospital Germans Trias I Pujol, Dept. of Urology, Badalona, Spain, ⁸IMIM, Dept. of Epidemiology, Barcelona, Spain, ⁹Hospital Universitario Canarias, Dept. of Epidemiology, Barcelona, Spain, ¹⁰Hospital Del Mar, Dept. of Pathology, Barcelona, Spain, ¹¹Consorci Hospitalari Parc Tauli, Dept. of Epidemiology, Sabadell, Spain, ¹²Hospital Elche, Dept. of Oncology, Elche, Spain, ¹³Hospital Central De Asturias, Dept. of Urology, Oviedo, Spain, ¹⁴Hospital Universitario De Canarias, Dept. of Urology, Santa Cruz de Tenerife, Spain, ¹⁵Hospital Cabueñes, Dept. of Urology, Cabueñes, Spain, ¹⁶Hospital Aviles, Dept. of Urology, Aviles, Spain, ¹⁷Hospital Manresa, Dept. of Urology, Manresa, Spain, ¹⁸Hospital Mieres, Dept. of Urology, Mieres, Spain, ¹⁹Hospital Coaña, Dept. of Urology, Coaña, Spain, ²⁰Hospital Cangas, Dept. of Urology, Cangas, Spain, ²¹Hospital Sant Boi, Dept. of Urology, Sant Boi De Llobregat, Spain, ²²Corporacio Parc Tauli, Dept. of Urology,

Sabadell, Spain, ²³Spanish National Cancer Research Centre (CNIO), Genetic and Molecular Epidemiology Group, Madrid, Spain

*749

Diagnostic utility of UroVysion for urothelial carcinoma of the upper urinary tract

By: Sassa N.¹, Tsuzuki T.², Hattori R.³, Kato M.¹, Ishida S.¹, Sano T.³, Gotoh M.¹

Institutes:¹Nagoya University, Dept. of Urology, Nagoya, Japan, ²Japanese Red Cross Nagoya Daini Hospital, Dept. of Pathology, Nagoya, Japan, ³Japanese Red Cross Nagoya Daiichi Hospital, Dept. of Urology, Nagoya, Japan

*750

Detection of carcinoma in situ (CIS) of urinary bladder cancer using UBC® Rapid as tumour marker

By: Ecke T.¹, Arndt C.², Gützlaff S.³, Stephan C.³, Lux O.¹, Otto T.², Hallmann S.¹, Ruttloff J.¹, Gerullis H.⁴

Institutes:¹Helios Hospital, Dept. of Urology, Bad Saarow, Germany, ²Lukaskrankenhaus, Dept. of Urology, Neuss, Germany, ³University Hospital Charité, Dept. of Urology, Berlin, Germany, ⁴University Oldenburg, Dept. of Urology, Oldenburg, Germany

*751

Colour and morphology combination for detection of low-grade urothelial cancer cells: Multi-center validation study

By: Yossepowitch O.¹, Leibovitch I.⁴, Nativ O.⁵, Cohen M.¹¹, Mor Y.⁶, Lindner U.⁷, Sidi A.¹⁰, Matzkin H.⁹, Gofrit O.⁸, Rona R.¹², Shtabsky A.², Lew S.³

Institutes:¹Rabin Medical Center, Dept. of Urology, Petach Tikva, Israel, ²Sourasky Medical Center, Dept. of Pathology, Tel-Aviv, Israel, ³Patho-Lab Diagnostics Ltd, Dept. of Pathology, Ness Ziona, Israel, ⁴Meir Medical Center, Dept. of Urology, Kfar Saba, Israel, ⁵Bnai Zion Medical Center, Dept. of Urology, Haifa, Israel, ⁶Sheba Medical Center, Dept. of Urology, Tel-Aviv, Israel, ⁷Kaplan Medical Center, Dept. of Urology, Rehovot, Israel, ⁸Hadassah Medical Center, Dept. of Urology, Jerusalem, Israel, ⁹Sourasky Medical Center, Dept. of Urology, Tel-Aviv, Israel, ¹⁰Wolfson Medical Center, Dept. of Urology, Holon, Israel, ¹¹HaEmek Medical Center, Dept. of Urology, Afula, Israel, ¹²Meir Medical Center, Dept. of Pathology, Kfar Saba, Israel

The post TKI era

Poster Session 60

Monday, 14 March
08:45 - 10:15

Location: Room Milan (Hall B2, level 0)

Chairs: J.P. Bedke, Tübingen (DE)
M. Fujisawa, Kobe (JP)
S. Oudard, Paris (FR)

Aims and objectives of this presentation

This session will focus on new management options for renal cell cancer in the post-TKI era.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *763 **Clinical impact of the dose modification of second-line targeted therapy for patients with metastatic renal cell carcinoma**
By: [Shirotake S.](#)¹, Yasumizu Y.¹, Tanaka N.², Mizuno R.², Ito Y.², Miyazaki Y.², Masunaga A.³, Ito K.³, Hagiwara M.⁴, Asano T.³, Oya M.², Oyama M.¹
Institutes:¹Saitama International Medical Center, Dept. of Urology, Hidaka City, Saitama, Japan, ²Keio University School of Medicine, Dept. of Urology, Shinjuku, Tokyo, Japan, ³National Defense Medical College, Dept. of Urology, Tokorozawa, Saitama, Japan, ⁴Ichikawa General Hospital, Tokyo Dental College, Dept. of Urology, Ichikawa, Chiba, Japan
- *752 **Prognostic significance of nephrectomy in patients with metastatic renal cell carcinoma treated with first-line systemic therapy: A 10-year retrospective analysis according to MSKCC and Heng risk criteria**
By: [Joung J.Y.](#)¹, Seo H.K.¹, Kim S.H.¹, Lee K.H.¹, Chung J.¹, Kwon W-A.²
Institutes:¹National Cancer Center, Dept. of Urology, center for Prostate Cancer, Goyang-Si., South Korea, ²School of Medicine, Institute of Wonkwang Medical Science, Wonkwang University Sanbon Hospital, Dept. of Urology, Gunpo, Gyeonggi-Do, South Korea
- *753 **Dynamic contrast-enhanced CT predicts response to antiangiogenic treatment in patients with metastatic renal cell cancer: Early results**
By: [Stahler M.](#)¹, Sterzik A.², Casuscelli J.¹, Karpitschka M.², Roosen A.¹, Szabados B.¹, Spek A.¹, Ziegelmüller B.¹, Stief C.¹, Reiser M.², Graser A.²
Institutes:¹LMU-Klinikum der Universität München, Dept. of Urology, Munich, Germany, ²LMU-Klinikum der Universität München, Dept. of Radiology, Munich, Germany
- *754 **Trends in cytoreductive nephrectomy in New South Wales, Australia**
By: [Beattie K.](#)¹, Patel M.I.¹, Bang A.², Smith D.P.²
Institutes:¹Westmead Hospital, Dept. of Urology, Sydney, Australia, ²Cancer Council, Cancer Research Division, Sydney, Australia
- *755 **Trends of metastasectomy for metastatic renal cell carcinoma and their impact on overall survival**
By: [Meyer C.](#)¹, Trinh Q-D.¹, Vetterlein M.¹, Löttenberg B.¹, Hanske J.¹, Leow J.¹, Sammon J.², Abdollah F.², Menon M.², Kibel A.¹, Chang S.¹, Choueiri T.³, Sun M.¹
Institutes:¹Brigham and Women's Hospital, Dept. of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Henry Ford Hospital, Vatikutti Urology Institute, Detroit, United States of America, ³Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America
- *756 **Active smoking is an adverse prognostic factor for survival outcome in metastatic renal cell**

carcinoma patients treated with targeted therapies

By: Kröger N.¹, Li H.², De Velasco G.³, Donskov F.⁴, Sim H-W.⁵, Wells C.², Stukalin I.², Agarwal N.⁶, Parekh H.⁷, Rini B.⁷, Knox J.⁵, Pantuck A.⁸, Choueiri T.³, Heng D.²

Institutes:¹University Medicine Greifswald, Dept. of Urology, Greifswald, Germany, ²Tom Baker Cancer Center, Dept. of Medicine, Calgary, Canada, ³Dana Farber Cancer Institute, Dept. of Medicine, Boston, United States of America, ⁴Aarhus University Hospital, Dept. of Medicine, Aarhus, Denmark, ⁵Princess Margaret Cancer Centre, Dept. of Medicine, Toronto, Canada, ⁶University of Utah, Dept. of Medicine, Salt Lake City, United States of America, ⁷Cleveland Clinic, Dept. of Solid Tumor Oncology, Cleveland, United States of America, ⁸David Geffen School of Medicine, Dept. of Urology, Institute of Urologic Oncology, Los Angeles, United States of America

*757

Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioliomyomatosis: Final long-term results from EXIST-2

By: Bissler J.J.¹², Radzikowska E.², Zonnenberg B.³, Belousova E.⁴, Frost M.D.⁵, Sauter M.⁶, Kingswood J.C.⁷, Brakemeier S.⁸, De Vries P.J.⁹, Berkowitz N.¹⁰, Voi M.¹⁰, Peyrard S.¹¹, Budde K.⁸, Franz D.N.¹

Institutes:¹Cincinnati Children's Hospital Medical Center, Dept. of Neurology, Cincinnati, United States of America, ²National Tuberculosis and Lung Diseases Research Institute, Dept. of Lung Disease, Warsaw, Poland, ³University Medical Center Utrecht, Dept. of Radiology and Nuclear Medicine, Utrecht, The Netherlands, ⁴Schlumberger Moscow Research Center, Moscow Research Institute of Pediatrics and Pediatric Surgery, Moscow, Russia, ⁵Minnesota Epilepsy Group, Dept. of Epilepsy, Saint Paul, United States of America, ⁶Klinikverbund Kempten-Oberallgäu GGmbH, Facharzt F. Innere Medizin, Nephrologie, Infektiologie, Kempten, Germany, ⁷Royal Sussex County Hospital, The Trafford Dept of Renal Medicine, Brighton, United Kingdom, ⁸Charite-Universitätsmedizin, Berlin, Germany, ⁹University of Cape Town, Faculty of Health Sciences, Cape Town, South Africa, ¹⁰Novartis Pharma MCH, Dept. of Oncology, East Hanover, United States of America, ¹¹Novartis Pharmaceuticals S.A.S, Dept. of Oncology, Rueil-Malmaison, France, ¹²University of Tennessee Health Science Center, St. Jude Children's Research Hospital and Le Bonheur Children's Hospital, Memphis, United States of America

*759

Comprehensive analysis and validation of contemporary survival prognosticators in patients with metastatic renal cell carcinoma treated with targeted therapy

By: Koo K.C.¹, Lee K.S.¹, Lee D.H.², Rha K.H.¹, Hong S.J.¹, Chung B.H.¹

Institutes:¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Busan National University College of Medicine, Dept. of Urology, Busan, South Korea

*760

Alternative treatment with every other day dosing of sunitinib for patients with metastatic renal cell carcinoma: Efficacy and safety

By: Ohba K., Miyata Y., Asai A., Matsuo T., Sakai H.

Institutes:Nagasaki University Hospital, Dept. of Urology and Renal Transplantation, Nagasaki, Japan

*761

Prognostic significance of early CRP response for metastatic renal cell carcinoma treated with tyrosine kinase inhibitor

By: Yasuda Y.¹, Saito K.¹, Kawamura N.¹, Yuasa T.², Yokoyama M.¹, Matsuoka Y.¹, Ishioka J.¹, Numao N.¹, Okuno T.³, Yamamoto S.², Takahashi S.², Yonese J.², Fujii Y.¹, Kihara K.⁴

Institutes:¹Tokyo Medical and Dental University, Dept. Of Urology, Tokyo, Japan, ²Cancer Institute Hospital, Dept. Of Urology, Tokyo, Japan, ³JA Toride Medical Center, Dept. Of Urology, Ibaraki, Japan, ⁴Tokyo Medical and Dental University, Dept. of Urology, Tokyo, Japan

*762

Results of a phase I/II study in metastatic renal cell carcinoma patients treated with an adjuvant HLA personalized peptide vaccine after resection of metastases and comparison to a contemporary cohort of patients with mRCC

By: Bedke J.¹, Rausch S.¹, Gouttefangeas C.², Kruck S.¹, Walter K.¹, Feyerabend S.¹, Hennenlotter J.¹, Laske K.², Stevanovic S.², Rammensee H-G.², Stenzl A.¹

Institutes:¹University of Tübingen, Dept. of Urology, Tübingen, Germany, ²University of Tübingen, Dept. of Immunology, Tübingen, Germany

10:00 - 10:07

Summary and context
J.P. Bedke, Tübingen (DE)

Castration resistant prostate cancer, beyond the usual treatment

Poster Session 61

Monday, 14 March
08:45 - 10:15

Location: Room 14b (ICM, Level 1)

Chairs: T.A. Borkowski, Warsaw (PL)
S. Egawa, Tokyo (JP)
A. Necchi, Milan (IT)

Aims and objectives of this presentation

The treatment Castration Resistant Prostate Cancer has been revolutionised over the years...Understanding its complexity is a major challenge for most urologists. This session will help understand the latest developments in the area.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*764

Radium-223 (Ra-223) re-treatment (re-tx): Experience from an international, multicenter, prospective study in patients (pts) with castration-resistant prostate cancer and bone metastases (mCRPC)

By: [Keizman D.](#)¹, Nordquist L.T.², Mariados N.³, Méndez Vidal M.J.⁴, Thellenberg Karlsson C.⁵, Peer A.⁶, Procopio G.⁷, Frank S.J.⁸, Pulkkanen K.⁹, Severi S.¹⁰, Trigo Perez J.M.¹¹, Schwarzenberger P.¹², Li R.¹³, Sartor O.¹⁴

Institutes:¹Meir Medical Center, Dept. of Genitourinary Oncology Service, Kfar-Saba, Israel, ²GU Research Network, LLC, Dept. of Medical Oncology, Omaha, Nebraska, United States of America, ³Associated Medical Professionals of New York, PLLC, Dept. of Radiation Oncology, Syracuse, New York, United States of America, ⁴Hospital Universitario Reina Sofía, Dept. of Medical Oncology, Cordoba, Spain, ⁵Cancer Center Norrland University, Dept. of Radiation Sciences, Umeå, Sweden, ⁶Rambam Medical Center, Dept. of Oncology, Haifa, Israel, ⁷Foundation IRCCS National Cancer Institute, Dept. of Medical Oncology, Milan, Italy, ⁸Hadassah Hebrew University Medical Center, Dept. of Oncology, Jerusalem, Israel, ⁹Kuopio University Hospital, Dept. of Oncology, Kuopio, Finland, ¹⁰Romagnolo Scientific Institute For The Study and Care of Cancer - IRST IRCCS, Dept. of Nuclear Medicine Therapeutic, Meldola, Italy, ¹¹Hospital Universitario Virgen De La Victoria, Dept. of Medical Oncology, Malaga, Spain, ¹²Bayer HealthCare, Dept. of Global Clinical Development, Whippany, New Jersey, United States of America, ¹³Bayer HealthCare, Dept. of Global Research & Development Statistics, Whippany, New Jersey, United States of America, ¹⁴Tulane Cancer Center, Dept. of Medicine and Urology, New Orleans, Louisiana, United States of America

*765

Updated long-term efficacy and safety of androgen receptor inhibitor ODM-201 in phase I/II trial

By: Fizazi K.¹, Massard C.¹, Bono P.², Kataja V.³, James N.⁴, [Tammela T.](#)⁵, Joensuu H.², Aspegren J.⁶, Mustonen M.V.⁶

Institutes:¹Institut Gustave Roussy, Dept. of Cancer Medicine, Villejuif, France, ²Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki, Finland, ³Kuopio University Hospital, Jyväskylä Central Hospital, Kuopio, Finland, ⁴Queen Elizabeth Hospital University Hospitals, Birmingham NHS Foundation Trust, Birmingham, Finland, ⁵Tampere University Hospital, Dept. of Urology, Tampere, Finland, ⁶Orion Corporation Orion Pharma, Research and Development, Espoo, Finland

*766

Statin use and prostate cancer mortality

By: [Benzon Larsen S.](#)¹, Skriver C.¹, Dehlendorff C.¹, Jespersen C.², Borre M.³, Nørgård M.⁴, Brasso K.⁵, Andersen K.K.¹, Sørensen H.⁴, Hallas J.⁶, Friis S.¹

Institutes:¹Danish Cancer Society, Research Centre, Copenhagen, Denmark, ²Viborg Hospital, Dept. of Urology, Viborg, Denmark, ³Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ⁴

Aarhus University Hospital, Dept. of Clinical Epidemiology, Aarhus, Denmark, ⁵Rigshospitalet, Dept. of Urology and Copenhagen Prostate Cancer Centre, Copenhagen, Denmark, ⁶University of Southern Denmark, Clinical Pharmacology, Odense, Denmark

- *767 **Testosterone bounce predicts cancer specific survival of prostate cancer patients treated with docetaxel therapy**
By: Shuhei K.¹, Sakamoto S.², Yamamoto S.¹, Inoue T.¹, Nozumi K.¹, Chiba K.¹, Miyazaki K.¹, Atsushi I.¹, Nagata M.¹
Institutes:¹Yokohama Rosai Hospital, Dept. of Urology, Yokohama City, Kanagawa, Japan, ²Chiba Univ. Hospital, Dept. of Urology, Chiba City, Chiba, Japan
- *768 **Effect of PSA response on overall and progression-free survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel (Caba): The non-interventional study QoLiTime**
By: Hammerer P.¹, Al-Batran S-E.², Windemuth-Kieselbach C.³, Hofheinz R-D.⁴
Institutes:¹Academic Hospital Braunschweig, Dept. of Urology and Uro-Oncology, Braunschweig, Germany, ²Nordwest Hospital, Institute of Clinical Research, Frankfurt, Germany, ³Alcedis GmbH, Dept. of Biometry, Gießen, Germany, ⁴University Hospital Mannheim, Interdisciplinary Tumor Center, Mannheim, Germany
- *769 **Initial clinical experience with 177Lu-PSMA I&T radionuclide therapy in patients with metastatic castration-resistant prostate cancer**
By: Heck M.M.¹, Retz M.¹, Rauscher I.², Scheidhauer K.², Maurer T.¹, Storz E.¹, Janssen F.¹, D'Alessandria C.², Wester H.-J.³, Gschwend J.E.¹, Schwaiger M.², Tauber R.¹, Eiber M.²
Institutes:¹Klinikum Rechts der Isar der Technischen Universität Muenchen, Dept. of Urology, Munich, Germany, ²Klinikum Rechts der Isar der Technischen Universität Muenchen, Dept. of Nuclear Medicine, Munich, Germany, ³Technische Universität München, Dept. of Pharmaceutical Radiochemistry, Garching, Germany
- *770 **Hormonal response after long-term androgen suppression in patients with prostate cancer**
By: Planas Morin J.¹, Celma A.¹, Regis L.¹, Cuadras M.¹, Trilla E.¹, Salvador C.¹, Placer J.¹, Lorente D.¹, Carles J.², Suárez C.², Morote J.¹
Institutes:¹Hospital Universitari Vall d'Hebron, Dept. of Urology, Barcelona, Spain, ²Hospital Universitari Vall d'Hebron, Dept. of Oncology, Barcelona, Spain
- *771 **Real-world treatment patterns and factors influencing the use of bone-targeted agents (BTAs) in combination with emerging therapeutics in patients with prostate cancer and bone-metastases**
By: Body J-J.¹, Von Moos R.², Rider A.³, Bhowmik D.⁴, Hallworth P.³, Hechmati G.⁵, Qian Y.⁴, Gatta F.⁵
Institutes:¹Chu Brugmann, Dept. Of Medicine, Brussels, Belgium, ²Kantonsspital Graubünden, Dept. of Oncology, Chur, Switzerland, ³Adelphi Real World, Bollington, United Kingdom, ⁴Amgen Inc., Dept. of Health Economics, Thousand Oaks, United States of America, ⁵Amgen (Europe) GmbH, Dept. of Health Economics, Zug, Switzerland
- *772 **Which factors predict overall survival in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate post-docetaxel?**
By: Van Praet C.¹, Rottey S.², Van Hende F.³, Pelgrims G.⁴, Demey W.⁵, Van Aelst F.⁶, Wynendaele W.⁷, Gil T.⁸, Schatteman P.⁹, Filleul B.¹⁰, Schallier D.¹¹, Machiels J-P.¹², Schrijvers D.¹³, Everaert E.¹⁴, D'Hondt L.¹⁵, Werbroeck P.¹⁶, Vermeij J.¹⁷, Mebis J.¹⁸, Classe M.¹⁹, Rasschaert M.²⁰, Van Erps J.²¹, Verheezzen J.²², Van Haverbeke J.²³, Goeminne J-C.²⁴, Lumen N.¹
Institutes:¹Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ²Ghent University Hospital, Dept. of Medical Oncology, Ghent, Belgium, ³Leuven University Hospital, Dept. of Medical Oncology, Leuven, Belgium, ⁴AZ Turnhout, Dept. of Medical Oncology, Turnhout, Belgium, ⁵AZ Klina, Dept. of Medical Oncology, Brasschaat, Belgium, ⁶AZ Delta, Dept. of Medical Oncology, Roeselare, Belgium, ⁷AZ Imelda, Dept. of Medical Oncology, Bonheiden, Belgium, ⁸Institut Jules Bordet, Dept. of Medical Oncology, Brussels, Belgium, ⁹OLV Aalst, Dept. of Urology, Aalst, Belgium, ¹⁰Hopital De Jolimont, Dept. of Medical Oncology, Haine Saint Paul, Belgium, ¹¹Brussels University Hospital, Dept. of Medical Oncology, Brussels, Belgium, ¹²Cliniques Uiversitaires Saint Luc, Dept. of

Medical Oncology, Brussels, Belgium, ¹³Ziekenhuis Netwerk Antwerpen Middelheim, Dept. of Medical Oncology, Antwerp, Belgium, ¹⁴AZ Nikolaas, Dept. of Medical Oncology, Sint-Niklaas, Belgium, ¹⁵CHU Dinant-Godinne, Dept. of Medical Oncology, Yvoir, Belgium, ¹⁶AZ Groeninge, Dept. of Urology, Kortrijk, Belgium, ¹⁷Ziekenhuis Netwerk Antwerpen Jan-Palfijn, Dept. of Medical Oncology, Antwerp, Belgium, ¹⁸AZ Jessa, Dept. of Medical Oncology, Hasselt, Belgium, ¹⁹St Luc Bouge, Dept. of Medical Oncology, Namur, Belgium, ²⁰AZ Monica, Dept. of Medical Oncology, Antwerp, Belgium, ²¹ASZ Aalst, Dept. of Medical Oncology, Aalst, Belgium, ²²AZ Sint-Trudo, Dept. of Medical Oncology, Sint-Truiden, Belgium, ²³AZ Sint-Andries, Dept. of Urology, Tielt, Belgium, ²⁴Sainte-Elisabeth, Dept. of Medical Oncology, Namur, Belgium

*773

Abiraterone for castration resistant prostate cancer: Adherence, survival and hospitalization: Analysis of a medical claims database

By: Mohamad Al-Ali B.¹, Madersbacher S.¹, Berger I.²

Institutes:¹Kaiser-Franz-Josef Spital, Dept. of Urology and Andrology, Vienna, Austria, ²Klinikum Wiener Neustadt, Dept. of Urology and Andrology, Wiener Neustadt, Austria

*774

ARV7 detected by a novel whole-blood RT-PCR assay correlates with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI)

By: Todenhöfer T.¹, Azad A.², Gao J.¹, Stewart C.¹, Eigl B.², Stenzl A.⁴, Black P.¹, Teich M.³, Joshua A.³, Chi K.²

Institutes:¹University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, ²British Columbia Cancer Agency, Dept. of Medical Oncology, Vancouver, Canada, ³University of Toronto, Princess Margret Cancer Centre, Toronto, Canada, ⁴Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany

*775

The phase 3 COU-AA-302 study of abiraterone acetate (AA) in men with chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC): Stratified analysis based on pain, prostate-specific antigen (PSA) and Gleason score (GS)

By: Miller K.¹, Carles J.², Gschwend J.E.³, Van Poppel H.⁴, Diels J.⁵, Brookman-May S.D.⁶

Institutes:¹Charité Berlin, Dept. of Urology, Berlin, Germany, ²Vall D'Hebron University Hospital, Dept. of Medical Oncology, Barcelona, Spain, ³Technical University of Munich, School of Medicine, Munich, Germany, ⁴Katholieke Universiteit Leuven, Dept. of Urology, Leuven, Belgium, ⁵Janssen EMEA, HEMAR, Beerse, Belgium, ⁶Ludwig Maximilians University of Munich, Janssen Research & Development, Munich, Germany

Prostate cancer diagnosis

Poster Session 62

Monday, 14 March
08:45 - 10:15

Location: Room 14c (ICM, Level 1)

Chairs: N. Al-Hamdani, Baghdad (IQ)
F.M.J. Debruyne, Arnhem (NL)
V. Scattoni, Milan (IT)

Aims and objectives of this presentation

This session is aiming to find the best and specific way for early diagnosis and detection of prostate cancer and the best way to prevent the disease if possible.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *776 **Prostate cancer incidence and cardiovascular mortality among users of testosterone replacement therapy in the Finnish Prostate Cancer Screening Trial**
By: [Murtola T.](#)¹, [Rytkönen J.](#)², [Talala K.](#)³, [Taari K.](#)⁴, [Tammela T.](#)², [Auvinen A.](#)⁵
Institutes:¹Tampere University Hospital, Dept. of Urology, Tampere, Finland, ²University of Tampere, School of Medicine, Tampere, Finland, ³Finnish Cancer Registry, Dept. of Statistics, Helsinki, Finland, ⁴University of Helsinki, Medical School, Helsinki, Finland, ⁵University of Tampere, School of Health Sciences, Tampere, Finland
- *777 **The impact of age-adjusted Charlson comorbidity index and age-adjusted prostate cancer specific comorbidity index in men underwent radical prostatectomy: A competing risk analysis of long-term survival data**
By: [Kang D.H.](#)¹, [Lee J.Y.](#)¹, [Jang W.S.](#)¹, [Kang H.W.](#)², [Kwon J.K.](#)¹, [Rha K.H.](#)¹, [Cho N.H.](#)³, [Oh C.K.](#)⁴, [Choi Y.D.](#)¹, [Hong S.J.](#)¹, [Cho K.S.](#)¹
Institutes:¹Yonsei University College of Medicine, Dept. of Urology, Urological Science Institute, Seoul, South Korea, ²Chungbuk National University College of Medicine, Dept. of Urology, Cheongju, South Korea, ³Yonsei University College of Medicine, Dept. of Pathology, Seoul, South Korea, ⁴Inje University College of Medicine, Dept. of Urology, Busan, South Korea
- *778 **Increase prostate cancer detection rate from 12- to 18-core prostate biopsy in patients with serum prostate-specific antigen level of 4.0-20.0 ng/ml**
By: [Wang B-R.](#)¹, [Chen C.C.](#)², [Ou Y-C.](#)²
Institutes:¹Taichung Arm Force General Hospital, Dept. of Urology and Dept. of Surgery, Taichung City, Taiwan, ²Taichung Veterans General Hospital, Dept. of Urology and Dept. of Surgery, Taichung City, Taiwan
- *779 **Comparison of MRI/ultrasound-fusion-biopsy to systematic prostate biopsy in prediction of final histopathology in prostatectomy specimen**
By: [Borkowetz A.](#)¹, [Platzek I.](#)², [Toma M.](#)³, [Renner T.](#)¹, [Fröhner M.](#)¹, [Zastrow S.](#)¹, [Wirth M.](#)¹
Institutes:¹University Hospital, TU Dresden, Dept. of Urology, Dresden, Germany, ²University Hospital, TU Dresden, Dept. of Radiology, Dresden, Germany, ³University Hospital, TU Dresden, Dept. of Pathology, Dresden, Germany
- *780 **Minimizing the Gleason score upgrade from biopsy to prostatectomy specimen through mpMRI and template mapping fusion biopsy**
By: [Gross O.](#), [Neuhaus L.](#), [Mortezavi A.](#), [Sulser T.](#), [Eberli D.](#)
Institutes:University Hospital Zurich, Dept. of Urology, Zürich, Switzerland

- *781 **Natural history of prostatic precancerous lesions: When to re-biopsy?**
By: Oderda M.¹, Agnello M.¹, Barale M.¹, Falcone M.¹, Marra G.¹, Preto M.¹, Daniele L.², Pacchioni D.², Delsedime L.², Nicolaiew N.³, Joniau S.³, De La Taille A.⁴, Gontero P.¹
Institutes:¹University of Turin, Dept. of Surgical Sciences/Urology, Turin, Italy, ²A.O.U. Città Della Salute E Della Scienza, Dept. of Pathology, Turin, Italy, ³University Hospitals of Leuven, Dept. of Urology, Leuven, Belgium, ⁴C.H.U. Henri Mondor, Dept. of Urology, Creteil, France
- *782 **Assessing the role of time from prostate cancer diagnosis to radical prostatectomy: Can surgery be postponed safely?**
By: Cucchiara V., Suardi N., Gallina A., Stabile A., Picozzi M., Zaffuto E., Fossati N., Gandaglia G., Larcher A., Salonia A., Montorsi F., Briganti A.
Institutes:IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy
- *783 **High-resolution magnetic resonance imaging differentiates between normal histomorphological signatures and prostate cancer in the resected prostate gland**
By: Durand M.¹, Jain M.², Robinson B.³, Aronowitz E.⁴, El Douahy Y.², Leung R.², Sherr D.², Ng A.⁴, Donzeau D.⁵, Amiel J.⁵, Pascal S.⁴, Villers A.⁶, Ballon D.⁴
Institutes:¹Hôpital Pasteur 2, CHU Nice, University of Nice-Sophia-Antipolis, INSERM U1189, Dept. of Urology, Nice, France, ²Weill Medical College of Cornell University, Dept. of Urology, New York, United States of America, ³Weill Medical College of Cornell University, Dept. of Pathology, New York, United States of America, ⁴Weill Medical College of Cornell University, Dept. of Radiology, New York, United States of America, ⁵Hôpital Pasteur 2, CHU Nice, University of Nice-Sophia-Antipolis, Dept. of Urology, Nice, France, ⁶CHU Lille, Université De Lille, INSERM U1189, Dept. of Urology, Lille, France
- *784 **Impact of PI-RADS version 2 on MRI diagnosis for extracapsular extension of prostate cancer: A multireader study**
By: Matsuoka Y.¹, Ishioka J.¹, Tanaka H.², Inoue M.¹, Ito M.¹, Yoshida S.¹, Yokoyama M.¹, Numao N.¹, Saito K.¹, Fujii Y.¹, Kihara K.¹
Institutes:¹Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, ²Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan
- *785 **Limitations in elastography based prostate biopsy**
By: Grindei-Nevrincean M.¹, Schiffmann J.¹, Tian Z.², Yassin D-J.¹, Steinwender T.¹, Leyh-Bannurah S-R.², Randazzo M.³, Kwiatkowski M.³, Karakiewicz P.I.², Hammerer P.¹, Manka L.¹
Institutes:¹Academic Hospital Braunschweig, Dept. of Urology, Braunschweig, Germany, ²University of Montreal Health Center, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Canada, ³Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland
- *786 **Phenotypic and molecular characterization of circulating tumor cells (EGFR and AR) and its correlation with prostate biopsy in early-stage prostate cancer**
By: Puche Sanz L.¹, Flores-Martín J.¹, Vázquez Alonso F.¹, Serrano Fernández M.J.², Cózar Olmo J.M.¹
Institutes:¹Complejo Hospitalario Universitario De Granada, Dept. of Urology, Granada, Spain, ²Centro Pfizer-Universidad De Granada-Junta De Andalucía De Genómica E Investigación Oncológica (GENY), Dept. of Circulating Tumor Cells, Granada, Spain

Regulation of urothelium carcinogenesis and progression

Poster Session 63

Monday, 14 March
08:45 - 10:15

Location: Room Paris (Hall B2, level 0)

Chairs: B.C. Jeong, Seoul (KR)
A. Vlahou, Athens (GR)
E. Zwarthoff, Rotterdam (NL)

Aims and objectives of this presentation

Factors from tumour microenvironment are recognised as regulators of cancer progression. In this session, novel chemokines and miRNA which have a key role in bladder carcinogenesis will be discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *787 **The Cancer Genome Atlas (TCGA) project analysis of micro-RNA and gene expression subtypes of high-grade, muscle-invasive urothelial carcinoma**
By: Robertson G.², Gunaratne P.³, Lerner S.¹, Mungall A.², Brooks D.², Bowlby R.², Sipahimalani P.², Jones S.², Marra M.², Hoadley K.⁴, Kwiatkowski D.⁵, Rosenberg J.⁶, Weinstein J.⁷
Institutes:¹Baylor College of Medicine, Dept. of Urology, Houston, United States of America, ²BC Cancer Agency, Genome Sciences Center, Vancouver, Canada, ³University of Houston, Dept. of Biology & Biochemistry, Houston, United States of America, ⁴University of North Carolina, Dept. of Genetics, Chapel Hill, United States of America, ⁵Harvard, Broad Institute, Boston, United States of America, ⁶Memorial Sloan Kettering Cancer Center, Dept. of Medical Oncology, New York, United States of America, ⁷MD Anderson Cancer Center, Computational Biology, Houston, United States of America
- *788 **Robust cancer-specific gene expression by a cassette with hTERT and CMV promoter elements as a novel system for detecting viable bladder cancer cells**
By: Sadahira T., Watanabe M., Araki M., Ebara S., Watanabe T., Nasu Y.
Institutes: Okayama University Graduate School, Dept. of Urology, Okayama, Japan
- *789 **Comprehensive analysis of immune infiltrates during BCG therapy reveals an immune profile strongly associated with bladder cancer recurrence**
By: Chevalier M.E.¹, Trabanelli S.², Gharbi D.¹, Cesson V.¹, Domingos-Pereira S.¹, Dartiguenave F.¹, Fritschi A-S.¹, Speiser D.², Romero P.², Jandus C.², Nardelli-Haefliger D.¹, Derré L.¹, Jichlinski P.¹
Institutes:¹Lausanne University Hospital, Dept. of Urology, Lausanne, Switzerland, ²University of Lausanne, Dept. of Cancer Research, Epalinges, Switzerland
- *790 **CXCL1 signalling is a crucial mediator between cancer cells and tumour-associated macrophages/cancer-associated fibroblasts for tumour invasion and progression in micro-environment of human bladder cancer**
By: Miyake M.¹, Hori S.¹, Morizawa Y.¹, Tatsumi Y.¹, Nakai Y.¹, Anai S.¹, Tanaka N.¹, Toritsuka M.², Kishimoto T.², Rosser C.³, Fujimoto K.¹
Institutes:¹Nara Medical University, Dept. of Urology, Kashihara-Shi, Japan, ²Nara Medical University, Dept. of Psychiatry, Kashihara-Shi, Japan, ³University of Hawaii Cancer Center, Dept. of Clinical and Translational Research, Honolulu, United States of America
- *791 **Notch2-HEY axis promotes tumour growth in bladder cancer through cell cycle progression and de-differentiation**
By: Hayashi T.¹, Goriki A.², Oo H.Z.², Seiler R.², Todenhofer T.², Jaeger W.², Awrey S.², Altamirano-Dimas M.², Fazli L.², Matsubara A.¹, Black P.²

Institutes:¹Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

- *792 **Advanced two-step transcriptional amplification as a novel system for cancer-specific gene expression and imaging**
By: [Sadahira T.](#), Watanabe M., Araki M., Ebara S., Watanabe T., Nasu Y.
Institutes: Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Dept. of Urology, Okayama, Japan
- *793 **Relationship of \square MV infection with transitional cell carcinoma of bladder**
By: [Kosova L.](#)
Institutes: Moscow City Hospital \square 68, Dept. of Urology, Moscow, Russia
- *794 **Stabilization of invadopodia by plectin-mediated conjunction to vimentin intermediate filament is a critical molecular step of invasion and extravasation for metastasis in bladder cancer**
By: [Yoneyama M.S.](#)¹, Hatakeyama S.², Habuchi T.³, Inoue T.³, Nakamura T.⁴, Funyu T.¹, Wiche G.⁵, Tsuboi S.¹, Ohyama C.²
Institutes:¹Oyokyo Kidney Research Institute, Dept. of Cancer Immunology and Cell Biology, Hirosaki, Japan, ²Graduate School of Medicine, Hirosaki University, Dept. of Urology, Hirosaki, Japan, ³Akita University, Dept. of Urology, Akita, Japan, ⁴Graduate School of Health Sciences, Hirosaki University, Dept. of Biomedical Sciences, Hirosaki, Japan, ⁵Vienna University, Dept. of Biochemistry and Cell Biology, Vienna, Austria
- *795 **Combination of human immunodeficiency virus protease inhibitors causes bladder cancer apoptosis synergistically by inducing endoplasmic reticulum stress and histone acetylation**
By: [Sato A.](#), Asano T., Isono M., Okubo K., Ito K., Asano T.
Institutes: National Defense Medical College, Dept. of Urology, Tokorozawa, Japan
- *796 **CCDC34 is up-regulated in bladder cancer and regulates bladder cancer cell proliferation, migration and invasion**
By: [Gong Y.](#)¹, Qiu W.², Ning X.¹, Yang X.¹, Li X.¹, Guo Y.¹
Institutes:¹Peking University First Hospital, Dept. of Urology, Beijing, China, ²Beijing Friendship Hospital, Capital Medical University, Dept. of Urology, Beijing, China
- *797 **MicroRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1**
By: [Fuji T.](#)¹, Tatsumi Y.¹, Asano A.¹, Izutsu C.¹, Fujimoto K.², Konishi N.¹
Institutes:¹Nara Medical University, Dept. of Pathology, Kashihara, Nara, Japan, ²Nara Medical University, Dept. of Urology, Kashihara, Nara, Japan
- *798 **Uncovering the TWEAK/Fn14 cytokine-receptor axis in bladder cancer**
By: Pompas-Veganzones N.¹, Calvo R.¹, Sanchez-Niño M.D.², Dominguez O.³, Ortiz A.², Gonzalez-Peramato P.⁴, [Sanchez-Carbayo M.](#)¹
Institutes:¹University of the Basque Country, Dept. of Translational Oncology Laboratory, Vitoria-Gasteiz, Spain, ²Fundacion Jimenez Diaz, Dept. of Nephrology, Madrid, Spain, ³Spanish National Cancer Research Center, Dept. of Genomics, Vitoria-Gasteiz, Spain, ⁴Hospital La Paz, Dept. of Pathology, Madrid, Spain
- *799 **Exosomal miRNAs: Key regulators of cell-cell communication among bladder cancer cells and tumor microenvironment?**
By: [Baumgart S.](#)¹, Heinzelmann J.¹, Krause E.², Stöckle M.¹, Stampe Ostenfeld M.³, Junker K.¹
Institutes:¹University Hospital of Saarland, Dept. of Urology, Homburg, Germany, ²University Hospital of Saarland, Dept. of Physiology, Homburg, Germany, ³University Hospital Aarhus, Dept. of Molecular Medicine, Aarhus, Denmark
- 10:00 - 10:07 **Summary and context**
A. Vlahou, Athens (GR)

Current risk stratification and adapted strategies for the management of upper tract urothelial carcinomas

Poster Session 64

Monday, 14 March
08:45 - 10:15

Location: Room Vienna (Hall B2, level 0)

Chairs: W.C. Loidl, Linz (AT)
V. Pansadoro, Rome (IT)
D. Yates, Sheffield (GB)

Aims and objectives of this presentation

Upper Tract Urothelial Carcinoma (UTUC) are relatively uncommon compared to bladder cancer, but 60% of UTUCs are invasive at diagnosis. The risk stratification appears to be crucial to elaborate appropriate strategy and select patients for kidney-sparing management. The purpose of the session is to provide an overview of available assessment tools and treatments.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*800

Oncological outcomes of radical nephroureterectomy versus kidney-sparing surgery for elective treatment of clinically organ-confined upper tract urothelial carcinoma of the distal ureter

By: [Seisen T.](#)¹, Nison L.², Remzi M.³, Klatte T.⁴, Lucca I.⁴, Mathieu R.⁵, Bozzini G.⁶, Capitanio U.⁷, Novara G.⁸, Cussenot O.⁹, Comp rat E.¹⁰, Renard Penna R.¹¹, Peyronnet B.¹², Merseburger A.¹³, Fritsche H-M.¹⁴, Hora M.¹⁵, Shariat S.⁴, Colin P.¹⁶, Roupr t M.¹²

Institutes:¹H pitaux universitaires La Piti -Salp tri re, Dept. of Urology, Paris, France, ²H pitaux Universitaires Lille, Dept. of Urology, Lille, France, ³Landeskrankenhaus Korneuburg, Dept. of Urology, Korneuburg, Austria, ⁴Medical University Vienna, Dept. of Urology, Vienna, Austria, ⁵Medical University Vienna, Dept. of Urology, Vienna, France, ⁶Medical University Lille, Dept. of Urology, Lille, France, ⁷IRCCS Ospedale San Raffaele University, Dept. of Urology, Milan, Italy, ⁸Urology Clinic, University of Padua, Dept. of Urology, Padua, Italy, ⁹Tenon Hospital, Dept. of Urology, Padua, Italy, ¹⁰Piti  Salp tri re Hospital, Dept. of Pathology, Paris, France, ¹¹Piti  Salp tri re Hospital, Dept. of Radiology, Paris, France, ¹²Piti  Salp tri re Hospital, Dept. of Urology, Paris, France, ¹³University Hospital Schleswig-Holstein, Dept. of Urology, L beck, Germany, ¹⁴St Josef Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, ¹⁵Faculty Hospital Plze  and Charles University In Prague, Dept. of Urology, Prague, Czech Republic, ¹⁶Private Hospital La Louvi re, Dept. of Urology, Lille, France

*801

The impact of ureteral ligation on clinical outcome during radical nephroureterectomy for upper urinary tract urothelial carcinoma: Multi-institutional case series study JCOG1110A

By: [Inokuchi J.](#)¹, Kuroiwa K.², Naito S.¹, Takehi Y.³, Sugimoto M.³, Tanikawa T.⁴, Fujimoto H.⁵, Gotoh M.⁶, Masumori N.⁷, Ogawa O.⁸, Etoh M.⁹, Ohyama C.¹⁰, Yamaguchi A.¹¹, Matsuyama H.¹², Ichikawa T.¹³, Asano T.¹⁴, Takenaka A.¹⁵, Fujimoto K.¹⁶, Yamaguchi R.¹⁷, Habuchi T.¹⁸, Hashine K.¹⁹, Arai Y.²⁰, Nagaoka A.²¹, Nishiyama H.²², Shinohara N.²³, Niwakawa M.²⁴, Egawa S.²⁵, Ozono S.²⁶, Kawano Y.²⁷, Ishizuka O.²⁸, Nishimura K.²⁹, Tochigi T.³⁰, Sugimura Y.³¹, Mizusawa J.³², Eba J.³²

Institutes:¹Kyushu University, Dept. of Urology, Fukuoka, Japan, ²Miyazaki Prefectural Miyazaki Hospital, Dept. of Urology, Miyazaki, Japan, ³Faculty of Medicine, Kagawa University, Dept. of Urology, Kagawa, Japan, ⁴Niigata Cancer Center Hospital, Dept. of Urology, Niigata, Japan, ⁵National Cancer Center Hospital, Dept. of Urology, Tokyo, Japan, ⁶Nagoya University Graduate School of Medicine, Dept. of Urology, Tokyo, Japan, ⁷Sapporo Medical University School of Medicine, Dept. of Urology, Sapporo, Japan, ⁸Kyoto University, Dept. of Urology, Kyoto, Japan, ⁹Graduate School of Medical Sciences, Kyushu University, Dept. of Urology, Fukuoka, Japan, ¹⁰Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ¹¹Harasanshin

Hospital, Dept. of Urology, Fukuoka, Japan, ¹²Graduate School of Medicine, Yamaguchi University, Dept. of Urology, Ube, Japan, ¹³Graduate School of Medicine, Chiba University, Dept. of Urology, Chiba, Japan, ¹⁴National Defense Medical College, Dept. of Urology, Tokorozawa, Japan, ¹⁵Tottori University Faculty of Medicine, Dept. of Urology and Surgery, Yonago, Japan, ¹⁶Nara Medical University, Dept. of Urology, Kashihara, Japan, ¹⁷Teikyo University School of Medicine, Dept. of Urology, Tokyo, Japan, ¹⁸Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, ¹⁹Shikoku Cancer Center Hospital, National Hospital Organization, Dept. of Urology, Matsuyama, Japan, ²⁰Tohoku University Graduate School of Medicine, Dept. of Urology, Sendai, Japan, ²¹Yamagata University Hospital, Dept. of Urology, Yamagata, Japan, ²²Faculty of Medicine, University of Tsukuba, Dept. of Urology, Ibaraki, Japan, ²³Hokkaido University Graduate School of Medicine, Dept. of Urology, Sapporo, Japan, ²⁴Shizuoka Cancer Center, Dept. of Urology, Shizuoka, Japan, ²⁵Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, ²⁶Hamamatsu University School of Medicine, Dept. of Urology, Hamamatsu, Japan, ²⁷Graduate School of Medical Sciences, Kumamoto University, Dept. of Urology, Kumamoto, Japan, ²⁸Shinshu University School of Medicine, Dept. of Urology, Matsumoto, Japan, ²⁹Osaka Medical Center For Cancer and Cardiovascular Diseases, Dept. of Urology, Osaka, Japan, ³⁰Miyagi Cancer Center, Dept. of Urology, Natori, Japan, ³¹Mie University Graduate School of Medicine, Dept. of Nephro-Urologic Surgery and Andrology, Tsu, Japan, ³²National Cancer Center, JCOG Data Center / Operations Office, Tokyo, Japan

*802

Risk stratification by means of the biological age related factors better predicts cancer-specific survival than the chronological age in patients with upper tract urothelial carcinoma (UTUC): A multi-institutional database study

By: Inamoto T.¹, Takahara K.¹, Matsuyama H.², Fujimoto K.³, Shiina H.⁴, Sakano S.², Nagao K.², Miyake M.³, Tatsumi Y.³, Yasumoto H.⁴, Azuma H.¹

Institutes:¹Osaka Medical College, Dept. of Urology, Osaka, Japan, ²Yamaguchi University, Dept. of Urology, Ube, Japan, ³Nara Medical University, Dept. of Urology, Kashihara, Japan, ⁴Shimane University School of Medicine, Dept. of Urology, Izumo, Japan

*803

Risk stratification model for lymphovascular invasion, pathological T stage, lymph node involvement, and c-reactive protein predicts high-risk patients - who are candidate for adjuvant chemotherapy in upper urinary tract urothelial cancer

By: Nagao K.¹, Matsuyama H.¹, Fujimoto K.², Azuma H.³, Shiina H.⁴, Tatsumi Y.², Sakano S.¹, Inamoto T.³, Yasumoto H.⁴

Institutes:¹Graduate School of Medicine, Yamaguchi University, Dept. of Urology, Ube, Japan, ²Nara Medical University, Dept. of Urology, Kashihara, Japan, ³Osaka Medical College, Dept. of Urology, Takatsuki, Japan, ⁴Shimane University Faculty of Medicine, Dept. of Urology, Izumo, Japan

*804

Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy

By: Vartolomei M.D.¹, Mathieu R.², Rouprêt M.³, Lucca I.⁴, Mbeutcha A.², Seitz C.², Karakiewicz P.⁵, Fajkovic H.², Rink M.⁶, Briganti A.⁷, Xylinas E.⁸, Shariat S.²

Institutes:¹Medical University Vienna and University of Medicine and Pharmacy, Dept. of Cell and Molecular Biology, Targu Mures, Romania, ²Medical University and General Hospital, Dept. of Urology, Vienna, Austria, ³Faculté De Médecine Pierre Et Marie Curie, University Paris 6, Dept. of Urology, Paris, France, ⁴Centre Hospitalier Universitaire Vaudois, Dept. of Urology, Lausanne, Switzerland, ⁵University of Montreal Health Centre, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Canada, ⁶University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁷Vita Salute San Raffaele University, Dept. of Urology, Milan, Italy, ⁸Cochin Hospital, Assistance Publique-Hôpitaux De Paris, Paris Descartes University, Dept. of Urology, Paris, France

*805

International multicentre validation of prognostic micrnas in upper tract urothelial carcinoma

By: Izquierdo Reyes L.¹, Montalbo R.¹, Ramirez-Backhaus M.², Solsona E.², Rubio J.², Van Der Heiden T.³, Schaafsma H.³, Lopez-Beltran A.⁴, Blanca A.⁴, Mengual L.¹, Alcaraz A.¹

Institutes:¹Hospital Clínic de Barcelona, Dept. of Urology, Barcelona, Spain, ²Fundacion IVO, Dept. of Urology, Valencia, Spain, ³Radbou University Centre, Dept. of Urology, Nijmegen, The Netherlands, ⁴Hospital Reina Sofia, Dept. of Urology, Cordoba, Spain

- *806 **Chronological changes of clinical outcome after radical nephroureterectomy in patients with localized upper urinary tract carcinoma treated in the last two decades: Are we succeeding?**
By: [Makito M.](#)¹, Tatsumi Y.¹, Fujimoto K.¹, Nagao K.², Sakano S.², Matsuyama H.², Inamoto T.³, Azuma H.³, Yasumoto H.⁴, Shiina H.⁴
Institutes:¹Nara Medical University, Dept. of Urology, Nara, Japan, ²Graduate School of Medicine, Yamaguchi University, Dept. of Urology, Yamaguchi, Japan, ³Osaka Medical College, Dept. of Urology, Osaka, Japan, ⁴Shimane University School of Medicine, Dept. of Urology, Shimane, Japan
- *807 **Long-term results of flexible ureteroscopy and laser photoablation for the treatment of patients with upper tract urothelial carcinoma: In whom an endourological management may not be enough to control the disease?**
By: [Villa L.](#)¹, Cloutier J.², Salonia A.³, Montorsi F.³, Traxer O.²
Institutes:¹Tenon Hospital, Pierre and Marie Curie University, Paris, France ²Division of Experimental Oncology, Dept. of Urology, Milan, Italy, ²Tenon Hospital, Pierre and Marie Curie University, Paris, France, Dept. of Urology, Paris, France, ³1 Division of Experimental Oncology/Unit of Urology; URI; IRCCS Ospedale San Raffaele 2 Università, Dept. of Urology, Milan, Italy
- *808 **Prognostic value of the pT3 subclassification for upper tract urothelial carcinomas of the renal pelvicalyceal system**
By: [Seisen T.](#)¹, Compérat E.², Colin P.³, Rioux-Leclercq N.⁴, Peyronnet B.⁵, Bensalah K.⁵, Pfister C.⁶, Gobet F.⁷, De La Taille A.⁸, Allory Y.⁹, Xylinas E.¹⁰, Sibony M.¹¹, Cussenot O.¹², Rouprêt M.¹³
Institutes:¹Hôpitaux universitaires La Pitié-Salpêtrière, Dept. of Urology, Paris, France, ²Hôpitaux universitaires La Pitié-Salpêtrière, Dept. of Pathology, Paris, France, ³Hôpital Privé De La Louvière, Dept. of Urology, Lille, France, ⁴Hôpital Universitaire De Rennes, Dept. of Pathology, Rennes, France, ⁵Hôpital Universitaire De Rennes, Dept. of Urology, Rennes, France, ⁶Hôpital Universitaire De Rouen, Dept. of Urology, Rouen, France, ⁷Hôpital Universitaire De Rouen, Dept. of Pathology, Rouen, France, ⁸Hôpital Universitaire Henri Mondor, Dept. of Urology, Créteil, France, ⁹Hôpital Universitaire Henri Mondor, Dept. of Pathology, Créteil, France, ¹⁰Hôpital Universitaire Cochin, Dept. of Urology, Paris, France, ¹¹Hôpital Universitaire Cochin, Dept. of Pathology, Paris, France, ¹²Hôpital Universitaire Tenon, Dept. of Urology, Paris, France, ¹³Hôpital Universitaire Pitié Salpêtrière, Dept. of Urology, Paris, France
- *809 **Prognostic significance of sarcopenia in upper tract urothelial carcinoma patients who underwent radical nephroureterectomy**
By: Fukushima H., Nakanishi Y., Kataoka M., Tobisu K., [Koga E.](#)
Institutes: Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan
- *810 **Neutrophil-to-lymphocyte ratio may predict recurrence in urothelial carcinoma of the urinary bladder: A prospective trial**
By: [Bahouth Z.](#)¹, Getzler I.¹, Mano R.², Baniel J.², Nativ O.¹, Rubinstein J.³, Halachmi S.¹
Institutes:¹Bnai-Zion Medical Center, Dept. of Urology, Haifa, Israel, ²Rabin Medical Center, Dept. of Urology, Petach-Tekva, Israel, ³Technion - Institute of Technology, Dept. of Mathematics, Haifa, Israel
- *811 **The utility of diffusion-weighted MRI as an imaging biomarker of upper urinary tract cancer: A preoperative prognostic indicator reflecting histological grade**
By: [Yoshida S.](#)¹, Uchida Y.¹, Kobayashi S.¹, Koga F.¹, Tanaka H.², Yokoyama M.¹, Ishioka J.¹, Matsuoka Y.¹, Saito K.¹, Fujii Y.¹, Kihara K.¹
Institutes:¹Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, ²Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan
- *813 **Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high-risk patients with upper tract urothelial carcinoma**
By: [Shirotake S.](#)¹, Kikuchi E.², Tanaka N.², Matsumoto K.², Miyazaki Y.², Kobayashi H.², Ide H.², Obata J.², Hoshino K.², Kosaka T.², Kanao K.², Miyajima A.², Nakagawa K.², Oyama M.¹, Oya M.²
Institutes:¹Saitama International Medical Center, Dept. of Urology, Hidaka City, Saitama, Japan, ²

Infertility: Basic to clinical

Poster Session 65

Monday, 14 March
08:45 - 10:15

Location: Room London (Hall B2, level 0)

Chairs: C. Bettocchi, Bari (IT)
S. Kliesch, Münster (DE)

Aims and objectives of this presentation

The session will introduce the audience to the newest preclinical and clinical developments regarding male factor infertility. The aim is to give the audience a glimpse of the future and to inspire further research within the area of male infertility.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *814 **Assessment of human sperm morphology: Comparison of strict Kruger's criteria versus inverted microscopy motile sperm organelle morphology examination (MSOME)**
By: Ragab A.⁴, Zohdi W.², Awad H.², Azab S.³, Salem H.¹, Elkarakasy A.², Amer M.²
Institutes:¹Kasr El Einy Hospital, Cairo University, Dept. of Urology, Giza Cairo, Egypt, ²Kasr El Einy Hospital, Cairo University, Dept. of Andrology, Giza Cairo, Egypt, ³October 6 University, Dept. of Urology, Giza Cairo, Egypt, ⁴Beni-Suef University Hospital, Beni-Suef University, Dept. of Andrology, Beni-Suef, Egypt
- *815 **Evaluation of immediate and late effects of chronic stress on testes of prepubertal and adult rats**
By: De Souza D., Ribeiro C., Gregório B., Costa W., Pereira-Sampaio M., Sampaio F.
Institutes:Rio de Janeiro State University, Dept. of Urogenital Research Unit, Rio de Janeiro, Brazil
- *816 **The role of Urocortin in the apoptosis of germ cells after experimental testicular ischemia-reperfusion in the rat**
By: Sumii K., Chiba K., Enatsu N., Matsushita K., Miyake H., Fujisawa M.
Institutes:Kobe University Graduate School of Medicine, Dept. of Urology, Kobe, Japan
- *817 **Fertilizing capacity of haploid cells generated in hamster testicular tissue transplanted in the anterior limbs of immune deficient rats: Clinical implications**
By: Giannakis D.², Tsounapi P.¹, Dimitriadis F.¹, Skouros S.², Stavrou S.², Seminis G.², Giannakis I.², Angelis D.², Baltogiannis D.², Takenaka A.¹, Sofikitis N.²
Institutes:¹Tottori University, Faculty of Medicine, Dept. of Urology, Yonago, Japan, ²University of Ioannina Medical School, Dept. of Urology, Ioannina, Greece
- *818 **Long-term ex vivo maintenance of testis tissues producing fertile sperm in a microfluidic device**
By: Komeya M.¹, Hayashi K.², Yamanaka H.¹, Sanjo H.¹, Sato T.², Katagiri K.², Kimura H.³, Fujii T.⁴, Yao M.¹, Ogawa T.¹
Institutes:¹Yokohama City University School of Medicine, Dept. of Urology, Yokohama, Japan, ²Yokohama City University, Dept. of Molecular Medicine and Life Science, Yokohama, Japan, ³Tokai University, Dept. of Mechanical Engineering, Kanagawa, Japan, ⁴Tokyo University, Dept. of International Research On Integrative Biomedical Systems, Tokyo, Japan
- *819 **Expression of Ten-Eleven-Translocation (TET) enzymes in human spermatogenesis and their role for male fertility**
By: Kai N.¹, Dansranjav T.¹, Rogenhofer N.², Bergmann M.³, Schuppe H-C.⁴, Wagenlehner F.⁴, Weidner W.⁴, Steger K.¹, Schagdarsurengin U.¹
Institutes:¹Clinic of Urology, Pediatric Urology and Andrology, JLU Giessen, Dept. of Molecular Andrology, Giessen, Germany, ²Clinical Center of LMU Munich, Dept. of Gynecological

Endocrinology and Reproductive Medicine, Dept. of Gynecology and Obstetrics, Munich, Germany, ³Veterinary Medicine, JLU Giessen, Institute of Veterinary Anatomy, Histology and Embryology, Giessen, Germany, ⁴Clinic of Urology, Pediatric Urology and Andrology, JLU Giessen, Giessen, Germany

- *820 **Seminal level of clusterin in infertile men as a significant biomarker reflecting spermatogenesis**
By: Sumii K., Fukuda T., Enatsu N., Chiba K., Matsushita K., Miyake H., Fujisawa M.
Institutes: Kobe University Graduate School of Medicine, Dept. of Urology, Kobe, Japan
- *821 **Loss of SLC9A3 can decrease the expression of Cftr gene in the male reproductive tract of mice and may potentially have the possibility to treat cystic fibrosis**
By: Wang Y-Y.¹, Lin Y-H.¹, Wu Y-N.¹, Chen Y-L.², Lin Y-C.¹, Cheng C-Y.¹, Chiang H-S.¹
Institutes:¹Fu Jen Catholic University, Graduate Institute of Basic Medicine, New Taipei City, Taiwan, ²Cardinal Tien Hospital, Dept. of Pathology, New Taipei City, Taiwan
- *822 **Congenital absence of the vas deferens: Do genetic disorders modify assisted reproductive techniques results?**
By: Gallego Matey A., Rogel Bertó R., Pérez Ardavín J., Luján Marco S., Plaza Viguer B., Boronat F
Institutes: University Hospital La Fe, Dept. of Urology, Valencia, Spain
- *823 **Prognostic value of sperm DNA integrity for ART (assisted reproductive technique) success: Empirical antioxidant therapy as a method of sperm DNA fragmentation and ART failure correction**
By: Korshunov M.N.¹, Korshunova E.S.⁴, Gabliya M.Y.¹, Kindarova L.B.², Shtyrya J.A.³
Institutes:¹The Federal State Budget Institution Peoples' Friendship University of Russia, Dept. of Clinical Andrology, Moscow, Russia, ²Russian-German Center for Reproduction and Clinical Embryology "Pokolenie NEXT", Dept. of Gynaecology, Moscow, Russia, ³Russian-German Center for Reproduction and Clinical Embryology "Pokolenie NEXT", Dept. of Embryology, Moscow, Russia, ⁴National Medical Research Centre of Radiology, Dept. of Oncoandrology, Moscow, Russia
- *824 **Prevalence of biochemical hypogonadism in men with non-obstructive azoospermia (NOA) before and after testicular sperm extraction (m-TESE)**
By: Almashat F.¹, Poullis C.¹, Johnson M.¹, Fontaine C.¹, Abumelha S.¹, Yap T.², Minhas S.¹
Institutes:¹University College Hospital, Dept. of Andrology, London, United Kingdom, ²St. Georges Hospital-NHS Foundation Trust, Dept. of Andrology, London, United Kingdom
- *825 **The outcome analysis of AZFc subdeletion in men with non-obstructive azoospermia**
By: Chen W.J., Huang W.J.S., Huang I-S., Lin A.T-L., Chen K-K.
Institutes: Taipei Veterans General Hospital, Dept. of Urology, Taipei City, Taiwan
- *826 **Spermatogenesis by gonadotropin hormone therapy in men with prepubertal-onset hypogonadotropic hypogonadism**
By: Lee S.H., Lee J.K., Kim S.W., Paick J-S.
Institutes: Seoul National University of Hospital, Dept. of Urology, Seoul, South Korea
- *827 **Assessment of ICSI outcome utilizing fresh/frozen epididymal and testicular sperm in obstructive and non-obstructive azoospermia**
By: Yap T.², Almashat F.¹, Abumelha S.¹, Poullis C.¹, Thum M.Y.³, Abdalla H.³, Minhas S.¹
Institutes:¹University College Hospital, Dept. of Andrology, London, United Kingdom, ²St. Georges Hospital-NHS Foundation Trust, Dept. of Andrology, London, United Kingdom, ³Lister Fertility Clinic, Dept. of Assisted Reproduction, London, United Kingdom
- *828 **Hyperbaric oxygen therapy in the treatment of idiopathic male infertility**
By: Metelev A.¹, Bogdanov A.¹, Ivkin E.¹, Mitrokhin A.², Sokolov E.³, Veliev E.³
Institutes:¹Botkinsky Hospital, Dept. of Urology, Moscow, Russia, ²Botkinsky Hospital, Dept. of Hyperbaric Oxygen Therapy, Moscow, Russia, ³Russian Medical Academy of Postgraduate Education, Dept. of Urology, Moscow, Russia

ESU/ESFFU Hands-on training in Sacral Neuromodulation Procedure Standardisation

HOT 33

Monday, 14 March
09:00 - 10:30

Location: Room Asia (Hall B0, level 0)

Chair: H. Hashim, Bristol (GB)

Aims and objectives of this presentation

A practical hands-on workshop that will allow the participants to practice on models the different steps of performing sacral neuromodulation including primary percutaneous nerve evaluation, tined lead and battery implantation and programming and also troubleshooting.

Aims and objectives

- o Understand the indications for SNM
- o Be able to perform the different steps of the procedure in a standardized format
- o Be able to troubleshoot problems with SNM

Target audience: Doctors, Nurses, technicians and clinical scientists who have little or no knowledge of sacral neuromodulation.

S. Musco, Rome (IT)
E. Chartier-Kastler, Paris (FR)
S. De Wachter, Nijlen (BE)
T.M. Kessler, Zürich (CH)
P.E. Van Kerrebroeck, Maastricht (NL)

ESU/ESFFU Hands-on training in Urodynamics

HOT 31

Monday, 14 March
09:00 - 12:00**Location:** Room South America (Hall B0, level 0)**Chair:** M.J. Drake, Bristol (GB)**Aims and objectives of this presentation**

This workshop aims to provide a practical course offering an interactive "hands-on" environment for doctors, nurses and technicians to improve their skills in urodynamics, with an emphasis on practical aspects including equipment used, interpretation of traces, quality control and trouble-shooting. The use of recorded tests, access to equipment and small groups means that individual problems can be addressed. All the speakers are involved in similar "hands-on" courses, which have ran successfully in the United Kingdom and abroad. The small group format has been shown to work well in addressing individual needs. Access to teaching aids and equipment will simulate the clinical scenario as much as possible within the constraints of the conference setting. At the end of the workshop delegates should feel more confident in their practice of urodynamics.

A. Gammie, Bristol (GB)

A. Garcia Mora

L. Thomas, Bristol (GB)

ESU Social Media Training

HOT 47

Monday, 14 March
09:00 - 09:45

Location: Room 0.305

Chair: M. Bultitude, London (GB)

Aims and objectives of this presentation

- EAU Congress Attendees will be instructed on how to harness professional Social Media to augment experience of professional meetings, follow urologic news feeds, and engage with the world-wide urologic community.
- Urologists who are expert in the use of Social Media will provide 45 minute small group hands-on workshops on the use of professional Social Media.
- Current Social Media users will have the opportunity to exchange expertise with other Social Media users during small group sessions.

F. O'Kelly, Dublin 16 (IE)

E-BLUS Exam

HOT 59

Monday, 14 March
09:15 - 10:00

Location: Room Europe (Hall B0, level 0)

Aims and objectives of this presentation

The European training in basic laparoscopic urological skills (E-BLUS) is a programme offered to residents and urologists who want to improve the basic skills in laparoscopy. It is a unique opportunity to train with international experts in laparoscopy. The E-BLUS programme includes:

- Hands-on training (HOT) sessions of different levels carried out under the guidance of experienced tutors
- A set of training-box exercises developed and validated by the Dutch project Training in Urology(TiU) to train basic skills needed in urological laparoscopy
- E-BLUS examination and certification
- An online theoretical course

M. Arslan, Izmir (TR)
Y. Akin, Sanliurfa (TR)
To be confirmed
F. Greco, Crotone (IT)
A. Sempere Gutierrez, Murcia (ES)
A.S. Gözen, Heilbronn (DE)
D. Veneziano, Minneapolis (US)
T. Kalogeropoulos, Athens (GR)

ESU/ESUT/EULIS Hands-on training in Ureterorenoscopy - Stone dusting

HOT 72

Monday, 14 March
09:15 - 10:45

Location: Room Africa (Hall B0, level 0)

Aims and objectives of this presentation

Ureteroscopy is an essential tool in the management of stone disease for all Endourologists. This hands-on-training course will provide a hands-on experience of the flexible and rigid Ureteroscopy procedures , by simulating the anatomy and the laser interaction in the Advanced Stone Trainer.

Course setup:

Real life interaction and haptic feedback.

An Operating Room-like experience using a real holmium laser system with a scope

Aims and objectives

- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of Laser stone dusting and fragmentation.

Target audience: Beneficial for novices wishing to learn Laser stone dusting and fragmentation and for experienced urologists wishing to train and teach the procedure.

C. Kastner, Cambridge (GB)

ESU/ESUT Hands-on training in HoLEP

HOT 67

Monday, 14 March
09:15 - 10:45

Location: Room Africa (Hall B0, level 0)

Aims and objectives of this presentation

This hands-on-training course will provide a hands-on experience of the HoLEP procedure, by simulating the anatomy and the laser tissue interaction in the HoLEP training simulator. Innovative prostate model provides real life practice of the laser-tissue interaction and haptic feedback

Course setup:

An Operating Room-like experience using a real holmium laser system with a scope
Mimics the anatomy seen during the procedure and the procedure steps

Aims and objectives

- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of the HoLEP procedure.

T. Aho, Great Shelford, Cambridge (GB)

ESU/ESUT/EULIS Hands-on training in Ureterorenoscopy

HOT 25

Monday, 14 March
09:15 - 10:45**Location:** Room North America (Hall B0, level 0)**Chair:** G. Giusti, Basiglio (IT)**Aims and objectives of this presentation**

Ureteroscopy is an essential tool in the management of stone disease for all Endourologists. This course will provide hands-on-training with tutor guided practical tips and tricks of doing ureteroscopy. Participants will get a chance to perform Semirigid and Flexible ureteroscopy in the models with a chance to navigate the pelvicalyceal system, stone manipulation and extraction.

Aims and objectives

- At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models
- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.

S. Proietti, Perugia (IT)
S. Doizi, Paris (FR)
A. Ploumidis, Athens (GR)
C.M. Scoffone, Turin (IT)
P.J.S. Osther, Fredericia (DK)
J. Baard, Amsterdam (NL)
S. Butticè, Messina (IT)

ESU Social Media Training

HOT 48

Monday, 14 March
10:00 - 10:45

Location: Room 0.305

Chair: D. Murphy, Melbourne (AU)

Aims and objectives of this presentation

- EAU Congress Attendees will be instructed on how to harness professional Social Media to augment experience of professional meetings, follow urologic news feeds, and engage with the world-wide urologic community.
- Urologists who are expert in the use of Social Media will provide 45 minute small group hands-on workshops on the use of professional Social Media.
- Current Social Media users will have the opportunity to exchange expertise with other Social Media users during small group sessions.

F. O'Kelly, Dublin 16 (IE)

ESU/ESUT Hands-on training in Laparoscopic suturing (anastomosis)

HOT 60

Monday, 14 March
10:15 - 11:45

Location: Room Europe (Hall B0, level 0)

Chair: J-T. Klein, Heilbronn (DE)

Aims and objectives of this presentation

The aim of this advanced laparoscopic suturing course is to develop skill and knowledge about laparoscopic suturing.

Supported by experienced laparoscopist and state of the art Laparoscopic technology, you can improve your suturing skills, shorten your learning curve with the help of HD vision and practice an anastomosis. An intermediate level in laparoscopy is mandatory for this course.

- A. Sempere Gutierrez, Murcia (ES)
- F. Greco, Crotone (IT)
- M. Arslan, Izmir (TR)
- A.S. Gözen, Heilbronn (DE)
- T. Tokas, Hall In Tirol (AT)
- D. Veneziano, Minneapolis (US)
- T. Kalogeropoulos, Athens (GR)

Prostate cancer diagnosis: Is mpMRI-guided prostate biopsy the new standard?

Thematic Session 11

Monday, 14 March
10:30 - 12:00

Location: Room Madrid (Hall B2, level 0)

Chair: P. Albers, Düsseldorf (DE)

Aims and objectives of this presentation

Multiparameter Magnetic Resonance Imaging (mpMRI) – guided biopsies have been introduced in the armamentarium of prostate cancer diagnosis in various scenarios. Still, the standard of care is the systematic biopsy of the prostate to diagnose or exclude cancer. In the primary biopsy indication data are available that anterior tumours and small tumour foci can be better detected by an mpMRI-guided approach. Randomised trials, however with some flaws, could not show a significant difference in the detection rate of tumours in this indication. MpMRI-guided biopsy technology leads to better quality and may be able to reduce the number of biopsies. In the secondary indication (patients with prior negative biopsies and rising PSA) tumour detection or exclusion is even more important and mpMRI-guided approaches may be able to reduce the number of biopsies to targeted ones only. Whether all this is already standard will be discussed in the session with a point – counterpoint discussion after an introduction regarding the technique. Finally the different techniques of mpMRI-guided biopsies will be presented.

10:30 - 10:45

State-of-the-art lecture Technique and interpretation of mpMRI with PI-RADS 2.0

G. Villeirs, Ghent (BE)

Aims and objectives of this presentation

mpMRI is a combination of morphologic T2-weighted imaging (T2WI) with functional imaging tools such as Diffusion-Weighted Imaging (DWI), dynamic contrast-enhanced MRI (DCE) and spectroscopic imaging. PIRADS 2.0 is an updated scoring system for predicting the clinical significance of any detected abnormality, using DWI as the dominant sequence in the peripheral zone, T2WI as the dominant sequence in the transition zone and DCE as a problem solver. The use of PIRADS 2.0 will be illustrated during the present lecture.

10:45 - 11:15

Debate mpMRI-guided biopsy

10:45 - 11:00

Pro

M. Emberton, London (GB)

Aims and objectives of this presentation

My aim is to convince urologists working in Europe that the time has come to abandon random biopsies and replace them with image guided biopsies. The result should be fewer men biopsied overall, fewer needle deployments, fewer clinically significant cancers missed, fewer unnecessary diagnoses, better risk stratification and less cost.

11:00 - 11:15

Con

C. Arsov, Düsseldorf (DE)

11:15 - 11:30

State-of-the-art lecture Different techniques of MRI biopsy

S. Kruck, Tübingen (DE)

11:30 - 11:45

Associated abstract presentations

*497

Blinded comparison of MRI targeted TRUS guided prostate biopsy and TRUS guided biopsy in the 5th screening round of the European Randomized study of Screening for Prostate Cancer Rotterdam

By: [Alberts A.](#)¹, Roobol M.¹, Bokhorst L.¹, Drost F-J.², Van Leenders G.³, Dwarkasing R.², Barentsz J.⁴, Schröder F.¹, Bangma C.¹, Schoots I.²

Institutes:¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, ³Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ⁴Radboudumc, Dept. of Radiology, Nijmegen, The Netherlands

State-of-the-art lecture

Aims and objectives of this presentation

The aim of our study was to compare the outcomes of MRI-targeted prostate biopsy with TRUS-guided systematic in a population-based prostate cancer screening (European randomized study of screening for prostate cancer Rotterdam). Population-based screening with TRUS-guided biopsy reduces mortality but also causes overdiagnosis of low-grade tumours. This study shows that the performance of MRI-targeted biopsy instead TRUS-guided systematic biopsy significantly reduces overdiagnosis while maintaining a comparable sensitivity for high-grade prostate cancer.

*499

A prospective randomized study comparing standard prostate biopsy and a new diagnostic path with MRI and fusion biopsy: Preliminary results

By: [Porpiglia F.](#)¹, Mele F.¹, Manfredi M.¹, Aimar R.¹, Checcucci E.¹, Cossu M.¹, Bollito E.², Russo F.³, Gned D.⁴, De Pascale A.⁴, Cirillo S.⁵, Fiori C.¹

Institutes:¹San Luigi Gonzaga Hospital, Dept. of Urology, University of Turin, Orbassano, Turin, Italy, ²San Luigi Gonzaga Hospital, Dept. of Pathology, University of Turin, Orbassano, Turin, Italy, ³Candiolo Cancer Institute, Division of Radiology, Candiolo, Turin, Italy, ⁴San Luigi Gonzaga Hospital, Division of Radiology, University of Turin, Orbassano, Turin, Italy, ⁵Mauriziano Hospital, Division of Radiology, Turin, Italy

State-of-the-art lecture

11:45 - 12:00

Discussion

Non-Muscle Invasive Bladder Cancer (NMIBC)

Thematic Session 13

Monday, 14 March
10:30 - 12:00

Location: Room Stockholm (Hall B2, level 0)

Chair: M. Rouprêt, Paris (FR)

Aims and objectives of this presentation

This thematic session aims to assess current controversies in the field of urothelial carcinomas: Non-Muscle Invasive Bladder Cancer (NMIBC) and Upper Tract Tumour (UTUC). Recent insights and meaningful data will be provided to understand discrepancies between EAU guidelines and daily practice especially for the detection of flat lesions, for transurethral resection of the bladder and for kidney-sparing management in UTUC. The whole urinary tract needs to be explored when urothelial carcinomas are diagnosed, not only the lower or the upper tract. The main purpose is to underline the link between these disparate twins (UTUC and NMIBC) and to explain how to translate theory into daily practice.

10:30 - 10:45

Hot topic lecture CIS: Low incidence or underdetection?

F. Algaba, Barcelona (ES)

Aims and objectives of this presentation

In a series of 3802 cases of bladder carcinomas concomitant CIS incidence is 38% (7.3 % in G1 , 15.6 % in G2 and G3 in 67 %) and 26.2 % among non invasive muscle carcinomas. According to these data we can speculate whether the CIS is low frequent lesion or an underdetected pathology

10:45 - 11:10

Hot topic lecture Does a high quality TURB make re-resection redundant?

10:45 - 11:00

Presenter:

T.R.W. Herrmann, Hannover (DE)

11:00 - 11:10

Challenger:

J.R. Oddens, Den Bosch (NL)

11:10 - 11:20

Hot topic lecture Evidence based UUT surveillance in patients with bladder cancer

G. Giannarini, Udine (IT)

Aims and objectives of this presentation

This lecture will focus on upper urinary tract surveillance in patients treated for non-muscle-invasive and muscle-invasive bladder cancer, an area where high-quality evidence is lacking. The risk of metachronous upper urinary tract tumours in bladder cancer patients accounts for up to 20% of cases, thus the issue is of clinical relevance. Several surveillance protocols including urinary markers and imaging have been used, however in most cases upper urinary tract tumours are still diagnosed through symptoms. Whether timing of diagnosis impacts on survival remains largely unknown. While awaiting personalised molecular markers for surveillance, the most cost-effective policy may be to adopt a risk-adapted schedule, where only high-risk patients undergo intensive imaging-based lifelong monitoring.

11:20 - 11:35

State-of-the-art lecture Exploring the limits of kidney sparing treatment of upper tract urothelial cancer

S. Shariat, Vienna (AT)

Aims and objectives of this presentation

Radical Nephroureterectomy (RNU) has been central to the treatment of UTUC for decades, but Kidney-Sparing Surgery (KSS) has been applied to a rising number of patients to preserve renal function (overtreatment). Ablation or resection through flexible ureteroscopy or the percutaneous route seems to provide comparable cancer-specific survival and overall survival to RNU, but the risk of local and bladder recurrence remains relatively high. Segmental ureterectomy is used for low-risk unifocal UTUC with recent studies confirming its oncologic safety and equivalence to RNU. Antegrade or retrograde instillation therapy may be considered as adjuvant treatment after conservative surgery, but their efficacy needs to be proven. Post-operative vigilant radiographic and endoscopic surveillance are obligatory because of the high probability of disease recurrence. The aim will be to discuss the current data and risk-stratification for optimal KSS candidates.

11:35 - 11:50

Urological Association of Asia (UAA) lecture New insights in diagnosis and management of urothelial carcinomas of the bladder and of the upper urinary tract

W-J. Wu, Kaohsiung (TW)

Aims and objectives of this presentation

Given the genomic heterogeneity of UC, optimal development of therapeutic agents requires adequate genomic characterisation. There has been a major shift in the development of new promising therapeutic remedies in recent years. The era of “molecular personalised medicine” has been launched and it may drastically change the conventional cancer treatment paradigm. Advances in genomics and bioinformatics are necessary requirements for the appropriate testing of novel targeted therapy strategies to meet the clinical needs of patients in a more precision way.

11:50 - 12:00

Associated abstract presentation

*216

Discrepancy between guidelines and daily practice in the management of non-muscle-invasive bladder cancer (NMIBC): Results of a European survey

By: Aziz A.², Bes P.¹², Chun F.K.², Dobruch J.³, Kluth L.A.², Gontero P.⁴, Necchi A.⁵, Noon A.⁶, Van Rhijn B.WG⁷, Rink M.², Roghmann F.⁸, Roupert M.⁹, Seiler R.¹⁰, Shariat S.F.¹¹, Qvick B.¹², Xylinas E.N.¹
Institutes:¹Cochin Hospital, Paris Descartes University, Dept. of Urology, Paris, France, ²University Medical Center Hamburg-Eppendorf, Hamburg, Dept. of Urology, Hamburg, Germany, ³Centre of Postgraduate Medical Education, Dept. of Urology, Warsaw, Poland, ⁴Città Della Salute E Della Scienza Di Torino, Dept. of Urology, Turin, Italy, ⁵Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, ⁶Division of Urology, University of Toronto, Dept. of Urology, Toronto, Canada, ⁷Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ⁸Marien Hospital, Ruhr-University Bochum, Dept. of Urology, Herne, Germany, ⁹Pitié-Salpêtrière APHP, Dept. of Urology, Paris, France, ¹⁰University of Berne, Dept. of Urology, Berne, Switzerland, ¹¹Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹²Ipsen, Dept. of Pharma, Paris, France

Urological Association of Asia (UAA) lecture

Questions in early diagnosis of prostate cancer

Thematic Session 12

Monday, 14 March
10:30 - 12:00

Location: Room 1 (ICM, Level 0)

Chair: C.H. Bangma, Rotterdam (NL)

Aims and objectives of this presentation

Early detection and treatment can decrease the mortality of prostate cancer, but only at the cost of the diagnosis of harmless tumours. This session will inform the urologist about the methods used to distinguish between low and higher risk cancers, and the management of men with indolent disease.

Objectives:

- The audience will know the arguments in favour and against population based screening
- The audience will be able to give a definition of low risk cancer together with risk factors for more aggressive disease
- The audience will know how to perform active surveillance, and when to switch to invasive therapy. Developments in technology to treat these intermediate risks with the least possible side effects will be discussed.

10:30 - 10:50

State-of-the-art lecture Individualised vs population-based screening

F.C. Hamdy, Oxford (GB)

Aims and objectives of this presentation

The objective is to review all the evidence on screening for prostate cancer. The talk will highlight the pros and cons of establishing a population-based early detection programme versus individualised and targeted screening and the way forward.

10:50 - 11:10

State-of-the-art lecture Is Gleason 6 cancer?

G. Van Leenders, Rotterdam (NL)

Aims and objectives of this presentation

Patients with Gleason score 6 prostate cancer on radical prostatectomy have excellent outcome. The objectives of this presentation are 1) to investigate whether Gleason score 6 tumors should still be considered cancer, and 2) to determine whether Gleason score 7 subpopulations with very good prognosis can be identified. Urologists will learn how recent developments in pathology can support their therapeutic decisions for individual prostate cancer patients.

11:10 - 11:30

State-of-the-art lecture Who fails active surveillance?

L. Klotz, Toronto (CA)

Aims and objectives of this presentation

1. To review current selection criteria for active surveillance
2. To review recent data on parameters predicting for risk of metastatic progression in men on surveillance
3. To review the role of MRI and biomarkers in patients selection and intervention

11:30 - 11:50

State-of-the-art lecture Image directed therapy for intermediate-risk PCa

M. Van Vulpen, Zeist (NL)

11:50 - 12:00

Associated abstract presentation

*86

The STHLM3 model improves prostate cancer testing in men 50-69 years - further health economic and clinic evaluation

By: Grönberg H.¹, Adolfsson J.², Aly M.¹, Nordström T.¹, Wiklund P.³, Brandberg Y.⁴, Thompson J.⁵, Wiklund F.¹, Lindberg J.¹, Clements M.¹, Egevad L.⁴, Eklund M.¹

Institutes:¹Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ²Karolinska Institutet, Dept. of Clinical Science, Intervention and Technology (CLINTEC), Stockholm, Sweden, ³Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, ⁴Karolinska Institutet, Dept. of Oncology-Pathology, Stockholm, Sweden, ⁵Karolinska Institutet, Biobank, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden

State-of-the-art lecture

Semi-live

Thematic Session 14

**Monday, 14 March
10:30 - 12:00**

Location: Room Milan (Hall B2, level 0)

Chair: M. Hohenfellner, Heidelberg (DE)

Aims and objectives of this presentation

Surgical exenteration of the bladder and/or the prostate need to afford the best possible oncological control despite severe functional side effects (i.e. continence, sexuality, and general quality of life). Thus, selective surgical techniques for radical cystectomy/prostatectomy have been proposed. The aim of preserving neurovascular bundles and/or the urethral sphincter is to improve the functional outcome notably in younger patients. The purpose of the current session is to illustrate the so-called "sparing techniques " through concrete videos and to discuss indications, results and outcomes with the faculty.

10:30 - 10:50

Video presentation Capsule/seminal vesicle sparing cystectomy

R. Colombo, Milan (IT)

10:50 - 11:10

Video presentation Nerve sparing

J.E. Gschwend, Munich (DE)

11:10 - 11:30

Video presentation Robot-assisted nerve sparing

E. Barret, Paris (FR)

11:30 - 11:50

Video presentation Female organ sparing

F.C. Burkhard, Berne (CH)

Aims and objectives of this presentation

To discuss the indication, risks and technique of female genital organ sparing cystectomy

11:50 - 12:00

Discussion

Systemic treatment for advanced prostate and urothelial cancer

Thematic Session 15

Monday, 14 March
10:30 - 12:00

Location: Room 14a (ICM, Level 1)

Chair: M. De Santis, Coventry (GB)

Aims and objectives of this presentation

This session will give an overview of systemic treatments for bladder and prostate cancer including chemotherapy and immunotherapy. It will focus on controversies and new insights as well as the treatment of subgroups and rarer histologies.

10:30 - 10:45

State-of-the-art lecture Peri-operative chemotherapy for invasive bladder cancer: Oncological aspects

C.N. Sternberg, Rome (IT)

10:45 - 11:00

State-of-the-art lecture Peri-operative chemotherapy for invasive bladder cancer: Urological aspects

M. Retz, Munich (DE)

11:00 - 11:15

State-of-the-art lecture Immunotherapy for bladder cancer - benefit for all patients?

I. Duran, Seville (ES)

11:15 - 11:30

State-of-the-art lecture Prostate cancer - Management of atypical histologies

J.P. Bedke, Tübingen (DE)

11:30 - 11:45

State-of-the-art lecture Immunotherapy for prostate cancer: What the future holds

P.F.A. Mulders, Nijmegen (NL)

Aims and objectives of this presentation

Prostate cancer was always considered as an immune indolent tumor, although in solid tumors the first effective vaccine approved was in prostate cancer. The immune response against prostate cancer cells can be enhanced by effective combinations of checkpoint inhibitors, specific proteins and antibodies. The future and implementations of these very promising treatment options will be discussed.

11:45 - 12:00

Questions and answers

PSMA-PET/CT for the diagnosis of PSA relapse

Thematic Session 10

Monday, 14 March
10:30 - 12:00

Location: Room 14b (ICM, Level 1)

Chair: I.J. De Jong, Groningen (NL)

Aims and objectives of this presentation

PSA relapse after curative treatment is always a troublesome situation for patients and doctors. Usually, patients have recovered well from surgery or radiotherapy and most of them may be potent and continent. Therefore, in terms of quality of life androgen deprivation treatment (ADT) is not really first choice. Deferred radiotherapy to the prostate field will miss lymph node metastasis. There is no clear pattern of relapse or clinical scenario that would predict the location of recurrence. Imaging tools are urgently needed for early detection of relapse in order to tailor treatment. Local treatment by lymph node dissection or radiotherapy may prevent early need for ADT. However, PET images suffer from low sensitivity to detect lesions below 5 mm. New PSMA data suggest an improvement of the specificity but large series of histological confirmation are missing. This session will summarise the current standard of care in the PET diagnosis of PSA-detected PCA relapse. In addition, possible treatment strategies using PSMA radionuclide conjugates will be discussed. Further, data concerning MRI versus CT imaging will be presented.

10:30 - 10:45

State-of-the-art lecture [The role of PSMA PET/CT or MRI in PSA relapse](#)

T. Maurer, Munich (DE)

Aims and objectives of this presentation

The objective of this presentation is to provide a current overview of PSMA PET-based hybrid imaging in recurrent prostate cancer. The value of PET/CT and PET/MR for detection as well as comparison to other PET tracers will be discussed. Future possible indications and limitations will be mentioned.

10:45 - 11:00

State-of-the-art lecture [Theragnostics: Will PSMA guided therapy be the future?](#)

U. Haberkorn, Heidelberg (DE)

11:00 - 11:15

State-of-the-art lecture [The clinical consequences of PET signals after curative treatment](#)

N. Suardi, Milan (IT)

Aims and objectives of this presentation

The recent advances in PET imaging lead to the management of patients with minimal recurrence of prostate cancer after curative treatment. Despite the lack of strong evidence regarding the treatment of such recurrences, to date the results of these imaging modalities can not be ignored. Recently, surgical and radiotherapeutic approaches have been described for the treatment of these recurrences. The aim of the presentation is to review the available results of these new treatment modalities.

11:15 - 12:00

Case discussion [Whole body MRI vs PET CT](#)

Moderator: I.J. De Jong, Groningen (NL)
U. Haberkorn, Heidelberg (DE)
T. Maurer, Munich (DE)

N. Suardi, Milan (IT)

11:15 - 11:25

Case presentation

I.J. De Jong, Groningen (NL)

11:25 - 12:00

Discussion

Challenges in reconstructive urology

Thematic Session 16

Monday, 14 March
10:30 - 12:00

Location: Room 14c (ICM, Level 1)

Chair: M-O. Grimm, Jena (DE)

Aims and objectives of this presentation

In this session frequently encountered clinical situations in reconstructive urology are addressed. These include urethral fistula repair, treatment of anastomotic strictures, ureteral reconstruction and continent urinary diversion with particular respect for female neobladder. The state-of-the-art lectures review current literature and provide technical tips even for experienced surgeons. Finally, the role of robotic surgery with regard to reconstruction is critically reviewed.

10:30 - 10:50

State-of-the-art lecture Management of urethral complications of prostate cancer treatment

M. Fisch, Hamburg (DE)

Aims and objectives of this presentation

Complications of prostate cancer treatment affecting the urethra are: Stenosis at the anastomosis after radical prostatectomy, urethral strictures and recto-urethral fistula. Diagnostic tools and treatment options are presented.

10:50 - 11:10

State-of-the-art lecture Optimising ureteral stricture repair

S. Roth, Wuppertal (DE)

11:10 - 11:30

State-of-the-art lecture Avoiding complications in female neobladder and continent urinary diversion

B. Ali-El-Dein, Mansoura (EG)

Aims and objectives of this presentation

To describe the prophylactic steps and technical modifications of the female cystectomy and orthotopic neobladder to prevent or minimize the incidence of 2 main functional (chronic retention and incontinence) and 1 surgical (pouch-vaginal fistula) complication.

11:30 - 11:50

State-of-the-art lecture Robotic reconstruction in urology: Perspective and limits

A. Breda, Barcelona (ES)

11:50 - 12:00

Associated video abstract presentation

*V26

Robotic assisted Boari flap with ureteroneocystostomy (RA-BFUR): Replicating the techniques of open surgery in robotics

By: [Kallidonis P.](#)¹, [Stolzenburg J-U.](#)², [Raia B.](#)², [Doa M.](#)², [Liatsikos E.](#)², [Dietel A.](#)², [Ganzer R.](#)², [Qazi H.](#)², [Meneses A.](#)²

Institutes:¹University of Patras, Dept. of Urology, Patras, Greece, ²University of Leipzig, Dept. of Urology, Leipzig, Germany

State-of-the-art lecture

Aims and objectives of this presentation

To describe a Robotic assisted approach for Boari Flap Ureteral Reimplantation which accurately replicates the open surgical technique.

Expert challenges expert

Thematic Session 17

Monday, 14 March
10:30 - 12:00

Location: Room Paris (Hall B2, level 0)

Chair: A. De La Taille, Créteil (FR)

Aims and objectives of this presentation

'Expert challenges expert' is always an attractive session with very practical tips or tricks. James Porter will present and discuss the real use of Firefly during a robotic partial nephrectomy and will be challenged by Jens-Uwe Stolzenburg. Then Andras Hoznek will try to convince us that ultraminiPERC is the future for stone disease surgery and will be challenged by Cesare Scoffone.

10:30 - 11:00

Debate Firefly® for robotic partial nephrectomy

10:30 - 10:45

Presenter

To be confirmed

10:45 - 11:00

Challenger

J-U. Stolzenburg, Leipzig (DE)

Aims and objectives of this presentation

PN is one of the few fields of laparoscopy where robotic assistance can not only do more easily what conventional laparoscopy does, but creates a totally new field of surgical management of renal tumours. This also includes the use of Firefly. Compared to classical laparoscopy larger and more complicated tumours can be managed, leading to lower WIT and more delicate tumour excision. There are cases of large, central and complex tumours that can be only managed by robotic (also without Firefly) which will be shown by different video clips.

11:00 - 11:30

Debate UltraminiPERC

11:00 - 11:15

Presenter

A. Hoznek, Creteil (FR)

11:15 - 11:30

Challenger

C.M. Scoffone, Turin (IT)

Aims and objectives of this presentation

The miniaturization of PNL is currently regarded as the cutting edge of endourology, being considered very trendy. MicroPerc, UMP, MIP, mini PNL can be very effective and safe approaches, but unusual the value of a technique is not intrinsic but highlighted by its correct clinical application. The limits of the miniaturized approaches should be kept in mind (don't carry the problems of RIRS into PNL!), and endourologists should look at them as further but not unique tools in their armamentarium. Tailoring the PNL approach on the single patient/urolithiasis/anatomy of the collecting system is fundamental, and standard PNL should not be set aside as outmoded, being safe and effective especially for the treatment of large/complex urolithiasis.

11:30 - 12:00

Debate Post-chemo open retroperitoneal lymphadenectomy in testis cancer

11:30 - 11:45

Presenter

A. Lusch, Duesseldorf (DE)

11:45 - 12:00

Challenger: Laparoscopic

C. Schwentner, Stuttgart (DE)

Rare urogenital diseases

Thematic Session 18

Monday, 14 March
10:30 - 12:00

Location: Room Vienna (Hall B2, level 0)

Chair: T.S. O'Brien, London (GB)

Aims and objectives of this presentation

Had too much PSA, MRI, OAB, BPH, robots...?

Then come and find out about something really new at EAU 2016!

The EU, national governments across Europe, and the EAU are making the investigation and treatment of rare diseases an organisational priority. Come to this session to find out from leading policy makers and clinicians how you and your department can be part of this work. Rare diseases are common in urology.

10:30 - 10:45

State-of-the-art lecture European Reference Networks (ERNs) on rare or low prevalence and complex diseases

E. Terol, Brussels (BE)

10:45 - 11:00

State-of-the-art lecture EAU development of a European Reference Network (ERN) on rare and complex urogenital diseases and conditions

M. Battye, Sheffield (GB)

11:00 - 11:15

State-of-the-art lecture Centralised treatment of testis cancer

A. Lorch, Düsseldorf (DE)

Aims and objectives of this presentation

This session will highlight and discuss the pro and cons of centralised treatment of germ cell cancer patients focussing on chemotherapy treatment and residual tumour resection in advanced and relapsed patients.

11:15 - 11:30

State-of-the-art lecture Paediatric urology rare congenital diseases

W.F.J. Feitz, Nijmegen (NL)

Aims and objectives of this presentation

Paediatric urology is taking care of congenital and required diseases of the urogenital tract. Recently national expert centers have been recognised on their expertise for different urological diseases. This is based on the multidisciplinary teams, the research involved and recognition by patient societies. An overview of current European developments will be presented within the field of paediatric urology, development of life long care tools, training tools and patient involvement.

11:30 - 11:45

State-of-the-art lecture Complex rare treatments

W. Artibani, Verona (IT)

11:45 - 12:00

Discussion

Management of T1a-b renal masses

Thematic Session 19

Monday, 14 March
10:30 - 12:00

Location: Room London (Hall B2, level 0)

Chair: A. Alcaraz, Barcelona (ES)

Aims and objectives of this presentation

Management of renal masses less than 7 cm is a matter of debate. Patient and renal masses characteristics open a variety of possible treatments. The objectives of the session are to review how to better characterise these tumours with a critical review of the role of biopsies. Afterwards a debate will be established trying to define when to go for active surveillance in the not-so-small (T1b) tumours as well as the role of the different types of focal therapy. Finally, it will explore the limits of nephron-sparing surgery.

10:30 - 11:10

Case discussion Are we getting conservative with larger renal masses as well?

10:30 - 10:40

Active surveillance for T1b renal masses: Role of biopsies and limits

A. Finelli, Toronto (CA)

10:40 - 10:50

Focal therapy of small renal masses: Imaging, energies and indications

R. Autorino, Cleveland (US)

Aims and objectives of this presentation

Aim of this presentation will be to review the current role of kidney ablation for the management of small renal masses. A critical analysis of the available evidence will be provided, including comparative outcomes with other treatment options.

10:50 - 11:00

What are the limits of nephron sparing surgery?

M. Musquera Felip, Barcelona (ES)

11:00 - 11:10

Discussion

11:10 - 11:25

State-of-the-art lecture Post-treatment follow-up

U. Capitanio, Milan (IT)

11:25 - 12:00

Associated abstract and video presentations

*634

Does an unexpected final pathology of pT3a renal tumour undermine cancer control in clinically T1N0M0 patients who were initially treated with nephron sparing surgery?

By: Capitanio U.¹, Stewart G.², Larcher A.¹, Klatter T.³, Volpe A.⁴, Akdogan B.⁵, Roscigno M.⁶, Lingard J.², Langenhuijsen H.⁷, Marszalek M.⁸, Rodriguez Faba O.⁹, Salagierski M.¹⁰, Carini M.¹¹, Stief C.¹², Minervini A.¹¹, Da Pozzo L.F.⁶, Brookman-May S.¹²

Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²Western General Hospital, Dept. of Urology, Edinburgh, United Kingdom, ³Vienna Medical University, Dept. of Urology, Vienna, Austria, ⁴Maggiore Della Carità Hospital, Dept. of Urology, Novara, Italy, ⁵Hacettepe University, Dept. of Urology, Ankara, Turkey, ⁶Papa Giovanni XXIII Hospital, Dept. of Urology, Bergamo, Italy, ⁷Radboud University Medical Center, Dept. of Urology, Nijmegen, The Netherlands, ⁸Donauspital, Dept. of Urology, Vienna, Austria, ⁹Fundacio-Puigvert, Dept. of Urology, Barcelona, Spain, ¹⁰Kent & Canterbury Hospital, Dept. of Urology, Canterbury, United Kingdom, ¹¹Azienda Ospedaliera Universitaria Careggi, Dept. of Urology, Florence, Italy, ¹²Lmu Grosshadern, Dept. of Urology,

Munich, Germany

State-of-the-art lecture

*409

Preoperative predictors of renal failure after robot-assisted partial nephrectomy: Analysis of the Vattikuti Global Quality Initiative in Robotic Urologic Surgery (GQI-RUS) database

By: [Gandaglia G.](#)¹, Zazzara M.², Abaza R.³, Adsheed J.⁴, Ahlawat R.⁵, Buffi N.M.⁶, Challacombe B.⁷, Dasgupta P.⁷, Moon D.A.⁸, Parekh D.J.⁹, Porpiglia F.¹⁰, Rawal S.¹¹, Novara G.², Rogers C.¹², Bhandari M.¹², Mottrie A.²

Institutes:¹Irccs Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, ²OLV Vattikuti Robotic Surgery Institute, Dept. of Urology, Melle, Belgium, ³Ohio Health Dublin Methodist Hospital, Dept. of Urology, Dublin, United States of America, ⁴Hertfordshire and South Bedfordshire Urological Cancer Centre, Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, ⁵Medanta Kidney and Urology Institute, Dept. of Urology and Renal Transplantation, Medanta, India, ⁶Humanitas Clinical and Research Center, Dept. of Urology, Rozzano Milan, Italy, ⁷MRC Centre For Transplantation, King's College London, Dept. of Urology, London, United Kingdom, ⁸Peter MacCallum Cancer Centre, Dept. of Urology, Melbourne, Australia, ⁹University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Dept. of Urology, Miami, United States of America, ¹⁰San Luigi Gonzaga Hospital, University of Turin, Dept. of Urology, Orbassano, Italy, ¹¹Rajiv Gandhi Cancer Hospital, Dept. of Urology, New Delhi, India, ¹²Vattikuti Urology Institute, Henry Ford Hospital, Dept. of Urology, Detroit, United States of America

State-of-the-art lecture**Aims and objectives of this presentation**

Previous studies assessed predictors of kidney failure after partial nephrectomy. However, evidence is scarce regarding the impact of preoperative patient characteristics on the risk of renal failure after robot-assisted partial nephrectomy (RAPN) in patients with renal cell carcinoma (RCC) and normal preoperative renal function. The aim of our multi-institutional study was to assess preoperative predictors of renal failure after RAPN in patients with normal renal function.

*405

Comparison of 1,800 robotic and open partial nephrectomies for renal tumors

By: [Peyronnet B.](#)¹, Vaessen C.², Grassano Y.³, Benoit T.⁴, Carrouget J.⁵, Pradère B.¹, Giwerc A.⁶, Beauval J-B.⁴, Seisen T.², Nouhaud F.⁶, Bigot P.⁵, Doumerc N.⁴, Bernhard J-C.³, Mejean A.⁷, Patard J-J.⁸, Roupret M.², Bensalah K.¹

Institutes:¹CHU Rennes, Dept. of Urology, Rennes, France, ²Pitié-Salpêtrière Hospital, Dept. of Urology, Paris, France, ³CHU Bordeaux, Dept. of Urology, Bordeaux, France, ⁴CHU Toulouse, Dept. of Urology, Toulouse, France, ⁵CHU Angers, Dept. of Urology, Angers, France, ⁶CHU Rouen, Dept. of Urology, Rouen, France, ⁷Georges Pompidou Hospital, Dept. of Urology, Paris, France, ⁸Kremlin-Bicetre Hospital, Dept. of Urology, Paris, France

State-of-the-art lecture**Aims and objectives of this presentation**

The aim was to compare perioperative and oncological outcomes of RPN and OPN.

The charts of all patients who underwent OPN or RPN from 2006 to 2014 at six academic departments of urology were retrospectively reviewed.

In this study, RPN was less morbid than OPN with lower complications, decreased blood loss and shorter length of stay. Intermediate-term oncologic outcomes were similar in both groups.

*V35

Robotic partial nephrectomy (RAPN) for highly complex renal masses (PADUA 10)

By: [Ohlmann C-H.](#), Saar M., Siemer S., Stöckle M., Janssen M.

Institutes:UKS Universitätsklinikum des Saarlandes, Dept. of Urology, Homburg, Germany

State-of-the-art lecture**Aims and objectives of this presentation**

Nephron sparing surgery (NSS) offers comparable oncological control with improved long-term

prevention form cardio-vascular disease compared to radical nephrectomy. However, since the introduction of minimal invasive surgery, radical nephrectomy rates increased. The aim of our study was to analyse the outcome of patients with complex renal tumours (PADUA score \geq 10) who underwent robot-assisted partial nephrectomy (RAPN). The results show that RAPN of highly complex renal tumours is feasible in experienced hands with acceptable major complication rates. Therefore even highly complex renal tumours may not limit the indication for using RAPN.

*V45

Benefit of the superselective clamping technique for multiple robot assisted tumorectomies

By: Vuong N-S., Michiels C., Grassano Y., Cornelis F., Tran P., Siméon H., Pierquet G., Yacoub M., Pasticier G., Robert G., Bensadoun H., Grenier N., Ferrière J-M., Bernhard J-C.

Institutes: University Hospital of Bordeaux, Dept. of Urology and Kidney Transplant, Bordeaux, France

State-of-the-art lecture

Aims and objectives of this presentation

This video present a case of laparoscopic partial nephrectomy for multiple tumors done with the Da Vinci surgical robot. It aims to illustrate the benefit of superselective clamping technique in minimizing renal ischaemia during the surgery of a 28 year-old patient suffering from the Von Hippel Lindau disease with 6 lesions on the left kidney, including one larger than 4cm.

ESU/ESFFU Hands-on training in Sacral Neuromodulation Procedure Standardisation

HOT 34

Monday, 14 March
11:00 - 12:30

Location: Room Asia (Hall B0, level 0)

Chair: H. Hashim, Bristol (GB)

Aims and objectives of this presentation

A practical hands-on workshop that will allow the participants to practice on models the different steps of performing sacral neuromodulation including primary percutaneous nerve evaluation, tined lead and battery implantation and programming and also troubleshooting.

Aims and objectives

- o Understand the indications for SNM
- o Be able to perform the different steps of the procedure in a standardized format
- o Be able to troubleshoot problems with SNM

Target audience: Doctors, Nurses, technicians and clinical scientists who have little or no knowledge of sacral neuromodulation.

To be confirmed

S. De Wachter, Nijlen (BE)

T.M. Kessler, Zürich (CH)

K-D. Sievert, Salzburg (AT)

ESU/ESUT/EULIS Hands-on training in Ureterorenoscopy - Stone dusting

HOT 73

Monday, 14 March
11:00 - 12:30

Location: Room Africa (Hall B0, level 0)

Aims and objectives of this presentation

Ureteroscopy is an essential tool in the management of stone disease for all Endourologists. This hands-on-training course will provide a hands-on experience of the flexible and rigid Ureteroscopy procedures , by simulating the anatomy and the laser interaction in the Advanced Stone Trainer.

Course setup:

Real life interaction and haptic feedback.

An Operating Room-like experience using a real holmium laser system with a scope

Aims and objectives

- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of Laser stone dusting and fragmentation.

Target audience: Beneficial for novices wishing to learn Laser stone dusting and fragmentation and for experienced urologists wishing to train and teach the procedure.

G. Giusti, Basiglio (IT)

ESU/ESUT Hands-on training in HoLEP

HOT 68

Monday, 14 March
11:00 - 12:30

Location: Room Africa (Hall B0, level 0)

Aims and objectives of this presentation

This hands-on-training course will provide a hands-on experience of the HoLEP procedure, by simulating the anatomy and the laser tissue interaction in the HoLEP training simulator. Innovative prostate model provides real life practice of the laser-tissue interaction and haptic feedback

Course setup:

An Operating Room-like experience using a real holmium laser system with a scope
Mimics the anatomy seen during the procedure and the procedure steps

Aims and objectives

- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of the HoLEP procedure.

C. Kastner, Cambridge (GB)

ESU/ESUT/EULIS Hands-on training in Ureterorenoscopy

HOT 26

Monday, 14 March
11:00 - 12:30**Location:** Room North America (Hall B0, level 0)**Chair:** A. Neisius, Mainz (DE)**Aims and objectives of this presentation**

Ureteroscopy is an essential tool in the management of stone disease for all Endourologists. This course will provide hands-on-training with tutor guided practical tips and tricks of doing ureteroscopy. Participants will get a chance to perform Semirigid and Flexible ureteroscopy in the models with a chance to navigate the pelvicalyceal system, stone manipulation and extraction.

Aims and objectives

- At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models
- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.

T.E. Sener, İstanbul (TR)
E. Emiliani, Barcelona (ES)
S. Butticè, Messina (IT)
J-T. Klein, Heilbronn (DE)
L. Villa, Milan (IT)
J. Baard, Amsterdam (NL)
P. Nyirády, Budapest (HU)

ESU Social Media Training

HOT 49

Monday, 14 March
11:00 - 11:45

Location: Room 0.305

Chair: M. Bultitude, London (GB)

Aims and objectives of this presentation

- EAU Congress Attendees will be instructed on how to harness professional Social Media to augment experience of professional meetings, follow urologic news feeds, and engage with the world-wide urologic community.
- Urologists who are expert in the use of Social Media will provide 45 minute small group hands-on workshops on the use of professional Social Media.
- Current Social Media users will have the opportunity to exchange expertise with other Social Media users during small group sessions.

Q-D. Trinh, Boston (US)

Chronic pelvic pain in men and women

ESU Course 37

Monday, 14 March
12:00 - 14:00

Location: Room 13a (ICM, Level 1)

Chair: E.J. Messelink, Groningen (NL)

Aims and objectives of this presentation

Chronic pelvic pain patients having concomitant urological symptoms are referred to the urologist. The urologist rules out well known diseases causing pain in the pelvic area. When there is no explanation found, the pain is seen as a disease on its own. Treatment should then be done within a multidisciplinary team. Participants can bring their own cases for discussion.

At the end of this course the participant will:

- Know the basic principles of treating patients with chronic pelvic pain.
- Know how to rule out well known causes.
- Have knowledge of the myofascial and psychological aspects.
- Be able to refer patients at the right time to the right team.

12:00 - 14:00

Chronic pelvic pain terminology and principles

E.J. Messelink, Groningen (NL)

12:00 - 14:00

Pelvic pain in men: Case presentation and discussion

D.S. Engeler, St. Gallen (CH)

12:00 - 14:00

Pelvic pain in women: Case presentation and discussion

E.J. Messelink, Groningen (NL)

12:00 - 14:00

The multidisciplinary approach: Exchange and discussions

D.S. Engeler, St. Gallen (CH)

E.J. Messelink, Groningen (NL)

12:00 - 14:00

Chronic pelvic pain take home messages

Testicular cancer

ESU Course 38

Monday, 14 March
12:00 - 14:00

Location: Room 13b (ICM, Level 1)

Chair: P. Albers, Düsseldorf (DE)

Aims and objectives of this presentation

The ESU Course on Testicular Cancer will cover all important issues in the diagnosis and treatment of patients with germ cell cancer. There will be time for discussion during and after the presentations. Case reports will be discussed to highlight special situations of controversy. In addition, short video clips will be presented to demonstrate surgical techniques in retroperitoneal residual tumor resection.

In brief, following items will be presented and discussed:

- EAU Guideline recommended staging procedures and classifications like IGCCCG
- Stage-by-stage treatment of low stage disease including TIN
- Chemotherapy and indication of post chemotherapy surgery according to EAU guidelines
- Recommended follow-up investigations, long-term toxicities, 2nd malignancies

12:00 - 14:00

Testis cancer – early stages

N.W. Clarke, Manchester (GB)

12:00 - 14:00

Testis cancer – case discussion

N.W. Clarke, Manchester (GB)

12:00 - 14:00

Testis cancer - advanced stages

P. Albers, Düsseldorf (DE)

12:00 - 14:00

Testis cancer - case discussion

P. Albers, Düsseldorf (DE)

Post-surgical urinary incontinence in males

ESU Course 39

Monday, 14 March
12:00 - 14:00

Location: Room 11 (ICM, Level 1)

Chair: E. Chartier-Kastler, Paris (FR)

Aims and objectives of this presentation

- To review
 - o mechanisms of continence in men and
 - o mechanisms of post surgical incontinence in men
- To analyse symptoms and to indicate conservative treatment
- To be able to select one surgical treatment, referring to literature and guidelines
- To learn about long term follow-up of each surgical technique and to be able to deliver the best and objective information to patients

12:00 - 14:00

Introduction

E. Chartier-Kastler, Paris (FR)

12:00 - 14:00

Aetiology

F. Van Der Aa, Leuven (BE)

12:00 - 14:00

Workout of post-surgical incontinence

E. Chartier-Kastler, Paris (FR)

12:00 - 14:00

Conservative treatment for post-surgical incontinence

F. Van Der Aa, Leuven (BE)

12:00 - 14:00

Postsurgical LUTS

F. Van Der Aa, Leuven (BE)

12:00 - 14:00

Surgical treatment for post-surgical incontinence

E. Chartier-Kastler, Paris (FR)

Surgical anatomy

ESU Course 40

Monday, 14 March
12:00 - 14:00

Location: Room 12 (ICM, Level 1)

Chair: J-U. Stolzenburg, Leipzig (DE)

Aims and objectives of this presentation

This course addresses comprehensively important anatomical considerations for open and minimally invasive radical prostatectomy and partial nephrectomy. Key technical aspects such access, port placement, robotic docking and each step of the procedures will be discussed. Additionally interfascial and intrafascial of nerve-sparing surgery will be discussed. In partial nephrectomy the focus is on pedicle control, tumour excision, how to achieve adequate haemostasis and how to shorten ischemia time.

12:00 - 14:00

Introduction

J-U. Stolzenburg, Leipzig (DE)

12:00 - 14:00

Pelvic and surgical anatomy for laparoscopic/robotic radical prostatectomy-trans-peritoneal vs. extra-peritoneal

H.A.R. Qazi, Glasgow (GB)

12:00 - 14:00

Port placement and robot docking-principles and approaches

H.A.R. Qazi, Glasgow (GB)
J-U. Stolzenburg, Leipzig (DE)

12:00 - 14:00

Prostate and the urethral sphincter anatomy. How to preserve urinary continence

J-U. Stolzenburg, Leipzig (DE)

12:00 - 14:00

Surgical anatomy for nerve sparing surgery

J-U. Stolzenburg, Leipzig (DE)

12:00 - 14:00

Boundaries and technique of pelvic lymph node dissection for radical prostatectomy (standard, extended PLNA) risk stratified approach

H.A.R. Qazi, Glasgow (GB)

12:00 - 14:00

Surgical anatomy of the kidney and the retroperitoneum

H.A.R. Qazi, Glasgow (GB)

12:00 - 14:00

Approaches (retroperitoneal/ transperitoneal access) and trocar placement in laparoscopic and robotic assisted kidney surgery

H.A.R. Qazi, Glasgow (GB)
J-U. Stolzenburg, Leipzig (DE)

12:00 - 14:00

Anatomical considerations for radical nephrectomy

H.A.R. Qazi, Glasgow (GB)

12:00 - 14:00

How does anatomy influences the technique of robotic/laparoscopic partial nephrectomy

H.A.R. Qazi, Glasgow (GB)
J-U. Stolzenburg, Leipzig (DE)

12:00 - 14:00

Summary

J-U. Stolzenburg, Leipzig (DE)

Prostate biopsy - tips and tricks

ESU Course 41

Monday, 14 March
12:00 - 14:00

Location: Room 21 (ICM, Level 2)

Chair: P. Hammerer, Braunschweig (DE)

Aims and objectives of this presentation

- Provide an update on recent imaging techniques like TRUS, Elastography, Histoscanning, multiparametric magnetic resonance imaging (mpMRI) and nuclear imaging techniques for prostate cancer diagnosis.
- Explain standard reporting systems for ultrasound and mpMRI like PI-RADS
- Discuss different prostate biopsy techniques
- Tips and Tricks to reduce morbidity of prostate biopsies

12:00 - 14:00

Indications for TRUS and biopsy

P. Hammerer, Braunschweig (DE)

12:00 - 14:00

Practical aspects of TRUS and TRUS guided biopsies

P. Hammerer, Braunschweig (DE)

12:00 - 14:00

Indications for rebiopsy

V. Scattoni, Milan (IT)

12:00 - 14:00

Update on new technical developments

V. Scattoni, Milan (IT)

A tool-kit for practising evidence based urology

ESU Course 42

Monday, 14 March
12:00 - 15:00

Location: Room 22 (ICM, Level 2)

Chairs: L. Marconi Serra De Oliveira, Coimbra (PT)
R.J. Sylvester, Brussels (BE)

Aims and objectives of this presentation

The primary aim of this course is to provide participants with the core skills needed to provide an evidence-based solution to clinical problems that may arise in everyday urological practice. These skills include understanding the precise nature of the clinical problem, asking the appropriate question in order to address it, having the ability to identify, collate, synthesise, interpret and summarise the best available evidence in a transparent, systematic and reproducible manner and being able to reliability assess its quality in order to inform and guide clinical practice.

- Understand the fundamentals of evidence-based medicine
- Learn how to construct a structured and answerable clinical question to solve a clinical problem (i.e. PICO approach) and understand the basic strategies to search for evidence in the literature
- Understand the processes involved in undertaking a systematic review, learn how to critically appraise a study and understand the basic principles of the GRADE approach
- Learn how to perform a meta-analysis

12:00 - 15:00

Introduction

J. N'Dow, Aberdeen (GB)

12:00 - 15:00

Are you really practising evidence-based urology?

T.B. Lam, Aberdeen (GB)

12:00 - 15:00

Ask an answerable question!

L. Marconi Serra De Oliveira, Coimbra (PT)

12:00 - 15:00

Finding the evidence beyond the tip of the Iceberg: How to develop a search strategy?

C. Yuan, Hamilton (CA)

12:00 - 15:00

All you need to know about bias in studies of effectiveness

L. Marconi Serra De Oliveira, Coimbra (PT)

12:00 - 15:00

Synthesising the evidence: How to perform a systematic review

S. MacLennan, Aberdeen (GB)

12:00 - 15:00

Finding the diamond: Basic principles in performing a meta-analysis

R.J. Sylvester, Brussels (BE)

12:00 - 15:00

From the question to the recommendation: Generating recommendations from systematic reviews used in EAU Guidelines

To be confirmed

12:00 - 15:00

Conclusion

Prolapse repair and prostate enucleation

Video Session 08

Monday, 14 March
12:15 - 13:45

Location: eURO Auditorium (Hall C1, Level 0)

Chairs: D.M. Castro-Diaz, La Laguna Santa Cruz Tenerife (ES)
M.J. Drake, Bristol (GB)
M. Speakman, Taunton (GB)

All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.

- *V56 **Vaginal lateral repair on both sides without mesh**
By: [Tzavaras A.](#), Buntbroich T., Mehlhose M., Ehrenheim J., Loertzer H.
Institutes: Westpfalz-Klinikum GmbH, Dept. of Urology, Kaiserslautern, Germany
- *V57 **Trans obturator plastron in vaginal cystocele repair**
By: [Polguer T.](#)¹, Pouget-Chabanon B.², Gayrel P.¹, Guy L.¹
Institutes: ¹CHU G. Montpied, Dept. of Urology, Clermont-Ferrand, France, ²CH E. Roux, Dept. of Gynaecology, Le Puy en Velay, France
- *V58 **Laparoscopic repair of pelvic organ prolapse by lateral suspension with mesh**
By: [Chira L.](#), Botea M., Gutue S., Budau M., Pascu M., Braticevici B., Ambert V., Jinga V.
Institutes: Prof. Dr. Th. Burghel Clinical Hospital, Dept. of Urology, Bucharest, Romania
- *V59 **Green laser enucleation of the prostate (GreenLEP) "en-bloc technique"**
By: [Rijo E.](#)¹, Lorente J.A.¹, Bielsa O.¹, Gomez-Sancha F.²
Institutes: ¹Hospital Quiron Barcelona, Dept. of Urology, Barcelona, Spain, ²ICUA-Clinica CEMTRO, Dept. of Urology, Madrid, Spain
- *V60 **Plasma kinetic enucleation and resection of the prostate (PKERP) vs holmium laser enucleation of the prostate (HoLEP): Technical differences and short-term outcome**
By: [Elshal A.](#), El-Demerdash Y., Mekki R., Taha D.E.-D., Elkhamisy M., Ibraheim E.-H.
Institutes: Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt
- *V61 **Comparison between en-bloc and 3 lobes HoLEP techniques**
By: [Chemaslé C.](#), Marshall D., King Q., Chrisp J.
Institutes: Palmerston North Hospital, Dept. of Urology, Palmerston North, New Zealand
- *V62 **Complications of prostate enucleation and morcellation with thulium laser for BPH**
By: [Codas Duarte R.](#)¹, Ravier E.², Crouzet S.³, Abid N.³, Colombel M.³, Martin X.³, Fassi-Fehri H.³
Institutes: ¹Hôpital Édouard Herriot, Dept. of Urology, Lyon, France, ²Hôpital Édouard Herriot, Dept. of Urology, dept. of transplantation surgery, (Pavillon V), Lyon, France, ³Hôpital Édouard Herriot, Dept. of Urology, dept. of transplantation surgery, (Pavillon V), Lyon, France
- *V63 **HoLEP (holmium laser enucleation of the prostate) - tips & tricks not just for beginners**
By: [Hussein Mohamed Ismail Y.](#), Taglialatela D., Ceresoli F., Milesi R., Del Rosso A., Vavassori I.
Institutes: Ospedale Treviglio Caravaggio, Dept. of Urology, Treviglio, Italy

Localised prostate cancer: Innovative strategies in active surveillance and focal therapy

Poster Session 66

Monday, 14 March
12:15 - 13:45

Location: Room Madrid (Hall B2, level 0)

Chairs: H.U. Ahmed, London (GB)
J-L. Descotes, Grenoble (FR)
G. Giannarini, Udine (IT)

Aims and objectives of this presentation

The session focuses on novel strategies in active surveillance and focal therapy for prostate cancer

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

*829

Multiparametric MRI features that poorer mid-term outcomes in active surveillance patients

By: [Sanguedolce F.](#)¹, [Petrulia G.](#)², [Sokhi H.](#)³, [Tagliabue E.](#)⁴, [Anyamene N.](#)⁵, [Hellawell G.](#)⁶, [Padhani A.R.](#)⁷

Institutes:¹Northampton General Hospital NHS Trust, Dept. of Urology, Northampton, United Kingdom, ²Istituto Europeo di Oncologia, Dept. of Urology, Milan, Italy, ³Hillingdon & Mount Vernon Hospital, Dept. of Radiology, London, United Kingdom, ⁴Istituto Europeo di Oncologia, Division of Epidemiology and Biostatistics, Milan, Italy, ⁵Mount Vernon Hospital, Dept. of Oncology, London, United Kingdom, ⁶Northwick Park Hospital, Dept. of Urology, London, United Kingdom, ⁷Mount Vernon Cancer Centre, Paul Strickland Scanner Centre, London, United Kingdom

*830

Multiparametric MRI predicts adverse pathological prostate cancer features in patients eligible for active surveillance

By: [Boesen L.](#)¹, [Nørgaard N.](#)¹, [Loegager V.](#)², [Jakobsen J.](#)¹, [Bisbjerg R.](#)¹, [Thomsen H.](#)², [Jakobsen H.](#)¹

Institutes:¹Herlev Hospital, Dept. of Urology, Herlev, Denmark, ²Herlev Hospital, Dept. of Radiology, Herlev, Denmark

*831

Multiparametric-MRI, PCA3 and PHI in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance

By: [Porpiglia F.](#)¹, [De Luca S.](#)¹, [Manfredi M.](#)¹, [Mele F.](#)¹, [Russo F.](#)², [Sottile A.](#)³, [Serra N.](#)¹, [Fiori C.](#)¹

Institutes:¹San Luigi Gonzaga Hospital, University of Turin, Dept. of Urology, Orbassano, Italy, ²Candiolo Cancer Institute, Dept. of Radiology, Candiolo, Italy, ³Candiolo Cancer Institute, Dept. of Laboratory Medicine, Candiolo, Italy

*832

Molecular profiling of prostate cancer derived from serial MRI targeted prostate biopsy in men on active surveillance

By: [Palapattu G.](#)², [Cani A.K.](#)³, [Hoevelson D.](#)³, [Mehra R.](#)³, [Montgomery J.S.](#)¹, [Morgan T.](#)¹, [Salami S.](#)¹, [Tomlins S.A.](#)³, [Marks L.S.](#)⁴

Institutes:¹University Of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ³University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, ⁴University of California, Los Angeles, Dept. of Urology, Los Angeles, United States of America

*833

Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic pro-static enlargement: A risk-adaptive strategy for the era of active surveillance

By: [Koo K.C.](#)¹, [Lee K.S.](#)¹, [Lee D.H.](#)², [Rha K.H.](#)¹, [Hong S.J.](#)¹, [Bang W.J.](#)³, [Chung B.H.](#)¹

Institutes:¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Busan

National University College of Medicine, Dept. of Urology, Busan, South Korea, ³Hallym University College of Medicine, Dept. of Urology, Seoul, South Korea

- *834 **Standardization in definitions in focal therapy for prostate cancer: Report from a Delphi consensus project**
 By: Postema A.¹, De Reijke T.¹, Ukimura O.², Van Den Bos W.¹, De La Rosette J.¹
 Institutes:¹AMC University Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Keck School of Medicine, University of Southern California, Dept. of Urology, Los Angeles, United States of America
- *835 **High intensity focused ultrasound hemiablation versus MRI guided 'lesion only' ablation of prostate cancer – genito-urinary functional outcomes and complications**
 By: Sivaraman A., Sanchez-Salas R., Linares Ospinos E., Perez Regetti J., Russo A., Armando Hernandez Palacios G., Barret E., Validire P., Rozet F., Galiano M., Cathelineau X.
 Institutes:Institute Mutualiste Montsouris, Dept. of Urology, Paris, France
- *836 **MRI-US fusion guided high-intensity focused ultrasound with Focal-One® system: Impact on PSA, complications and genito-urinary functions during initial experience**
 By: Perez Reggeti J.L., Sanchez-Salas R., Linares Espinos E., Sivaraman A., Russo A., Hernandez Palacios G., Barret E., Galiano M., Rozet F., Prapotnich D., Cathala N., Mombet A., Cathelineau X.
 Institutes:Institute Mutualiste Montsouris, Dept. of Urology, Paris, France
- *837 **Intraprostatic spatial distribution of prostate cancer: A pre versus post HIFU comparison based on 15.000 biopsies**
 By: Thüroff S.¹, Chaussy C.²
 Institutes:¹Klinikum Harlaching, Dept. of Urology, Munich, Germany, ²St. Josephs Klinik, Dept. of Urology, Regensburg, Germany
- *838 **Magnetic resonance imaging-guided transurethral ultrasound prostate ablation in patients with localized prostate cancer: 12-Month outcomes of a prospective phase I clinical trial**
 By: Billia M.¹, Pahernik S.², Relle J.³, Popenciu I.V.², Kuru T.², Hafron J.³, Romagnoli C.⁴, Burtnyk M.⁵, Schlemmer H-P.², Chin J.L.⁴
 Institutes:¹London Health Sciences Center University of Western Ontario, Dept. of Urology and Radiology, London, Canada, ²German Cancer Research Center (DKFZ), Dept. of Urology and Radiology, Heidelberg, Germany, ³Beaumont Health System, Dept. of Urology and Radiology, Royal Oak, United States of America, ⁴London Health Sciences Center University of Western Ontario, Dept. of Urology and Radiology, London Ontario, Canada, ⁵Profound Medical Inc., Dept. of Engineering, Toronto, Canada
- *839 **A prospective development study evaluating focal irreversible electroporation in men with localised prostate cancer: The NEAT trial**
 By: Valerio M.¹, Dickinson L.¹, Ali A.², Ramachadran N.³, Donaldson I.¹, McCartan N.¹, Freeman A.⁴, Ahmed H.¹, Emberton M.¹
 Institutes:¹UCLH NHS Foundation Trust, Dept. of Urology, London, United Kingdom, ²UCL, Dept. of Mental Health Sciences, London, United Kingdom, ³UCLH NHS Foundation Trust, Dept. of Radiology, London, United Kingdom, ⁴UCLH NHS Foundation Trust, Dept. of Pathology, London, United Kingdom
- *840 **Can small lesions of Gleason 3+4 be left untreated in focal therapy? Analysis of radical prostatectomy specimens**
 By: Kanao K., Kajikawa K., Kobayashi I., Muramatsu H., Morinaga S., Nishikawa G., Yoshizawa T., Kato Y., Watanabe M., Nakamura K., Sumitomo M.
 Institutes:Aichi Medical University, Dept. of Urology, Nagakute, Japan
- *841 **Medium term outcomes following focal HIFU for the treatment of non-metastatic prostate cancer: A UK registry analysis of 625 cases**
 By: Guillaumier S.¹, Hamid S.¹, Charman S.¹, Van Der Meulen J.¹, McCartan N.¹, Shah K.¹, Hindley R.², Nigam R.³, Dudderidge T.⁴, Afzal N.⁵, Cornaby A.⁵, Lewi H.⁶, Persad R.⁷, Moore C.¹, Virdi J.⁸, Arya

M.⁸, Emberton M.¹, Ahmed H.U.¹

Institutes:¹University College London, Dept. of Surgery and Interventional Sciences, London, United Kingdom, ²Basingstoke Hospital, Dept. of Urology, Basingstoke, United Kingdom, ³Royal Surrey County Hospital, Dept. of Urology, Surrey, United Kingdom, ⁴Southampton Hospital, Dept. of Urology, Southampton, United Kingdom, ⁵Dorset County Hospital, Dept. of Urology, Dorset, United Kingdom, ⁶Springfield Hospital, Dept. of Urology, Chelmsford, United Kingdom, ⁷North Bristol NHS Trust, Dept. of Urology, Bristol, United Kingdom, ⁸Princess Alexandra Hospital, Dept. of Urology, Essex, United Kingdom

*842

An open, single dose, anti-tumour effect study of 2-hydroxyflutamide as a controlled release product (Liproca® Depot) injected into the prostate in patients with localized prostate cancer

By: Tammela T.¹, Bjartell A.², Häggman M.³

Institutes:¹Tampere University Hospital, Dept. of Surgery, Tampere, Finland, ²Skåne University Hospital, Dept. of Urology, Malmö, Sweden, ³Uppsala University Hospital, Dept. of Urology, Uppsala, Sweden

Hormone therapies in prostate cancer, less but better

Poster Session 67

Monday, 14 March
12:15 - 13:45

Location: Room Stockholm (Hall B2, level 0)

Chairs: S. Bracarda, Perugia (IT)
F. Calais Da Silva Junior, Lisbon (PT)
J. Morote Robles, Barcelona (ES)

Aims and objectives of this presentation

Hormone therapy remains the mainstay systemic treatment of advanced prostate cancer. Despite almost 60 years of use the optimal timing and modalities remain to be determined. This session will focus on recent updates.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*843

Phase III study of intermittent monotherapy versus continuous combined androgen deprivation

By: Calais Da Silva Junior F.¹, Calais Da Silva Senior F.E.², Gonçalves F.³, Kliment J.⁴, Santos A.⁵, Spyros P.⁶, Queimadelos A.⁷, Robertson C.⁸

Institutes:¹CHLC - Hospital De São José, Dept. of Urology, Lisbon, Portugal, ²CHLC - H.S.José, Dept. of Urology, Lisbon, Portugal, ³CUIMED A Saint Michal Hospital, Dept. of Urology, Bratislava, Slovakia, ⁴Jessenius School of Medicine, Dept. of Urology, Martin, Slovakia, ⁵Hospital De Braga, Dept. of Urology, Braga, Portugal, ⁶Amalia Fleming Hospital, Dept. of Urology, Athens, Greece, ⁷Policlinica La Rosaleda, Dept. of Urology, Santiago Compostela, Spain, ⁸University of Strathclyde, Dept. of Statistics, Glasgow, United Kingdom

*844

Survival outcomes in octogenarian and nonagenarian patients treated with first-line androgen deprivation therapy for localized prostate cancer

By: Dell'Oglio P.¹, Bishr M.¹, Boehm K.², Trudeau V.¹, Larcher A.³, Tian Z.⁴, Saad F.⁵, Capitanio U.³, Briganti A.³, Graefen M.², Montorsi F.³, Karakiewicz P.¹

Institutes:¹Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Dept. of Urology, Montreal, Canada, ²Martini-Clinic, Prostate Cancer Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ³Irccs Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ⁴McGill University, Dept. of Epidemiology, Biostatistics and Occupational Health, Montreal, Canada, ⁵University of Montreal Health Center, Dept. of Urology, Montreal, Canada

*845

Timing of the development of metastasis and initiation of treatment are important prognostic factors in prostate cancer

By: Frees S., Akamatsu S., Lynch K., Chavez-Munoz C., Black P., Gleave M., Goldenberg L., Chi K., So A.

Institutes: Vancouver Prostate Centre, Dept. of Urological Sciences, Vancouver, Canada

*846

Peri-prostatic fat volume predicts castration resistance in advanced prostate cancer

By: Hendry J.¹, Patel A.², Leung H.¹, Salji M.¹

Institutes:¹Beatson Institute For Cancer Research, Dept. of Urology, Glasgow, United Kingdom, ²Queen Elizabeth University Hospital, Dept. of Radiology, Glasgow, United Kingdom

*847

Impact of free testosterone levels on the outcome of androgen deprivation therapy in metastatic prostate cancer

By: Mandhani A., Agnihotri S., Singh R.

Institutes: Sanjay Gandhi Post Graduate Institute of Medical Sciences, Dept. of Urology, Lucknow, India

- *848 **Degarelix is well tolerated and effective for the treatment of prostate cancer: Results from a phase III study in China**
By: Xie L.¹, Bosnyák Z.², Sun Y.³, Malmberg A.², Neijber A.², Fen W.X.⁴
Institutes:¹The First Affiliated Hospital of College of Medicine, Zhejiang University School of Medicine, Dept. of Urology, Zhejiang Province, China, ²Ferring Pharmaceuticals A/S, Dept. of Global Clinical Research and Development, Copenhagen, Denmark, ³Changhai Hospital The First Affiliated Hospital of The Second Military Medical University (SMMU), Dept. of Urology, Shanghai, China, ⁴Peking University People's Hospital, Dept. of Urology, Beijing, China
- *849 **Nomograms to estimate castration resistance and cancer specific survival in patients with advanced prostate cancer - GESCAP Study**
By: Gómez-Veiga E.¹, Rodríguez-Antolín A.², Miñana B.³, Cozar J.M.⁴, Pedrosa E.⁵
Institutes:¹Hospital Universitario De Salamanca IBSAL, Dept. of Urology, Salamanca, Spain, ²Hospital Universitario 12 De Octubre, Dept. of Urology, Madrid, Spain, ³Hospital Morales Meseguer, Dept. of Urology, Murcia, Spain, ⁴Hospital Universitario Virgen De Las Nieves, Dept. of Urology, Granada, Spain, ⁵Astellas Pharma S.A., Medical Department, Madrid, Spain
- *850 **Toremifene plus androgen deprivation therapy (TOPADT) significantly improved biochemical recurrence in bone metastatic prostate cancer: A randomized controlled phase IIA trial**
By: Fujimura T.¹, Takahashi S.², Kume H.¹, Urano T.³, Takayama K.³, Yamada Y.¹, Suzuki M.¹, Fukuhara H.¹, Nakagawa T.¹, Inoue S.⁴, Homma Y.¹
Institutes:¹The University of Tokyo, Dept. of Urology, Tokyo, Japan, ²The Nihon University, Dept. of Urology, Tokyo, Japan, ³The University of Tokyo, Dept. of Geriatric Medicine, Tokyo, Japan, ⁴The University of Tokyo, Dept. of Anti-Aging Medicine, Tokyo, Japan
- *851 **Clinicopathological features of patients progressed into castration-resistant prostate cancer after radical prostatectomy**
By: Yoo S., Han J.H., Shin J., Lee C., You D., Jeong I.G., Hong J., Ahn H., Kim C.S.
Institutes:Asan Medical Center, Dept. of Urology, Seoul, South Korea
- *852 **The impact of androgen deprivation therapy on body composition and hepatic fat content among men with prostate cancer**
By: Ostergren P.B.¹, Chabanova E.², Fode M.¹, Bennedbæk F.N.³, Faber J.³, Sonksen J.¹, Kistorp C.³
Institutes:¹Herlev and Gentofte University Hospital, Faculty of Health and Medical Sciences, Copenhagen Universi, Dept. of Urology, Herlev, Denmark, ²Herlev and Gentofte University Hospital, Faculty of Health and Medical Sciences, Copenhagen Universi, Dept. of Radiology, Herlev, Denmark, ³Herlev and Gentofte University Hospital, Faculty of Health and Medical Sciences, Copenhagen Universi, Dept. of Endocrinology, Herlev, Denmark
- *853 **Prevalence of hand joint symptoms of androgen deprivation therapy in Japanese prostate cancer patients**
By: Inoue S., Kitano H., Hieda K., Shinmei S., Shoji K., Hayashi T., Teishima J., Matsubara A.
Institutes:Hiroshima University, Dept. of Urology, Hiroshima, Japan
- *854 **Fracture risk assessment of men treated with androgen deprivation therapy for prostate cancer**
By: Turo R.¹, Calinciuc A.¹, Horsu S.¹, Stephens L.¹, Nikomanis P.¹, Smolski M.², Gulur D.¹, Das S.¹, Awsare N.¹, Pettersson B.¹, Sinclair A.³, Oakley N.³, Adeyoju A.³, Bromage S.³, Brown S.³, Brough R.³, Collins G.³, Cross W.⁴
Institutes:¹Countess of Chester Hospital, Dept. of Urology, Chester, United Kingdom, ²Royal Preston Hospital, Dept. of Urology, Preston, United Kingdom, ³Stepping Hill Hospital, Dept. of Urology, Stockport, United Kingdom, ⁴St James's University Hospital, Dept. of Urology, Leeds, United Kingdom
- 13:30 - 13:37 **Summary and context**
 F. Calais Da Silva Junior, Lisbon (PT)

Tips and tricks for partial nephrectomy

Poster Session 68

Monday, 14 March
12:15 - 13:45

Location: Room Milan (Hall B2, level 0)

Chairs: Y. Fujii, Tokyo (JP)
V. Matveev, Moscow (RU)
R. Zigeuner, Graz (AT)

Aims and objectives of this presentation

To discuss various surgical aspects of partial nephrectomy.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *855 **Prospective assessment of the adherent perinephric fat in partial nephrectomies - predictors and impact on peri-operative outcomes**
By: [Dariane C.](#)¹, [Badoual C.](#)², [Tordjman J.](#)³, [Clément K.](#)⁴, [Le Guilchet T.](#)¹, [Hurel S.](#)¹, [Pietak M.](#)¹, [Méjean A.](#)¹, [Timsit M-O.](#)¹
Institutes:¹Hôpital Européen Georges Pompidou, Dept. of Urology, Paris, France, ²Hôpital Européen Georges Pompidou, Dept. of Pathology, Paris, France, ³INSERM and Université Pierre Et Marie Curie-Paris, UMR S1166, Nutriomique Team, Paris, France, ⁴ICAN Cardiometabolism and Nutrition Institute, Pitié-Salpêtrière Hospital, UMR S1166, Nutriomique Team, Paris, France
- *856 **What is the impact of anticoagulant and antiplatelet treatment on peri-operative outcomes of robot-assisted partial nephrectomy?**
By: [Pradere B.](#)¹, [Peyronnet B.](#)², [Ruggiero M.](#)³, [Seisen T.](#)³, [Parra J.](#)³, [Verhoest G.](#)², [Vaessen C.](#)³, [Rouprêt M.](#)³, [Bensalah K.](#)²
Institutes:¹CHU de Tours, Hospital Bretonneau, Dept. of Urology, Tours, France, ²CHU Rennes, Dept. of Urology, Rennes, France, ³Hopital Pitié-Salpêtrière, Dept. of Urology, Paris, France
- *857 **Bovine derived gel matrix (BDGM) and argon energy as the only hemostatic procedures for in situ VLP renal tumor enucleation: Results of a phase II study**
By: [Brausi M.](#), [Peracchia G.](#), [Peluso G.](#), [Viola M.](#), [Romano A.](#)
Institutes:Ausl Modena, Dept. of Urology, Carpi, Italy
- *858 **The role of Hemopatch® in zero ischemia laparoscopic partial nephrectomy**
By: [Imkamp F.](#), [Von Klot C.](#), [Wolters M.](#), [Husmann S.](#), [Herrmann T.](#), [Tolkach Y.](#)
Institutes:Hanover Medical School, Dept. of Urology, Hanover, Germany
- *859 **Comparison of perioperative outcomes with or without renorrhaphy in open partial nephrectomy: A propensity score-matched study**
By: [Tachibana H.](#), [Takagi T.](#), [Iizuka J.](#), [Kondo T.](#), [Tanabe K.](#)
Institutes:Tokyo Women's Medical University, Dept. of Urology, Tokyo, Japan
- *860 **Is the V-loc suture better for renorrhaphy during laparoscopic partial nephrectomy to treat low and moderate complexity lesions?**
By: [Wang M.](#), [Yang F.](#), [Song L.](#), [Kang N.](#), [Niu Y.](#), [Xing N.](#)
Institutes:Beijing Chao-Yang Hospital, Dept. of Urology, Beijing, China
- *861 **Nephron sparing surgery in patients with intravenous extension of renal cell carcinoma**
By: [Stakhovsky E.A.](#)², [Shchukin D.V.](#)¹, [Lesovoy V.N.](#)¹, [Vitruk I.](#)², [Voylenko O.A.](#)², [Stakhovskiy O.E.](#)², [Garagatyi I.A.](#)¹, [Polyakov M.M.](#)¹, [Antonyan I.M.](#)³, [Khareba G.G.](#)¹

Institutes:¹Kharkiv National Medical University, Dept. of Urology, Nephrology and Andrology, Kharkiv, Ukraine, ²National Cancer Institute, Dept. of Plastic and Reconstructive Onco-Urology, Kyiv, Ukraine, ³Kharkiv Medical Academy of Postgraduate Education, Dept. of General, Pediatric and Oncological Urology, Kharkiv, Ukraine

*862 **Factors predicting the conversion to radical nephrectomy during robot-assisted radical nephrectomy**

By: [Abdel Raheem A.](#), Alatawi A., Kim D.K., Alabdulaali I., Alabdulaali I., Han W.K., Choi Y.D., Soto I., Rha K.H.

Institutes:Yonsei University College of Medicine, Dept. of Urology and Urological Science Institute, Seoul, South Korea

*863 **Distant control of the renal pedicle and late-clamping, late-declamping technique: A new surgical procedure to reduce ischemia and complications in open partial nephrectomy**

By: [Staezler M.](#), Spek A., Szabados B., Ziegelmueller B., Casuscelli J., Schlenker B., Stief C.

Institutes:LMU-Klinikum der Universität München, Dept. of Urology, Munich, Germany

*864 **Beyond the complexity of tumour excision during partial nephrectomy: Ideation and histopathological validation of the Surface-Intermediate-Base (SIB) margin score**

By: Minervini A.¹, [Campi R.](#)¹, Raspollini M.R.², Montagnani I.², Mari A.¹, Smaldone M.³, Uzzo R.³, Lapini A.¹, Carini M.¹, Kutikov A.⁴

Institutes:¹University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, ²University of Florence, Careggi Hospital, Dept. of Pathology, Florence, Italy, ³Fox Chase Cancer Center, Division of Urologic Oncology, Philadelphia, United States of America, ⁴Fox Chase Cancer Center, Division of Urologic Oncology, Philadelphia, United States of America

*865 **Predictive factors of resection techniques during partial nephrectomy in a cohort of "enucleative" centres: Insights from the Surface-Intermediate-Base (SIB) Margin score International Consortium**

By: [Campi R.](#)¹, Minervini A.¹, Mari A.¹, De Cobelli O.², Sanguedolce F.³, Hatzichristodoulou G.⁴, Antonelli A.⁵, Lane B.⁶, Akdogan B.⁷, Capitano U.⁸, Marszalek M.⁹, Volpe A.¹⁰, Karakoyunlu N.¹¹, Langenhuijsen H.¹², Klatte T.¹³, Rodriguez-Faba O.¹⁴, Brookman-May S.¹⁵, Roscigno M.¹⁶, Uzzo R.¹⁷, Serni S.¹, Kutikov A.¹⁷

Institutes:¹University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, ²European Institute of Oncology (IEO), Dept. of Urology, Milan, Italy, ³Southmead Hospital-North Bristol NHS Trust, Dept. of Urology, Bristol, United Kingdom, ⁴Technical University of Munich, University Hospital Klinikum Rechts Der Isar, Dept. of Urology, Munich, Germany, ⁵University of Brescia, Dept. of Urology, Brescia, Italy, ⁶Spectrum Health Cancer Center, Dept. of Urology, Grand Rapids, United States of America, ⁷Hacettepe University, School of Medicine, Dept. of Urology, Ankara, Turkey, ⁸Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy, ⁹Donauspital, Dept. of Urology and Andrology, Vienna, Austria, ¹⁰Maggiore Della Carità Hospital, University of Eastern Piedmont, Dept. of Urology, Novara, Italy, ¹¹Diş kapı Yıldırım Beyazıt Training and Research Hospital, Dept. of Urology, Ankara, Turkey, ¹²Radboud University Nijmegen Medical Centre, Dept. of Laparoscopy, Robotics and Endourology, Nijmegen, The Netherlands, ¹³Medical University of Vienna, Dept. of Urology, Vienna, Austria, ¹⁴Fundacio Puigvert, Uro-Oncology Unit, Barcelona, Spain, ¹⁵Ludwig Maximilians University, Dept. of Urology, Munich, Germany, ¹⁶AO Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy, ¹⁷Fox Chase Cancer Center, Division of Urologic Oncology, Philadelphia, United States of America

*866 **Discrimination ability of the Surface-Intermediate-Base margin (SIB) score: An external histopathological evaluation**

By: [Antonelli A.](#)¹, Furlan M.¹, Sodano M.¹, Tardanico R.², Fisogni S.², Cozzoli A.¹, Zanotelli T.¹, Simeone C.¹

Institutes:¹Spedali Civili Di Brescia, Dept. of Urology, Brescia, Italy, ²Spedali Civili Di Brescia, Dept. of Pathology, Brescia, Italy

13:26 - 13:33

Summary and context
R. Zigeuner, Graz (AT)

LUTS pharmacotherapy: Any news?

Poster Session 69

Monday, 14 March
12:15 - 13:45

Location: Room 14a (ICM, Level 1)

Chairs: A. Ergen, Ankara (TR)
R. Umbas, Jakarta (ID)
A. Sahai, London (GB)

Aims and objectives of this presentation

Basic and clinical news from the wide field of LUTS pharmacotherapy will be covered during this session

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *867 **Long term efficacy of a combination therapy with an anticholinergic agent and an α 1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: A randomized, prospective, comparative trial using a urodynamic study**
By: [Matsukawa Y.](#), Takai S., Fujita T., Majima T., Kato M., Yamamoto T., Gotoh M.
Institutes: Nagoya University School of Medicine, Dept. of Urology, Nagoya, Japan
- *868 **Dutasteride in combination with imidafenacin versus dutasteride alone for management of benign prostatic enlargement with overactive bladder: A multicenter, randomized controlled trial**
By: [Yamanishi T.](#)¹, Asakura H.², Seki N.³, Tokunaga S.⁴
Institutes:¹Dokkyo Medical University, Dept. of Urology, Continence Center, Tochigi, Japan, ²Saitama Medical University Hospital, Dept. of Urology, Saitama, Japan, ³Kyushu Central Hospital, Dept. of Urology, Fukuoka, Japan, ⁴Kyushu University Hospital, Medical Information Center, Fukuoka, Japan
- *869 **Effects of withdrawing the alpha-1 blocker from alpha-1 blocker plus 5-alpha-reductase inhibitor combination therapy on patients with benign prostatic hyperplasia from the perspective of urodynamic study**
By: Matsukawa Y., Funahashi Y., Matsuo K., [Ishida S.](#), Yoshino Y., Yamamoto T., Gotoh M.
Institutes: Nagoya University School of Medicine, Dept. of Urology, Nagoya, Japan
- *871 **Surgical outcome of BPH patients with storage symptoms requiring antimuscarinics before surgery – a nationwide population-based study**
By: [Huang E.Y-H.](#), Chung H.J., Lin C-C., Fan Y.H., Peng R.S., Chang Y.H., Lin A.T.L., Chen K.K.
Institutes: Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan
- *872 **Cardiovascular (CV) assessments in a randomized, double-blind, phase 3b trial of mirabegron add-on treatment in incontinent overactive bladder (OAB) patients with an inadequate response to solifenacin monotherapy**
By: [Drake M.J.](#)¹, Chapple C.², Esen A.A.³, Athanasiou S.⁴, Cambronero J.⁵, Mitcheson D.⁶, Herschorn S.⁷, Huang M.⁸, Siddiqui E.⁸, Stozel M.⁹, Herholdt C.⁸, Mac Diarmid S.¹⁰
Institutes:¹University of Bristol, Bristol Urological Institute, Bristol, United Kingdom, ²Royal Hallamshire Hospital, Sheffield Hallam University, Sheffield, United Kingdom, ³Dokuz Eylül University School of Medicine, Dept. of Urology, Izmir, Turkey, ⁴University of Athens Medical School, Dept. of Urology, Athens, Greece, ⁵Hospital Universitario Infanta Leonor, Madrid, Spain, ⁶St Elizabeths Medical Center, Brighton, Massachusetts, United States of America, ⁷Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada, ⁸Astellas Pharma Europe Ltd, Chertsey, Surrey, United Kingdom, ⁹Astellas Pharma Global Development, Leiden, The Netherlands, ¹⁰Alliance Urology Specialists, Greensboro, North Carolina, United States of America

- *873 **Tadalafil improves storage dysfunction via increase in bladder blood flow and suppression of ATP release from the urothelium in metabolic syndrome rats**
 By: Zha X., Ito H., Aoki Y., Matsuta Y., Yamaguchi H., Yokoyama O.
 Institutes: Faculty of Medical Science, University Of Fukui, Dept. of Urology, Yoshida-gun, Japan
- *874 **Alpha1-adrenoceptor antagonist ameliorates memory impairment in the patient with LUTS? A study about the influence of tamsulosin on the memory impairment through enhancement of alpha1A-adrenoceptor in the hippocampus of old-aged rats**
 By: Kim S.¹, Kim CH², Cho Y.S.³, Yoon S.J.², Kim K.T.², Kim T.B.², Kim K.H.²
 Institutes:¹The Catholic University of Korea, Kangnam St. Mary's Hospital, Dept. of Urology, Seoul, South Korea, ²Gachon University Gil Medical Center, Gachon University School of Medicine, Dept. of Urology, Incheon, South Korea, ³Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea
- *875 **Evaluation of tamsulosin therapy in the treatment of indwelling double-J stent related discomfort**
 By: Moussa A., Mohammed H., Abd-Bary A., Gaber A., El-Dessouky A., Masoud, A.
 Institutes: Beni Suef University, Dept. of Urology, Beni Suef, Egypt
- *876 **Role of silodosin in decreasing lower urinary tract and sexual problems in male patients with double J ureteral stents**
 By: Hussein H.A.¹, Shaker H.², Fathy H.¹, Sheeba M.¹, Abdelazim M.S.¹, Bedair A.S.¹, Aly A.H.¹
 Institutes:¹Cairo University, Dept. of Urology, Cairo, Egypt, ²Fayoum University, Dept. of Urology, Fayoum, Egypt
- *877 **The efficacy and safety of onabotulinumtoxinA and solifenacin compared to placebo in solifenacin-naïve patients with idiopathic overactive bladder: Results from a multicentre, randomised, double-blind, phase 3b trial**
 By: Everaert K.¹, Sriram R.², Kohan A.³, Aliotta P.⁴, Mc Cammon K.⁵, Abrams S.⁶, Lam W.⁷, Herschorn S.⁸
 Institutes:¹Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ²University Hospital Coventry, Dept. of Urology, Coventry, United Kingdom, ³Advanced Urology Centers of New York, Dept. of Urology, Bethpage, United States of America, ⁴Western New York Urology Associates, Dept. of Urology, Williamsville, United States of America, ⁵Eastern Virginia Medical School, Dept. of Urology, Norfolk, United States of America, ⁶Allergan Plc, Dept. of Urology, Irvine, United States of America, ⁷Allergan Plc, Dept. of Biostatistics, Irvine, United States of America, ⁸University of Toronto, Dept. of Urology, Toronto, Canada
- *878 **Licensed and approved vs traditional dose of onabotulinumtoxinA in refractory overactive bladder?**
 By: Eldred-Evans D.¹, Seth J.¹, Dowson C.², Malde S.³, Watkins J.¹, Khan M.S.¹, Dasgupta P.¹, Sahai A.¹
 Institutes:¹Guy's and St Thomas' Nhs Trust, Pelvic floor unit, London, United Kingdom, ²Guy's and St Thomas' Nhs Trust, Dept. of Urology, London, United Kingdom, ³University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom
- *879 **Preoperative serum C-reactive protein in patients with pelvic organ prolapse is a predictor of de novo overactive bladder**
 By: Tomohiro M., Ohba K., Yasuda T., Asai A., Miyata Y., Sakai H.
 Institutes: Nagasaki University School of Medicine, Dept. of Urology, Nagasaki, Japan
- 13:30 - 13:37 **Summary and context**
 A. Sahai, London (GB)

Preclinical innovation: Latest news in future treatment of erectile dysfunction

Poster Session 70

Monday, 14 March
12:15 - 13:45

Location: Room 14b (ICM, Level 1)

Chairs: F. Fusco, Naples (IT)
A. Muneer, London (GB)

Aims and objectives of this presentation

The session will include animal studies with stem cell based interventions for erectile dysfunction. Furthermore, latest news in regeneration of pelvic nerves and the role of endothelial and smooth muscle in erectile dysfunction will be presented. The audience will walk away with an idea of what may lie ahead in the world of andrology.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *880 **Combination therapy using human adipose-derived stem cells on the cavernous nerve and low-energy shockwaves on the corpus cavernosum in a rat model of postprostatectomy erectile dysfunction**
By: Kwon O., Choi J.B., Park Y.H., Cho H.J., Ha U-S., Hong S.H., Kim S.W., Lee J.Y.
Institutes: Seoul St. Mary's Hospital, Dept. of Urology, Seoul, South Korea
- *881 **Tissue sealing sheet attenuates erectile dysfunction after nerve-sparing surgery in a rat model**
By: Yamashita S., Kamiyama Y., Fujii S., Endo E., Kawasaki Y., Izumi H., Kawamorita N., Mitsuzuka K., Adachi H., Kaiho Y., Ito A., Arai Y.
Institutes: Tohoku University Graduate School of Medicine, Dept. of Urology, Sendai, Japan
- *882 **Damage and repair processes of cavernous nerve after crushing injury in rat model - evidence of transmission electron microscopy in correlation with serial intracavernous pressure and molecular histological change**
By: Wu Y-N.¹, Liao C-H.², Shang H-S.³, Chiang H-S.¹
Institutes: ¹Fu Jen Catholic University, Graduate Institute of Basic Medicine, New Taipei City, Taiwan, ²Fu Jen Catholic University, School of Medicine, New Taipei City, Taiwan, ³Tri-Service General Hospital, Dept. of Clinical Pathology, Taipei City, Taiwan
- *883 **Ganglion cell size after bilateral cavernous nerve resection and reconstruction**
By: May F.¹, Buchner A.², Brinkmann K.³, Weidner N.⁴, Stief C.², Matiasek K.³
Institutes: ¹Private Practice, Dept. of Urology, Dachau, Germany, ²Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, ³Ludwig-Maximilians-University, Dept. of Clinical and Comapartive Neuropathology and Clinical Veterinary Medicine, Munich, Germany, ⁴Ruprechts-Karls-University, Dept. of Spinal Cord Injury Centre, Heidelberg, Germany
- *885 **Osteopontin is an important player in endogenous neuroregeneration after cavernous nerve injury**
By: Weyne E.¹, Matsui H.², Hannan J.³, Fabio C.⁴, Liu X.², Van Der Aa F.¹, Bivalacqua T.², Albersen M.¹
Institutes: ¹UZ Leuven, Dept. of Urology, Leuven, Belgium, ²Johns Hopkins, Dept. of Urology, Baltimore, United States of America, ³East Carolina University, Dept. of Physiology, Greenville, United States of America, ⁴San Raffaele, Dept. of Urology, Milan, Italy
- *886 **Improvement of erectile function by suppression of corporal fibrosis with LIM-kinase2 inhibitors in a rat model of cavernous nerve injury**
By: Jung G.¹, Kim B.S.¹, Song W.H.¹, Park J.¹, Park K.¹, Kim S.W.¹, Paick J-S.¹, Ryu K.H.³, Cho S.Y.², Jeong H.², Son H.², Cho M.C.²

Institutes:¹Seoul National University Hospital, Dept. of Urology, Seoul, South Korea, ²SMG-SNU Boramae Medical Center, Dept. of Urology, Seoul, South Korea, ³Gwangmyeong Sungae Hospital, Dept. of Urology, Gwangmyeong, South Korea

*887 **SDF-1 treatment facilitates axonal regeneration from the major pelvic ganglion in a dose-dependent fashion**

By: Sopko N., Matsui H., Kates M., Xiaopu L., Bivalacqua T.

Institutes:The Johns Hopkins School Of Medicine, Dept. of Urology, Baltimore, United States of America

*888 **Effects of eupatilin on the contractility of corpus cavernosal smooth muscle through nitric oxide independent pathways**

By: Choo S.H.¹, Lee S.W.², Kim J.J.², Sung H.H.², Chae M.R.², Kang S.J.², Han D.H.², So I.³, Lee S.W.²

Institutes:¹Ajou University School of Medicine, Dept. of Urology, Suwon-Si, South Korea, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea, ³Seoul National University College of Medicine, Dept. of Physiology, Seoul, South Korea

*889 **Effect of the BKCa channel opener LDD175 on the erectile function of in vivo diabetic rat model**

By: Lee S.W.¹, Sung H.H.¹, Chae M.R.¹, Kang S.J.¹, Han D.H.², Park J.K.², Lee S.W.¹

Institutes:¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea, ²Chonbuk National University School of Medicine, Dept. of Urology, Jeonju, South Korea

*890 **Treatment of diabetes mellitus-induced erectile dysfunction using endothelial progenitor cells genetically modified with human telomerase reverse transcriptase**

By: Zhang Y.¹, Wang T.¹, Yang J.¹, Li R.¹, Chen Z.², Wang S.¹, Liu J-H.¹, Ye Z.¹

Institutes:¹Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China, ²Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Dept. of Geriatrics, Wuhan, China

*891 **Erectile dysfunction correlates with hyperhomocysteinemia: International Index of Erectile Function (IIEF) and penile Doppler ultrasound evaluation**

By: Busetto G.M., Giovannone R., Antonini G., Del Giudice F., Tricarico S., Ragonesi G., Gentile V., De Berardinis E.

Institutes:Sapienza Rome University Policlinico Umberto I, Dept. of Urology, Rome, Italy

*892 **Sub-albuginean adipocyte accumulation is associated with erectile dysfunction: First clinical evidence and pathophysiological implications**

By: Vinay J.¹, Sarquella J.¹, Sanchez J.¹, Algaba F.², Gallegos I.³, Rojas-Cruz C.⁵, Palma C.⁴

Institutes:¹Fundació Puigvert, Dept. of Andrology, Barcelona, Spain, ²Fundació Puigvert, Dept. of Pathology, Barcelona, Spain, ³University of Chile Clinical Hospital, Dept. of Pathology, Santiago, Chile, ⁴University of Chile Clinical Hospital, Dept. of Urology, Santiago, Chile, ⁵FOSCAL, Clínica Carlos Ardila Lulle, Dept. of Urology, Bucaramanga, Colombia

*893 **Simvastatin treatment improves endothelial function in the corpus cavernosum in uremic apolipoprotein E deficient mice**

By: Ivanovski O.¹, Nikolov I.², Davceva O.³, Petrushevska G.⁴

Institutes:¹Medical Faculty, University ss Cyril and Methodius, Dept. of Urology, Skopje, Macedonia, ²Medical Faculty, University ss Cyril and Methodius, University Clinic of Nephrology, Skopje, Macedonia, ³Medical Faculty, University ss Cyril and Methodius, University Clinic of Clinical Biochemistry, Skopje, Macedonia, ⁴Medical Faculty, University ss Cyril and Methodius, Dept. of Pathology, Skopje, Macedonia

*894 **A novel therapeutic strategy for patients with premature ejaculation: Possibility of electrical stimulation of dorsal penile nerves**

By: Kimura Y., Saitoh C.

Institutes:Astellas Pharma Inc., Evolving Medical Solutions, Tsukuba-Shi, Japan

Functional outcome in urinary reconstruction

Poster Session 71

Monday, 14 March
12:15 - 13:45

Location: Room 14c (ICM, Level 1)

Chairs: S. Deger, Ostfildern (DE)
M. Gallucci, Rome (IT)
I. Moncada, Madrid (ES)

Aims and objectives of this presentation

Overview of functional outcome of reconstructive urology.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *895 **The results of 21 ureteral substitutions with appendix**
By: Komyakov B., Guliev B., [Ochelenko V.A.](#)
Institutes:North-West State Medical University, Dept. of Urology, Saint-Petersburg, Russia
- *896 **Laparoscopic ileal ureteral substitution**
By: Komyakov B., Guliev B., [Ochelenko V.](#)
Institutes:North-West State Medical University, Dept. of Urology, Saint-Petersburg, Russia
- *897 **Continent urinary diversion to rectal bladder constructed by a modified Duhamel's technique in children**
By: [Fahmy M.A.B.](#)
Institutes:Al Azhar, Cairo, Egypt
- *898 **The medium term outcomes of stoma formation for patients undergoing conduit diversion for functional aetiology: 5 Year follow-up**
By: Kose O., Solomon E., Pakzad M., Shah J.R., Hamid R., Greenwell T.J., [Ockrim J.](#)
Institutes:University College London Hospitals, Dept. of Urology, London, United Kingdom
- *899 **Benign uretero-ileal strictures after urinary diversion: Endo-urological treatment versus open surgical revision**
By: [Fransen Van De Putte E.](#)¹, De Wall L.², Heldeweg E.², Leijte J.¹, Bex A.¹, Van Der Poel H.¹, Van Rhijn B.¹, Horenblas S.¹, Hendricksen K.¹
Institutes:¹The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²Onze Lieve Vrouwe Gasthuis - West, Dept. of Urology, Amsterdam, The Netherlands
- *900 **Pelvic fistulas post-radiotherapy: Conservative surgical management is doomed to fail**
By: [Schudel H.](#), Thalmann G.N., Nguyen D.P.
Institutes:University Hospital Berne, Dept. of Urology, Berne, Switzerland
- *901 **Safety of vaginal mesh - a population based study**
By: [Forde J.](#)¹, Chughtai B.¹, Barber M.², Mao J.³, Te A.¹, Sedrakyan A.³
Institutes:¹Weill Cornell Medical College/New York Presbyterian Hospital, Dept. of Urology, New York, United States of America, ²Cleveland Clinic, Obstetrics, Gynecology, and Women's Health Institute, Cleveland, United States of America, ³Weill Cornell Medical College/New York Presbyterian Hospital, Dept. of Healthcare Policy and Research, New York, United States of America

- *902 **Is there a difference in outcome between early versus delayed removal of suburethral mid-urethral sling?**
By: Aggarwal H., Foster J., Singla N., Alhalabi F., Lemack G., [Zimmern P.](#)
Institutes: Ut Southwestern Medical Center, Dept. of Urology, Dallas, United States of America
- *903 **Residual pelvic pain/dyspareunia management after synthetic vaginal mesh and/or sling removal**
By: Abraham A.¹, Scott K.², [Zimmern P.](#)¹
Institutes:¹UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ² UT Southwestern Medical Center, Dept. of PMR, Dallas, United States of America
- *904 **Successful treatment of vesico-vaginal fistula: A single-centre 35 years experience on 106 consecutive cases**
By: [Mancini M.](#), Righetto M.L., Dal Moro F., Calpista A., Zattoni F.
Institutes: Urological Clinic, University of Padua, Dept. of Surgical and Oncological Sciences, Padua, Italy
- *905 **Factors associated with success or failure in VVF repair**
By: Beardmore-Gray A., Pakzad M., Hamid R., Ockrim J.L., [Greenwell T.](#)
Institutes: University College London Hospital, Dept. of Urology, London, United Kingdom
- *906 **Risk of prolapse recurrence after native tissue anterior prolapse repair with intermediate to long-term follow-up**
By: [Lavelle R.](#)¹, Christie A.², Alhalabi F.¹, Zimmern P.¹
Institutes:¹UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ² UT Southwestern Medical Center, Dept. of Biostatistics, Dallas, United States of America
- *908 **Urinary tract reconstruction outcomes following total pelvic exenteration for locally advanced and recurrent rectal cancer**
By: [Khan O.](#)¹, Patsouras D.², Thuiraja R.¹, Khan M.¹, Schizas A.², George M.², Sahai A.¹
Institutes:¹Guy's and St Thomas' Nhs Foundation Trust & King's College London, Dept. of Urology, London, United Kingdom, ²Guy's and St Thomas' Nhs Foundation Trust & King's College London, Dept. of Colorectal Surgery, London, United Kingdom
- *909 **Genetically modified human muscle precursor cells overexpressing PGC-1 α support early myofiber formation for bioengineering of slow twitch sphincter muscle**
By: Haralampieva D.¹, Salemi S.¹, Dinulovic I.², Sulser T.¹, Ametamey S.M.³, Handschin C.², [Eberli D.](#)¹
Institutes:¹University Hospital Zurich, Dept. of Urology, Zürich, Switzerland, ²University of Basel, Biocenter, Zürich, Switzerland, ³ETH Zurich, Institute of Pharmaceutical Sciences Biocenter, Zürich, Switzerland

Stone metabolics and basic research

Poster Session 72

Monday, 14 March
12:15 - 13:45

Location: Room Paris (Hall B2, level 0)

Chairs: A. Skolarikos, Athens (GR)
Y-H. Sun, Shanghai (CN)
C. Türk, Vienna (AT)

Aims and objectives of this presentation

Stone removal means treatment of symptoms not causes. This session will give an update on what is going on in epidemiology, pathophysiology and metabolics of urinary stone disease.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *910 **Food intake assessed by food dairy and PRODI6 analysis in Swiss kidney stone formers: Comparison to 24 hour urine excretion**
By: Roth B.¹, Mohebbi N.², Fuster D.³, Kim M-J.⁴, Wagner C.A.², Wuerzner G.⁵, Dhayat N.², Bonny O.⁶
Institutes:¹University Hospital Berne, Dept. of Urology, Berne, Switzerland, ²University Hospital Zurich, Dept. of Urology and Nephrology, Zurich, Switzerland, ³University Hospital Berne, Dept. of Nephrology, Berne, Switzerland, ⁴University Hospital Basel, Dept. of Urology and Nephrology, Basel, Switzerland, ⁵University Hospital Geneva, Dept. of Urology and Nephrology, Geneva, Switzerland, ⁶University Hospital Lausanne, Dept. of Urology and Nephrology, Lausanne, Switzerland
- *911 **Hypertension and renal impairment in patients with cystinuria: Findings from a specialist cystinuria centre**
By: Kum E.¹, Wong K.¹, Game D.², Glass J.¹, Bultitude M.¹, Thomas K.¹
Institutes:¹Guy's and St. Thomas' Hospitals, London, Dept. of Urology, London, United Kingdom, ²Guy's and St. Thomas' Hospitals, London, Dept. of Nephrology, London, United Kingdom
- *912 **The impact of uric acid stone components on renal function deterioration**
By: Tanaka T., Noro D., Hatakeyama S., Terayama Y., Saitoh F., Saitoh H., Hashimoto Y., Koie T., Ohyama C.
Institutes:Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan
- *913 **Upper urinary tract stone is an independent risk factor for stroke: A nation-wide population-based and with an 8-year follow-up study**
By: Chung H.J.¹, Lin A.T.¹, Huang Y-H.¹, Lin C-C.¹, Fan Y-H.¹, Chen T-J.², Chen K-K.¹
Institutes:¹Taipei Veterans General Hospital, Dept. of Urology, Taipei City, Taiwan, ²Taipei Veterans General Hospital, Dept. of Family Medicine, Taipei City, Taiwan
- *914 **Do stones still kill? An analysis of death from stone disease 1999 to 2013 in England and Wales**
By: Kum E., Mahmalji W., Hale J., Thomas K., Bultitude M., Glass J.
Institutes:Guy's and St. Thomas' Hospitals, Dept. of Urology, London, United Kingdom
- *915 **Comparison of micro-elemental composition of the urinary stones in adult and pediatric patients**
By: Abdel-Gawad Elnagar M.¹, Elsobky E.², Ali-El-Dein B.³
Institutes:¹Emirates International Hospital, Dept. of Urology and Radiology, Al-Ain, United Arab Emirates, ²Al-Noor Hospital, Dept. of Urology, Abu Dhabi, United Arab Emirates, ³Mansoura Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt
- *916 **Murine model for the evaluation of hyperoxaluria on metabolic syndrome patients**

By: Saenz J.¹, Jorge E.², Corbacho C.³, Santos M.⁴, Sanchez A.⁴, Soblechero P.², Virumbrales E.², Ramil E.⁴, Coronado M.J.⁴, Carballido J.¹

Institutes:¹Hospital Universitario Puerta De Hierro, Dept. of Urology, Majadahonda- Madrid, Spain, ²Hospital Universitario Puerta De Hierro, Dept. of Biochemistry, Majadahonda- Madrid, Spain, ³Hospital Universitario Puerta De Hierro, Dept. of Pathologic Anatomy, Majadahonda- Madrid, Spain, ⁴Hospital Universitario Puerta De Hierro, Dept. of Investigation, Majadahonda- Madrid, Spain

*917 **Potassium-sodium citrate prevents the progression of renal microcalculi into symptomatic stones in patients with calcium stones**

By: Unno R.¹, Taguchi K.², Hamamoto S.², Ando R.², Okada A.², Tozawa K.², Kohri K.², Yasui T.²

Institutes:¹Nagoya City University, Dept. Of Nephro-urology, Nagoya, Japan, ²Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan

*918 **Papillary calcifications – a new prognostic factor in idiopathic calcium oxalate urolithiasis (CaOxU)**

By: Strohmaier W.L.¹, Hörmann M.¹, Schubert G.²

Institutes:¹Klinikum Coburg, Dept. of Urology and Peadiatric Urology, Coburg, Germany, ²Labor Berlin Charité Vivantes, Urinary Stone Laboratory, Berlin, Germany

*919 **The role of M1/M2 macrophages for CaOx stone and Randall's plaque formation**

By: Taguchi K., Okada A., Hamamoto S., Unno R., Kamisawa H., Naiki T., Ando R., Umemoto Y., Itoh Y., Tozawa K., Kohri K., Yasui T.

Institutes:Nagoya City University Graduate School of Medical Sciences, Dept. of Nephro-Urology, Nagoya, Japan

*920 **Does matrix material affect urinary stone formation?**

By: Elsobky E.¹, Elnagar M.², Ali-El-Dein B.³

Institutes:¹Al-Noor Hospital, Dept. of Urology, Abu Dhabi, United Arab Emirates, ²Emirates International Hospital, Dept. of Urology, Al Ain, United Arab Emirates, ³Mansoura Urology and Nephrology Center, Dept. of Urology, Mansoura, Egypt

*921 **Modified magnetic separation and enhanced Raman sensitivity for detecting urolithiasis via phosphonic acid-terminated Fe₃O₄ nanoclusters**

By: Lin H-F.¹, Chiu Y-C.¹, Chen P-A.², Chang P-Y.², Hsu C-Y.³, Tao C-W.², Huang C-C.⁴, Chiang H.K.⁵

Institutes:¹Zhong Xiao Branch, Taipei City Hospital, Dept. of Urology and Surgery, Taipei, Taiwan, ²National Yang-Ming University, Institute of Biophotonics, Taipei, Taiwan, ³National Yang-Ming University, Institute of Biomedical Engineering, Taipei, Taiwan, ⁴National Cheng Kung University, Dept. of Photonics, Center For Micro/Nano Science and Technology and Advanced Optoelectronic Technology Center, Tainan, Taiwan, ⁵National Yang-Ming University, Biophotonics and Molecular Imaging Research Center (BMIRC), Taipei, Taiwan

13:34 - 13:41 **Summary and context**

A. Skolarikos, Athens (GR)

Scientific basis of experimental therapy in bladder cancer

Poster Session 73

Monday, 14 March
12:15 - 13:45

Location: Room Vienna (Hall B2, level 0)

Chairs: N. Fujimoto, Kitakyushu (JP)
M. Knowles, Leeds (GB)
M. Sanchez-Carbayo, Vitoria-Gasteiz (ES)

Aims and objectives of this presentation

Transcription factors have been investigated in multiple tumours in order to improve chemotherapy. Targeting these transcription factors in urothelial cancer will be presented. In addition, the session will address the role of modulation of tumour metabolism and inhibition of steroid receptors in that tumour.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *924 **Prediction of therapeutic resistance using ERBB2 expression status and Ki-67 labelling index in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach**
By: Inoue M.¹, Koga F.², Yoshida S.¹, Tanaka H.¹, Kobayashi S.¹, Yokoyama M.¹, Ishioka J.¹, Matsuoka Y.¹, Numao N.¹, Saito K.¹, Fujii Y.¹, Kihara K.¹
Institutes:¹Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, ²Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Dept. of Urology, Tokyo, Japan
- *925 **STAT1 inhibition restored chemotherapy sensitivity in cisplatin/gemcitabine resistant bladder cancer**
By: Hayashi T.¹, Seiler R.², Bell R.², Ettinger S.², Wang K.², Goriki A.², Oo H.Z.², Awrey S.², Gust K.², Jaeger W.², Todenhöfer T.², Altamirano-Dimas M.², Matsubara A.¹, Collins C.², Black P.²
Institutes:¹Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada
- *926 **Transcription factor STAT3 is a potential therapeutic target in bladder cancer**
By: Schmid S.C., Yousef A., Sathe A., Horn T., Maurer T., Retz M., Gschwend J.E., Holm P.S., Nawroth R.
Institutes:Technische Universität München, Dept. of Urology, Munich, Germany
- *927 **Effective treatment of cisplatin-resistant bladder cancer using a glycosaminoglycan binding malaria protein**
By: Seiler R.¹, Oo H.¹, Lee S.¹, Tortora D.¹, Kumar G.¹, Chris W.¹, Clausen T.M.², Agerbæk M.Ø.², Gustavsson T.², Rich J.R.³, Babcook J.³, Black P.C.⁴, Salanti A.², Daugaard M.¹
Institutes:¹University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, ²Centre For Medical Parasitology, Dept. of Immunology and Microbiology, University of Copenhagen and Department of Infectious Diseases, Copenhagen, Denmark, ³Centre For Drug Research and Development, Dept. of Pharmaceutical Sciences, Vancouver, Canada, ⁴University of British Columbia, Dept of Urologic Sciences, Vancouver, Canada
- *928 **Androgen receptor signals reduce sensitivity to cisplatin in bladder cancer cells**
By: Kashiwagi E.¹, Ide H.², Kawahara T.², Reis L.², Eto M.¹, Miyamoto H.², Baras A.²
Institutes:¹Kyushu University, Dept. of Urology, Fukuoka, Japan, ²Johns Hopkins School of Medicine, Dept. of Pathology, Baltimore, United States of America

- *929 **Targeting lactate transporters for the treatment of urothelial carcinoma**
 By: Todenhöfer T.¹, Seiler R.¹, Stewart C.¹, Moskalev I.¹, Gao J.¹, Ladar S.¹, Kamyabi A.¹, Al Nakouzi N.¹, Hayashi T.¹, Choi S.¹, Wang Y.¹, Frees S.¹, Daugaard M.¹, Zarni Ooh H.¹, Hennenlotter J.², Bedke J.², Fazli L.¹, Stenzl A.², Black P.¹
Institutes:¹University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, ²Eberhard-Karls-Universität, Dept. of Urology, Tübingen, Germany
- *930 **The PCNA targeting peptide drug ATX-101 enhances the efficacy of intravenous chemotherapy for muscle-invasive bladder cancer in a orthotopic rat bladder model**
 By: Blindheim A.J.¹, Sjøgaard C.D.², Gederaas O.², Viset T.³, Arum C-J.¹, Otterlei M.²
Institutes:¹St. Olavs Hospital, University Hospital of Trondheim, Dept. of Surgery, Trondheim, Norway, ²The Norwegian University of Science and Technology, Dept. of Cancer Research and Molecular Medicine, Trondheim, Norway, ³St. Olavs Hospital, University Hospital of Trondheim, Dept. of Pathology, Trondheim, Norway
- *931 **Synergistic antitumor effect of satraplatin and NVP-BE235 in cisplatin-resistant human bladder cancer cells**
 By: Yoon C.Y.¹, Kong M.K.¹, Ahn H.G.¹, Kang S.G.¹, Han J.H.¹, Kang Y.J.¹, Jang W.S.¹, Lee J.S.², Kim Y.S.³, Park H.S.⁴, Cho I.R.⁵, Cheon J.⁴, Choi Y.D.¹
Institutes:¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Cheil General Hospital and Women's Healthcare Center, Dankook University, College of Medicine, Dept. of Urology, Seoul, South Korea, ³National Health Insurance Service Ilsan Hospital, Dept. of Urology, Ilsan, South Korea, ⁴Korea University, College of Medicine, Dept. of Urology, Seoul, South Korea, ⁵Inje University, Ilsan Paik Hospital, Dept. of Urology, Ilsan, South Korea
- *932 **HYAL4: A novel molecular biomarker and determinant of bladder cancer**
 By: Hennig M.¹, Lokeshwar S.², Knapp J.³, Hupe M.¹, Kramer M.¹, Manoharan M.², Merseburger A.¹, Lokeshwar V.⁴
Institutes:¹University Of Lübeck, Dept. of Urology, Lübeck, Germany, ²Miller-School of Medicine, Dept. of Urology, Miami, United States of America, ³University of Lübeck, Dept. of Urology, Lübeck, Germany, ⁴Medical College of Georgia, Dept. of Biochemistry & Molecular Biology, Augusta, United States of America
- *933 **Establishment of a new orthotopic in vivo examinable model of non-muscle invasive bladder cancer using RT112 reporter cells**
 By: Fragoulis A.¹, Fera C.², Schemmert S.², Strick K.², Anton M.³, Möhring M.⁴, Steitz J.⁴, Tolba R.⁴, Grosse J.O.²
Institutes:¹Uniklinik RWTH Aachen, Dept. of Orthopaedic Surgery, Aachen, Germany, ²Uniklinik RWTH Aachen, Dept. of Urology, Aachen, Germany, ³TU Munich, Institute of Molecular Immunology and Experimental Oncology, Munich, Germany, ⁴Uniklinik RWTH Aachen, Institute for Laboratory Animal Science, Aachen, Germany
- *934 **Tumour-suppressive microRNA-26a/b inhibit cancer cell migration and invasion through targeting collagen cross-linking enzyme, PLOD2 in bladder cancer**
 By: Miyamoto K.¹, Seki N.², Matsushita R.¹, Yonemori M.¹, Yoshino H.¹, Goto Y.², Kato M.², Kurozumi A.², Nakagawa M.¹, Enokida H.¹
Institutes:¹Kagoshima University Graduate School of Medical and Dental Sciences, Dept. of Urology, Kagoshima, Japan, ²Chiba University Graduate School of Medicine, Dept. of Functional Genomics, Chiba, Japan
- *935 **Potential role of an IRE1 α /XBP1 inhibitor in preventing therapeutic failure of intravesical BCG in bladder cancer**
 By: Lewicki P.¹, Liu H.¹, Golombos D.¹, O'Malley P.¹, Cubillos-Ruiz J.², Scherr D.¹
Institutes:¹Weill Cornell Medical College, Dept. of Urology, New York, United States of America, ²Weill Cornell Medical College, Dept. of Obstetrics and Gynaecology, New York, United States of America

*937

Attenuated XPC expression is not associated with impaired DNA repair in bladder cancer

By: Boormans J.L.¹, Naipal K.A.T.², Raams A.², Van Leenders G.J.L.H.³, Kanaar R.⁴, Van Gent D.C.²

Institutes:¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Genetics, Rotterdam, The Netherlands, ³Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, ⁴Erasmus MC, Dept. of Radiation Oncology, Rotterdam, The Netherlands

New technologies in endo-urology

Poster Session 74

Monday, 14 March
12:15 - 13:45

Location: Room London (Hall B2, level 0)

Chairs: J.H. Hong, Seoul (KR)
P.M. Kronenberg, Amadora (PT)
E. Nemr, Beirut (LB)

Aims and objectives of this presentation

During this session, several new technologies will be presented such as biodegradable ureteral stents, new grasp integrated flexible cystoscope, burst laser lithotripsy and 3D printing of renal tumours.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *938 **Biodegradable drug-eluting stents: Targeting urothelial tumors of upper urinary tract**
By: Barros A.¹, Browne S.², Oliveira C.³, Reis R.L.¹, Duarte A.¹, Healy K.⁴, Lima E.E.³
Institutes:¹3b's Research Group, Dept. of Polymer Engineering, Gmr, Portugal, ²Centre for Research in Medical Devices (CÚRAM), National University of Ireland Galway, Galway, Ireland, ³Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal, ⁴University of California, Dept. of Bioengineering, Berkeley, United States of America
- *939 **The new grasp-integrated flexible cystoscope (FC) Isiris (Coloplast®) for double J (DJ) removal: Evaluation of image quality, flow and flexibility**
By: Talso M., Servan P., Emiliani E., Orosa A., Baghdadi M., Barreiro A., Proietti S., Traxer O.
Institutes:Hôpital Tenon, Université Pierre et Marie Curie - Paris VI, Dept. of Urology, Paris, France
- *940 **A multicentric evaluation of a new single use solution for ureteral stent removal**
By: Traxer O.¹, Giusti G.², Patterson J.³, Palmero J.L.⁴, Straub M.⁵, De La Rosette J.⁶
Institutes:¹Tenon Hospital, Assitance Publique-Hopitaux De Paris. Pierre Et Marie Curie University, Paris 6, Dept. of Urology, Paris, France, ²Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy, ³Sheffield Teaching Hospitals NHS Foundation Trust, Dept. of Urology, Sheffield, United Kingdom, ⁴Hospital Universitario La Ribera, Dept. of Urology, Valencia, Spain, ⁵Klinikum Rechts Der Isar Der Technischen Universität München, Dept. of Urology, Munich, Germany, ⁶AMC University Hospital, Dept. of Urology, Amsterdam, The Netherlands
- *941 **Burst laser lithotripsy – a novel lithotripsy mode**
By: Kronenberg P.¹, Traxer O.²
Institutes:¹Hospital Prof. Doutor Fernando Fonseca, Dept. of Urology, Amadora, Portugal, ²Université Paris 6 Pierre Et Marie Curie – Hôpital Tenon, Dept. of Urology, Paris, France
- *942 **Stone retropulsion with the use of a recently introduced holmium laser system**
By: Panagopoulos V.¹, Kallidonis P.¹, Amanatides L.², Ioannou P.², Spiliopoulos N.³, Koukiou G.³, Vasilas M.¹, Kyriazis I.¹, Kemal W.¹, Liatsikos E.¹
Institutes:¹University of Patras, Dept. of Urology, Patras, Greece, ²University of Patras, Dept. of Chemical Engineering, Patras, Greece, ³University of Patras, Dept. of Physics, Patras, Greece
- *943 **Results from a comparative multicentric study of Xenx™, the latest ureteric occlusion device with guide-wire utility**
By: Sanguedolce F.¹, Montanari E.², Alvarez-Maestro M.⁹, Macchione N.², Hruby S.³, Papatsoris A.⁴, Kallidonis P.⁵, Villa L.⁶, Honeck P.⁷, Traxer O.⁶, Greco F.⁸

Institutes:¹King's College Hospital, Dept. of Urology, London, United Kingdom, ²San Paolo Hospital, Dept. of Urology, Milan, Italy, ³Paracelsus Medical University, Dept. of Urology, Salzburg, Austria, ⁴Sismanoglio General Hospital, Dept. of Urology, Athens, Greece, ⁵Patras University Hospital, Dept. of Urology, Patras, Greece, ⁶Tenon University Hospital, Dept. of Urology, Paris, France, ⁷Sindelfingen-Böblingen University Hospital, Dept. of Urology, Sindelfingen-Böblingen, Germany, ⁸Romolo Hospital, Dept. of Urology, Rocca Di Neto, Italy, ⁹Hospital Universitario Infanta Sofia, Dept. of Urology, Madrid, Spain

*944

A new gesture-controlled tool using three-dimensional reconstruction of renovascular-collecting system-tumor anatomy to assist navigation of kidney during "zero ischemia" minimally invasive nephron sparing surgery in high complex renal cancer

By: Dourado Meneses A.¹, Aragao Rocha B.², Tolstenko Nogueira A.³, Lima Mattos P.A.¹, Madeira Campos R.S.⁴, Cardoso Guimaraes G.⁴, Zequi S.C.⁴

Institutes:¹Sao Marcos Hospital, Dept. of Urology, Teresina, Brazil, ²FCM-USP, Dept. of Radiology, Sao Paulo, Brazil, ³UFPI, Dept. of Computer Science, Teresina, Brazil, ⁴AC Camargo Cancer Center, Dept. of Urology, Sao Paulo, Brazil

*946

3D printing of renal tumors for preoperative simulation

By: Von Rundstedt F-C., Scovell J.S., Agrawal S.A., Zaneveld J., Link R.E.

Institutes:Baylor College of Medicine, Dept. of Urology, Houston, United States of America

*947

The use of portable video media versus standard verbal communication in the urological consent process: A randomised controlled clinical trial

By: Nalavenkata S.¹, Winter M.², Kam J.³, Hardy E.³, Handmer M.³, Ainsworth H.³, Lee D.³, Louie-Johnsun M.³

Institutes:¹Royal Prince Alfred Hospital, Dept. of Urology, Sydney, Australia, ²Royal North Shore Hospital, Dept. of Urology, Sydney, Australia, ³Gosford Hospital, Dept. of Urology, Gosford, Australia

*948

Extracorporeal shock wave therapy for chronic prostatitis III-a-b

By: Kulchavenya E., Shevchenko S., Brizhatyuk E.

Institutes:Novosibirsk Research TB Institute, Medical University, Dept. of Urology, Novosibirsk, Russia

13:28 - 13:32

Late Breaking News: Phase I/II CANON study: Novel oncolytic immunotherapy for the treatment of Non-Muscle Invasive Bladder Cancer using intravesical CAVATAK (Coxsackievirus A21)

H. Pandha, Guildford (GB)

ESU/ESUT Hands-on training in basic Laparoscopic Skills

HOT 61

**Monday, 14 March
12:15 - 13:45****Location:** Room Europe (Hall B0, level 0)**Chair:** D. Veneziano, Minneapolis (US)**Aims and objectives of this presentation**

In this course basic laparoscopic and suturing skills can be learned and trained. Psychomotor skills such as depth perception and bimanual dexterity are trained by the validated exercises of the European Basic Laparoscopic Urological Skills (E-BLUS) training programme.

Experienced laparoscopist-tutors will guide you to master such basic laparoscopy skills as instrument handling, pattern cutting and intracorporal suturing.

This course can be used as an additional training to prepare for the E-BLUS examination. Finally, all remaining questions can be answered and discussed with all tutors including the demonstration of tips and tricks.

- E. Gallyamov, Moscow (RU)
- F. Greco, Crotone (IT)
- Y. Akin, Sanliurfa (TR)
- A. Sempere Gutierrez, Murcia (ES)
- T. Tokas, Hall In Tirol (AT)
- T. Kalogeropoulos, Athens (GR)
- C. Wagner, Gronau (DE)

ESU/ESUT Hands-on training in HoLEP

HOT 69

Monday, 14 March
12:45 - 14:15

Location: Room Africa (Hall B0, level 0)

Aims and objectives of this presentation

This hands-on-training course will provide a hands-on experience of the HoLEP procedure, by simulating the anatomy and the laser tissue interaction in the HoLEP training simulator. Innovative prostate model provides real life practice of the laser-tissue interaction and haptic feedback

Course setup:

An Operating Room-like experience using a real holmium laser system with a scope
Mimics the anatomy seen during the procedure and the procedure steps

Aims and objectives

- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of the HoLEP procedure.

C.M. Scoffone, Turin (IT)

ESU/ESUT/EULIS Hands-on training in Ureterorenoscopy - Stone dusting

HOT 74

Monday, 14 March
12:45 - 14:15

Location: Room Africa (Hall B0, level 0)

Aims and objectives of this presentation

Ureteroscopy is an essential tool in the management of stone disease for all Endourologists. This hands-on-training course will provide a hands-on experience of the flexible and rigid Ureteroscopy procedures , by simulating the anatomy and the laser interaction in the Advanced Stone Trainer.

Course setup:

Real life interaction and haptic feedback.

An Operating Room-like experience using a real holmium laser system with a scope

Aims and objectives

- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of Laser stone dusting and fragmentation.

Target audience: Beneficial for novices wishing to learn Laser stone dusting and fragmentation and for experienced urologists wishing to train and teach the procedure.

M. Cynk, Tunbridge Wells (GB)

ESU/ESFFU Hands-on training in Urodynamics

HOT 32

Monday, 14 March
13:00 - 16:00

Location: Room South America (Hall B0, level 0)

Chair: H. Hashim, Bristol (GB)

Aims and objectives of this presentation

This workshop aims to provide a practical course offering an interactive “hands-on” environment for doctors, nurses and technicians to improve their skills in urodynamics, with an emphasis on practical aspects including equipment used, interpretation of traces, quality control and trouble-shooting. The use of recorded tests, access to equipment and small groups means that individual problems can be addressed. All the speakers are involved in similar “hands-on” courses, which have ran successfully in the United Kingdom and abroad. The small group format has been shown to work well in addressing individual needs. Access to teaching aids and equipment will simulate the clinical scenario as much as possible within the constraints of the conference setting. At the end of the workshop delegates should feel more confident in their practice of urodynamics.

A. Gammie, Bristol (GB)

A. Garcia Mora

L. Thomas, Bristol (GB)

ESU Social Media Training

HOT 50

Monday, 14 March
13:00 - 13:45

Location: Room 0.305

Chair: M. Bultitude, London (GB)

Aims and objectives of this presentation

- EAU Congress Attendees will be instructed on how to harness professional Social Media to augment experience of professional meetings, follow urologic news feeds, and engage with the world-wide urologic community.
- Urologists who are expert in the use of Social Media will provide 45 minute small group hands-on workshops on the use of professional Social Media.
- Current Social Media users will have the opportunity to exchange expertise with other Social Media users during small group sessions.

Q-D. Trinh, Boston (US)

ESU/ESUT/EULIS Hands-on training in Ureterorenoscopy

HOT 27

Monday, 14 March
13:30 - 15:00

Location: Room North America (Hall B0, level 0)

Chair: B.K. Somani, Southampton (GB)

Aims and objectives of this presentation

Ureteroscopy is an essential tool in the management of stone disease for all Endourologists. This course will provide hands-on-training with tutor guided practical tips and tricks of doing ureteroscopy. Participants will get a chance to perform Semirigid and Flexible ureteroscopy in the models with a chance to navigate the pelvicalyceal system, stone manipulation and extraction.

Aims and objectives

- At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models
- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.

G.M. Kamphuis, Amsterdam (NL)

B. Geavlete, Bucharest (RO)

A.J. Gross, Hamburg (DE)

To be confirmed

To be confirmed

F. Keeley, Bristol (GB)

S. Doizi, Paris (FR)

Male and female reconstructive surgery

Video Session 09

Monday, 14 March
14:00 - 15:30

Location: eURO Auditorium (Hall C1, Level 0)

Chairs: S.A. Ahyai, Göttingen (DE)
D.E. Andrigh, Kingston upon Thames (GB)
F. Van Der Aa, Leuven (BE)

Aims and objectives of this presentation

The aims of this session are to present nine unique videos on male and female genitourinary reconstruction.

Each video shall be shown (maximum of 10 minutes) followed by a 4-minute question and answer session when attendees can question the author.

Objectives:

1. Attendees will have the opportunity to view the unique videos presented
2. Attendees should understand the highlights and limitations of the presentations.

All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.

- *V64 **Genitoplasty in girls with adrenogenital syndrome: Focus on the reconstruction technique**
By: [Waterloos M.](#), Claeys T., Spinoit A-F., Sempels M., Van Laecke E., Hoebeke P.
Institutes: Ghent University Hospital, Dept. of Urology, Ghent, Belgium
- *V65 **Non-transecting anastomotic urethroplasty is a new type of urethroplasty for short bulbar urethral stricture**
By: [Kotov S.](#)
Institutes: First City Hospital Named after N.i.pirogov, Dept. of Urology, Moscow, Russia
- *V66 **Single session urethroplasty with bilateral buccal mucosal grafts in a patient with panurethral stricture**
By: [Zumrutbas A.E.](#), Toktas C., Baser A., Bingolo G., Aybek Z.
Institutes: Pamukkale University School of Medicine, Dept. of Urology, Denizli, Turkey
- *V67 **Substitution urethroplasty with biaxial epilated scrotal flap in urethral stent obliteration**
By: [Gil-Vernet A.](#)¹, Céspedes M.¹, Ropero J.², Díaz F.¹, Mallafré J.M.¹
Institutes: ¹Hospital General, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Dept. of Urology, Barcelona, Spain, ²Hospital Universitari Vall d'Hebron, Dept. of Urology, Barcelona, Spain
- *V68 **Simple technique to identify stricture site during laparoscopic ureteral reconstruction**
By: [Chen P.H.](#), Huang S.H., Chen Y.L., Chiang H.C., Wang B.F., Lin J., Chang C.P., Chen J.T.
Institutes: Changhua Christian Hospital, Dept. of Urology, Changhua City, Changhua County, Taiwan
- *V69 **A novel minimally invasive technique of transposing omentum to perineum for recto urethral fistula**
By: Kulkarni S.B.¹, Barbagli G.², [Joshi P.](#)³, Surana S.³, Hamouda A.³
Institutes: ¹Kulkarni's Reconstructive Urology Centre, Dept. of Urology, Pune, India, ²Centre for Urethral Reconstruction, Dept. of Urology, Arezzo, Italy, ³Kulkarni's Reconstructive Urology Centre, Dept. of Urology, Pune, India
- *V70 **Bilateral impending distal erosion of soft penile implant treated by device removal, bilateral distal re-tunneling upon penile MRI guidance, and inflatable device insertion**

By: Pescatori E.¹, Drei B.¹, Ghidini N.², Pisi P.³

Institutes:¹Hesperia Hospital, Dept. of Andrology Service, Modena, Italy, ²Hesperia Hospital, Dept. of Urology, Modena, Italy, ³Hesperia Hospital, Dept. of Radiology, Modena, Italy

*V71

Surgical treatment of erectile dysfunction and Peyronie disease

By: Amo Garcia A., Conde Redondo M.C., Garcia Viña A., Castroviejo Royo F., Alonso Villalba A., De La Cruz Martin B., Martinez Sagarra J.M.

Institutes:Hospital Universitario Río Hortega, Dept. of Urology, Valladolid, Spain

Prostate cancer: Outcomes of active surveillance

Poster Session 75

Monday, 14 March
14:00 - 15:30

Location: Room Madrid (Hall B2, level 0)

Chairs: A.R. Azzouzi, Angers (FR)
A. Finelli, Toronto (CA)
T. Pickles, Vancouver (CA)

Aims and objectives of this presentation

The session focuses on outcomes of active surveillance

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *949 **Long-term quality of life outcomes after active surveillance or curative treatment for prostate cancer**
By: [Venderbos L.D.F.](#)¹, [Aluwini S.A.](#)², [Roobol M.J.](#)¹, [Bokhorst L.P.](#)¹, [Oomens E.H.G.M.](#)³, [Bangma C.H.](#)¹, [Korfage I.J.](#)⁴
Institutes:¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, ³Amphia Hospital, Dept. of Urology, Breda, The Netherlands, ⁴Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands
- *950 **Comparative analysis of immediate vs delayed prostatectomy in prostate cancer patients eligible for active surveillance**
By: [Mallya A.](#)¹, [Karthikeyan V.S.](#)¹, [Sivaraman A.](#)², [Sanchez-Salas R.](#)², [Galiano M.](#)², [Rozet F.](#)², [Barret E.](#)², [Cathelineau X.](#)²
Institutes:¹Institute of Nephrourology, Dept. of Urology, Bangalore, India, ²Institut Mutualiste Montsouris, Dept. of Urology, Paris, France
- *951 **Use of initial active surveillance among men with low-risk prostate cancer**
By: [Finelli A.](#)¹, [Komisarenko M.](#)², [Timilshina N.](#)³, [Ahmad A.](#)², [Alibhai S.](#)⁴, [Zlotta A.](#)⁵, [Hamilton R.](#)², [Kulkarni G.](#)², [Fleshner N.](#)²
Institutes:¹Princess Margaret Hospital, Dept. of Surgical Oncology, Toronto, Canada, ²Princess Margaret Cancer Centre, Dept. of Surgical Oncology, Toronto, Canada, ³University of Toronto, Dept. of Health Services, Toronto, Canada, ⁴Toronto General Hospital, Dept. of Internal Medicine, Toronto, Canada, ⁵Mount Sinai Hospital, Dept. of Surgical Oncology, Toronto, Canada
- *952 **Active surveillance (AS) following transperineal template guided saturation biopsy (TPSB) demonstrates a low rate of progression and conversion to radical treatment, with age and PSA associated with upgrading, upstaging and treatment**
By: [Sarkar D.](#), [Parr N.J.](#)
Institutes:Wirral University Teaching Hospital, Dept. of Urology, Wirral, United Kingdom
- *953 **Reclassified in active surveillance for prostate cancer: Was it worthwhile taking the risk?**
By: [Hefermehl L.](#), [Lehmann K.](#)
Institutes:Kantonsspital Baden, Dept. of Urology, Baden, Switzerland
- *954 **Longitudinal assessment of general health related QoL in Japanese patients undergoing active surveillance (AS): From an interim analysis of PRIAS-JAPAN**
By: [Sugimoto M.](#), [Hirama H.](#), [Takechi Y.](#)
Institutes:Kagawa University, Dept. of Urology, Kagawa, Japan

- *955 **Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared to standard 12-core systematic biopsies for selection of prostate cancer patients for active surveillance**
By: [Radtke J.P.](#)¹, Kuru T.H.², Bonekamp D.³, Freitag M.³, Kesch C.¹, Wolf M.³, Alt C.⁴, Hatiboglu G.¹, Boxler S.⁵, Pahernik S.¹, Roth W.⁶, Roethke M.C.³, Schlemmer H-P.³, Hohenfellner M.¹, Hadaschik B.¹
Institutes:¹University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ²University Hospital Cologne, Dept. of Urology, Cologne, Germany, ³German Cancer Research Center, Dept. of Radiology, Heidelberg, Germany, ⁴Heinrich-Heine University, Dept. of Radiology, Düsseldorf, Germany, ⁵University Hospital Berne, Dept. of Urology, Berne, Switzerland, ⁶Heidelberg University, Dept. of Pathology, Heidelberg, Germany
- *956 **Stability of health-related quality of life of patients included in an active surveillance program for prostate cancer**
By: [De La Peña E.](#)¹, Guijarro A.¹, Hernández V.¹, Fernández E.², De La Morena J.M.¹, Pozo C.¹, Llorente C.¹
Institutes:¹Hospital Universitario Fundación Alcorcón, Dept. of Urology, Alcorcon, Spain, ²Hospital Universitario Fundación Alcorcón, Dept. of Research, Alcorcon, Spain
- *957 **A single center comparison between protocol based (PRIAS) and non-protocol based (ERSPC) prostate cancer active surveillance cohorts**
By: [Kalalahti L.](#), Vasarainen H., Rannikko A.
Institutes:Helsinki University Central Hospital and University of Helsinki, Dept. of Urology, Helsinki, Finland
- *958 **Integrating large datasets for the Movember Global Action Plan on active surveillance for low risk prostate cancer**
By: [Hulslen T.](#)¹, Obbink H.¹, Van Der Linden W.¹, De Jonge C.², Nieboer D.³, Bruinsma S.⁴, Roobol M.⁴, Bangma C.⁴
Institutes:¹Philips Research, Dept. of Professional Health Solutions & Services, Eindhoven, The Netherlands, ²Philips Research, Dept. of Data Science, Eindhoven, The Netherlands, ³Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands, ⁴Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands
- *959 **HAROW - a prospective non-interventional study comparing treatment options in localized prostate cancer: Observation of "active surveillance" patients with a mean follow up of 47.6 months**
By: [Herden J.](#)¹, Schnell D.², Weissbach L.²
Institutes:¹Universityhospital Cologne, Dept. of Urology, Cologne, Germany, ²Stiftung Männergesundheit, Fondation of Men's Health, Berlin, Germany
- 15:13 - 15:20 **Summary and context**
T. Pickles, Vancouver (CA)

TURP and enucleation: Tips and tricks

Poster Session 76

Monday, 14 March
14:00 - 15:30

Location: Room Stockholm (Hall B2, level 0)

Chairs: A. Descazeaud, Limoges (FR)
K.A.O. Tikkinen, Helsinki (FI)
H. Woo, Sydney (AU)

Aims and objectives of this presentation

Old and new technologies in prostate removal with a focus on large prostates will be discussed. Also the issue of octogenarians surgery will be discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *961 **Photoselective vaporisation of prostate (PVP) for urinary retention: Changing paradigm – effective in octagenarians and chronic urinary retention**
By: Omorphos S., Young M., Singh Mudhar G., Gogoi N.K.
Institutes: Mid-Yorkshire Hospitals Nhs Trust, Dept. of Urology, Wakefield, United Kingdom
- *962 **Photovaporization of prostate with the Greenlight® laser in octogerians: Results of a comparative, multicentric study**
By: Pradere B.¹, Peyronnet B.², Misraï V.³, Bruyère F.⁴
Institutes: ¹CHU de Tours, Hospital Bretonneau, Dept. of Urology, Tours, France, ²CHU Rennes, Dept. of Urology, Rennes, France, ³Clinique Pasteur, Dept. of Urology, Toulouse, France, ⁴CHU Tours, Dept. of Urology, Tours, France
- *963 **Holmium laser enucleation of the prostate versus open prostatectomy: A prospective cost analysis**
By: Pérez-Carral Garcia J.R.¹, Pozo Salido C.¹, Del Riego S.², Capitán Manjón C.¹, Sola Galarza I.¹, Llorente Abarca C.¹
Institutes: ¹Hospital Universitario Fundación Alcorcón, Dept. of Urology, Madrid, Spain, ²Hospital Universitario Fundación Alcorcón, Dept. of Accounting, Madrid, Spain
- *964 **A prospective, randomised trial comparing holmium laser enucleation of the prostate (HoLEP) to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: Two-year follow-up results**
By: Yuan Y., Zou X., Xiao R., Zhang G., Liu F., Liao Y.
Institutes: First Affiliated Hospital of Gannan Medical University, Dept. of Urology, Ganzhou, China
- *965 **Holmium laser enucleation of the prostate (HoLEP) as a day case surgery**
By: Comat V., Pierquet G., Bernhard J-C., Capon G., Pasticier G., Ferrière J-M., Robert G.
Institutes: Bordeaux Pellegrin University Hospital, Dept. of Urology, Bordeaux, France
- *966 **Efficacy of holmium laser enucleation of the prostate (HoLEP) in men with bladder outlet obstruction (BOO) and non-neurogenic bladder dysfunction: Results of prospective trial**
By: Pyun J.H., Cho S, Oh M.M., Kang S.G., Bae J.H., Kang S.H., Moon D.G., Cheon J., Kim J.J., Tae J.H., Lee J.G.
Institutes: Korea University College Medicine, Dept. of Urology, Seoul, South Korea
- *967 **An emerging HoLEP reality: 50 watt HoLEP surgery outcomes from a single unit in the UK**
By: Khan F.¹, Saleemi M.¹, Taneja S.¹, Alam A.¹, Al-Sheikh M.¹, Nunney I.²

Institutes:¹Luton and Dunstable Hospital NHS Foundation trust, Dept. of Urology, Luton, United Kingdom, ²Norwich Medical School, University of East Anglia, Dept. of Medical Statistics, Norwich, United Kingdom

*968

Pneumocystoscopy after morcellation of prostatic adenoma: A simple trick to reduce the risk of reintervention after HoLEP

By: Fiori C.¹, Pigato M.², Cossu M.¹, Guermani P.², Cattaneo G.¹, Amparore D.¹, Serra N.¹, Di Stasio A.¹, Ragni F.¹, Porpiglia F.¹

Institutes:¹San Luigi Gonzaga Hospital, Dept. of Urology, University of Turin, Orbassano Turin, Italy, ²Koelliker Hospital, Dept. of Urology, Turin, Italy

*969

Open prostatectomy versus 180-W XPS GreenLight laser vaporization: Long-term functional outcome for prostatic adenomas >80g

By: Lanchon C., Thuillier C., Fiard G., Descotes J-L., Rambeaud J-J., Long J-A.

Institutes:Grenoble University Hospital, Dept. of Urology, Grenoble, France

*970

For patients with smaller resection weight of transurethral resection of prostate, could combined incision of bladder neck lead to less acute urinary retention after surgery? A nationwide database study

By: Wei T-C., Lin T-P., Lin A., Chen K-K.

Institutes:Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan

*973

The effectiveness of Hemi TURP in treatment of very large BPH

By: Al Sudani M.¹, Al-Qassim Z.¹, Katmawi-Sabbagh S.², Uraiby J.³

Institutes:¹Kettering General Hospital, Dept. of Urology, Kettering, United Kingdom, ²St. George's Hospital, Dept. of Urology, London, United Kingdom, ³Kettering General Hospital, Dept. of Pathology, Kettering, United Kingdom

15:15 - 15:22

Summary and context

A. Descazeaud, Limoges (FR)

Nephron sparing surgery: Renal function preservation and outcome

Poster Session 77

Monday, 14 March
14:00 - 15:30

Location: Room Milan (Hall B2, level 0)

Chairs: A. Bex, Amsterdam (NL)

K. Touijer, New York (US)

Aims and objectives of this presentation

To discuss outcomes of nephron-sparing surgery with regard to kidney function and Long-term cardiovascular mortality.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *974 **Impact of preoperative proteinuria on postoperative renal functional outcome after open partial nephrectomy: A propensity score matching study**
By: Tachibana H., Takagi T., Iizuka J., Kondo T., Tanabe K.
Institutes: Tokyo Women's Medical University, Dept. of Urology, Tokyo, Japan
- *975 **Preoperative plasma fibrinogen level as a significant prognostic factor in patients with localized renal cell carcinoma after surgical treatment**
By: Lee H.¹, Oh J.J.¹, Byun S-S.¹, Lee S.E.¹, Kwak C.², Kim H.H.², Hong S.K.¹
Institutes:¹Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, South Korea, ²Seoul National University Hospital, Dept. of Urology, Seongnam, South Korea
- *976 **Predictors of overall and new-onset renal function impairment after partial nephrectomy: Results from two-years follow up of a prospective multicentre study (RECORD 1 project)**
By: Minervini A.¹, Mari A.¹, Campi R.¹, Novara G.², Antonelli A.³, Bertolo R.⁴, Bianchi G.⁵, Fiori C.⁴, Giancane S.¹, Longo N.⁶, Mirone V.⁶, Morgia G.⁷, Porpiglia F.⁴, Schiavina R.⁸, Serni S.¹, Simeone C.³, Sodano M.³, Rocco B.⁹, Terrone C.¹⁰, Carini M.¹
Institutes:¹University of Florence, Dept. of Urology, Florence, Italy, ²University of Padua, Dept. of Urology, Padua, Italy, ³Spedali Civili, Dept. of NephroUrology, Brescia, Italy, ⁴University of Turin, S.Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy, ⁵University of Modena, Dept. of Urology, Modena, Italy, ⁶University of Naples, Federico II, Dept. of Urology, Naples, Italy, ⁷Luna Foundation, - , Italy, ⁸University of Bologna, S. Orsola-Malpighi Hospital, Dept. of Urology, Bologna, Italy, ⁹University of Milan, IRCCS Ca' Granda Hospital, Dept. of Urology, Milan, Italy, ¹⁰A.O. Maggiore Della Carità Hospital, Dept. of Urology, Novara, Italy
- *977 **Nephron sparing surgery decreases other-causes mortality relative to radical nephrectomy only in specific subgroups of patients with renal cell carcinoma**
By: Larcher A.¹, Capitanio U.¹, Terrone C.², Dehò F.¹, Volpe A.², Antonelli A.³, Minervini A.⁴, Fiori C.⁵, Furlan M.³, Serni S.⁴, Carini M.⁴, Novara G.⁵, Porpiglia F.⁵, Simeone C.³, Fossati N.¹, Briganti A.¹, Montorsi F.¹, Bertini R.¹
Institutes:¹IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, ²University of Piemonte Orientale, Dept. of Urology, Novara, Italy, ³Università Degli Studi E Spedali Civili Di Brescia, Dept. of Urology, Brescia, Italy, ⁴Clinica Urologica I, Azienda Ospedaliera Universitaria Careggi, Università Degli Studi Di Firenze, Dept. of Urology, Florence, Italy, ⁵Azienda Ospedaliera Universitaria San Luigi Gonzaga, Dept. of Urology, Turin, Italy
- *978 **Diabetes mellitus as an independent predictor of survival of patients surgically treated for renal cell carcinoma: A propensity score matching study**
By: Lee H.¹, Song B.¹, Kwak C.², Kim H.H.², Byun S-S.¹, Lee S.E.¹, Kook H.R.¹, Hong S.K.¹

Institutes:¹Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, South Korea, ²Seoul National University Hospital, Dept. of Urology, Seoul, South Korea

- *979 **Assessment of long term functional outcomes in more than 1000 patients treated with minimally ischemic partial nephrectomy**
By: Simone G.¹, Misuraca L.¹, Papalia R.², Ferriero M.¹, Mastroianni R.², Minisola F.¹, Tuderti G.¹, Pompeo V.¹, Costantini M.¹, Guaglianone S.¹, Muto G.², Gallucci M.¹
Institutes:¹"Regina Elena" National Cancer Institute, Dept. of Urology, Rome, Italy, ²Campus Biomedico University, Dept. of Urology, Rome, Italy
- *980 **Zero ischemia resection of renal masses has no benefit on mid-term renal function: Results from a nephrometry matched pair analysis**
By: Kriegmair M.¹, Mandel P.², Huck N.¹, Fenner L.¹, Wagener N.¹, Michel M-S.¹, Pfalzgraf D.¹
Institutes:¹University Medical Center Mannheim, Dept. of Urology, Mannheim, Germany, ²University Medical Centre Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany
- *981 **Do we really need to perform partial nephrectomy with zero ischemia?**
By: Volkova M., Matveev V., Figurin K., Chernyaev V., Klimov A.
Institutes:N.N. Blokhin Russian Cancer Research Center, Dept. of Urology, Moscow, Russia
- *982 **Longitudinal preservation of renal function after clamp-less partial nephrectomy: An analysis of patients with chronic kidney disease**
By: Kawamura N., Yokoyama M., Fujii Y., Inoue M., Ito M., Yoshida S., Ishioka J., Numao N., Matsuoka Y., Saito K., Kihara K.
Institutes:Tokyo Medical and Dental University Graduate School, Dept. Of Urology, Tokyo, Japan
- *983 **Intraoperative, postoperative and functional outcomes of clampless laparoscopic partial nephrectomy (LPN) for renal tumours with high surgical complexity**
By: Chiancone E.¹, Fedelini P.², Meccariello C.², Fedelini M.², Carrino M.², Giannella R.², Venturino L.¹, Verze P.¹, Imbimbo C.¹, Mirone V.¹
Institutes:¹University of Naples Federico II, Dept. of Urology, Naples, Italy, ²A.O.R.N. A. Cardarelli, Dept. of Urology, Naples, Italy
- *984 **Partial nephrectomy shows significant benefit over radical nephrectomy in older patient and patients with arterial hypertension**
By: Pop D.¹, Bütow Z.¹, Elsäßer J.¹, Saar M.¹, Heinzlbecker J.¹, Ohlmann C.¹, Siemer S.¹, Gräber S.², Stöckle M.¹, Janssen M.¹
Institutes:¹UKS Universitätsklinikum des Saarlandes, Dept. of Urology and Child Urology, Homburg/Saar, Germany, ²UKS Universitätsklinikum des Saarlandes, Institute Medical Biometric, Epidemiology and Medical Information, Homburg/Saar, Germany
- *985 **Value of partial nephrectomy across the tumour size spectrum: A risk-benefit analysis of renal function preservation versus increased morbidity**
By: Vilaseca Cabo A.¹, Guglielmetti G.¹, Vertosick E.², Sjoberg D.², Grasso A.¹, Benfante N.², Coleman J.¹, Russo P.¹, Vickers A.², Touijer K.¹
Institutes:¹Memorial Sloan-Kettering Cancer Center, Dept. of Urology, New York, United States of America, ²Memorial Sloan-Kettering Cancer Center, Epidemiology and Biostatistics, New York, United States of America
- 15:11 - 15:18 **Summary and context**
 K. Touijer, New York (US)

The lazy and the lively bladder

Poster Session 78

Monday, 14 March
14:00 - 15:30

Location: Room 14a (ICM, Level 1)

Chairs: F. Bagheri, Dubai (AE)
K. Monastyrskaya, Berne (CH)
T. Tarcan, Istanbul (TR)

Aims and objectives of this presentation

Overview of new developments in the under- and overactive detrusor

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *986 **The histopathologic and pharmacodynamic effects of intradetrusor decorin injection for partial bladder outlet obstruction model of rabbits**
By: [Kaya E.](#)¹, Kibar Y.¹, Yilmaz S.¹, Ebiloglu T.², Ozcan A.³, Seyrek M.⁴, Yildiz O.⁴
Institutes:¹Gulhane Military Medical Academy, Dept. of Urology, Ankara, Turkey, ²Etimesgut Military Hospital, Dept. of Urology, Ankara, Turkey, ³Gulhane Military Medical Academy, Dept. of Pathology, Ankara, Turkey, ⁴Gulhane Military Medical Academy, Dept. of Medical Pharmacology, Ankara, Turkey
- *987 **Association between free flow and bladder outlet obstruction index and bladder contractility index**
By: [Abdelmoteleb H.](#), Hashim H.
Institutes:Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom
- *988 **Defining urodynamic bladder outlet obstruction (BOO) and detrusor underactivity (DU), with a novel common for both genders nomogram**
By: [Mytilekas K.](#), Ioannidou E., Kalaitzi M., Georgopoulos P., Ioannidis E., Apostolidis A.
Institutes:Aristoteles University Thessalonikis, Dept. of Urology, Thessaloniki, Greece
- *989 **A novel non-invasive test for the evaluation of detrusor muscle reserve in young adult males to overcome outflow resistance**
By: Abdelmoula A.², [Shoukry M.S.](#)¹, Hassouna M.¹, Eid A.¹
Institutes:¹University of Alexandria, Dept. of Urology, Alexandria, Egypt, ²University of Tripoli, Dept. of Urology, Tripoli, Libya
- *990 **International Continence Society definition of detrusor underactivity; analysis of clinical parameters and comparison with contractility grading methods**
By: Ten Donkelaar C.S., [Rosier P.F.W.M.](#), De Kort L.M.O.
Institutes:University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands
- *991 **Using the degree of bladder outlet obstruction to predict bladder contractility in men**
By: [Abrams P.](#)¹, Gammie A.¹, Kaper M.², Dorrepaal C.², Kos T.²
Institutes:¹Bristol Urological Institute, Dept. of Urodynamics, Bristol, United Kingdom, ²Astellas Pharma Europe B.V., Therapeutic Area Urology, Leiden, The Netherlands
- *992 **Glycemic control is associated with the prevalence of overactive bladder (OAB) and lower urinary tract symptoms (LUTS) but also with the management of LUTS in diabetic patients: A controlled study**
By: Tsilioni A.², Tsanikidis H.², Georgopoulos P.¹, Kazakos K.³, [Apostolidis A.](#)¹
Institutes:¹Aristotle University of Thessaloniki, Dept. of Urology, Thessaloniki, Greece, ²General

Hospital of Katerini, Dept. of Internal Medicine, Katerini, Greece, ³Alexandreion Technological Institute, Dept. Nursing, Thessaloniki, Greece

- *993 **Role of phosphodiesterase 5 inhibitors in the treatment of over-active bladder in older patients**
By: [Dell'Atti L.](#), Ughi G., Capparelli G., Papa S., Fornasari L., Ippolito C.
Institutes: University Hospital "St. Anna", Dept. of Urology, Ferrara, Italy
- *994 **Inhibition of smooth muscle contraction by the inhibitor for cytohesin family guanosine nucleotide exchange factors, secin H3 in the hyperplastic human prostate**
By: [Hennenberg M.](#), Keller P., Schott M., Tamalunas A., Ciotkowska A., Rutz B., Waidelich R., Strittmatter F., Stief C., Gratzke C.
Institutes: LMU Munich, Dept. of Urology, Munich, Germany
- *995 **The patient experience of underactive bladder**
By: [Uren A.](#)¹, Cotterill N.¹, Harding C.², Hillary C.³, Chapple C.³, Klaver M.⁴, Bongaerts D.⁴, Hakimi Z.⁴, Abrams P.¹
Institutes:¹Bristol Urological Institute, Southmead Hospital, Bristol, United Kingdom, ²Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, ³Royal Hallamshire Hospital, Dept. of Urology, Sheffield, United Kingdom, ⁴Astellas, Astellas Pharma B.V., Leiden, The Netherlands
- *996 **MicroRNA biomarkers of urodynamically-defined states of bladder outlet obstruction-induced lower urinary tract dysfunction**
By: [Hashemi Gheinani A.](#)¹, Burkhard F.C.², Rehrauer H.³, Aquino Fournier C.³, Keller I.³, Bruggmann R.⁴, Monastyrskaya K.¹
Institutes:¹Urology Research Laboratory, Dept. of Clinical Research, Berne, Switzerland, ²University Hospital Berne, Dept. of Urology, Berne, Switzerland, ³Functional Genomics Center, Zurich, Switzerland, ⁴University of Berne, Interfaculty Bioinformatics Unit, Berne, Switzerland
- *997 **Prediction of sacral neuromodulation treatment success in men with detrusor underactivity using a bladder outlet obstruction-tractility nomogram**
By: Rademakers K.¹, [Drossaerts J.](#)¹, Van Kerrebroeck P.¹, Oelke M.², Van Koeveringe G.¹
Institutes:¹Maastricht UMC+, Dept. of Urology, Maastricht, The Netherlands, ²Hanover Medical School, Dept. of Urology, Hanover, Germany
- *998 **Detrusor muscle reserve, do we have a definition?**
By: Abdelmoula A.², Shoukry M.¹, Hassona M.¹, [Abulfotooh Eid A.](#)¹
Institutes:¹University of Alexandria, Dept. of Urology, Alexandria, Egypt, ²University of Tripoli, Dept. of Urology, Tripoli, Libya
- *999 **How many days do patients with overactive bladder (OAB) receive treatment in real clinical practice? Comparison of anti-cholinergic agents and beta3-adrenergic receptor agonist**
By: [Ito N.](#), Hirobe M., Hashimoto J.
Institutes: Ntt-east Corporation Sapporo Medical Center, Dept. of Urology, Sapporo, Japan
- 15:19 - 15:26 **Summary and context**
 K. Monastyrskaya, Berne (CH)

Men's sexual health: Focus on premature ejaculation, hypogonadism and lower urinary tract and ejaculatory dysfunction

Poster Session 79

Monday, 14 March
14:00 - 15:30

Location: Room 14b (ICM, Level 1)

Chairs: B. Cuzin, Lyon (FR)
E.J.H. Meuleman, Amsterdam (NL)
A. Salonia, Milan (IT)

Aims and objectives of this presentation

The session will describe the most recent clinical evidence accumulated within the field of men's sexual health including the treatment of premature ejaculation and hypogonadism. The main aim is to leave the audience with ideas which can be implemented in the every day clinical practice.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *1000 **A prospective randomized study comparing the efficacy and safety of sildenafil with dapoxetine in treatment of premature ejaculation**
By: [Elbakary M.](#), Elgamasy A.E., Essa A., Elmattit S.
Institutes: Tanta University, Dept. of Urology, Tanta, Egypt
- *1001 **The efficiency and safety of tramadol, paroxetine and placebo in treatment of life long premature ejaculation**
By: Hamidi Madani A., [Motiee R.](#), Mokhtari G., Nasseh H., Esmaeili S., Kazemnezhad E.
Institutes: Urology Research Center, Guilan University of Medical Sciences, Dept. of Urology, Rasht, Iran
- *1002 **Effect of silodosin on premature ejaculation**
By: [Sato Y.](#)¹, Otani T.², Amano T.³, Araki T.⁴
Institutes: ¹Sanjukai Hospital, Dept. of Urology, Sapporo, Japan, ²Chubu Rosai Hospital, Dept. of Urology, Nagoya, Japan, ³Nagano Red Cross Hospital, Dept. of Urology, Nagano, Japan, ⁴Araki Kidney and Urology Department Clinic, Dept. of Urology, Kurashiki, Japan
- *1003 **A placebo controlled prospective randomized study to compare acupuncture and dapoxetine for treatment of lifelong premature ejaculation**
By: Sahin S.¹, Bicer M.², [Seker K.G.](#)¹, Yenice M.G.¹, Tugcu V.¹
Institutes: ¹Bakirkoy Dr.Sadi Konuk Training and Research Hospital, Dept. of Urology, Istanbul, Turkey, ²Bakirkoy Dr.Sadi Konuk Training and Research Hospital, Dept. of Physical Medicine and Rehabilitation, Istanbul, Turkey
- *1004 **Clinical study on the treatment of lifelong premature ejaculation with paroxetine hydrochloride and tamsulosin**
By: [Li Y-F.](#), Zhang C., Zhang K-Q., Jin F-S.
Institutes: Daping Hospital, Dept. of Urology, Chongqing, China
- *1005 **Long-term effects on urinary function in hypogonadal men treated with testosterone undecanoate injections (TU) vs untreated controls from a single urologist's office: Real-life data from a registry study**
By: [Haider A.](#)¹, Haider K.¹, Doros G.², Traish A.³
Institutes: ¹Private Urology Practice, Dept. of Urology, Bremerhaven, Germany, ²Boston University

School of Public Health, Dept. of Epidemiology and Statistics, Boston, United States of America,³
 Boston University School of Medicine, Dept. of Urology, Boston, United States of America

- *1006 **Can concomitant dutasteride reduce the effect of testosterone replacement therapy in men with late-onset hypogonadism? A 24-week, randomized, parallel study**
 By: Park H.J.¹, Park N.C.¹, Ha H.K.¹, Moon D.G.²
 Institutes:¹Pusan National University Hospital, Dept. of Urology, Busan, South Korea, ²Korea University Hospital, Dept. of Urology, Seoul, South Korea
- *1008 **The effect of testosterone replacement in men with testosterone deficiency syndrome on cognitive performance and depression**
 By: Shin H.S.¹, Park J.S.¹, Moon K.H.²
 Institutes:¹Catholic University of Daegu School of Medicine, Dept. of Urology, Daegu, South Korea, ²College of Medicine, Yeungnam University, Dept. of Urology, Daegu, South Korea
- *1009 **Testosterone deficiency is associated with increased aortic stiffness in hypertensive patients at low and moderate cardiovascular risk**
 By: Kratiras Z.¹, Makarounis K.¹, Ioakeimidis N.², Angelis A.², Sidiropoulos D.¹, Vlachopoulos C.², Tousoulis D.², Fasoulakis C.¹
 Institutes:¹Hippokration General Hospital, Dept. of Urology, Athens, Greece, ²Hippokration General Hospital, Medical School, University of Athens, 1st Dept. of Cardiology, Athens, Greece
- *1010 **Predictors of inadequate initial response to clomiphene citrate in the treatment of hypogonadism**
 By: Nimeh T.², Luján S.¹, Kathrins M.², Niederberger C.²
 Institutes:¹Hospital Universitari i Politècnic La Fe, Dept. of Urology, Valencia, Spain, ²University of Illinois at Chicago, Dept. of Urology, Chicago, United States of America
- *1011 **Study on the applied anatomy of the ejaculatory duct region**
 By: Li Y-E., Wang M-S., Zhang K-Q., Jin F-S., Jiang J.
 Institutes:Daping Hospital, Dept. of Urology, Chongqing, China
- *1012 **When does ejaculatory dysfunction recover after transrectal ultrasound guided prostate biopsy?**
 By: Song P.H., Lee K.S., Choi J.Y., Ko Y.H., Jung H.C., Moon K.H.
 Institutes:Yeungnam University, College of Medicine, Dept. of Urology, Daegu, South Korea
- *1013 **Does concomitant testosterone replacement improve the response of tadalafil 5 mg once daily in men with lower urinary tract symptoms?**
 By: Park H.J.¹, Park N.C.¹, Moon D.G.²
 Institutes:¹Pusan National University Hospital, Dept. of Urology, Busan, South Korea, ²Korea University Hospital, Dept. of Urology, Seoul, South Korea

Functional reconstruction of the urogenital tract

Poster Session 80

Monday, 14 March
14:00 - 15:30

Location: Room 14c (ICM, Level 1)

Chairs: M. Lu, Shanghai (CN)
T. Rashid, London (GB)
G.C. Teh, Kuching (MY)

Aims and objectives of this presentation

Functional reconstruction of the urogenital tract update

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *1014 **Functional outcomes of rendezvous procedure to treat complex ureteric discontinuities**
By: Mazzon G.¹, Choong S., Smith D., Allen S., Pallavi P., Bolgeri M., Dale R., Allen C., Ramachandran N., Philp T.
Institutes: University College Hospital, Dept. of Urology, London, United Kingdom
- *1015 **Transvesical laparoscopic surgery in complexed patients of vesicoureteral reflux with ureterovesical junction stenosis or complete double pelvis and ureter**
By: Naito Y.¹, Yamada Y.¹, Fujihara A.¹, Hongo F.¹, Naya Y.¹, Kamoi K.¹, Okihara K.¹, Kawauchi A.², Ukimura O.¹
Institutes:¹Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan, ²Shiga University of Medical Science, Dept. of Urology, Otsu, Japan
- *1016 **Are continent urinary diversions feasible at the time of radical cystectomy after pelvic radiotherapy? Analysis of a large retrospective multicenter series**
By: Pisano E.¹, Rink M.², Atiquallah A.², Fish M.², Joniau S.³, Albersen M.³, Battaglia A.¹, Destefanis P.¹, Colombo R.⁴, Briganti A.⁴, Pellucchi F.⁴, Burgio G.⁴, Van Rhijn B.⁵, Van De Putte E.E.F.⁵, Esquena S.⁶, Palou J.⁷, Babjuk M.⁸, Fritsche H.M.⁹, Mayr R.⁹, Albers P.¹⁰, Niegisch G.¹⁰, De La Taille A.¹¹, Masson-Lecomte A.¹¹, Roupret M.¹², Cai T.¹³, Witjes A.¹⁴, Bruins M.¹⁴, Baniel J.¹⁵, Mano R.¹⁵, Brausi M.¹⁶, Lapini A.¹⁷, Sessa F.¹⁷, Irani J.¹⁸, Stenzl A.¹⁹, Gakis G.¹⁹, Karnes J.²⁰, Zattoni F.²⁰, Scherr D.²¹, O'Malley P.²¹, Shariat S.⁷, Black P.²², Abdi H.²², Matveev V.⁷, Peters M.⁷, Samuseva O.⁷, Parekh D.²³, Gonzalgo M.²³, Gontero P.¹
Institutes:¹Azienda Ospedaliero Universitaria S. Giovanni Battista - Molinette, Dept. of Urology, Turin, Italy, ²Hamburg-Eppendor University Hospital, Dept. of Urology, Hamburg, Germany, ³Oncologic and Reconstructive Urology, University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁴URI, IRCCS Ospedale San Raffaele, Dept. of Oncology, Unit of Urology, Milan, Italy, ⁵Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Dept. of Surgical Oncology (Urology), Amsterdam, The Netherlands, ⁶Fundació Puigvert, Universitat Autònoma De Barcelona, Dept. of Uro Oncology, Barcelona, Spain, ⁷Dept of Urology and N.N. Blokhin Cancer Research Center, Dept. of Urology, Moscow, Russia, ⁸Hospital Motol and 2nd Faculty of Medicine, Charles University, Dept. of Urology, Prague, Czech Republic, ⁹Regensburg University, Dept. of Urology, Regensburg, Germany, ¹⁰Heinrich-Heine-University, Medical Faculty, Dept. of Urology, Dusseldorf, Germany, ¹¹CHU Mondor, Assistance Publique Des Hopitaux De Paris, Dept. of Urology, Paris, France, ¹²Hopital Pitié-Salpêtrière, Paris 6 University, Dept. of Urology, Paris, France, ¹³Osp. S. Chiara, Dept. of Urology, Trento, Italy, ¹⁴Radboud University Nijmegen Medical Centre, Dept. of Urology, Amsterdam, The Netherlands, ¹⁵Rabin Medical Centre, Dept. of Urology, Tel Aviv, Israel, ¹⁶Ospedale Di Carpi-Modena, Dept. of Urology, Carpi, Italy, ¹⁷AOU Careggi, University of Florence, Dept. of Urology, Florence, Italy, ¹⁸Centre Hospitalier Universitaire La Milétrie, University of Poitiers, Dept. of Urology, Poitiers, France, ¹⁹University Clinic of Tübingen, University of Tübingen, Dept. of Urology, Tübingen, Germany, ²⁰Mayo Clinic, Rochester, MN, Dept. of Urology, Rochester, United

States of America, ²¹Weill Medical College of Cornell University, Dept. of Urology, New York, United States of America, ²²Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada, ²³University of Miami Miller School of Medicine, Dept. of Urology, Miami, United States of America

- *1017 **Quality of life in 73 women with bladder cancer undergoing ileal orthotopic neobladder and ileal conduit: A multicentre study among long-term survivors**
By: Siracusano S.¹, Cerruto M.A.¹, Ciciliato S.², Gacci M.³, Simonato A.⁴, D'Elia C.¹, Porcaro A.B.¹, De Marco V.¹, Talamini R.⁵, Toffoli L.⁵, Saleh O.³, Visalli F.², Belgrano E.², Niero M.⁶, Lonardi C.⁶, Imbimbo C.⁷, Verze P.⁷, Racioppi M.⁸, Iafrate M.⁹, Cacciamani G.¹, De Marchi D.¹, Bassi P.⁸, Artibani W.¹
Institutes:¹University of Verona, Dept. of Urology, Verona, Italy, ²University of Trieste, Dept. of Urology, Trieste, Italy, ³University of Florence, Dept. of Urology, Florence, Italy, ⁴IRCCS San Martino, Dept. of Urology, Genova, Italy, ⁵IRCSS CRO, Dept. of Epidemiology and Biostatistics, Aviano, Italy, ⁶University of Verona, Dept. of TESIS, Verona, Italy, ⁷University of Naples, Dept. of Urology, Naples, Italy, ⁸Catholic University of Sacred Heart - Policlinico Gemelli, Dept. of Urology, Rome, Italy, ⁹University of Padua, Dept. of Urology, Padua, Italy
- *1018 **Predictors of bladder neck contracture following radical prostatectomy**
By: Viers B., Sharma V., Elliott D., Karnes R.J.
Institutes: Mayo Clinic, Dept. of Urology, Rochester, United States of America
- *1019 **Cystoscopic findings in pubic symphysis osteomyelitis**
By: Lavien G.D., Zaid U.B., Peterson A.C.
Institutes: Duke University Medical Center, Dept. of Urology, Durham, United States of America
- *1020 **Effect of unfavorable bladder and urethral condition on continence and complication rate of the primary artificial urinary sphincter for post-prostatectomy urinary incontinence**
By: Son H.S.¹, Soto Troya I.¹, Kim S.W.¹, Kim S.J.¹, Kim J.Y.¹, Kim H.W.², Rha K.H.¹, Kim J.H.¹
Institutes:¹Yonsei University College of Medicine, Dept. of Urology, Seoul, South Korea, ²Konyang University College of Medicine, Dept. of Urology, Daejeon, South Korea
- *1021 **The staged approach to artificial urinary sphincter implantation in complex cases**
By: Bugeja S., Ivaz S., Frost A., Fes E., Campos F., Andrich D., Mundy A.
Institutes: University College London Hospitals, Dept. of Reconstructive Urology, London, United Kingdom
- *1023 **High midline levator myorrhaphy for vaginal vault prolapse: Long-term results**
By: Wu Y.¹, Christie A.², Alhalabi F.², Zimmern P.¹
Institutes:¹UT Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ²UT Southwestern Medical Center, Dept. of Biostatistics, Dallas, United States of America
- *1024 **The cost effectiveness of vaginal versus abdominal repair of VVF**
By: Warner R., Grewal M., Beardmore-Gray A., Pakzad M., Hamid R., Ockrim J., Greenwell T.
Institutes: University College London Hospital, Dept. of Urology, London, United Kingdom
- *1026 **Bladder reconstruction using autologous peritoneum and ileal seromuscular flaps in porcine model**
By: Shen J.¹, Li S.², Wu J.², Shen H.², Song Z.¹, Huang C.¹, Zhang L.¹, Wang W.¹
Institutes:¹Tsinghua University, Medical Center, Beijing, China, ²The First Hospital of Tsinghua University, Dept. of Urology, Beijing, China
- *1027 **Augmentation of rat bladder with human amniotic membrane graft**
By: Barski D.¹, Gerullis H.², Winter A.², Pintelon I.³, Timmermans J-P.³, Ramon A.⁶, Boros M.⁴, Varga G.⁴, Otto T.⁵
Institutes:¹Lukas Hospital Neuss, Dept. of Urology, Neuss, Germany, ²School of Medicine and Health Sciences, Carl Von Ossietzky University, Dept. of Urology, Oldenburg, Germany, ³University of Antwerp, Dept. of Laboratory of Cell Biology and Histology, Antwerp, Belgium, ⁴University of Szeged, Dept. of Experimental Surgery, Szeged, Hungary, ⁵Lukas Hospital Neuss and German

Centre For Assessment and Evaluation of Innovative Techniques In Med, Dept. of Urology, Neuss, Germany, ⁶ITERA (International Tissue Engineering Research Association), University of Antwerp, Antwerp, Belgium

*1028

Estradiol releasing polylactic acid scaffolds stimulate blood vessel formation-towards better integration of biomaterials for pelvic floor repair

By: Mangir N.¹, Hillary C.², Roman S.³, Chapple C.², MacNeil S.³

Institutes:¹University of Sheffield, Dept. of Materials Science and Engineering, Sheffield, United Kingdom, ²Royal Hallamshire Hospital, Dept. of Urology, Sheffield, United Kingdom, ³University of Sheffield, Dept. of Materials Science Engineering, Sheffield, United Kingdom

Ureteroscopy: New technology and stents

Poster Session 81

Monday, 14 March
14:00 - 15:30

Location: Room Paris (Hall B2, level 0)

Chairs: M. Brehmer, Aarhus N (DK)
L. Cindolo, Vasto (IT)
P.J.S. Osther, Fredericia (DK)

Aims and objectives of this presentation

Ureteroscopy became the treatment of choice for most stones. Technology still advances rapidly and this session will give an update on latest developments in URS and stenting

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *1029 **Durability of flexible ureteroscopy and predictors of repair: A prospective multi-center study**
By: Chi T.¹, Usawachintachit M.¹, Chu C.¹, Allen I.¹, Xu A.¹, Duty B.², Sur R.³, Zaid U.¹, Ramaswamy K.¹, Sorensen M.⁴, Harper J.⁴, Stoller M.¹
Institutes:¹University of California, San Francisco, Dept. of Urology, San Francisco, United States of America, ²Oregon Health & Science University, Dept. of Urology, Portland, United States of America, ³University of California, San Diego, Dept. of Urology, La Jolla, United States of America, ⁴University of Washington, Dept. of Urology, Seattle, United States of America
- *1030 **Flexible ureteroscopy durability in the hands of UK surgeons: A snapshot**
By: Finch W.¹, Rukin N.², Kumar P.³, Wiseman O.⁴
Institutes:¹Norfolk and Norwich University Hospital, Dept. of Urology, Norwich, United Kingdom, ²New Cross Hospital, Dept. of Urology, Wolverhampton, United Kingdom, ³Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, ⁴Addenbrookes Hospital, Dept. of Urology, Cambridge, United Kingdom
- *1031 **Evaluation of a novel single use flexible ureteroscope**
By: Kaplan A.G.¹, Neisius A.³, Radvak D.², Shin R.¹, Ackerman A.J.¹, Chen T.T.¹, Dale J.¹, Scales, Jr. C.D.¹, Ferrandino M.N.¹, Simmons W.N.², Preminger G.M.¹, Lipkin M.E.¹
Institutes:¹Duke University Medical Center, Dept. of Urologic Surgery, Durham, United States of America, ²Duke University, Dept. of Mechanical Engineering and Materials Science, Durham, United States of America, ³Universitätsmedizin der Johannes Gutenberg-Universität, Dept. of Urology, Mainz, Germany
- *1032 **Prospective European multicentre clinical results of kidney stone treatment using the Avicenna Roboflex URS robot**
By: Klein J.-T.¹, Fiedler M.², Kabuki A.S.⁴, Saglam R.³, Rassweiler J.²
Institutes:¹Universitätsklinikum Ulm, Dept. of Urology & Pediatric Urology, Ulm, Germany, ²SLK-Klinikum Am Gesundbrunnen, Dept. of Urology & Pediatric Urology, Heilbronn, Germany, ³Saglam's Hospital, Dept. of Urology & Pediatric Urology, Ankara, Turkey, ⁴Medicana International Hospital, Dept. of Urology, Ankara, Turkey

*1033

Mechanisms relevant to therapy resistance in urothelial tumours

Poster Session 82

Monday, 14 March
14:00 - 15:30

Location: Room Vienna (Hall B2, level 0)

Chairs: R. Nawroth, Munich (DE)
E. Oosterwijk, Nijmegen (NL)

Aims and objectives of this presentation

Therapy resistance in prostate cancer develops as a result of activation of multiple signaling pathways. Understanding these mechanisms is a condition for a more efficient therapy. Several abstracts in this session will focus on experimental approaches to combat resistance.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

*1042

Association between PDL1 variants and muscle invasive bladder cancer prognosis

By: Masson-Lecomte A.J.A.M.¹, Pineda S.², Rava M.², Carrato A.³, Tàrdon A.⁴, Silverman D.⁵, Rothman N.⁵, Garcia-Closas M.⁵, Chanock S.⁵, Allory Y.⁶, Real F.X.⁷, Malats N.²

Institutes:¹Hôpitaux Universitaires Henri Mondor, Dept. of Urology, Créteil, France, ²CNIO, Dept. of Genetic and Molecular Epidemiology, Madrid, Spain, ³Ramon Y Cajal Hospital, Dept. of Oncology, Madrid, Spain, ⁴Oviedo University, Dept. of Preventive Medicine, Oviedo, Spain, ⁵NCI, Dept. of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, Maryland, United States of America, ⁶Hôpitaux Universitaires Henri Mondor, Dept. of Pathology, Créteil, France, ⁷CNIO, Dept. of Epithelial Carcinogenesis, Madrid, Spain

*1043

Pretreatment neutrophil-to-lymphocyte ratio predicts worse survival outcomes and advanced tumour staging in patients undergoing radical cystectomy for bladder cancer

By: Tan Y.G., Eu E., Huang H.H., Lau W.K.O.

Institutes: Singapore General Hospital, Dept. of Urology, Singapore, Singapore

*1044

Neutrophil-to-lymphocyte ratio as a prognostic factor for survival in patients with bladder cancer undergoing radical cystectomy

By: Jiménez Marrero P.¹, Perez Sanchez M.¹, Jorge Pérez N.¹, González J.M.², Kim Lee D.¹, Marrero Umpierrez N.¹, Hernández Hernández C.¹, Hernández Escobar S.¹, Marrero Dominguez R.¹

Institutes:¹University Hospital of Gran Canaria Dr. Negrín, Dept. of Urology, Las Palmas de Gran Canaria, Spain, ²University Hospital of Gran Canaria Dr. Negrín, Dept. of Research, Las Palmas de Gran Canaria, Spain

*1045

EpCAM (epithelial cell adhesion molecule) as the most common target for circulating tumor cells (CTC) identification: Comparison between manual and automated system of isolation and future prospective

By: Busetto G.M.¹, Giovannone R.¹, Antonini G.¹, Gazzaniga P.², Gentile V.¹, De Berardinis E.¹

Institutes:¹Sapienza Rome University Policlinico Umberto I, Dept. of Urology, Rome, Italy, ²Sapienza Rome University Policlinico Umberto I, Dept. of Molecular Medicine, Rome, Italy

*1046

Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma

By: Todenhöfer T.¹, Kamyabi A.¹, Hennenlotter J.², Seiler R.¹, McDonald P.³, Moskalev I.¹, Stewart C.¹, Gao J.¹, Bedke J.², Oo H.Z.¹, Fazli L.¹, Dedhar S.³, Stenzl A.², Black P.¹

Institutes:¹University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, ²Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany, ³British Columbia Cancer Research Centre, Dept. of Integrative Oncology, Vancouver, Canada

- *1047 **En bloc bipolar resection to optimize TURB samples for organotypic culture and development of targeted treatments in non-muscle invasive bladder cancer**
By: [Daniel G.](#)¹, Roumiguie M.², Fons P.³, Herbert C.⁴, Brousset P.¹, Mazerolles C.¹, Malavaud B.²
Institutes:¹Institut Universitaire Du Cancer, Dept. of Pathology, Toulouse, France, ²Institut Universitaire Du Cancer, Dept. of Urology, Toulouse, France, ³EVOTEC France, Clinical Translation Group, Toulouse, France, ⁴EVOTEC France, Dept. of Biology, Toulouse, France
- *1048 **Assessment of the efficacy of repeated instillations of TC-gel mixed with MMC in an invasive rat bladder cancer model**
By: [Van Valenberg F.J.P.](#)¹, Strauss-Ayali D.², Agmon-Gerstein Y.², Friedman A.², Arentsen H.C.¹, Witjes J.A.¹, Oosterwijk E.¹
Institutes:¹Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²UroGen Pharma Ltd., Intravesical Drug Delivery Solutions, Ra'anana, Israel
- *1049 **Benzyl isothiocyanate up-regulates miR-99a-5p and induces autophagy by suppressing mTOR expression**
By: Tsai T-F.¹, Lin J-F.², Lin Y-C.¹, [Chen H-E.](#)¹, Chou K-Y.¹, Hwang T.I.S.¹
Institutes:¹Shin Kong Wu Ho-Su Mem. Hospital, Dept. of Urology, Taipei, Taiwan, ²Shin Kong Wu Ho-Su Mem. Hospital, Central Laboratory, Taipei, Taiwan
- *1050 **Foxp3 interacts with and regulates HIF-1 α -VEGF signaling in human bladder cancer**
By: Tsai Y-S.¹, Kao Y-L.³, [Wu K-Y.](#)¹, Jou Y-C.², Chen S-Y.², Tsai H-T.³, Tzai T-S.³
Institutes:¹National Cheng Kung University Hospital, Dept. of Urology, Tainan, Taiwan, ²Christian Chia-Yi Hospital, Dept. of Urology, Chia-Yi, Taiwan, ³National Cheng Kung Hospital, Dept. of Urology, Tainan, Taiwan
- *1051 **Multiple drug induced feedback loops limit the efficacy of PI3K/AKT/mTOR inhibition as a therapy in bladder cancer**
By: Sathe A., Wong K.W., Oppolzer I., Von Busch M., Schmid S.C., Seitz A.K., Heck M.M., Gschwend J.E., Retz M., [Nawroth R.](#)
Institutes:Klinikum Rechts der Isar der Technischen Universität Muenchen, Dept. of Urology, Munich, Germany
- *1052 **Inhibition of cisplatin-induced autophagy enhances apoptotic cell death in human bladder cancer cells**
By: Hwang T.¹, Lin J-F.², Lin Y-C.¹, Tsai T-F.¹, [Chen H-E.](#)¹, Chou K-Y.¹
Institutes:¹Shin Kong Wu Ho-Su Mem. Hospital, Dept. of Urology, Taipei, Taiwan, ²Shin Kong Wu Ho-Su Mem. Hospital, Central Laboratory, Taipei, Taiwan
- *1053 **Endoplasmic reticulum stress as a putative mechanism for attenuated response to intravesical BCG in bladder cancer**
By: Lewicki P.¹, Liu H.¹, O' Malley P.¹, [Golombos D.](#)¹, Cubillos-Ruiz J.², Scherr D.¹
Institutes:¹Weill Cornell Medical College, Dept. of Urology, New York, United States of America, ²Weill Cornell Medical College, Dept. of Obstetrics and Gynecology, New York, United States of America

New technologies: Robotic and laparoscopic surgery

Poster Session 83

Monday, 14 March
14:00 - 15:30

Location: Room London (Hall B2, level 0)

Chairs: U. Nagele, Hall in Tirol (AT)
P. Chlosta, Cracow (PL)

Aims and objectives of this presentation

Several new approaches and techniques will be presented: new Alf-X robot, laparoscopic stapler, SITUS pyeloplasty and description of NOTES in urology.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *1054 **Validation of the European Association of Urology robotic training curriculum: Pilot study III**
By: Novara G.¹, Gandaglia G.¹, Ahmed K.², Dasgupta P.², Van Der Poel H.³, Mottrie A.¹
Institutes:¹OLV Vattikuti Robotic Surgery Institute, ORSI, Melle, Belgium, ²MRC Centre for Transplantation, Kings College London, Guy's Hospital, Dept. of Urology, London, United Kingdom, ³The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands
- *1055 **Robot-assisted laparoscopic partial nephrectomy with Alf-X Robot on pig model**
By: Bozzini G.¹, Seveso M.¹, Mandressi A.¹, Buffi N.², Lughezzani G.², Guazzoni G.², Taverna G.¹
Institutes:¹Humanitas Mater Domini, Dept. of Urology, Castellanza, Italy, ²Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy
- *1056 **Can maneuverability in the robot assisted laparoscopic stapler compensate for shorter stapler length?**
By: Kingo P.S.¹, Lam G.W.², Jensen J.B.¹
Institutes:¹Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ²Herlev University Hospital, Dept. of Urology, Herlev, Denmark
- *1057 **Laparoscopic single-incision triangulated umbilical surgery (SITUS) pyeloplasty: A description of our first 30 cases**
By: Schachtner J.R., Habicher M., Tokas T., Nagele U.
Institutes:Hall in Tirol General Hospital, Dept. of Urology, Hall in Tirol, Austria
- *1058 **Transvaginal natural orifice transluminal endoscopic surgery (NOTES) in urology: Report of 261 cases in a single center**
By: Zou X., Zhang G., Xiao R., Yuan Y., Wu G., Wang X.
Institutes:First Affiliated Hospital of Gannan Medical University, Dept. of Urology, Ganzhou, China
- *1059 **Indocyanine green fluorescence-guided sentinel lymph node (SLN) identification is an emerging and promising technique. Accurate staging of urologic cancer is enhanced by a thorough evaluation of the sentinel lymph nodes.**
By: Aoun F., Albisinni S., Biaou I., Zanaty M., Van Velthoven R.
Institutes:Institut Jules Bordet, Dept. of Urology, Brussels, Belgium
- *1060 **Magnetic resonance sentinel lymph node imaging in prostate cancer using intraprostatic injection of superparamagnetic iron oxide nanoparticles: The first in-human results**
By: Winter A.¹, Kowald T.², Paulo T.², Goos P.¹, Engels S.¹, Gerullis H.¹, Chavan A.², Wawroschek F.¹
Institutes:¹Carl Von Ossietzky University Oldenburg, School of Medicine and Health Sciences, Klinikum Oldenburg, University Hospital For Urology, Oldenburg, Germany, ²Klinikum Oldenburg,

Dept. of Diagnostic and Interventional Radiology, Oldenburg, Germany

- *1061 **Activated carbon fiber filter could reduce the risk of surgical smoke exposure during the laparoscopic surgery**
By: [Choi S.H.](#)¹, Chung J-W.¹, Lee J.N.¹, Ha Y-S.¹, Kim B.S.¹, Kim H.T.¹, Kim T-H.¹, Yoo E.S.¹, Kwon T.G.¹, Chung S.K.¹, Kim B.W.¹, Cho D-H.², Kim J.S.³
Institutes:¹Kyungpook University Hospital, Dept. of Urology, Daegu, South Korea, ²CHA Gumi Medical Center, Dept. of Urology, Gumi-Si, South Korea, ³Daegu Fatima Hospital, Dept. of Urology, Daegu, South Korea
- *1062 **Does 3D technology affect visual system?**
By: [Benedetto G.](#)¹, Nigro F.¹, Bartolomei L.², Pisani S.³, Minicucci N.⁴, Tasca A.¹
Institutes:¹Sant Bortolo Hopital, Dept. of Urology, Vicenza, Italy, ²Sant Bortolo Hopital, Dept. of Neurology, Vicenza, Italy, ³Optical Optometrist, , Milan, Italy, ⁴Neuroscience Institute, Dept. of CNR, Padua, Italy
- *1063 **Renal and adrenal mini-laparoscopy: A prospective multicentric study**
By: Breda A.⁷, [Territo A.](#)¹, Schwartzmann I.¹, Castellan P.¹, Freitas Rui A.¹, Álvarez Osorio J.L.², Amón-Sesmero J.H.³, Bellido J.A.⁴, Ramos E.⁵, Rengifo D.⁶, Peña J.A.¹, Villavicencio H.⁷
Institutes:¹Universitat Autònoma de Barcelona - Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ²Hospital Puerta Del Mar, Dept. of Urology, Cádiz, Spain, ³Hospital Rio Hortega, Dept. of Urology, Valladolid, Spain, ⁴Hospital General De Vic, Dept. of Urology, Vic, Spain, ⁵Hospital Universitario Marqués De Valdecilla, Dept. of Urology, Santander, Spain, ⁶Hospital Universitario Puerta De Hierro Majadahonda, Dept. of Urology, Madrid, Spain, ⁷Universitat Autònoma De Barcelona - Fundació Puigvert, Dept. of Urology, Barcelona, Spain

ESU Social Media Training

HOT 51

Monday, 14 March
14:00 - 14:45

Location: Room 0.305

Chair: A. Noon, Sheffield (GB)

Aims and objectives of this presentation

- EAU Congress Attendees will be instructed on how to harness professional Social Media to augment experience of professional meetings, follow urologic news feeds, and engage with the world-wide urologic community.
- Urologists who are expert in the use of Social Media will provide 45 minute small group hands-on workshops on the use of professional Social Media.
- Current Social Media users will have the opportunity to exchange expertise with other Social Media users during small group sessions.

H. Borgmann, Frankfurt (DE)

ESU/ESUT Hands-on training in Fluorescence guided laparoscopic surgery

HOT 62

Monday, 14 March
14:15 - 15:15

Location: Room Europe (Hall B0, level 0)

Chair: I.C. Acar, Ankara (TR)

Aims and objectives of this presentation

This course will be based on a brief presentations about intraoperative fluorescence imaging in urology and training on phantom setup.

Aims and objectives

- o The course aims to illustrate the concept of fluorescence guided surgery using near-infrared (NIR) imaging systems.
- o Provides hands-on with the latest NIR-camera system for laparoscopic surgery.
- o Teach the applications in urological surgery for NIR imaging.

P. Macek, Prague (CZ)

G. Pini, Cologno Monzese (MI) (IT)

Renal transplantation: Technical aspects, diagnosis and management of early and late urological complications

ESU Course 43

**Monday, 14 March
14:30 - 16:30**

Location: Room 5 (ICM, Level 0)

Chair: F.J. Burgos Revilla, Madrid (ES)

Aims and objectives of this presentation

Renal transplant is an essential part of Urology. The aims of the course are:

- To show surgical techniques of organ procurement in deceased and living donation settings
- To establish the basic principles for evaluation of candidates to donation and recipients of kidney graft
- To show the different approaches and surgical details of kidney transplant in conventional and complex recipients
- To review the algorithms for diagnosis and treatment of medical and surgical complications after kidney transplantation

14:30 - 16:30

Selection and urological preparation of transplant recipients; surgical aspects of nephrectomy in living and deceased donor

A.J. Figueiredo, Coimbra (PT)

14:30 - 16:30

Laparoscopic living donor nephrectomy: Technical aspects and controversies

F.J. Burgos Revilla, Madrid (ES)

14:30 - 16:30

Avoiding complications by proper techniques of renal transplantation; tricks and tips

A.J. Figueiredo, Coimbra (PT)

14:30 - 16:30

How to diagnose and manage postoperative and long-term complications following renal transplantation

F.J. Burgos Revilla, Madrid (ES)

Dealing with the challenge of infection in urology

ESU Course 44

Monday, 14 March
14:30 - 17:30

Location: Room 4 (ICM, Level 0)

Chair: F.M.E. Wagenlehner, Gießen (DE)

Aims and objectives of this presentation

This ESU course on infection diseases provides a broad, up to date coverage of the most important and recent problems of infectious diseases in urology. Antimicrobial resistance is one of the biggest worldwide challenges in medicine and gains increasing importance in urology. The management of infections in general and of urogenital tract infections especially, has been compromised by this rapid and continuous increase of antimicrobial resistance. Basic biologic principles and strategies to treat urogenital tract infections from benign infections to life threatening infections will be discussed in this workshop:

- Definitions and classifications of urogenital tract infections
- Diagnosis, treatment and prophylaxis strategies of urogenital tract infections
- Uncomplicated and recurrent cystitis
- Complicated urinary tract infections
- Urosepsis and Fournier gangrene
- Male genital tract infections

14:30 - 17:30

Classification of UTI and surgical field contamination categories as a basis for treatment and prophylaxis

Z. Tandođ du, Newcastle Upon Tyne (GB)

14:30 - 17:30

Low grade and recurrent UTI

F.M.E. Wagenlehner, Gießen (DE)

14:30 - 17:30

Male genital infections: Prostatitis, epididymitis and urethritis

T. Cai, Trento (IT)

14:30 - 17:30

Hospital acquired UTI and antibiotic resistance

Z. Tandođ du, Newcastle Upon Tyne (GB)

14:30 - 17:30

Perioperative prophylaxis with special focus on prostate biopsies, stone surgery and prosthesis implantation

T. Cai, Trento (IT)

14:30 - 17:30

Sepsis and Fournier’s gangrene

F.M.E. Wagenlehner, Gießen (DE)

Laparoscopic and robot-assisted laparoscopic radical cystectomy

ESU Course 45

Monday, 14 March
14:30 - 17:30

Location: Room 13a (ICM, Level 1)

Chair: N.P. Wiklund, Stockholm (SE)

Aims and objectives of this presentation

The course is Video based. The steps in the surgical treatment of muscle invasive bladder cancer by conventional laparoscopy and robot-assisted technique will be described. The surgical technique to perform Male and female cystectomy, lymph node dissection, urinary diversion with extracorporeal and intracorporeal technique, conduits as well as orthotopic neobladders, will be shown. Indications, contraindications, outcomes and handling of complications will be discussed.

- The surgical steps in nerve sparing and non-nerve sparing male cystectomy
- The surgical steps in female cystectomy with and without organ sparing technique
- The surgical steps in lymph node dissection during cystectomy
- The technique in urinary diversion, conduit and neobladder, with intra and extracorporeal technique
- Indications, outcomes and complications after minimally invasive cystectomy
- The handling of the most common complications after minimally invasive cystectomy.

14:30 - 17:30

Laparoscopic cystectomy in males (video based teaching)

14:30 - 17:30

Conventional laparoscopy

R.F. Van Velthoven, Brussels (BE)

14:30 - 17:30

Robot-assisted technique with nerve sparing technique

N.P. Wiklund, Stockholm (SE)

14:30 - 17:30

Laparoscopic cystectomy in Females (video based teaching)

14:30 - 17:30

Conventional cystectomy

J. Rassweiler, Heilbronn (DE)

14:30 - 17:30

Robot-assisted cystectomy with organ preservation

N.P. Wiklund, Stockholm (SE)

14:30 - 17:30

Laparoscopic lymph node dissection (video based teaching)

J. Rassweiler, Heilbronn (DE)

14:30 - 17:30

Laparoscopic urinary diversion (video based teaching)

14:30 - 17:30

Intracorporeal urinary diversion

R.F. Van Velthoven, Brussels (BE)

14:30 - 17:30

Intracorporeal urinary diversion

N.P. Wiklund, Stockholm (SE)

14:30 - 17:30

Extracorporeal urinary diversion

J. Rassweiler, Heilbronn (DE)

- 14:30 - 17:30** **Controversies in laparoscopic and robotic cystectomy challenge the expert**
- 14:30 - 17:30** **Oncological outcomes in laparoscopic cystectomy - Challenger**
R.F. Van Velthoven, Brussels (BE)
- 14:30 - 17:30** **Oncological outcomes in laparoscopic cystectomy - Pro**
N.P. Wiklund, Stockholm (SE)
- 14:30 - 17:30** **Complications and functional outcomes in laparoscopic cystectomy - challenger**
J. Rassweiler, Heilbronn (DE)
- 14:30 - 17:30** **Complications and functional outcomes in laparoscopic cystectomy - Pro**
N.P. Wiklund, Stockholm (SE)

Percutaneous nephrolithotripsy (PCNL)

ESU Course 46

Monday, 14 March
14:30 - 17:30

Location: Room 13b (ICM, Level 1)

Chair: E. Liatsikos, Patras (GR)

Aims and objectives of this presentation

Aims

Aim of this course is to describe in detail the surgical techniques of all available treatment options in percutaneous surgery of renal stones. In addition, to tips and tricks aiming into improving the efficacy of the operation, the most common complications associated with the procedure will be reviewed focusing on their prevention and proper management.

Objectives

- Describe the basic percutaneous nephrolithotripsy techniques
- Provide tips to improve the efficacy of the operation
- Provide evidence on the comparison of percutaneous with ureteroscopic and extracorporeal treatment options; Which approach for which stone.
- Describe associate complications including their management

14:30 - 17:30

PCNL instrumentation – Suite organisation, wires, dilators and lithotriptors

C.M. Scoffone, Turin (IT)

14:30 - 17:30

PCNL versus ESWL versus URS; The debate continues

T. Knoll, Sindelfingen (DE)

14:30 - 17:30

From Skin to Stone: Step-by-Step access using only fluoroscopy (Prone position)

E. Liatsikos, Patras (GR)

14:30 - 17:30

From Skin to Stone: Step-by-Step access using US and fluoroscopy (Supine position)

C.M. Scoffone, Turin (IT)

14:30 - 17:30

MiniPerc- Indications, equipment and technique

T. Knoll, Sindelfingen (DE)

14:30 - 17:30

Tips and tricks in PCNL

E. Liatsikos, Patras (GR)

14:30 - 17:30

Round Table: Complications of PCNL: Diagnosis, management, prevention

T. Knoll, Sindelfingen (DE)

E. Liatsikos, Patras (GR)

C.M. Scoffone, Turin (IT)

Evaluation of risk in comorbidity in uro oncology

ESU Course 47

Monday, 14 March
14:30 - 16:30

Location: Room 11 (ICM, Level 1)

Chair: N. Mottet, Saint-Étienne (FR)

Aims and objectives of this presentation

Senior adults represent a growing population with specific problems. Individual life expectancy is a key decision driver . . . provided it is approachable.

The key points to be covered are the following

- Age by itself is usually irrelevant, unlike comorbidities
- Survival predictive factor exist, combined in practical tools
- Reliable screening tools for geriatrician referral exist
- A multidisciplinary program with geriatricians is key

14:30 - 16:30

Introduction: Who we are, objectives

N. Mottet, Saint-Étienne (FR)

14:30 - 16:30

Senior adults: A growing population

S. O'Hanlon

14:30 - 16:30

Senior adults are undertreated

N. Mottet, Saint-Étienne (FR)

14:30 - 16:30

Age is not a key factor regarding major surgery (muscle invasive bladder experience)

N. Mottet, Saint-Étienne (FR)

14:30 - 16:30

Clinical cases (to set the scene): Evaluation of comorbidities in practice / individual life expectancy

N. Mottet, Saint-Étienne (FR)

S. O'Hanlon

14:30 - 16:30

How to evaluate individual life expectancy in practice

S. O'Hanlon

14:30 - 16:30

How to evaluate individual comorbidities in practice

S. O'Hanlon

14:30 - 16:30

An example of the added value of a dedicated program and its prerequisites / what to do in real life

S. O'Hanlon

14:30 - 16:30

Conclusion

N. Mottet, Saint-Étienne (FR)

Metastatic prostate cancer

ESU Course 48

Monday, 14 March
14:30 - 17:30

Location: Room 12 (ICM, Level 1)

Chair: K. Pummer, Graz (AT)

Aims and objectives of this presentation

The three lectures of ESU course 48 will provide comprehensive state-of-the-art information about currently available therapies for hormone-naïve and castration resistant prostate cancer, such as various forms of primary androgen deprivation, immunotherapy, chemotherapy, and therapies approved for CRPC. After the course, attendees should be able to adequately treat patients with metastatic prostate cancer at all disease stages.

14:30 - 17:30

First and second line hormonal therapy: What should be considered?

K. Miller, Berlin (DE)

14:30 - 17:30

What is the role of chemotherapy and immunotherapy in patients with CRPC?

G. Mickisch, Bremen (DE)

14:30 - 17:30

New therapeutic options for patients with CRPC – more possibilities, more questions?

K. Pummer, Graz (AT)

14:30 - 17:30

Case discussion

G. Mickisch, Bremen (DE)

K. Miller, Berlin (DE)

K. Pummer, Graz (AT)

Video and imaging urodynamics

ESU Course 49

Monday, 14 March
14:30 - 16:30

Location: Room 21 (ICM, Level 2)

Chair: G. Van Koeveringe, Maastricht (NL)

Aims and objectives of this presentation

This course aims to convey the additional value of the combination of imaging techniques with a urodynamic investigation. In addition to Radiological imaging, also other imaging techniques such as ultrasound will be discussed. The logistic requirements, equipment, preparation and personnel will be pointed out. The interpretation of the acquired data and trouble shooting tips and tricks will be explained by speakers experienced in the field of functional and neurourology.

M. Oelke, Hannover (DE)

14:30 - 16:30

Context and indications:

14:30 - 16:30

• What additional information does imaging bring?

14:30 - 16:30

• What imaging modalities may be combined with Urodynamics

14:30 - 16:30

• Who will benefit from Video / imaging urodynamics

M. Oelke, Hannover (DE)

G. Van Koeveringe, Maastricht (NL)

14:30 - 16:30

Technical aspects

14:30 - 16:30

• Setting up a unit

14:30 - 16:30

• Personnel requirements

14:30 - 16:30

• How to do a video urodynamic test

M. Oelke, Hannover (DE)

G. Van Koeveringe, Maastricht (NL)

14:30 - 16:30

Interpretation

14:30 - 16:30

• Real time interpretation

14:30 - 16:30

• What should be stored and how

M. Oelke, Hannover (DE)

G. Van Koeveringe, Maastricht (NL)

14:30 - 16:30

Trouble shooting

M. Oelke, Hannover (DE)

G. Van Koeveringe, Maastricht (NL)

14:30 - 16:30

Take home messages

M. Oelke, Hannover (DE)

G. Van Koeveringe, Maastricht (NL)

ESU/ESUT/EULIS Hands-on training in Ureterorenoscopy - Stone dusting

HOT 75

Monday, 14 March
14:30 - 16:00

Location: Room Africa (Hall B0, level 0)

Aims and objectives of this presentation

Ureteroscopy is an essential tool in the management of stone disease for all Endourologists. This hands-on-training course will provide a hands-on experience of the flexible and rigid Ureteroscopy procedures , by simulating the anatomy and the laser interaction in the Advanced Stone Trainer.

Course setup:

Real life interaction and haptic feedback.

An Operating Room-like experience using a real holmium laser system with a scope

Aims and objectives

- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of Laser stone dusting and fragmentation.

Target audience: Beneficial for novices wishing to learn Laser stone dusting and fragmentation and for experienced urologists wishing to train and teach the procedure.

M.B.K. Shaw, Newcastle-Upon-Tyne (GB)

ESU/ESUT Hands-on training in HoLEP

HOT 70

Monday, 14 March
14:30 - 16:00

Location: Room Africa (Hall B0, level 0)

Aims and objectives of this presentation

This hands-on-training course will provide a hands-on experience of the HoLEP procedure, by simulating the anatomy and the laser tissue interaction in the HoLEP training simulator. Innovative prostate model provides real life practice of the laser-tissue interaction and haptic feedback

Course setup:

An Operating Room-like experience using a real holmium laser system with a scope
Mimics the anatomy seen during the procedure and the procedure steps

Aims and objectives

- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of the HoLEP procedure.

E. Habib, Cairo (EG)

ESU Social Media Training

HOT 52

Monday, 14 March
15:00 - 15:45

Location: Room 0.305

Chair: A. Noon, Sheffield (GB)

Aims and objectives of this presentation

- EAU Congress Attendees will be instructed on how to harness professional Social Media to augment experience of professional meetings, follow urologic news feeds, and engage with the world-wide urologic community.
- Urologists who are expert in the use of Social Media will provide 45 minute small group hands-on workshops on the use of professional Social Media.
- Current Social Media users will have the opportunity to exchange expertise with other Social Media users during small group sessions.

H. Borgmann, Frankfurt (DE)

ESU/ESUT/EULIS Hands-on training in Ureterorenoscopy

HOT 28

Monday, 14 March
15:15 - 16:45

Location: Room North America (Hall B0, level 0)

Chair: B.K. Somani, Southampton (GB)

Aims and objectives of this presentation

Ureteroscopy is an essential tool in the management of stone disease for all Endourologists. This course will provide hands-on-training with tutor guided practical tips and tricks of doing ureteroscopy. Participants will get a chance to perform Semirigid and Flexible ureteroscopy in the models with a chance to navigate the pelvicalyceal system, stone manipulation and extraction.

Aims and objectives

- At the end of the course, the participants will be able to perform rigid and flexible ureteroscopy in the models
- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of basic and advanced ureteroscopy.

G.M. Kamphuis, Amsterdam (NL)

To be confirmed

To be confirmed

A. Ploumidis, Athens (GR)

E. Emiliani, Barcelona (ES)

To be confirmed

D. Djordjevic, Belgrade (RS)

UTUC: Diagnosis and management

ESU Course 50

Monday, 14 March
15:30 - 17:30

Location: Room 22 (ICM, Level 2)

Chair: S. Shariat, Vienna (AT)

Aims and objectives of this presentation

This course will address contemporary concepts and controversies in UTUC such as

- Accurate staging and its role in clinical decision making/risk stratification
- Risks, benefits, and side effects of current and novel therapeutic approaches including endoscopic and minimal-invasive surgery
- Optimal management of the bladder cuff as well as indication and extent of lymphadenectomy
- Systemic therapy for high-risk and metastatic patients

15:30 - 17:30

Epidemiology, diagnosis, evaluation

M. Rouprêt, Paris (FR)

15:30 - 17:30

Prognostic and predictive factors, pathology

S. Shariat, Vienna (AT)

15:30 - 17:30

Treatment of low risk cancer (high grade Ta, T1 and CIS)

M. Rouprêt, Paris (FR)

15:30 - 17:30

Treatment of localized high risk (invasive) and metastatic cancer

S. Shariat, Vienna (AT)

ESU/ESUT Hands-on training in Fluorescence guided laparoscopic surgery

HOT 63

Monday, 14 March
15:30 - 16:30

Location: Room Europe (Hall B0, level 0)

Chair: I.C. Acar, Ankara (TR)

Aims and objectives of this presentation

This course will be based on a brief presentations about intraoperative fluorescence imaging in urology and training on phantom setup.

Aims and objectives

- o The course aims to illustrate the concept of fluorescence guided surgery using near-infrared (NIR) imaging systems.
- o Provides hands-on with the latest NIR-camera system for laparoscopic surgery.
- o Teach the applications in urological surgery for NIR imaging.

P. Macek, Prague (CZ)

G. Pini, Cologno Monzese (MI) (IT)

New trends in stone surgery

Video Session 10

Monday, 14 March
15:45 - 17:15

Location: eURO Auditorium (Hall C1, Level 0)

Chairs: P.A. Geavlete, Bucharest (RO)
J-T. Klein, Heilbronn (DE)
O. Traxer, Paris (FR)

Aims and objectives of this presentation

This session is an update on nowadays stonesurgery – from stoneformation via challenging stonelocations including treatmentoptions to the latest brandnew equipment for effective stonetreatment

All presentations have a maximum lenght of 10 minutes, followed by 4 minutes of discussion.

- *V72 **Urine acidity is the most important factor in uric acid stone formation: An illustration**
By: Doizi S.¹, Hill K.², Poindexter J.², Pearle M.², Sakhaee K.², Maalouf N.²
Institutes:¹University of Texas Southwestern Medical Center, Dept. of Clinical Research, Dallas, United States of America, ²University of Texas Southwestern Medical Center, The Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, Dallas, United States of America
- *V73 **RIRS in lower calyx stones with infundibular stenosis**
By: Cepeda M., Amón J.H., Tapia A.M., Mainez A., De La Cruz B., Martínez-Sagarra J.M.
Institutes:Río Hortega University Hospital, Dept. of Urology, Valladolid, Spain
- *V74 **Differences between high-frequency and long-pulse laser lithotripsy – a practical explanation and an objective evaluation**
By: Kronenberg P.¹, Traxer O.²
Institutes:¹Hospital Prof. Doutor Fernando Fonseca, Dept. of Urology, Amadora, Portugal, ²Université Paris 6 Pierre Et Marie Curie – Hôpital Tenon, Dept. of Urology, Paris, France
- *V75 **Transurethral contact cysto- and ureterolithotripsy in a gas (CO2) medium**
By: Arzumanyan E.G., Glybochko P., Alyaev Y., Rapoport L.M., Tsarichenko D.G., Proskura A.
Institutes:l.m. Sechenov First Moscow Medical University, Moscow, Dept. of Urology, Moscow, Russia
- *V76 **A single-use disposable digital flexible ureteroscope (Lithovue™) compared to a non-disposable fibre-optic flexible ureteroscope in a live porcine model**
By: Wiseman O.¹, Keeley F.², Traxer O.³, Giusti G.⁴, Lipkin M.⁵, Preminger G.⁵
Institutes:¹Cambridge University Teaching Hospitals NHS Trust, Dept. of Urology, Cambridge, United Kingdom, ²Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom, ³Tenon Hospital, Dept. of Urology, Paris, France, ⁴Ospedale San Raffaele-Turro, Dept. of Urology, Milan, Italy, ⁵Duke University Medical Center, Dept. of Urology, Durham, United States of America
- *V77 **Evolution of the robotic assisted retrograde intra-renal surgery (RA-RIRS) with Avicenna Roboflex to improve functions and user friendliness**
By: Patel A.¹, Rassweiler J.², Klein J.⁷, Traxer O.³, Al Zarooni A.⁴, Geavlete P.⁵, Tokatli N.Z.¹², Giusti G.¹¹, Tugcu V.⁸, Imamoglu M.A.⁹, Muslumanoglu A.Y.¹⁰, Saglam R.⁶
Institutes:¹Barts Health Nhs Trust, Dept. of Urology, London, United Kingdom, ²SLK-Kliniken Heilbronn GmbH, Dept. of Urology, Heilbronn, Germany, ³Tenon University Hospital, Dept. of Urology, Paris, France, ⁴Sheikh Khalifa General Hospital, Dept. of Urology, Umm Al Quwain, United Arab Emirates, ⁵Saint John Emergency Clinical Hospital, Dept. of Urology, Bucharest, Romania, ⁶

Medicana International Ankara Hospital, Dept. of Urology, Ankara, Turkey, ⁷Ulm University Clinic, Dept. of Urology, Ulm, Germany, ⁸Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Dept. of Urology, Istanbul, Turkey, ⁹Diskapi Yildirim Beyazit Training and Research Hospital, Dept. of Urology, Ankara, Turkey, ¹⁰Bagcilar Training and Research Hospital, Dept. of Urology, Istanbul, Turkey, ¹¹San Raffaele Hospital, Dept. of Urology, Milan, Italy, ¹²Cankaya Private Doruk Hospital, Dept. of Urology, Ankara, Turkey

*V78

Challenging renal stone management during robotic pyeloplasty

By: Guzman S.², Susaeta R.³, Vera Veliz A.I.¹, Mercado A.¹, Palma C.¹, Kerkebe M.¹, Zambrano N.¹, Chiang H.¹

Institutes:¹Clinica Las Condes, Dept. of Urology, Santiago, Chile, ²Clinica Las Condes, Technical Director Center of Robotics, Dept. of Urology, Santiago, Chile, ³Clinica Las Condes, Dept. of Endourology and Stone Unit, Dept. of Urology, Santiago, Chile

*V79

Bipolar approach in ureteral stenosis

By: Geavlete P., Georgescu D., Multescu R., Mirciulescu V., Geavlete B.

Institutes: Saint John Clinical Emergency Hospital, Dept. of Urology, Bucharest, Romania

Advances in prostate cancer biomarker research

Poster Session 84

Monday, 14 March
15:45 - 17:15

Location: Room Madrid (Hall B2, level 0)

Chairs: M. Lazzeri, Florence (IT)
H.G. Lilja, New York (US)
T. Steuber, Hamburg (DE)

Aims and objectives of this presentation

There is an increasing interest in the role of truncated androgen receptors in prostate cancer. These potentially very important biomarkers have been identified in several publications, however scientific consensus has to be reached. In addition, controversies on activated transcription factors as biomarkers will be discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

16:08 - 16:18

Prostate cancer biomarkers: What's new?

H.G. Lilja, New York (US)

*1064

Delivery of precision medicine in advanced prostate cancer using circulating tumour cells

By: Rhee H.¹, Gunter J.², Javanovic L.², Williams E.², Hollier B.², Nelson C.², Vela I.¹

Institutes:¹Princess Alexandra Hospital/Queensland University of Technology, Dept. of Urology and Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia, ²Queensland University of Technology, Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia

*1065

Detection of AR-V7 in circulating tumour cells before ADT is a negative prognostic marker in castration-naïve men with metastatic prostate cancer

By: Josefsson A., Damber J-E., Welén K.

Institutes:Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Dept. of Urology, Gothenburg, Sweden

*1067

SIK2 is a novel secreted protein associated with a malignant phenotype in prostate cancer

By: Wadhwa K.¹, Bon H.², Holmes K.³, Warren A.⁴, Whittaker H.⁵, Kay J.⁵, Fryer L.², Neal D.², Gnanapragasam V.¹, Carroll J.³

Institutes:¹Academic Urology Group, Dept. of Urology, Cambridge, United Kingdom, ²Neal Laboratory, Dept. of Uro-Oncology, Cambridge, United Kingdom, ³Carroll Laboratory, Cambridge Institute CRUK, Cambridge, United Kingdom, ⁴Addenbrooke's Trust University of Cambridge, Dept. of Pathology, Cambridge, United Kingdom, ⁵Biomarker Group, Cambridge Institute CRUK, Cambridge, United Kingdom

*1068

Expression of pSTAT3 in prostate cancer metastases from different organs

By: Don-Doncow N.¹, Marginean F.¹, Morrissey C.², Hellsten R.¹, Bjartell A.¹

Institutes:¹Lund University Hospital, Dept. of Translational Medicine Malmö, Malmö, Sweden, ²University of Washington, Dept. of Urology, Seattle, United States of America

*1069

Intratumoral heterogeneity of mTOR-pathway parameters in prostate cancer

By: Schanz M.¹, Hennenlotter J.¹, Dlugosch J.¹, Kuehs U.¹, Dettmer M.², Schilling D.³, Schwentner C.¹, Stenzl A.¹, Todenhöfer T.¹

Institutes:¹Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany, ²Universitätsklinik Bern, Dept. of Pathology, Berne, Germany, ³Isar Klinikum, Dept. of Urology, Munich, Germany

- *1070 **Regenerating islet-derived related protein 4 as candidate of a novel biomarker in castration-resistant prostate cancer patients**
By: [Teishima J.](#)¹, Nagamatsu H.¹, Shoji K.¹, Yamanaka R.¹, Kobatake K.¹, Kitano H.¹, Goto K.¹, Shinmei S.¹, Hayashi T.¹, Oue N.², Yasui W.², Matsubara A.¹
Institutes:¹Institute of Biomedical and Health Sciences, Integrated Health Sciences, Hiroshima University, Dept. of Urology, Hiroshima, Japan, ²Institute of Biomedical and Health Sciences, Integrated Health Sciences, Hiroshima University, Dept. of Molecular Pathology, Hiroshima, Japan
- *1071 **The role of genomic classifier to assess post-operative metastatic risk for prostate cancer patients based on final pathology characteristics**
By: Woodlief T.L., [Rocco B.](#), Ramharack R., Gnpathi H., Ogaya G., Mouravieva V., Patel V.
Institutes:Florida Hospital, Global Robotics Institute, Celebration, United States of America
- *1072 **A 2-gene panel derived from prostate cancer-enhanced transcripts in whole blood is prognostic for survival and predicts treatment benefit in metastatic castration-resistant prostate cancer**
By: [Heck M.](#)¹, Thalgott M.¹, Schmid S.¹, Oh W.², Gong Y.², Wang L.³, Zhu J.³, Seitz A-K.¹, Porst D.¹, Höppner M.¹, Retz M.¹, Gschwend J.¹, Nawroth R.¹
Institutes:¹Klinikum Rechts der Isar der Technischen Universität Muenchen, Dept. of Urology, Munich, Germany, ²Mount Sinai Hospital, The Tisch Cancer Institute, Dept. of Hematology/Oncology, New York, United States of America, ³Mount Sinai Hospital, The Tisch Cancer Institute, Dept. of Genetic and Genomic Sciences, New York, United States of America
- *1073 **Prostate cancer copy number score predicts metastatic disease**
By: [Van Den Broeck T.](#)¹, Gevaert T.¹, Prekovic S.², Smeets E.², Helsen C.², Lambrechts D.³, Boeckx B.³, Joniau S.¹, Claessens F.²
Institutes:¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²KU Leuven, Laboratory of Molecular Endocrinology, Leuven, Belgium, ³KU Leuven, Laboratory For Translational Genetics, Vesalius Research Center, VIB, Leuven, Belgium
- *1074 **Microseminoprotein-beta expression in different stages of prostate cancer**
By: Sjöblom L.², Saramäki O.², Annala M.², Leinonen K.², Nättinen J.², Tolonen T.³, Wahlfors T.², Nykter M.², Bova G.², Schleutker J.⁴, [Tammela T.](#)¹, Lilja H.², Visakorpi T.²
Institutes:¹Tampere University Hospital, Dept. of Surgery, Tampere, Finland, ²University of Tampere, BioMediTech, Tampere, Finland, ³Fimlab Laboratories, Dept. of Pathology, Tampere, Finland, ⁴University of Turku, BioMediTech, Tampere, Finland
- *1075 **PD-L1 expression in castration-resistant prostate cancer (CRPC)**
By: [Fankhauser C.](#)¹, Schöffler P.², Gillissen S.³, Omlin A.³, Hermanns T.¹, Poyet C.⁴, Sulser T.¹, Moch H.⁴, Wild P.J.⁴
Institutes:¹University Hospital Zurich, Dept. of Urology, Zurich, Switzerland, ²Memorial Sloan Kettering Cancer Center, The Thomas Fuchs Lab, New York, United States of America, ³Cantonal Hospital, St. Gallen, Dept. of Medical Oncology and Hematology, St. Gallen, Switzerland, ⁴University Hospital Zurich, Institute of Surgical Pathology, Zurich, Switzerland

Minimally invasive treatment for BOO: Towards a new standard?

Poster Session 85

Monday, 14 March
15:45 - 17:15

Location: Room Stockholm (Hall B2, level 0)

Chairs: C. Gratzke, Munich (DE)
T.Y. Lee, Seoul (KR)
G.Y. Robert, Bordeaux CEDEX (FR)

Aims and objectives of this presentation

Recently a number of new methods for BOO removal have been evaluated. The session discusses if we are ready for them and which of them could possibly become a new standard?

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

*1076

Two year results of the BPH6 trial: A multi-center, prospective, randomized study of the prostatic urethral lift (PUL) vs transurethral resection of the prostate (TURP)

By: [Gratzke C.](#)¹, Barber N.J.², Speakman M.J.³, Berges R.⁴, Wetterauer U.⁵, Greene D.⁶, Sievert K-D.⁷, Chapple C.R.⁸, Montorsi F.⁹, Patterson J.M.⁸, Fahrenkrug L.¹⁰, Schoenthaler M.⁵, Sønksen J.¹⁰

Institutes:¹LMU-Klinikum der Universität München, Dept. of Urology, Munich, Germany, ²Frimley Park Hospital NHS Foundation Trust, Dept. of Urology, Surrey, United Kingdom, ³Musgrove Park Hospital, Dept. of Urology, Taunton, United Kingdom, ⁴PAN Klinik Köln, Dept. of Urology, Köln, Germany, ⁵University Hospital Freiburg, Dept. of Urology, Freiburg, Germany, ⁶City Hospitals Sunderland, Dept. of Urology, Sunderland, United Kingdom, ⁷University Clinic of Lubeck, Dept. of Urology, Lubeck, Germany, ⁸Sheffield Teaching Hospitals NHS Foundation Trust, Dept. of Urology, Sheffield, United Kingdom, ⁹Instituto San Raffaele, Dept. of Urology, Milan, Italy, ¹⁰Herlev Hospital, Dept. of Urology, Herlev, Denmark

*1077

Four year results from the largest, prospective, randomized study of prostatic urethral lift (PUL)

By: [Roehrborn C.](#)¹, Gange S.², Shore N.³, Giddens J.⁴, Bolton D.⁵, Cowan B.⁶, Cantwell A.⁷, McVary K.⁸, Chin P.⁹, Te A.¹⁰, Gholami S.¹¹, Rashid P.¹², Moseley W.¹³, Tutrone R.¹⁴, Freedman S.¹⁵, Incze P.¹⁶, Coffield K.¹⁷, Borges F.¹⁸, Rukstalis D.¹⁹

Institutes:¹University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, ²Western Urological Clinic, Dept. of Urology, Salt Lake City, United States of America, ³Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, ⁴Jonathan Giddens Medicine Professional Corporation, Dept. of Urology, Brampton, Canada, ⁵Austin Health, Dept. of Urology, Heidelberg, Australia, ⁶Urology Associates of Denver, Dept. of Urology, Englewood, United States of America, ⁷Advanced Urology Institute, Dept. of Urology, Daytona Beach, United States of America, ⁸Southern Illinois University School of Medicine, Dept. of Urology, Springfield, United States of America, ⁹Illawarra Urology, Dept. of Urology, Figtree, Australia, ¹⁰Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, ¹¹Urology Associates of Silicon Valley, Dept. of Urology, San Jose, United States of America, ¹²Urology Centre, Dept. of Urology, Port Macquarie, Australia, ¹³Genesis Research LLC, Dept. of Urology, San Diego, United States of America, ¹⁴Chesapeake Urology Research Associates, Dept. of Urology, Baltimore, United States of America, ¹⁵Sheldon J. Freedman, M.D., Ltd., Dept. of Urology, Las Vegas, United States of America, ¹⁶The Fe/Male Health Centres, Dept. of Urology, Oakville, Canada, ¹⁷Scott and White Healthcare, Dept. of Urology, Temple, United States of America, ¹⁸Pinellas Urology Inc., Dept. of Urology, St. Petersburg, United States of America, ¹⁹Wake Forest Baptist Health, Dept. of Urology, Winston Salem, United States of America

*1078

Combined urethral lift and resection of the prostate (CURP): A novel surgical treatment of LUTS secondary to benign prostatic enlargement with preservation of antegrade ejaculation

By: Schoenthaler M.¹, Sievert K-D.², Miernik A.¹, Hein S.¹, Kunit T.², Wilhelm K.¹
Institutes:¹University Medical Centre Freiburg, Dept. of Urology, Freiburg, Germany, ²Paracelsus Medical University Salzburg, Dept. of Urology, Salzburg, Austria

- *1079 **A randomized clinical trial comparing prostatic injection of botulinum neurotoxin type A (Botox®) to optimized medical therapy in patients with BPH-related LUTS: End-of-study results of the PROTOX trial**
 By: Delongchamps N.B.¹, Descazeaud A.², Benard A.³, Azzouzi R.⁵, Saussine C.⁶, De La Taille A.⁷, Desgrandchamp F.⁸, Faix A.⁹, Karsenty G.¹⁰, Georget A.³, Fourmarier M.¹¹, Robert G.⁴
Institutes:¹Cochin Hospital, Paris Descartes University, Dept. of Urology, Paris, France, ²Limoges University Hospital, Dept. of Urology, Limoges, France, ³Bordeaux University Hospital, Clinical Epidemiology Unit, Bordeaux, France, ⁴Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ⁵Angers University Hospital, Dept. of Urology, Angers, France, ⁶Strasbourg University Hospital, Dept. of Urology, Strasbourg, France, ⁷Henri-Mondor Hospital, University Paris-Est, Dept. of Urology, Créteil, France, ⁸Saint Louis Hospital, Paris Diderot University, Dept. of Urology, Paris, France, ⁹Montpellier University Hospital, Dept. of Urology, Montpellier, France, ¹⁰Hôpital De La Conception, Marseille University, Dept. of Urology, Marseille, France, ¹¹Centre Hospitalier Du Pays D'Aix, Dept. of Urology, Aix en Provence, France
- *1080 **Prostatic artery embolization vs conventional TUR-P in the treatment of benign prostatic hyperplasia: First results of a prospective, randomized non-inferiority trial**
 By: Abt D.¹, Hechelhammer L.², Müllhaupt G.¹, Kessler T.³, Schmid H-P.¹, Engeler D.S.¹, Mordasini L.¹
Institutes:¹Cantonal Hospital St. Gallen, Dept. of Urology, St. Gallen, Switzerland, ²Cantonal Hospital St. Gallen, Dept. of Radiology, St. Gallen, Switzerland, ³Balgrist University Hospital, Dept. of Neuro-Urology, Zürich, Switzerland
- *1081 **Prostatic artery embolization as an alternative treatment to remove catheter in patients with indwelling bladder catheter due to benign prostatic hyperplasia**
 By: Secco S.¹, Barbosa F.², Di Trapani D.¹, Migliorisi C.², Galfano A.¹, Carnevale F.C.³, Rampoldi A.G.², Bocciardi A.M.¹
Institutes:¹Niguarda Ca' Granda Hospital, Dept. of Urology, Milan, Italy, ²Niguarda Ca' Granda Hospital, Dept. of Interventional Radiology, Milan, Italy, ³University of Sao Paulo Medical School, InRad Institute, Sao Paulo, Brazil
- *1082 **First experiences of prostatic artery embolization for large benign prostatic hyperplasia ahead of a prospective randomized controlled trial**
 By: Niklas C.¹, Saar M.¹, Schneider G.², Siemer S.¹, Buecker A.², Stöckle M.¹, Massmann A.²
Institutes:¹UKS Universitätsklinikum des Saarlandes, Dept. of Urology and Pediatric Urology, Homburg, Germany, ²UKS Universitätsklinikum des Saarlandes, Dept. of Diagnostic and Interventional Radiology, Homburg, Germany
- *1083 **Multicenter experience of a novel treatment for BPH; aquablation - image guided robot-assisted water-jet ablation of the prostate: 1 Year follow-up**
 By: Anderson P.¹, Gilling P.², Tan A.³
Institutes:¹The Royal Melbourne Hospital, Dept. of Urology, Parkville, Australia, ²Tauranga Hospital, Dept. of Urology, Tauranga, New Zealand, ³The Mount Hospital, Dept. of Urology, Perth, Australia
- *1084 **Is absorption of irrigation fluid a problem in thulium laser vaporization of the prostate? A prospective investigation using the expired breath ethanol test**
 By: Schwab C.¹, Müllhaupt G.¹, Mordasini L.¹, Abt D.¹, Engeler D.¹, Gramann T.¹, Lüthi A.², Schmid H-P.¹
Institutes:¹Kantonsspital St. Gallen, Dept. of Urology, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, Dept. of Anesthesiology, St. Gallen, Switzerland
- *1085 **TES (thulium ejaculation sparing): Impact of thuep/thuvap on sexual outcomes**
 By: Carmignani L., Vizziello D., Signorini C., Ratti D., Marengi C., Finkelberg E., Nazzani S.,

Stubinski R., Casellato S., Picozzi S.

Institutes: Policlinico San Donato, Dept. of Urology, San Donato Milanese, Italy

*1086 **Thulium laser enucleation (thulep) versus transurethral resection of the prostate in saline (turis): A randomized prospective trial to compare intra and early postoperative outcomes**

By: Bozzini G.¹, Taverna G.¹, Seveso M.¹, De Francesco O.¹, Bono P.¹, Buffi N.², Guazzoni G.², Provenzano M.³, Mandressi A.¹

Institutes:¹Humanitas Mater Domini, Dept. of Urology, Castellanza, Italy, ²Humanitas Research Hospital, Dept. of Urology, Rozzano, Italy, ³Humanitas Research Hospital, Rozzano, Italy

*1087 **Surgical treatment of benign prostatic obstruction – consecutive real life data of 2648 patients**

By: Wölbling F., Brunken C., Gross A.J., Wülfing C., Bach T.

Institutes: Asklepios Hospitals Hamburg, Dept. of Urology, Hamburg, Germany

*1088 **Effects of 5 α -reductase inhibition on benign prostatic hyperplasia treated by photoselective vaporization prostatectomy with the 180 Watt GreenLight XPS laser system: Results from the GOLIATH population**

By: Brassetti A.¹, Bachmann A.², Tubaro A.³, Barber N.⁴, D'Ancona F.⁵, Muir G.⁶, Witzsch U.⁷, Grimm M.O.⁸, Benejam J.⁹, Stolzenburg J.U.¹⁰, Riddick A.¹¹, Pahernik S.¹², Roelink J.¹³, Ameye F.¹⁴, Saussine C.¹⁵, Bruyere F.¹⁶, Loidl W.¹⁷, Larner T.¹⁸, Gogoi N.¹⁹, Hindley R.²⁰, Muschter R.²¹, Thorpe A.²², Shrotri N.²³, Graham S.²⁴, Hamann M.²⁵, Miller K.²⁶, Schostak M.²⁷, Capitan C.²⁸, Knispel H.²⁹, Thomas A.³⁰

Institutes:¹Sant'andrea Hospital, "la Sapienza" University of Rome, Dept. of Urology, Rome, Italy, ²University Hospital Basel, University Basel, Dept. of Urology, Basel, Switzerland, ³Sant'Andrea Hospital, "la Sapienza" University of Rome, Dept. of Urology, Rome, Italy, ⁴Frimley Park Hospital, Dept. of Urology, Frimley, United Kingdom, ⁵Radboud University Nijmegen Medical Centre, Dept. of Urology, Nijmegen, The Netherlands, ⁶King's College Hospital and King's Health Partners, Dept. of Urology, London, United Kingdom, ⁷Krankenhaus Nordwest, Dept. of Urology, Frankfurt, Germany, ⁸University Hospital of Jena, Dept. of Urology, Jena, Germany, ⁹Hospital De Manacor, Dept. of Urology, Manacor, Spain, ¹⁰University of Leipzig, Dept. of Urology, Leipzig, Germany, ¹¹NHS Lothian, Dept. of Urology, Eningurgh, United Kingdom, ¹²University Hospital of Heidelberg, Dept. of Urology, Heidelberg, Germany, ¹³Ziekenhuis Groep Twente, Dept. of Urology, Almelo/Hengelo, The Netherlands, ¹⁴AZ Maria Middelaes Gent, Dept. of Urology, Ghent, Belgium, ¹⁵Nouvel Hopital Civil De Strasbourg, Strasbourg University, Dept. of Urology, Strasbourg, France, ¹⁶CHRU Bretonneau, Dept. of Urology, Tours, France, ¹⁷Krankenhaus Der Barmherzigen Schwestern, Dept. of Urology, Linz, Australia, ¹⁸Brighton and Sussex University Hospitals NHS Trust, Dept. of Urology, Brighton, United Kingdom, ¹⁹Pinderfield Hospital Mid Yorkshire NHS Trust, Dept. of Urology, Wakefield, United Kingdom, ²⁰Basingstoke and North Hampshire NHS Foundation Trust, Dept. of Urology, Hampshire, United Kingdom, ²¹Diakoniekrankenhaus Rotenburg, Dept. of Urology, Rotenburg, Germany, ²²Freeman Hospital Newcastle, Dept. of Urology, Newcastle upon Tyne, United Kingdom, ²³Kent and Canterbury Hospital, Dept. of Urology, Kent, United Kingdom, ²⁴Whipps Cross University Hospital, Barth Health, Dept. of Urology, London, United Kingdom, ²⁵Universitätsklinikum Schleswig-Holstein, Campus Kiel, Dept. of Urology, Kiel, Germany, ²⁶Charite, Dept. of Urology, Berlin, Germany, ²⁷University Hospital Magdeburg, Dept. of Urology, Magdeburg, Germany, ²⁸Hospital Universitario Fundacion Alcorcon, Dept. of Urology, Madrid, Spain, ²⁹Uro-Forschungs GmbH Im St. Hedwig Krankenhaus, Dept. of Urology, Berlin, Germany, ³⁰Princess of Wales Hospital, Dept. of Urology, Bridgend, United Kingdom

17:00 - 17:07

Summary and context

G.Y. Robert, Bordeaux CEDEX (FR)

The small renal mass: Surgery, ablation, complications and relapse

Poster Session 86

Monday, 14 March
15:45 - 17:15

Location: Room Milan (Hall B2, level 0)

Chairs: T.A. Leslie, Oxford (GB)
A. Volpe, Torino (IT)
S. Zastrow, Dresden (DE)

Aims and objectives of this presentation

Discussion of alternative treatment options and how to deal with complications and relapse.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *1089 **Changes in surgical treatment modalities for renal cell carcinoma \leq 7 cm; A Norwegian population based study 2008-2013**
By: Hjelle K.¹, Johannesen T.², Beisland C.¹
Institutes:¹Haukeland University Hospital, Dept. of Urology, Bergen, Norway, ²Cancer Registry of Norway, Oslo, Norway
- *1090 **Glomerular volumetric density is reduced after renal radio-frequency ablation as well as after warm ischemia**
By: Abreu L., Damasceno-Ferreira J., Pereira-Sampaio M., Gregório B., Costa W., Sampaio E., De Souza D.
Institutes:Rio de Janeiro State University, Dept. of Urogenital Research Unit, Rio de Janeiro, Brazil
- *1091 **Comparing zero ischemia laparoscopic radiofrequency ablation assisted tumor enucleation and laparoscopic partial nephrectomy for clinical T1a renal tumor: A randomized clinical trial**
By: Jiwei H., Zhang J., Wang Y., Kong W., Xue W., Liu D., Chen Y., Huang Y.
Institutes:Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China
- *1092 **Imperative indications of nephron sparing technique: Partial nephrectomy vs percutaneous ablative therapy**
By: Long J.-A.¹, Bernhard J.-C.², Bigot P.³, Paparel P.⁴, Boissier R.⁵, Rioux-Leclercq N.⁶, Albiges L.⁷, Bodin T.⁸, Nouhaud F.-X.⁹, Gimel P.¹⁰, Mejean A.¹¹, Roupert M.¹², Masson-Lecomte A.¹³, Grenier N.¹⁴, Cornelis F.¹⁴, Grassano Y.¹⁵, Comat V.¹⁵, Le Clerc Q.C.¹⁶, Rigaud J.¹⁶, Salomon L.¹³, Rambeaud J.-J.¹, Sengel C.¹⁷, Verhoest G.¹⁸, Patard J.-J.¹⁹, Bensalah K.¹⁸
Institutes:¹Grenoble University Hospital, Dept. of Urology, Grenoble, France, ²Bordeaux University Hospital, Dept. of Urology, Bordeaux, France, ³Angers University Hospital, Dept. of Urology, Angers, France, ⁴Lyon Sud University Hospital, Dept. of Urology, Lyon, France, ⁵La Conception University Hospital, Dept. of Urology, Marseille, France, ⁶Rennes University Hospital, Dept. of Pathology, Rennes, France, ⁷Institut Gustave Roussy, Dept. of Oncology, Paris, France, ⁸Centre Prado-Louvain, Dept. of Urology, Marseille, France, ⁹Rouen University Hospital, Dept. of Urology, Rouen, France, ¹⁰Medipole, Dept. of Urology, Cabestany, France, ¹¹Hopital Georges Pompidou, Dept. of Urology, Paris, France, ¹²La Pitie Hospital, Dept. of Urology, Paris, France, ¹³Mondor University Hospital, Dept. of Urology, Paris, France, ¹⁴Bordeaux University Hospital, Dept. of Radiology, Bordeaux, France, ¹⁵Bordeaux University Hospital, Bordeaux, France, ¹⁶Nantes University Hospital, Nantes, France, ¹⁷Grenoble University Hospital, Dept. of Radiology, Grenoble, France, ¹⁸Rennes University Hospital, Dept. of Urology, Rennes, France, ¹⁹Kremlin Bicêtre University Hospital, Dept. of Urology, Paris, France
- *1093 **Comparison of laparoscopic radio frequency ablation and partial nephrectomy for the treatment of**

cT1a renal masses

By: [Park J.M.](#)¹, Lim J.S.¹, Na Y.G.¹, Kim H.S.², Song K.H.¹

Institutes:¹Chungnam National University School of Medicine, Dept. of Urology, Daejeon, South Korea, ²Konkuk University Chung-Ju Hospital, Dept. of Urology, Chungju, South Korea

- *1094 **Outcomes after laparoscopic assisted renal cryoablation: A retrospective EuRECA multinational analysis**
By: [Nielsen T.K.](#)¹, Lagerveld B.W.², Keeley F.³, Lughezzani G.⁴, Sriprasad S.⁵, Barber N.J.⁶, Hansen L.U.⁷, Larcher A.⁴, Guazzoni G.⁴, Van Der Zee J.A.², Ismail M.³, Farrag K.⁵, Emara A.M.⁶, Lund L.⁷, Østraat Ø.⁸, Borre M.⁸
Institutes:¹Aarhus University Hospital, Dept. of Urology, Aarhus N, Denmark, ²Onze Lieve Vrouwe Gasthuis, Dept. of Urology, Amsterdam, The Netherlands, ³Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom, ⁴Istituto Clinico Humanitas, Dept. of Urology, Milan, Italy, ⁵Darent Vally Hospital, Dept. of Urology, Dartford, United Kingdom, ⁶Frimley Park Hospital, Dept. of Urology, Camberley, United Kingdom, ⁷Odense University Hospital, Dept. of Urology, Odense, Denmark, ⁸Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark
- *1095 **High nephrometry is an independent predictor for symptomatic renal pseudoaneurysms after open partial nephrectomy**
By: [Kriegmair M.C.](#)¹, Mandel P.², Rathmann N.³, Diehl S.J.³, Pfalzgraf D.¹, Ritter M.¹
Institutes:¹Universitätsmedizin Mannheim, Dept. of Urology, Mannheim, Germany, ²University of Hamburg, Dept. of Urology, Hamburg, Germany, ³Universitätsmedizin Mannheim, Dept. of Radiology, Mannheim, Germany
- *1096 **Risk factors for asymptomatic renal artery pseudoaneurysm after partial nephrectomy detected by enhanced CT in the early postoperative period**
By: [Takagi T.](#)¹, Kondo T.¹, Omae K.¹, Iizuka J.¹, Kobayashi H.¹, Hashimoto Y.¹, Morita S.², Tanabe K.¹
Institutes:¹Tokyo Women's Medical University, Dept. of Urology, Tokyo, Japan, ²Tokyo Women's Medical University, Dept. of Diagnostic Imaging and Nuclear Medicine, Tokyo, Japan
- *1098 **Pathogenesis, features and prognosis of renal relapse after partial nephrectomy**
By: [Antonelli A.](#)¹, Sodano M.¹, Tardanico R.², Furlan M.¹, Carobbio F.¹, Fisogni S.², Cozzoli A.¹, Zanutelli T.¹, Simeone C.¹
Institutes:¹Spedali Civili Di Brescia, Dept. of Urology, Brescia, Italy, ²Spedali Civili Di Brescia, Dept. of Pathology, Brescia, Italy
- *1099 **Recurrence and relapse after partial nephrectomy for small renal masses**
By: [Torres Gomez J.J.](#), Vilaseca A., Huguet J., Musquera M., Peri L., García-Cruz E., Ribal M.J., Alcaraz A.
Institutes:Universitary Clinic Hospital of Barcelona, Dept. of Urology, Barcelona, Spain
- *1100 **Management of follow-up detected potentially curable recurrence after (partial) nephrectomy in non-metastatic renal cell carcinoma (RCC) of low, intermediate and high risk**
By: Kuijpers Y.², Meijer R.², Bosch R.², Horenblas S.¹, [Bex A.](#)¹
Institutes:¹Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²University Hospital Utrecht, Dept. of Urology, Utrecht, The Netherlands
- *1101 **Metastatic capacity of T1a renal cell carcinoma**
By: Lee H.¹, [Kim T.J.](#)¹, Kwak C.², Kim H.H.², Lee S.E.¹, Byun S-S.¹, Hong S.K.¹
Institutes:¹Seoul National University Bundang Hospital, Dept. of Urology, Seongnam, South Korea, ²Seoul National University Hospital, Dept. of Urology, Seoul, South Korea
- 17:00 - 17:07 **Summary and context**
 T.A. Leslie, Oxford (GB)

LUTS dilemmas

Poster Session 87

Monday, 14 March
15:45 - 17:15

Location: Room 14a (ICM, Level 1)

Chairs: C. De Nunzio, Rome (IT)
B. Dybowski, Warsaw (PL)
P. Zimmern, Dallas (US)

Aims and objectives of this presentation

Diagnostic methods, new tools and theories on LUTS diagnosis and LUTS dysfunctions will be presented

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *1102 **Diagnostic accuracy of non-invasive penile cuff test for the assessment of bladder outlet obstruction comparing by pressure flow study in men with lower urinary tract symptom**
By: Ko K.J.¹, Yoo J.H.², Suh Y.S.², Sung H.H.², Lee K-S.²
Institutes:¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea
- *1103 **The seasonal variation of acute urinary retention secondary to benign prostatic hyperplasia**
By: Song J.M.¹, Kang T.W.¹, Chung H.², Lee C.M.¹, Ryang S.H.¹, Chung H.C.¹, Kim K.J.¹, Jung J.H.¹, Kim H.S.²
Institutes:¹Yonsei University College of Medicine, Dept. of Urology, Wonju, South Korea, ²School of Medicine, Konkuk University, Dept. of Urology, Chungju, South Korea
- *1104 **Are seasonal temperature and geographical difference influencing factor for incidence of overactive bladder in outpatient department? A research by using nation-wide database**
By: Lin C-C.¹, Chung H.J.¹, Huang Y.H.¹, Lin A.T.L.¹, Fan Y.H.¹, Chen K.K.¹, Chen T.Z.²
Institutes:¹Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, ²Taipei Veterans General Hospital, Dept. of Family Medicine, Taipei, Taiwan
- *1105 **Perceptual urgency sensation, differences between patients with overactive bladder and healthy volunteers**
By: Vrijens D.¹, Drossaerts J.¹, Leue C.², Van Koeveringe G.²
Institutes:¹Maastricht UMC+, Dept. of Urology, Maastricht, The Netherlands, ²Maastricht UMC+, Dept. of Psychiatry, Maastricht, The Netherlands
- *1106 **Urological dysfunctions in young women. "Is it an inheritance of childhood?"**
By: Illiano E.¹, Appignani A.², Giannitsas K.³, Balsamo R.⁴, Mirone V.⁵, Natale F.⁶, Mariuccia S.⁷, Carbone A.⁸, Palleschi G.⁸, Prestipino M.², Fragalà E.⁹, Filocamo M.T.¹⁰, Donata V.¹¹, Bini V.¹², Costantini E.¹³
Institutes:¹University Federico II of Naples, Dept. of Neuroscience, Reproductive Sciences and Dentistry, University Federico II of Naples, Naples, Italy, ²University of Perugia, Dept. of Pediatric Surgery, Perugia, Italy, ³Patras University Hospital, Dept. of Urology, Patras, Greece, ⁴Doctorate Research Program, Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, ⁵University Federico II of Naples, Dept. of Neuroscience, Reproductive Sciences and Dentistry, Naples, Italy, ⁶IDI-Hospital, Urogynecology San Carlo, Rome, Italy, ⁷Sapienza University, Umberto I Hospital, Dept. of Urology U.Bracci, Rome, Italy, ⁸Sapienza University, Dept. of Medical-Surgical Sciences and Biotechnologies, Latina, Italy, ⁹Romolo Hospital, Dept. of Urology, Rocca Di Neto, Italy, ¹⁰ASL CN1, Dept. of Urology, Savigliano, Italy, ¹¹University of Florence, Dept. of Urology,

Florence, Italy, ¹²University of Perugia, Dept. of Medicine Section of Internal Medicine Endocrine and Metabolic Sciences, Perugia, Italy, ¹³University of Perugia, Dept. of Surgical and Biomedical Sciences, Perugia, Italy

- *1108 **Urodynamic findings of female urethral diverticulum**
By: [Lin K-J.](#), Fan Y-H., Lin T-L.
Institutes: Taipei Veterans General Hospital, Dept. of Urology, Taipei City, Taiwan
- *1109 **Female urethral diverticula: Presenting features and symptomatic outcomes**
By: [Malde S.](#), Sihra N., Naseeri S., Pakzad M., Hamid R., Ockrim J., Greenwell T.
Institutes: University College London Hospital, Dept. of Urology, London, United Kingdom
- *1110 **A quality assessment of patient reported outcome measures for sexual function in neurological patients using the COSMIN checklist: A systematic review**
By: 't Hoen L.¹, [Groen J.](#)¹, Scheepe J.¹, Reuvers S.¹, Castro Díaz D.², Padilla Fernández B.², Del Popolo G.³, Musco S.³, Hamid R.⁴, Ecclestone H.⁴, Karsenty G.⁵, Phé V.⁵, Boissier R.⁵, Kessler T.⁶, Gross T.⁷, Schneider M.⁶, Pannek J.⁸, Blok B.¹
Institutes:¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²University Hospital of The Canary Islands, Dept. of Urology, Tenerife, Spain, ³Careggi University Hospital, Dept. of Neuro-Urology, Florence, Italy, ⁴London Spinal Injuries Centre, Dept. of Neuro-Urology, Stanmore, United Kingdom, ⁵Aix Marseille University, Dept. of Urology, Marseille, France, ⁶Spinal Cord Injury Center & Research, University of Zürich, Balgrist University Hospital, Dept. of Neuro-Urology, Zürich, Switzerland, ⁷University of Berne, Dept. of Urology, Berne, Switzerland, ⁸Swiss Paraplegic Center, Dept. of Neuro-Urology, Nottwil, Switzerland
- *1111 **Examination of the risk factors for pelvic floor descent in women using magnetic resonance images in the sitting posture**
By: [Ninomiya S.](#)¹, Okayama H.², Naito K.³, Nakanishi K.², Endo Y.², Morikawa S.²
Institutes:¹Kyoto University, Dept. of Nursing, Human Health Science, Kyoto, Japan, ²Shiga University of Medical Science, Dept. of Nursing, Shiga, Japan, ³Biwako Gakuin University, Dept. of Childhood Care, Faculty of Education Welfare, Shiga, Japan
- *1112 **Lower urinary tract symptoms in male BRCA mutation carriers**
By: Goldberg H., Mano R., Shavit Grievink L., Ozalvo R., Tuval S., Baniel J., [Margel D.](#)
Institutes: Rabin Medical Center, Dept. of Urology, Petah Tikva, Israel
- *1113 **Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: Do we need urodynamic investigation for outcome assessment?**
By: [Tornic J.](#)¹, Leitner L.², Koschorke M.¹, Walter M.¹, Knüpfer S.¹, Schneider M.P.³, Mehnert U.¹, Kessler T.M.¹
Institutes:¹Balgrist University Hospital, Neuro-Urology, Zürich, Switzerland, ²Balgrist University Hospital and University Hospital of Basel, Neuro-Urology/Urology, Zürich and Basel, Switzerland, ³ETH Zürich, Brain Research Institute, Zürich, Switzerland
- *1114 **Bladder diary filling rate in idiopathic OAB: A new variable to take into account?**
By: [Gomez de Vicente J.M.](#), López-Fando L., Orosa Andrada A., Donis F., Jiménez Cidre M., Burgos Revilla F.J.
Institutes: Hospital Ramón Y Cajal, Dept. of Urology, Madrid, Spain
- 17:00 - 17:07 **Summary and context**
P. Zimmern, Dallas (US)

Men's sexual health: Focus on erectile dysfunction and Peyronie's disease

Poster Session 88

Monday, 14 March
15:45 - 17:15

Location: Room 14b (ICM, Level 1)

Chairs: M. Fode, Herlev (DK)
G. Garaffa, London (GB)

Aims and objectives of this presentation

The session will describe the most recent clinical evidence accumulated within the field of men's sexual health including treatment of erectile dysfunction with low intensity shockwave therapy and intracavernous injection of adipose tissue.

Furthermore, the latest news in the treatment of Peyronies disease and sexual outcome after pelvic and abdominal surgery will be presented. The main aim is to provide the audience with ideas which can be implemented in the every day clinical practice.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *1115 **Low-intensity extracorporeal shock wave therapy for severe erectile dysfunction in poor responders to phosphodiesterase type-5 inhibitors: A short-term prospective study**
By: [Zewin T.](#), El-Assmy A., Harraz A., Elsherbini A., Musa Z., Bayoumi A., Al-Kenawy M., Sheir K., Shokeir A.
Institutes:Urology and Nephrology Center, Mansoura University, Dept. of Urology, Mansoura, Egypt
- *1116 **Use of stromal vascular fraction of adipose tissue in patients with vasculogenic erectile dysfunction: Evaluation of clinical effectiveness and safety (Preliminary results: Phases 1-2, 6 months of follow-up). NCT02472431**
By: Chalyy M., Epifanova M., [Krasnov A.](#)
Institutes:Research Institute For Uronephrology and Reproductive Health, Dept. of Urology, Moscow, Russia
- *1117 **Erectile dysfunction analysis using "Men's Sexual Medicine App®" users data**
By: [García-Cruz E.](#)¹, Verze P.², Tomada N.³, Albersen M.⁴, Carrión Puig A.¹, Florensa A.⁵, Garaffa G.⁶, Margreiter M.⁷, Romano B.⁸, Romero Otero J.⁹, Serefoglu E.C.¹⁰, Tomada I.¹¹, Alcaraz A.¹
Institutes:¹Hospital Clínic, Dept. of Urology, Barcelona, Spain, ²Universita Federico II, Dept. of Urology, Naples, Italy, ³Hospital Sao Joao, Dept. of Urology, Porto, Portugal, ⁴University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁵KOA, Dept. of Physical Exercise, Barcelona, Spain, ⁶Hospital of St John and St Elizabeth, Dept. of Urology, London, United Kingdom, ⁷Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁸Hospital Clínic, Dept. of Nutrition, Barcelona, Spain, ⁹Hospital 12 De Octubre, Dept. of Urology, Madrid, Spain, ¹⁰Bagcilar Research and Training Hospital, Dept. of Urology, Istanbul, Turkey, ¹¹CUF Porto Hospital, Dept. of Nutrition, Porto, Portugal
- *1118 **Sexual outcomes following treatment of abdominal aortic aneurysm, endovascular repair vs open surgery: A prospective study**
By: [Rebibo J-D.](#), Nouhaud F-X., Hourie A., Pfister C., Cornu J-N., Sibert L.
Institutes:CHU de Rouen, Hôpital Charles Nicolle, Dept. of Urology, Rouen, France
- *1119 **Predictors of recoverability of erectile function after urethroplasty**
By: [Behnsawy H.M.](#), Hassab El-Nabi A.
Institutes:Asyut University Hospital, Dept. of Urology, Asyut, Egypt
- *1120 **Spontaneous recovery of cavernous function after radical prostatectomy**

By: Miyake T.¹, Kawanishi Y.¹, Izumi K.¹, Muguruma H.¹, Sasaki Y.¹, Yura K.¹, Kishimoto T.¹, Yamanaka M.¹, Fukawa T.², Hiroomi K.²
Institutes:¹Takamatsu Red Cross Hospital, Dept. of Urology, Takamatsu, Japan, ²Tokushima University, Dept. of Urology, Tokushima, Japan

- *1121 **The impact of age difference between the patient and his female partner on the couple's sexual life after bilateral nerve sparing radical prostatectomy**
 By: Jordan T.B.¹, Dinkel A.², Gschwend J.E.³, Herkommer K.³
Institutes:¹Klinikum Rechts Der Isar Der Tu Muenchen, Dept. of Urology, Munich, Germany, ²Klinikum Rechts Der Isar Der TU Muenchen, Dept. of Psychosomatic Medicine and Psychotherapy, Munich, Germany, ³Klinikum Rechts Der Isar Der TU Muenchen, Dept. of Urology, Munich, Germany
- *1122 **Which factors influence female sexual function after repairing pelvic organ prolapse with mesh?**
 By: Azevedo N.¹, Carrasquinho E.², Cardoso De Oliveira E.², Branco F.⁴, Osório L.¹, Cavadas V.³, Fraga A.³
Institutes:¹Centro Hospitalar do Porto, Dept. of Urology, Porto, Portugal, ²Hospital Do Espírito Santo - Évora, Dept. of Urology, Évora, Portugal, ³Centro Hospitalar Do Porto, Dept. of Urology, Porto, Portugal, ⁴Hospital Da Prelada, Dept. of Urology, Porto, Portugal
- *1123 **Comparative analysis of surgery vs intralesional injection therapy for ventral Peyronie's disease**
 By: Hatzichristodoulou G.¹, Yafi F.², Knoedler C.², Trost L.³, Gschwend J.¹, Hellstrom W.²
Institutes:¹Technical University of Munich, University Hospital Klinikum Rechts Der Isar, Dept. of Urology, Munich, Germany, ²Tulane University School of Medicine, Dept. of Urology, New Orleans, United States of America, ³Mayo Clinic, Dept. of Urology, Rochester, United States of America
- *1124 **The Egydio geometrical procedure for managing penile curvature using a single relaxing incision: A single-centre experience with 330 patients**
 By: Konstantinidis K.¹, Fliatouras C.¹, Papatsoris A.², Drettas P.¹, Sofikitis N.³, Sofras F.⁴
Institutes:¹International Andrology, Dept. of Urology, Athens, Greece, ²University of Athens-Sismanogleio Hospital, Dept. of Urology, Athens, Greece, ³University of Ioannina, Dept. of Urology, Athens, Greece, ⁴University of Crete, Dept. of Urology, Athens, Greece
- *1125 **Italian registry for penile implants: The first European experience. Preliminary results**
 By: Pescatori E.¹, Franco G.², Caraceni E.³, Colombo F.⁴, Dehò F.⁵, Utizi L.³
Institutes:¹Hesperia Hospital, Andrology Service, Modena, Italy, ²Policlinico Umberto I°, Dept. of Urology, Rome, Italy, ³Area Vasta 3, Dept. of Urology, Civitanova Marche, Italy, ⁴Policlinico S.Orsola-Malpighi, Dept. of Andrology, Bologna, Italy, ⁵San Raffaele, Dept. of Urology, Milan, Italy
- *1126 **Correction of retrograde ejaculation in patients with diabetes mellitus using endourethral collagen injection: Preliminary results**
 By: Kurbatov D.¹, Russo G.L.², Galstyan G.¹, Rozhivanov R.¹, Lepetukhin A.¹, Dubsky S.¹, Shwartz Y.¹, Cimino S.², Morgia G.², Sansalone S.³
Institutes:¹Endocrinological Research Centre, Dept. of Andrological and Urological, Moscow, Russia, ²University of Catania, Dept. of Urology, Catania, Italy, ³Tor Vergata University of Rome, Dept. of Experimental Medicine and Surgery, Rome, Italy
- *1127 **Response of refractory category-III nonbacterial chronic prostatitis/chronic pelvic pain syndrome to intraprostatic injection of onabotulinumtoxinA**
 By: Abdel-Meguid T., Mosli H., Farsi H., Al-Sayyad A., Tayeb A., Sait M.
Institutes:King Abdulaziz University, Dept. of Urology, Jeddah, Saudi Arabia
- *1128 **The application of vesiculoscopy in the patients of hematospermia and ejaculatory duct obstruction (216 cases report)**
 By: Li Y-F., Liao L-G., Li B-J., Li K., Zhang K-Q., Jin F-S.
Institutes:Daping Hospital, Dept. of Urology, Chongqing, China

17:04 - 17:11

Summary and context
 G. Garaffa, London (GB)

Ureteroscopy: Has it reached the limit?

Poster Session 89

Monday, 14 March
15:45 - 17:15

Location: Room Paris (Hall B2, level 0)

Chairs: G. Giusti, Milan (IT)
I. Saltirov, Sofia (BG)

Aims and objectives of this presentation

Is URS the potential treatment of choice for all upper urinary tract stones and has it taken the places of PNL and SWL? This session focuses on outcomes of URS compared to its competitors

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *1129 **Emergency versus elective URS: What do the patients choose?**
By: [Malkhasyan V.](#)¹, Semenyakin I.², Ivanov V.³
Institutes:¹Moscow State University of Medicine and Dentistry, Dept. of Urology, Moscow, Russia, ²Moscow City Hospital, Dept. of Urology, Moscow, Russia, ³Moscow City Hospital, Dept. of Urology, Moscow, Russia
- *1130 **The surgical experience influences the safety but not efficacy of RIRS for kidney stones: A propensity score analysis**
By: [Berardinelli F.](#)¹, De Francesco P.¹, Cindolo L.¹, Pellegrini F.¹, Proietti S.², Pescechera R.², Dalpiaz O.³, Dennessy D.⁴, Cracco C.⁵, Scoffone C.⁵, Schips L.¹, Giusti G.⁶
Institutes:¹Ospedale S. Pio Da Pitrelcina, Dept. of Urology, Vasto, Italy, ²Humanitas Clinical and Research Center, Dept. of Urology, Stone Center, Rozzano, Italy, ³Medizinische Universität Graz, Dept. of Urology, Graz, Austria, ⁴Craigavon Area Hospital, Dept. of Urology, Portadown, United Kingdom, ⁵Ospedale Cottolengo, Dept. of Urology, Turin, Italy, ⁶Humanitas Clinical and Research Center, Stone Center At Department of Urology, Rozzano, Italy
- *1131 **To evaluate efficacy of mini-percutaneous nephrolithotomy and retrograde intrarenal surgery for stones 10-30 mm size**
By: [Sharma A.K.](#), Yadav R., Singh K., Gulia A., Dassi V., Chauhan U., Kumar A.
Institutes:Max Superspecialty Hospital, Dept. of Urology, Delhi, India
- *1132 **A randomized controlled trial comparing flexible ureteroscopy, semirigid ureteroscopy (URS) and extracorporeal shockwaves lithotripsy (SWL) for treatment of 0.5-1cm proximal ureteric stones**
By: [Abdulateef M.](#), Shoma A., Sheir K., El-Nahas A., Mansour A., Elshal A., Ibrahiem E-H.
Institutes:Mansoura University, Dept. of Urology, Mansoura, Egypt
- *1133

Urothelial tumours: New systemic treatment options and multidisciplinary management

Poster Session 90

Monday, 14 March
15:45 - 17:15

Location: Room Vienna (Hall B2, level 0)

Chairs: I. Duran, Seville (ES)
B.R. Konety, Minneapolis (US)
C.N. Sternberg, Rome (IT)

Aims and objectives of this presentation

This session will focus on new systemic treatment options with targeted agent and immunotherapy and the importance of multidisciplinary management.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- *1142
- Efficacy of atezolizumab (MPDL3280A) in platinum-treated metastatic urothelial carcinoma (mUC): Update from the IMvigor 210 phase II clinical trial**
By: Van Der Heijden M.¹, Retz M.², Perez-Gracia J.L.³, Necchi A.⁴, Powles T.⁵, Sridhar S.S.⁶, Neigisch G.⁷, Theodore C.⁸, Bracarda S.⁹, Duran I.¹⁰, Carles J.¹¹, Rosenberg J.¹², Dreicer R.¹³, Grande E.¹⁴, Cui N.¹⁵, Mariathasan S.¹⁵, Thåström A.¹⁵, Loriot Y.¹⁶
Institutes:¹The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ²Technische Universität München, Dept. of Urology, Munich, Germany, ³Clinica Universidad De Navarra, Dept. of Urology, Pamplona, Spain, ⁴Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, ⁵Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, ⁶University Health Network, Princess Margaret Cancer Center, Toronto, Canada, ⁷Universitätsklinikum Düsseldorf, Dept. of Urology, Düsseldorf, Germany, ⁸Hopital Foch, Dept. of Oncology, Suresnes, France, ⁹Ospedale San Donato, Istituto Toscano Tumori, Arezzo, Italy, ¹⁰Hospital Universitario Virgen Del Rocio, Dept. of Urology, Seville, Spain, ¹¹Vall D'Hebron University Hospital, Vall D'Hebron Institute of Oncology, Barcelona, Spain, ¹²Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, ¹³University of Virginia, Dept. of Hematology/Oncology, Charlottesville, United States of America, ¹⁴Hospital Universitario Ramón Y Cajal, Dept. of Urology, Madrid, Spain, ¹⁵Genentech, Inc., Dept. of Oncology, South San Francisco, United States of America, ¹⁶Gustave Roussy, Dept. of Oncology, Villejuif, France
- *1143
- A phase III study of the efficacy and safety of adjuvant atezolizumab (anti-PDL1) vs observation in patients with muscle-invasive urothelial carcinoma of the bladder (IMvigor 010)**
By: Castellano D.¹, Albers P.², Gschwend J.E.³, Culine S.⁴, Bullmunt J.⁵, Hussain M.⁶, Shen X.⁷, Nelson B.⁸, Powles T.⁹
Institutes:¹Hospital Universitario 12 De Octubre, Dept. of Oncology, Madrid, Spain, ²University of Düsseldorf, Dept. of Urology, Dusseldorf, Germany, ³Technical University of Munich, Dept. of Urology, Munich, Germany, ⁴Hôpital Saint-Louis, Dept. of Urology, Paris, France, ⁵Harvard Medical School, Bladder Cancer Center, Boston, United States of America, ⁶University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ⁷Genentech, Inc., Dept of Oncology, South San Francisco, United States of America, ⁸Genentech, Inc., Dept. of Oncology, South San Francisco, United States of America, ⁹Queen Mary University of London, Barts Cancer Institute, London, United Kingdom
- *1144
- A phase 2 study of the Aurora Kinase-A (AAK) tyrosine kinase inhibitor (TKI) alisertib (MLN8237) in patients (pts) with pre-treated urothelial cancer (UC)**
By: Necchi A.¹, Raggi D.¹, Lo Vullo S.², Mariani L.², Giannatempo P.¹, Calareso G.³, Togliardi E.⁴, Nicolai N.⁵, Perrone F.⁶, Pelosi G.⁶, Salvioni R.⁵, De Braud F.¹

Institutes:¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²Fondazione IRCCS - Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, ³Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, ⁴Fondazione IRCCS - Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, ⁵Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, ⁶Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy

- *1146 **FDG PET/CT imaging as a diagnostic tool for response evaluation in bladder cancer patients following neoadjuvant chemotherapy**
By: Fransen Van De Putte E.¹, Vegt E.², Mertens L.¹, Fioole-Bruining A.³, Van Der Heijden M.⁴, Horenblas S.¹, Van Rhijn B.¹
Institutes:¹The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, ²The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Dept. of Nuclear Medicine, Amsterdam, The Netherlands, ³The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Dept. of Radiology, Amsterdam, The Netherlands, ⁴The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Dept. of Medical Oncology, Amsterdam, The Netherlands
- *1147 **Neutrophil-to-lymphocyte ratio as a predictor of response to neo-adjuvant chemotherapy in muscle-invasive bladder cancer**
By: Van Kessel K.¹, De Haan L.², Fransen Van De Putten E.³, Van Rhijn B.³, De Wit R.⁴, Van Der Heijden M.⁵, Zwarthoff E.², Boormans J.¹
Institutes:¹Erasmus MC Cancer Institute, Erasmus Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC Cancer Institute, Erasmus Medical Center, Dept. of Pathology, Rotterdam, The Netherlands, ³Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept. of Surgical Oncology, Division of Urology, Amsterdam, The Netherlands, ⁴Erasmus MC Cancer Institute, Erasmus Medical Center, Dept. of Medical Oncology, Rotterdam, The Netherlands, ⁵Netherlands Cancer Institute, Dept. of Medical Oncology, Division of Molecular Carcinogenesis, Amsterdam, The Netherlands
- *1149 **Non-invasive characterization of metastatic urothelial carcinoma by next-generation sequencing of cell free DNA**
By: Todenhöfer T.¹, Volik S.¹, Eigl B.², North S.³, Brahmbhatt S.¹, Haegert A.¹, Stenzl A.⁴, Mischinger J.⁴, Le Bihan S.¹, Wyatt A.¹, Collins C.¹, Black P.C.¹
Institutes:¹University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, ²British Columbia Cancer Agency, Medical Oncology, Vancouver, Canada, ³University of Alberta, Medical Oncology, Edmonton, Canada, ⁴Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany
- *1150 **Adjuvant chemotherapy after radical cystectomy decreases mortality in locally advanced or lymph node positive tumours**
By: Fröhner M.¹, Koch R.², Heberling U.¹, Novotny V.¹, Oehlschlaeger S.¹, Wirth M.¹
Institutes:¹Technical University Dresden, Dept. of Urology, Dresden, Germany, ²Technical University Dresden, Dept. of Medical Informatics, Dresden, Germany
- *1151 **Gemcitabine plus paclitaxel as third-line chemotherapy: A feasible option for metastatic urothelial carcinoma patients**
By: Iida K., Nagai T., Etani T., Naiki T., Ando R., Kawai N., Tozawa K., Yasui T.
Institutes:Nagoya City University, Graduate School Of Medical Sciences, Dept. of Nephro-urology, Nagoya, Japan
- *1152 **Neoadjuvant chemotherapy before radical cystectomy in patients with urothelial carcinoma of the bladder: Current practice among clinicians**
By: Martini T.¹, Gilfrich C.², Deuschle F.¹⁸, Mayr R.³, Burger M.³, Pycha A.⁴, Aziz A.⁵, Gierth M.³, Stief C.G.⁶, Müller S.C.⁷, Wagenlehner F.⁸, Roigas J.⁹, Hakenberg O.W.¹⁰, Roghmann F.¹¹, Nuhn P.¹⁸, Wirth M.¹², Hadaschik B.¹³, Grimm M-O.¹⁴, Schramek P.¹⁵, Haferkamp A.¹⁶, Kloss B.¹⁷, Colleselli D.¹⁷, Herrmann E.¹⁹, Fisch M.⁵, May M.², Bolenz C.¹
Institutes:¹University of Ulm Medical School, Dept. of Urology, Ulm, Germany, ²Urologische Klinik, Klinikum St. Elisabeth Straubing, Dept. of Urology, Straubing, Germany, ³Caritas St. Josef Medical

Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, ⁴General Hospital of Bolzano, Dept. of Urology, Bolzano, Italy, ⁵University Medical Centre Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁶Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, ⁷Klinik Und Poliklinik Für Urologie Und Kinderurologie, Dept. of Urology, Bonn, Germany, ⁸Clinic For Urology, Pediatric Urology and Andrology, Justus-Liebig University, Giessen, Dept. of Urology, Giessen, Germany, ⁹Vivantes Medical Centre Im Friedrichshain and Am Urban, Berlin, Dept. of Urology, Berlin, Germany, ¹⁰University Hospital Rostock, Dept. of Urology, Rostock, Germany, ¹¹Marienhospital Herne, Ruhr-University Bochum, Dept. of Urology, Bochum, Germany, ¹²University Hospital "Carl Gustav Carus", Dresden University of Technology, Dept. of Urology, Dresden, Germany, ¹³University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, ¹⁴University Hospital of Jena, Dept. of Urology, Jena, Germany, ¹⁵Hospital Saint John of God Vienna, Dept. of Urology, Vienna, Austria, ¹⁶Goethe-University Frankfurt, Dept. of Urology, Frankfurt, Germany, ¹⁷Paracelsus Medical University, Salzburg, Dept. of Urology, Salzburg, Austria, ¹⁸Mannheim Medical Center, University of Heidelberg, Dept. of Urology, Mannheim, Germany, ¹⁹University of Münster, Münster, Dept. of Urology, Münster, Germany

16:58 - 17:05

Summary and context

I. Duran, Seville (ES)

Urethral strictures and urogenital reconstruction

Poster Session 91

Monday, 14 March
15:45 - 17:15

Location: Room London (Hall B2, level 0)

Chairs: M. Fisch, Hamburg (DE)
S.J. Hosseini, Tehran (IR)

Aims and objectives of this presentation

Overview of clinical and research aspects of urethral problems and urogenital reconstructions.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- *1153 **Endoscopic treatment of posterior urethral strictures following simple and radical prostatectomy: Success and incontinence rates**
By: [Rosenbaum C.M.](#)¹, Ludwig T.A.¹, Reiss C.P.¹, Salomon G.², Fisch M.¹, Ahyai S.A.³
Institutes:¹University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ²University Hospital Hamburg-Eppendorf, Martini-Clinic Prostate Cancer Center, Hamburg, Germany, ³University Medical Center Göttingen, Dept. of Urology, Göttingen, Germany
- *1154 **Is the laser mightier than the sword? A comparative study for the urethrotomy**
By: Holzhauser C., Roelofs A.W.T.M., [Kums A.C.](#), Weijerman P.C., van Balken M.R.
Institutes:Rijnstate Hospital, Dept. of Urology, Arnhem, The Netherlands
- *1155 **Penile prosthesis implantation after female to male total phallic reconstruction: A single-center retrospective analysis on 247 consecutive patients**
By: [Falcone M.](#)¹, Garaffa G.², Gillo A.³, Raheem A.², De Luca F.², Christopher A.N.², Ralph D.J.²
Institutes:¹University of Turin - Citta Della Salute E Della Scienza / UCLH, St. Peter's Andrology and The Institute of Urology, Turin, Italy, ²UCLH, St. Peter's Andrology and The Institute of Urology, London, United Kingdom, ³University of Turin, Dept. of Urology, Turin, Italy
- *1156 **Urethral reconstruction following artificial urinary sphincter cuff infection-erosion**
By: Martins F., Marcelino J., Sandul A., [Ribeiro De Oliveira T.](#), Oliveira P., Martinho D., Lopes T.
Institutes:University of Lisbon School of Medicine, Santa Maria Hospital, Dept. of Urology, Lisbon, Portugal
- *1157 **Tissue atrophy after artificial urinary sphincter AMS 800: Options of management and outcome**
By: [Sayed Ahmed K.](#), Kaftan B., Aragona M., Ekrutt J., Olianias R.
Institutes:Lueneburg Hospital, Dept. of Urology, Lueneburg, Germany
- *1158 **Kulkarni technique of perineal approach with penile inversion for surgical repair of anterior urethral strictures: Functional and cosmetic outcomes**
By: [Martins F.](#)¹, Kulkarni S.², Joshi P.², Marcelino J.¹, Ribeiro De Oliveira T.¹, Oliveira P.¹, Martinho D.¹, Martins N.³, Lopes T.¹
Institutes:¹University of Lisbon School of Medicine, Santa Maria Hospital, Dept. of Urology, Lisbon, Portugal, ²Kulkarni Reconstructive Urology Center, Dept. of Urology, Pune, India, ³Portalegre Hospital, Dept. of Urology, Portalegre, Portugal
- *1159 **Functional outcomes following penile fracture repair: A tertiary referral centre experience**
By: [De Luca F.](#)¹, Raheem A.A.¹, Zacharakis E.², Shabbir M.², Spilotros M.¹, Holden F.¹, Akers C.¹, Garaffa G.¹, Christopher N.¹, Ralph D.¹
Institutes:¹University College London Hospital, Dept. of Urology, London, United Kingdom, ²Guy's

Hospital, King's College London, Dept. of Urology, London, United Kingdom

- *1160 **A new technique of staged urethroplasty for complex penile strictures**
 By: Kulkarni S.¹, Barbagli G.², Joshi P.³
 Institutes:¹Kulkarni's Reconstructive Urology Centre, Dept. of Urology, Pune, India, ²Center For Reconstructive Urology, Dept. of Urology, Arezzo, Italy, ³Kulkarni's Reconstructive Urology Centre, Dept. of Urology, Pune, India
- *1161 **Augmented anastomosis versus graft onlay urethroplasty for repair of long bulbar stricture, a prospective comparative study**
 By: Hussein M., Gamal W., Salem E., Zaki M., Rashed A.
 Institutes:Sohag University Hospital, Dept. of Urology, Sohag, Egypt
- *1162 **Long term outcomes of a combined one and two stage urethroplasty for full length urethral stricture disease secondary to lichen sclerosis**
 By: Boxall N., Mangera A., Inman R., Chapple C.
 Institutes:Sheffield Teaching Hospitals Nhs Trust, Dept. of Urology, Sheffield, United Kingdom
- *1163 **The outcome of anterior urethroplasty after long term follow up**
 By: Hassab El-Nabi A.
 Institutes:Asyut University Hospital, Dept. of Urology, Asyut, Egypt
- *1164 **Complex genitourinary fistulae: A 10 year experience at a tertiary centre**
 By: Hillary C., Gulamhusein A., Inman R., Chapple C.
 Institutes:Sheffield Teaching Hospitals, Dept. of Reconstructive Urology, Sheffield, United Kingdom
- *1165 **Transperineal anastomotic urethroplasty on male traumatic urethral stricture in Hasan Sadikin Hospital, Bandung, Indonesia**
 By: Adi K., Agil A.
 Institutes:Hasan Sadikin Hospital, Dept. of Urology, Bandung, Indonesia
- *1166 **A novel use of methylene blue in anterior urethroplasty**
 By: Kulkarni S., Joshi P., Surana S., Homuda A.
 Institutes:Kulkarni's Reconstructive Urology Centre, Dept. of Urology, Pune, India
- *1167 **Excision of urethral diverticula in women: Risk factors for recurrence and de novo stress urinary incontinence**
 By: Beganović A., De Kort L., Bosch J.
 Institutes:University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands

ESU/ESUT/EULIS Hands-on training in Ureterorenoscopy - Stone dusting

HOT 76

Monday, 14 March
16:15 - 17:45

Location: Room Africa (Hall B0, level 0)

Aims and objectives of this presentation

Ureteroscopy is an essential tool in the management of stone disease for all Endourologists. This hands-on-training course will provide a hands-on experience of the flexible and rigid Ureteroscopy procedures , by simulating the anatomy and the laser interaction in the Advanced Stone Trainer.

Course setup:

Real life interaction and haptic feedback.

An Operating Room-like experience using a real holmium laser system with a scope

Aims and objectives

- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of Laser stone dusting and fragmentation.

Target audience: Beneficial for novices wishing to learn Laser stone dusting and fragmentation and for experienced urologists wishing to train and teach the procedure.

To be confirmed

ESU/ESUT Hands-on training in HoLEP

HOT 71

Monday, 14 March
16:15 - 17:45

Location: Room Africa (Hall B0, level 0)

Aims and objectives of this presentation

This hands-on-training course will provide a hands-on experience of the HoLEP procedure, by simulating the anatomy and the laser tissue interaction in the HoLEP training simulator. Innovative prostate model provides real life practice of the laser-tissue interaction and haptic feedback

Course setup:

An Operating Room-like experience using a real holmium laser system with a scope
Mimics the anatomy seen during the procedure and the procedure steps

Aims and objectives

- The participants will be able to interact with tutors and gain valuable insights into the tips and tricks of the HoLEP procedure.

E. Habib, Cairo (EG)

Urothelial cancer

Plenary Session 4

Tuesday, 15 March
08:00 - 13:15

Location: eURO Auditorium (Hall C1, Level 0)

Chairs: C.R. Chapple, Sheffield (GB)
A. Stenzl, Tübingen (DE)

Aims and objectives of this presentation

The last plenary session of the meeting is devoted to various aspects of urothelial cancer. This includes the treatment and classification of non-muscle invasive bladder cancer, major surgical treatment of advanced urothelial cancer in frail patients as well as systemic treatment of advanced disease and non-urothelial cancer. The traditional "Souvenir Session" will conclude the highlights of the 2016 meeting in Munich together with an outlook on various fields in urology for the upcoming years.

08:00 - 08:15

Société Internationale d'Urologie (SIU) lecture Non-urothelial bladder cancer

B.R. Konety

Aims and objectives of this presentation

Non-urothelial bladder cancer comprises approximately 5% of all bladder neoplasms in general. Most common non urothelial tumours include squamous cell carcinoma and adenocarcinoma. This presentation will discuss management of the various non-urothelial forms of bladder cancer and touch upon the distinction between pure non-urothelial tumours and histologic variants of urothelial bladder cancer which may have different biologic behavior and respond to different treatment approaches.

08:15 - 08:50

Point-counterpoint session TURBT: Is optical enhancement worth the trouble?

J.A. Witjes, Nijmegen (NL)

08:20 - 08:30

No

K. Thomas, London (GB)

08:30 - 08:40

Yes

P. Gontero, Turin (IT)

08:40 - 08:50

Future

M. Kramer, Lübeck (DE)

08:50 - 09:05

State-of-the-art lecture From new genetic and histological classifications to direct treatment

E. Compérat, Paris (FR)

Aims and objectives of this presentation

New molecular classifications have been discovered recently. Although these classifications are pathology independent, a link between morphology and molecular biology exists. The aim is to include these new findings into daily practice for a better and personalized treatment of our patients.

09:05 - 09:35

EAU Guidelines point-counterpoint session Single installation of chemotherapy post TURBT: Statistically significant and also clinically significant?

P-U. Malmström, Uppsala (SE)

09:05 - 09:20

Yes

R.J. Sylvester, Brussels (BE)

09:20 - 09:35

No

L. Türkeri, Istanbul (TR)

09:35 - 10:15

Case discussion Making cystectomy safe in the frail patient

C. Stief, Munich (DE)

09:35 - 09:45

Anesthesiologist

P.Y. Wüthrich, Bern (CH)

09:45 - 09:55

Geriatrist

J. Dhesi, London (GB)

09:55 - 10:05

Surgeon

I.S. Gill, Los Angeles (US)

10:05 - 10:15

Discussion

10:15 - 10:30

State-of-the-art lecture Is immunological treatment set to replace chemotherapy in the management of advanced disease?

T. Powles, London (GB)

10:30 - 10:45

State-of-the-art lecture Hematuria: Who really needs investigating and how?

B.J. Schmitz-Dräger, Fürth (DE)

10:45 - 11:00

State-of-the-art lecture 2016 WHO classification of urogenital tumours - What's new?

H. Moch, Zurich (CH)

Aims and objectives of this presentation

The new "Blue Book" of the 2016 World Health Organization (WHO) classification of urogenital tumours contains significant changes, which were discussed at the WHO Consensus Conference in March 2015 in Zurich, Switzerland. The revision of the 2004 WHO urogenital tumour classification was performed by a large group of uropathologists under consideration of new knowledge on pathology, epidemiology and genetics. This presentation will summarise the most important changes of the new WHO classification, including changes from existing tumour types, novel tumours, provisional/emerging tumour entities and novel grading system and/or prognostic groups.

11:00 - 13:10

Souvenir session By the EAU Scientific Committee

11:00 - 11:10

Benign prostatic disease

P. Radziszewski, Warsaw (PL)

11:10 - 11:20

Urolithiasis and endourology

T. Knoll, Sindelfingen (DE)

Aims and objectives of this presentation

This lecture will summarise the pearls and news of presentations on all aspects of urinary stone disease and endourology, including pathogenesis, epidemiology, treatment and intervention.

11:20 - 11:30

Prostate cancer: Early detection and screening

To be confirmed

11:30 - 11:40

Prostate cancer: Localised and advanced disease

A. De La Taille, Créteil (FR)

Aims and objectives of this presentation

The goal of the presentation is to review all new informations that physicians can get from EAU meeting on localised and metastatic prostate cancer.

11:40 - 11:50

Systemic therapy in GU cancer

M. De Santis, Coventry (GB)

Aims and objectives of this presentation

This talk will summarise the most interesting results and findings concerning systemic treatment of genitourinary cancers.

11:50 - 12:00

Urothelial cancer

L. Martínez-Piñero, Madrid (ES)

Aims and objectives of this presentation

Comprehensive summary of the most important presentations (abstracts and non-abstracts) made during this meeting in the area of urothelial cancer.

12:00 - 12:10

Renal cancer and transplantation

A. Alcaraz, Barcelona (ES)

Aims and objectives of this presentation

To review the most interesting data in research, clinical practice and surgery for renal cancer and kidney transplantation.

12:10 - 12:20

Functional urology

D.J.M.K. De Ridder, Leuven (BE)

Aims and objectives of this presentation

The most relevant and innovative abstracts and lectures on functional and female urology will be summarised.

12:20 - 12:30

Imaging in urology

P. Albers, Düsseldorf (DE)

12:30 - 12:40

Guideline take home messages

J. N'Dow, Aberdeen (GB)

12:40 - 12:50

Paediatric urology

W.F.J. Feitz, Nijmegen (NL)

Aims and objectives of this presentation

Paediatric urology overview 2016. New developments in the field and short term future aspects will be presented. Important take home message involves the policy to share, care and cure and European networks for expertise and continuation of care.

12:50 - 13:00

Rare diseases in urology

T.S. O'Brien, London (GB)

Aims and objectives of this presentation

To highlight clinical and research progress in rare diseases across the urological spectrum.

13:00 - 13:10

Andrology

J.O.R. Sonksen, Herlev (DK)

Aims and objectives of this presentation

To give the audience an update on current gold standards and future developments within erectile dysfunction, peyronies disease, hypogonadism and male infertility.

13:10 - 13:15

[Close](#)